det||susceptibility-3/NN||the-1/DT	amod||susceptibility-3/NN||baseline-2/JJ	prep_of||most-23/JJS||susceptibility-3/NN	nsubjpass||determined-68/VBN||susceptibility-3/NN	num||isolates-8/NNS||14-5/CD	amod||isolates-8/NNS||representative-6/JJ	amod||isolates-8/NNS||hiv-1-7/JJ	prep_of||susceptibility-3/NN||isolates-8/NNS	num||crf07_bc-11/NNS||5-10/CD	dep||isolates-8/NNS||crf07_bc-11/NNS	num||crf01_ae-14/NNS||4-13/CD	dep||isolates-8/NNS||crf01_ae-14/NNS	conj_and||crf07_bc-11/NNS||crf01_ae-14/NNS	num||bâ-18/NN||5-17/CD	dep||isolates-8/NNS||bâ-18/NN	conj_and||crf07_bc-11/NNS||bâ-18/NN	dep||bâ-18/NN||$-19/$	num||$-19/$||²-20/CD	nsubj||viruses-28/NNS||most-23/JJS	cop||viruses-28/NNS||were-26/VBD	amod||viruses-28/NNS||r5-27/JJ	rcmod||susceptibility-3/NN||viruses-28/NNS	vmod||viruses-28/NNS||obtained-30/VBN	amod||patients-35/NNS||drug-naã-32/JJ	amod||patients-35/NNS||¯-33/JJ	nn||patients-35/NNS||ve-34/NN	prep_from||obtained-30/VBN||patients-35/NNS	aux||hiv-37/VB||to-36/TO	xcomp||obtained-30/VBN||hiv-37/VB	nn||inhibitors-39/NNS||entry-38/NN	dobj||hiv-37/VB||inhibitors-39/NNS	num||inhibitors-44/NNS||two-42/CD	nn||inhibitors-44/NNS||fusion-43/NN	prep_including||viruses-28/NNS||inhibitors-44/NNS	dep||inhibitors-44/NNS||enfuvirtide-46/JJ	dep||inhibitors-44/NNS||c34-48/JJ	conj_and||enfuvirtide-46/JJ||c34-48/JJ	num||antagonists-53/NNS||two-51/CD	amod||antagonists-53/NNS||ccr5-52/JJ	prep_including||viruses-28/NNS||antagonists-53/NNS	conj_and||inhibitors-44/NNS||antagonists-53/NNS	dep||antagonists-53/NNS||maraviroc-55/JJ	dep||antagonists-53/NNS||tak779-57/JJ	conj_and||maraviroc-55/JJ||tak779-57/JJ	num||antagonist-62/NN||one-60/CD	amod||antagonist-62/NN||cxcr4-61/JJ	prep_including||viruses-28/NNS||antagonist-62/NN	conj_and||inhibitors-44/NNS||antagonist-62/NN	appos||antagonist-62/NN||amd3100-64/NNP	auxpass||determined-68/VBN||were-67/VBD	root||ROOT-0/null||determined-68/VBN	nn||assay-72/NN||virus-70/NN	nn||assay-72/NN||inhibition-71/NN	agent||determined-68/VBN||assay-72/NN	virus-70||viruses-28||no||the baseline susceptibility of 14 representative hiv-1 isolates (5 crf07_bc, 4 crf01_ae, and 5 bâ€²), most of which were r5 viruses, obtained from drug-naã¯ve patients to hiv entry inhibitors, including two fusion inhibitors (enfuvirtide and c34), two ccr5 antagonists (maraviroc and tak779) and one cxcr4 antagonist (amd3100), were determined by virus inhibition assay.
advmod||cause-16/NN||probably-1/RB	nsubj||cause-16/NN||loss-3/NN	prep_of||loss-3/NN||potassium-5/NN	det||stream-9/NN||the-7/DT	nn||stream-9/NN||urine-8/NN	prep_via||potassium-5/NN||stream-9/NN	amod||aldosteronism-12/NN||secondary-11/JJ	prep_with||stream-9/NN||aldosteronism-12/NN	cop||cause-16/NN||was-13/VBD	det||cause-16/NN||the-14/DT	amod||cause-16/NN||main-15/JJ	root||ROOT-0/null||cause-16/NN	det||hypokalaemia-19/NN||the-18/DT	prep_of||cause-16/NN||hypokalaemia-19/NN	aldosteronism-12||potassium-5||no_rel||probably, loss of potassium via the urine stream with secondary aldosteronism was the main cause of the hypokalaemia.
det||method-2/NN||the-1/DT	nsubjpass||illustrated-4/VBN||method-2/NN	auxpass||illustrated-4/VBN||is-3/VBZ	root||ROOT-0/null||illustrated-4/VBN	xcomp||illustrated-4/VBN||using-5/VBG	dobj||using-5/VBG||data-6/NNS	det||study-12/NN||a-8/DT	amod||study-12/NN||sertraline-9/JJ	amod||study-12/NN||randomized-10/JJ	nn||study-12/NN||withdrawal-11/NN	prep_from||using-5/VBG||study-12/NN	prep_in||study-12/NN||patients-14/NNS	amod||depressivedisorder-17/NN||major-16/JJ	prep_with||patients-14/NNS||depressivedisorder-17/NN	depressivedisorder-17||sertraline-9||yes||the method is illustrated using data from a sertraline randomized withdrawal study in patients with major depressivedisorder.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	amod||infiltration-13/NN||pre-incisional-12/JJ	prep_of||effect-10/NN||infiltration-13/NN	prep_of||infiltration-13/NN||tonsils-15/NNS	prep_with||tonsils-15/NNS||dexamethasone-17/NN	det||incidence-20/NN||the-19/DT	prep_on||dexamethasone-17/NN||incidence-20/NN	prep_on||dexamethasone-17/NN||severity-22/NN	conj_and||incidence-20/NN||severity-22/NN	amod||pain-25/NN||postoperative-24/JJ	prep_of||incidence-20/NN||pain-25/NN	prep_of||incidence-20/NN||vomiting-27/NN	conj_and||pain-25/NN||vomiting-27/NN	prep_in||evaluate-8/VB||children-29/NNS	vmod||children-29/NNS||undergoing-30/VBG	advmod||undergoing-30/VBG||tonsillectomy-31/RB	amod||anesthesia-34/NN||general-33/JJ	prep_under||undergoing-30/VBG||anesthesia-34/NN	vomiting-27||dexamethasone-17||yes||the aim of this study was to evaluate the effect of pre-incisional infiltration of tonsils with dexamethasone on the incidence and severity of postoperative pain and vomiting in children undergoing tonsillectomy under general anesthesia.
det||borreliarecurrentis-3/NNS||the-1/DT	amod||borreliarecurrentis-3/NNS||spirochete-2/JJ	nsubj||agent-7/NN||borreliarecurrentis-3/NNS	nsubjpass||transmitted-12/VBN||borreliarecurrentis-3/NNS	cop||agent-7/NN||is-4/VBZ	det||agent-7/NN||the-5/DT	amod||agent-7/NN||causal-6/JJ	root||ROOT-0/null||agent-7/NN	prep_of||agent-7/NN||louse-bornerelapsingfever-9/NN	auxpass||transmitted-12/VBN||is-11/VBZ	conj_and||agent-7/NN||transmitted-12/VBN	prep_to||transmitted-12/VBN||humans-14/NNS	det||humanus-21/NNS||the-16/DT	amod||humanus-21/NNS||infected-17/JJ	nn||humanus-21/NNS||body-18/NN	nn||humanus-21/NNS||louse-19/NN	nn||humanus-21/NNS||pediculus-20/NNS	agent||transmitted-12/VBN||humanus-21/NNS	louse-bornerelapsingfever-9||borreliarecurrentis-3||no||the spirochete borreliarecurrentis is the causal agent of louse-bornerelapsingfever and is transmitted to humans by the infected body louse pediculus humanus .
det||correlation-3/NN||a-1/DT	amod||correlation-3/NN||similar-2/JJ	nsubjpass||reported-15/VBN||correlation-3/NN	amod||responses-7/NNS||certain-5/JJ	amod||responses-7/NNS||allergic-6/JJ	prep_between||correlation-3/NN||responses-7/NNS	amod||expression-12/NN||increased-9/VBN	amod||expression-12/NN||ifn-î-10/JJ	nn||expression-12/NN||³-11/NN	prep_between||correlation-3/NN||expression-12/NN	conj_and||responses-7/NNS||expression-12/NN	aux||reported-15/VBN||has-13/VBZ	auxpass||reported-15/VBN||been-14/VBN	root||ROOT-0/null||reported-15/VBN	amod||studies-19/NNS||human-17/JJ	amod||studies-19/NNS||clinical-18/JJ	prep_in||reported-15/VBN||studies-19/NNS	prep_of||studies-19/NNS||allergy-21/NN	det||model-25/NN||this-23/DT	nn||model-25/NN||pig-24/NN	nsubj||indicative-30/JJ||model-25/NN	prep_of||model-25/NN||allergy-27/NN	aux||indicative-30/JJ||may-28/MD	cop||indicative-30/JJ||be-29/VB	parataxis||reported-15/VBN||indicative-30/JJ	amod||modulation-34/NN||potential-32/JJ	amod||modulation-34/NN||probiotic-33/JJ	prep_of||indicative-30/JJ||modulation-34/NN	amod||lungdisease-37/NN||allergic-36/JJ	prep_of||modulation-34/NN||lungdisease-37/NN	prep_in||indicative-30/JJ||humans-39/NNS	ifn--1||lungdisease-37||no_rel||a similar correlation between certain allergic responses and increased ifn-î³ expression has been reported in human clinical studies of allergy; this pig model of allergy may be indicative of potential probiotic modulation of allergic lungdisease in humans.
det||proof-3/NN||this-2/DT	prep_for||compared-9/VBD||proof-3/NN	amod||study-6/NN||principal-5/JJ	prep_of||proof-3/NN||study-6/NN	nsubj||compared-9/VBD||we-8/PRP	root||ROOT-0/null||compared-9/VBD	amod||clearance-11/NN||bacillary-10/JJ	dobj||compared-9/VBD||clearance-11/NN	det||lungs-14/NNS||the-13/DT	prep_from||compared-9/VBD||lungs-14/NNS	prep_of||lungs-14/NNS||mtb-16/NN	amod||mice-19/NNS||infected-18/JJ	nsubj||treated-20/VBN||mice-19/NNS	parataxis||compared-9/VBD||treated-20/VBN	det||isoniazid-25/NN||the-22/DT	amod||isoniazid-25/NN||anti-tb-23/JJ	nn||isoniazid-25/NN||drug-24/NN	prep_with||treated-20/VBN||isoniazid-25/NN	appos||isoniazid-25/NN||inh-27/NN	det||presence-31/NN||the-30/DT	prep_in||treated-20/VBN||presence-31/NN	prep_in||treated-20/VBN||absence-33/NN	conj_and||presence-31/NN||absence-33/NN	det||inhibitor-39/NN||an-35/DT	amod||inhibitor-39/NN||immunomodulatory-36/JJ	amod||inhibitor-39/NN||phosphodiesterase-37/JJ	dep||phosphodiesterase-37/JJ||4-38/CD	prep_of||presence-31/NN||inhibitor-39/NN	appos||inhibitor-39/NN||pde4i-41/NNP	dep||treated-20/VBN||cc-3052-44/JJ	tb--1||inh-27||yes||for this proof of principal study, we compared bacillary clearance from the lungs of mtb -infected mice treated with the anti-tb drug isoniazid (inh) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (pde4i), cc-3052.
nsubjpass||assessed-3/VBN||pain-1/NN	auxpass||assessed-3/VBN||was-2/VBD	root||ROOT-0/null||assessed-3/VBN	xcomp||assessed-3/VBN||using-4/VBG	xcomp||assessed-3/VBN||using-4/VBG	conj_and||using-4/VBG||using-4/VBG	det||scale-8/NN||a-5/DT	amod||scale-8/NN||visual-6/JJ	amod||scale-8/NN||analog-7/JJ	dobj||using-4/VBG||scale-8/NN	num||=-11/NNS||0-10/CD	dep||scale-8/NN||=-11/NNS	neg||pain-13/NN||no-12/DT	dep||=-11/NNS||pain-13/NN	dep||pain-13/NN||100-15/CD	dep||pain-20/NN||=-16/SYM	det||pain-20/NN||the-17/DT	amod||pain-20/NN||worst-18/JJS	amod||pain-20/NN||possible-19/JJ	rcmod||100-15/CD||pain-20/NN	prep_at||using-4/VBG||0-23/NNP	num||0-23/NNP||5-25/CD	num||0-23/NNP||10-27/CD	num||minutes-31/NNS||30-30/CD	npadvmod||using-4/VBG||minutes-31/NNS	prepc_after||using-4/VBG||stopping-33/VBG	det||infusion-36/NN||the-34/DT	amod||infusion-36/NN||remifentanil-35/JJ	dobj||stopping-33/VBG||infusion-36/NN	pain-20||remifentanil-35||yes||pain was assessed using a visual analog scale (0 = no pain; 100 = the worst possible pain) at 0, 5, 10, and 30 minutes after stopping the remifentanil infusion.
det||2003-3/CD||the-2/DT	prep_during||randomised-26/VBN||2003-3/CD	num||seasons-8/NNS||2004-5/CD	nn||seasons-8/NNS||malaria-6/NN	nn||seasons-8/NNS||transmission-7/NN	conj_and||2003-3/CD||seasons-8/NNS	prep_during||randomised-26/VBN||seasons-8/NNS	num||children-12/NNS||1200-10/CD	nn||children-12/NNS||gambian-11/NN	nsubjpass||randomised-26/VBN||children-12/NNS	nsubj||receive-28/VB||children-12/NNS	amod||anaemia-17/NN||moderate-14/JJ	conj_or||moderate-14/JJ||severe-16/JJ	amod||anaemia-17/NN||severe-16/JJ	prep_with||children-12/NNS||anaemia-17/NN	nn||<-21/NNS||hb-19/NN	nn||<-21/NNS||concentration-20/NN	dep||g/dl-23/JJ||<-21/NNS	number||g/dl-23/JJ||7-22/CD	dep||anaemia-17/NN||g/dl-23/JJ	auxpass||randomised-26/VBN||were-25/VBD	root||ROOT-0/null||randomised-26/VBN	aux||receive-28/VB||to-27/TO	xcomp||randomised-26/VBN||receive-28/VB	det||sulfadoxine-pyrimethamine-31/NN||either-29/DT	amod||sulfadoxine-pyrimethamine-31/NN||monthly-30/JJ	dobj||receive-28/VB||sulfadoxine-pyrimethamine-31/NN	appos||sulfadoxine-pyrimethamine-31/NN||sp-33/NN	dobj||receive-28/VB||placebo-36/NN	conj_or||sulfadoxine-pyrimethamine-31/NN||placebo-36/NN	det||end-39/NN||the-38/DT	prep_until||receive-28/VB||end-39/NN	det||season-44/NN||the-41/DT	nn||season-44/NN||malaria-42/NN	nn||season-44/NN||transmission-43/NN	prep_of||end-39/NN||season-44/NN	prep_in||enrolled-49/VBN||season-44/NN	nsubjpass||enrolled-49/VBN||they-47/PRP	auxpass||enrolled-49/VBN||were-48/VBD	rcmod||season-44/NN||enrolled-49/VBN	det||trial-54/NN||a-52/DT	amod||trial-54/NN||double-blind-53/JJ	prep_in||enrolled-49/VBN||trial-54/NN	malaria-42||pyrimethamine--1||yes||during the 2003 and 2004 malaria transmission seasons, 1200 gambian children with moderate or severe anaemia (hb concentration <7 g/dl) were randomised to receive either monthly sulfadoxine-pyrimethamine (sp) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial.
det||incidence-2/NN||the-1/DT	nsubj||lower-17/JJR||incidence-2/NN	conj_and||incidence-2/NN||severity-4/NN	nsubj||lower-17/JJR||severity-4/NN	prep_of||incidence-2/NN||pain-6/NN	det||injection-10/NN||the-8/DT	amod||injection-10/NN||propofol-9/JJ	prep_from||pain-6/NN||injection-10/NN	det||group-14/NN||the-12/DT	nn||group-14/NN||combination-13/NN	prep_in||injection-10/NN||group-14/NN	cop||lower-17/JJR||was-15/VBD	advmod||lower-17/JJR||significantly-16/RB	root||ROOT-0/null||lower-17/JJR	prep_than||lower-17/JJR||that-19/DT	det||remifentanil-22/NN||the-21/DT	prep_in||that-19/DT||remifentanil-22/NN	amod||groups-25/NNS||cold-24/JJ	prep_in||that-19/DT||groups-25/NNS	conj_and||remifentanil-22/NN||groups-25/NNS	pain-6||propofol-9||yes||the incidence and severity of pain from the propofol injection in the combination group was significantly lower than that in the remifentanil and cold groups.
det||hemagglutinin-6/NN||the-1/DT	amod||hemagglutinin-6/NN||main-2/JJ	amod||hemagglutinin-6/NN||influenzavirus-3/JJ	nn||hemagglutinin-6/NN||surface-4/NN	nn||hemagglutinin-6/NN||glycoprotein-5/NN	nsubjpass||shown-18/VBN||hemagglutinin-6/NN	nsubj||susceptible-22/JJ||hemagglutinin-6/NN	appos||hemagglutinin-6/NN||ha-8/NN	advmod||pathogenic-12/JJ||highly-11/RB	amod||avianinfluenzaviruses-13/NNS||pathogenic-12/JJ	prep_of||hemagglutinin-6/NN||avianinfluenzaviruses-13/NNS	appos||avianinfluenzaviruses-13/NNS||hpaiv-15/NNP	auxpass||shown-18/VBN||was-17/VBD	root||ROOT-0/null||shown-18/VBN	aux||susceptible-22/JJ||to-19/TO	cop||susceptible-22/JJ||be-20/VB	advmod||susceptible-22/JJ||more-21/RBR	xcomp||shown-18/VBN||susceptible-22/JJ	amod||treatment-26/NN||acidic-24/JJ	nn||treatment-26/NN||ph-25/NN	prep_to||susceptible-22/JJ||treatment-26/NN	prep_than||treatment-26/NN||that-28/DT	amod||avianinfluenzaviruses-34/NNS||human-30/JJ	conj_or||human-30/JJ||low-32/JJ	amod||avianinfluenzaviruses-34/NNS||low-32/JJ	amod||avianinfluenzaviruses-34/NNS||pathogenic-33/JJ	prep_of||that-28/DT||avianinfluenzaviruses-34/NNS	avianinfluenza--1||influenzavirus-3||no||the main influenzavirus surface glycoprotein hemagglutinin (ha) of highly pathogenic avianinfluenzaviruses (hpaiv) was shown to be more susceptible to acidic ph treatment than that of human or low pathogenic avianinfluenzaviruses.
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||ability-6/NN||the-5/DT	dobj||investigated-4/VBD||ability-6/NN	prep_of||ability-6/NN||quercetin-8/NN	aux||sensitise-10/VB||to-9/TO	vmod||investigated-4/VBD||sensitise-10/VB	vmod||investigated-4/VBD||sensitise-10/VB	conj_and||sensitise-10/VB||sensitise-10/VB	amod||cells-12/NNS||primary-11/JJ	dobj||sensitise-10/VB||cells-12/NNS	prep_from||sensitise-10/VB||chroniclymphocyticleukaemia-14/NN	appos||chroniclymphocyticleukaemia-14/NN||cll-16/NN	nn||agonists-24/NNS||death-19/NN	nn||agonists-24/NNS||receptor-20/NN	nn||agonists-24/NNS||dr-22/NN	prep_to||chroniclymphocyticleukaemia-14/NN||agonists-24/NNS	amod||ligand-28/NN||recombinant-26/JJ	amod||ligand-28/NN||tnf-related-apoptosis-inducing-27/JJ	prep_from||sensitise-10/VB||ligand-28/NN	conj_and||chroniclymphocyticleukaemia-14/NN||ligand-28/NN	dep||ligand-28/NN||rtrail-30/JJ	prep_from||sensitise-10/VB||anti-cd95-33/JJ	conj_and||chroniclymphocyticleukaemia-14/NN||anti-cd95-33/JJ	prep_to||sensitise-10/VB||fludarabine-37/NN	det||drug-43/NN||a-39/DT	advmod||used-41/VBN||widely-40/RB	amod||drug-43/NN||used-41/VBN	amod||drug-43/NN||chemotherapeutic-42/JJ	appos||fludarabine-37/NN||drug-43/NN	prep_against||investigated-4/VBD||cll-45/NN	chroniclymphocyticleukaemia-14||fludarabine-37||yes||here, we investigated the ability of quercetin to sensitise primary cells from chroniclymphocyticleukaemia (cll) to death receptor (dr) agonists, recombinant tnf-related-apoptosis-inducing ligand (rtrail) and anti-cd95, and to fludarabine, a widely used chemotherapeutic drug against cll.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubjpass||designed-5/VBN||study-3/NN	nsubj||investigate-7/VB||study-3/NN	auxpass||designed-5/VBN||was-4/VBD	root||ROOT-0/null||designed-5/VBN	aux||investigate-7/VB||to-6/TO	xcomp||designed-5/VBN||investigate-7/VB	mark||suppress-18/VB||if-8/IN	det||gw5074-12/NN||the-9/DT	amod||gw5074-12/NN||raf-1-10/JJ	nn||gw5074-12/NN||inhibitor-11/NN	nsubj||suppress-18/VB||gw5074-12/NN	det||dexamethasone-17/NN||the-14/DT	amod||dexamethasone-17/NN||anti-inflammatory-15/JJ	nn||dexamethasone-17/NN||drug-16/NN	conj_and||gw5074-12/NN||dexamethasone-17/NN	nsubj||suppress-18/VB||dexamethasone-17/NN	advcl||investigate-7/VB||suppress-18/VB	advmod||suppress-18/VB||airwayhyperreactivity-19/RB	det||model-23/NN||a-21/DT	nn||model-23/NN||mouse-22/NN	prep_in||suppress-18/VB||model-23/NN	nn||exposure-27/NN||sidestream-25/NN	nn||exposure-27/NN||smoke-26/NN	prep_of||model-23/NN||exposure-27/NN	airwayhyperreactivity-19||dexamethasone-17||yes||the present study was designed to investigate if the raf-1 inhibitor gw5074 and the anti-inflammatory drug dexamethasone suppress airwayhyperreactivity in a mouse model of sidestream smoke exposure.
nsubj||reported-3/VBN||we-1/PRP	aux||reported-3/VBN||have-2/VBP	root||ROOT-0/null||reported-3/VBN	det||rate-11/NN||a-4/DT	amod||rate-11/NN||promising-5/JJ	amod||remission-7/JJ||complete-6/JJ	amod||rate-11/NN||remission-7/JJ	appos||rate-11/NN||cr-9/NN	dobj||reported-3/VBN||rate-11/NN	advmod||diagnosed-14/JJ||newly-13/RB	amod||patients-16/NNS||diagnosed-14/JJ	nn||patients-16/NNS||myeloma-15/NN	prep_for||rate-11/NN||patients-16/NNS	vmod||patients-16/NNS||treated-17/VBN	det||approach-21/NN||a-19/DT	amod||approach-21/NN||staged-20/JJ	agent||treated-17/VBN||approach-21/NN	prep_in||underwent-27/VBD||approach-21/NN	amod||patients-26/NNS||chemosensitive-25/JJ	nsubj||underwent-27/VBD||patients-26/NNS	rcmod||approach-21/NN||underwent-27/VBD	nsubj||stem-30/VB||autologous-28/NNS	dep||stem-30/VB||haematopoietic-29/JJ	xcomp||underwent-27/VBD||stem-30/VB	nn||transplantation-32/NN||cell-31/NN	dobj||stem-30/VB||transplantation-32/NN	appos||transplantation-32/NN||auto-hsct-34/NN	mark||received-40/VBD||while-36/IN	amod||patients-39/NNS||less-37/JJR	nn||patients-39/NNS||chemosensitive-38/NN	nsubj||received-40/VBD||patients-39/NNS	dep||transplantation-32/NN||received-40/VBD	nn||therapy-42/NN||salvage-41/NN	dobj||received-40/VBD||therapy-42/NN	prep_with||received-40/VBD||bortezomib/thalidomide/dexamethasone-44/NN	prep_prior_to||received-40/VBD||auto-hsct-47/NN	myeloma-15||bortezomib--1||yes||we have reported a promising complete remission (cr) rate for newly diagnosed myeloma patients treated by a staged approach, in which chemosensitive patients underwent autologous haematopoietic stem cell transplantation (auto-hsct) while less chemosensitive patients received salvage therapy with bortezomib/thalidomide/dexamethasone prior to auto-hsct.
nsubjpass||observed-7/VBN||electroacupuncture-1/NN	nsubj||reduce-9/VB||electroacupuncture-1/NN	appos||electroacupuncture-1/NN||ea-3/NN	aux||observed-7/VBN||has-5/VBZ	auxpass||observed-7/VBN||been-6/VBN	root||ROOT-0/null||observed-7/VBN	aux||reduce-9/VB||to-8/TO	xcomp||observed-7/VBN||reduce-9/VB	dobj||reduce-9/VB||insulinresistance-10/NN	prep_in||reduce-9/VB||obesity-12/NN	prep_in||reduce-9/VB||diabetes-14/NN	conj_and||obesity-12/NN||diabetes-14/NN	insulinresistance-10||ea-3||no_rel||electroacupuncture (ea) has been observed to reduce insulinresistance in obesity and diabetes.
mark||occur-10/VB||although-1/IN	amod||deposits-5/NNS||renal-2/JJ	nn||deposits-5/NNS||calcium-3/NN	nn||deposits-5/NNS||crystal-4/NN	nsubj||occur-10/VB||deposits-5/NNS	appos||deposits-5/NNS||nephrocalcinosis-7/NNS	aux||occur-10/VB||may-9/MD	advcl||common-28/JJ||occur-10/VB	amod||poisoning-14/NN||acute-12/JJ	nn||poisoning-14/NN||phosphate-13/NN	prep_in||occur-10/VB||poisoning-14/NN	prep_in||occur-10/VB||type-18/NN	conj_and||poisoning-14/NN||type-18/NN	num||renaltubularacidosis-20/NNS||1-19/CD	dep||type-18/NN||renaltubularacidosis-20/NNS	appos||renaltubularacidosis-20/NNS||rta-22/NN	amod||hypocalcemia-26/NN||hyperphosphatemic-25/JJ	nsubj||common-28/JJ||hypocalcemia-26/NN	cop||common-28/JJ||is-27/VBZ	root||ROOT-0/null||common-28/JJ	det||former-31/JJ||the-30/DT	prep_in||common-28/JJ||former-31/JJ	mark||typical-36/JJ||while-32/IN	amod||hypokalemia-34/NN||normocalcemic-33/JJ	nsubj||typical-36/JJ||hypokalemia-34/NN	cop||typical-36/JJ||is-35/VBZ	advcl||common-28/JJ||typical-36/JJ	det||latter-39/NN||the-38/DT	prep_in||typical-36/JJ||latter-39/NN	calcium-3||rta-22||no_rel||although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renaltubularacidosis (rta), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter.
amod||evidences-2/NNS||recent-1/JJ	nsubj||demonstrated-4/VBN||evidences-2/NNS	aux||demonstrated-4/VBN||have-3/VBP	root||ROOT-0/null||demonstrated-4/VBN	mark||play-16/VB||that-5/IN	det||presence-7/NN||the-6/DT	nsubj||play-16/VB||presence-7/NN	amod||pathogenic-10/JJ||low-9/JJ	amod||avianinfluenzaviruses-11/NNS||pathogenic-10/JJ	prep_of||presence-7/NN||avianinfluenzaviruses-11/NNS	appos||avianinfluenzaviruses-11/NNS||lpaiv-13/NNP	aux||play-16/VB||may-15/MD	ccomp||demonstrated-4/VBN||play-16/VB	det||role-19/NN||an-17/DT	amod||role-19/NN||important-18/JJ	dobj||play-16/VB||role-19/NN	nn||ecology-22/NN||host-21/NN	prep_in||play-16/VB||ecology-22/NN	prep_in||play-16/VB||transmission-24/NN	conj_and||ecology-22/NN||transmission-24/NN	prep_of||ecology-22/NN||avianinfluenzaviruses-26/NNS	appos||avianinfluenzaviruses-26/NNS||aiv-28/NN	avianinfluenza--1||influenzaviruses--1||no||recent evidences have demonstrated that the presence of low pathogenic avianinfluenzaviruses (lpaiv) may play an important role in host ecology and transmission of avianinfluenzaviruses (aiv).
det||types-2/NNS||all-1/DT	nsubjpass||included-8/VBN||types-2/NNS	amod||studies-6/NNS||prospective-4/JJ	amod||studies-6/NNS||clinical-5/JJ	prep_of||types-2/NNS||studies-6/NNS	auxpass||included-8/VBN||were-7/VBD	root||ROOT-0/null||included-8/VBN	mark||used-12/VBN||if-9/IN	nsubjpass||used-12/VBN||magnesiumsulfate-10/NN	nsubj||manage-14/VB||magnesiumsulfate-10/NN	auxpass||used-12/VBN||was-11/VBD	advcl||included-8/VBN||used-12/VBN	aux||manage-14/VB||to-13/TO	xcomp||used-12/VBN||manage-14/VB	dobj||manage-14/VB||pre-eclampsia-15/NN	dobj||manage-14/VB||eclampsia-17/NN	conj_or||pre-eclampsia-15/NN||eclampsia-17/NN	det||study-20/NN||the-19/DT	nsubjpass||conducted-22/VBN||study-20/NN	auxpass||conducted-22/VBN||was-21/VBD	dep||included-8/VBN||conducted-22/VBN	det||country-29/NN||a-24/DT	amod||country-29/NN||low-25/JJ	conj_or||low-25/JJ||middle-income-28/JJ	amod||country-29/NN||middle-income-28/JJ	prep_in||conducted-22/VBN||country-29/NN	det||study-33/NN||the-32/DT	nsubj||included-34/VBD||study-33/NN	conj_and||included-8/VBN||included-34/VBD	det||recording-36/NN||the-35/DT	dobj||included-34/VBD||recording-36/NN	det||incidence-39/NN||the-38/DT	prep_of||recording-36/NN||incidence-39/NN	det||effect-44/NN||any-41/DT	amod||effect-44/NN||adverse-42/JJ	nn||effect-44/NN||side-43/NN	prep_of||incidence-39/NN||effect-44/NN	vmod||effect-44/NN||resulting-45/VBG	amod||use-48/NN||magnesiumsulfate-47/JJ	prep_from||resulting-45/VBG||use-48/NN	pre-eclampsia-15||magnesiumsulfate-47||yes||all types of prospective clinical studies were included if magnesiumsulfate was used to manage pre-eclampsia or eclampsia, the study was conducted in a low- or middle-income country, and the study included the recording of the incidence of any adverse side effect resulting from magnesiumsulfate use.
nsubj||targets-10/VBZ||laropiprant-1/NN	det||inhibitor-7/NN||a-3/DT	amod||inhibitor-7/NN||selective-4/JJ	amod||inhibitor-7/NN||prostaglandin-2-5/JJ	nn||inhibitor-7/NN||receptor-6/NN	appos||laropiprant-1/NN||inhibitor-7/NN	advmod||targets-10/VBZ||specifically-9/RB	root||ROOT-0/null||targets-10/VBZ	det||cascade-12/NN||the-11/DT	dobj||targets-10/VBZ||cascade-12/NN	prep_of||cascade-12/NN||events-14/NNS	vmod||events-14/NNS||causing-15/VBG	det||flushing-17/NN||the-16/DT	dobj||causing-15/VBG||flushing-17/NN	flushing-17||prostaglandin--1||no_rel||laropiprant, a selective prostaglandin-2 receptor inhibitor, specifically targets the cascade of events causing the flushing.
mark||offered-6/VBN||since-1/IN	amod||cross-protection-3/NN||limited-2/JJ	nsubjpass||offered-6/VBN||cross-protection-3/NN	aux||offered-6/VBN||would-4/MD	auxpass||offered-6/VBN||be-5/VB	advcl||taken-18/VBN||offered-6/VBN	nn||types-9/NNS||hpv-8/NN	prep_between||offered-6/VBN||types-9/NNS	nsubjpass||taken-18/VBN||heterogeneity-11/NN	amod||distribution-15/NN||hpv-13/JJ	amod||distribution-15/NN||type-specific-14/JJ	prep_in||heterogeneity-11/NN||distribution-15/NN	aux||taken-18/VBN||should-16/MD	auxpass||taken-18/VBN||be-17/VB	root||ROOT-0/null||taken-18/VBN	prep_into||taken-18/VBN||account-20/NN	advmod||predicting-22/VBG||when-21/WRB	advcl||taken-18/VBN||predicting-22/VBG	det||effect-24/NN||the-23/DT	dobj||predicting-22/VBG||effect-24/NN	amod||vaccines-28/NNS||current-26/JJ	amod||vaccines-28/NNS||prophylactic-27/JJ	prep_of||effect-24/NN||vaccines-28/NNS	advcl||taken-18/VBN||forming-30/VBG	conj_and||predicting-22/VBG||forming-30/VBG	det||basic-32/JJ||the-31/DT	dobj||forming-30/VBG||basic-32/JJ	det||vaccines-36/NNS||the-34/DT	amod||vaccines-36/NNS||second-generation-35/JJ	prep_for||forming-30/VBG||vaccines-36/NNS	vmod||vaccines-36/NNS||targeted-37/VBN	amod||regions-40/NNS||specific-39/JJ	prep_to||targeted-37/VBN||regions-40/NNS	cross--1||vaccines-36||no_rel||since limited cross-protection would be offered between hpv types, heterogeneity in hpv type-specific distribution should be taken into account when predicting the effect of current prophylactic vaccines and forming the basic for the second-generation vaccines targeted to specific regions.
nsubj||become-5/VBN||gemcitabine-1/NN	prep||gemcitabine-1/NN||plus-2/CC	pobj||plus-2/CC||cisplatin-3/NN	aux||become-5/VBN||has-4/VBZ	root||ROOT-0/null||become-5/VBN	det||standard-8/NN||a-6/DT	amod||standard-8/NN||new-7/JJ	xcomp||become-5/VBN||standard-8/NN	amod||treatment-11/NN||first-line-10/JJ	prep_for||become-5/VBN||treatment-11/NN	amod||cancer-15/NN||advanced-13/JJ	amod||cancer-15/NN||biliary-14/JJ	prep_of||treatment-11/NN||cancer-15/NN	cancer-15||cisplatin-3||no_rel||gemcitabine plus cisplatin has become a new standard for first-line treatment of advanced biliary cancer.
advmod||appears-7/VBZ||furthermore-1/RB	det||effectiveness-4/NN||the-3/DT	nsubj||appears-7/VBZ||effectiveness-4/NN	nsubj||greater-10/JJR||effectiveness-4/NN	prep_of||effectiveness-4/NN||vildagliptin-6/NN	root||ROOT-0/null||appears-7/VBZ	aux||greater-10/JJR||to-8/TO	cop||greater-10/JJR||be-9/VB	xcomp||appears-7/VBZ||greater-10/JJR	advmod||used-14/VBN||when-11/WRB	nsubjpass||used-14/VBN||insulin-12/NN	auxpass||used-14/VBN||is-13/VBZ	ccomp||greater-10/JJR||used-14/VBN	det||regimen-18/NN||a-16/DT	amod||regimen-18/NN||basal-17/JJ	prep_as||used-14/VBN||regimen-18/NN	advmod||opposed-20/VBN||as-19/RB	amod||regimen-18/NN||opposed-20/VBN	auxpass||used-23/VBN||being-22/VBG	prepc_to||greater-10/JJR||used-23/VBN	aux||reduce-25/VB||to-24/TO	xcomp||used-23/VBN||reduce-25/VB	amod||hyperglycemia-27/NN||postprandial-26/JJ	dobj||reduce-25/VB||hyperglycemia-27/NN	mark||plays-35/VBZ||since-29/IN	nsubj||plays-35/VBZ||improvement-30/NN	nn||secretion-33/NN||insulin-32/NN	prep_in||improvement-30/NN||secretion-33/NN	advmod||plays-35/VBZ||likely-34/RB	advcl||appears-7/VBZ||plays-35/VBZ	det||role-38/NN||a-36/DT	amod||role-38/NN||minor-37/JJ	dobj||plays-35/VBZ||role-38/NN	tmod||administered-46/VBN||role-38/NN	advmod||administered-46/VBN||when-39/WRB	advmod||high-41/JJ||relatively-40/RB	amod||doses-42/NNS||high-41/JJ	nsubjpass||administered-46/VBN||doses-42/NNS	prep_of||doses-42/NNS||insulin-44/NN	auxpass||administered-46/VBN||are-45/VBP	rcmod||role-38/NN||administered-46/VBN	prep_before||administered-46/VBN||meals-48/NNS	hyperglycemia-27||insulin-44||yes||furthermore, the effectiveness of vildagliptin appears to be greater when insulin is used as a basal regimen as opposed to being used to reduce postprandial hyperglycemia, since improvement in insulin secretion likely plays a minor role when relatively high doses of insulin are administered before meals.
det||study-2/NN||this-1/DT	nsubj||draws-3/VBZ||study-2/NN	root||ROOT-0/null||draws-3/VBZ	dobj||draws-3/VBZ||attention-4/NN	det||phenotype-8/NN||a-6/DT	amod||phenotype-8/NN||particular-7/JJ	prep_to||draws-3/VBZ||phenotype-8/NN	advmod||leads-14/VBZ||where-9/WRB	nsubj||leads-14/VBZ||na-10/NNP	nsubj||irondeficiency-16/VB||na-10/NNP	amod||paradoxically-13/NN||excess-12/JJ	prep_in||na-10/NNP||paradoxically-13/NN	rcmod||phenotype-8/NN||leads-14/VBZ	aux||irondeficiency-16/VB||to-15/TO	xcomp||leads-14/VBZ||irondeficiency-16/VB	advmod||irondeficiency-16/VB||probably-18/RB	det||increase-22/NN||an-21/DT	prep_because_of||irondeficiency-16/VB||increase-22/NN	det||iron-29/NN||the-24/DT	amod||iron-29/NN||na-25/JJ	amod||iron-29/NN||apoplastic-26/JJ	nn||iron-29/NN||pool-27/NN	nn||iron-29/NN||sequestering-28/NN	prep_of||increase-22/NN||iron-29/NN	irondeficiency-16||iron-29||yes||this study draws attention to a particular phenotype where na in excess paradoxically leads to irondeficiency, probably because of an increase of the na apoplastic pool sequestering iron.
prep_after||observed-17/VBD||adjustment-2/NN	nn||sex-6/NN||age-4/NN	prep_for||adjustment-2/NN||sex-6/NN	nn||circumference-10/NN||waist-9/NN	prep_for||adjustment-2/NN||circumference-10/NN	conj_and||sex-6/NN||circumference-10/NN	det||ors-14/NN||the-12/DT	amod||ors-14/NN||standardized-13/JJ	nsubj||observed-17/VBD||ors-14/NN	prep_for||ors-14/NN||incident-16/NN	root||ROOT-0/null||observed-17/VBD	nsubj||identical-20/JJ||apnea-18/NN	cop||identical-20/JJ||were-19/VBD	ccomp||observed-17/VBD||identical-20/JJ	prepc_for||identical-20/JJ||fasting-22/VBG	dobj||fasting-22/VBG||insulin-23/NN	det||assessment-28/NN||the-25/DT	amod||assessment-28/NN||homeostasis-26/JJ	nn||assessment-28/NN||model-27/NN	dobj||fasting-22/VBG||assessment-28/NN	conj_and||insulin-23/NN||assessment-28/NN	prep_of||assessment-28/NN||insulinresistance-30/NN	num||insulinresistance-30/NN||1.31-31/CD	npadvmod||â-34/RB||1.13-33/CD	dep||$-35/$||â-34/RB	dep||insulinresistance-30/NN||$-35/$	num||$-35/$||1.51-37/CD	prep_of||assessment-28/NN||1.24-40/CD	conj_and||insulinresistance-30/NN||1.24-40/CD	npadvmod||â-43/RB||1.09-42/CD	dep||$-44/$||â-43/RB	dep||insulinresistance-30/NN||$-44/$	num||$-44/$||1.41-46/CD	prep_for||fasting-22/VBG||triglycerides-49/CD	prep_for||fasting-22/VBG||1.52-51/CD	conj_and||triglycerides-49/CD||1.52-51/CD	dep||triglycerides-49/CD||1.12-53/CD	dep||triglycerides-49/CD||$-55/$	conj_â||1.12-53/CD||$-55/$	num||$-55/$||2.05-57/CD	prep_for||fasting-22/VBG||smoking-60/NN	triglycerides-49||apnea-18||no_rel||after adjustment for age, sex, and waist circumference, the standardized ors for incident observed apnea were identical for fasting insulin and the homeostasis model assessment of insulinresistance 1.31 (1.13â€“1.51) and 1.24 (1.09â€“1.41) for triglycerides and 1.52 (1.12â€“2.05) for smoking.
det||patients-2/NNS||the-1/DT	nsubjpass||evaluated-4/VBN||patients-2/NNS	auxpass||evaluated-4/VBN||were-3/VBD	root||ROOT-0/null||evaluated-4/VBN	xcomp||evaluated-4/VBN||using-5/VBG	xcomp||evaluated-4/VBN||using-5/VBG	conj_and||using-5/VBG||using-5/VBG	det||scale-9/NN||the-6/DT	amod||scale-9/NN||visual-7/JJ	amod||scale-9/NN||analogue-8/JJ	dobj||using-5/VBG||scale-9/NN	appos||scale-9/NN||vas-11/NN	nn||scores-15/NNS||pain-14/NN	prep_for||scale-9/NN||scores-15/NNS	prep_at||using-5/VBG||rest-17/NN	prep_after||using-5/VBG||cough-20/NN	appos||cough-20/NN||consumption-22/NN	nsubjpass||noted-34/VBN||consumption-22/NN	prep_of||consumption-22/NN||fentanyl-24/NN	nn||score-27/NN||sedation-26/NN	prep_of||consumption-22/NN||score-27/NN	conj_and||fentanyl-24/NN||score-27/NN	det||effects-31/NNS||any-29/DT	nn||effects-31/NNS||side-30/NN	prep_of||consumption-22/NN||effects-31/NNS	conj_and||fentanyl-24/NN||effects-31/NNS	auxpass||noted-34/VBN||were-33/VBD	rcmod||consumption-22/NN||noted-34/VBN	det||period-40/NN||the-36/DT	num||period-40/NN||48-37/CD	nn||period-40/NN||h-38/NN	nn||period-40/NN||postoperative-39/NN	prep_over||noted-34/VBN||period-40/NN	pain-14||fentanyl-24||yes||the patients were evaluated using the visual analogue scale (vas) for pain scores at rest and after cough, consumption of fentanyl, sedation score and any side effects that were noted over the 48 h postoperative period.
nsubj||pathogen-12/NN||groupastreptococcus-1/NNS	dep||groupastreptococcus-1/NNS||gas-3/NN	amod||pyogenes-6/NNS||streptococcus-5/JJ	appos||gas-3/NN||pyogenes-6/NNS	cop||pathogen-12/NN||is-8/VBZ	det||pathogen-12/NN||a-9/DT	amod||pathogen-12/NN||gram-positive-10/JJ	amod||pathogen-12/NN||human-11/JJ	root||ROOT-0/null||pathogen-12/NN	amod||pathogen-12/NN||responsible-13/JJ	det||variety-17/NN||a-15/DT	amod||variety-17/NN||diverse-16/JJ	prep_for||responsible-13/JJ||variety-17/NN	prep_of||pathogen-12/NN||diseases-19/NNS	prep_including||pathogen-12/NN||pharyngitis-22/NNS	nn||infections-25/NNS||skin-24/NN	prep_including||pathogen-12/NN||infections-25/NNS	conj_and||pharyngitis-22/NNS||infections-25/NNS	amod||necrotizingfasciitis-28/NNS||invasive-27/JJ	prep_including||pathogen-12/NN||necrotizingfasciitis-28/NNS	conj_and||pharyngitis-22/NNS||necrotizingfasciitis-28/NNS	amod||sequelae-31/NN||autoimmune-30/JJ	prep_including||pathogen-12/NN||sequelae-31/NN	conj_and||pharyngitis-22/NNS||sequelae-31/NN	necrotizingfasciitis-28||groupastreptococcus-1||no||groupastreptococcus (gas, streptococcus pyogenes ) is a gram-positive human pathogen responsible for a diverse variety of diseases, including pharyngitis, skin infections, invasive necrotizingfasciitis and autoimmune sequelae.
det||phenomenon-2/NN||another-1/DT	nsubj||association-5/NN||phenomenon-2/NN	cop||association-5/NN||is-3/VBZ	det||association-5/NN||the-4/DT	root||ROOT-0/null||association-5/NN	nn||tags-8/NNS||skin-7/NN	prep_of||association-5/NN||tags-8/NNS	amod||patients-11/NNS||obese-10/JJ	prep_in||tags-8/NNS||patients-11/NNS	nsubjpass||explained-17/VBN||patients-11/NNS	aux||explained-17/VBN||may-14/MD	advmod||explained-17/VBN||also-15/RB	auxpass||explained-17/VBN||be-16/VB	rcmod||patients-11/NNS||explained-17/VBN	det||interplay-20/NN||the-19/DT	agent||explained-17/VBN||interplay-20/NN	nn||steroids-23/NNS||sex-22/NN	prep_of||interplay-20/NN||steroids-23/NNS	poss||receptors-26/NNS||their-25/PRP$	agent||explained-17/VBN||receptors-26/NNS	conj_and||interplay-20/NN||receptors-26/NNS	nn||tags-29/NNS||skin-28/NN	prep_in||receptors-26/NNS||tags-29/NNS	steroids-23||obese-10||no_rel||another phenomenon is the association of skin tags in obese patients, which may also be explained by the interplay of sex steroids and their receptors in skin tags.
nsubj||test-15/VBP||rhinoconjunctivitis-1/NNS	amod||symptoms-4/NNS||asthma-like-3/JJ	conj_and||rhinoconjunctivitis-1/NNS||symptoms-4/NNS	nsubj||test-15/VBP||symptoms-4/NNS	conj_and||rhinoconjunctivitis-1/NNS||fev1-6/NNS	nsubj||test-15/VBP||fev1-6/NNS	amod||challenge-11/NN||ar-8/JJ	amod||challenge-11/NN||post-methacholine-9/JJ	amod||challenge-11/NN||bronchial-10/JJ	conj_and||rhinoconjunctivitis-1/NNS||challenge-11/NN	nsubj||test-15/VBP||challenge-11/NN	appos||rhinoconjunctivitis-1/NNS||mbc-13/NN	root||ROOT-0/null||test-15/VBP	nn||measurements-19/NNS||results-16/NNS	conj_and||measurements-19/NNS||feno-18/NN	nsubjpass||investigated-24/VBN||feno-18/NN	nsubjpass||investigated-24/VBN||measurements-19/NNS	conj_and||measurements-19/NNS||ep-21/NN	nsubjpass||investigated-24/VBN||ep-21/NN	auxpass||investigated-24/VBN||were-22/VBD	advmod||investigated-24/VBN||all-23/RB	ccomp||test-15/VBP||investigated-24/VBN	amod||bakers-27/NNS||apprentice-26/JJ	prep_in||investigated-24/VBN||bakers-27/NNS	prep_in||investigated-24/VBN||pastry-makers-29/NNS	conj_and||bakers-27/NNS||pastry-makers-29/NNS	prep_in||investigated-24/VBN||hairdressers-31/NNS	conj_and||bakers-27/NNS||hairdressers-31/NNS	neg||suffering-33/VBG||not-32/RB	vmod||bakers-27/NNS||suffering-33/VBG	prep_from||suffering-33/VBG||asthma-35/NN	methacholine--1||ar-8||no_rel||rhinoconjunctivitis, asthma-like symptoms, fev1 and ar post-methacholine bronchial challenge (mbc) test results, feno measurements and ep were all investigated in apprentice bakers, pastry-makers and hairdressers not suffering from asthma.
nsubj||remains-2/VBZ||it-1/PRP	root||ROOT-0/null||remains-2/VBZ	acomp||remains-2/VBZ||unclear-3/JJ	nsubj||determines-5/VBZ||what-4/WP	nsubj||particles-20/VBZ||what-4/WP	ccomp||unclear-3/JJ||determines-5/VBZ	det||localization-8/NN||the-6/DT	nn||localization-8/NN||subcellular-7/NN	dobj||determines-5/VBZ||localization-8/NN	amod||protein-15/NN||hepatitisbvirus-10/JJ	nn||protein-15/NN||hbv-12/NN	amod||protein-15/NN||core-14/JJ	prep_of||localization-8/NN||protein-15/NN	appos||protein-15/NN||hbc-17/NN	ccomp||unclear-3/JJ||particles-20/VBZ	conj_and||determines-5/VBZ||particles-20/VBZ	hbv-12||hepatitisbvirus-10||no||it remains unclear what determines the subcellular localization of hepatitisbvirus (hbv) core protein (hbc) and particles.
nsubj||likely-15/JJ||patients-1/NNS	nsubjpass||infected-18/VBN||patients-1/NNS	nn||bacteremia-4/NN||mrsa-3/NN	prep_with||patients-1/NNS||bacteremia-4/NN	det||icu-7/NN||the-6/DT	prep_in||bacteremia-4/NN||icu-7/NN	nsubj||had-10/VBD||who-9/WP	prep_with||patients-1/NNS||had-10/VBD	conj_or||bacteremia-4/NN||had-10/VBD	amod||hospitalization-12/NN||prolonged-11/VBN	dobj||had-10/VBD||hospitalization-12/NN	cop||likely-15/JJ||were-13/VBD	advmod||likely-15/JJ||more-14/RBR	root||ROOT-0/null||likely-15/JJ	aux||infected-18/VBN||to-16/TO	auxpass||infected-18/VBN||be-17/VB	xcomp||likely-15/JJ||infected-18/VBN	amod||strains-21/NNS||s.aureus-20/JJ	prep_with||infected-18/VBN||strains-21/NNS	amod||mics-25/NNS||high-23/JJ	nn||mics-25/NNS||vancomycin-24/NN	prep_with||infected-18/VBN||mics-25/NNS	mrsa-3||s.aureus-20||no||patients with mrsa bacteremia in the icu or who had prolonged hospitalization were more likely to be infected with s.aureus strains with high vancomycin mics .
nsubjpass||studied-4/VBN||liraglutide-1/NN	nsubjpass||studied-4/VBN||liraglutide-1/NN	aux||studied-4/VBN||has-2/VBZ	auxpass||studied-4/VBN||been-3/VBN	root||ROOT-0/null||studied-4/VBN	conj_and||studied-4/VBN||studied-4/VBN	prep_as||studied-4/VBN||monotherapy-6/NN	prep_in||studied-4/VBN||combination-9/NN	prep_with||studied-4/VBN||metformin-11/NN	prep_with||studied-4/VBN||glimepiride-13/NN	conj_and||metformin-11/NN||glimepiride-13/NN	prep_with||studied-4/VBN||rosiglitazone-16/NN	conj_and||metformin-11/NN||rosiglitazone-16/NN	det||treatment-19/NN||the-18/DT	prep_for||metformin-11/NN||treatment-19/NN	prep_of||treatment-19/NN||type2diabetes-21/CD	type2diabetes-21||metformin-11||yes||liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type2diabetes.
nn||studies-3/NNS||lipid-1/NN	nn||studies-3/NNS||metabolism-2/NN	nsubjpass||started-8/VBN||studies-3/NNS	nsubjpass||concentrated-18/VBN||studies-3/NNS	prep_in||studies-3/NNS||psoriasis-5/NNS	aux||started-8/VBN||have-6/VBP	auxpass||started-8/VBN||been-7/VBN	root||ROOT-0/null||started-8/VBN	det||beginning-11/NN||the-10/DT	prep_at||started-8/VBN||beginning-11/NN	det||century-15/NN||the-13/DT	amod||century-15/NN||20th-14/JJ	prep_of||beginning-11/NN||century-15/NN	auxpass||concentrated-18/VBN||are-17/VBP	conj_and||started-8/VBN||concentrated-18/VBN	nn||lipids-22/NNS||skin-20/NN	nn||lipids-22/NNS||surface-21/NN	prep_on||concentrated-18/VBN||lipids-22/NNS	nn||lipids-26/NNS||stratum-24/NN	nn||lipids-26/NNS||corneum-25/NN	appos||lipids-22/NNS||lipids-26/NNS	nn||phospholipids-29/NNS||epidermal-28/NN	appos||lipids-22/NNS||phospholipids-29/NNS	conj_and||lipids-26/NNS||phospholipids-29/NNS	nn||lipids-32/NNS||serum-31/NN	appos||lipids-22/NNS||lipids-32/NNS	amod||lipoproteins-36/NNS||dermal-34/JJ	nn||lipoproteins-36/NNS||low-density-35/NN	appos||lipids-22/NNS||lipoproteins-36/NNS	det||skin-40/NN||the-38/DT	amod||skin-40/NN||psoriatic-39/JJ	prep_in||lipoproteins-36/NNS||skin-40/NN	nn||metabolism-43/NN||lipid-42/NN	prep_in||lipoproteins-36/NNS||metabolism-43/NN	conj_and||skin-40/NN||metabolism-43/NN	amod||stress-46/NN||oxidative-45/JJ	prep_in||lipoproteins-36/NNS||stress-46/NN	conj_and||skin-40/NN||stress-46/NN	prep_in||lipoproteins-36/NNS||correlations-48/NNS	conj_and||skin-40/NN||correlations-48/NNS	amod||parameters-51/NNS||inflammatory-50/JJ	prep_between||lipoproteins-36/NNS||parameters-51/NNS	nn||parameters-54/NNS||lipid-53/NN	appos||lipids-22/NNS||parameters-54/NNS	amod||symptoms-57/NNS||clinical-56/JJ	prep_on||concentrated-18/VBN||symptoms-57/NNS	conj_and||lipids-22/NNS||symptoms-57/NNS	det||disease-60/NN||the-59/DT	prep_of||symptoms-57/NNS||disease-60/NN	psoriasis-5||lipid-53||no_rel||lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||formoterol--1||no||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||implemented-11/VBN||treatment-3/NN	prep_with||treatment-3/NN||sulphadoxine-pyrimethamine-5/NN	appos||treatment-3/NN||iptp-sp-7/NN	aux||implemented-11/VBN||is-9/VBZ	auxpass||implemented-11/VBN||being-10/VBG	root||ROOT-0/null||implemented-11/VBN	advmod||malaria-14/JJ||most-13/RBS	amod||countries-16/NNS||malaria-14/JJ	amod||countries-16/NNS||endemic-15/JJ	prep_in||implemented-11/VBN||countries-16/NNS	det||regimen-21/NN||a-18/DT	amod||regimen-21/NN||standard-19/JJ	amod||regimen-21/NN||two-doses-20/JJ	prep_as||countries-16/NNS||regimen-21/NN	mark||reduces-24/VBZ||as-22/IN	nsubj||reduces-24/VBZ||it-23/PRP	advcl||implemented-11/VBN||reduces-24/VBZ	det||risk-26/NN||the-25/DT	dobj||reduces-24/VBZ||risk-26/NN	amod||weight-30/NN||low-28/JJ	nn||weight-30/NN||birth-29/NN	prep_of||risk-26/NN||weight-30/NN	appos||weight-30/NN||lbw-32/NN	det||prevalence-36/NN||the-35/DT	dobj||reduces-24/VBZ||prevalence-36/NN	conj_and||risk-26/NN||prevalence-36/NN	amod||anaemia-39/NN||maternal-38/JJ	prep_of||prevalence-36/NN||anaemia-39/NN	malaria-14||pyrimethamine--1||no||intermittent preventive treatment with sulphadoxine-pyrimethamine (iptp-sp) is being implemented in most malaria endemic countries as a standard two-doses regimen as it reduces the risk of low birth weight (lbw) and the prevalence of maternal anaemia.
amod||meta-analysis-2/NNS||prospective-1/JJ	root||ROOT-0/null||meta-analysis-2/NNS	amod||trials-6/NNS||randomized-4/JJ	amod||trials-6/NNS||clinical-5/JJ	prep_of||meta-analysis-2/NNS||trials-6/NNS	nsubj||evaluated-11/VBN||trials-6/NNS	appos||trials-6/NNS||rcts-8/NNS	rcmod||trials-6/NNS||evaluated-11/VBN	det||effectiveness-13/NN||the-12/DT	dobj||evaluated-11/VBN||effectiveness-13/NN	amod||chemoprophylaxis-16/NNS||isoniazid-15/JJ	prep_of||effectiveness-13/NN||chemoprophylaxis-16/NNS	prep_versus||chemoprophylaxis-16/NNS||placebo-18/NN	prepc_for||evaluated-11/VBN||preventing-20/VBG	det||incidence-22/NN||the-21/DT	dobj||preventing-20/VBG||incidence-22/NN	nn||disease-25/NN||tuberculosis-24/NNP	prep_of||incidence-22/NN||disease-25/NN	prep_among||preventing-20/VBG||humanimmunodeficiencyvirus-27/NNS	appos||humanimmunodeficiencyvirus-27/NNS||hiv-29/NN	amod||individuals-33/NNS||positive-32/JJ	nsubj||testing-34/VBG||individuals-33/NNS	dep||meta-analysis-2/NNS||testing-34/VBG	amod||derivative-37/NN||purified-35/JJ	nn||derivative-37/NN||protein-36/NN	nsubj||negative-38/JJ||derivative-37/NN	xcomp||testing-34/VBG||negative-38/JJ	tuberculosis-24||isoniazid-15||yes||prospective meta-analysis of randomized clinical trials (rcts) that evaluated the effectiveness of isoniazid chemoprophylaxis versus placebo for preventing the incidence of tuberculosis disease among humanimmunodeficiencyvirus (hiv)-positive individuals testing purified protein derivative negative.
det||implementation-2/NN||the-1/DT	root||ROOT-0/null||implementation-2/NN	advmod||active-5/JJ||highly-4/RB	amod||therapy-7/NN||active-5/JJ	amod||therapy-7/NN||antiretroviral-6/JJ	prep_of||implementation-2/NN||therapy-7/NN	appos||therapy-7/NN||haart-9/NN	amod||results-14/NNS||hiv-positive-12/JJ	nn||results-14/NNS||patients-13/NNS	prep_among||implementation-2/NN||results-14/NNS	amod||reconstitution-17/NN||immune-16/JJ	prep_in||results-14/NNS||reconstitution-17/NN	amod||progression-20/NN||slower-19/JJR	prep_among||implementation-2/NN||progression-20/NN	conj_and||results-14/NNS||progression-20/NN	prep_of||progression-20/NN||hivdisease-22/NN	det||decrease-26/NN||a-25/DT	prep_among||implementation-2/NN||decrease-26/NN	conj_and||results-14/NNS||decrease-26/NN	det||occurrence-29/NN||the-28/DT	prep_in||decrease-26/NN||occurrence-29/NN	amod||infections-32/NNS||opportunistic-31/JJ	prep_of||occurrence-29/NN||infections-32/NNS	hivdisease-22||hiv--1||no||the implementation of highly active antiretroviral therapy (haart) among hiv-positive patients results in immune reconstitution, slower progression of hivdisease, and a decrease in the occurrence of opportunistic infections.
advmod||shown-8/VBN||recently-1/RB	amod||waves-5/NNS||astrocyte-2/JJ	nn||waves-5/NNS||intercellular-3/NN	nn||waves-5/NNS||calcium-4/NN	nsubjpass||shown-8/VBN||waves-5/NNS	nsubj||underlie-10/VB||waves-5/NNS	aux||shown-8/VBN||have-6/VBP	auxpass||shown-8/VBN||been-7/VBN	root||ROOT-0/null||shown-8/VBN	aux||underlie-10/VB||to-9/TO	xcomp||shown-8/VBN||underlie-10/VB	dobj||underlie-10/VB||seizures-11/NNS	amod||drugs-16/NNS||conventional-14/JJ	amod||drugs-16/NNS||antiepileptic-15/JJ	nsubjpass||shown-19/VBN||drugs-16/NNS	nsubj||attenuate-21/VB||drugs-16/NNS	aux||shown-19/VBN||have-17/VBP	auxpass||shown-19/VBN||been-18/VBN	conj_and||shown-8/VBN||shown-19/VBN	aux||attenuate-21/VB||to-20/TO	xcomp||shown-19/VBN||attenuate-21/VB	det||waves-24/NNS||these-22/DT	nn||waves-24/NNS||calcium-23/NN	dobj||attenuate-21/VB||waves-24/NNS	calcium-23||seizures-11||no_rel||recently astrocyte intercellular calcium waves have been shown to underlie seizures, and conventional antiepileptic drugs have been shown to attenuate these calcium waves.
nsubj||herpesvirus-17/NNS||varicella-zostervirus-1/NNS	nsubj||first-24/JJ||varicella-zostervirus-1/NNS	appos||varicella-zostervirus-1/NNS||vzv-3/NN	det||cause-7/NN||the-6/DT	appos||varicella-zostervirus-1/NNS||cause-7/NN	prep_of||cause-7/NN||chickenpox-9/NN	prep_of||cause-7/NN||zoster-11/NN	conj_and||chickenpox-9/NN||zoster-11/NN	cop||herpesvirus-17/NNS||was-13/VBD	det||herpesvirus-17/NNS||the-14/DT	amod||herpesvirus-17/NNS||first-15/JJ	amod||herpesvirus-17/NNS||human-16/JJ	root||ROOT-0/null||herpesvirus-17/NNS	aux||sequenced-20/VBN||to-18/TO	auxpass||sequenced-20/VBN||be-19/VB	vmod||herpesvirus-17/NNS||sequenced-20/VBN	advmod||sequenced-20/VBN||fully-21/RB	det||first-24/JJ||the-23/DT	conj_and||herpesvirus-17/NNS||first-24/JJ	prep_for||licensed-30/VBN||first-24/JJ	nsubjpass||licensed-30/VBN||vaccines-27/NNS	nsubjpass||used-33/VBN||vaccines-27/NNS	aux||licensed-30/VBN||have-28/VBP	auxpass||licensed-30/VBN||been-29/VBN	rcmod||first-24/JJ||licensed-30/VBN	advmod||used-33/VBN||widely-32/RB	rcmod||first-24/JJ||used-33/VBN	conj_and||licensed-30/VBN||used-33/VBN	zoster-11||vzv-3||no||varicella-zostervirus (vzv), the cause of chickenpox and zoster, was the first human herpesvirus to be sequenced fully and the first for which vaccines have been licensed and widely used.
det||nature-3/NN||the-1/DT	amod||nature-3/NN||staggered-2/JJ	nsubj||shifts-11/VBZ||nature-3/NN	det||events-6/NNS||these-5/DT	prep_of||nature-3/NN||events-6/NNS	vmod||events-6/NNS||induced-7/VBN	agent||induced-7/VBN||serotonin-9/NN	advmod||shifts-11/VBZ||slowly-10/RB	root||ROOT-0/null||shifts-11/VBZ	det||balance-13/NN||the-12/DT	dobj||shifts-11/VBZ||balance-13/NN	det||epithelium-16/NN||the-15/DT	prep_in||balance-13/NN||epithelium-16/NN	prep_from||shifts-11/VBZ||reversible-18/JJ	aux||irreversible-20/VB||to-19/TO	vmod||shifts-11/VBZ||irreversible-20/VB	serotonin-9||staggered-2||no_rel||the staggered nature of these events induced by serotonin slowly shifts the balance in the epithelium from reversible to irreversible.
nsubjpass||induced-3/VBN||coagulopathy-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	num||pigs-7/NNS||18-5/CD	amod||pigs-7/NNS||anaesthetized-6/JJ	prep_in||induced-3/VBN||pigs-7/NNS	num||â-10/NN||32-9/CD	nsubj||±-11/VBZ||â-10/NN	parataxis||induced-3/VBN||±-11/VBZ	num||weight-15/NN||1.6-12/CD	nn||weight-15/NN||kg-13/NN	nn||weight-15/NN||body-14/NN	dobj||±-11/VBZ||weight-15/NN	agent||induced-3/VBN||replacing-18/VBG	num||%-20/NN||80-19/CD	dobj||replacing-18/VBG||%-20/NN	nn||volume-23/NN||blood-22/NN	prep_of||%-20/NN||volume-23/NN	amod||.4-27/CD||hydroxyethylstarch-25/JJ	number||.4-27/CD||130/0-26/CD	prep_with||replacing-18/VBG||.4-27/CD	poss||solution-32/NN||ringer-29/NN	amod||solution-32/NN||lactated-31/JJ	prep_with||replacing-18/VBG||solution-32/NN	conj_and||.4-27/CD||solution-32/NN	prep_with||replacing-18/VBG||re-transfusion-35/NN	conj_and||.4-27/CD||re-transfusion-35/NN	prep_of||re-transfusion-35/NN||erythrocytes-37/NNS	coagulopathy-1||hydroxyethylstarch-25||no||coagulopathy was induced in 18 anaesthetized pigs (32 â± 1.6 kg body weight) by replacing 80% of blood volume with hydroxyethylstarch 130/0.4 and ringer's lactated solution, and re-transfusion of erythrocytes.
amod||hyperglycemia-2/NN||postprandial-1/JJ	nsubjpass||characterized-6/VBN||hyperglycemia-2/NN	prep_in||hyperglycemia-2/NN||type2diabetes-4/CD	auxpass||characterized-6/VBN||is-5/VBZ	root||ROOT-0/null||characterized-6/VBN	amod||secretion-10/NN||impaired-8/VBN	nn||secretion-10/NN||insulin-9/NN	agent||characterized-6/VBN||secretion-10/NN	agent||characterized-6/VBN||action-12/NN	conj_and||secretion-10/NN||action-12/NN	amod||effectiveness-16/NN||decreased-14/VBN	nn||effectiveness-16/NN||glucose-15/NN	appos||action-12/NN||effectiveness-16/NN	amod||suppression-19/NN||defective-18/JJ	appos||action-12/NN||suppression-19/NN	conj_and||effectiveness-16/NN||suppression-19/NN	nn||secretion-22/NN||glucagon-21/NN	prep_of||suppression-19/NN||secretion-22/NN	type2diabetes-4||insulin-9||yes||postprandial hyperglycemia in type2diabetes is characterized by impaired insulin secretion and action, decreased glucose effectiveness and defective suppression of glucagon secretion.
nsubj||pathogen-6/NN||hcmv-1/NNP	cop||pathogen-6/NN||is-2/VBZ	advmod||pathogen-6/NN||also-3/RB	det||pathogen-6/NN||an-4/DT	amod||pathogen-6/NN||opportunistic-5/JJ	root||ROOT-0/null||pathogen-6/NN	amod||individuals-9/NNS||immunocompromised-8/JJ	prep_in||pathogen-6/NN||individuals-9/NNS	prep_including||pathogen-6/NN||humanimmunodeficiencyvirus-12/NNS	appos||humanimmunodeficiencyvirus-12/NNS||hiv-14/NN	amod||patients-18/NNS||infected-17/JJ	conj_and||pathogen-6/NN||patients-18/NNS	prep_with||patients-18/NNS||aids-20/NNS	amod||organ-24/NN||solid-23/JJ	conj_and||pathogen-6/NN||organ-24/NN	amod||recipients-30/NNS||allogeneic-26/JJ	nn||recipients-30/NNS||stem-27/NN	nn||recipients-30/NNS||cell-28/NN	nn||recipients-30/NNS||transplantation-29/NN	conj_and||pathogen-6/NN||recipients-30/NNS	conj_and||organ-24/NN||recipients-30/NNS	aids-20||hiv-14||no||hcmv is also an opportunistic pathogen in immunocompromised individuals, including humanimmunodeficiencyvirus (hiv)- infected patients with aids, and solid organ and allogeneic stem cell transplantation recipients.
det||study-3/NN||this-2/DT	prep_in||is-13/VBZ||study-3/NN	det||prevalence-6/NN||the-5/DT	nsubj||is-13/VBZ||prevalence-6/NN	nn||abnormalities-9/NNS||glucose-8/NN	prep_of||prevalence-6/NN||abnormalities-9/NNS	amod||children-12/NNS||obese-11/JJ	prep_in||abnormalities-9/NNS||children-12/NNS	root||ROOT-0/null||is-13/VBZ	dep||than-15/IN||higher-14/JJR	advmod||is-13/VBZ||than-15/IN	amod||series-18/NN||other-17/JJ	prep_in||is-13/VBZ||series-18/NN	advmod||present-25/JJ||furthermore-20/RB	det||correlation-23/NN||a-22/DT	nsubj||present-25/JJ||correlation-23/NN	cop||present-25/JJ||is-24/VBZ	parataxis||is-13/VBZ||present-25/JJ	prep_between||present-25/JJ||markers-27/NNS	amod||inflammation-32/NN||systemic-29/JJ	conj_and||systemic-29/JJ||intestinal-31/JJ	amod||inflammation-32/NN||intestinal-31/JJ	prep_of||markers-27/NNS||inflammation-32/NN	nn||abnormalities-35/NNS||glucose-34/NN	prep_of||markers-27/NNS||abnormalities-35/NNS	conj_and||inflammation-32/NN||abnormalities-35/NNS	inflammation-32||glucose-34||no_rel||in this study, the prevalence of glucose abnormalities in obese children is higher than in other series; furthermore, a correlation is present between markers of systemic and intestinal inflammation and glucose abnormalities.
amod||infection-2/NN||human-1/JJ	nsubj||influenzavirus-5/VBZ||infection-2/NN	prep_with||infection-2/NN||swine-4/NNS	root||ROOT-0/null||influenzavirus-5/VBZ	auxpass||underrecognized-7/VBN||is-6/VBZ	advcl||influenzavirus-5/VBZ||underrecognized-7/VBN	prep_in||underrecognized-7/VBN||canada-9/NN	mark||adapt-16/VB||because-12/IN	amod||strains-14/NNS||viral-13/JJ	nsubj||adapt-16/VB||strains-14/NNS	nsubj||reassort-18/VB||strains-14/NNS	aux||adapt-16/VB||could-15/MD	advcl||influenzavirus-5/VBZ||adapt-16/VB	conj_and||underrecognized-7/VBN||adapt-16/VB	conj_and||underrecognized-7/VBN||reassort-18/VB	conj_or||adapt-16/VB||reassort-18/VB	det||form-21/NN||a-20/DT	prep_into||adapt-16/VB||form-21/NN	mark||considered-36/VBN||that-22/IN	nsubjpass||considered-36/VBN||results-23/NNS	amod||transmission-27/NN||efficient-25/JJ	amod||transmission-27/NN||human-to-human-26/JJ	prep_in||results-23/NNS||transmission-27/NN	amod||surveillance-30/NN||routine-29/JJ	appos||transmission-27/NN||surveillance-30/NN	amod||workers-33/NNS||swine-32/JJ	prep_of||surveillance-30/NN||workers-33/NNS	aux||considered-36/VBN||should-34/MD	auxpass||considered-36/VBN||be-35/VB	ccomp||adapt-16/VB||considered-36/VBN	prep_as||considered-36/VBN||part-38/NN	amod||preparedness-42/NN||pandemic-40/JJ	nn||preparedness-42/NN||influenza-41/NN	prep_of||part-38/NN||preparedness-42/NN	influenza-41||influenzavirus-5||no||human infection with swine influenzavirus is underrecognized in canada, and because viral strains could adapt or reassort into a form that results in efficient human-to-human transmission, routine surveillance of swine workers should be considered as part of pandemic influenza preparedness.
nsubj||knowledge-4/NN||it-1/PRP	cop||knowledge-4/NN||is-2/VBZ	amod||knowledge-4/NN||common-3/JJ	root||ROOT-0/null||knowledge-4/NN	mark||causes-8/VBZ||that-5/IN	nn||exposure-7/NN||asbestos-6/NN	nsubj||causes-8/VBZ||exposure-7/NN	dep||knowledge-4/NN||causes-8/VBZ	amod||diseases-10/NNS||asbestos-related-9/JJ	dobj||causes-8/VBZ||diseases-10/NNS	prep_such_as||diseases-10/NNS||asbestosis-13/NNS	nn||cancer-16/NN||lung-15/NN	prep_such_as||diseases-10/NNS||cancer-16/NN	conj_and||asbestosis-13/NNS||cancer-16/NN	amod||mesothelioma-19/NN||malignant-18/JJ	prep_such_as||diseases-10/NNS||mesothelioma-19/NN	conj_and||asbestosis-13/NNS||mesothelioma-19/NN	appos||knowledge-4/NN||mm-21/NN	neg||only-24/RB||not-23/RB	dep||knowledge-4/NN||only-24/RB	dep||only-24/RB||in-25/IN	conj||knowledge-4/NN||people-26/NNS	nsubj||handled-29/VBN||people-26/NNS	aux||handled-29/VBN||have-28/VBP	rcmod||people-26/NNS||handled-29/VBN	dobj||handled-29/VBN||asbestos-30/NN	det||environment-34/NN||the-32/DT	nn||environment-34/NN||work-33/NN	prep_in||handled-29/VBN||environment-34/NN	cc||in-38/IN||but-36/CC	dep||in-38/IN||also-37/RB	dep||handled-29/VBN||in-38/IN	nsubj||living-40/VBG||residents-39/NNS	pcomp||in-38/IN||living-40/VBG	amod||factories-42/NNS||near-41/JJ	dobj||living-40/VBG||factories-42/NNS	mark||handle-44/VBP||that-43/IN	ccomp||handled-29/VBN||handle-44/VBP	dobj||handle-44/VBP||asbestos-45/NN	asbestosis-13||asbestos-45||no||it is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, lung cancer and malignant mesothelioma (mm) not only in people who have handled asbestos in the work environment, but also in residents living near factories that handle asbestos.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	amod||levels-5/NNS||serum-3/JJ	amod||levels-5/NNS||il-33-4/JJ	dobj||evaluate-2/VB||levels-5/NNS	det||group-8/NN||a-7/DT	prep_in||evaluate-2/VB||group-8/NN	prep_of||group-8/NN||patients-10/NNS	amod||1b-17/NN||chronichepatitisc-12/JJ	nn||1b-17/NN||chc-14/NN	amod||1b-17/NN||genotype-16/JJ	prep_with||patients-10/NNS||1b-17/NN	prep_at||1b-17/NN||enrolment-19/NN	cc||evaluate-2/VB||and-20/CC	dep||evaluate-2/VB||after-21/IN	det||course-23/NN||a-22/DT	pobj||after-21/IN||course-23/NN	prep_of||course-23/NN||pegylated-25/NN	appos||pegylated-25/NN||peg-27/NNP	dep||pegylated-25/NN||ifn-30/NNP	dep||pegylated-25/NN||ribavirin-32/NNP	conj_plus||ifn-30/NNP||ribavirin-32/NNP	chronichepatitisc-12||ifn-30||yes||to evaluate serum il-33 levels in a group of patients with chronichepatitisc (chc) genotype 1b at enrolment and after a course of pegylated (peg)-ifn plus ribavirin.
det||protease-3/NN||the-1/DT	amod||protease-3/NN||3c-like-2/JJ	nsubjpass||required-10/VBN||protease-3/NN	appos||protease-3/NN||3clpro-5/NNP	prep_of||protease-3/NN||severeacuterespiratorysyndrome-coronavirus-8/NNS	auxpass||required-10/VBN||is-9/VBZ	root||ROOT-0/null||required-10/VBN	prepc_for||required-10/VBN||autoprocessing-12/VBG	det||polyprotein-15/NN||the-14/DT	prep_of||autoprocessing-12/VBG||polyprotein-15/NN	cop||target-21/NN||is-18/VBZ	det||target-21/NN||a-19/DT	amod||target-21/NN||potential-20/JJ	conj_and||required-10/VBN||target-21/NN	prepc_for||target-21/NN||treating-23/VBG	dobj||treating-23/VBG||coronaviralinfection-24/NN	severeacuterespiratorysyndrome--1||coronavirus--1||no||the 3c-like protease (3clpro) of severeacuterespiratorysyndrome-coronavirus is required for autoprocessing of the polyprotein, and is a potential target for treating coronaviralinfection.
amod||methods-2/NNS||various-1/JJ	nsubjpass||used-5/VBN||methods-2/NNS	nsubj||minimize-7/VB||methods-2/NNS	aux||used-5/VBN||have-3/VBP	auxpass||used-5/VBN||been-4/VBN	root||ROOT-0/null||used-5/VBN	aux||minimize-7/VB||to-6/TO	xcomp||used-5/VBN||minimize-7/VB	det||incidence-9/NN||the-8/DT	dobj||minimize-7/VB||incidence-9/NN	dobj||minimize-7/VB||severity-11/NN	conj_and||incidence-9/NN||severity-11/NN	prep_of||incidence-9/NN||pain-13/NN	prep_on||minimize-7/VB||injection-15/NN	nn||propofol-19/NN||lipid-17/NN	nn||propofol-19/NN||emulsion-18/NN	prep_of||injection-15/NN||propofol-19/NN	pain-13||propofol-19||yes||various methods have been used to minimize the incidence and severity of pain on injection of lipid emulsion propofol.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	amod||reductase-10/NN||polyol-6/JJ	nn||reductase-10/NN||pathway-7/NN	nn||reductase-10/NN||enzymes-8/NNS	nn||reductase-10/NN||aldose-9/NN	prep_of||role-4/NN||reductase-10/NN	appos||reductase-10/NN||ar-12/NN	amod||dehydrogenase-16/NN||sorbitol-15/JJ	prep_of||role-4/NN||dehydrogenase-16/NN	conj_and||reductase-10/NN||dehydrogenase-16/NN	appos||reductase-10/NN||sdh-18/NN	prepc_in||investigated-2/VBD||mediating-21/VBG	dobj||mediating-21/VBG||injury-22/NN	amod||ischemia-reperfusion-25/JJ||due-23/JJ	dep||ischemia-reperfusion-25/JJ||to-24/TO	amod||injury-22/NN||ischemia-reperfusion-25/JJ	appos||injury-22/NN||ir-27/NN	amod||hearts-35/NNS||type-30/NN	number||type-30/NN||2-31/CD	amod||hearts-35/NNS||diabetic-32/JJ	amod||hearts-35/NNS||bbz-33/JJ	nn||hearts-35/NNS||rat-34/NN	prep_in||mediating-21/VBG||hearts-35/NNS	ar-12||sorbitol-15||no_rel||we investigated the role of polyol pathway enzymes aldose reductase (ar) and sorbitol dehydrogenase (sdh) in mediating injury due to ischemia-reperfusion (ir) in type 2 diabetic bbz rat hearts.
advmod||cultured-2/VBD||when-1/WRB	advcl||showed-19/VBD||cultured-2/VBD	nn||selenium-7/NN||insulin-4/NN	dep||selenium-7/NN||transferrin-6/NN	prep_in||cultured-2/VBD||selenium-7/NN	nn||media-10/NNS||fibronectin-9/NN	prep_in||cultured-2/VBD||media-10/NNS	conj_and||selenium-7/NN||media-10/NNS	amod||factors-15/NNS||basic-12/JJ	nn||factors-15/NNS||fibroblast-13/NN	nn||factors-15/NNS||growth-14/NN	prep_with||cultured-2/VBD||factors-15/NNS	nn||cells-18/NNS||tumour-17/NN	nsubj||showed-19/VBD||cells-18/NNS	nsubj||phenotypes-23/VBZ||cells-18/NNS	root||ROOT-0/null||showed-19/VBD	amod||morphology-21/NN||neuronal-20/JJ	dobj||showed-19/VBD||morphology-21/NN	conj_and||showed-19/VBD||phenotypes-23/VBZ	insulin-4||tumour-17||no_rel||when cultured in insulin, transferrin selenium and fibronectin media with basic fibroblast growth factors, tumour cells showed neuronal morphology and phenotypes.
det||relationship-2/NN||the-1/DT	nsubjpass||investigated-21/VBN||relationship-2/NN	amod||hbp-5/NN||on-treatment-4/JJ	prep_between||relationship-2/NN||hbp-5/NN	vmod||relationship-2/NN||measured-7/VBN	advmod||measured-7/VBN||twice-8/RB	det||morning-11/NN||the-10/DT	prep_in||measured-7/VBN||morning-11/NN	prep_in||measured-7/VBN||twice-13/RB	advmod||morning-11/NN||twice-13/RB	conj_and||morning-11/NN||twice-13/RB	prep_at||measured-7/VBN||bedtime-15/JJ	nn||events-19/NNS||cv-18/NN	prep_at||measured-7/VBN||events-19/NNS	conj_and||bedtime-15/JJ||events-19/NNS	auxpass||investigated-21/VBN||was-20/VBD	root||ROOT-0/null||investigated-21/VBN	prt||investigated-21/VBN||in-22/RP	amod||patients-28/NNS||20â-24/JJ	num||patients-28/NNS||$-25/$	number||000-27/CD||‰-26/CD	num||$-25/$||000-27/CD	prep_over||investigated-21/VBN||patients-28/NNS	det||study-48/NN||the-30/DT	amod||study-48/NN||honest-31/JJ	nn||measurement-36/NN||home-33/NN	nn||measurement-36/NN||blood-34/NN	nn||measurement-36/NN||pressure-35/NN	dep||study-48/NN||measurement-36/NN	amod||naive-39/JJ||olmesartan-38/JJ	amod||patients-40/NNS||naive-39/JJ	prep_with||measurement-36/NN||patients-40/NNS	aux||establish-42/VB||to-41/TO	vmod||measurement-36/NN||establish-42/VB	amod||pressure-46/NN||standard-43/JJ	nn||pressure-46/NN||target-44/NN	nn||pressure-46/NN||blood-45/NN	dobj||establish-42/VB||pressure-46/NN	prep_in||investigated-21/VBN||study-48/NN	det||study-55/NN||a-50/DT	amod||study-55/NN||prospective-51/JJ	amod||study-55/NN||2-year-53/JJ	amod||study-55/NN||observational-54/JJ	appos||study-48/NN||study-55/NN	prep_of||study-55/NN||treatment-57/NN	det||blocker-62/NN||an-59/DT	nn||blocker-62/NN||angiotensin-60/NN	nn||blocker-62/NN||receptor-61/NN	prep_with||treatment-57/NN||blocker-62/NN	appos||study-48/NN||olmesartan-64/NN	appos||olmesartan-64/NN||olm-66/NN	amod||patients-72/NNS||olm-naive-70/JJ	nn||patients-72/NNS||hypertensive-71/NN	prep_in||olmesartan-64/NN||patients-72/NNS	hbp-5||olmesartan-64||yes||the relationship between on-treatment hbp, measured twice in the morning and twice at bedtime, and cv events was investigated in over 20â€‰000 patients in the honest (home blood pressure measurement with olmesartan naive patients to establish standard target blood pressure) study, a prospective, 2-year observational study of treatment with an angiotensin receptor blocker, olmesartan (olm), in olm-naive hypertensive patients.
nn||penicillin-2/NN||intramuscular-1/NN	nsubj||cures-20/VBZ||penicillin-2/NN	nsubj||prevents-23/VBZ||penicillin-2/NN	det||antibiotic-6/NN||an-4/DT	amod||antibiotic-6/NN||inexpensive-5/JJ	appos||penicillin-2/NN||antibiotic-6/NN	det||list-11/NN||the-8/DT	amod||list-11/NN||essential-9/JJ	nn||list-11/NN||medicine-10/NN	prep_on||antibiotic-6/NN||list-11/NN	prep_of||list-11/NN||nations-13/NNS	advmod||nations-13/NNS||all-14/DT	det||world-17/NN||the-16/DT	prep_over||nations-13/NNS||world-17/NN	advmod||cures-20/VBZ||effectively-19/RB	root||ROOT-0/null||cures-20/VBZ	dobj||cures-20/VBZ||infection-21/NN	conj_and||cures-20/VBZ||prevents-23/VBZ	dobj||prevents-23/VBZ||congenitalsyphilis-24/NNS	congenitalsyphilis-24||antibiotic-6||no_rel||intramuscular penicillin, an inexpensive antibiotic on the essential medicine list of nations all over the world, effectively cures infection and prevents congenitalsyphilis.
nsubj||taking-3/VBG||he-1/PRP	aux||taking-3/VBG||was-2/VBD	root||ROOT-0/null||taking-3/VBG	amod||mg-6/NN||atenolol-4/JJ	dep||atenolol-4/JJ||100-5/CD	dobj||taking-3/VBG||mg-6/NN	punct||day-8/NN||/-7/:	dep||mg-6/NN||day-8/NN	appos||day-8/NN||amlodipine-10/NN	num||amlodipine-10/NN||10-11/CD	advmod||taking-3/VBG||mg/day-12/RB	det||combination-16/NN||a-15/DT	nsubj||mg/hydrochlorothiazide-20/VBP||combination-16/NN	nsubj||experienced-25/VBD||combination-16/NN	amod||20-19/CD||lisinopril-18/JJ	prep_of||combination-16/NN||20-19/CD	conj_and||taking-3/VBG||mg/hydrochlorothiazide-20/VBP	num||mg-22/NN||12.5-21/CD	dobj||mg/hydrochlorothiazide-20/VBP||mg-22/NN	advmod||mg/hydrochlorothiazide-20/VBP||daily-23/RB	conj_and||taking-3/VBG||experienced-25/VBD	conj_but||mg/hydrochlorothiazide-20/VBP||experienced-25/VBD	amod||peaks-28/NNS||several-26/JJ	nn||peaks-28/NNS||hypertension-27/NN	dobj||experienced-25/VBD||peaks-28/NNS	dobj||experienced-25/VBD||hypotension-30/NN	conj_and||peaks-28/NNS||hypotension-30/NN	hypertension-27||hydrochlorothiazide--1||yes||he was taking atenolol 100 mg /day, amlodipine 10 mg/day, and a combination of lisinopril 20 mg/hydrochlorothiazide 12.5 mg daily but experienced several hypertension peaks and hypotension.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
amod||options-2/NNS||several-1/JJ	nsubjpass||licensed-10/VBN||options-2/NNS	det||treatment-5/NN||the-4/DT	prep_for||options-2/NNS||treatment-5/NN	prep_of||treatment-5/NN||hepatitisb-7/NN	aux||licensed-10/VBN||have-8/VBP	auxpass||licensed-10/VBN||been-9/VBN	root||ROOT-0/null||licensed-10/VBN	det||interferon-15/NN||the-12/DT	amod||interferon-15/NN||last-13/JJ	nn||interferon-15/NN||years-14/NNS	prep_in||licensed-10/VBN||interferon-15/NN	amod||interferon-18/NN||pegylated-17/JJ	prep_in||licensed-10/VBN||interferon-18/NN	conj_and||interferon-15/NN||interferon-18/NN	prep_in||licensed-10/VBN||lamivudine-20/NN	conj_and||interferon-15/NN||lamivudine-20/NN	prep_in||licensed-10/VBN||adefovir-22/NN	conj_and||interferon-15/NN||adefovir-22/NN	prep_in||licensed-10/VBN||entecavir-24/NN	conj_and||interferon-15/NN||entecavir-24/NN	prep_in||licensed-10/VBN||telbivudine-27/NN	conj_and||interferon-15/NN||telbivudine-27/NN	hepatitisb-7||adefovir-22||yes||several options for the treatment of hepatitisb have been licensed in the last years interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine.
nsubj||have-2/VBP||rotaviruses-1/NNS	root||ROOT-0/null||have-2/VBP	det||range-6/NN||a-3/DT	amod||range-6/NN||wide-4/JJ	nn||range-6/NN||host-5/NN	dobj||have-2/VBP||range-6/NN	vmod||range-6/NN||infecting-7/VBG	det||range-10/NN||a-8/DT	amod||range-10/NN||broad-9/JJ	dobj||infecting-7/VBG||range-10/NN	nn||species-13/NNS||animal-12/NN	prep_of||range-10/NN||species-13/NNS	advmod||known-18/VBN||however-15/RB	nsubjpass||known-18/VBN||little-16/RB	auxpass||known-18/VBN||is-17/VBZ	parataxis||have-2/VBP||known-18/VBN	prep_about||known-18/VBN||rotavirusinfection-20/NN	amod||animals-23/NNS||exotic-22/JJ	prep_in||rotavirusinfection-20/NN||animals-23/NNS	rotavirusinfection-20||rotaviruses-1||no||rotaviruses have a wide host range infecting a broad range of animal species, however little is known about rotavirusinfection in exotic animals.
amod||diets-4/NNS||atlantic-1/JJ	nn||diets-4/NNS||salmon-2/NN	nn||diets-4/NNS||fed-3/NN	nsubj||show-14/VBP||diets-4/NNS	amod||qualities-7/NNS||standard-6/JJ	prep_with||diets-4/NNS||qualities-7/NNS	nn||meal-10/NN||soybean-9/NN	prep_of||qualities-7/NNS||meal-10/NN	appos||diets-4/NNS||sbm-12/NN	root||ROOT-0/null||show-14/VBP	dobj||show-14/VBP||enteritis-15/NNS	det||intestine-19/NN||the-17/DT	amod||intestine-19/NN||distal-18/JJ	prep_of||enteritis-15/NNS||intestine-19/NN	amod||activity-24/NN||increased-23/VBN	dobj||show-14/VBP||activity-24/NN	conj_and||enteritis-15/NNS||activity-24/NN	prep_of||activity-24/NN||trypsin-26/NN	preconj||contents-30/NNS||both-28/DT	amod||contents-30/NNS||luminal-29/JJ	prep_in||activity-24/NN||contents-30/NNS	nn||tissue-33/NN||wall-32/NN	prep_in||activity-24/NN||tissue-33/NN	conj_and||contents-30/NNS||tissue-33/NN	enteritis-15||trypsin-26||no_rel||atlantic salmon fed diets with standard qualities of soybean meal (sbm) show enteritis of the distal intestine as well as increased activity of trypsin in both luminal contents and wall tissue.
nsubj||belong-15/VBP||endostatin-1/NN	conj_and||endostatin-1/NN||anastellin-3/NN	nsubj||belong-15/VBP||anastellin-3/NN	appos||endostatin-1/NN||fragments-5/NNS	nn||xviii-9/NNS||collagen-7/NN	nn||xviii-9/NNS||type-8/NN	prep_of||fragments-5/NNS||xviii-9/NNS	appos||endostatin-1/NN||fibronectin-11/NN	conj_and||fragments-5/NNS||fibronectin-11/NN	advmod||fibronectin-11/NN||respectively-13/RB	root||ROOT-0/null||belong-15/VBP	det||family-18/NN||a-17/DT	prep_to||belong-15/VBP||family-18/NN	amod||inhibitors-21/NNS||endogenous-20/JJ	prep_of||family-18/NN||inhibitors-21/NNS	prep_of||inhibitors-21/NNS||angiogenesis-23/NNS	nsubj||inhibit-25/VBP||angiogenesis-23/NNS	rcmod||angiogenesis-23/NNS||inhibit-25/VBP	nn||growth-27/NN||tumor-26/NN	dobj||inhibit-25/VBP||growth-27/NN	dobj||inhibit-25/VBP||metastasis-29/NNS	conj_and||growth-27/NN||metastasis-29/NNS	det||number-32/NN||a-31/DT	prep_in||growth-27/NN||number-32/NN	nn||models-35/NNS||mouse-34/NN	prep_of||number-32/NN||models-35/NNS	amod||cancer-38/NN||human-37/JJ	prep_of||models-35/NNS||cancer-38/NN	collagen-7||cancer-38||no_rel||endostatin and anastellin, fragments of collagen type xviii and fibronectin, respectively, belong to a family of endogenous inhibitors of angiogenesis which inhibit tumor growth and metastasis in a number of mouse models of human cancer.
nsubj||demonstrated-13/VBN||chondroitinsulfate-1/NN	conj_and||chondroitinsulfate-1/NN||diacereine-3/NN	nsubj||demonstrated-13/VBN||diacereine-3/NN	amod||sulfate-6/NN||glucosamine-5/JJ	conj_and||chondroitinsulfate-1/NN||sulfate-6/NN	nsubj||demonstrated-13/VBN||sulfate-6/NN	nn||unsaponifiables-9/NNS||avocado/soybean-8/NN	conj_and||chondroitinsulfate-1/NN||unsaponifiables-9/NNS	nsubj||demonstrated-13/VBN||unsaponifiables-9/NNS	conj_and||chondroitinsulfate-1/NN||hyaluronicacid-11/NN	nsubj||demonstrated-13/VBN||hyaluronicacid-11/NN	aux||demonstrated-13/VBN||have-12/VBP	root||ROOT-0/null||demonstrated-13/VBN	nn||reduction-15/NN||pain-14/NN	dobj||demonstrated-13/VBN||reduction-15/NN	amod||improvement-19/NN||physical-17/JJ	nn||improvement-19/NN||function-18/NN	dobj||demonstrated-13/VBN||improvement-19/NN	conj_and||reduction-15/NN||improvement-19/NN	advmod||low-22/JJ||very-21/RB	amod||toxicity-23/NN||low-22/JJ	prep_with||demonstrated-13/VBN||toxicity-23/NN	amod||high-28/JJ||moderate-26/JJ	dep||high-28/JJ||to-27/TO	amod||evidence-30/NN||high-28/JJ	nn||evidence-30/NN||quality-29/NN	prep_with||demonstrated-13/VBN||evidence-30/NN	pain-14||chondroitinsulfate-1||yes||chondroitinsulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronicacid have demonstrated pain reduction and physical function improvement with very low toxicity, with moderate to high quality evidence.
det||individuals-2/NNS||the-1/DT	nsubj||have-16/VBP||individuals-2/NNS	nsubj||identified-4/VBD||we-3/PRP	rcmod||individuals-2/NNS||identified-4/VBD	prepc_as||identified-4/VBD||having-6/VBG	amod||influence-10/NN||regional-7/JJ	conj_or||regional-7/JJ||international-9/JJ	amod||influence-10/NN||international-9/JJ	dobj||having-6/VBG||influence-10/NN	det||field-13/NN||the-12/DT	prep_in||influence-10/NN||field-13/NN	prep_of||field-13/NN||hiv/aids-15/NNS	root||ROOT-0/null||have-16/VBP	det||ability-18/NN||the-17/DT	dobj||have-16/VBP||ability-18/NN	prep_to||ability-18/NN||leverage-20/NN	det||environment-25/NN||an-21/DT	advmod||conducive-23/JJ||increasingly-22/RB	amod||environment-25/NN||conducive-23/JJ	nn||environment-25/NN||funding-24/NN	dep||leverage-20/NN||environment-25/NN	det||base-30/NN||a-27/DT	amod||base-30/NN||growing-28/VBG	nn||base-30/NN||evidence-29/NN	prep_to||ability-18/NN||base-30/NN	conj_and||leverage-20/NN||base-30/NN	aux||address-32/VB||to-31/TO	vmod||have-16/VBP||address-32/VB	det||challenges-39/NNS||the-33/DT	amod||challenges-39/NNS||policy-34/NN	conj_and||policy-34/NN||programmatic-36/JJ	amod||challenges-39/NNS||programmatic-36/JJ	conj_and||policy-34/NN||operational-38/JJ	amod||challenges-39/NNS||operational-38/JJ	dobj||address-32/VB||challenges-39/NNS	prepc_to||address-32/VB||integrating-41/VBG	nn||planning-43/NN||family-42/NN	dobj||integrating-41/VBG||planning-43/NN	prep_with||integrating-41/VBG||hiv/aids-45/NNS	aids--1||hiv--1||no||the individuals we identified as having regional or international influence in the field of hiv/aids have the ability to leverage an increasingly conducive funding environment and a growing evidence base to address the policy, programmatic and operational challenges to integrating family planning with hiv/aids.
nsubj||complication-9/NN||heparin-inducedthrombocytopenia-1/NN	dep||heparin-inducedthrombocytopenia-1/NN||hit-3/VBN	cop||complication-9/NN||is-5/VBZ	det||complication-9/NN||an-6/DT	amod||complication-9/NN||immunoglobulin-mediated-7/JJ	amod||complication-9/NN||serious-8/JJ	root||ROOT-0/null||complication-9/NN	nn||therapy-12/NN||heparin-11/NN	prep_of||complication-9/NN||therapy-12/NN	vmod||therapy-12/NN||characterized-13/VBN	nn||risk-18/NN||thrombocytopenia-15/NN	conj_and||thrombocytopenia-15/NN||high-17/JJ	nn||risk-18/NN||high-17/JJ	agent||characterized-13/VBN||risk-18/NN	amod||syndrome-26/NN||venous-20/JJ	conj_and||venous-20/JJ||arterialthrombosis-22/JJ	amod||syndrome-26/NN||arterialthrombosis-22/JJ	amod||syndrome-26/NN||hit-23/NN	conj_and||hit-23/NN||thrombosis-25/JJ	amod||syndrome-26/NN||thrombosis-25/JJ	prep_for||risk-18/NN||syndrome-26/NN	appos||syndrome-26/NN||hitts-28/NNS	heparin-inducedthrombocytopenia-1||heparin-11||no||heparin-inducedthrombocytopenia (hit) is an immunoglobulin-mediated serious complication of heparin therapy characterized by thrombocytopenia and high risk for venous and arterialthrombosis hit and thrombosis syndrome (hitts).
det||article-2/NN||this-1/DT	nsubj||describes-3/VBZ||article-2/NN	root||ROOT-0/null||describes-3/VBZ	det||design-5/NN||the-4/DT	dobj||describes-3/VBZ||design-5/NN	det||placebo-9/NN||a-7/DT	amod||placebo-9/NN||randomised-8/JJ	prep_of||design-5/NN||placebo-9/NN	vmod||placebo-9/NN||controlled-10/VBN	dobj||controlled-10/VBN||trial-11/NN	aux||evaluate-13/VB||to-12/TO	vmod||controlled-10/VBN||evaluate-13/VB	det||efficacy-15/NN||the-14/DT	dobj||evaluate-13/VB||efficacy-15/NN	amod||hyaluronan-18/NN||intra-articular-17/JJ	prep_of||efficacy-15/NN||hyaluronan-18/NN	nn||®-21/NNP||synviscâ-20/NNP	appos||hyaluronan-18/NN||®-21/NNP	aux||reduce-24/VB||to-23/TO	vmod||evaluate-13/VB||reduce-24/VB	dobj||reduce-24/VB||pain-25/NN	vmod||evaluate-13/VB||improve-27/VB	conj_and||reduce-24/VB||improve-27/VB	dobj||improve-27/VB||function-28/NN	prep_in||improve-27/VB||people-30/NNS	nn||limitus-33/NNS||hallux-32/NN	prep_with||people-30/NNS||limitus-33/NNS	pain-25||hyaluronan-18||yes||this article describes the design of a randomised placebo controlled trial to evaluate the efficacy of intra-articular hyaluronan (synviscâ®) to reduce pain and improve function in people with hallux limitus.
det||repeats-4/NNS||the-1/DT	amod||repeats-4/NNS||human-2/JJ	amod||repeats-4/NNS||leucine-rich-3/JJ	nsubjpass||identified-17/VBN||repeats-4/NNS	nn||domain-8/NN||wd-6/NN	nn||domain-8/NN||repeat-7/NN	conj_and||repeats-4/NNS||domain-8/NN	nsubjpass||identified-17/VBN||domain-8/NN	vmod||repeats-4/NNS||containing-9/VBG	dobj||containing-9/VBG||1-10/CD	dep||identified-17/VBN||lrwd1-12/NNP	nsubjpass||identified-17/VBN||gene-14/NN	auxpass||identified-17/VBN||was-15/VBD	advmod||identified-17/VBN||originally-16/RB	root||ROOT-0/null||identified-17/VBN	nn||microarray-20/NN||cdna-19/NN	agent||identified-17/VBN||microarray-20/NN	prep_as||identified-17/VBN||one-22/CD	det||genes-25/NNS||the-24/DT	prep_of||one-22/CD||genes-25/NNS	vmod||genes-25/NNS||down-regulated-26/VBN	det||tissues-30/NNS||the-28/DT	nn||tissues-30/NNS||testicular-29/NN	prep_in||down-regulated-26/VBN||tissues-30/NNS	prep_of||tissues-30/NNS||patients-32/NNS	amod||defects-36/NNS||severe-34/JJ	amod||defects-36/NNS||spermatogenic-35/JJ	prep_with||patients-32/NNS||defects-36/NNS	leucine--1||wd-6||no_rel||the human leucine-rich repeats and wd repeat domain containing 1 ( lrwd1 ) gene was originally identified by cdna microarray as one of the genes down-regulated in the testicular tissues of patients with severe spermatogenic defects.
prepc_compared_with||had-11/VBD||with-2/IN	nn||subjects-4/NNS||control-3/NN	pobj||had-11/VBD||subjects-4/NNS	amod||patients-7/NNS||type2diabetes-low-6/JJ	conj_and||subjects-4/NNS||patients-7/NNS	pobj||had-11/VBD||patients-7/NNS	amod||patients-10/NNS||type2diabetes-high-9/JJ	nsubj||had-11/VBD||patients-10/NNS	root||ROOT-0/null||had-11/VBD	det||perfusion-16/NN||the-12/DT	amod||perfusion-16/NN||lowest-13/JJS	amod||perfusion-16/NN||hepatic-14/JJ	amod||perfusion-16/NN||parenchymal-15/JJ	dobj||had-11/VBD||perfusion-16/NN	dep||perfusion-16/NN||p-18/VBN	dep||0.004-20/CD||=-19/SYM	ccomp||p-18/VBN||0.004-20/CD	amod||uptake-26/NN||insulin-stimulated-23/JJ	amod||uptake-26/NN||hepatic-24/JJ	nn||uptake-26/NN||glucose-25/NN	dobj||had-11/VBD||uptake-26/NN	conj_and||perfusion-16/NN||uptake-26/NN	dep||uptake-26/NN||p-28/VBN	dep||0.013-30/CD||=-29/SYM	ccomp||p-28/VBN||0.013-30/CD	insulin--1||type2diabetes--1||no_rel||compared with control subjects and type2diabetes-low patients, type2diabetes-high patients had the lowest hepatic parenchymal perfusion ( p = 0.004) and insulin-stimulated hepatic glucose uptake ( p = 0.013).
det||results-2/NNS||these-1/DT	nsubj||show-3/VBP||results-2/NNS	root||ROOT-0/null||show-3/VBP	mark||affects-6/VBZ||that-4/IN	nsubj||affects-6/VBZ||measlesvirus-5/NNS	nsubj||suggest-11/VBP||measlesvirus-5/NNS	ccomp||show-3/VBP||affects-6/VBZ	amod||homeostasis-9/NNS||regulatory-7/JJ	amod||homeostasis-9/NNS||t-cell-8/JJ	dobj||affects-6/VBZ||homeostasis-9/NNS	ccomp||show-3/VBP||suggest-11/VBP	conj_and||affects-6/VBZ||suggest-11/VBP	mark||plays-23/VBZ||that-12/IN	det||interplay-14/NN||an-13/DT	nsubj||plays-23/VBZ||interplay-14/NN	amod||responses-18/NNS||virus-specific-16/JJ	nn||responses-18/NNS||effector-17/NN	prep_between||interplay-14/NN||responses-18/NNS	amod||cells-22/NNS||regulatory-20/JJ	nn||cells-22/NNS||t-21/NN	prep_between||interplay-14/NN||cells-22/NNS	conj_and||responses-18/NNS||cells-22/NNS	ccomp||suggest-11/VBP||plays-23/VBZ	det||role-26/NN||an-24/DT	amod||role-26/NN||important-25/JJ	dobj||plays-23/VBZ||role-26/NN	amod||immunopathogenesis-29/NNS||measles-28/JJ	prep_in||role-26/NN||immunopathogenesis-29/NNS	measles-28||measlesvirus-5||no||these results show that measlesvirus affects regulatory t-cell homeostasis and suggest that an interplay between virus-specific effector responses and regulatory t cells plays an important role in measles immunopathogenesis.
nsubj||constructed-3/VBN||we-1/PRP	aux||constructed-3/VBN||have-2/VBP	dep||take-52/VB||constructed-3/VBN	det||model-5/NN||a-4/DT	dobj||constructed-3/VBN||model-5/NN	prep_of||model-5/NN||hivinfection-7/NN	mark||types-13/VBZ||that-8/IN	nsubj||types-13/VBZ||differentiates-9/NNS	nsubj||used-17/VBN||differentiates-9/NNS	det||hla-12/NN||these-11/DT	prep_between||differentiates-9/NNS||hla-12/NN	ccomp||constructed-3/VBN||types-13/VBZ	aux||used-17/VBN||have-16/VBP	ccomp||constructed-3/VBN||used-17/VBN	conj_and||types-13/VBZ||used-17/VBN	amod||estimates-19/NNS||reported-18/VBN	dobj||used-17/VBN||estimates-19/NNS	det||number-22/NN||the-21/DT	prep_of||estimates-19/NNS||number-22/NN	prep_of||number-22/NN||people-24/NNS	vmod||people-24/NNS||infected-25/VBN	prep_with||infected-25/VBN||hiv-27/NN	det||rates-31/NNS||the-29/DT	amod||rates-31/NNS||different-30/JJ	prep_with||infected-25/VBN||rates-31/NNS	conj_and||hiv-27/NN||rates-31/NNS	prep_of||rates-31/NNS||progression-33/NN	aux||acquiredimmunodeficiencysyndrome-35/VB||to-34/TO	xcomp||infected-25/VBN||acquiredimmunodeficiencysyndrome-35/VB	dobj||acquiredimmunodeficiencysyndrome-35/VB||aids-37/NNS	nsubj||provide-40/VB||aids-37/NNS	aux||provide-40/VB||to-39/TO	xcomp||acquiredimmunodeficiencysyndrome-35/VB||provide-40/VB	det||estimate-44/NN||a-41/DT	dep||bound-43/VBN||lower-42/JJR	amod||estimate-44/NN||bound-43/VBN	dobj||provide-40/VB||estimate-44/NN	det||length-47/NN||the-46/DT	prep_on||provide-40/VB||length-47/NN	prep_of||length-47/NN||time-49/NN	nsubj||take-52/VB||it-50/PRP	nsubj||impose-56/VB||it-50/PRP	aux||take-52/VB||would-51/MD	root||ROOT-0/null||take-52/VB	prep_for||take-52/VB||hiv-54/NN	aux||impose-56/VB||to-55/TO	xcomp||take-52/VB||impose-56/VB	amod||change-59/NN||major-57/JJ	amod||change-59/NN||genetic-58/JJ	dobj||impose-56/VB||change-59/NN	prep_in||impose-56/VB||humans-61/NNS	acquiredimmunodeficiencysyndrome-35||hiv-54||no||we have constructed a model of hivinfection that differentiates between these hla types, and have used reported estimates of the number of people infected with hiv and the different rates of progression to acquiredimmunodeficiencysyndrome (aids) to provide a lower bound estimate on the length of time it would take for hiv to impose major genetic change in humans.
prep_in||enhanced-7/VBD||summary-2/NN	nsubj||enhanced-7/VBD||c-4/SYM	conj_and||c-4/SYM||ecg-6/NN	nsubj||enhanced-7/VBD||ecg-6/NN	root||ROOT-0/null||enhanced-7/VBD	det||effect-10/NN||the-8/DT	amod||effect-10/NN||antibacterial-9/JJ	dobj||enhanced-7/VBD||effect-10/NN	nn||²-13/NNS||î-12/NN	prep_of||effect-10/NN||²-13/NNS	nn||antibiotics-16/NNS||lactam-15/NN	dep||effect-10/NN||antibiotics-16/NNS	prep_against||antibiotics-16/NNS||mrsa-18/NN	prep_in||enhanced-7/VBD||vitro-20/NN	prep_in||enhanced-7/VBD||in-22/IN	conj_and||vitro-20/NN||in-22/IN	pobj||in-22/IN||vivo-23/NN	nsubjpass||related-28/VBN||vivo-23/NN	aux||related-28/VBN||might-26/MD	auxpass||related-28/VBN||be-27/VB	rcmod||vivo-23/NN||related-28/VBN	det||accumulation-32/NN||the-30/DT	amod||accumulation-32/NN||increased-31/VBN	prep_to||related-28/VBN||accumulation-32/NN	prep_of||accumulation-32/NN||antibiotics-34/NNS	prep_within||antibiotics-34/NNS||mrsa-36/NN	prep_via||mrsa-36/NN||suppression-38/NN	amod||pumpsâ-42/NNS||important-40/JJ	nn||pumpsâ-42/NNS||efflux-41/NN	nn||expression-46/NN||pumpsâ-42/NNS	amod||expression-46/NN||$-43/$	dep||$-43/$||™-44/JJ	nn||expression-46/NN||gene-45/NN	prep_of||suppression-38/NN||expression-46/NN	mrsa-36||antibiotics-34||no_rel||in summary, c and ecg enhanced the antibacterial effect of î²-lactam antibiotics against mrsa in vitro and in vivo , which might be related to the increased accumulation of antibiotics within mrsa via suppression of important efflux pumpsâ€™ gene expression.
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||âˆ-17/JJ	dep||âˆ-17/JJ||’60-18/CD	num||min-21/NN||180-20/CD	prep_through||âˆ-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||âˆ-36/JJ	dep||âˆ-36/JJ||’30-37/CD	dep||âˆ-36/JJ||1-39/CD	conj_and||’30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||diazoxide-86||no||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from âˆ’60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at âˆ’30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
nsubj||drug-8/NN||ethambutol-1/NN	appos||ethambutol-1/NN||emb-3/NN	cop||drug-8/NN||is-5/VBZ	det||drug-8/NN||a-6/DT	amod||drug-8/NN||first-line-7/JJ	root||ROOT-0/null||drug-8/NN	det||treatment-11/NN||the-10/DT	prep_for||drug-8/NN||treatment-11/NN	prep_of||treatment-11/NN||tuberculosis-13/NNP	appos||tuberculosis-13/NNP||tb-15/NN	tuberculosis-13||ethambutol-1||yes||ethambutol (emb) is a first-line drug for the treatment of tuberculosis (tb).
prep_in||correlated-8/VBN||addition-2/NN	amod||concentration-5/NN||formate-4/JJ	nsubjpass||correlated-8/VBN||concentration-5/NN	nsubjpass||correlated-38/VBN||concentration-5/NN	auxpass||correlated-8/VBN||was-6/VBD	advmod||correlated-8/VBN||negatively-7/RB	root||ROOT-0/null||correlated-8/VBN	amod||pc20-11/NNS||methacholine-10/JJ	prep_with||correlated-8/VBN||pc20-11/NNS	num||0.39-21/NNS||râ-13/CD	amod||0.39-21/NNS||$-14/$	number||=-16/CD||š-15/CD	num||$-14/$||=-16/CD	amod||0.39-21/NNS||â-17/JJ	amod||0.39-21/NNS||$-18/$	dep||$-18/$||šâˆ-19/JJ	nsubj||asthmatics-32/VBZ||0.39-21/NNS	nn||â-27/NN||pâ-23/NN	amod||â-27/NN||$-24/$	dep||$-24/$||š-25/JJ	nn||â-27/NN||=-26/NNP	appos||0.39-21/NNS||â-27/NN	dep||â-27/NN||$-28/$	num||$-28/$||š0-29/CD	num||$-28/$||.002-30/CD	dep||pc20-11/NNS||asthmatics-32/VBZ	advmod||asthmatics-32/VBZ||only-33/RB	advmod||correlated-38/VBN||positively-37/RB	conj_and||correlated-8/VBN||correlated-38/VBN	det||nitrite-43/NN||the-40/DT	amod||nitrite-43/NN||no-derived-41/JJ	nn||nitrite-43/NN||ion-42/NN	prep_with||correlated-38/VBN||nitrite-43/NN	dep||nitrite-43/NN||râ-45/VBN	dobj||râ-45/VBN||$-46/$	number||=-48/CD||š-47/CD	num||$-46/$||=-48/CD	dep||râ-45/VBN||â-49/VB	dobj||â-49/VB||$-50/$	number||.46-52/CD||š0-51/CD	num||$-50/$||.46-52/CD	appos||$-50/$||p-54/NN	number||0.0001-56/CD||<-55/CD	dep||p-54/NN||0.0001-56/CD	amod||ige-64/NN||total-62/JJ	nn||ige-64/NN||serum-63/NN	prep_with||correlated-38/VBN||ige-64/NN	conj_and||nitrite-43/NN||ige-64/NN	dep||ige-64/NN||râ-66/VBN	num||â-70/NN||$-67/$	number||=-69/CD||š-68/CD	num||$-67/$||=-69/CD	dobj||râ-66/VBN||â-70/NN	nsubj||asthmatics-84/VBZ||$-71/$	num||$-71/$||š0-72/CD	num||$-71/$||.28-73/CD	nn||â-79/NN||pâ-75/NN	amod||â-79/NN||$-76/$	dep||$-76/$||š-77/JJ	nn||â-79/NN||=-78/NNP	appos||$-71/$||â-79/NN	dep||â-79/NN||$-80/$	num||$-80/$||š0-81/CD	num||$-80/$||.016-82/CD	rcmod||â-70/NN||asthmatics-84/VBZ	advmod||asthmatics-84/VBZ||only-85/RB	nitrite-43||asthmatics-84||no_rel||in addition, formate concentration was negatively correlated with methacholine pc20 (râ€š=â€šâˆ’0.39, pâ€š=â€š0.002, asthmatics only), and positively correlated with the no-derived ion nitrite (râ€š=â€š0.46, p<0.0001) as well as with total serum ige (râ€š=â€š0.28, pâ€š=â€š0.016, asthmatics only).
det||prevalence-3/NN||the-1/DT	amod||prevalence-3/NN||overall-2/JJ	nsubj||%-21/NN||prevalence-3/NN	prep_of||prevalence-3/NN||anaemia-5/NN	advmod||%-21/NN||irondeficiency-7/RB	amod||anaemia-10/NN||iron-deficiency-9/JJ	nsubj||%-21/NN||anaemia-10/NN	appos||anaemia-10/NN||deficiency-12/NN	amod||infestations-18/NNS||folicacid-14/JJ	conj_and||folicacid-14/JJ||parasitic-17/JJ	amod||infestations-18/NNS||parasitic-17/JJ	prep_of||deficiency-12/NN||infestations-18/NNS	cop||%-21/NN||was-19/VBD	num||%-21/NN||30.4-20/CD	root||ROOT-0/null||%-21/NN	num||%-24/NN||50.1-23/CD	conj_and||%-21/NN||%-24/NN	num||%-27/NN||18.1-26/CD	conj_and||%-21/NN||%-27/NN	num||%-30/NN||31.3-29/CD	conj_and||%-21/NN||%-30/NN	num||%-34/NN||13.7-33/CD	conj_and||%-21/NN||%-34/NN	advmod||%-21/NN||respectively-35/RB	irondeficiency-7||iron--1||yes||the overall prevalence of anaemia, irondeficiency, iron-deficiency anaemia, deficiency of folicacid, and parasitic infestations was 30.4%, 50.1%, 18.1%, 31.3%, and 13.7% respectively.
nsubjpass||analyzed-30/VBN||frequency-1/NN	conj_and||frequency-1/NN||intensity-3/NN	nsubjpass||analyzed-30/VBN||intensity-3/NN	amod||production-7/NN||intrathecal-5/JJ	nn||production-7/NN||antibody-6/NN	prep_of||frequency-1/NN||production-7/NN	prep_against||production-7/NN||ebv-9/NN	advmod||ebv-9/NN||as-10/RB	prepc_compared_to||ebv-9/NN||to-12/TO	nn||zoster-18/NN||measles-13/NN	dep||zoster-18/NN||rubella-15/NN	amod||zoster-18/NN||varicella-17/JJ	pobj||ebv-9/NN||zoster-18/NN	appos||zoster-18/NN||vzv-20/NN	amod||virus-25/NN||herpes-23/JJ	nn||virus-25/NN||simplex-24/NN	pobj||ebv-9/NN||virus-25/NN	conj_and||zoster-18/NN||virus-25/NN	appos||zoster-18/NN||hsv-27/NN	auxpass||analyzed-30/VBN||were-29/VBD	root||ROOT-0/null||analyzed-30/VBN	agent||analyzed-30/VBN||determination-32/NN	amod||indices-37/NNS||virus-specific-34/JJ	amod||indices-37/NNS||csf-to-serum-35/JJ	nn||indices-37/NNS||antibody-36/NN	prep_of||determination-32/NN||indices-37/NNS	appos||indices-37/NNS||ai-39/NNP	varicella-17||vzv-20||yes||frequency and intensity of intrathecal antibody production against ebv as compared to measles, rubella, varicella zoster (vzv) and herpes simplex virus (hsv) were analyzed by determination of virus-specific csf-to-serum antibody indices (ai).
amod||treatment-2/NN||adefovirdipivoxil-1/JJ	nsubj||improved-5/VBN||treatment-2/NN	aux||improved-5/VBN||has-3/VBZ	advmod||improved-5/VBN||significantly-4/RB	root||ROOT-0/null||improved-5/VBN	det||outcome-7/NN||the-6/DT	dobj||improved-5/VBN||outcome-7/NN	amod||infection-14/NN||chronichepatitisb-9/JJ	nn||infection-14/NN||virus-10/NN	appos||infection-14/NN||hbv-12/NN	prep_of||outcome-7/NN||infection-14/NN	hbv-12||adefovirdipivoxil-1||yes||adefovirdipivoxil treatment has significantly improved the outcome of chronichepatitisb virus (hbv) infection.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||effectiveness-6/NN||the-3/DT	amod||effectiveness-6/NN||overall-4/JJ	amod||effectiveness-6/NN||long-term-5/JJ	dobj||evaluate-2/VB||effectiveness-6/NN	prep_of||effectiveness-6/NN||aripiprazole-8/NN	prep_in||evaluate-2/VB||patients-10/NNS	prep_with||patients-10/NNS||schizophrenia-12/NN	det||setting-18/NN||a-14/DT	amod||setting-18/NN||general-15/JJ	amod||setting-18/NN||psychiatric-16/JJ	nn||setting-18/NN||practice-17/NN	prep_in||evaluate-2/VB||setting-18/NN	prep_in||setting-18/NN||taiwan-20/NN	schizophrenia-12||aripiprazole-8||yes||to evaluate the overall long-term effectiveness of aripiprazole in patients with schizophrenia in a general psychiatric practice setting in taiwan.
det||report-2/NN||this-1/DT	nsubj||describes-3/VBZ||report-2/NN	root||ROOT-0/null||describes-3/VBZ	det||efficacy-5/NN||the-4/DT	dobj||describes-3/VBZ||efficacy-5/NN	prep_of||efficacy-5/NN||sitagliptin-7/NN	num||patients-11/NNS||three-9/CD	amod||patients-11/NNS||japanese-10/JJ	prep_in||sitagliptin-7/NN||patients-11/NNS	nsubj||had-41/VBD||patients-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||91-year-old-14/JJ	nn||woman-16/NN||japanese-15/NN	dep||patients-11/NNS||woman-16/NN	prep_with||woman-16/NN||type1diabetes-18/CD	det||man-23/NN||a-20/DT	amod||man-23/NN||54-year-old-21/JJ	nn||man-23/NN||japanese-22/NN	dep||patients-11/NNS||man-23/NN	conj_and||woman-16/NN||man-23/NN	prep_with||man-23/NN||type2diabetes-25/CD	det||man-30/NN||a-27/DT	amod||man-30/NN||30-year-old-28/JJ	nn||man-30/NN||japanese-29/NN	conj_and||woman-16/NN||man-30/NN	conj_and||man-23/NN||man-30/NN	prep_with||man-30/NN||features-32/NNS	det||type-35/NN||both-34/DT	prep_of||features-32/NNS||type-35/NN	num||type-35/NN||1-36/CD	dep||patients-11/NNS||type2diabetes-38/NNS	conj_and||woman-16/NN||type2diabetes-38/NNS	rcmod||patients-11/NNS||had-41/VBD	neg||levels-46/NNS||no-42/DT	amod||levels-46/NNS||detectable-43/JJ	amod||levels-46/NNS||post-meal-44/JJ	amod||levels-46/NNS||c-peptide-45/JJ	dobj||had-41/VBD||levels-46/NNS	type2diabetes-38||sitagliptin-7||yes||this report describes the efficacy of sitagliptin in three japanese patients (a 91-year-old japanese woman with type1diabetes, a 54-year-old japanese man with type2diabetes and a 30-year-old japanese man with features of both type 1 and type2diabetes) who had no detectable post-meal c-peptide levels.
amod||gattii-2/NNS||cryptococcus-1/JJ	nsubj||cause-5/VBP||gattii-2/NNS	conj_and||gattii-2/NNS||c.neoformans-4/NNS	nsubj||cause-5/VBP||c.neoformans-4/NNS	root||ROOT-0/null||cause-5/VBP	dobj||cause-5/VBP||pulmonary-6/NNS	dobj||cause-5/VBP||systemiccryptococcosis-8/NNS	conj_and||pulmonary-6/NNS||systemiccryptococcosis-8/NNS	systemiccryptococcosis-8||cryptococcus-1||no||cryptococcus gattii and c.neoformans cause pulmonary and systemiccryptococcosis .
poss||aim-2/NN||our-1/PRP$	nsubj||is-3/VBZ||aim-2/NN	nsubj||define-5/VB||aim-2/NN	root||ROOT-0/null||is-3/VBZ	aux||define-5/VB||to-4/TO	xcomp||is-3/VBZ||define-5/VB	det||targets-8/NNS||the-6/DT	amod||targets-8/NNS||potential-7/JJ	dobj||define-5/VB||targets-8/NNS	nsubj||makes-11/VBZ||targets-8/NNS	rcmod||targets-8/NNS||makes-11/VBZ	amod||cells-16/NNS||drug-sensitive-12/JJ	amod||cells-16/NNS||mcf-7-13/JJ	nn||cells-16/NNS||breast-14/NN	nn||cells-16/NNS||cancer-15/NN	nsubj||turn-17/VBP||cells-16/NNS	nsubj||drug-resistant-19/VB||cells-16/NNS	ccomp||makes-11/VBZ||turn-17/VBP	aux||drug-resistant-19/VB||to-18/TO	xcomp||turn-17/VBP||drug-resistant-19/VB	det||development-24/NN||the-22/DT	amod||development-24/NN||anti-cancerdrug-23/JJ	prep_for||define-5/VB||development-24/NN	nn||cells-30/NNS||drug-26/NN	amod||breast-28/JJ||resistant-27/JJ	amod||cells-30/NNS||breast-28/JJ	nn||cells-30/NNS||cancer-29/NN	prep_against||development-24/NN||cells-30/NNS	cancer-29||cancerdrug--1||no_rel||our aim is to define the potential targets, that makes drug-sensitive mcf-7 breast cancer cells turn to drug-resistant, for the anti-cancerdrug development against drug resistant breast cancer cells.
nsubj||orphaned-3/VBN||hiv/aids-1/NNS	aux||orphaned-3/VBN||has-2/VBZ	root||ROOT-0/null||orphaned-3/VBN	number||million-5/CD||11.6-4/CD	num||children-6/NNS||million-5/CD	dobj||orphaned-3/VBN||children-6/NNS	amod||africa-9/NN||sub-saharan-8/JJ	prep_in||orphaned-3/VBN||africa-9/NN	aids--1||hiv--1||no||hiv/aids has orphaned 11.6 million children in sub-saharan africa.
det||sample-6/NN||any-1/DT	amod||sample-6/NN||patient-2/JJ	prep_with||patient-2/JJ||one-4/CD	nn||sample-6/NN||blood-5/NN	nsubj||received-15/VBD||sample-6/NN	vmod||sample-6/NN||containing-7/VBG	quantmod||than-9/IN||more-8/JJR	num||genomes-12/NNS||than-9/IN	num||cytomegalovirus-11/NNS||3000-10/CD	dep||than-9/IN||cytomegalovirus-11/NNS	dobj||containing-7/VBG||genomes-12/NNS	prep_per||genomes-12/NNS||ml-14/NN	root||ROOT-0/null||received-15/VBD	dobj||received-15/VBD||ganciclovir-16/NN	num||measurements-23/NNS||two-18/CD	amod||measurements-23/NNS||consecutive-19/JJ	amod||measurements-23/NNS||undetectable-20/JJ	nn||measurements-23/NNS||cytomegalovirus-21/NN	nn||measurements-23/NNS||dna-22/NN	prep_until||received-15/VBD||measurements-23/NNS	cytomegalovirus-21||ganciclovir-16||yes||any patient with one blood sample containing more than 3000 cytomegalovirus genomes per ml received ganciclovir until two consecutive undetectable cytomegalovirus dna measurements.
nsubj||drug-4/NN||disulfiram-1/NN	cop||drug-4/NN||is-2/VBZ	det||drug-4/NN||the-3/DT	root||ROOT-0/null||drug-4/NN	nsubjpass||prescribed-8/VBN||drug-4/NN	auxpass||prescribed-8/VBN||is-6/VBZ	advmod||prescribed-8/VBN||commonly-7/RB	rcmod||drug-4/NN||prescribed-8/VBN	det||treatment-11/NN||the-10/DT	prep_for||prescribed-8/VBN||treatment-11/NN	prep_of||treatment-11/NN||alcoholdependencesyndrome-13/NN	amod||psychosis-18/NNS||transient-16/JJ	nn||psychosis-18/NNS||functional-17/NN	nsubjpass||reported-21/VBN||psychosis-18/NNS	aux||reported-21/VBN||has-19/VBZ	auxpass||reported-21/VBN||been-20/VBN	conj_and||drug-4/NN||reported-21/VBN	nsubjpass||prescribed-8/VBN||reported-21/VBN	prep_as||reported-21/VBN||one-23/CD	poss||side-effects-26/NNS||its-25/PRP$	prep_of||one-23/CD||side-effects-26/NNS	alcoholdependencesyndrome-13||disulfiram-1||yes||disulfiram is the drug that is commonly prescribed for the treatment of alcoholdependencesyndrome, and transient functional psychosis has been reported as one of its side-effects.
amod||budesonide-2/NN||nebulized-1/JJ	nsubjpass||used-5/VBN||budesonide-2/NN	aux||used-5/VBN||is-3/VBZ	auxpass||used-5/VBN||being-4/VBG	root||ROOT-0/null||used-5/VBN	det||attacks-9/NNS||the-7/DT	amod||attacks-9/NNS||acute-8/JJ	prep_in||used-5/VBN||attacks-9/NNS	prep_of||attacks-9/NNS||bronchialasthma-11/NN	preconj||used-5/VBN||either-12/CC	prep_in||used-5/VBN||children-14/NNS	conj_or||attacks-9/NNS||children-14/NNS	prep_in||used-5/VBN||adults-17/NNS	conj_or||attacks-9/NNS||adults-17/NNS	bronchialasthma-11||budesonide-2||yes||nebulized budesonide is being used in the acute attacks of bronchialasthma either in children or in adults.
det||mechanisms-3/NNS||the-1/DT	amod||mechanisms-3/NNS||anti-metastatic-2/JJ	nsubj||underpin-6/VB||mechanisms-3/NNS	nsubj||warrant-24/VBP||mechanisms-3/NNS	aux||underpin-6/VB||may-5/MD	rcmod||mechanisms-3/NNS||underpin-6/VB	det||effects-8/NNS||the-7/DT	dobj||underpin-6/VB||effects-8/NNS	amod||heparins-13/NNS||low-10/JJ	amod||heparins-13/NNS||molecular-11/JJ	nn||heparins-13/NNS||weight-12/NN	prep_of||effects-8/NNS||heparins-13/NNS	appos||heparins-13/NNS||lmwhs-15/NNS	prep||underpin-6/VB||in-17/IN	pcomp||in-17/IN||in-18/IN	amod||models-23/NNS||vitro-19/NN	conj_and||vitro-19/NN||preclinical-21/NN	amod||models-23/NNS||preclinical-21/NN	nn||models-23/NNS||melanoma-22/NN	pobj||in-18/IN||models-23/NNS	root||ROOT-0/null||warrant-24/VBP	xcomp||warrant-24/VBP||translating-25/VBG	det||setting-29/NN||a-27/DT	amod||setting-29/NN||clinical-28/JJ	prep_to||translating-25/VBG||setting-29/NN	heparins-13||melanoma-22||no_rel||the anti-metastatic mechanisms that may underpin the effects of low molecular weight heparins (lmwhs) in in vitro and preclinical melanoma models warrant translating to a clinical setting.
nsubj||use-2/VBP||we-1/PRP	root||ROOT-0/null||use-2/VBP	det||model-6/NN||a-3/DT	amod||model-6/NN||multiple-4/JJ	nn||model-6/NN||regression-5/NN	dobj||use-2/VBP||model-6/NN	nsubj||attribute-15/VB||model-6/NN	vmod||model-6/NN||guided-7/VBN	amod||patterns-11/NNS||longitudinal-9/JJ	amod||patterns-11/NNS||weekly-10/JJ	agent||guided-7/VBN||patterns-11/NNS	prep_of||patterns-11/NNS||influenzavirus-13/NNS	aux||attribute-15/VB||to-14/TO	xcomp||use-2/VBP||attribute-15/VB	det||pattern-21/NN||the-16/DT	amod||pattern-21/NN||weekly-17/JJ	nn||pattern-21/NN||ili-18/NN	nn||pattern-21/NN||consultation-19/NN	nn||pattern-21/NN||incidence-20/NN	dobj||attribute-15/VB||pattern-21/NN	det||type-28/NN||each-23/DT	nn||type-28/NN||influenza-24/NN	appos||type-28/NN||sub-26/NN	prep_to||attribute-15/VB||type-28/NN	mark||epidemics-42/VBZ||while-30/IN	nsubj||epidemics-42/VBZ||controlling-31/VBG	det||effect-34/NN||the-33/DT	prep_for||controlling-31/VBG||effect-34/NN	advmod||syncytial-37/JJ||respiratory-36/RB	amod||virus-38/NN||syncytial-37/JJ	prep_of||effect-34/NN||virus-38/NN	appos||virus-38/NN||rsv-40/NN	advcl||use-2/VBP||epidemics-42/VBZ	influenza-24||influenzavirus-13||no||we use a multiple regression model guided by longitudinal weekly patterns of influenzavirus to attribute the weekly ili consultation incidence pattern to each influenza (sub)type, while controlling for the effect of respiratory syncytial virus (rsv) epidemics.
amod||endpoints-2/NNS||secondary-1/JJ	nsubj||parameters-4/NNS||endpoints-2/NNS	cop||parameters-4/NNS||are-3/VBP	root||ROOT-0/null||parameters-4/NNS	amod||morbidity-7/NN||post-transplant-6/JJ	prep_of||parameters-4/NNS||morbidity-7/NN	prep_like||parameters-4/NNS||rates-10/NNS	prep_of||rates-10/NNS||infections-12/NNS	amod||complications-15/NNS||biliary-14/JJ	appos||infections-12/NNS||complications-15/NNS	prep_of||rates-10/NNS||need-17/NN	conj_or||infections-12/NNS||need-17/NN	prep_of||need-17/NN||clottingfactors-19/NNS	amod||therapy-23/NN||renal-21/JJ	nn||therapy-23/NN||replacement-22/NN	prep_of||rates-10/NNS||therapy-23/NN	conj_or||infections-12/NNS||therapy-23/NN	det||survival-29/NN||the-25/DT	nn||survival-29/NN||graft-26/NN	conj_and||graft-26/NN||patient-28/NN	nn||survival-29/NN||patient-28/NN	conj_or||infections-12/NNS||survival-29/NN	conj_and||therapy-23/NN||survival-29/NN	clottingfactors-19||secondary-1||no_rel||secondary endpoints are parameters of post-transplant morbidity, like rates of infections, biliary complications, need of clottingfactors or renal replacement therapy and the graft and patient survival.
det||study-3/NN||this-2/DT	prep_in||recruited-53/VBN||study-3/NN	nsubj||assessed-5/VBD||we-4/PRP	rcmod||study-3/NN||assessed-5/VBD	det||smear-8/NN||the-6/DT	nn||smear-8/NN||sputum-7/NN	iobj||assessed-5/VBD||smear-8/NN	nn||conversion-11/NN||culture-10/NN	iobj||assessed-5/VBD||conversion-11/NN	conj_and||smear-8/NN||conversion-11/NN	dobj||assessed-5/VBD||rates-12/NNS	amod||patients-21/NNS||hivpositive-14/JJ	conj_and||hivpositive-14/JJ||hiv-16/JJ	amod||patients-21/NNS||hiv-16/JJ	amod||patients-21/NNS||negative-17/JJ	nn||patients-21/NNS||smear-18/NN	amod||patients-21/NNS||positive-19/JJ	nn||patients-21/NNS||pulmonarytuberculosis-20/NN	prep_among||rates-12/NNS||patients-21/NNS	nn||salaam-25/NN||dar-23/NN	nn||salaam-25/NN||es-24/NN	prep_in||patients-21/NNS||salaam-25/NN	nsubj||lasted-34/VBD||salaam-25/NN	det||study-27/NN||the-26/DT	nsubj||study-32/NN||study-27/NN	cop||study-32/NN||was-28/VBD	det||study-32/NN||a-29/DT	amod||study-32/NN||prospective-30/JJ	nn||study-32/NN||cohort-31/NN	rcmod||salaam-25/NN||study-32/NN	rcmod||study-32/NN||lasted-34/VBD	num||months-37/NNS||nine-36/CD	prep_for||lasted-34/VBD||months-37/NNS	prep_from||lasted-34/VBD||april-40/NNP	prep_to||lasted-34/VBD||december-42/NNP	num||december-42/NNP||2008-43/CD	det||total-45/NN||a-44/DT	nsubjpass||recruited-53/VBN||total-45/NN	num||patients-51/NNS||502-47/CD	amod||patients-51/NNS||smear-48/JJ	amod||patients-51/NNS||positive-49/JJ	nn||patients-51/NNS||pulmonarytuberculosis-50/NN	prep_of||total-45/NN||patients-51/NNS	auxpass||recruited-53/VBN||were-52/VBD	root||ROOT-0/null||recruited-53/VBN	hivpositive-14||hiv-16||no||in this study we assessed the sputum smear and culture conversion rates among hivpositive and hiv negative smear positive pulmonarytuberculosis patients in dar es salaam the study was a prospective cohort study which lasted for nine months, from april to december 2008 a total of 502 smear positive pulmonarytuberculosis patients were recruited.
root||ROOT-0/null||aim-1/VB	aux||compare-3/VB||to-2/TO	xcomp||aim-1/VB||compare-3/VB	det||effect-5/NN||the-4/DT	dobj||compare-3/VB||effect-5/NN	nn||degludec-8/NN||insulin-7/NN	prep_of||effect-5/NN||degludec-8/NN	conj_and||aim-1/VB||insulinglargine-10/VB	amod||quality-13/NN||health-related-12/JJ	prep_on||insulinglargine-10/VB||quality-13/NN	prep_of||quality-13/NN||life-15/NN	prep_in||life-15/NN||patients-17/NNS	prep_with||patients-17/NNS||type2diabetes-19/CD	prep||insulinglargine-10/VB||starting-20/VBG	pcomp||starting-20/VBG||on-21/IN	nn||therapy-23/NN||insulin-22/NN	pobj||on-21/IN||therapy-23/NN	type2diabetes-19||insulin-22||yes||aim to compare the effect of insulin degludec and insulinglargine on health-related quality of life in patients with type2diabetes starting on insulin therapy.
amod||factors-2/NNS||occupational-1/JJ	nsubjpass||suggested-21/VBN||factors-2/NNS	nn||type-6/NN||job-5/NN	prep_such_as||factors-2/NNS||type-6/NN	prep_such_as||factors-2/NNS||industry-8/NN	conj_and||type-6/NN||industry-8/NN	prep_such_as||factors-2/NNS||exposures-11/NNS	conj_and||type-6/NN||exposures-11/NNS	prep_to||exposures-11/NNS||chemicals-13/NNS	prep_such_as||chemicals-13/NNS||herbicides-16/NNS	prep_such_as||chemicals-13/NNS||chlorophenols-18/NNS	conj_and||herbicides-16/NNS||chlorophenols-18/NNS	aux||suggested-21/VBN||have-19/VBP	auxpass||suggested-21/VBN||been-20/VBN	root||ROOT-0/null||suggested-21/VBN	nn||factors-24/NNS||risk-23/NN	prep_as||suggested-21/VBN||factors-24/NNS	prep_for||factors-24/NNS||sarcomas-26/NNS	sarcomas-26||chemicals-13||no_rel||occupational factors such as job type, industry, and exposures to chemicals such as herbicides and chlorophenols have been suggested as risk factors for sarcomas.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	neg||correlation-4/NN||no-3/DT	dobj||found-2/VBD||correlation-4/NN	amod||rates-8/NNS||high-6/JJ	nn||rates-8/NNS||mdr-7/NN	prep_between||correlation-4/NN||rates-8/NNS	nn||incidence-11/NN||tb-10/NN	dobj||found-2/VBD||incidence-11/NN	conj_and||correlation-4/NN||incidence-11/NN	amod||rates-15/NNS||hiv/tb-13/JJ	amod||rates-15/NNS||co-infection-14/JJ	appos||incidence-11/NN||rates-15/NNS	dobj||found-2/VBD||year-18/NN	conj_or||correlation-4/NN||year-18/NN	prep_of||year-18/NN||introduction-20/NN	prep_of||introduction-20/NN||rifampin-22/NN	tb-10||rifampin-22||yes||we found no correlation between high mdr rates and tb incidence, hiv/tb co-infection rates, or year of introduction of rifampin.
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	viralmeningoencephalitis-35||immunoglobulin-16||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
amod||creutzfeldt-jakobdisease-2/NN||sporadic-1/JJ	nsubj||â-6/VBP||creutzfeldt-jakobdisease-2/NN	dep||creutzfeldt-jakobdisease-2/NN||scjd-4/VBN	root||ROOT-0/null||â-6/VBP	dobj||â-6/VBP||$-7/$	num||$-7/$||affected-9/NNS	quantmod||affected-9/NNS||human-10/IN	quantmod||affected-9/NNS||brains-11/JJ	dep||â-6/VBP||show-12/VB	det||increase-15/NN||a-13/DT	amod||increase-15/NN||similar-14/JJ	dobj||show-12/VB||increase-15/NN	amod||iron-18/NN||total-17/JJ	prep_in||increase-15/NN||iron-18/NN	det||correlation-22/NN||a-20/DT	amod||correlation-22/NN||direct-21/JJ	dobj||show-12/VB||correlation-22/NN	conj_and||increase-15/NN||correlation-22/NN	nn||levels-27/NNS||prp-24/NN	conj_and||prp-24/NN||tf-26/NN	nn||levels-27/NNS||tf-26/NN	prep_between||correlation-22/NN||levels-27/NNS	xcomp||â-6/VBP||implicating-29/VBG	acomp||implicating-29/VBG||prpsc-30/JJ	det||cause-34/NN||the-32/DT	amod||cause-34/NN||underlying-33/VBG	prep_as||prpsc-30/JJ||cause-34/NN	prep_of||cause-34/NN||irondeficiency-36/NN	irondeficiency-36||iron-18||yes||sporadic creutzfeldt-jakobdisease (scjd)â€“affected human brains show a similar increase in total iron and a direct correlation between prp and tf levels, implicating prpsc as the underlying cause of irondeficiency.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||organization-5/NN||the-3/DT	amod||organization-5/NN||nuclear-4/JJ	dobj||investigated-2/VBD||organization-5/NN	nn||genes-15/NNS||estrogen-7/NN	dep||alpha-9/NN||receptor-8/JJ	amod||genes-15/NNS||alpha-9/NN	number||±-12/CD||erî-11/CD	dep||alpha-9/NN||±-12/CD	nn||genes-15/NNS||target-14/NN	prep_of||organization-5/NN||genes-15/NNS	amod||epithelial-19/NN||human-17/JJ	nn||epithelial-19/NN||breast-18/NN	prep_in||investigated-2/VBD||epithelial-19/NN	nn||lines-23/NNS||cancer-21/NN	nn||lines-23/NNS||cell-22/NN	prep_in||investigated-2/VBD||lines-23/NNS	conj_and||epithelial-19/NN||lines-23/NNS	prep||investigated-2/VBD||before-25/IN	prep||investigated-2/VBD||after-27/IN	conj_and||before-25/IN||after-27/IN	amod||activation-29/NN||transcriptional-28/JJ	pobj||after-27/IN||activation-29/NN	vmod||activation-29/NN||induced-30/VBN	prep_with||induced-30/VBN||estradiol-32/NN	estrogen-7||cancer-21||no_rel||we investigated the nuclear organization of estrogen receptor alpha (erî±) target genes in human breast epithelial and cancer cell lines, before and after transcriptional activation induced with estradiol.
det||extracts-2/NNS||these-1/DT	nsubjpass||tested-4/VBN||extracts-2/NNS	auxpass||tested-4/VBN||were-3/VBD	ccomp||herpes-10/VBZ||tested-4/VBN	num||viruses-8/NNS||two-6/CD	amod||viruses-8/NNS||mammalian-7/JJ	prep_against||tested-4/VBN||viruses-8/NNS	root||ROOT-0/null||herpes-10/VBZ	nn||virus-12/NN||simplex-11/NN	dobj||herpes-10/VBZ||virus-12/NN	dep||virus-12/NN||hsv-1-14/JJ	nn||stomatitis-18/NNS||vesicular-17/NN	dobj||herpes-10/VBZ||stomatitis-18/NNS	conj_and||virus-12/NN||stomatitis-18/NNS	nsubj||herpes-10/VBZ||virus-19/NN	appos||virus-19/NN||vsv-21/NN	vmod||herpes-10/VBZ||using-24/VBG	nn||cells-26/NNS||vero-25/NN	dobj||using-24/VBG||cells-26/NNS	det||system-31/NN||the-28/DT	nn||system-31/NN||cell-29/NN	nn||system-31/NN||culture-30/NN	prep_as||cells-26/NNS||system-31/NN	num||counterparts-37/NNS||two-34/CD	amod||counterparts-37/NNS||marine-35/JJ	nn||counterparts-37/NNS||virus-36/NN	dobj||using-24/VBG||counterparts-37/NNS	conj_and||cells-26/NNS||counterparts-37/NNS	nn||virus-41/NN||channel-39/NN	nn||virus-41/NN||catfish-40/NN	dobj||using-24/VBG||virus-41/NN	conj_and||cells-26/NNS||virus-41/NN	appos||virus-41/NN||ccv-43/NN	amod||rhabdovirus-47/NNS||snakehead-46/JJ	dobj||using-24/VBG||rhabdovirus-47/NNS	conj_and||cells-26/NNS||rhabdovirus-47/NNS	appos||rhabdovirus-47/NNS||shrv-49/NNP	poss||cultures-56/NNS||their-53/PRP$	amod||cultures-56/NNS||respective-54/JJ	nn||cultures-56/NNS||cell-55/NN	prep_in||rhabdovirus-47/NNS||cultures-56/NNS	dep||rhabdovirus-47/NNS||cco-58/NN	dep||rhabdovirus-47/NNS||epc-60/NN	conj_and||cco-58/NN||epc-60/NN	virus-41||viruses-8||no||these extracts were tested against two mammalian viruses, herpes simplex virus (hsv-1) and vesicular stomatitis virus (vsv), using vero cells as the cell culture system, and two marine virus counterparts, channel catfish virus (ccv) and snakehead rhabdovirus (shrv), in their respective cell cultures (cco and epc).
amod||administration-5/NN||pre-1/JJ	conj_and||pre-1/JJ||post-operative-4/JJ	amod||administration-5/NN||post-operative-4/JJ	nsubj||reduced-9/VBD||administration-5/NN	prep_of||administration-5/NN||iv-ibuprofen-7/NN	advmod||reduced-9/VBD||significantly-8/RB	root||ROOT-0/null||reduced-9/VBD	preconj||use-14/NN||both-10/DT	nn||use-14/NN||pain-11/NN	conj_and||pain-11/NN||morphine-13/NN	nn||use-14/NN||morphine-13/NN	dobj||reduced-9/VBD||use-14/NN	amod||patients-18/NNS||orthopedic-16/JJ	nn||patients-18/NNS||surgery-17/NN	prep_in||reduced-9/VBD||patients-18/NNS	det||trial-24/NN||this-20/DT	amod||trial-24/NN||prospective-21/JJ	amod||trial-24/NN||randomized-22/JJ	amod||trial-24/NN||placebo-controlled-23/JJ	prep_in||reduced-9/VBD||trial-24/NN	pain-11||ibuprofen--1||yes||pre- and post-operative administration of iv-ibuprofen significantly reduced both pain and morphine use in orthopedic surgery patients in this prospective randomized placebo-controlled trial.
det||structure-3/NN||the-1/DT	nn||structure-3/NN||crystal-2/NN	nsubj||consists-16/VBZ||structure-3/NN	nsubj||consists-16/VBZ||structure-3/NN	det||compound-7/NN||the-5/DT	nn||compound-7/NN||title-6/NN	prep_of||structure-3/NN||compound-7/NN	nn||-RSB--14/NNP||-LSB--9/NNP	nn||-RSB--14/NNP||zncl2-10/NNP	appos||-RSB--14/NNP||c10h8n2s-12/NNP	appos||structure-3/NN||-RSB--14/NNP	root||ROOT-0/null||consists-16/VBZ	conj_and||consists-16/VBZ||consists-16/VBZ	det||ring-21/NN||a-18/DT	amod||ring-21/NN||six-membered-19/JJ	nn||ring-21/NN||chelate-20/NN	prep_of||consists-16/VBZ||ring-21/NN	prep_in||tetraâhedrally-29/JJ||ring-21/NN	det||atom-26/NN||the-24/DT	nn||atom-26/NN||zn-25/NN	nsubj||tetraâhedrally-29/JJ||atom-26/NN	cop||tetraâhedrally-29/JJ||is-27/VBZ	advmod||tetraâhedrally-29/JJ||approximately-28/RB	rcmod||ring-21/NN||tetraâhedrally-29/JJ	dep||tetraâhedrally-29/JJ||coordinated-30/VBN	num||chlorideions-33/NNS||two-32/CD	prep_by||coordinated-30/VBN||chlorideions-33/NNS	det||atoms-40/NNS||the-36/DT	num||atoms-40/NNS||two-37/CD	amod||atoms-40/NNS||pyridyl-38/JJ	nn||atoms-40/NNS||n-39/NN	prep_by||consists-16/VBZ||atoms-40/NNS	det||sulfide-45/NN||a-42/DT	amod||sulfide-45/NN||single-43/JJ	amod||sulfide-45/NN||di-2-pyridyl-44/JJ	prep_of||atoms-40/NNS||sulfide-45/NN	vmod||sulfide-45/NN||ligand-46/VBN	chlorideions-33||di--1||no_rel||the crystal structure of the title compound, [zncl2(c10h8n2s)], consists of a six-membered chelate ring in which the zn atom is approximately tetraâ­hedrally coordinated by two chlorideions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand.
poss||study-2/NN||our-1/PRP$	nsubj||showed-3/VBD||study-2/NN	root||ROOT-0/null||showed-3/VBD	mark||effective-19/JJ||that-4/IN	number||%-6/NN||1-5/CD	amod||tropicamide-7/NN||%-6/NN	nsubj||effective-19/JJ||tropicamide-7/NN	poss||mechanism-13/NN||its-10/PRP$	amod||mechanism-13/NN||parasympathetic-11/JJ	amod||mechanism-13/NN||antagonistic-12/JJ	prep_with||tropicamide-7/NN||mechanism-13/NN	prep_of||mechanism-13/NN||action-15/NN	cop||effective-19/JJ||was-17/VBD	advmod||effective-19/JJ||more-18/RBR	ccomp||showed-3/VBD||effective-19/JJ	prepc_at||effective-19/JJ||inducing-21/VBG	dobj||inducing-21/VBG||pupillarydilation-22/NN	number||%-25/NN||2.5-24/CD	amod||phenylephrine-26/NN||%-25/NN	prep_than||inducing-21/VBG||phenylephrine-26/NN	det||combination-30/NN||the-29/DT	nsubj||effective-41/JJ||combination-30/NN	number||%-33/NN||1-32/CD	amod||tropicamide-34/NN||%-33/NN	prep_of||combination-30/NN||tropicamide-34/NN	number||%-37/NN||2.5-36/CD	amod||phenylephrine-38/NN||%-37/NN	prep_of||combination-30/NN||phenylephrine-38/NN	conj_and||tropicamide-34/NN||phenylephrine-38/NN	cop||effective-41/JJ||was-39/VBD	advmod||effective-41/JJ||more-40/RBR	conj_and||showed-3/VBD||effective-41/JJ	amod||drops-44/NNS||multiple-43/JJ	prep_than||effective-41/JJ||drops-44/NNS	amod||drops-48/NNS||single-46/JJ	nn||drops-48/NNS||eye-47/NN	prep_of||drops-44/NNS||drops-48/NNS	pupillarydilation-22||phenylephrine-38||no||our study showed that 1% tropicamide, with its parasympathetic antagonistic mechanism of action, was more effective at inducing pupillarydilation than 2.5% phenylephrine, and the combination of 1% tropicamide and 2.5% phenylephrine was more effective than multiple drops of single eye drops.
mark||have-4/VBP||since-1/IN	det||compounds-3/NNS||the-2/DT	nsubj||have-4/VBP||compounds-3/NNS	advcl||$-17/VBD||have-4/VBP	neg||activity-7/NN||no-5/DT	amod||activity-7/NN||insulinotropic-6/JJ	dobj||have-4/VBP||activity-7/NN	amod||concentrations-11/NNS||lower-9/JJR	nn||concentrations-11/NNS||glucose-10/NN	prep_at||activity-7/NN||concentrations-11/NNS	det||risk-13/NN||the-12/DT	nsubj||$-17/VBD||risk-13/NN	nn||â-16/NN||hypoglycemia-15/NN	prep_of||risk-13/NN||â-16/NN	root||ROOT-0/null||$-17/VBD	det||shortcoming-21/NN||a-19/DT	amod||shortcoming-21/NN||well-known-20/JJ	nsubj||low-30/JJ||shortcoming-21/NN	amod||treatments-25/NNS||existing-23/JJ	nn||treatments-25/NNS||antidiabetes-24/NNS	poss||$-27/NN||treatments-25/NNS	prep_of||shortcoming-21/NN||$-27/NN	cop||low-30/JJ||is-29/VBZ	ccomp||$-17/VBD||low-30/JJ	hypoglycemia-15||glucose-10||yes||since the compounds have no insulinotropic activity at lower glucose concentrations the risk of hypoglycemia â€“ a well-known shortcoming of existing antidiabetes treatments â€“ is low.
aux||compare-2/VB||to-1/TO	csubj||treated-14/VBN||compare-2/VB	det||incidence-4/NN||the-3/DT	dobj||compare-2/VB||incidence-4/NN	amod||events-7/NNS||cardiovascular-6/JJ	prep_of||incidence-4/NN||events-7/NNS	prep_of||incidence-4/NN||mortality-9/NN	conj_and||events-7/NNS||mortality-9/NN	prep_in||compare-2/VB||patients-11/NNS	prep_with||patients-11/NNS||type2diabetesmellitus-13/CD	root||ROOT-0/null||treated-14/VBN	nn||comparators-19/NNS||sitagliptin-16/NN	conj_or||sitagliptin-16/NN||non-sitagliptin-18/NN	nn||comparators-19/NNS||non-sitagliptin-18/NN	prep_with||treated-14/VBN||comparators-19/NNS	type2diabetesmellitus-13||sitagliptin-16||yes||to compare the incidence of cardiovascular events and mortality in patients with type2diabetesmellitus treated with sitagliptin or non-sitagliptin comparators.
prep_in||decreased-18/VBN||comparison-2/NN	det||group-6/NN||the-4/DT	nn||group-6/NN||control-5/NN	prep_to||comparison-2/NN||group-6/NN	det||capacity-11/NN||the-8/DT	nn||capacity-11/NN||insulin-9/NN	nn||capacity-11/NN||secretory-10/NN	nsubjpass||decreased-18/VBN||capacity-11/NN	nsubj||more-21/JJR||capacity-11/NN	det||states-16/NNS||the-13/DT	num||states-16/NNS||two-14/CD	amod||states-16/NNS||hyperglycemic-15/JJ	prep_in||capacity-11/NN||states-16/NNS	auxpass||decreased-18/VBN||was-17/VBD	root||ROOT-0/null||decreased-18/VBN	conj_and||decreased-18/VBN||more-21/JJR	amod||hyperglycemia-24/NN||intermittent-23/JJ	prep_with||more-21/JJR||hyperglycemia-24/NN	prep||more-21/JJR||than-25/IN	pcomp||than-25/IN||with-26/IN	amod||hyperglycemia-28/NN||chronic-27/JJ	pobj||with-26/IN||hyperglycemia-28/NN	hyperglycemia-28||insulin-9||yes||in comparison to the control group, the insulin secretory capacity in the two hyperglycemic states was decreased, and more with intermittent hyperglycemia than with chronic hyperglycemia.
det||model-5/NN||the-2/DT	nn||model-5/NN||nod-3/NN	nn||model-5/NN||mouse-4/NN	prep_in||induces-15/VBZ||model-5/NN	prep_of||model-5/NN||type1diabetes-7/CD	amod||administration-12/NN||oral-9/JJ	conj_or||oral-9/JJ||nasal-11/JJ	amod||administration-12/NN||nasal-11/JJ	nsubj||induces-15/VBZ||administration-12/NN	nsubj||protects-21/VBZ||administration-12/NN	prep_of||administration-12/NN||insulin-14/NN	root||ROOT-0/null||induces-15/VBZ	amod||tolerance-17/NN||immune-16/JJ	dobj||induces-15/VBZ||tolerance-17/NN	prep_to||induces-15/VBZ||insulin-19/NN	conj_and||induces-15/VBZ||protects-21/VBZ	amod||diabetes-24/NN||autoimmune-23/JJ	prep_against||protects-21/VBZ||diabetes-24/NN	type1diabetes-7||insulin-19||yes||in the nod mouse model of type1diabetes, oral or nasal administration of insulin induces immune tolerance to insulin and protects against autoimmune diabetes.
prepc_compared_with||had-11/VBD||with-2/IN	nn||subjects-4/NNS||control-3/NN	pobj||had-11/VBD||subjects-4/NNS	amod||patients-7/NNS||type2diabetes-low-6/JJ	conj_and||subjects-4/NNS||patients-7/NNS	pobj||had-11/VBD||patients-7/NNS	amod||patients-10/NNS||type2diabetes-high-9/JJ	nsubj||had-11/VBD||patients-10/NNS	root||ROOT-0/null||had-11/VBD	det||perfusion-16/NN||the-12/DT	amod||perfusion-16/NN||lowest-13/JJS	amod||perfusion-16/NN||hepatic-14/JJ	amod||perfusion-16/NN||parenchymal-15/JJ	dobj||had-11/VBD||perfusion-16/NN	dep||perfusion-16/NN||p-18/VBN	dep||0.004-20/CD||=-19/SYM	ccomp||p-18/VBN||0.004-20/CD	amod||uptake-26/NN||insulin-stimulated-23/JJ	amod||uptake-26/NN||hepatic-24/JJ	nn||uptake-26/NN||glucose-25/NN	dobj||had-11/VBD||uptake-26/NN	conj_and||perfusion-16/NN||uptake-26/NN	dep||uptake-26/NN||p-28/VBN	dep||0.013-30/CD||=-29/SYM	ccomp||p-28/VBN||0.013-30/CD	type2diabetes--1||insulin--1||yes||compared with control subjects and type2diabetes-low patients, type2diabetes-high patients had the lowest hepatic parenchymal perfusion ( p = 0.004) and insulin-stimulated hepatic glucose uptake ( p = 0.013).
det||genotypes-2/NNS||some-1/DT	nsubjpass||related-5/VBN||genotypes-2/NNS	auxpass||related-5/VBN||were-3/VBD	advmod||related-5/VBN||directly-4/RB	root||ROOT-0/null||related-5/VBN	prep_with||related-5/VBN||humaninfluenzaviruses-7/NNS	nsubj||include-10/VBP||humaninfluenzaviruses-7/NNS	rcmod||humaninfluenzaviruses-7/NNS||include-10/VBP	dobj||include-10/VBP||strains-11/NNS	mark||derived-15/VBD||that-12/IN	amod||genes-14/NNS||harbored-13/JJ	nsubj||derived-15/VBD||genes-14/NNS	ccomp||include-10/VBP||derived-15/VBD	prep_from||derived-15/VBD||humaninfluenzaviruses-17/NNS	humaninfluenza--1||influenzaviruses--1||no||some genotypes were directly related with humaninfluenzaviruses, which include strains that harbored genes derived from humaninfluenzaviruses.
amod||fibers-3/NNS||viscous-1/JJ	nn||fibers-3/NNS||dietary-2/NN	nsubj||blunt-4/VB||fibers-3/NNS	root||ROOT-0/null||blunt-4/VB	det||rise-7/NN||the-5/DT	amod||rise-7/NN||postprandial-6/JJ	dobj||blunt-4/VB||rise-7/NN	nn||glucose-10/NN||blood-9/NN	prep_in||blunt-4/VB||glucose-10/NN	advmod||known-22/VBN||however-12/RB	poss||effect-14/NN||their-13/PRP$	nsubjpass||known-22/VBN||effect-14/NN	prep_on||effect-14/NN||type2diabetes-16/NN	prep_on||effect-14/NN||obesity-18/NN	conj_and||type2diabetes-16/NN||obesity-18/NN	auxpass||known-22/VBN||are-19/VBP	neg||known-22/VBN||not-20/RB	advmod||known-22/VBN||entirely-21/RB	parataxis||blunt-4/VB||known-22/VBN	type2diabetes-16||glucose-10||no_rel||viscous dietary fibers blunt the postprandial rise in blood glucose, however their effect on type2diabetes and obesity are not entirely known.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||chloroquine-38||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
poss||hypothesis-3/NNS||our-1/PRP$	amod||hypothesis-3/NNS||overarching-2/JJ	nsubj||is-4/VBZ||hypothesis-3/NNS	root||ROOT-0/null||is-4/VBZ	mark||ai-9/VBP||that-5/IN	det||susceptibility-7/NN||the-6/DT	nsubj||ai-9/VBP||susceptibility-7/NN	prep||susceptibility-7/NN||of-8/IN	ccomp||is-4/VBZ||ai-9/VBP	nn||smoking-12/NN||cigarette-11/NN	prep_to||ai-9/VBP||smoking-12/NN	prep_to||ai-9/VBP||nicotinedependence-14/NN	conj_and||smoking-12/NN||nicotinedependence-14/NN	poss||consequences-17/NNS||its-16/PRP$	nsubj||has-18/VBZ||consequences-17/NNS	ccomp||is-4/VBZ||has-18/VBZ	conj_and||ai-9/VBP||has-18/VBZ	predet||component-24/NN||both-19/PDT	det||component-24/NN||an-20/DT	amod||component-24/NN||underlying-21/JJ	nn||component-24/NN||nicotine-22/NN	nn||component-24/NN||metabolism-23/NN	dobj||has-18/VBZ||component-24/NN	amod||cultural-30/JJ||psychosocial-28/JJ	dobj||has-18/VBZ||cultural-30/JJ	conj_and||component-24/NN||cultural-30/JJ	nn||causes-34/NNS||environment-33/NN	conj_and||component-24/NN||causes-34/NNS	conj_and||cultural-30/JJ||causes-34/NNS	nicotinedependence-14||nicotine-22||no||our overarching hypothesis is that the susceptibility of ai to cigarette smoking and nicotinedependence and its consequences has both an underlying nicotine metabolism component as well as psychosocial, cultural, and environment causes.
det||bortezomib-4/NN||the-1/DT	amod||bortezomib-4/NN||proteasome-2/JJ	nn||bortezomib-4/NN||inhibitor-3/NN	nsubj||represents-5/VBZ||bortezomib-4/NN	root||ROOT-0/null||represents-5/VBZ	det||advance-8/NN||an-6/DT	amod||advance-8/NN||important-7/JJ	dobj||represents-5/VBZ||advance-8/NN	det||treatment-11/NN||the-10/DT	prep_in||advance-8/NN||treatment-11/NN	prep_of||treatment-11/NN||multiplemyeloma-13/NN	appos||multiplemyeloma-13/NN||mm-15/NN	multiplemyeloma-13||bortezomib-4||yes||the proteasome inhibitor bortezomib represents an important advance in the treatment of multiplemyeloma (mm).
det||study-2/NN||this-1/DT	nsubj||focuses-3/VBZ||study-2/NN	nsubj||ixodes-17/VBZ||study-2/NN	root||ROOT-0/null||focuses-3/VBZ	det||effects-6/NNS||the-5/DT	prep_on||focuses-3/VBZ||effects-6/NNS	det||pathogen-11/NN||an-8/DT	amod||pathogen-11/NN||invasive-9/JJ	nn||pathogen-11/NN||plant-10/NN	prep_of||effects-6/NNS||pathogen-11/NN	det||community-15/NN||a-13/DT	amod||community-15/NN||vertebrate-14/JJ	prep_on||pathogen-11/NN||community-15/NN	conj_and||focuses-3/VBZ||ixodes-17/VBZ	dobj||ixodes-17/VBZ||pacificus-18/NNS	det||vector-21/NN||the-20/DT	appos||pacificus-18/NNS||vector-21/NN	det||pathogen-25/NN||the-23/DT	amod||pathogen-25/NN||lymedisease-24/JJ	prep_of||vector-21/NN||pathogen-25/NN	appos||pathogen-25/NN||borreliaburgdorferi-27/NNP	prep_in||ixodes-17/VBZ||california-30/NN	lymedisease-24||borreliaburgdorferi-27||no||this study focuses on the effects of an invasive plant pathogen on a vertebrate community and ixodes pacificus , the vector of the lymedisease pathogen ( borreliaburgdorferi ) in california.
nsubj||present-4/VB||uti-1/NN	aux||present-4/VB||may-2/MD	advmod||present-4/VB||therefore-3/RB	root||ROOT-0/null||present-4/VB	det||â-7/NN||an-5/DT	amod||â-7/NN||attractive-6/JJ	nn||option-12/NN||â-7/NN	dep||â-7/NN||$-8/$	num||$-8/$||œrescueâ-9/CD	amod||option-12/NN||$-10/$	number||$-10/$||therapeutic-11/CD	dobj||present-4/VB||option-12/NN	prep_for||present-4/VB||systemicinflammatoryresponsesyndromes-14/NNS	prep_such_as||systemicinflammatoryresponsesyndromes-14/NNS||dic-17/NN	amod||injury-21/NN||acute-19/JJ	nn||injury-21/NN||lung-20/NN	prep_such_as||systemicinflammatoryresponsesyndromes-14/NNS||injury-21/NN	conj_and||dic-17/NN||injury-21/NN	amod||dysfunction-26/NN||multiple-24/JJ	nn||dysfunction-26/NN||organ-25/NN	prep_such_as||systemicinflammatoryresponsesyndromes-14/NNS||dysfunction-26/NN	conj_and||dic-17/NN||dysfunction-26/NN	dic-17||uti-1||no_rel||uti may therefore present an attractive â€œrescueâ€? therapeutic option for systemicinflammatoryresponsesyndromes such as dic, acute lung injury, and multiple organ dysfunction.
det||understanding-2/NN||an-1/DT	nsubj||evolving-24/VBG||understanding-2/NN	nsubj||become-55/VBN||understanding-2/NN	det||risks-5/NNS||the-4/DT	prep_of||understanding-2/NN||risks-5/NNS	prep_of||understanding-2/NN||benefits-7/NNS	conj_and||risks-5/NNS||benefits-7/NNS	amod||value-11/NN||relative-10/JJ	prep_of||understanding-2/NN||value-11/NN	conj_and||risks-5/NNS||value-11/NN	prep_of||value-11/NN||glatirameracetate-13/NN	appos||glatirameracetate-13/NN||ga-15/NN	prep_in||glatirameracetate-13/NN||multiplesclerosis-18/NNS	appos||multiplesclerosis-18/NNS||ms-20/NN	aux||evolving-24/VBG||has-22/VBZ	aux||evolving-24/VBG||been-23/VBN	root||ROOT-0/null||evolving-24/VBG	prepc_based_on||evolving-24/VBG||on-26/IN	advmod||completed-28/VBN||recently-27/RB	amod||studies-30/NNS||completed-28/VBN	amod||studies-30/NNS||head-to-head-29/JJ	pobj||evolving-24/VBG||studies-30/NNS	dep||studies-30/NNS||regard-31/VBP	parataxis||regard-31/VBP||rebif-33/VB	nn||glatirameracetate-35/NN||vs-34/NN	dobj||rebif-33/VB||glatirameracetate-35/NN	prepc_in||rebif-33/VB||relapsing-37/VBG	nn||disease-39/NN||ms-38/NN	dobj||relapsing-37/VBG||disease-39/NN	prep||evolving-24/VBG||beyond-42/IN	amod||outcomes-47/NNS||betaseron-44/JJ	advmod||yielding-46/JJ||efficacy-45/RB	amod||outcomes-47/NNS||yielding-46/JJ	dep||evolving-24/VBG||outcomes-47/NNS	det||dose-51/NN||a-49/DT	amod||dose-51/NN||new-50/JJ	prep_of||outcomes-47/NNS||dose-51/NN	conj_and||evolving-24/VBG||become-55/VBN	nn||copaxone-59/NN||betaseron-57/NN	nn||copaxone-59/NN||vs-58/NN	dep||become-55/VBN||copaxone-59/NN	prep_in||copaxone-59/NN||multiplesclerosis-61/NNS	amod||gadolinium-64/NN||triple-dose-63/JJ	prep_with||multiplesclerosis-61/NNS||gadolinium-64/NN	amod||endpoints-68/NNS||3-tesla-66/JJ	nn||endpoints-68/NNS||mri-67/NN	prep_with||multiplesclerosis-61/NNS||endpoints-68/NNS	conj_and||gadolinium-64/NN||endpoints-68/NNS	glatirameracetate-35||multiplesclerosis-61||no_rel||an understanding of the risks, benefits, and relative value of glatirameracetate (ga) in multiplesclerosis (ms) has been evolving based on recently completed head-to-head studies regard (rebif vs glatirameracetate in relapsing ms disease); beyond (betaseron efficacy yielding outcomes of a new dose); and become (betaseron vs copaxone in multiplesclerosis with triple-dose gadolinium and 3-tesla mri endpoints).
nsubjpass||settled-5/VBN||it-1/PRP	aux||settled-5/VBN||has-2/VBZ	neg||settled-5/VBN||not-3/RB	auxpass||settled-5/VBN||been-4/VBN	root||ROOT-0/null||settled-5/VBN	mark||increases-12/VBZ||if-6/IN	det||fraction-11/NN||a-7/DT	amod||fraction-11/NN||high-8/JJ	amod||fraction-11/NN||inspiratory-9/JJ	nn||fraction-11/NN||oxygen-10/NN	nsubj||increases-12/VBZ||fraction-11/NN	advcl||settled-5/VBN||increases-12/VBZ	det||risk-14/NN||the-13/DT	dobj||increases-12/VBZ||risk-14/NN	amod||complications-17/NNS||pulmonary-16/JJ	prep_of||risk-14/NN||complications-17/NNS	prep_such_as||risk-14/NN||atelectasis-21/NNS	prep_such_as||risk-14/NN||pneumonia-23/NN	conj_and||atelectasis-21/NNS||pneumonia-23/NN	amod||failure-26/NN||respiratory-25/JJ	prep_such_as||risk-14/NN||failure-26/NN	conj_and||atelectasis-21/NNS||failure-26/NN	pneumonia-23||oxygen-10||yes||it has not been settled if a high inspiratory oxygen fraction increases the risk of pulmonary complications, such as atelectasis, pneumonia and respiratory failure.
advmod||showed-10/VBD||however-1/RB	det||r5-5/NN||the-3/DT	nn||r5-5/NN||group-4/NN	nsubj||showed-10/VBD||r5-5/NN	num||ng/ml-8/NN||5-7/CD	appos||r5-5/NN||ng/ml-8/NN	root||ROOT-0/null||showed-10/VBD	advmod||intense-13/JJ||significantly-11/RB	advmod||intense-13/JJ||less-12/RBR	amod||pain-14/NN||intense-13/JJ	dobj||showed-10/VBD||pain-14/NN	vmod||pain-14/NN||induced-15/VBN	amod||r3-22/NNS||propofol-17/JJ	prep||propofol-17/JJ||than-18/IN	pcomp||than-18/IN||in-19/IN	det||group-21/NN||the-20/DT	pobj||in-19/IN||group-21/NN	agent||induced-15/VBN||r3-22/NNS	num||ng/ml-25/NN||3-24/CD	appos||r3-22/NNS||ng/ml-25/NN	pain-14||propofol-17||yes||however, the group r5 (5 ng/ml) showed significantly less intense pain induced by propofol than in the group r3 (3 ng/ml).
det||report-2/NN||this-1/DT	nsubj||describes-3/VBZ||report-2/NN	root||ROOT-0/null||describes-3/VBZ	number||old-6/JJ||3-4/CD	npadvmod||old-6/JJ||year-5/NN	amod||girl-7/NN||old-6/JJ	dobj||describes-3/VBZ||girl-7/NN	det||presentation-11/NN||the-9/DT	amod||presentation-11/NN||unusual-10/JJ	prep_with||describes-3/VBZ||presentation-11/NN	nn||juvenileidiopathicarthritis-14/NNS||polyarticular-13/NN	prep_of||presentation-11/NN||juvenileidiopathicarthritis-14/NNS	appos||juvenileidiopathicarthritis-14/NNS||jia-16/NN	amod||citrullinated-20/JJ||anti-cyclic-19/JJ	amod||antibodies-25/NNS||citrullinated-20/JJ	nn||antibodies-25/NNS||peptide-21/NN	appos||antibodies-25/NNS||anti-ccp-23/NN	prep_with||describes-3/VBZ||antibodies-25/NNS	det||factor-30/NN||a-27/DT	amod||factor-30/NN||positive-28/JJ	amod||factor-30/NN||rheumatoid-29/JJ	prep_with||describes-3/VBZ||factor-30/NN	conj_and||antibodies-25/NNS||factor-30/NN	appos||factor-30/NN||rf-32/NN	juvenileidiopathicarthritis-14||antibodies-25||no_rel||this report describes 3 year old girl with the unusual presentation of polyarticular juvenileidiopathicarthritis (jia) with anti-cyclic citrullinated peptide (anti-ccp) antibodies and a positive rheumatoid factor (rf).
prep_in||examined-55/VBN||total-2/NN	nn||lines-5/NNS||cell-4/NN	nsubjpass||examined-55/VBN||lines-5/NNS	num||carcinomas-9/NNS||three-7/CD	nn||carcinomas-9/NNS||endometrium-8/NN	prep_from||lines-5/NNS||carcinomas-9/NNS	nn||an3-15/NNS||ishikawa-11/NN	amod||an3-15/NNS||hec-1-a-13/JJ	nsubj||ca-16/MD||an3-15/NNS	dep||carcinomas-9/NNS||ca-16/MD	num||carcinomas-21/NNS||three-19/CD	amod||carcinomas-21/NNS||cervical-20/JJ	appos||carcinomas-9/NNS||carcinomas-21/NNS	nn||siha-27/NN||hela-23/NN	dep||siha-27/NN||caski-25/NN	appos||carcinomas-21/NNS||siha-27/NN	num||chorioncarcinomas-31/NNS||three-30/CD	appos||carcinomas-9/NNS||chorioncarcinomas-31/NNS	conj_and||carcinomas-21/NNS||chorioncarcinomas-31/NNS	nn||bewo-37/NN||jeg-33/NN	dep||bewo-37/NN||jar-35/NN	appos||chorioncarcinomas-31/NNS||bewo-37/NN	num||cancers-42/NNS||two-40/CD	nn||cancers-42/NNS||ovarian-41/NN	appos||carcinomas-9/NNS||cancers-42/NNS	conj_and||carcinomas-21/NNS||cancers-42/NNS	amod||oaw-42-46/JJ||bg-1-44/JJ	dep||cancers-42/NNS||oaw-42-46/JJ	num||teratocarcinoma-50/NN||one-49/CD	appos||carcinomas-9/NNS||teratocarcinoma-50/NN	conj_and||carcinomas-21/NNS||teratocarcinoma-50/NN	dep||teratocarcinoma-50/NN||pa-1-52/JJ	auxpass||examined-55/VBN||were-54/VBD	root||ROOT-0/null||examined-55/VBN	ca-16||carcinomas-21||no_rel||in total, cell lines from three endometrium carcinomas (ishikawa, hec-1-a, an3 ca), three cervical carcinomas (hela, caski, siha), three chorioncarcinomas (jeg, jar, bewo), two ovarian cancers (bg-1, oaw-42) and one teratocarcinoma (pa-1) were examined.
aux||evaluate-2/VB||to-1/TO	csubj||differing-10/VBD||evaluate-2/VB	csubj||differing-10/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	num||diets-9/NNS||two-6/CD	amod||diets-9/NNS||low-fat-7/JJ	amod||diets-9/NNS||hypocaloric-8/JJ	prep_of||effects-4/NNS||diets-9/NNS	root||ROOT-0/null||differing-10/VBD	conj_and||differing-10/VBD||differing-10/VBD	det||ratio-14/NN||the-12/DT	amod||ratio-14/NN||carbohydrate-to-protein-13/JJ	prep_in||differing-10/VBD||ratio-14/NN	nn||training-21/NN||resistance-19/NN	nn||training-21/NN||exercise-20/NN	prep_with||differing-10/VBD||training-21/NN	prep_without||differing-10/VBD||training-21/NN	appos||training-21/NN||rt-23/NN	nn||loss-28/NN||weight-27/NN	prep_on||differing-10/VBD||loss-28/NN	nn||composition-31/NN||body-30/NN	prep_on||differing-10/VBD||composition-31/NN	conj_and||loss-28/NN||composition-31/NN	amod||outcomes-39/NNS||cardiovasculardisease-34/JJ	dep||cardiovasculardisease-34/JJ||cvd-36/NN	nn||outcomes-39/NNS||risk-38/NN	prep_on||differing-10/VBD||outcomes-39/NNS	conj_and||loss-28/NN||outcomes-39/NNS	amod||patients-42/NNS||overweight/obese-41/JJ	prep_in||outcomes-39/NNS||patients-42/NNS	prep_with||patients-42/NNS||type2diabetes-44/CD	obese--1||fat--1||no_rel||to evaluate the effects of two low-fat hypocaloric diets differing in the carbohydrate-to-protein ratio, with and without resistance exercise training (rt), on weight loss, body composition, and cardiovasculardisease (cvd) risk outcomes in overweight/obese patients with type2diabetes.
amod||mitis-2/NNS||streptococcus-1/JJ	nsubjpass||investigated-45/VBN||mitis-2/NNS	nn||salivarius-5/NNS||s.-4/NN	appos||mitis-2/NNS||salivarius-5/NNS	nn||sanguinis-8/NNS||s.-7/NN	appos||mitis-2/NNS||sanguinis-8/NNS	conj_and||salivarius-5/NNS||sanguinis-8/NNS	amod||inhabitants-11/NNS||typical-10/JJ	appos||mitis-2/NNS||inhabitants-11/NNS	det||cavity-16/NN||the-13/DT	amod||cavity-16/NN||healthy-14/JJ	amod||cavity-16/NN||oral-15/JJ	prep_of||inhabitants-11/NNS||cavity-16/NN	nn||mutans-19/NNS||s.-18/NN	appos||mitis-2/NNS||mutans-19/NNS	amod||species-23/NNS||main-21/JJ	amod||species-23/NNS||carriogenic-22/JJ	prep_as||mutans-19/NNS||species-23/NNS	amod||gingivalis-27/NNS||porphyromonas-26/JJ	appos||mitis-2/NNS||gingivalis-27/NNS	conj_and||mutans-19/NNS||gingivalis-27/NNS	nn||nucleatum-30/NN||fusobacterium-29/NN	appos||mitis-2/NNS||nucleatum-30/NN	amod||micra-33/NN||parvimonas-32/JJ	appos||mitis-2/NNS||micra-33/NN	nn||intermedius-36/NNS||s.-35/NN	appos||mitis-2/NNS||intermedius-36/NNS	nn||actinomycetemcomitans-39/NNS||aggregatibacter-38/NN	appos||mitis-2/NNS||actinomycetemcomitans-39/NNS	conj_and||intermedius-36/NNS||actinomycetemcomitans-39/NNS	amod||bacteria-42/NNS||periodontitis-associated-41/JJ	prep_as||intermedius-36/NNS||bacteria-42/NNS	auxpass||investigated-45/VBN||were-44/VBD	root||ROOT-0/null||investigated-45/VBN	poss||biofilm-48/NN||their-47/PRP$	prep_for||investigated-45/VBN||biofilm-48/NN	xcomp||investigated-45/VBN||forming-49/VBG	dobj||forming-49/VBG||ability-50/NN	cavity-16||bacteria-42||no||streptococcus mitis , s. salivarius and s. sanguinis , typical inhabitants of the healthy oral cavity , s. mutans as main carriogenic species , and porphyromonas gingivalis , fusobacterium nucleatum , parvimonas micra , s. intermedius and aggregatibacter actinomycetemcomitans as periodontitis-associated bacteria , were investigated for their biofilm forming ability .
det||mutation-3/NN||a-1/DT	amod||mutation-3/NN||nonsense-2/JJ	nsubj||encodes-8/VBZ||mutation-3/NN	nsubjpass||identified-26/VBN||mutation-3/NN	prep_in||mutation-3/NN||tmlhe-5/NN	rcmod||mutation-3/NN||encodes-8/VBZ	det||é-10/NN||the-9/DT	poss||hydroxylase-16/NN||é-10/NN	dep||hydroxylase-16/NN||n-13/NN	nn||hydroxylase-16/NN||trimethyllysine-15/NN	dobj||encodes-8/VBZ||hydroxylase-16/NN	vmod||hydroxylase-16/NN||catalyzing-17/VBG	det||step-20/NN||the-18/DT	amod||step-20/NN||first-19/JJ	dobj||catalyzing-17/VBG||step-20/NN	amod||biosynthesis-23/NNS||carnitine-22/JJ	prep_of||step-20/NN||biosynthesis-23/NNS	auxpass||identified-26/VBN||was-25/VBD	root||ROOT-0/null||identified-26/VBN	num||brothers-29/NNS||two-28/CD	prep_in||identified-26/VBN||brothers-29/NNS	prep_with||brothers-29/NNS||autism-31/NN	prep_with||brothers-29/NNS||id-33/NN	conj_and||autism-31/NN||id-33/NN	carnitine-22||autism-31||no_rel||a nonsense mutation in tmlhe , which encodes the é›- n -trimethyllysine hydroxylase catalyzing the first step of carnitine biosynthesis, was identified in two brothers with autism and id.
nsubj||induced-5/VBN||subjects-1/NNS	vmod||subjects-1/NNS||judged-2/VBN	det||pain-4/NN||the-3/DT	dobj||judged-2/VBN||pain-4/NN	root||ROOT-0/null||induced-5/VBN	prep_by||induced-5/VBN||capsaicin-7/NN	det||0â-10/NN||a-9/DT	prep_through||induced-5/VBN||0â-10/NN	dep||0â-10/NN||$-11/$	num||vas-14/NN||100-13/CD	npadvmod||before-16/IN||vas-14/NN	advmod||vas-14/NN||scale-15/RB	dep||10-28/CD||before-16/IN	conj_and||before-16/IN||after-18/IN	dep||10-28/CD||after-18/IN	amod||rtms-21/NNS||5â-19/JJ	nn||rtms-21/NNS||hz-20/NN	pobj||after-18/IN||rtms-21/NNS	amod||dlpfc-26/NN||left-23/NN	conj_and||left-23/NN||right-25/JJ	amod||dlpfc-26/NN||right-25/JJ	prep_over||after-18/IN||dlpfc-26/NN	advmod||after-18/IN||at-27/IN	num||$-11/$||10-28/CD	amod||min-31/NN||20â-30/JJ	prep_through||induced-5/VBN||min-31/NN	conj_or||0â-10/NN||min-31/NN	nn||application-34/NN||capsaicin-33/NN	prep_after||min-31/NN||application-34/NN	num||groups-38/NNS||two-36/CD	amod||groups-38/NNS||separate-37/JJ	prep_in||induced-5/VBN||groups-38/NNS	num||subjects-41/NNS||8-40/CD	dep||groups-38/NNS||subjects-41/NNS	dep||subjects-41/NNS||each-42/DT	pain-4||capsaicin-33||yes||subjects judged the pain induced by capsaicin through a 0â€“100 vas scale before and after 5â hz rtms over left and right dlpfc at 10 or 20â min after capsaicin application in two separate groups (8 subjects each).
poss||data-2/NNS||our-1/PRP$	nsubj||confirm-3/VBP||data-2/NNS	root||ROOT-0/null||confirm-3/VBP	mark||leprosy-10/VBD||that-4/IN	amod||multibacillary-6/NN||chinese-5/JJ	nsubj||leprosy-10/VBD||multibacillary-6/NN	appos||multibacillary-6/NN||mb-8/NN	ccomp||confirm-3/VBP||leprosy-10/VBD	nsubj||have-12/VBP||patients-11/NNS	ccomp||leprosy-10/VBD||have-12/VBP	amod||responses-15/NNS||strong-13/JJ	nn||responses-15/NNS||antibody-14/NN	dobj||have-12/VBP||responses-15/NNS	amod||antigens-18/NNS||mycobacteriumleprae-17/JJ	prep_against||have-12/VBP||antigens-18/NNS	amod||antigens-18/NNS||nd-o-bsa-19/JJ	amod||antigens-18/NNS||lid-1-21/JJ	conj_and||nd-o-bsa-19/JJ||lid-1-21/JJ	leprosy-10||mycobacteriumleprae-17||no||our data confirm that chinese multibacillary (mb) leprosy patients have strong antibody responses against mycobacteriumleprae antigens nd-o-bsa and lid-1.
nsubj||appears-3/VBZ||hypersensitivity-1/NN	advmod||appears-3/VBZ||usually-2/RB	root||ROOT-0/null||appears-3/VBZ	amod||infusions-6/NNS||multiple-5/JJ	prep_after||appears-3/VBZ||infusions-6/NNS	xcomp||appears-3/VBZ||suggesting-8/VBG	nn||allergicreactions-11/NNS||type-9/NN	nn||allergicreactions-11/NNS||i-10/NN	dobj||suggesting-8/VBG||allergicreactions-11/NNS	advmod||seem-20/VBP||however-13/RB	amod||types-16/NNS||other-15/JJ	nsubj||seem-20/VBP||types-16/NNS	nsubjpass||implicated-23/VBN||types-16/NNS	prep_of||types-16/NNS||hypersensitivity-18/NN	advmod||seem-20/VBP||also-19/RB	parataxis||appears-3/VBZ||seem-20/VBP	aux||implicated-23/VBN||to-21/TO	auxpass||implicated-23/VBN||be-22/VB	xcomp||seem-20/VBP||implicated-23/VBN	hypersensitivity-18||allergicreactions-11||no||hypersensitivity usually appears after multiple infusions, suggesting type i allergicreactions; however, other types of hypersensitivity also seem to be implicated.
poss||guidelines-4/NNS||afghanistan-1/NN	amod||guidelines-4/NNS||national-3/JJ	nsubj||recommend-5/VBP||guidelines-4/NNS	root||ROOT-0/null||recommend-5/VBP	acomp||recommend-5/VBP||chloroquine-6/JJ	det||treatment-9/NN||the-8/DT	prep_for||chloroquine-6/JJ||treatment-9/NN	nn||infection-13/NN||plasmodium-11/NN	nn||infection-13/NN||vivax-12/NN	prep_of||treatment-9/NN||infection-13/NN	det||parasite-16/NN||the-15/DT	appos||infection-13/NN||parasite-16/NN	dep||recommend-5/VBP||responsible-17/JJ	det||majority-20/NN||the-19/DT	prep_for||responsible-17/JJ||majority-20/NN	poss||burden-24/NN||its-22/PRP$	nn||burden-24/NN||malaria-23/NN	prep_of||majority-20/NN||burden-24/NN	malaria-23||chloroquine-6||yes||afghanistan's national guidelines recommend chloroquine for the treatment of plasmodium vivax infection, the parasite responsible for the majority of its malaria burden.
prep_as||included-14/VBD||part-2/NN	det||survey-6/NN||a-4/DT	amod||survey-6/NN||larger-5/JJR	prep_of||part-2/NN||survey-6/NN	vmod||survey-6/NN||assessing-7/VBG	nn||management-9/NN||gp-8/NN	dobj||assessing-7/VBG||management-9/NN	prep_of||management-9/NN||nvaf-11/NN	nsubj||included-14/VBD||we-13/PRP	root||ROOT-0/null||included-14/VBD	dobj||included-14/VBD||questions-15/NNS	aux||explore-17/VB||to-16/TO	vmod||included-14/VBD||explore-17/VB	poss||assessment-21/NN||gps-18/NNP	nn||assessment-21/NN||risk-20/NN	dobj||explore-17/VB||assessment-21/NN	dobj||explore-17/VB||estimates-23/NNS	conj_and||assessment-21/NN||estimates-23/NNS	nn||risk-26/NN||stroke-25/NN	prep_of||estimates-23/NNS||risk-26/NN	poss||perceptions-30/NNS||gps-28/NNP	dobj||explore-17/VB||perceptions-30/NNS	conj_and||assessment-21/NN||perceptions-30/NNS	det||risks-33/NNS||the-32/DT	prep_of||perceptions-30/NNS||risks-33/NNS	prep_of||perceptions-30/NNS||benefits-35/NNS	conj_and||risks-33/NNS||benefits-35/NNS	prep_of||risks-33/NNS||anticoagulation-37/NN	prep_with||anticoagulation-37/NN||warfarin-39/NN	stroke-25||warfarin-39||yes||as part of a larger survey assessing gp management of nvaf, we included questions to explore gps' risk assessment, estimates of stroke risk and gps' perceptions of the risks and benefits of anticoagulation with warfarin.
amod||deficiency-2/NN||vitamind-1/JJ	nsubj||concern-7/NN||deficiency-2/NN	cop||concern-7/NN||is-3/VBZ	det||concern-7/NN||a-4/DT	amod||concern-7/NN||global-5/JJ	nn||concern-7/NN||public-health-6/NN	root||ROOT-0/null||concern-7/NN	advmod||concern-7/NN||even-9/RB	amod||regions-12/NNS||tropical-11/JJ	prep_in||concern-7/NN||regions-12/NNS	advmod||assumed-20/VBN||where-13/WRB	det||risk-15/NN||the-14/DT	nsubjpass||assumed-20/VBN||risk-15/NN	nsubj||due-24/JJ||risk-15/NN	prep_of||risk-15/NN||deficiency-17/NN	auxpass||assumed-20/VBN||was-18/VBD	advmod||assumed-20/VBN||previously-19/RB	rcmod||regions-12/NNS||assumed-20/VBN	aux||due-24/JJ||to-21/TO	cop||due-24/JJ||be-22/VB	advmod||due-24/JJ||low-23/RB	xcomp||assumed-20/VBN||due-24/JJ	amod||synthesis-28/NN||cutaneous-26/JJ	amod||synthesis-28/NN||vitamind-27/JJ	prep_to||due-24/JJ||synthesis-28/NN	vmod||synthesis-28/NN||stimulated-29/VBN	agent||stimulated-29/VBN||exposure-31/NN	prep_to||stimulated-29/VBN||sun-33/NN	vitamind-27||vitaminddeficiency--1||no_rel||vitamind deficiency is a global public-health concern, even in tropical regions where the risk of deficiency was previously assumed to be low due to cutaneous vitamind synthesis stimulated by exposure to sun.
amod||knowledge-2/NN||proper-1/JJ	nsubj||enough-8/JJ||knowledge-2/NN	nsubj||adopt-12/VB||knowledge-2/NN	nn||transmission-5/NN||hiv-4/NN	prep_of||knowledge-2/NN||transmission-5/NN	cop||enough-8/JJ||is-6/VBZ	neg||enough-8/JJ||not-7/RB	root||ROOT-0/null||enough-8/JJ	prep_for||enough-8/JJ||people-10/NNS	aux||adopt-12/VB||to-11/TO	xcomp||enough-8/JJ||adopt-12/VB	amod||behaviors-14/NNS||protective-13/JJ	dobj||adopt-12/VB||behaviors-14/NNS	nsubj||increase-22/VB||deficits-17/NNS	det||information-20/NN||this-19/DT	prep_in||deficits-17/NNS||information-20/NN	aux||increase-22/VB||may-21/MD	conj_but||enough-8/JJ||increase-22/VB	amod||vulnerability-24/NN||hiv/aids-23/JJ	dobj||increase-22/VB||vulnerability-24/NN	aids--1||hiv-4||no||proper knowledge of hiv transmission is not enough for people to adopt protective behaviors, but deficits in this information may increase hiv/aids vulnerability.
det||asthma-3/NN||the-1/DT	nn||asthma-3/NN||jamaica-2/NN	nsubj||population-12/NN||asthma-3/NN	amod||survey-8/NN||allergies-5/JJ	amod||survey-8/NN||national-6/JJ	nn||survey-8/NN||prevalence-7/NN	conj_and||asthma-3/NN||survey-8/NN	nsubj||population-12/NN||survey-8/NN	cop||population-12/NN||is-9/VBZ	det||population-12/NN||the-10/DT	amod||population-12/NN||first-11/JJ	root||ROOT-0/null||population-12/NN	prep||population-12/NN||based-14/VBN	pobj||based-14/VBN||survey-15/NN	det||caribbean-18/NN||the-17/DT	prep_in||survey-15/NN||caribbean-18/NN	aux||determine-20/VB||to-19/TO	vmod||caribbean-18/NN||determine-20/VB	det||prevalence-22/NN||the-21/DT	dobj||determine-20/VB||prevalence-22/NN	prep_of||prevalence-22/NN||asthma-24/NN	prep_of||prevalence-22/NN||allergies-26/NNS	conj_and||asthma-24/NN||allergies-26/NNS	dep||determine-20/VB||both-27/DT	prep_in||determine-20/VB||adults-29/NNS	prep_in||determine-20/VB||children-31/NNS	conj_and||adults-29/NNS||children-31/NNS	vmod||adults-29/NNS||using-32/VBG	amod||methods-34/NNS||standardized-33/JJ	dobj||using-32/VBG||methods-34/NNS	allergies-26||allergies-26||no||the jamaica asthma and allergies national prevalence survey is the first population- based survey in the caribbean to determine the prevalence of asthma and allergies both in adults and children using standardized methods.
det||advent-2/NN||the-1/DT	nsubj||led-13/VBD||advent-2/NN	nsubj||led-13/VBD||advent-2/NN	advmod||active-5/JJ||highly-4/RB	amod||therapy-7/NN||active-5/JJ	amod||therapy-7/NN||antiretroviral-6/JJ	prep_of||advent-2/NN||therapy-7/NN	appos||therapy-7/NN||haart-9/NN	prep_in||advent-2/NN||1996-12/CD	root||ROOT-0/null||led-13/VBD	conj_but||led-13/VBD||led-13/VBD	det||decrease-16/NN||a-15/DT	prep_to||led-13/VBD||decrease-16/NN	det||incidence-19/NN||the-18/DT	prep_in||decrease-16/NN||incidence-19/NN	poss||sarcoma-23/NN||kaposi-21/NNS	prep_of||incidence-19/NN||sarcoma-23/NN	appos||sarcoma-23/NN||ks-25/NN	amod||nhl-32/NNS||non-hodgkin-28/JJ	amod||nhl-32/NNS||slymphoma-30/JJ	prep_in||decrease-16/NN||nhl-32/NNS	conj_and||incidence-19/NN||nhl-32/NNS	neg||led-13/VBD||not-36/RB	amod||cancers-39/NNS||other-38/JJ	prep_of||led-13/VBD||cancers-39/NNS	prep_among||led-13/VBD||people-42/NNS	prep_with||people-42/NNS||hiv-44/NN	prep_with||people-42/NNS||aids-46/NNS	conj_or||hiv-44/NN||aids-46/NNS	appos||hiv-44/NN||pwha-48/NNP	aids-46||hiv-44||no||the advent of highly active antiretroviral therapy (haart) in 1996 led to a decrease in the incidence of kaposi's sarcoma (ks) and non-hodgkin'slymphoma (nhl), but not of other cancers, among people with hiv or aids (pwha).
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	melanoma-54||interferon--1||yes||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
nn||lines-2/NNS||melanoma-1/NN	nsubj||resistant-8/JJ||lines-2/NNS	nsubj||tmz-10/VB||lines-2/NNS	nsubj||fotemustine-12/JJ||lines-2/NNS	vmod||lines-2/NNS||expressing-3/VBG	nn||wild-type-5/NN||p53-4/NN	dobj||expressing-3/VBG||wild-type-5/NN	cop||resistant-8/JJ||were-6/VBD	advmod||resistant-8/JJ||more-7/RBR	root||ROOT-0/null||resistant-8/JJ	aux||tmz-10/VB||to-9/TO	xcomp||resistant-8/JJ||tmz-10/VB	conj_and||resistant-8/JJ||fotemustine-12/JJ	num||lines-17/NNS||p53-14/CD	amod||lines-17/NNS||mutant-15/JJ	nn||lines-17/NNS||melanoma-16/NN	prep_than||fotemustine-12/JJ||lines-17/NNS	nsubj||is-20/VBZ||lines-17/NNS	rcmod||lines-17/NNS||is-20/VBZ	amod||contrast-23/NN||marked-22/JJ	prep_in||is-20/VBZ||contrast-23/NN	amod||data-26/NNS||previous-25/JJ	prep_to||is-20/VBZ||data-26/NNS	vmod||data-26/NNS||reported-27/VBN	nn||cells-30/NNS||glioma-29/NN	prep_for||reported-27/VBN||cells-30/NNS	vmod||cells-30/NNS||treated-31/VBN	prep_with||treated-31/VBN||tmz-33/NN	melanoma-16||tmz-33||yes||melanoma lines expressing p53 wild-type were more resistant to tmz and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with tmz.
nn||acetylsalicylicacid-4/NN||background-1/NN	conj_and||background-1/NN||aim-3/NN	nn||acetylsalicylicacid-4/NN||aim-3/NN	nsubj||drug-16/NN||acetylsalicylicacid-4/NN	num||-RSB--9/NNS||asa-6/CD	nn||-RSB--9/NNS||-LSB--7/NNP	nn||-RSB--9/NNS||aspirin-8/NN	appos||acetylsalicylicacid-4/NN||-RSB--9/NNS	cop||drug-16/NN||is-11/VBZ	det||drug-16/NN||a-12/DT	advmod||used-14/VBN||commonly-13/RB	amod||drug-16/NN||used-14/VBN	amod||drug-16/NN||over-the-counter-15/JJ	root||ROOT-0/null||drug-16/NN	det||treatment-19/NN||the-18/DT	prep_for||drug-16/NN||treatment-19/NN	prep_of||treatment-19/NN||pain-21/NN	prep_of||treatment-19/NN||fever-23/NN	conj_or||pain-21/NN||fever-23/NN	prep_of||treatment-19/NN||colds-26/NNS	conj_or||pain-21/NN||colds-26/NNS	nsubj||limited-38/JJ||data-29/NNS	det||safety-32/NN||the-31/DT	prep_on||data-29/NNS||safety-32/NN	det||use-35/NN||this-34/DT	prep_of||safety-32/NN||use-35/NN	cop||limited-38/JJ||are-36/VBP	advmod||limited-38/JJ||very-37/RB	conj_but||drug-16/NN||limited-38/JJ	pain-21||aspirin-8||yes||background and aim acetylsalicylicacid (asa [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited.
amod||mortality-4/NN||significant-2/JJ	amod||mortality-4/NN||aids-related-3/JJ	prep_despite||neglected-25/VBN||mortality-4/NN	conj_and||mortality-4/NN||morbidity-6/NN	prep_despite||neglected-25/VBN||morbidity-6/NN	det||area-9/NN||this-8/DT	prep_in||morbidity-6/NN||area-9/NN	det||commitment-15/NN||a-12/DT	amod||commitment-15/NN||national-13/JJ	nn||commitment-15/NN||level-14/NN	conj_and||mortality-4/NN||commitment-15/NN	prep_despite||neglected-25/VBN||commitment-15/NN	amod||care-19/NN||universal-17/JJ	nn||care-19/NN||hiv-18/NN	prep_to||commitment-15/NN||care-19/NN	nsubjpass||neglected-25/VBN||hiv-21/NN	aux||neglected-25/VBN||has-22/VBZ	auxpass||neglected-25/VBN||been-23/VBN	advmod||neglected-25/VBN||largely-24/RB	root||ROOT-0/null||neglected-25/VBN	aids--1||hiv-21||no||despite significant aids-related mortality and morbidity in this area, and a national level commitment to universal hiv care, hiv has been largely neglected.
nsubj||alternative-5/NN||daptomycin-1/NN	cop||alternative-5/NN||was-2/VBD	det||alternative-5/NN||an-3/DT	amod||alternative-5/NN||effective-4/JJ	root||ROOT-0/null||alternative-5/NN	aux||vancomycin/gentamicin-7/VB||to-6/TO	vmod||alternative-5/NN||vancomycin/gentamicin-7/VB	nn||bacteraemia-10/NN||mrsa-9/NN	prep_for||vancomycin/gentamicin-7/VB||bacteraemia-10/NN	amod||endocarditis-13/NNS||right-sided-12/JJ	prep_for||vancomycin/gentamicin-7/VB||endocarditis-13/NNS	conj_or||bacteraemia-10/NN||endocarditis-13/NNS	vancomycin--1||endocarditis-13||no_rel||daptomycin was an effective alternative to vancomycin/gentamicin for mrsa bacteraemia or right-sided endocarditis.
nsubjpass||found-3/VBN||it-1/PRP	auxpass||found-3/VBN||was-2/VBD	root||ROOT-0/null||found-3/VBN	mark||initiated-15/VBN||that-4/IN	prep_between||initiated-15/VBN||2002-6/CD	conj_and||2002-6/CD||2006-8/CD	prep_between||initiated-15/VBN||2006-8/CD	advmod||users-13/NNS||most-10/RBS	amod||users-13/NNS||adhd-11/JJ	nn||users-13/NNS||drug-12/NN	nsubjpass||initiated-15/VBN||users-13/NNS	auxpass||initiated-15/VBN||were-14/VBD	ccomp||found-3/VBN||initiated-15/VBN	amod||ir-18/NN||methylphenidate-17/JJ	prep_on||initiated-15/VBN||ir-18/NN	adhd-11||methylphenidate-17||yes||it was found that between 2002 and 2006, most adhd drug users were initiated on methylphenidate ir.
det||1.3-2/CD||a-1/DT	dep||similar-31/JJ||1.3-2/CD	ccomp||similar-31/JJ||ã-4/VB	nn||structure-7/NN||crystal-6/NN	dobj||ã-4/VB||structure-7/NN	parataxis||ã-4/VB||structure-7/NN	det||protein-10/NN||the-9/DT	prep_of||structure-7/NN||protein-10/NN	appos||protein-10/NN||tp0298-12/NNP	vmod||protein-10/NN||encoded-14/VBN	agent||encoded-14/VBN||treponemapallidum-16/NN	det||spirochete-20/NN||the-18/DT	amod||spirochete-20/NN||syphilis-19/JJ	nsubj||similar-31/JJ||spirochete-20/NN	vmod||spirochete-20/NN||demonstrated-22/VBN	mark||fold-29/JJ||that-23/IN	det||$-26/$||the-24/DT	amod||$-26/$||proteinâ-25/JJ	nsubj||fold-29/JJ||$-26/$	num||$-26/$||™-27/CD	cop||fold-29/JJ||s-28/VBZ	ccomp||demonstrated-22/VBN||fold-29/JJ	cop||similar-31/JJ||is-30/VBZ	root||ROOT-0/null||similar-31/JJ	det||components-35/NNS||the-33/DT	amod||components-35/NNS||ligand-binding-34/JJ	prep_to||similar-31/JJ||components-35/NNS	amod||transporters-38/NNS||abc-type-37/JJ	prep_of||components-35/NNS||transporters-38/NNS	syphilis-19||treponemapallidum-16||no||a 1.3-ã… crystal structure of the protein (tp0298) encoded by treponemapallidum , the syphilis spirochete, demonstrated that the proteinâ€™s fold is similar to the ligand-binding components of abc-type transporters.
nn||depletion-2/NN||iron-1/NN	nsubjpass||evaluated-16/VBN||depletion-2/NN	appos||depletion-2/NN||lack-4/NN	nn||stores-7/NNS||iron-6/NN	prep_of||lack-4/NN||stores-7/NNS	advmod||evaluated-16/VBN||irondeficiency-9/RB	amod||anemia-12/NN||irondeficiency-11/JJ	nsubjpass||evaluated-16/VBN||anemia-12/NN	conj_and||anemia-12/NN||anemia-14/NN	nsubjpass||evaluated-16/VBN||anemia-14/NN	auxpass||evaluated-16/VBN||were-15/VBD	root||ROOT-0/null||evaluated-16/VBN	prep_among||evaluated-16/VBN||them-18/PRP	irondeficiency-11||iron-6||yes||iron depletion, lack of iron stores, irondeficiency, irondeficiency anemia and anemia were evaluated among them.
amod||analyses-5/NNS||classical-1/JJ	conj_and||classical-1/JJ||quantitative-3/JJ	amod||analyses-5/NNS||quantitative-3/JJ	nn||analyses-5/NNS||linkage-4/NN	nsubjpass||used-12/VBN||analyses-5/NNS	amod||crosses-8/NNS||genetic-7/JJ	prep_of||analyses-5/NNS||crosses-8/NNS	aux||used-12/VBN||have-9/VBP	advmod||used-12/VBN||traditionally-10/RB	auxpass||used-12/VBN||been-11/VBN	root||ROOT-0/null||used-12/VBN	nn||genes-15/NNS||map-14/NN	prep_to||used-12/VBN||genes-15/NNS	prep_of||genes-15/NNS||interest-17/NN	prep_such_as||genes-15/NNS||those-21/DT	vmod||those-21/DT||conferring-22/VBG	amod||resistance-26/NN||chloroquine-23/JJ	conj_or||chloroquine-23/JJ||quinine-25/JJ	amod||resistance-26/NN||quinine-25/JJ	dobj||conferring-22/VBG||resistance-26/NN	nn||parasites-29/NNS||malaria-28/NN	prep_in||resistance-26/NN||parasites-29/NNS	malaria-28||chloroquine-23||yes||classical and quantitative linkage analyses of genetic crosses have traditionally been used to map genes of interest, such as those conferring chloroquine or quinine resistance in malaria parasites.
num||hundred-2/CD||one-1/CD	nsubjpass||interviewed-17/VBN||hundred-2/CD	amod||users-6/NNS||twenty-six-4/JJ	nn||users-6/NNS||methamphetamine-5/NN	conj_and||hundred-2/CD||users-6/NNS	nsubj||had-8/VBD||users-6/NNS	nsubjpass||interviewed-17/VBN||users-6/NNS	rcmod||users-6/NNS||had-8/VBD	det||history-13/NN||a-9/DT	amod||history-13/NN||current-10/JJ	conj_or||current-10/JJ||past-12/JJ	amod||history-13/NN||past-12/JJ	dobj||had-8/VBD||history-13/NN	prep_of||history-13/NN||methamphetaminedependence-15/NN	auxpass||interviewed-17/VBN||were-16/VBD	root||ROOT-0/null||interviewed-17/VBN	poss||experiences-20/NNS||their-19/PRP$	prep_about||interviewed-17/VBN||experiences-20/NNS	cc||perceived-24/VBD||and-23/CC	dep||experiences-20/NNS||perceived-24/VBD	dobj||perceived-24/VBD||barriers-25/NNS	prep||perceived-24/VBD||to-26/TO	prep_of||experiences-20/NNS||treatment-28/NN	methamphetaminedependence-15||methamphetamine-5||no||one hundred and twenty-six methamphetamine users who had a current or past history of methamphetaminedependence were interviewed about their experiences of, and perceived barriers to, treatment.
nsubj||well-investigated-10/JJ||corynebacteriumdiphtheriae-1/NN	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||corynebacteriumdiphtheriae-1/NN||agent-5/NN	prep_of||agent-5/NN||diphtheria-7/NN	cop||well-investigated-10/JJ||is-9/VBZ	root||ROOT-0/null||well-investigated-10/JJ	prep_in||well-investigated-10/JJ||respect-12/NN	nn||production-15/NN||toxin-14/NN	prep_to||well-investigated-10/JJ||production-15/NN	mark||known-20/VBN||while-17/IN	nsubjpass||known-20/VBN||little-18/RB	auxpass||known-20/VBN||is-19/VBZ	advcl||well-investigated-10/JJ||known-20/VBN	nn||factors-24/NNS||c.-22/NN	nn||factors-24/NNS||diphtheriae-23/NN	prep_about||known-20/VBN||factors-24/NNS	amod||factors-24/NNS||crucial-25/JJ	prep_for||crucial-25/JJ||colonization-27/NN	det||host-30/NN||the-29/DT	prep_of||colonization-27/NN||host-30/NN	diphtheria-7||corynebacteriumdiphtheriae-1||no||corynebacteriumdiphtheriae , the causative agent of diphtheria , is well-investigated in respect to toxin production , while little is known about c. diphtheriae factors crucial for colonization of the host .
prep_in||conducted-11/VBD||collaboration-2/NN	det||mbale-8/NN||the-4/DT	nn||mbale-8/NN||aids-5/NNS	nn||mbale-8/NN||support-6/NN	nn||mbale-8/NN||organisation-7/NN	prep_with||collaboration-2/NN||mbale-8/NN	nsubj||conducted-11/VBD||we-10/PRP	root||ROOT-0/null||conducted-11/VBD	det||survey-14/NN||a-12/DT	amod||survey-14/NN||cross-sectional-13/JJ	dobj||conducted-11/VBD||survey-14/NN	num||mothers-18/NNS||235-16/CD	amod||mothers-18/NNS||hiv-positive-17/JJ	prep_involving||survey-14/NN||mothers-18/NNS	prep_in||mothers-18/NNS||uganda-20/NN	aids-5||hiv--1||no||in collaboration with the aids support organisation mbale, we conducted a cross-sectional survey involving 235 hiv-positive mothers in uganda.
advmod||investigate-4/VB||here-1/RB	nsubj||investigate-4/VB||we-3/PRP	root||ROOT-0/null||investigate-4/VB	mark||determinant-39/NN||whether-5/IN	nn||variation-8/NN||copy-6/NN	nn||variation-8/NN||number-7/NN	nsubj||determinant-39/NN||variation-8/NN	appos||variation-8/NN||cnv-10/NN	prep_at||variation-8/NN||ccl3-13/CD	prep_like||variation-8/NN||genes-16/NNS	appos||genes-16/NNS||ccl3l-18/NNP	det||factor-25/NN||a-21/DT	amod||factor-25/NN||key-22/JJ	amod||factor-25/NN||genetic-23/JJ	nn||factor-25/NN||host-24/NN	appos||genes-16/NNS||factor-25/NN	amod||susceptibility-28/NN||hiv/aids-27/JJ	prep_for||factor-25/NN||susceptibility-28/NN	amod||response-32/NN||cell-mediated-30/JJ	amod||response-32/NN||immune-31/JJ	prep_like||variation-8/NN||response-32/NN	conj_and||genes-16/NNS||response-32/NN	prep_in||response-32/NN||humans-34/NNS	cop||determinant-39/NN||is-36/VBZ	advmod||determinant-39/NN||also-37/RB	det||determinant-39/NN||a-38/DT	ccomp||investigate-4/VB||determinant-39/NN	prep_of||determinant-39/NN||time-41/NN	prep_until||determinant-39/NN||onset-43/NN	prep_of||onset-43/NN||simian-aids-45/NNS	amod||macaques-48/NNS||rhesus-47/JJ	prep_in||simian-aids-45/NNS||macaques-48/NNS	aids--1||hiv--1||no||here, we investigate whether copy number variation (cnv) at ccl3 -like genes ( ccl3l ), a key genetic host factor for hiv/aids susceptibility and cell-mediated immune response in humans, is also a determinant of time until onset of simian-aids in rhesus macaques.
advmod||inhibits-4/VBZ||moreover-1/RB	nsubj||inhibits-4/VBZ||curcumin-3/NN	root||ROOT-0/null||inhibits-4/VBZ	amod||angiogenesis-8/NNS||microvascular-5/JJ	amod||angiogenesis-8/NNS||endothelial-6/JJ	nn||angiogenesis-8/NNS||cell-7/NN	dobj||inhibits-4/VBZ||angiogenesis-8/NNS	prep_through||inhibits-4/VBZ||inhibition-10/NN	amod||expression-13/NN||cox-2-12/JJ	prep_of||inhibition-10/NN||expression-13/NN	amod||production-16/NN||pge2-15/JJ	prep_of||inhibition-10/NN||production-16/NN	conj_and||expression-13/NN||production-16/NN	vmod||inhibits-4/VBZ||suggesting-18/VBG	mark||possesses-23/VBZ||that-19/IN	det||product-22/NN||this-20/DT	amod||product-22/NN||natural-21/JJ	nsubj||possesses-23/VBZ||product-22/NN	ccomp||suggesting-18/VBG||possesses-23/VBZ	amod||properties-25/NNS||antiangiogenic-24/JJ	dobj||possesses-23/VBZ||properties-25/NNS	nsubj||warrants-28/VBZ||properties-25/NNS	rcmod||properties-25/NNS||warrants-28/VBZ	amod||investigation-30/NN||further-29/JJ	dobj||warrants-28/VBZ||investigation-30/NN	amod||treatment-33/NN||adjuvant-32/JJ	prep_as||warrants-28/VBZ||treatment-33/NN	prep_of||treatment-33/NN||ibd-35/NN	prep_of||treatment-33/NN||cancer-37/NN	conj_and||ibd-35/NN||cancer-37/NN	ibd-35||adjuvant-32||no_rel||moreover, curcumin inhibits microvascular endothelial cell angiogenesis through inhibition of cox-2 expression and pge2 production, suggesting that this natural product possesses antiangiogenic properties, which warrants further investigation as adjuvant treatment of ibd and cancer.
nsubj||preserved-9/VBD||attachment-1/NN	amod||chains-5/NNS||neutral-3/JJ	amod||chains-5/NNS||amide-linked-4/JJ	prep_of||attachment-1/NN||chains-5/NNS	amod||chains-8/NNS||thiourea-containing-7/JJ	prep_of||attachment-1/NN||chains-8/NNS	conj_or||chains-5/NNS||chains-8/NNS	root||ROOT-0/null||preserved-9/VBD	det||affinity-12/NN||the-10/DT	amod||affinity-12/NN||moderate-11/JJ	dobj||preserved-9/VBD||affinity-12/NN	dobj||preserved-9/VBD||efficacy-14/NN	conj_and||affinity-12/NN||efficacy-14/NN	det||subtype-19/NN||the-16/DT	amod||subtype-19/NN||a1-17/JJ	nn||subtype-19/NN||ar-18/NN	prep_at||preserved-9/VBD||subtype-19/NN	expl||was-23/VBD||there-22/EX	conj_but||preserved-9/VBD||was-23/VBD	neg||selectivity-25/NN||no-24/DT	nsubj||was-23/VBD||selectivity-25/NN	det||ar-29/NN||the-27/DT	amod||ar-29/NN||a3-28/JJ	prep_for||selectivity-25/NN||ar-29/NN	ar-29||thiourea--1||no_rel||attachment of neutral amide-linked chains or thiourea-containing chains preserved the moderate affinity and efficacy at the a1 ar subtype, but there was no selectivity for the a3 ar.
det||dipeptidase-7/NN||another-1/DT	amod||family-4/NN||non-s28-3/JJ	appos||dipeptidase-7/NN||family-4/NN	amod||dipeptidase-7/NN||dipeptidyl-6/JJ	nsubj||target-15/NN||dipeptidase-7/NN	appos||dipeptidase-7/NN||dpp4-9/NNP	cop||target-15/NN||is-11/VBZ	det||target-15/NN||a-12/DT	amod||target-15/NN||major-13/JJ	nn||target-15/NN||drug-14/NN	root||ROOT-0/null||target-15/NN	prep_in||target-15/NN||type2diabetes-17/CD	nsubj||developed-23/VBN||merck-20/NN	aux||developed-23/VBN||has-21/VBZ	advmod||developed-23/VBN||already-22/RB	conj_and||target-15/NN||developed-23/VBN	det||inhibitor-26/NN||a-24/DT	amod||inhibitor-26/NN||successful-25/JJ	dobj||developed-23/VBN||inhibitor-26/NN	prep_of||inhibitor-26/NN||dpp4-28/NNS	det||sitagliptin-33/NN||the-30/DT	amod||sitagliptin-33/NN||anti-hyperglycemic-31/JJ	nn||sitagliptin-33/NN||drug-32/NN	appos||dpp4-28/NNS||sitagliptin-33/NN	det||treatment-37/NN||the-36/DT	prep_for||developed-23/VBN||treatment-37/NN	prep_of||treatment-37/NN||type2diabetes-39/CD	type2diabetes-39||sitagliptin-33||yes||another (non-s28 family) dipeptidyl dipeptidase (dpp4) is a major drug target in type2diabetes, and merck has already developed a successful inhibitor of dpp4, the anti-hyperglycemic drug sitagliptin, for the treatment of type2diabetes.
det||problem-3/NN||a-1/DT	amod||problem-3/NN||major-2/JJ	nsubj||lack-14/NN||problem-3/NN	det||diagnosis-7/NN||the-5/DT	amod||diagnosis-7/NN||effective-6/JJ	prep_for||problem-3/NN||diagnosis-7/NN	prep_for||problem-3/NN||management-9/NN	conj_and||diagnosis-7/NN||management-9/NN	prep_of||diagnosis-7/NN||priondiseases-11/NNS	cop||lack-14/NN||is-12/VBZ	det||lack-14/NN||the-13/DT	root||ROOT-0/null||lack-14/NN	amod||assays-18/NNS||rapid-16/JJ	amod||assays-18/NNS||high-throughput-17/JJ	prep_of||lack-14/NN||assays-18/NNS	aux||measure-20/VB||to-19/TO	vmod||lack-14/NN||measure-20/VB	amod||levels-22/NNS||low-21/JJ	dobj||measure-20/VB||levels-22/NNS	prep_of||levels-22/NNS||prions-24/NNS	priondiseases-11||prions-24||no||a major problem for the effective diagnosis and management of priondiseases is the lack of rapid high-throughput assays to measure low levels of prions.
nsubjpass||treated-7/VBN||pmvec-1/NN	vmod||pmvec-1/NN||isolated-2/VBN	amod||lung-5/NN||human-4/JJ	prep_from||isolated-2/VBN||lung-5/NN	auxpass||treated-7/VBN||were-6/VBD	root||ROOT-0/null||treated-7/VBN	amod||albumin-45/NN||vitro-9/NN	amod||stimulation-12/NN||septic-11/JJ	prep_with||vitro-9/NN||stimulation-12/NN	amod||-RSB--17/NNS||lipopolysaccharide-14/JJ	amod||-RSB--17/NNS||-LSB--15/JJ	nn||-RSB--17/NNS||lps-16/NN	dep||stimulation-12/NN||-RSB--17/NNS	det||mixture-20/NN||a-19/DT	dep||stimulation-12/NN||mixture-20/NN	conj_or||-RSB--17/NNS||mixture-20/NN	amod||-RSB--26/NNS||clinically-relevant-22/JJ	nn||-RSB--26/NNS||cytokines-23/NNS	nn||-RSB--26/NNS||-LSB--24/NN	nn||-RSB--26/NNS||cytomix-25/NN	prep_of||mixture-20/NN||-RSB--26/NNS	dep||stimulation-12/NN||plasma-29/NN	conj_or||-RSB--17/NNS||plasma-29/NN	prep_from||plasma-29/NN||patients-31/NNS	amod||sepsis-34/NN||severe-33/JJ	prep_with||patients-31/NNS||sepsis-34/NN	det||leak-40/NN||the-38/DT	amod||leak-40/NN||trans-pmvec-39/JJ	prep_with||vitro-9/NN||leak-40/NN	conj_and||stimulation-12/NN||leak-40/NN	prep_of||leak-40/NN||evans-42/NNS	amod||albumin-45/NN||blue-43/JJ	amod||albumin-45/NN||dye-labeled-44/JJ	prep_in||treated-7/VBN||albumin-45/NN	vmod||albumin-45/NN||assessed-46/VBN	sepsis-34||dye--1||no_rel||pmvec isolated from human lung were treated in vitro with septic stimulation (lipopolysaccharide [lps], a mixture of clinically-relevant cytokines [cytomix], or plasma from patients with severe sepsis), and the trans-pmvec leak of evans blue dye-labeled albumin assessed.
det||study-6/NN||the-1/DT	amod||study-6/NN||alpha-tocopherol-2/JJ	amod||study-6/NN||beta-carotene-3/JJ	nn||study-6/NN||cancer-4/NN	nn||study-6/NN||prevention-5/NN	nsubj||examined-7/VBD||study-6/NN	root||ROOT-0/null||examined-7/VBD	det||effects-9/NNS||the-8/DT	dobj||examined-7/VBD||effects-9/NNS	amod||carotene-22/NN||vitamine-11/JJ	num||mg-14/NN||50-13/CD	dep||vitamine-11/JJ||mg-14/NN	prep_per||mg-14/NN||day-16/NN	npadvmod||²-20/JJ||î-19/NN	conj_and||vitamine-11/JJ||²-20/JJ	amod||carotene-22/NN||²-20/JJ	prep_of||effects-9/NNS||carotene-22/NN	num||mg-25/NN||20-24/CD	dep||carotene-22/NN||mg-25/NN	prep_per||mg-25/NN||day-27/NN	nn||cancer-31/NN||lung-30/NN	prep_on||examined-7/VBD||cancer-31/NN	num||smokers-35/NNS||29,133-33/CD	amod||smokers-35/NNS||male-34/JJ	prep_in||cancer-31/NN||smokers-35/NNS	vmod||smokers-35/NNS||aged-36/VBN	xcomp||aged-36/VBN||50â-37/VBG	num||years-41/NNS||$-38/$	num||$-38/$||69-40/CD	tmod||50â-37/VBG||years-41/NNS	vmod||50â-37/VBG||using-42/VBG	det||ã-45/NN||a-43/DT	num||ã-45/NN||2-44/CD	dobj||using-42/VBG||ã-45/NN	num||design-49/NN||2-47/CD	amod||design-49/NN||factorial-48/JJ	dep||ã-45/NN||design-49/NN	alpha-tocopherol-2||cancer-31||no_rel||the alpha-tocopherol beta-carotene cancer prevention study examined the effects of vitamine (50 mg per day) and î²-carotene (20 mg per day) on lung cancer in 29,133 male smokers aged 50â€“69 years using a 2 ã— 2 factorial design.
nn||ebv-3/NN||type-1/NN	num||ebv-3/NN||1-2/CD	nsubj||genotypes-12/NNS||ebv-3/NN	amod||zp-p-6/NN||bzlf1-5/JJ	conj_and||ebv-3/NN||zp-p-6/NN	nsubj||genotypes-12/NNS||zp-p-6/NN	prep_of||zp-p-6/NN||ebv-8/NN	cop||genotypes-12/NNS||were-9/VBD	det||genotypes-12/NNS||the-10/DT	amod||genotypes-12/NNS||predominant-11/JJ	root||ROOT-0/null||genotypes-12/NNS	amod||ebv-15/NN||nonmalignant-14/JJ	prep_in||genotypes-12/NNS||ebv-15/NN	vmod||ebv-15/NN||associated-16/VBN	dobj||associated-16/VBN||diseases-17/NNS	amod||children-20/NNS||chinese-19/JJ	prep_in||diseases-17/NNS||children-20/NNS	amod||variant-23/NN||zp-v3-22/JJ	nsubj||correlates-25/VB||variant-23/NN	aux||correlates-25/VB||may-24/MD	conj_and||genotypes-12/NNS||correlates-25/VB	prep_with||correlates-25/VB||the-27/DT	amod||the-27/DT||developing-28/VBG	amod||diseases-32/NNS||severe-30/JJ	nn||diseases-32/NNS||ebvinfection-31/NN	prep_of||the-27/DT||diseases-32/NNS	prep_such_as||the-27/DT||caebv-36/NN	prep_such_as||the-27/DT||ebv-hlh-38/NN	conj_and||caebv-36/NN||ebv-hlh-38/NN	ebvinfection-31||ebv-15||no||type 1 ebv and bzlf1 zp-p of ebv were the predominant genotypes in nonmalignant ebv associated diseases in chinese children and zp-v3 variant may correlates with the developing of severe ebvinfection diseases, such as caebv and ebv-hlh.
det||treatment-3/NN||the-2/DT	prep_in||modality-15/NN||treatment-3/NN	prepc_of||treatment-3/NN||gravesâ-5/VBG	dep||basedowdisease-8/JJ||$-6/NNP	dep||gravesâ-5/VBG||basedowdisease-8/JJ	nsubj||modality-15/NN||radiotherapy-10/NN	cop||modality-15/NN||is-11/VBZ	det||modality-15/NN||a-12/DT	amod||modality-15/NN||well-tolerated-13/JJ	nn||modality-15/NN||treatment-14/NN	root||ROOT-0/null||modality-15/NN	basedowdisease-8||graves--1||no||in the treatment of gravesâ€“basedowdisease, radiotherapy is a well-tolerated treatment modality.
det||prevalence-2/NN||the-1/DT	nsubj||%-7/NN||prevalence-2/NN	prep_of||prevalence-2/NN||isoniazid-resistance-4/NN	cop||%-7/NN||was-5/VBD	num||%-7/NN||14.2-6/CD	root||ROOT-0/null||%-7/NN	dep||%-7/NN||n-9/VBN	dep||21-11/CD||=-10/SYM	ccomp||n-9/VBN||21-11/CD	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-7/NN||ci-16/NN	num||%-20/NN||9.0-20-18/CD	num||%-20/NN||.9-19/CD	appos||ci-16/NN||%-20/NN	det||prevalence-24/NN||the-23/DT	conj_and||%-7/NN||prevalence-24/NN	number||8.8-27/CD||mdr-tb-26/CD	num||%-28/NN||8.8-27/CD	prep_of||prevalence-24/NN||%-28/NN	dep||%-28/NN||n-30/VBN	dep||13-32/CD||=-31/SYM	ccomp||n-30/VBN||13-32/CD	number||%-36/NN||95-35/CD	amod||ci-37/NN||%-36/NN	dep||prevalence-24/NN||ci-37/NN	num||%-41/NN||4.8-14-39/CD	num||%-41/NN||.6-40/CD	appos||ci-37/NN||%-41/NN	tb--1||isoniazid--1||yes||the prevalence of isoniazid-resistance was 14.2% (n = 21) (95%ci, 9.0-20.9%) and the prevalence of mdr-tb 8.8% (n = 13) (95%ci, 4.8-14.6%).
amod||disposal-4/NN||impaired-1/VBN	amod||disposal-4/NN||insulin-dependent-2/JJ	nn||disposal-4/NN||glucose-3/NN	nsubj||harbinger-11/NN||disposal-4/NN	prep_in||disposal-4/NN||muscle-6/NN	prep_in||disposal-4/NN||fat-8/NN	conj_and||muscle-6/NN||fat-8/NN	cop||harbinger-11/NN||is-9/VBZ	det||harbinger-11/NN||a-10/DT	root||ROOT-0/null||harbinger-11/NN	prep_of||harbinger-11/NN||type2diabetes-13/CD	amod||models-17/NNS||murine-16/JJ	nsubj||conspicuous-26/JJ||models-17/NNS	amod||insulinresistance-20/NN||selective-19/JJ	prep_of||models-17/NNS||insulinresistance-20/NN	det||sites-24/NNS||these-22/DT	num||sites-24/NNS||two-23/CD	prep_at||insulinresistance-20/NN||sites-24/NNS	cop||conspicuous-26/JJ||are-25/VBP	conj_but||harbinger-11/NN||conspicuous-26/JJ	poss||failure-29/NN||their-28/PRP$	prep_by||conspicuous-26/JJ||failure-29/NN	aux||cause-31/VB||to-30/TO	vmod||failure-29/NN||cause-31/VB	dobj||cause-31/VB||hyperglycemia-32/NN	hyperglycemia-32||glucose-3||no||impaired insulin-dependent glucose disposal in muscle and fat is a harbinger of type2diabetes, but murine models of selective insulinresistance at these two sites are conspicuous by their failure to cause hyperglycemia.
prep_conclusionsâ||demonstrate-6/VBP||$-2/$	det||studies-5/NNS||these-4/DT	nsubj||demonstrate-6/VBP||studies-5/NNS	root||ROOT-0/null||demonstrate-6/VBP	det||variety-9/NN||a-8/DT	prep_in||demonstrate-6/VBP||variety-9/NN	amod||models-12/NNS||rodent-11/JJ	prep_of||variety-9/NN||models-12/NNS	mark||/-19/VBZ||that-13/IN	amod||delivery-15/NN||systemic-14/JJ	nsubj||/-19/VBZ||delivery-15/NN	num||.2-18/CD||kir6-17/CD	prep_of||delivery-15/NN||.2-18/CD	ccomp||demonstrate-6/VBP||/-19/VBZ	amod||$-21/NNS||sur-1â-20/JJ	dobj||/-19/VBZ||$-21/NNS	amod||kcos-24/NNS||selective-23/JJ	nsubj||enhance-25/VB||kcos-24/NNS	dep||/-19/VBZ||enhance-25/VB	det||response-29/NN||the-26/DT	nn||response-29/NN||glucose-27/NN	nn||response-29/NN||counterregulatory-28/NN	dobj||enhance-25/VB||response-29/NN	amod||hypoglycemia-32/NN||insulin-induced-31/JJ	prep_to||enhance-25/VB||hypoglycemia-32/NN	insulin--1||hypoglycemia-32||no_rel||conclusionsâ€” these studies demonstrate in a variety of rodent models that systemic delivery of kir6.2/sur-1â€“selective kcos enhance the glucose counterregulatory response to insulin-induced hypoglycemia.
nn||falciparum-2/NN||plasmodium-1/NN	nsubj||evolved-13/VBN||falciparum-2/NN	nsubj||become-15/VB||falciparum-2/NN	det||agent-6/NN||the-4/DT	amod||agent-6/NN||causative-5/JJ	appos||falciparum-2/NN||agent-6/NN	amod||malaria-10/NN||severe-8/JJ	amod||malaria-10/NN||human-9/JJ	prep_of||agent-6/NN||malaria-10/NN	aux||evolved-13/VBN||has-12/VBZ	root||ROOT-0/null||evolved-13/VBN	aux||become-15/VB||to-14/TO	xcomp||evolved-13/VBN||become-15/VB	acomp||become-15/VB||resistant-16/JJ	advmod||successful-19/JJ||previously-18/RB	amod||chemotherapies-21/NNS||successful-19/JJ	amod||chemotherapies-21/NNS||antimalarial-20/JJ	prep_to||resistant-16/JJ||chemotherapies-21/NNS	advmod||notably-24/RB||most-23/RBS	advmod||chemotherapies-21/NNS||notably-24/RB	dep||chemotherapies-21/NNS||chloroquine-25/NN	det||antifolates-28/NNS||the-27/DT	dep||chemotherapies-21/NNS||antifolates-28/NNS	conj_and||chloroquine-25/NN||antifolates-28/NNS	malaria-10||chloroquine-25||yes||plasmodium falciparum , the causative agent of severe human malaria, has evolved to become resistant to previously successful antimalarial chemotherapies, most notably chloroquine and the antifolates.
advmod||identical-20/JJ||however-1/RB	det||prevalence-4/NN||the-3/DT	nsubj||identical-20/JJ||prevalence-4/NN	prep_of||prevalence-4/NN||borreliaburgdorferi-6/NNS	det||bacterium-9/NN||the-8/DT	appos||borreliaburgdorferi-6/NNS||bacterium-9/NN	nsubj||causes-11/VBZ||bacterium-9/NN	rcmod||bacterium-9/NN||causes-11/VBZ	acomp||causes-11/VBZ||lymedisease-12/JJ	det||vector-17/NN||the-15/DT	nn||vector-17/NN||tick-16/NN	prep_in||causes-11/VBZ||vector-17/NN	cop||identical-20/JJ||is-18/VBZ	advmod||identical-20/JJ||nearly-19/RB	root||ROOT-0/null||identical-20/JJ	det||regions-24/NNS||the-22/DT	num||regions-24/NNS||2-23/CD	prep_in||identical-20/JJ||regions-24/NNS	lymedisease-12||bacterium-9||no||however, the prevalence of borreliaburgdorferi , the bacterium that causes lymedisease, in the tick vector is nearly identical in the 2 regions.
amod||treatments-2/NNS||current-1/JJ	nsubj||included-6/VBN||treatments-2/NNS	prep_for||treatments-2/NNS||ibs-c-4/NN	aux||included-6/VBN||have-5/VBP	root||ROOT-0/null||included-6/VBN	nn||laxatives-14/NNS||fiber-7/NN	conj_and||fiber-7/NN||antispasmodics-9/NNS	nn||laxatives-14/NNS||antispasmodics-9/NNS	conj_and||fiber-7/NN||osmotic-11/NN	nn||laxatives-14/NNS||osmotic-11/NN	conj_and||fiber-7/NN||stimulant-13/NN	nn||laxatives-14/NNS||stimulant-13/NN	dobj||included-6/VBN||laxatives-14/NNS	det||agonist-22/NN||the-17/DT	advmod||limited-20/JJ||now-18/RB	advmod||limited-20/JJ||severely-19/RB	amod||agonist-22/NN||limited-20/JJ	amod||agonist-22/NN||5-ht4-21/JJ	nsubj||tegaserod-23/VBD||agonist-22/NN	conj_and||included-6/VBN||tegaserod-23/VBD	ibs--1||tegaserod-23||yes||current treatments for ibs-c have included fiber, antispasmodics, osmotic and stimulant laxatives, and the now severely limited 5-ht4 agonist tegaserod.
det||change-3/NN||the-1/DT	amod||change-3/NN||recent-2/JJ	nsubjpass||accompanied-20/VBN||change-3/NN	nn||policy-6/NN||treatment-5/NN	prep_of||change-3/NN||policy-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||policy-6/NN||malaria-9/NN	prep_from||malaria-9/NN||sulfadoxine-pyrime-thamine-11/NN	prep_to||sulfadoxine-pyrime-thamine-11/NN||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	prep_in||artemether-lumefantrine-13/NN||kenya-18/NN	auxpass||accompanied-20/VBN||was-19/VBD	root||ROOT-0/null||accompanied-20/VBN	amod||recommendations-25/NNS||revised-22/VBN	nn||recommendations-25/NNS||malaria-23/NN	nn||recommendations-25/NNS||diagnosis-24/NN	nsubj||promoting-26/VBG||recommendations-25/NNS	agent||accompanied-20/VBN||promoting-26/VBG	amod||treatment-29/NN||presumptive-27/JJ	amod||treatment-29/NN||antimalarial-28/JJ	dobj||promoting-26/VBG||treatment-29/NN	amod||children-32/NNS||young-31/JJ	prep_in||treatment-29/NN||children-32/NNS	amod||diagnosis-35/NN||parasitological-34/JJ	dobj||promoting-26/VBG||diagnosis-35/NN	conj_and||treatment-29/NN||diagnosis-35/NN	prep_in||diagnosis-35/NN||patients-37/NNS	num||years-39/NNS||5-38/CD	dep||promoting-26/VBG||years-39/NNS	dep||promoting-26/VBG||older-41/JJR	conj_and||years-39/NNS||older-41/JJR	malaria-23||lumefantrine--1||yes||the recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-thamine to artemether-lumefantrine (al) in kenya was accompanied by revised malaria diagnosis recommendations promoting presumptive antimalarial treatment in young children and parasitological diagnosis in patients 5 years and older.
nsubjpass||accompanied-11/VBN||apoptosis-1/NNS	nn||cells-4/NNS||melanoma-3/NN	prep_in||apoptosis-1/NNS||cells-4/NNS	vmod||cells-4/NNS||induced-5/VBN	agent||induced-5/VBN||tmz-7/NN	agent||induced-5/VBN||fotemustine-9/NN	conj_and||tmz-7/NN||fotemustine-9/NN	auxpass||accompanied-11/VBN||was-10/VBD	root||ROOT-0/null||accompanied-11/VBN	amod||break-14/NN||double-strand-13/JJ	agent||accompanied-11/VBN||break-14/NN	appos||break-14/NN||dsb-16/NN	dep||break-14/NN||formation-18/NN	mark||determined-21/VBN||as-20/IN	dep||break-14/NN||determined-21/VBN	amod||phosphorylation-24/NN||h2ax-23/JJ	prep_by||determined-21/VBN||phosphorylation-24/NN	amod||activation-30/NN||caspase-3-27/JJ	conj_and||caspase-3-27/JJ||-7-29/JJ	amod||activation-30/NN||-7-29/JJ	agent||accompanied-11/VBN||activation-30/NN	conj_and||break-14/NN||activation-30/NN	nn||cleavage-35/NN||parp-34/NN	conj_and||break-14/NN||cleavage-35/NN	conj_and||activation-30/NN||cleavage-35/NN	melanoma-3||tmz-7||yes||apoptosis in melanoma cells induced by tmz and fotemustine was accompanied by double-strand break (dsb) formation (as determined by h2ax phosphorylation) and caspase-3 and -7 activation as well as parp cleavage.
amod||index-4/NN||left-1/JJ	nn||index-4/NN||ventricular-2/NN	nn||index-4/NN||mass-3/NN	nsubj||decreased-219/VBD||index-4/NN	dep||index-4/NN||lvmi-6/NNS	num||â-9/NN||38.5-8/CD	dep||lvmi-6/NNS||â-9/NN	num||â-29/NN||$-10/$	number||â-12/CD||‰-11/CD	num||$-10/$||â-12/CD	amod||â-29/NN||±-13/JJ	amod||â-29/NN||â-14/JJ	amod||â-29/NN||$-15/$	number||10.7-17/CD||‰-16/CD	num||$-15/$||10.7-17/CD	nn||â-29/NN||vs-18/NN	nn||â-29/NN||35.2-19/NN	amod||â-29/NN||â-20/JJ	amod||â-29/NN||$-21/$	number||â-23/CD||‰-22/CD	num||$-21/$||â-23/CD	nn||â-29/NN||±-24/NN	nn||â-29/NN||â-25/NN	amod||â-29/NN||$-26/$	number||7.5-28/CD||‰-27/CD	num||$-26/$||7.5-28/CD	dep||â-9/NN||â-29/NN	amod||â-29/NN||g/m2-30/JJ	dep||g/m2-30/JJ||.7-31/CD	nn||â-34/NN||p-33/NN	appos||â-9/NN||â-34/NN	num||â-38/NN||$-35/$	number||=-37/CD||‰-36/CD	num||$-35/$||=-37/CD	dep||â-34/NN||â-38/NN	num||â-38/NN||$-39/$	number||0.0001-41/CD||‰-40/CD	num||$-39/$||0.0001-41/CD	appos||index-4/NN||prevalence-44/NN	prep_of||prevalence-44/NN||leftventricularhypertrophy-46/NN	num||%-49/NN||46.5-48/CD	dep||prevalence-44/NN||%-49/NN	number||31.4-51/CD||vs-50/CD	num||%-52/NN||31.4-51/CD	dep||%-49/NN||%-52/NN	nn||â-55/NN||p-54/NN	dep||%-52/NN||â-55/NN	num||â-59/NN||$-56/$	number||=-58/CD||‰-57/CD	num||$-56/$||=-58/CD	dep||â-55/NN||â-59/NN	num||â-59/NN||$-60/$	number||0.0001-62/CD||‰-61/CD	num||$-60/$||0.0001-62/CD	amod||thickness-67/NN||carotid-65/JJ	amod||thickness-67/NN||intima-media-66/JJ	appos||index-4/NN||thickness-67/NN	dep||thickness-67/NN||cimt-69/VB	num||â-72/NN||0.44-71/CD	nsubj||â-75/VBP||â-72/NN	dep||â-72/NN||$-73/$	num||$-73/$||‰-74/CD	dep||cimt-69/VB||â-75/VBP	amod||mm-93/NN||±-76/JJ	amod||mm-93/NN||â-77/JJ	amod||mm-93/NN||$-78/$	number||0.05-80/CD||‰-79/CD	num||$-78/$||0.05-80/CD	nn||mm-93/NN||vs-81/NN	num||mm-93/NN||0.42-82/CD	amod||mm-93/NN||â-83/JJ	amod||mm-93/NN||$-84/$	num||$-84/$||‰-85/CD	nn||mm-93/NN||â-86/NN	num||mm-93/NN||±-87/CD	amod||mm-93/NN||â-88/JJ	amod||mm-93/NN||$-89/$	number||0.04-91/CD||‰-90/CD	num||$-89/$||0.04-91/CD	nn||mm-93/NN||â-92/NN	dobj||â-75/VBP||mm-93/NN	advmod||â-100/VBP||p-95/RB	advmod||â-100/VBP||â-96/RB	nsubj||â-100/VBP||$-97/$	number||=-99/CD||‰-98/CD	num||$-97/$||=-99/CD	parataxis||â-75/VBP||â-100/VBP	dobj||â-100/VBP||$-101/$	number||0.0001-103/CD||‰-102/CD	num||$-101/$||0.0001-103/CD	nn||area-109/NN||wall-106/NN	amod||area-109/NN||cross-107/JJ	amod||area-109/NN||sectional-108/JJ	appos||index-4/NN||area-109/NN	dep||area-109/NN||wcsa-111/NN	num||â-114/NN||7.5-113/CD	dep||p-137/VB||â-114/NN	dep||â-119/JJ||$-115/$	number||â-117/CD||‰-116/CD	num||$-115/$||â-117/CD	advmod||â-119/JJ||±-118/RB	amod||â-114/NN||â-119/JJ	num||mm2-135/NNS||$-120/$	number||1.3-122/CD||‰-121/CD	num||$-120/$||1.3-122/CD	nn||mm2-135/NNS||vs-123/NNP	num||mm2-135/NNS||6.9-124/CD	amod||mm2-135/NNS||â-125/JJ	num||mm2-135/NNS||$-126/$	number||â-128/CD||‰-127/CD	num||$-126/$||â-128/CD	amod||mm2-135/NNS||±-129/JJ	amod||mm2-135/NNS||â-130/JJ	num||mm2-135/NNS||$-131/$	number||1.2-133/CD||‰-132/CD	num||$-131/$||1.2-133/CD	nn||mm2-135/NNS||â-134/NN	dep||p-137/VB||mm2-135/NNS	dep||wcsa-111/NN||p-137/VB	acomp||p-137/VB||â-138/JJ	num||â-142/NN||$-139/$	number||=-141/CD||‰-140/CD	num||$-139/$||=-141/CD	dep||â-138/JJ||â-142/NN	num||â-142/NN||$-143/$	number||0.002-145/CD||‰-144/CD	num||$-143/$||0.002-145/CD	appos||index-4/NN||hscrp-148/NN	num||â-151/NN||1.1-150/CD	dep||hscrp-148/NN||â-151/NN	num||vs-160/NN||$-152/$	number||â-154/CD||‰-153/CD	num||$-152/$||â-154/CD	nn||vs-160/NN||±-155/NN	nn||vs-160/NN||â-156/NN	amod||vs-160/NN||$-157/$	number||1.0-159/CD||‰-158/CD	num||$-157/$||1.0-159/CD	prep||â-151/NN||vs-160/NN	number||â-162/JJ||0.7-161/CD	amod||vs-160/NN||â-162/JJ	num||â-167/NNS||$-163/$	number||â-165/CD||‰-164/CD	num||$-163/$||â-165/CD	amod||â-167/NNS||±-166/JJ	dep||vs-160/NN||â-167/NNS	num||â-171/NN||$-168/$	number||0.7-170/CD||‰-169/CD	num||$-168/$||0.7-170/CD	npadvmod||mg/l-172/JJ||â-171/NN	amod||â-167/NNS||mg/l-172/JJ	vmod||â-167/NNS||p-174/VBN	acomp||p-174/VBN||â-175/JJ	num||â-179/NN||$-176/$	number||=-178/CD||‰-177/CD	num||$-176/$||=-178/CD	dep||â-175/JJ||â-179/NN	num||â-179/NN||$-180/$	number||0.002-182/CD||‰-181/CD	num||$-180/$||0.002-182/CD	conj_and||index-4/NN||ldl-cholesterol-186/NN	nsubj||decreased-219/VBD||ldl-cholesterol-186/NN	amod||â-210/NN||115â-188/JJ	dep||115â-188/JJ||$-189/$	number||â-191/CD||‰-190/CD	num||$-189/$||â-191/CD	amod||â-210/NN||±-192/JJ	amod||â-210/NN||â-193/JJ	amod||â-210/NN||$-194/$	number||33-196/CD||‰-195/CD	num||$-194/$||33-196/CD	amod||â-210/NN||vs-197/JJ	amod||â-210/NN||107â-198/JJ	amod||â-210/NN||$-199/$	number||â-201/CD||‰-200/CD	num||$-199/$||â-201/CD	amod||â-210/NN||±-202/JJ	amod||â-210/NN||â-203/JJ	amod||â-210/NN||$-204/$	number||26â-206/CD||‰-205/CD	num||$-204/$||26â-206/CD	amod||â-210/NN||mg/dl-207/JJ	dep||â-210/NN||p-209/NN	dep||ldl-cholesterol-186/NN||â-210/NN	dep||â-210/NN||$-211/$	number||=-213/CD||‰-212/CD	num||$-211/$||=-213/CD	vmod||$-211/$||â-214/VBN	dobj||â-214/VBN||$-215/$	number||0.001-217/CD||‰-216/CD	num||$-215/$||0.001-217/CD	root||ROOT-0/null||decreased-219/VBD	cross-107||cholesterol--1||no_rel||left ventricular mass index (lvmi; 38.5â€‰â±â€‰10.7 vs 35.2â€‰â±â€‰7.5â g/m2.7, p â€‰=â€‰0.0001), prevalence of leftventricularhypertrophy (46.5% vs 31.4%; p â€‰=â€‰0.0001), carotid intima-media thickness (cimt; 0.44â€‰â±â€‰0.05 vs 0.42â€‰â±â€‰0.04â mm, p â€‰=â€‰0.0001), wall cross sectional area (wcsa; 7.5â€‰â±â€‰1.3 vs 6.9â€‰â±â€‰1.2â mm2, p â€‰=â€‰0.002), hscrp (1.1â€‰â±â€‰1.0 vs 0.7â€‰â±â€‰0.7â mg/l, p â€‰=â€‰0.002), and ldl-cholesterol (115â€‰â±â€‰33 vs 107â€‰â±â€‰26â mg/dl, p â€‰=â€‰0.001) decreased.
advmod||understood-20/VBN||however-1/RB	det||mechanism-4/NN||the-3/DT	agent||involved-11/VBN||mechanism-4/NN	nsubjpass||understood-20/VBN||mechanism-4/NN	amod||ligase-9/NN||e3-7/JJ	nn||ligase-9/NN||ubiquitin-8/NN	nsubjpass||involved-11/VBN||ligase-9/NN	auxpass||involved-11/VBN||is-10/VBZ	rcmod||mechanism-4/NN||involved-11/VBN	nn||synthesis-14/NN||collagen-13/NN	prep_in||involved-11/VBN||synthesis-14/NN	nn||fibrosis-17/NN||liver-16/NN	prep_in||synthesis-14/NN||fibrosis-17/NN	auxpass||understood-20/VBN||is-18/VBZ	advmod||understood-20/VBN||incompletely-19/RB	root||ROOT-0/null||understood-20/VBN	collagen-13||fibrosis-17||no_rel||however, the mechanism by which e3 ubiquitin ligase is involved in collagen synthesis in liver fibrosis is incompletely understood.
nsubj||drug-4/NN||disulfiram-1/NN	cop||drug-4/NN||is-2/VBZ	det||drug-4/NN||the-3/DT	root||ROOT-0/null||drug-4/NN	nsubjpass||prescribed-8/VBN||drug-4/NN	auxpass||prescribed-8/VBN||is-6/VBZ	advmod||prescribed-8/VBN||commonly-7/RB	rcmod||drug-4/NN||prescribed-8/VBN	det||treatment-11/NN||the-10/DT	prep_for||prescribed-8/VBN||treatment-11/NN	prep_of||treatment-11/NN||alcoholdependencesyndrome-13/NN	amod||psychosis-18/NNS||transient-16/JJ	nn||psychosis-18/NNS||functional-17/NN	nsubjpass||reported-21/VBN||psychosis-18/NNS	aux||reported-21/VBN||has-19/VBZ	auxpass||reported-21/VBN||been-20/VBN	conj_and||drug-4/NN||reported-21/VBN	nsubjpass||prescribed-8/VBN||reported-21/VBN	prep_as||reported-21/VBN||one-23/CD	poss||side-effects-26/NNS||its-25/PRP$	prep_of||one-23/CD||side-effects-26/NNS	disulfiram-1||psychosis-18||no_rel||disulfiram is the drug that is commonly prescribed for the treatment of alcoholdependencesyndrome, and transient functional psychosis has been reported as one of its side-effects.
det||prevalence-3/NN||the-1/DT	amod||prevalence-3/NN||overall-2/JJ	nsubj||%-21/NN||prevalence-3/NN	prep_of||prevalence-3/NN||anaemia-5/NN	advmod||%-21/NN||irondeficiency-7/RB	amod||anaemia-10/NN||iron-deficiency-9/JJ	nsubj||%-21/NN||anaemia-10/NN	appos||anaemia-10/NN||deficiency-12/NN	amod||infestations-18/NNS||folicacid-14/JJ	conj_and||folicacid-14/JJ||parasitic-17/JJ	amod||infestations-18/NNS||parasitic-17/JJ	prep_of||deficiency-12/NN||infestations-18/NNS	cop||%-21/NN||was-19/VBD	num||%-21/NN||30.4-20/CD	root||ROOT-0/null||%-21/NN	num||%-24/NN||50.1-23/CD	conj_and||%-21/NN||%-24/NN	num||%-27/NN||18.1-26/CD	conj_and||%-21/NN||%-27/NN	num||%-30/NN||31.3-29/CD	conj_and||%-21/NN||%-30/NN	num||%-34/NN||13.7-33/CD	conj_and||%-21/NN||%-34/NN	advmod||%-21/NN||respectively-35/RB	irondeficiency-7||iron--1||yes||the overall prevalence of anaemia, irondeficiency, iron-deficiency anaemia, deficiency of folicacid, and parasitic infestations was 30.4%, 50.1%, 18.1%, 31.3%, and 13.7% respectively.
nsubj||gambiae-2/VBP||anopheles-1/NNS	ccomp||developed-11/VBN||gambiae-2/VBP	det||vector-7/NN||the-4/DT	amod||vector-7/NN||main-5/JJ	nn||vector-7/NN||malaria-6/NN	nsubj||developed-11/VBN||vector-7/NN	prep_in||vector-7/NN||benin-9/NN	aux||developed-11/VBN||has-10/VBZ	root||ROOT-0/null||developed-11/VBN	amod||level-13/NN||high-12/JJ	dobj||developed-11/VBN||level-13/NN	prep_of||level-13/NN||resistance-15/NN	amod||insecticides-18/NNS||pyrethroid-17/JJ	prep_to||developed-11/VBN||insecticides-18/NNS	nsubj||concern-24/NN||insecticides-18/NNS	cop||concern-24/NN||is-21/VBZ	det||concern-24/NN||a-22/DT	amod||concern-24/NN||serious-23/JJ	rcmod||insecticides-18/NNS||concern-24/NN	det||use-28/NN||the-26/DT	amod||use-28/NN||future-27/JJ	prep_to||concern-24/NN||use-28/NN	amod||nets-32/NNS||long-lasting-30/JJ	amod||nets-32/NNS||insecticidal-31/JJ	prep_of||use-28/NN||nets-32/NNS	appos||nets-32/NNS||llin-34/NN	amod||spraying-39/NNS||indoor-37/JJ	amod||spraying-39/NNS||residual-38/JJ	prep_of||use-28/NN||spraying-39/NNS	conj_and||nets-32/NNS||spraying-39/NNS	appos||nets-32/NNS||irs-41/NN	malaria-6||pyrethroid-17||no_rel||anopheles gambiae , the main malaria vector in benin has developed high level of resistance to pyrethroid insecticides, which is a serious concern to the future use of long-lasting insecticidal nets (llin) and indoor residual spraying (irs).
det||authors-2/NNS||the-1/DT	nsubj||assessed-3/VBD||authors-2/NNS	root||ROOT-0/null||assessed-3/VBD	det||resistance-8/NN||the-4/DT	amod||resistance-8/NN||efficacy-5/JJ	conj_and||efficacy-5/JJ||antiviral-7/JJ	amod||resistance-8/NN||antiviral-7/JJ	dobj||assessed-3/VBD||resistance-8/NN	amod||therapy-12/NN||48-week-10/JJ	nn||therapy-12/NN||clevudine-11/NN	prep_of||resistance-8/NN||therapy-12/NN	amod||patients-21/NNS||lamivudine-14/JJ	prep_in||lamivudine-14/JJ||treatment-16/NN	nn||¯-19/NNS||naã-18/NN	prep_of||treatment-16/NN||¯-19/NNS	nn||patients-21/NNS||ve-20/NN	prep_versus||therapy-12/NN||patients-21/NNS	prepc_with||assessed-3/VBD||hbeag-23/VBG	amod||chronichepatitisb-25/NN||positive-24/JJ	dobj||hbeag-23/VBG||chronichepatitisb-25/NN	chronichepatitisb-25||lamivudine-14||no_rel||the authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naã¯ve patients with hbeag positive chronichepatitisb.
agent||formed-32/VBN||conjugating-2/VBG	amod||antibodies-4/NNS||anti-h5n1-3/JJ	dobj||conjugating-2/VBG||antibodies-4/NNS	det||chemistry-19/NN||the-6/DT	amod||chemistry-19/NN||ps@pdav-7/JJ	prep_via||ps@pdav-7/JJ||n-9/NN	dep||n-9/NN||hydroxysuccinimide-11/JJ	dep||n-9/NN||1-ethyl3-13/JJ	conj_and||hydroxysuccinimide-11/JJ||1-ethyl3-13/JJ	dep||n-9/NN||3-dimethylaminopropyl-16/JJ	nn||chemistry-19/NN||carbodiimide-18/NN	prep_to||conjugating-2/VBG||chemistry-19/NN	det||microsphere-27/NN||a-21/DT	amod||microsphere-27/NN||stable-22/JJ	amod||microsphere-27/NN||blue-23/JJ	amod||microsphere-27/NN||complex-24/JJ	amod||microsphere-27/NN||anti-h5n1-26/JJ	nsubjpass||formed-32/VBN||microsphere-27/NN	dep||microsphere-27/NN||ps@pdav-anti-h5n1-29/JJ	auxpass||formed-32/VBN||was-31/VBD	root||ROOT-0/null||formed-32/VBN	antibodies-4||h5n1--1||no_rel||by conjugating anti-h5n1 antibodies to the ps@pdav via n -hydroxysuccinimide and 1-ethyl3-(3-dimethylaminopropyl) carbodiimide chemistry, a stable blue complex, anti-h5n1 microsphere (ps@pdav-anti-h5n1) was formed.
amod||resonance-4/NN||manganese-enhanced-1/JJ	amod||resonance-4/NN||cardiovascular-2/JJ	amod||resonance-4/NN||magnetic-3/JJ	nsubj||assess-10/VB||resonance-4/NN	appos||resonance-4/NN||mecmr-6/NN	aux||assess-10/VB||can-8/MD	advmod||assess-10/VB||non-invasively-9/RB	root||ROOT-0/null||assess-10/VB	amod||influx-13/NN||myocardial-11/JJ	nn||influx-13/NN||calcium-12/NN	dobj||assess-10/VB||influx-13/NN	nn||levels-17/NNS||calcium-16/NN	nsubjpass||known-19/VBN||levels-17/NNS	nsubjpass||elevated-22/VBN||levels-17/NNS	auxpass||known-19/VBN||are-18/VBP	conj_and||assess-10/VB||known-19/VBN	aux||elevated-22/VBN||to-20/TO	auxpass||elevated-22/VBN||be-21/VB	xcomp||known-19/VBN||elevated-22/VBN	amod||cardiomyopathy-25/NN||musculardystrophy-24/JJ	prep_in||elevated-22/VBN||cardiomyopathy-25/NN	prepc_based_on||elevated-22/VBN||on-27/IN	amod||studies-29/NNS||cellular-28/JJ	pobj||elevated-22/VBN||studies-29/NNS	calcium-16||musculardystrophy-24||no_rel||manganese-enhanced cardiovascular magnetic resonance (mecmr) can non-invasively assess myocardial calcium influx, and calcium levels are known to be elevated in musculardystrophy cardiomyopathy based on cellular studies.
advmod||show-4/VBP||here-1/RB	nsubj||show-4/VBP||we-3/PRP	root||ROOT-0/null||show-4/VBP	mark||promotes-32/VBZ||that-5/IN	amod||expression-7/NN||ectopic-6/JJ	nsubj||promotes-32/VBZ||expression-7/NN	det||isoform-13/NN||a-9/DT	advmod||important-11/JJ||clinically-10/RB	amod||isoform-13/NN||important-11/JJ	amod||isoform-13/NN||oncogenic-12/JJ	prep_of||expression-7/NN||isoform-13/NN	prep_of||isoform-13/NN||her2-15/NNS	appos||her2-15/NNS||her2î-17/NNS	dep||expression-7/NN||16-19/CD	nsubjpass||expressed-23/VBN||16-19/CD	auxpass||expressed-23/VBN||is-22/VBZ	rcmod||16-19/CD||expressed-23/VBN	num||%-27/NN||>-25/CD	num||%-27/NN||30-26/CD	prep_in||expressed-23/VBN||%-27/NN	amod||breasttumors-30/NNS||er-positive-29/JJ	prep_of||%-27/NN||breasttumors-30/NNS	ccomp||show-4/VBP||promotes-32/VBZ	nn||resistance-34/NN||tamoxifen-33/NN	dobj||promotes-32/VBZ||resistance-34/NN	nn||independence-37/NN||estrogen-36/NN	dobj||promotes-32/VBZ||independence-37/NN	conj_and||resistance-34/NN||independence-37/NN	amod||xenografts-40/NNS||mcf-7-39/JJ	prep_of||resistance-34/NN||xenografts-40/NNS	breasttumors-30||tamoxifen-33||yes||here, we show that ectopic expression of a clinically important oncogenic isoform of her2, her2î”16, which is expressed in >30% of er-positive breasttumors, promotes tamoxifen resistance and estrogen independence of mcf-7 xenografts.
prep_in||estimated-31/VBN||india-2/NN	amod||prevalence-5/NN||hbsag-4/VBG	nsubjpass||estimated-31/VBN||prevalence-5/NN	nsubj||million-35/CD||prevalence-5/NN	amod||ranges-9/NNS||general-7/JJ	nn||ranges-9/NNS||population-8/NN	prep_among||prevalence-5/NN||ranges-9/NNS	number||%-15/NN||2-11/CD	dep||%-15/NN||%-12/NN	dep||%-15/NN||to-13/TO	number||%-15/NN||8-14/CD	prep_from||ranges-9/NNS||%-15/NN	nn||india-18/NN||placing-17/NN	prep_among||prevalence-5/NN||india-18/NN	conj_and||ranges-9/NNS||india-18/NN	amod||zone-23/NN||intermediate-20/JJ	nn||zone-23/NN||hbv-21/NN	nn||zone-23/NN||endemicity-22/NN	prep_in||india-18/NN||zone-23/NN	det||number-26/NN||the-25/DT	prep_among||prevalence-5/NN||number-26/NN	conj_and||ranges-9/NNS||number-26/NN	nn||carriers-29/NNS||hbv-28/NN	prep_of||number-26/NN||carriers-29/NNS	auxpass||estimated-31/VBN||is-30/VBZ	root||ROOT-0/null||estimated-31/VBN	aux||million-35/CD||to-32/TO	cop||million-35/CD||be-33/VB	number||million-35/CD||50-34/CD	xcomp||estimated-31/VBN||million-35/CD	vmod||million-35/CD||forming-37/VBG	det||pool-42/NN||the-38/DT	amod||pool-42/NN||second-39/JJ	amod||pool-42/NN||largest-40/JJS	amod||pool-42/NN||global-41/JJ	dobj||forming-37/VBG||pool-42/NN	amod||infections-46/NNS||chronic-44/JJ	nn||infections-46/NNS||hbv-45/NN	prep_of||pool-42/NN||infections-46/NNS	hbv-45||hbsag-4||yes||in india, hbsag prevalence among general population ranges from 2% to 8%, placing india in intermediate hbv endemicity zone and the number of hbv carriers is estimated to be 50 million, forming the second largest global pool of chronic hbv infections.
advmod||demonstrate-3/VBP||here-1/RB	nsubj||demonstrate-3/VBP||we-2/PRP	root||ROOT-0/null||demonstrate-3/VBP	mark||infected-7/VBD||that-4/IN	amod||influenzavirus-6/NNS||h5n1-5/JJ	nsubj||infected-7/VBD||influenzavirus-6/NNS	ccomp||demonstrate-3/VBP||infected-7/VBD	nsubj||increased-10/VBN||mice-8/NNS	aux||increased-10/VBN||had-9/VBD	ccomp||infected-7/VBD||increased-10/VBN	dobj||increased-10/VBN||levels-11/NNS	amod||byproducts-17/NNS||c5a-13/JJ	conj_and||c5a-13/JJ||c3-15/JJ	amod||byproducts-17/NNS||c3-15/JJ	nn||byproducts-17/NNS||activation-16/NN	prep_of||levels-11/NNS||byproducts-17/NNS	prep||increased-10/VBN||as-18/IN	prepc_compared_to||increased-10/VBN||to-20/TO	pobj||increased-10/VBN||mice-21/NNS	vmod||mice-21/NNS||infected-22/VBN	preconj||seasonal-25/JJ||either-24/DT	prep_with||infected-22/VBN||seasonal-25/JJ	amod||influenzaviruses-30/NNS||pandemic-27/JJ	num||influenzaviruses-30/NNS||2009-28/CD	amod||influenzaviruses-30/NNS||h1n1-29/JJ	prep_with||infected-22/VBN||influenzaviruses-30/NNS	conj_or||seasonal-25/JJ||influenzaviruses-30/NNS	h5n1-5||influenzavirus-6||no||here we demonstrate that h5n1 influenzavirus infected mice had increased levels of c5a and c3 activation byproducts as compared to mice infected with either seasonal or pandemic 2009 h1n1 influenzaviruses.
amod||¦-4/NNP||mgl1med/cd11c-1/JJ	nn||¦-4/NNP||+-2/NNP	nn||¦-4/NNP||atmî-3/NNP	nsubj||expressing-6/VBG||¦-4/NNP	aux||expressing-6/VBG||s-5/VBZ	root||ROOT-0/null||expressing-6/VBG	amod||±-9/NNS||elevated-7/JJ	amod||±-9/NNS||pgc-1î-8/JJ	dobj||expressing-6/VBG||±-9/NNS	nn||±-12/NNP||ppar-î-11/NNP	appos||±-9/NNS||±-12/NNP	amod||transcripts-16/NNS||ym-1-15/JJ	nsubjpass||enriched-19/VBN||transcripts-16/NNS	auxpass||enriched-19/VBN||were-17/VBD	advmod||enriched-19/VBN||selectively-18/RB	conj_and||expressing-6/VBG||enriched-19/VBN	prepc_in||enriched-19/VBN||eat-21/VBG	amod||mice-24/NNS||obese-23/JJ	prep_of||eat-21/VBG||mice-24/NNS	vmod||mice-24/NNS||fed-25/VBN	acomp||fed-25/VBN||pioglitazone-26/JJ	num||days-29/NNS||6-28/CD	prep_for||fed-25/VBN||days-29/NNS	prepc_in||enriched-19/VBN||confirming-31/VBG	conj_and||eat-21/VBG||confirming-31/VBG	det||features-34/NNS||the-32/DT	amod||features-34/NNS||m2-33/JJ	dobj||confirming-31/VBG||features-34/NNS	det||profile-42/NN||the-36/DT	amod||profile-42/NN||mgl1med/cd11c-37/JJ	nn||profile-42/NN||+-38/NNP	nn||profile-42/NN||eatmî-39/NNP	nn||profile-42/NN||¦-40/NNP	amod||profile-42/NN||transcriptional-41/JJ	prep_of||features-34/NNS||profile-42/NN	prepc_in||enriched-19/VBN||implicating-44/VBG	conj_and||eat-21/VBG||implicating-44/VBG	nn||activation-46/NN||ppar-45/NN	dobj||implicating-44/VBG||activation-46/NN	poss||elicitation-49/NN||its-48/PRP$	prep_in||activation-46/NN||elicitation-49/NN	obese-23||pioglitazone-26||no_rel||mgl1med/cd11c+ atmî¦s expressing elevated pgc-1î±, ppar-î±, and ym-1 transcripts were selectively enriched in eat of obese mice fed pioglitazone for 6 days, confirming the m2 features of the mgl1med/cd11c+ eatmî¦ transcriptional profile and implicating ppar activation in its elicitation.
num||weeks-2/NNS||3-1/CD	npadvmod||increased-12/VBN||weeks-2/NNS	nn||diets-5/NNS||wj-4/NN	prep_after||increased-12/VBN||diets-5/NNS	amod||levels-9/NNS||serum-7/JJ	amod||levels-9/NNS||hdl-cholesterol-8/JJ	nsubjpass||increased-12/VBN||levels-9/NNS	auxpass||increased-12/VBN||were-10/VBD	advmod||increased-12/VBN||significantly-11/RB	root||ROOT-0/null||increased-12/VBN	nn||groups-16/NNS||wj-14/NN	nn||groups-16/NNS||diet-15/NN	prep_in||increased-12/VBN||groups-16/NNS	prepc_compared_with||increased-12/VBN||with-18/IN	det||rats-23/NNS||the-19/DT	amod||rats-23/NNS||normal-20/JJ	nn||rats-23/NNS||diet-21/NN	nn||rats-23/NNS||hypercholesterolemia-22/NN	pobj||increased-12/VBN||rats-23/NNS	hypercholesterolemia-22||cholesterol--1||no||3 weeks after wj diets, serum hdl-cholesterol levels were significantly increased in wj diet groups compared with the normal diet hypercholesterolemia rats.
det||study-6/NN||the-1/DT	amod||study-6/NN||chinese-2/JJ	nn||study-6/NN||hypertension-3/NN	nn||study-6/NN||intervention-4/NN	nn||study-6/NN||efficacy-5/NN	nsubj||randomized-13/NN||study-6/NN	appos||study-6/NN||chief-8/NN	cop||randomized-13/NN||is-10/VBZ	det||randomized-13/NN||a-11/DT	amod||randomized-13/NN||multi-centre-12/JJ	root||ROOT-0/null||randomized-13/NN	dep||randomized-13/NN||controlled-14/VBN	amod||trial-16/NN||clinical-15/JJ	dobj||controlled-14/VBN||trial-16/NN	xcomp||controlled-14/VBN||comparing-17/VBG	det||effects-19/NNS||the-18/DT	dobj||comparing-17/VBG||effects-19/NNS	amod||angiotensiniireceptorblocker-23/NN||amlodipine-21/JJ	amod||angiotensiniireceptorblocker-23/NN||+-22/JJ	prep_of||effects-19/NNS||angiotensiniireceptorblocker-23/NN	nn||diuretics-27/NNS||amlodipine-25/NN	nn||diuretics-27/NNS||+-26/NN	prep_of||effects-19/NNS||diuretics-27/NNS	conj_and||angiotensiniireceptorblocker-23/NN||diuretics-27/NNS	det||incidence-30/NN||the-29/DT	prep_on||comparing-17/VBG||incidence-30/NN	amod||events-33/NNS||cardiovascular-32/JJ	prep_of||incidence-30/NN||events-33/NNS	dep||controlled-14/VBN||represented-35/VBN	det||composite-38/NN||a-37/DT	prep_as||represented-35/VBN||composite-38/NN	amod||stroke-41/NN||non-fatal-40/JJ	prep_of||composite-38/NN||stroke-41/NN	amod||myocardialinfarction-44/NN||non-fatal-43/JJ	dobj||controlled-14/VBN||myocardialinfarction-44/NN	amod||events-48/NNS||cardiovascular-46/JJ	nn||events-48/NNS||death-47/NN	dobj||controlled-14/VBN||events-48/NNS	conj_and||myocardialinfarction-44/NN||events-48/NNS	amod||patients-53/NNS||high-risk-50/JJ	nn||patients-53/NNS||chinese-51/NN	nn||patients-53/NNS||hypertensive-52/NN	prep_in||myocardialinfarction-44/NN||patients-53/NNS	hypertension-3||amlodipine-25||yes||the chinese hypertension intervention efficacy study (chief) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensiniireceptorblocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardialinfarction and cardiovascular death events in high-risk chinese hypertensive patients.
advmod||observed-34/VBN||importantly-1/RB	det||correlation-11/NN||a-3/DT	advmod||significant-5/JJ||highly-4/RB	amod||correlation-11/NN||significant-5/JJ	dep||significant-5/JJ||p-7/VBN	dep||0.000009-9/CD||=-8/SYM	ccomp||p-7/VBN||0.000009-9/CD	nsubjpass||observed-34/VBN||correlation-11/NN	amod||antigen-15/NN||hepatitisb-13/JJ	nn||antigen-15/NN||surface-14/NN	prep_between||correlation-11/NN||antigen-15/NN	appos||antigen-15/NN||hbsag-17/NN	vmod||correlation-11/NN||stimulated-19/VBN	amod||expression-22/NN||il-2-20/JJ	nn||expression-22/NN||gene-21/NN	dobj||stimulated-19/VBN||expression-22/NN	advmod||detectable-25/JJ||as-24/RB	dobj||stimulated-19/VBN||detectable-25/JJ	amod||expression-22/NN||detectable-25/JJ	conj_and||expression-22/NN||detectable-25/JJ	prep_in||detectable-25/JJ||wb-27/NN	amod||titers-32/NNS||specific-30/JJ	nn||titers-32/NNS||antibody-31/NN	dobj||stimulated-19/VBN||titers-32/NNS	conj_and||expression-22/NN||titers-32/NNS	auxpass||observed-34/VBN||was-33/VBD	root||ROOT-0/null||observed-34/VBN	prep_in||observed-34/VBN||donors-36/NNS	vmod||donors-36/NNS||vaccinated-37/VBN	amod||virus-40/NN||hepatitisb-39/JJ	prep_against||vaccinated-37/VBN||virus-40/NN	appos||virus-40/NN||hbv-42/NN	num||months-46/NNS||six-45/CD	prep_between||virus-40/NN||months-46/NNS	num||years-49/NNS||twenty-48/CD	prep_between||virus-40/NN||years-49/NNS	conj_and||months-46/NNS||years-49/NNS	det||tests-52/NNS||the-51/DT	prep_before||vaccinated-37/VBN||tests-52/NNS	hbv-42||hbsag-17||yes||importantly, a highly significant (p = 0.000009) correlation between hepatitisb surface antigen (hbsag) stimulated il-2 gene expression, as detectable in wb, and specific antibody titers was observed in donors vaccinated against hepatitisb virus (hbv) between six months and twenty years before the tests.
nsubjpass||used-11/VBN||indomethacin-1/NN	det||drug-7/NN||a-3/DT	amod||drug-7/NN||potent-4/JJ	amod||drug-7/NN||nonsteroidal-5/JJ	amod||drug-7/NN||anti-inflammatory-6/JJ	appos||indomethacin-1/NN||drug-7/NN	aux||used-11/VBN||has-9/VBZ	auxpass||used-11/VBN||been-10/VBN	root||ROOT-0/null||used-11/VBN	det||treatment-14/NN||the-13/DT	prep_in||used-11/VBN||treatment-14/NN	amod||kinds-17/NNS||various-16/JJ	prep_of||treatment-14/NN||kinds-17/NNS	prep_of||kinds-17/NNS||pains-19/NNS	prep_of||kinds-17/NNS||inflammation-21/NN	conj_and||pains-19/NNS||inflammation-21/NN	prep_of||kinds-17/NNS||arthritis-23/NN	conj_and||pains-19/NNS||arthritis-23/NN	pains-19||indomethacin-1||yes||indomethacin, a potent nonsteroidal anti-inflammatory drug, has been used in the treatment of various kinds of pains, inflammation and arthritis.
det||aminosalicylates-2/NNS||the-1/DT	nsubjpass||considered-14/VBN||aminosalicylates-2/NNS	dep||aminosalicylates-2/NNS||5-asa-4/JJ	advmod||referred-7/NN||also-6/RB	dep||5-asa-4/JJ||referred-7/NN	dep||referred-7/NN||to-8/TO	advmod||mesalamine-based-10/JJ||as-9/RB	amod||agents-11/NNS||mesalamine-based-10/JJ	dep||referred-7/NN||agents-11/NNS	auxpass||considered-14/VBN||are-13/VBP	root||ROOT-0/null||considered-14/VBN	prep_as||considered-14/VBN||first-line-16/NN	det||maintenance-19/NN||the-18/DT	prep_in||considered-14/VBN||maintenance-19/NN	prep_of||maintenance-19/NN||remission-21/NN	amod||moderate-25/JJ||mild-23/JJ	dep||moderate-25/JJ||to-24/TO	amod||ulcerativecolitis-26/NNS||moderate-25/JJ	prep_of||remission-21/NN||ulcerativecolitis-26/NNS	appos||ulcerativecolitis-26/NNS||uc-28/NN	uc-28||mesalamine--1||yes||the aminosalicylates (5-asa; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerativecolitis (uc).
nn||acquisition-2/NN||iron-1/NN	nsubj||determinant-8/NN||acquisition-2/NN	cop||determinant-8/NN||is-3/VBZ	det||determinant-8/NN||a-4/DT	amod||microbial-6/JJ||known-5/JJ	amod||determinant-8/NN||microbial-6/JJ	nn||determinant-8/NN||virulence-7/NN	root||ROOT-0/null||determinant-8/NN	amod||diseases-11/NNS||human-10/JJ	nsubjpass||found-16/VBN||diseases-11/NNS	nsubj||correlate-18/VB||diseases-11/NNS	prep_of||diseases-11/NNS||ironoverload-13/NN	aux||found-16/VBN||have-14/VBP	auxpass||found-16/VBN||been-15/VBN	conj_and||determinant-8/NN||found-16/VBN	aux||correlate-18/VB||to-17/TO	xcomp||found-16/VBN||correlate-18/VB	amod||burden-22/NN||increased-20/VBN	amod||burden-22/NN||bacterial-21/JJ	prep_with||correlate-18/VB||burden-22/NN	ironoverload-13||iron-1||no||iron acquisition is a known microbial virulence determinant and human diseases of ironoverload have been found to correlate with increased bacterial burden.
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	det||review-5/NN||this-4/DT	prep_of||purpose-2/NN||review-5/NN	root||ROOT-0/null||is-6/VBZ	aux||address-8/VB||to-7/TO	dep||is-6/VBZ||address-8/VB	det||number-10/NN||a-9/DT	dobj||address-8/VB||number-10/NN	nn||strategies-13/NNS||counseling-12/NN	prep_of||number-10/NN||strategies-13/NNS	vmod||strategies-13/NNS||used-14/VBN	prep_for||used-14/VBN||education-16/NN	prep_for||used-14/VBN||counseling-18/NN	conj_and||education-16/NN||counseling-18/NN	prep_of||education-16/NN||individuals-20/NNS	prep_at||used-14/VBN||risk-22/NN	prepc_of||risk-22/NN||getting-24/VBG	dobj||getting-24/VBG||hiv/aids-25/NNS	advmod||among-28/IN||also-27/RB	dep||is-6/VBZ||among-28/IN	conj_and||address-8/VB||among-28/IN	pobj||among-28/IN||those-29/DT	nsubj||hiv-infected-32/JJ||those-29/DT	cop||hiv-infected-32/JJ||are-31/VBP	rcmod||those-29/DT||hiv-infected-32/JJ	aids--1||hiv--1||no||the purpose of this review is to address a number of counseling strategies used for education and counseling of individuals at risk of getting hiv/aids and also among those who are hiv-infected.
amod||subjects-2/NNS||adult-1/JJ	nsubj||underwent-5/VBD||subjects-2/NNS	prep_with||subjects-2/NNS||type1diabetes-4/CD	root||ROOT-0/null||underwent-5/VBD	num||study-8/NN||one-6/CD	amod||study-8/NN||closed-loop-7/JJ	dobj||underwent-5/VBD||study-8/NN	prep_with||study-8/NN||insulin-10/NN	dobj||underwent-5/VBD||placebo-12/NN	conj_plus||study-8/NN||placebo-12/NN	num||study-15/NN||one-14/CD	conj_plus||study-8/NN||study-15/NN	conj_and||placebo-12/NN||study-15/NN	prep_with||underwent-5/VBD||insulin-17/NN	prep||insulin-17/NN||plus-18/CC	pobj||plus-18/CC||glucagon-19/NN	prep||underwent-5/VBD||given-21/VBN	pcomp||given-21/VBN||at-22/IN	pobj||at-22/IN||times-23/NNS	amod||hypoglycemia-26/NN||impending-25/JJ	prep_of||times-23/NNS||hypoglycemia-26/NN	type1diabetes-4||insulin-17||yes||adult subjects with type1diabetes underwent one closed-loop study with insulin plus placebo and one study with insulin plus glucagon, given at times of impending hypoglycemia.
det||compound-3/NN||the-1/DT	nn||compound-3/NN||title-2/NN	nsubj||contains-12/VBZ||compound-3/NN	nn||-RSB--10/NNP||-LSB--5/NNP	nn||-RSB--10/NNP||zni2-6/NNP	appos||-RSB--10/NNP||c10h8n2s-8/NNP	appos||compound-3/NN||-RSB--10/NNP	root||ROOT-0/null||contains-12/VBZ	det||ring-16/NN||a-13/DT	amod||ring-16/NN||six-membered-14/JJ	nn||ring-16/NN||chelate-15/NN	dobj||contains-12/VBZ||ring-16/NN	vmod||ring-16/NN||adopting-17/VBG	vmod||ring-16/NN||adopting-17/VBG	conj_and||adopting-17/VBG||adopting-17/VBG	det||conformation-20/NN||a-18/DT	nn||conformation-20/NN||boat-19/NN	dobj||adopting-17/VBG||conformation-20/NN	dobj||coordinated-27/VBN||which-22/WDT	det||atom-25/NN||the-23/DT	nn||atom-25/NN||zn-24/NN	nsubjpass||coordinated-27/VBN||atom-25/NN	auxpass||coordinated-27/VBN||is-26/VBZ	prepc_in||adopting-17/VBG||coordinated-27/VBN	num||ions-31/NNS||two-29/CD	amod||ions-31/NNS||iodide-30/JJ	agent||coordinated-27/VBN||ions-31/NNS	det||atoms-38/NNS||the-34/DT	num||atoms-38/NNS||two-35/CD	amod||atoms-38/NNS||pyridyl-36/JJ	nn||atoms-38/NNS||n-37/NN	agent||adopting-17/VBG||atoms-38/NNS	det||sulfide-43/NN||a-40/DT	amod||sulfide-43/NN||single-41/JJ	amod||sulfide-43/NN||di-2-pyridyl-42/JJ	prep_of||atoms-38/NNS||sulfide-43/NN	vmod||sulfide-43/NN||ligand-44/VBN	det||tetraâhedron-49/NN||a-46/DT	advmod||distorted-48/JJ||slightly-47/RB	amod||tetraâhedron-49/NN||distorted-48/JJ	prep_within||ligand-44/VBN||tetraâhedron-49/NN	iodide-30||di--1||no_rel||the title compound, [zni2(c10h8n2s)], contains a six-membered chelate ring adopting a boat conformation in which the zn atom is coordinated by two iodide ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand within a slightly distorted tetraâ­hedron.
det||cohort-6/NN||a-1/DT	amod||cohort-6/NN||12-matched-2/JJ	amod||cohort-6/NN||new-3/JJ	nn||cohort-6/NN||insulin-4/NN	nn||cohort-6/NN||user-5/NN	nsubjpass||selected-31/VBN||cohort-6/NN	prep_on||cohort-6/NN||age-8/NN	nn||±-11/NNS||â-10/NN	dep||age-8/NN||±-11/NNS	num||years-13/NNS||3-12/CD	dep||±-11/NNS||years-13/NNS	amod||status-17/NN||smoking-16/VBG	prep_on||cohort-6/NN||status-17/NN	conj_and||age-8/NN||status-17/NN	prep_on||cohort-6/NN||likelihood-20/NN	conj_and||age-8/NN||likelihood-20/NN	prepc_of||likelihood-20/NN||initiating-22/VBG	nn||therapy-24/NN||insulin-23/NN	dobj||initiating-22/VBG||therapy-24/NN	dep||selected-31/VBN||â-26/VB	num||0.05-28/CD||±-27/CD	dobj||â-26/VB||0.05-28/CD	auxpass||selected-31/VBN||was-30/VBD	root||ROOT-0/null||selected-31/VBN	det||cohort-34/NN||a-33/DT	prep_from||selected-31/VBN||cohort-34/NN	num||patients-38/NNS||4,623-36/CD	amod||patients-38/NNS||chinese-37/JJ	prep_of||cohort-34/NN||patients-38/NNS	prep_with||selected-31/VBN||type2diabetes-40/JJ	prep_with||selected-31/VBN||free-42/JJ	conj_and||type2diabetes-40/JJ||free-42/JJ	prep_of||free-42/JJ||cancer-44/NN	prep_with||selected-31/VBN||naive-47/JJ	conj_and||type2diabetes-40/JJ||naive-47/JJ	prep_to||naive-47/JJ||insulin-49/NN	prep_at||insulin-49/NN||enrollment-51/NN	insulin-49||cancer-44||no_rel||a 12-matched new insulin user cohort on age (â±3 years), smoking status, and likelihood of initiating insulin therapy (â±0.05) was selected from a cohort of 4,623 chinese patients with type2diabetes, free of cancer, and naive to insulin at enrollment.
det||development-2/NN||the-1/DT	nsubjpass||needed-15/VBN||development-2/NN	nsubj||control-17/VB||development-2/NN	det||microbicide-6/NN||a-4/DT	amod||microbicide-6/NN||topical-5/JJ	prep_of||development-2/NN||microbicide-6/NN	vmod||microbicide-6/NN||blocking-7/VBG	det||transmission-10/NN||the-8/DT	amod||transmission-10/NN||sexual-9/JJ	dobj||blocking-7/VBG||transmission-10/NN	prep_of||transmission-10/NN||hiv-1-12/CD	auxpass||needed-15/VBN||is-13/VBZ	advmod||needed-15/VBN||urgently-14/RB	root||ROOT-0/null||needed-15/VBN	aux||control-17/VB||to-16/TO	xcomp||needed-15/VBN||control-17/VB	det||hiv/aids-20/NNS||the-18/DT	amod||hiv/aids-20/NNS||global-19/JJ	nsubj||pandemic-21/JJ||hiv/aids-20/NNS	xcomp||control-17/VB||pandemic-21/JJ	aids--1||hiv--1||no||the development of a topical microbicide blocking the sexual transmission of hiv-1 is urgently needed to control the global hiv/aids pandemic.
det||plurality-2/NN||a-1/DT	nsubjpass||treated-8/VBN||plurality-2/NN	prep_of||plurality-2/NN||patients-4/NNS	prep_with||patients-4/NNS||schizophrenia-6/NN	auxpass||treated-8/VBN||was-7/VBD	root||ROOT-0/null||treated-8/VBN	prep_with||treated-8/VBN||clozapine-10/NN	num||%-13/NN||39-12/CD	appos||clozapine-10/NN||%-13/NN	nsubjpass||followed-18/VBN||this-16/DT	auxpass||followed-18/VBN||was-17/VBD	parataxis||treated-8/VBN||followed-18/VBN	agent||followed-18/VBN||risperidone-20/JJ	agent||followed-18/VBN||sulpride-22/JJ	conj_and||risperidone-20/JJ||sulpride-22/JJ	agent||followed-18/VBN||chlorpromazine-24/JJ	conj_and||risperidone-20/JJ||chlorpromazine-24/JJ	agent||followed-18/VBN||perphenazine-26/JJ	conj_and||risperidone-20/JJ||perphenazine-26/JJ	agent||followed-18/VBN||haloperidol-29/JJ	conj_and||risperidone-20/JJ||haloperidol-29/JJ	schizophrenia-6||risperidone-20||yes||a plurality of patients with schizophrenia was treated with clozapine (39%); this was followed by risperidone, sulpride, chlorpromazine, perphenazine, and haloperidol.
amod||prick-3/NN||titrated-1/JJ	nn||prick-3/NN||skin-2/NN	nsubj||indicated-17/VBD||prick-3/NN	vmod||prick-3/NN||testing-4/VBG	amod||responses-9/NNS||wheal-6/JJ	conj_and||wheal-6/JJ||flare-8/JJ	amod||responses-9/NNS||flare-8/JJ	prep_with||testing-4/VBG||responses-9/NNS	advmod||testing-4/VBG||up-10/RB	det||dilution-14/NN||an-12/DT	nn||dilution-14/NN||enoxaparin-13/NN	prep_to||up-10/RB||dilution-14/NN	prep_of||dilution-14/NN||110.000-16/CD	root||ROOT-0/null||indicated-17/VBD	det||mechanism-21/NN||a-18/DT	amod||mechanism-21/NN||probable-19/JJ	amod||mechanism-21/NN||allergic-20/JJ	dobj||indicated-17/VBD||mechanism-21/NN	det||anaphylaxis-25/NNS||the-23/DT	amod||anaphylaxis-25/NNS||enoxaparin-induced-24/JJ	prep_of||mechanism-21/NN||anaphylaxis-25/NNS	anaphylaxis-25||enoxaparin-13||no_rel||titrated skin prick testing with wheal and flare responses up to an enoxaparin dilution of 110.000 indicated a probable allergic mechanism of the enoxaparin-induced anaphylaxis.
aux||test-2/VB||to-1/TO	advcl||detected-7/VBD||test-2/VB	det||hypothesis-4/NNS||this-3/DT	dobj||test-2/VB||hypothesis-4/NNS	nsubj||detected-7/VBD||we-6/PRP	root||ROOT-0/null||detected-7/VBD	xcomp||detected-7/VBD||î-8/VB	number||2,3-10/CD||±-9/CD	dobj||î-8/VB||2,3-10/CD	nn||acid-17/NN||î-13/NN	amod||acid-17/NN||±-14/JJ	amod||acid-17/NN||2,6-linked-15/JJ	amod||acid-17/NN||sialic-16/JJ	dobj||î-8/VB||acid-17/NN	conj_and||2,3-10/CD||acid-17/NN	amod||polyp-21/NN||human-19/JJ	amod||polyp-21/NN||nasal-20/JJ	prep_in||acid-17/NN||polyp-21/NN	amod||tissues-26/NNS||normal-23/JJ	amod||tissues-26/NNS||nasal-24/JJ	amod||tissues-26/NNS||mucosal-25/JJ	dobj||î-8/VB||tissues-26/NNS	conj_and||2,3-10/CD||tissues-26/NNS	nn||staining-29/NN||lectin-28/NN	prep_by||tissues-26/NNS||staining-29/NN	amod||explants-32/NNS||infected-31/JJ	conj_and||2,3-10/CD||explants-32/NNS	conj_and||tissues-26/NNS||explants-32/NNS	det||tissues-35/NNS||those-34/DT	prep_of||explants-32/NNS||tissues-35/NNS	amod||h5n1-38/NNS||avianinfluenzaviruses-37/JJ	prep_with||î-8/VB||h5n1-38/NNS	amod||influenzaviruses-41/NNS||seasonal-40/JJ	prep_with||î-8/VB||influenzaviruses-41/NNS	conj_and||h5n1-38/NNS||influenzaviruses-41/NNS	h5n1-38||influenzaviruses-41||no||to test this hypothesis, we detected î±2,3- and î±2,6-linked sialic acid in human nasal polyp and normal nasal mucosal tissues by lectin staining and infected explants of those tissues with avianinfluenzaviruses h5n1 and seasonal influenzaviruses.
amod||immunity-2/NN||pre-existing-1/JJ	nsubj||useful-7/JJ||immunity-2/NN	amod||influenzaviruses-5/NNS||seasonal-4/JJ	prep_against||immunity-2/NN||influenzaviruses-5/NNS	cop||useful-7/JJ||is-6/VBZ	root||ROOT-0/null||useful-7/JJ	prepc_in||useful-7/JJ||offering-9/VBG	dobj||offering-9/VBG||protection-10/NN	amod||infection-13/NN||h5n1-12/JJ	prep_against||offering-9/VBG||infection-13/NN	h5n1-12||influenzaviruses-5||no||pre-existing immunity against seasonal influenzaviruses is useful in offering protection against h5n1 infection.
amod||lines-4/NNS||colorectal-1/JJ	nn||lines-4/NNS||cancer-2/NN	nn||lines-4/NNS||cell-3/NN	nsubjpass||treated-6/VBN||lines-4/NNS	nsubjpass||treated-6/VBN||lines-4/NNS	nsubj||analyse-16/VB||lines-4/NNS	auxpass||treated-6/VBN||were-5/VBD	root||ROOT-0/null||treated-6/VBN	conj_and||treated-6/VBN||treated-6/VBN	prep_with||treated-6/VBN||5-aza-dc-8/JJ	prep_with||treated-6/VBN||tsa-13/NN	prep_without||treated-6/VBN||tsa-13/NN	aux||analyse-16/VB||to-15/TO	xcomp||treated-6/VBN||analyse-16/VB	amod||decreases-19/NNS||global-17/JJ	nn||decreases-19/NNS||methylation-18/NN	dobj||analyse-16/VB||decreases-19/NNS	amod||chromatography-24/NN||high-21/JJ	nn||chromatography-24/NN||performance-22/NN	nn||chromatography-24/NN||liquid-23/NN	prep_by||analyse-16/VB||chromatography-24/NN	dep||chromatography-24/NN||hplc-26/JJ	aza--1||cancer-2||no_rel||colorectal cancer cell lines were treated with 5-aza-dc, with and without tsa, to analyse global methylation decreases by high performance liquid chromatography (hplc).
det||review-3/NN||this-2/DT	prep_in||summarise-6/VBP||review-3/NN	nsubj||summarise-6/VBP||we-5/PRP	root||ROOT-0/null||summarise-6/VBP	cc||critically-8/RB||and-7/CC	dep||summarise-6/VBP||critically-8/RB	ccomp||critically-8/RB||evaluate-9/VB	det||data-12/NNS||the-10/DT	amod||data-12/NNS||existing-11/VBG	dobj||evaluate-9/VB||data-12/NNS	det||link-16/NN||the-14/DT	amod||link-16/NN||possible-15/JJ	prep_on||data-12/NNS||link-16/NN	prep_between||link-16/NN||vitamind-18/NN	prep_between||link-16/NN||multiplesclerosis-20/NNS	conj_and||vitamind-18/NN||multiplesclerosis-20/NNS	prep_in||data-12/NNS||light-22/NN	det||question-26/NN||the-24/DT	amod||question-26/NN||crucial-25/JJ	prep_of||light-22/NN||question-26/NN	mark||impact-33/VB||whether-27/IN	nsubj||impact-33/VB||optimization-28/NN	amod||status-31/NN||vitamind-30/JJ	prep_of||optimization-28/NN||status-31/NN	aux||impact-33/VB||may-32/MD	ccomp||summarise-6/VBP||impact-33/VB	det||risk-35/NN||the-34/DT	dobj||impact-33/VB||risk-35/NN	vmod||risk-35/NN||and/or-36/VBG	det||course-38/NN||the-37/DT	dobj||and/or-36/VBG||course-38/NN	prep_of||course-38/NN||multiplesclerosis-40/NNS	vitamind-30||multiplesclerosis-40||no_rel||in this review, we summarise and critically evaluate the existing data on the possible link between vitamind and multiplesclerosis in light of the crucial question whether optimization of vitamind status may impact the risk and/or the course of multiplesclerosis.
amod||virus-2/NN||japaneseencephalitis-1/JJ	nsubj||endemic-17/JJ||virus-2/NN	appos||virus-2/NN||jev-4/NN	det||agent-9/NN||the-7/DT	amod||agent-9/NN||causative-8/JJ	appos||virus-2/NN||agent-9/NN	prep_of||agent-9/NN||japaneseencephalitis-11/NNS	appos||japaneseencephalitis-11/NNS||je-13/NN	cop||endemic-17/JJ||is-16/VBZ	root||ROOT-0/null||endemic-17/JJ	det||republic-20/NN||the-19/DT	prep_to||endemic-17/JJ||republic-20/NN	prep_of||republic-20/NN||korea-22/NN	appos||korea-22/NN||rok-24/NN	advmod||unvaccinated-27/VBD||where-26/WRB	advcl||endemic-17/JJ||unvaccinated-27/VBD	amod||states-29/NNS||united-28/VBN	dobj||unvaccinated-27/VBD||states-29/NNS	appos||states-29/NNS||u.s.-31/NNP	amod||members-35/NNS||military-33/JJ	nn||members-35/NNS||service-34/NN	nsubjpass||stationed-42/VBN||members-35/NNS	conj_and||members-35/NNS||civilians-37/NNS	nsubjpass||stationed-42/VBN||civilians-37/NNS	nn||members-40/NNS||family-39/NN	conj_and||members-35/NNS||members-40/NNS	nsubjpass||stationed-42/VBN||members-40/NNS	auxpass||stationed-42/VBN||are-41/VBP	rcmod||states-29/NNS||stationed-42/VBN	japaneseencephalitis-11||japaneseencephalitisvirus--1||no||japaneseencephalitis virus (jev), the causative agent of japaneseencephalitis (je), is endemic to the republic of korea (rok) where unvaccinated united states (u.s.) military service members, civilians and family members are stationed.
nsubj||safe-4/JJ||placeboxetine-1/NN	nsubj||effective-6/JJ||placeboxetine-1/NN	cop||safe-4/JJ||is-2/VBZ	advmod||safe-4/JJ||as-3/RB	root||ROOT-0/null||safe-4/JJ	conj_and||safe-4/JJ||effective-6/JJ	prep_as||safe-4/JJ||sertraline-8/NN	nn||patients-11/NNS||indian-10/NN	prep_in||sertraline-8/NN||patients-11/NNS	amod||depressivedisorder-14/NN||major-13/JJ	prep_with||patients-11/NNS||depressivedisorder-14/NN	depressivedisorder-14||sertraline-8||yes||placeboxetine is as safe and effective as sertraline in indian patients with major depressivedisorder.
amod||resources-2/NNS||substantial-1/JJ	nsubjpass||invested-4/VBN||resources-2/NNS	nsubjpass||made-13/VBN||resources-2/NNS	auxpass||invested-4/VBN||are-3/VBP	root||ROOT-0/null||invested-4/VBN	amod||support-7/NN||psychological-6/JJ	prep_in||invested-4/VBN||support-7/NN	nn||orphaned-10/NNS||children-9/NNS	prep_for||support-7/NN||orphaned-10/NNS	advmod||made-13/VBN||otherwise-12/RB	conj_or||invested-4/VBN||made-13/VBN	acomp||made-13/VBN||vulnerable-14/JJ	det||context-17/NN||the-16/DT	prep_in||made-13/VBN||context-17/NN	prep_of||context-17/NN||hiv/aids-19/NNS	appos||hiv/aids-19/NNS||ovc-21/NN	aids--1||hiv--1||no||substantial resources are invested in psychological support for children orphaned or otherwise made vulnerable in the context of hiv/aids (ovc).
mark||subject-15/NN||while-1/IN	nn||outcomes-3/NNS||health-2/NN	nsubj||subject-15/NN||outcomes-3/NNS	amod||treatments-6/NNS||hiv/aids-5/JJ	prep_of||outcomes-3/NNS||treatments-6/NNS	prep_in||treatments-6/NNS||terms-8/NNS	amod||longevity-11/NN||increased-10/VBN	prep_of||terms-8/NNS||longevity-11/NN	aux||subject-15/NN||has-12/VBZ	cop||subject-15/NN||been-13/VBN	det||subject-15/NN||the-14/DT	advcl||appears-21/VBZ||subject-15/NN	amod||research-18/NN||much-17/JJ	prep_of||subject-15/NN||research-18/NN	expl||appears-21/VBZ||there-20/EX	root||ROOT-0/null||appears-21/VBZ	aux||research-26/NN||to-22/TO	cop||research-26/NN||be-23/VB	advmod||limited-25/JJ||very-24/RB	amod||research-26/NN||limited-25/JJ	xcomp||appears-21/VBZ||research-26/NN	det||quality-32/NN||the-28/DT	amod||quality-32/NN||improved-29/VBN	nn||quality-32/NN||health-30/NN	amod||quality-32/NN||related-31/VBN	prep_on||research-26/NN||quality-32/NN	prep_of||quality-32/NN||life-34/NN	nsubjpass||applied-41/VBN||life-34/NN	dep||life-34/NN||hrql-36/JJ	aux||applied-41/VBN||can-39/MD	auxpass||applied-41/VBN||be-40/VB	rcmod||life-34/NN||applied-41/VBN	amod||analyses-44/NNS||cost-utility-43/JJ	prep_in||applied-41/VBN||analyses-44/NNS	nn||south-47/NN||africa-46/NN	prep_in||analyses-44/NNS||south-47/NN	det||sahara-50/NN||the-49/DT	prep_of||south-47/NN||sahara-50/NN	appos||sahara-50/NN||ssa-52/NN	aids--1||hiv--1||no||while health outcomes of hiv/aids treatments in terms of increased longevity has been the subject of much research, there appears to be very limited research on the improved health related quality of life (hrql) that can be applied in cost-utility analyses in africa south of the sahara (ssa).
advmod||demonstrate-5/VBP||overall-1/RB	det||data-4/NNS||these-3/DT	nsubj||demonstrate-5/VBP||data-4/NNS	root||ROOT-0/null||demonstrate-5/VBP	mark||ameliorates-12/VBZ||that-6/IN	det||administration-8/NN||the-7/DT	nsubj||ameliorates-12/VBZ||administration-8/NN	amod||trail-11/NN||recombinant-10/JJ	prep_of||administration-8/NN||trail-11/NN	ccomp||demonstrate-5/VBP||ameliorates-12/VBZ	det||severity-14/NN||the-13/DT	dobj||ameliorates-12/VBZ||severity-14/NN	amod||type1diabetes-17/NNS||stz-induced-16/JJ	prep_of||severity-14/NN||type1diabetes-17/NNS	det||effect-21/NN||this-20/DT	nsubjpass||accompanied-23/VBN||effect-21/NN	auxpass||accompanied-23/VBN||was-22/VBD	conj_and||demonstrate-5/VBP||accompanied-23/VBN	det||upregulation-26/NN||the-25/DT	agent||accompanied-23/VBN||upregulation-26/NN	amod||expression-29/NN||socs1-28/JJ	prep_of||upregulation-26/NN||expression-29/NN	type1diabetes-17||stz--1||no_rel||overall, these data demonstrate that the administration of recombinant trail ameliorates the severity of stz-induced type1diabetes, and this effect was accompanied by the upregulation of socs1 expression.
amod||function-2/NN||myocardial-1/JJ	nsubjpass||assessed-25/VBN||function-2/NN	nsubjpass||assessed-25/VBN||function-2/NN	dep||imaging-5/NN||cine-4/NNP	dep||function-2/NN||imaging-5/NN	conj_and||function-2/NN||ischemia-8/NN	nsubjpass||assessed-25/VBN||ischemia-8/NN	dep||ischemia-8/NN||adenosine-10/VB	dobj||adenosine-10/VB||stress-11/NN	advmod||adenosine-10/VB||first-12/RB	dep||adenosine-10/VB||pass-13/VB	amod||perfusion-15/NN||myocardial-14/JJ	dobj||pass-13/VB||perfusion-15/NN	conj_and||function-2/NN||scar-18/NN	nsubjpass||assessed-25/VBN||scar-18/NN	amod||enhancement-22/NN||late-20/JJ	nn||enhancement-22/NN||gadolinium-21/NN	appos||function-2/NN||enhancement-22/NN	auxpass||assessed-25/VBN||were-24/VBD	root||ROOT-0/null||assessed-25/VBN	conj_and||assessed-25/VBN||assessed-25/VBN	nn||2â-28/NNS||cmr-27/NN	agent||assessed-25/VBN||2â-28/NNS	num||days-32/NNS||$-29/$	num||$-29/$||6-31/CD	dep||2â-28/NNS||days-32/NNS	prep_after||assessed-25/VBN||presentation-34/NN	det||procedure-40/NN||any-37/DT	amod||procedure-40/NN||invasive-38/JJ	nn||procedure-40/NN||revascularisation-39/NN	prep_before||assessed-25/VBN||procedure-40/NN	adenosine-10||ischemia-8||no_rel||myocardial function (cine imaging), ischemia (adenosine stress first pass myocardial perfusion) and scar (late gadolinium enhancement) were assessed by cmr 2â€“6 days after presentation and before any invasive revascularisation procedure.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	nn||discomfort-4/NN||ocular-3/NN	dobj||assess-2/VB||discomfort-4/NN	prep_upon||assess-2/VB||instillation-6/NN	amod||preference-9/NN||patient-8/JJ	prep_upon||assess-2/VB||preference-9/NN	conj_and||instillation-6/NN||preference-9/NN	prep_for||preference-9/NN||brinzolamide/timolol-11/NN	amod||dorzolamide/timolol-14/JJ||relative-12/JJ	dep||dorzolamide/timolol-14/JJ||to-13/TO	amod||preference-9/NN||dorzolamide/timolol-14/JJ	prep_in||preference-9/NN||patients-17/NNS	nn||hypertension-22/NN||open-angleglaucoma-19/NN	conj_or||open-angleglaucoma-19/NN||ocular-21/NN	nn||hypertension-22/NN||ocular-21/NN	prep_with||patients-17/NNS||hypertension-22/NN	open-angleglaucoma-19||timolol--1||yes||to assess ocular discomfort upon instillation and patient preference for brinzolamide/timolol relative to dorzolamide/timolol, in patients with open-angleglaucoma or ocular hypertension.
det||vaccine-7/NN||the-1/DT	amod||vaccine-7/NN||only-2/JJ	nn||vaccine-7/NN||tuberculosis-3/NNP	appos||vaccine-7/NN||tb-5/NN	nsubj||rin-14/NN||vaccine-7/NN	advmod||available-9/JJ||currently-8/RB	amod||vaccine-7/NN||available-9/JJ	cop||rin-14/NN||is-10/VBZ	amod||calmette-guã-12/JJ||bacillus-11/JJ	amod||rin-14/NN||calmette-guã-12/JJ	amod||rin-14/NN||©-13/JJ	root||ROOT-0/null||rin-14/NN	appos||rin-14/NN||bcg-16/NN	mark||has-21/VBZ||although-19/IN	nsubj||has-21/VBZ||it-20/PRP	advcl||rin-14/NN||has-21/VBZ	neg||efficacy-23/NN||no-22/DT	dobj||has-21/VBZ||efficacy-23/NN	prep_in||efficacy-23/NN||adults-25/NNS	tb-5||bcg-16||no||the only tuberculosis (tb) vaccine currently available is bacillus calmette-guã©rin (bcg), although it has no efficacy in adults.
vmod||established-18/VBD||based-1/VBN	amod||similarities-8/NNS||clinical-3/JJ	conj_and||clinical-3/JJ||histopathological-5/JJ	amod||similarities-8/NNS||histopathological-5/JJ	conj_and||clinical-3/JJ||serological-7/JJ	amod||similarities-8/NNS||serological-7/JJ	prep_on||based-1/VBN||similarities-8/NNS	amod||celiacdisease-11/NN||human-10/JJ	prep_to||based-1/VBN||celiacdisease-11/NN	appos||celiacdisease-11/NN||cd-13/NN	nsubj||established-18/VBD||we-16/PRP	advmod||established-18/VBD||recently-17/RB	root||ROOT-0/null||established-18/VBD	det||model-22/NN||the-19/DT	amod||model-22/NN||rhesus-20/JJ	nn||model-22/NN||macaque-21/NN	dobj||established-18/VBD||model-22/NN	prep_of||model-22/NN||glutensensitivity-24/NN	cd-13||celiacdisease-11||no_rel||based on clinical, histopathological and serological similarities to human celiacdisease (cd), we recently established the rhesus macaque model of glutensensitivity.
amod||hbsag-2/NN||quantitative-1/JJ	nsubjpass||recognized-5/VBN||hbsag-2/NN	nsubj||assist-7/VB||hbsag-2/NN	aux||recognized-5/VBN||has-3/VBZ	auxpass||recognized-5/VBN||been-4/VBN	root||ROOT-0/null||recognized-5/VBN	aux||assist-7/VB||to-6/TO	xcomp||recognized-5/VBN||assist-7/VB	det||management-10/NN||the-9/DT	prep_in||assist-7/VB||management-10/NN	amod||infection-17/NN||chronichepatitisb-12/JJ	nn||infection-17/NN||virus-13/NN	appos||infection-17/NN||hbv-15/NN	prep_of||management-10/NN||infection-17/NN	hbv-15||hbsag-2||yes||quantitative hbsag has been recognized to assist in the management of chronichepatitisb virus (hbv) infection.
mark||distributed-4/VBN||although-1/IN	nsubjpass||distributed-4/VBN||ivermectin-2/NN	auxpass||distributed-4/VBN||is-3/VBZ	advcl||receive-25/VBP||distributed-4/VBN	advmod||distributed-4/VBN||free-5/JJ	prep_of||free-5/JJ||charge-7/NN	det||programme-11/NN||the-9/DT	nn||programme-11/NN||african-10/NN	prep_through||distributed-4/VBN||programme-11/NN	amod||control-14/NN||onchocerciasis-13/JJ	prep_for||programme-11/NN||control-14/NN	dep||control-14/NN||apoc-16/JJ	neg||individuals-22/NNS||not-19/RB	det||individuals-22/NNS||all-20/DT	amod||individuals-22/NNS||eligible-21/JJ	nsubj||receive-25/VBP||individuals-22/NNS	prep_within||individuals-22/NNS||communities-24/NNS	root||ROOT-0/null||receive-25/VBP	det||treatment-28/NN||the-26/DT	amod||treatment-28/NN||annual-27/JJ	dobj||receive-25/VBP||treatment-28/NN	onchocerciasis-13||ivermectin-2||yes||although ivermectin is distributed free of charge through the african programme for onchocerciasis control (apoc), not all eligible individuals within communities receive the annual treatment.
det||associations-3/NNS||the-1/DT	amod||associations-3/NNS||strongest-2/JJS	nsubjpass||found-10/VBN||associations-3/NNS	nn||responsiveness-8/NNS||atopy-5/NN	conj_and||atopy-5/NN||airway-7/NN	nn||responsiveness-8/NNS||airway-7/NN	prep_with||associations-3/NNS||responsiveness-8/NNS	auxpass||found-10/VBN||were-9/VBD	root||ROOT-0/null||found-10/VBN	amod||onset-13/NN||intermediate-12/JJ	prep_for||found-10/VBN||onset-13/NN	num||months-16/NNS||18-15/CD	appos||onset-13/NN||months-16/NNS	dep||onset-13/NN||wheezing-18/VBG	cc||for-21/IN||or-20/CC	dep||wheezing-18/VBG||for-21/IN	amod||8.36-23/CD||atopy-22/JJ	pobj||for-21/IN||8.36-23/CD	num||%-26/NN||95-25/CD	nsubj||ci-27/VBP||%-26/NN	dep||for-21/IN||ci-27/VBP	number||13.4-30/CD||5.2-28/CD	dep||13.4-30/CD||to-29/TO	dobj||ci-27/VBP||13.4-30/CD	amod||difference-33/NN||mean-32/JJ	dep||13.4-30/CD||difference-33/NN	nn||response-36/NN||dose-35/NN	prep_in||difference-33/NN||response-36/NN	aux||methacholine-38/VB||to-37/TO	vmod||ci-27/VBP||methacholine-38/VB	dobj||methacholine-38/VB||1.76-39/CD	number||%-42/NN||95-41/CD	amod||fev1-48/NNS||%-42/NN	nn||fev1-48/NNS||ci-43/NN	number||2.12-46/CD||1.41-44/CD	dep||2.12-46/CD||to-45/TO	dep||%-47/NN||2.12-46/CD	dep||fev1-48/NNS||%-47/NN	appos||1.76-39/CD||fev1-48/NNS	number||1/4-51/CD||î-50/CD	num||mol-52/NN||1/4-51/CD	prep_per||fev1-48/NNS||mol-52/NN	prepc_compared_with||methacholine-38/VB||with-55/IN	nn||phenotype-58/NN||infrequent/never-56/NN	nn||phenotype-58/NN||wheeze-57/NN	pobj||methacholine-38/VB||phenotype-58/NN	atopy-22||methacholine-38||no_rel||the strongest associations with atopy and airway responsiveness were found for intermediate onset (18 months) wheezing (or for atopy 8.36, 95% ci 5.2 to 13.4; mean difference in dose response to methacholine 1.76, 95% ci 1.41 to 2.12 %fev1 per î¼mol, compared with infrequent/never wheeze phenotype).
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	amod||interviews-6/NNS||in-depth-3/JJ	amod||interviews-6/NNS||open-ended-5/JJ	dobj||conducted-2/VBD||interviews-6/NNS	num||individuals-9/NNS||47-8/CD	prep_with||conducted-2/VBD||individuals-9/NNS	num||women-12/NNS||30-11/CD	appos||individuals-9/NNS||women-12/NNS	num||men-15/NNS||17-14/CD	dep||women-12/NNS||men-15/NNS	dep||conducted-2/VBD||living-17/VBG	prep_with||living-17/VBG||hiv/aids-19/NNS	vmod||hiv/aids-19/NNS||recruited-20/VBN	nn||programs-24/NNS||aids-22/NNS	nn||programs-24/NNS||treatment-23/NN	prep_from||recruited-20/VBN||programs-24/NNS	prep_in||recruited-20/VBN||mbarara-26/NN	prep_in||recruited-20/VBN||kampala-28/NN	conj_and||mbarara-26/NN||kampala-28/NN	acomp||conducted-2/VBD||uganda-30/JJ	aux||understand-32/VB||to-31/TO	xcomp||uganda-30/JJ||understand-32/VB	advmod||interferes-36/VBZ||how-33/WRB	nn||insecurity-35/NN||food-34/NN	nsubj||interferes-36/VBZ||insecurity-35/NN	ccomp||understand-32/VB||interferes-36/VBZ	nn||regimens-40/NNS||arv-38/NN	nn||regimens-40/NNS||therapy-39/NN	prep_with||interferes-36/VBZ||regimens-40/NNS	aids-22||hiv--1||no||we conducted in-depth, open-ended interviews with 47 individuals (30 women, 17 men) living with hiv/aids recruited from aids treatment programs in mbarara and kampala, uganda to understand how food insecurity interferes with arv therapy regimens.
nn||cytokines-4/NNS||objectiveâ-1/NNP	nn||cytokines-4/NNS||$-2/NNP	nsubjpass||elevated-6/VBN||cytokines-4/NNS	auxpass||elevated-6/VBN||are-5/VBP	root||ROOT-0/null||elevated-6/VBN	amod||states-10/NNS||various-8/JJ	amod||states-10/NNS||insulin-resistant-9/JJ	prep_in||elevated-6/VBN||states-10/NNS	prep_including||elevated-6/VBN||type2diabetes-13/NNS	prep_including||elevated-6/VBN||obesity-15/NN	conj_and||type2diabetes-13/NNS||obesity-15/NN	mark||controversial-32/JJ||although-17/IN	det||contribution-19/NN||the-18/DT	nsubj||controversial-32/JJ||contribution-19/NN	prep_of||contribution-19/NN||interleukin-6-21/JJ	dep||interleukin-6-21/JJ||il-6-23/JJ	det||induction-27/NN||the-26/DT	prep_in||interleukin-6-21/JJ||induction-27/NN	det||diseases-30/NNS||these-29/DT	prep_of||induction-27/NN||diseases-30/NNS	cop||controversial-32/JJ||is-31/VBZ	advcl||elevated-6/VBN||controversial-32/JJ	type2diabetes-13||insulin--1||yes||objectiveâ€” cytokines are elevated in various insulin-resistant states, including type2diabetes and obesity, although the contribution of interleukin-6 (il-6) in the induction of these diseases is controversial.
det||study-2/NN||the-1/DT	nsubj||demonstrated-3/VBD||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||similar-10/JJ||that-4/IN	det||risk-6/NN||the-5/DT	nsubj||similar-10/JJ||risk-6/NN	prep_of||risk-6/NN||intussusception-8/NN	cop||similar-10/JJ||was-9/VBD	ccomp||demonstrated-3/VBD||similar-10/JJ	nn||recipients-15/NNS||vaccine-12/NN	conj_and||vaccine-12/NN||placebo-14/NN	nn||recipients-15/NNS||placebo-14/NN	prep_in||similar-10/JJ||recipients-15/NNS	mark||prevented-20/VBD||that-17/IN	det||vaccine-19/NN||the-18/DT	nsubj||prevented-20/VBD||vaccine-19/NN	nsubj||ameliorated-23/VBD||vaccine-19/NN	nsubj||reduced-37/VBD||vaccine-19/NN	ccomp||demonstrated-3/VBD||prevented-20/VBD	conj_and||similar-10/JJ||prevented-20/VBD	dobj||prevented-20/VBD||rotavirusgastroenteritis-21/NNS	conj_and||similar-10/JJ||ameliorated-23/VBD	conj_and||prevented-20/VBD||ameliorated-23/VBD	det||severity-25/NN||the-24/DT	dobj||ameliorated-23/VBD||severity-25/NN	prep_of||severity-25/NN||disease-27/NN	prep_in||ameliorated-23/VBD||those-29/DT	nsubj||had-31/VBD||those-29/DT	rcmod||those-29/DT||had-31/VBD	det||disease-33/NN||any-32/DT	dobj||had-31/VBD||disease-33/NN	advmod||reduced-37/VBD||substantially-36/RB	conj_and||similar-10/JJ||reduced-37/VBD	conj_and||prevented-20/VBD||reduced-37/VBD	amod||hospitalizations-39/NNS||rotavirus-associated-38/JJ	dobj||reduced-37/VBD||hospitalizations-39/NNS	amod||contacts-44/NNS||other-41/JJ	nn||contacts-44/NNS||health-42/NN	nn||contacts-44/NNS||care-43/NN	dobj||reduced-37/VBD||contacts-44/NNS	conj_and||hospitalizations-39/NNS||contacts-44/NNS	rotavirusgastroenteritis-21||rotavirus--1||no||the study demonstrated that the risk of intussusception was similar in vaccine and placebo recipients and that the vaccine prevented rotavirusgastroenteritis, ameliorated the severity of disease in those who had any disease, and substantially reduced rotavirus-associated hospitalizations and other health care contacts.
nsubj||dna-10/NN||temozolomide-1/NN	appos||temozolomide-1/NN||tmz-3/NN	cop||dna-10/NN||is-5/VBZ	det||dna-10/NN||a-6/DT	amod||dna-10/NN||new-7/JJ	amod||dna-10/NN||second-8/JJ	nn||dna-10/NN||generation-9/NN	root||ROOT-0/null||dna-10/NN	vmod||dna-10/NN||alkylating-11/VBG	dobj||alkylating-11/VBG||agent-12/NN	nsubj||become-15/VBN||agent-12/NN	aux||become-15/VBN||has-14/VBZ	rcmod||agent-12/NN||become-15/VBN	xcomp||become-15/VBN||part-16/NN	amod||paradigms-21/NNS||malignant-18/JJ	nn||paradigms-21/NNS||astrocytoma-19/NN	nn||paradigms-21/NNS||management-20/NN	prep_of||part-16/NN||paradigms-21/NNS	poss||efficacy-26/NN||its-24/PRP$	amod||efficacy-26/NN||proven-25/JJ	prep_because_of||paradigms-21/NNS||efficacy-26/NN	xcomp||become-15/VBN||ease-28/NN	conj_and||part-16/NN||ease-28/NN	prep_of||ease-28/NN||administration-30/NN	amod||profile-35/NN||favorable-33/JJ	nn||profile-35/NN||toxicity-34/NN	xcomp||become-15/VBN||profile-35/NN	conj_and||part-16/NN||profile-35/NN	astrocytoma-19||temozolomide-1||yes||temozolomide (tmz) is a new second generation dna alkylating agent that has become part of malignant astrocytoma management paradigms because of its proven efficacy, ease of administration, and favorable toxicity profile.
prep_in||have-16/VB||addition-2/NN	nsubj||have-16/VB||development-4/NN	amod||tools-7/NNS||new-6/JJ	prep_of||development-4/NN||tools-7/NNS	amod||tools-7/NNS||capable-8/JJ	prepc_to||capable-8/JJ||targeting-10/VBG	dobj||targeting-10/VBG||m.tuberculosis-11/NNS	amod||cells-14/NNS||infected-13/JJ	dep||m.tuberculosis-11/NNS||cells-14/NNS	aux||have-16/VB||may-15/MD	root||ROOT-0/null||have-16/VB	amod||applications-18/NNS||potential-17/JJ	dobj||have-16/VB||applications-18/NNS	prep_to||have-16/VB||diagnosis-20/NN	prep_to||have-16/VB||treatment-22/NN	conj_and||diagnosis-20/NN||treatment-22/NN	prep_to||have-16/VB||prevention-25/NN	conj_and||diagnosis-20/NN||prevention-25/NN	nn||-rrb--30/NNP||tuberculosis-27/NNP	nn||-rrb--30/NNP||-lrb--28/NNP	nn||-rrb--30/NNP||tb-29/NNP	prep_of||diagnosis-20/NN||-rrb--30/NNP	tb-29||m.tuberculosis-11||no||in addition , development of new tools capable to targeting m.tuberculosis - infected cells may have potential applications to diagnosis , treatment , and prevention of tuberculosis -lrb- tb -rrb- .
num||subjects-4/NNS||one-1/CD	num||subjects-4/NNS||hundred-2/CD	amod||subjects-4/NNS||fifty-one-3/JJ	nsubj||received-8/VBD||subjects-4/NNS	amod||falciparummalaria-7/NN||uncomplicated-6/JJ	prep_with||subjects-4/NNS||falciparummalaria-7/NN	root||ROOT-0/null||received-8/VBD	advmod||observed-10/JJ||directly-9/RB	amod||therapy-11/NN||observed-10/JJ	dobj||received-8/VBD||therapy-11/NN	num||artesunate-15/NN||12-13/CD	amod||artesunate-15/NN||mg/kg-14/VBG	prep_with||received-8/VBD||artesunate-15/NN	num||days-19/NNS||three-18/CD	prep_over||artesunate-15/NN||days-19/NNS	number||mg/kg-23/JJ||25-22/CD	amod||mefloquine-37/NN||mg/kg-23/JJ	amod||mefloquine-37/NN||mefloquine-24/JJ	amod||mefloquine-37/NN||up-26/IN	det||dose-30/NN||a-28/DT	amod||dose-30/NN||maximum-29/JJ	prep_to||up-26/IN||dose-30/NN	num||mg-33/NN||600-32/CD	prep_of||dose-30/NN||mg-33/NN	amod||mefloquine-37/NN||artesunate/1-34/JJ	num||mefloquine-37/NN||,000-35/CD	nn||mefloquine-37/NN||mg-36/NN	prep_with||received-8/VBD||mefloquine-37/NN	conj_and||artesunate-15/NN||mefloquine-37/NN	falciparummalaria-7||mefloquine-37||yes||one hundred fifty-one subjects with uncomplicated falciparummalaria received directly observed therapy with 12 mg/kg artesunate (over three days) and 25 mg/kg mefloquine, up to a maximum dose of 600 mg artesunate/1,000 mg mefloquine.
amod||information-2/NN||little-1/JJ	nsubj||available-4/JJ||information-2/NN	nsubj||available-4/JJ||information-2/NN	cop||available-4/JJ||is-3/VBZ	root||ROOT-0/null||available-4/JJ	conj_and||available-4/JJ||available-4/JJ	det||management-7/NN||the-6/DT	prep_on||available-4/JJ||management-7/NN	prep_of||management-7/NN||patients-9/NNS	amod||dm2-13/NNS||type2diabetesmellitus-11/JJ	prep_with||patients-9/NNS||dm2-13/NNS	amod||practice-18/NN||regular-16/JJ	amod||practice-18/NN||clinical-17/JJ	prep_in||dm2-13/NNS||practice-18/NN	advmod||dm2-13/NNS||prior-20/RB	prep||prior-20/RB||to-21/TO	det||point-25/NN||the-24/DT	prep_at||available-4/JJ||point-25/NN	prepc_of||point-25/NN||initiating-27/VBG	dobj||initiating-27/VBG||treatment-28/NN	prep_with||initiating-27/VBG||insulin-30/NN	type2diabetesmellitus-11||insulin-30||yes||little information is available on the management of patients with type2diabetesmellitus (dm2) in regular clinical practice, prior to and at the point of initiating treatment with insulin.
num||2005-4/CD||2002-2/CD	dep||2005-4/CD||to-3/TO	prep_from||identified-9/VBD||2005-4/CD	num||reviews-8/NNS||two-6/CD	nn||reviews-8/NNS||literature-7/NN	appos||2005-4/CD||reviews-8/NNS	root||ROOT-0/null||identified-9/VBD	det||number-11/NN||a-10/DT	dobj||identified-9/VBD||number-11/NN	nsubj||appeared-16/VBD||number-11/NN	nsubj||neglected-20/JJ||number-11/NN	amod||issues-14/NNS||reproductive-health-13/JJ	prep_of||number-11/NN||issues-14/NNS	rcmod||number-11/NN||appeared-16/VBD	aux||neglected-20/JJ||to-17/TO	cop||neglected-20/JJ||be-18/VB	advmod||neglected-20/JJ||relatively-19/RB	xcomp||appeared-16/VBD||neglected-20/JJ	prep_in||neglected-20/JJ||relation-22/NN	amod||information-26/NN||hiv/aids-24/JJ	amod||information-26/NN||contraceptive-25/JJ	prep_to||neglected-20/JJ||information-26/NN	vmod||information-26/NN||tailored-27/VBN	det||needs-30/NNS||the-29/DT	prep_to||tailored-27/VBN||needs-30/NNS	amod||people-33/NNS||hiv-positive-32/JJ	prep_of||needs-30/NNS||people-33/NNS	amod||hiv-36/NN||voluntary-35/JJ	dobj||identified-9/VBD||hiv-36/NN	conj_and||number-11/NN||hiv-36/NN	nsubj||appeared-16/VBD||hiv-36/NN	nsubj||neglected-20/JJ||hiv-36/NN	vmod||hiv-36/NN||counselling-37/VBG	vmod||hiv-36/NN||testing-39/VBG	conj_and||counselling-37/VBG||testing-39/VBG	amod||care-42/NN||antenatal-41/JJ	prep_during||counselling-37/VBG||care-42/NN	prep_during||counselling-37/VBG||labour-44/NN	conj_and||care-42/NN||labour-44/NN	prep_during||counselling-37/VBG||delivery-47/NN	conj_and||care-42/NN||delivery-47/NN	nn||options-50/NNS||parenting-49/NN	dobj||identified-9/VBD||options-50/NNS	conj_and||number-11/NN||options-50/NNS	nsubj||appeared-16/VBD||options-50/NNS	nsubj||neglected-20/JJ||options-50/NNS	amod||people-53/NNS||hiv-positive-52/JJ	prep_for||options-50/NNS||people-53/NNS	dep||conception-62/NN||pregnancy-55/NNP	amod||-lrb--59/NNS||unprotected-57/JJ	nn||-lrb--59/NNS||intercourse-58/NN	prep_through||pregnancy-55/NNP||-lrb--59/NNS	advmod||assisted-61/VBN||i.e.-60/RB	amod||conception-62/NN||assisted-61/VBN	prep_besides||people-53/NNS||conception-62/NN	amod||adoption-65/NN||legal-64/JJ	dobj||identified-9/VBD||adoption-65/NN	conj_and||number-11/NN||adoption-65/NN	nsubj||appeared-16/VBD||adoption-65/NN	nsubj||neglected-20/JJ||adoption-65/NN	amod||care-68/NN||foster-67/JJ	conj_and||number-11/NN||care-68/NN	conj_or||adoption-65/NN||care-68/NN	nsubj||identified-9/VBD||-rrb--69/NNP	amod||pregnancy-72/NN||unwanted-71/JJ	nsubj||identified-9/VBD||pregnancy-72/NN	conj_and||-rrb--69/NNP||pregnancy-72/NN	amod||care-76/NN||abortion-related-75/JJ	nsubj||identified-9/VBD||care-76/NN	conj_and||-rrb--69/NNP||care-76/NN	aids--1||hiv-36||no||from 2002 to 2005 , two literature reviews identified a number of reproductive-health issues that appeared to be relatively neglected in relation to hiv/aids contraceptive information tailored to the needs of hiv-positive people ; voluntary hiv counselling and testing during antenatal care , labour , and delivery ; parenting options for hiv-positive people besides pregnancy through unprotected intercourse -lrb- i.e. assisted conception and legal adoption or foster care -rrb- ; unwanted pregnancy ; and abortion-related care .
amod||responses-2/NNS||cytokine-1/JJ	nsubj||comparable-10/JJ||responses-2/NNS	vmod||responses-2/NNS||induced-3/VBN	amod||viruses-6/NNS||pdmh1n1-5/JJ	agent||induced-3/VBN||viruses-6/NNS	prep_in||viruses-6/NNS||vitro-8/NNP	cop||comparable-10/JJ||are-9/VBP	root||ROOT-0/null||comparable-10/JJ	amod||influenzaviruses-14/NNS||other-12/JJ	amod||influenzaviruses-14/NNS||seasonal-13/JJ	prep_to||comparable-10/JJ||influenzaviruses-14/NNS	vmod||influenzaviruses-14/NNS||suggesting-15/VBG	det||dysregulation-18/NN||the-16/DT	amod||dysregulation-18/NN||cytokine-17/JJ	dobj||suggesting-15/VBG||dysregulation-18/NN	mark||feature-27/NN||as-19/IN	csubj||feature-27/NN||seen-20/VBN	amod||infection-23/NN||h5n1-22/JJ	prep_in||seen-20/VBN||infection-23/NN	cop||feature-27/NN||is-24/VBZ	neg||feature-27/NN||not-25/RB	det||feature-27/NN||a-26/DT	advcl||suggesting-15/VBG||feature-27/NN	det||virus-31/NN||the-29/DT	amod||virus-31/NN||pdmh1n1-30/JJ	prep_of||feature-27/NN||virus-31/NN	h5n1-22||influenzaviruses-14||no||cytokine responses induced by pdmh1n1 viruses in vitro are comparable to other seasonal influenzaviruses suggesting the cytokine dysregulation as seen in h5n1 infection is not a feature of the pdmh1n1 virus.
aux||study-2/VB||to-1/TO	csubj||used-8/VBD||study-2/VB	det||effect-4/NN||the-3/DT	dobj||study-2/VB||effect-4/NN	amod||gabapentin-7/NN||oral-6/JJ	prep_of||effect-4/NN||gabapentin-7/NN	root||ROOT-0/null||used-8/VBD	amod||analgesia-11/NN||preemptive-10/JJ	prep_as||used-8/VBD||analgesia-11/NN	aux||attenuate-13/VB||to-12/TO	xcomp||used-8/VBD||attenuate-13/VB	nn||pain-16/NN||post-14/NN	amod||pain-16/NN||operative-15/JJ	dobj||attenuate-13/VB||pain-16/NN	prep_in||pain-16/NN||patients-18/NNS	vmod||patients-18/NNS||undergoing-19/VBG	amod||surgery-21/NN||abdominal-20/JJ	dobj||undergoing-19/VBG||surgery-21/NN	amod||anesthesia-24/NN||general-23/JJ	prep_under||undergoing-19/VBG||anesthesia-24/NN	pain-16||gabapentin-7||yes||to study the effect of oral gabapentin used as preemptive analgesia to attenuate post operative pain in patients undergoing abdominal surgery under general anesthesia.
amod||data-2/NNS||epidemiological-1/JJ	nsubj||implicated-7/VBN||data-2/NNS	nn||studies-5/NNS||animal-4/NN	conj_and||data-2/NNS||studies-5/NNS	nsubj||implicated-7/VBN||studies-5/NNS	aux||implicated-7/VBN||have-6/VBP	root||ROOT-0/null||implicated-7/VBN	amod||particulate-9/JJ||airborne-8/JJ	amod||matter-10/NN||particulate-9/JJ	dobj||implicated-7/VBN||matter-10/NN	dobj||implicated-7/VBN||dep-12/NN	conj_and||matter-10/NN||dep-12/NN	amod||morbidity-15/NN||increased-14/VBN	prep_in||implicated-7/VBN||morbidity-15/NN	prep_in||implicated-7/VBN||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	det||number-21/NN||a-20/DT	prep_due_to||morbidity-15/NN||number-21/NN	prep_of||number-21/NN||cardiopulmonarydiseases-23/NNS	prep_including||morbidity-15/NN||asthma-25/NN	amod||pulmonarydisorder-29/NN||chronic-27/JJ	nn||pulmonarydisorder-29/NN||obstructive-28/NN	prep_including||morbidity-15/NN||pulmonarydisorder-29/NN	conj_and||asthma-25/NN||pulmonarydisorder-29/NN	nn||cancer-33/NN||lung-32/NN	prep_including||morbidity-15/NN||cancer-33/NN	conj_and||asthma-25/NN||cancer-33/NN	cardiopulmonarydiseases-23||pulmonarydisorder-29||no||epidemiological data and animal studies have implicated airborne particulate matter and dep in increased morbidity and mortality due to a number of cardiopulmonarydiseases including asthma, chronic obstructive pulmonarydisorder, and lung cancer.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	amod||male-7/NN||47-yr-old-6/JJ	prep_of||case-4/NN||male-7/NN	vmod||male-7/NN||presented-9/VBN	amod||cancer-13/NN||sigmoid-11/JJ	nn||cancer-13/NN||colon-12/NN	prep_with||presented-9/VBN||cancer-13/NN	amod||liver-16/NN||multiple-15/JJ	prep_with||presented-9/VBN||liver-16/NN	prep_in||was-24/VBD||liver-16/NN	amod||metastases-19/NNS||peritoneal-18/JJ	prep_with||presented-9/VBN||metastases-19/NNS	conj_and||liver-16/NN||metastases-19/NNS	prep_in||was-24/VBD||metastases-19/NNS	expl||was-24/VBD||there-23/EX	rcmod||liver-16/NN||was-24/VBD	det||response-27/NN||a-25/DT	amod||response-27/NN||complete-26/JJ	nsubj||was-24/VBD||response-27/NN	det||cancer-32/NN||the-29/DT	amod||cancer-32/NN||primary-30/JJ	nn||cancer-32/NN||colon-31/NN	prep_for||response-27/NN||cancer-32/NN	prep_after||was-24/VBD||administration-34/NN	amod||chemotherapy-37/NN||preoperative-36/JJ	prep_of||administration-34/NN||chemotherapy-37/NN	vmod||chemotherapy-37/NN||selected-38/VBN	agent||selected-38/VBN||atp-cra-40/NN	cancer-32||atp--1||no_rel||we report a case of 47-yr-old male, presented with sigmoid colon cancer with multiple liver and peritoneal metastases, in which there was a complete response for the primary colon cancer after administration of preoperative chemotherapy selected by atp-cra.
det||study-3/NN||a-1/DT	nn||study-3/NN||pilot-2/NN	nsubjpass||undertaken-13/VBN||study-3/NN	nsubj||test-24/VB||study-3/NN	amod||infection-6/NN||experimental-5/JJ	prep_of||study-3/NN||infection-6/NN	det||americanus-11/NNS||the-8/DT	amod||americanus-11/NNS||hookworm-9/JJ	nn||americanus-11/NNS||necator-10/NN	prep_with||infection-6/NN||americanus-11/NNS	auxpass||undertaken-13/VBN||was-12/VBD	root||ROOT-0/null||undertaken-13/VBN	det||group-16/NN||a-15/DT	prep_among||undertaken-13/VBN||group-16/NN	advmod||healthy-19/JJ||otherwise-18/RB	amod||people-20/NNS||healthy-19/JJ	prep_of||group-16/NN||people-20/NNS	prep_with||undertaken-13/VBN||celiacdisease-22/NN	aux||test-24/VB||to-23/TO	xcomp||undertaken-13/VBN||test-24/VB	det||potential-26/NN||the-25/DT	dobj||test-24/VB||potential-26/NN	det||helminth-29/NN||the-28/DT	prep_of||potential-26/NN||helminth-29/NN	aux||suppress-31/VB||to-30/TO	vmod||helminth-29/NN||suppress-31/VB	det||immunopathology-33/NN||the-32/DT	dobj||suppress-31/VB||immunopathology-33/NN	vmod||immunopathology-33/NN||induced-34/VBN	agent||induced-34/VBN||gluten-36/NN	celiacdisease-22||gluten-36||no||a pilot study of experimental infection with the hookworm necator americanus was undertaken among a group of otherwise healthy people with celiacdisease to test the potential of the helminth to suppress the immunopathology induced by gluten.
nsubj||reduced-9/VBD||conclusion-1/NN	amod||doses-4/NNS||lower-2/JJR	nn||doses-4/NNS||statin-3/NN	nsubj||advised-8/VBD||doses-4/NNS	prep_than||doses-4/NNS||those-6/DT	advmod||advised-8/VBD||currently-7/RB	rcmod||conclusion-1/NN||advised-8/VBD	root||ROOT-0/null||reduced-9/VBD	det||risk-11/NN||the-10/DT	dobj||reduced-9/VBD||risk-11/NN	prep_of||risk-11/NN||coronaryheartdisease-13/NN	det||extent-17/NN||a-15/DT	amod||extent-17/NN||greater-16/JJR	prep_to||reduced-9/VBD||extent-17/NN	advmod||anticipated-19/VBN||than-18/IN	vmod||extent-17/NN||anticipated-19/VBN	prep_in||anticipated-19/VBN||patients-21/NNS	amod||hypercholesterolaemia-24/NN||familial-23/JJ	prep_with||patients-21/NNS||hypercholesterolaemia-24/NN	coronaryheartdisease-13||statin-3||no_rel||conclusion lower statin doses than those currently advised reduced the risk of coronaryheartdisease to a greater extent than anticipated in patients with familial hypercholesterolaemia.
poss||method-2/NN||our-1/PRP$	nsubj||detected-3/VBD||method-2/NN	root||ROOT-0/null||detected-3/VBD	det||combination-5/NN||the-4/DT	dobj||detected-3/VBD||combination-5/NN	prep_of||combination-5/NN||metformin-7/NN	nsubj||avandamet-14/NN||metformin-7/NN	prep_of||combination-5/NN||rosiglitazone-9/NN	conj_and||metformin-7/NN||rosiglitazone-9/NN	nsubj||avandamet-14/NN||rosiglitazone-9/NN	cop||avandamet-14/NN||is-12/VBZ	advmod||avandamet-14/NN||actually-13/RB	rcmod||metformin-7/NN||avandamet-14/NN	det||drug-17/NN||a-16/DT	appos||avandamet-14/NN||drug-17/NN	nsubjpass||used-22/VBN||drug-17/NN	nsubj||treat-24/VB||drug-17/NN	aux||used-22/VBN||has-19/VBZ	auxpass||used-22/VBN||been-20/VBN	advmod||used-22/VBN||successfully-21/RB	rcmod||drug-17/NN||used-22/VBN	aux||treat-24/VB||to-23/TO	xcomp||used-22/VBN||treat-24/VB	dobj||treat-24/VB||type2diabetes-25/NNS	type2diabetes-25||metformin-7||yes||our method detected the combination of metformin and rosiglitazone, which is actually avandamet, a drug that has been successfully used to treat type2diabetes.
amod||knowledge-2/NN||proper-1/JJ	nsubj||enough-8/JJ||knowledge-2/NN	nsubj||adopt-12/VB||knowledge-2/NN	nn||transmission-5/NN||hiv-4/NN	prep_of||knowledge-2/NN||transmission-5/NN	cop||enough-8/JJ||is-6/VBZ	neg||enough-8/JJ||not-7/RB	root||ROOT-0/null||enough-8/JJ	prep_for||enough-8/JJ||people-10/NNS	aux||adopt-12/VB||to-11/TO	xcomp||enough-8/JJ||adopt-12/VB	amod||behaviors-14/NNS||protective-13/JJ	dobj||adopt-12/VB||behaviors-14/NNS	nsubj||increase-22/VB||deficits-17/NNS	det||information-20/NN||this-19/DT	prep_in||deficits-17/NNS||information-20/NN	aux||increase-22/VB||may-21/MD	conj_but||enough-8/JJ||increase-22/VB	amod||vulnerability-24/NN||hiv/aids-23/JJ	dobj||increase-22/VB||vulnerability-24/NN	aids--1||hiv-4||no||proper knowledge of hiv transmission is not enough for people to adopt protective behaviors, but deficits in this information may increase hiv/aids vulnerability.
nsubjpass||increased-3/VBN||il-15-1/JJ	nsubj||has-13/VBZ||il-15-1/JJ	auxpass||increased-3/VBN||is-2/VBZ	root||ROOT-0/null||increased-3/VBN	det||intestine-6/NN||the-5/DT	prep_in||increased-3/VBN||intestine-6/NN	prep_of||intestine-6/NN||patients-8/NNS	vmod||patients-8/NNS||affected-9/VBN	agent||affected-9/VBN||cd-11/NN	conj_and||increased-3/VBN||has-13/VBZ	amod||activity-15/NN||pleiotropic-14/JJ	dobj||has-13/VBZ||activity-15/NN	nsubj||results-18/VBZ||activity-15/NN	advmod||results-18/VBZ||ultimately-17/RB	rcmod||activity-15/NN||results-18/VBZ	amod||cross-talk-21/NN||immunoregulatory-20/JJ	prep_in||results-18/VBZ||cross-talk-21/NN	prep_between||cross-talk-21/NN||cells-23/NNS	vmod||cells-23/NNS||belonging-24/VBG	det||branches-30/NNS||the-26/DT	amod||branches-30/NNS||innate-27/JJ	conj_and||innate-27/JJ||adaptive-29/JJ	amod||branches-30/NNS||adaptive-29/JJ	prep_to||belonging-24/VBG||branches-30/NNS	det||response-34/NN||the-32/DT	amod||response-34/NN||immune-33/JJ	prep_of||branches-30/NNS||response-34/NN	cross--1||cd-11||no_rel||il-15 is increased in the intestine of patients affected by cd and has pleiotropic activity that ultimately results in immunoregulatory cross-talk between cells belonging to the innate and adaptive branches of the immune response.
nsubj||represents-5/VBZ||culture-1/NN	prep_of||culture-1/NN||mycobacteriumtuberculosis-3/NNS	advmod||represents-5/VBZ||currently-4/RB	root||ROOT-0/null||represents-5/VBZ	det||â-8/NN||the-6/DT	amod||â-8/NN||closest-7/JJS	dobj||represents-5/VBZ||â-8/NN	amod||â-8/NN||$-9/$	dep||$-9/$||œgold-10/JJ	vmod||â-8/NN||standardâ-11/VBG	dobj||standardâ-11/VBG||$-12/$	quantmod||diagnosis-14/CD||for-13/IN	num||$-12/$||diagnosis-14/CD	prep_of||$-12/$||tuberculosis-16/NNP	appos||â-8/NN||tb-18/NN	amod||data-23/NNS||operational-22/JJ	nsubj||scant-25/JJ||data-23/NNS	cop||scant-25/JJ||are-24/VBP	conj_but||represents-5/VBZ||scant-25/JJ	det||impact-28/NN||the-27/DT	prep_on||scant-25/JJ||impact-28/NN	prep_on||scant-25/JJ||cost-effectiveness-30/NNS	conj_and||impact-28/NN||cost-effectiveness-30/NNS	nn||culture-33/NN||tb-32/NN	prep_of||impact-28/NN||culture-33/NN	amod||immunodeficiency-36/NN||human-35/JJ	prep_for||culture-33/NN||immunodeficiency-36/NN	dep||scant-25/JJ||hiv-38/RB	amod||individuals-42/NNS||infected-41/JJ	npadvmod||scant-25/JJ||individuals-42/NNS	amod||settings-45/NNS||resource-limited-44/JJ	prep_in||scant-25/JJ||settings-45/NNS	tuberculosis-16||mycobacteriumtuberculosis-3||no||culture of mycobacteriumtuberculosis currently represents the closest â€œgold standardâ€? for diagnosis of tuberculosis (tb), but operational data are scant on the impact and cost-effectiveness of tb culture for human immunodeficiency (hiv-) infected individuals in resource-limited settings.
det||total-2/NN||a-1/DT	nsubjpass||enrolled-17/VBN||total-2/NN	num||volunteers-6/NNS||16-4/CD	amod||volunteers-6/NNS||healthy-5/JJ	prep_of||total-2/NN||volunteers-6/NNS	num||patients-9/NNS||45-8/CD	conj_and||total-2/NN||patients-9/NNS	nsubjpass||enrolled-17/VBN||patients-9/NNS	amod||virus-12/NN||chronichepatitisc-11/JJ	prep_with||patients-9/NNS||virus-12/NN	appos||total-2/NN||hcv-14/NN	auxpass||enrolled-17/VBN||were-16/VBD	root||ROOT-0/null||enrolled-17/VBN	nsubj||n-20/VBZ||f0-19/NNS	parataxis||enrolled-17/VBN||n-20/VBZ	dep||16-22/CD||=-21/SYM	ccomp||n-20/VBZ||16-22/CD	amod||n-25/NN||f1-24/JJ	nsubj||7-27/CD||n-25/NN	dep||7-27/CD||=-26/SYM	ccomp||n-20/VBZ||7-27/CD	amod||n-30/NN||f2-29/JJ	nsubj||17-32/CD||n-30/NN	dep||17-32/CD||=-31/SYM	ccomp||n-20/VBZ||17-32/CD	amod||n-35/NN||f3-34/JJ	nsubj||13-42/CD||n-35/NN	num||n-35/NN||=-36/CD	num||n-35/NN||8-37/CD	amod||n-40/NN||f4-39/JJ	conj_and||n-35/NN||n-40/NN	nsubj||13-42/CD||n-40/NN	dep||13-42/CD||=-41/SYM	ccomp||n-20/VBZ||13-42/CD	prepc_according_to||n-20/VBZ||to-45/TO	det||classification-48/NN||the-46/DT	nn||classification-48/NN||metavir-47/NN	pobj||n-20/VBZ||classification-48/NN	f3-34||chronichepatitisc-11||no_rel||a total of 16 healthy volunteers and 45 patients with chronichepatitisc virus (hcv) were enrolled (f0 n = 16, f1 n = 7, f2 n = 17, f3 n = 8 and f4 n = 13, according to the metavir classification).
amod||antigen-3/NN||hepatitisb-1/JJ	nn||antigen-3/NN||surface-2/NN	nsubjpass||done-23/VBN||antigen-3/NN	appos||antigen-3/NN||hbsag-5/NN	amod||antigen-10/NN||hepatitisb-8/JJ	nn||antigen-10/NN||envelope-9/NN	appos||antigen-3/NN||antigen-10/NN	appos||antigen-10/NN||hbeag-12/NN	conj_and||antigen-3/NN||hbv-dna-15/NN	nsubjpass||done-23/VBN||hbv-dna-15/NN	nn||biopsy-19/NN||liver-18/NN	conj_and||antigen-3/NN||biopsy-19/NN	nsubjpass||done-23/VBN||biopsy-19/NN	prep_before||biopsy-19/NN||rt-21/NN	auxpass||done-23/VBN||were-22/VBD	root||ROOT-0/null||done-23/VBN	det||patients-26/NNS||all-25/DT	prep_in||done-23/VBN||patients-26/NNS	hbv--1||hbsag-5||yes||hepatitisb surface antigen (hbsag), hepatitisb envelope antigen (hbeag), hbv-dna, and liver biopsy before rt were done in all patients.
det||procedure-2/NN||this-1/DT	nsubj||resulted-3/VBD||procedure-2/NN	root||ROOT-0/null||resulted-3/VBD	det||modulation-6/NN||the-5/DT	prep_in||resulted-3/VBD||modulation-6/NN	mwe||than-9/IN||more-8/JJR	quantmod||100-10/CD||than-9/IN	num||genes-11/NNS||100-10/CD	prep_of||modulation-6/NN||genes-11/NNS	appos||genes-11/NNS||some-13/DT	nsubj||coding-16/VBG||them-15/PRP	prepc_of||some-13/DT||coding-16/VBG	amod||proteins-19/NNS||other-18/JJ	prep_for||coding-16/VBG||proteins-19/NNS	advmod||involved-21/VBN||also-20/RB	vmod||proteins-19/NNS||involved-21/VBN	prep_in||involved-21/VBN||adhesion-23/NN	prep_of||adhesion-23/NN||thymocytes-25/NNS	dep||related-28/VBN||others-27/NNS	parataxis||resulted-3/VBD||related-28/VBN	prepc_to||related-28/VBN||signaling-30/VBG	dobj||signaling-30/VBG||pathways-31/NNS	vmod||pathways-31/NNS||triggered-32/VBN	nn||activation-35/NN||integrin-34/NN	prep_after||triggered-32/VBN||activation-35/NN	advmod||involved-39/VBN||even-38/RB	parataxis||resulted-3/VBD||involved-39/VBN	conj_or||related-28/VBN||involved-39/VBN	det||control-42/NN||the-41/DT	prep_in||involved-39/VBN||control-42/NN	amod||formation-47/NN||f-actin-44/JJ	nn||formation-47/NN||stress-45/NN	nn||formation-47/NN||fiber-46/NN	prep_of||control-42/NN||formation-47/NN	adhesion-23||f---1||no_rel||this procedure resulted in the modulation of more than 100 genes, some of them coding for other proteins also involved in adhesion of thymocytes; others related to signaling pathways triggered after integrin activation, or even involved in the control of f-actin stress fiber formation.
nsubjpass||involved-3/VBN||nk-1r-1/JJ	auxpass||involved-3/VBN||is-2/VBZ	root||ROOT-0/null||involved-3/VBN	det||pathogenesis-6/NNS||the-5/DT	prep_in||involved-3/VBN||pathogenesis-6/NNS	prep_of||pathogenesis-6/NNS||asthma-8/NN	det||budesonide-11/NN||that-10/DT	nsubj||downregulate-13/VB||budesonide-11/NN	aux||downregulate-13/VB||may-12/MD	conj_and||involved-3/VBN||downregulate-13/VB	det||expression-15/NN||the-14/DT	dobj||downregulate-13/VB||expression-15/NN	prep_of||expression-15/NN||nk-1r-17/CD	det||asmcs-20/NNS||the-19/DT	prep_in||downregulate-13/VB||asmcs-20/NNS	prep_in||downregulate-13/VB||airways-22/NNS	conj_and||asmcs-20/NNS||airways-22/NNS	amod||rats-25/NNS||asthmatic-24/JJ	prep_of||asmcs-20/NNS||rats-25/NNS	nsubj||alleviate-29/VB||rats-25/NNS	aux||alleviate-29/VB||may-28/MD	rcmod||rats-25/NNS||alleviate-29/VB	amod||inflammation-32/NN||neurogenic-30/JJ	nn||inflammation-32/NN||airway-31/NN	dobj||alleviate-29/VB||inflammation-32/NN	asthma-8||budesonide-11||no||nk-1r is involved in the pathogenesis of asthma and that budesonide may downregulate the expression of nk-1r in the asmcs and airways of asthmatic rats, which may alleviate neurogenic airway inflammation.
advmod||provide-4/VBP||here-1/RB	nsubj||provide-4/VBP||we-3/PRP	root||ROOT-0/null||provide-4/VBP	det||review-7/NN||a-5/DT	amod||review-7/NN||comprehensive-6/JJ	dobj||provide-4/VBP||review-7/NN	poss||knowledge-11/NN||our-9/PRP$	amod||knowledge-11/NN||current-10/JJ	prep_on||review-7/NN||knowledge-11/NN	det||role-14/NN||the-13/DT	nsubj||mediating-29/VBG||role-14/NN	nn||molecules-19/NNS||junctional-16/NN	conj_and||junctional-16/NN||adhesion-18/NN	nn||molecules-19/NNS||adhesion-18/NN	prep_of||role-14/NN||molecules-19/NNS	amod||factors-22/NNS||soluble-21/JJ	prep_of||role-14/NN||factors-22/NNS	conj_and||molecules-19/NNS||factors-22/NNS	amod||enzymes-25/NNS||proteolytic-24/JJ	prep_of||role-14/NN||enzymes-25/NNS	conj_and||molecules-19/NNS||enzymes-25/NNS	amod||pathways-28/NNS||signaling-27/JJ	prep_of||role-14/NN||pathways-28/NNS	conj_and||molecules-19/NNS||pathways-28/NNS	prepc_about||provide-4/VBP||mediating-29/VBG	det||attachment-31/NN||the-30/DT	dobj||mediating-29/VBG||attachment-31/NN	nn||cells-34/NNS||tumor-33/NN	prep_of||attachment-31/NN||cells-34/NNS	nn||cells-38/NNS||brain-36/NN	nn||cells-38/NNS||endothelial-37/NN	prep_to||mediating-29/VBG||cells-38/NNS	det||migration-42/NN||the-40/DT	amod||migration-42/NN||transendothelial-41/JJ	prep_to||mediating-29/VBG||migration-42/NN	conj_and||cells-38/NNS||migration-42/NN	amod||cells-45/NNS||metastatic-44/JJ	prep_of||migration-42/NN||cells-45/NNS	enzymes-25||tumor-33||no_rel||here, we provide a comprehensive review on our current knowledge about the role of junctional and adhesion molecules, soluble factors, proteolytic enzymes and signaling pathways mediating the attachment of tumor cells to brain endothelial cells and the transendothelial migration of metastatic cells.
nn||control-2/NN||tobacco-1/NN	nsubj||benefited-6/VBN||control-2/NN	aux||benefited-6/VBN||has-3/VBZ	neg||benefited-6/VBN||not-4/RB	advmod||benefited-6/VBN||yet-5/RB	root||ROOT-0/null||benefited-6/VBN	det||mechanisms-11/NNS||the-8/DT	amod||mechanisms-11/NNS||innovative-9/JJ	nn||mechanisms-11/NNS||finance-10/NN	prep_from||benefited-6/VBN||mechanisms-11/NNS	nsubj||are-13/VBP||mechanisms-11/NNS	rcmod||mechanisms-11/NNS||are-13/VBP	prep_in||are-13/VBP||place-15/NN	prep_for||place-15/NN||hiv/aids-17/NNS	prep_for||place-15/NN||tuberculosis-19/NN	conj_and||hiv/aids-17/NNS||tuberculosis-19/NN	prep_for||place-15/NN||malaria-21/NN	conj_and||hiv/aids-17/NNS||malaria-21/NN	aids--1||hiv--1||no||tobacco control has not yet benefited from the innovative finance mechanisms that are in place for hiv/aids, tuberculosis and malaria.
expl||increasing-3/VBG||there-1/EX	aux||increasing-3/VBG||is-2/VBZ	root||ROOT-0/null||increasing-3/VBG	dobj||increasing-3/VBG||evidence-4/NN	nsubj||increasing-3/VBG||evidence-4/NN	amod||effects-7/NNS||anti-tumour-6/JJ	prep_of||evidence-4/NN||effects-7/NNS	prep_of||effects-7/NNS||bisphosphonates-9/NNS	amod||studies-12/NNS||pre-clinical-11/JJ	prep_from||increasing-3/VBG||studies-12/NNS	vmod||increasing-3/VBG||supporting-14/VBG	det||role-16/NN||a-15/DT	dobj||supporting-14/VBG||role-16/NN	det||drugs-19/NNS||these-18/DT	prep_for||role-16/NN||drugs-19/NNS	poss||use-23/NN||their-21/PRP$	amod||use-23/NN||traditional-22/JJ	prep_beyond||supporting-14/VBG||use-23/NN	prep_in||use-23/NN||treatment-25/NN	amod||disease-29/NN||cancer-induced-27/JJ	nn||disease-29/NN||bone-28/NN	prep_of||treatment-25/NN||disease-29/NN	tumour--1||bisphosphonates-9||no_rel||there is increasing evidence of anti-tumour effects of bisphosphonates from pre-clinical studies, supporting a role for these drugs beyond their traditional use in treatment of cancer-induced bone disease.
nn||testing-2/NN||hiv-1/NN	nsubj||critical-7/JJ||testing-2/NN	nn||patients-5/NNS||tuberculosis-4/NNP	prep_among||testing-2/NN||patients-5/NNS	cop||critical-7/JJ||is-6/VBZ	root||ROOT-0/null||critical-7/JJ	prepc_in||critical-7/JJ||improving-9/VBG	dobj||improving-9/VBG||morbidity-10/NN	dobj||improving-9/VBG||mortality-12/NN	conj_and||morbidity-10/NN||mortality-12/NN	mark||found-15/VBD||as-13/IN	nsubj||found-15/VBD||those-14/DT	nsubj||hivpositive-18/JJ||those-14/DT	advcl||improving-9/VBG||found-15/VBD	aux||hivpositive-18/JJ||to-16/TO	cop||hivpositive-18/JJ||be-17/VB	xcomp||found-15/VBD||hivpositive-18/JJ	aux||offered-21/VBN||will-19/MD	auxpass||offered-21/VBN||be-20/VB	ccomp||hivpositive-18/JJ||offered-21/VBN	det||continuum-23/NN||a-22/DT	dobj||offered-21/VBN||continuum-23/NN	prep_of||continuum-23/NN||care-25/NN	prep_including||care-25/NN||art-27/NN	mark||indicated-29/VBD||if-28/IN	advcl||hivpositive-18/JJ||indicated-29/VBD	hivpositive-18||hiv-1||no||hiv testing among tuberculosis patients is critical in improving morbidity and mortality as those found to be hivpositive will be offered a continuum of care including art if indicated.
aux||describe-2/VB||to-1/TO	csubj||associated-21/VBN||describe-2/VB	nn||persistence-4/NN||insulin-3/NN	dobj||describe-2/VB||persistence-4/NN	prep_among||describe-2/VB||patients-6/NNS	amod||therapy-11/NN||type2diabetes-8/JJ	amod||therapy-11/NN||initiating-9/JJ	nn||therapy-11/NN||insulin-10/NN	prep_with||patients-6/NNS||therapy-11/NN	amod||insulin-14/NN||basal-13/JJ	prep_with||therapy-11/NN||insulin-14/NN	nn||mixtures-17/NNS||insulin-16/NN	prep_with||therapy-11/NN||mixtures-17/NNS	conj_or||insulin-14/NN||mixtures-17/NNS	conj_and||describe-2/VB||determine-19/VB	csubj||associated-21/VBN||determine-19/VB	dobj||determine-19/VB||factors-20/NNS	root||ROOT-0/null||associated-21/VBN	prep_with||associated-21/VBN||nonpersistence-23/NN	type2diabetes-8||insulin-16||yes||to describe insulin persistence among patients with type2diabetes initiating insulin therapy with basal insulin or insulin mixtures and determine factors associated with nonpersistence.
det||humanimmunodeficiencyvirus-2/NNS||the-1/DT	nsubj||acquired-7/VBD||humanimmunodeficiencyvirus-2/NNS	appos||humanimmunodeficiencyvirus-2/NNS||hiv-4/NN	advmod||acquired-7/VBD||/-6/RB	root||ROOT-0/null||acquired-7/VBD	amod||syndrome-9/NN||immunedeficiency-8/JJ	nsubj||has-14/VBZ||syndrome-9/NN	appos||syndrome-9/NN||aids-11/NNS	amod||syndrome-9/NN||pandemic-13/JJ	ccomp||acquired-7/VBD||has-14/VBZ	amod||effects-16/NNS||pervasive-15/JJ	dobj||has-14/VBZ||effects-16/NNS	prep_on||effects-16/NNS||culture-18/NN	prep_on||effects-16/NNS||economics-20/NNS	conj_and||culture-18/NN||economics-20/NNS	prep_on||effects-16/NNS||policy-22/NN	conj_and||culture-18/NN||policy-22/NN	amod||development-26/NN||human-25/JJ	prep_on||effects-16/NNS||development-26/NN	conj_and||culture-18/NN||development-26/NN	aids-11||hiv-4||no||the humanimmunodeficiencyvirus (hiv)/ acquired immunedeficiency syndrome (aids) pandemic has pervasive effects on culture, economics, policy, and human development.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	prep_with||gene-44/NN||graves-51/NNS	conj_and||type1diabetesmellitus-46/NNS||graves-51/NNS	dep||graves-51/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	dm-48||graves'disease--1||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves'disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
nsubj||provides-2/VBZ||this-1/DT	root||ROOT-0/null||provides-2/VBZ	dobj||provides-2/VBZ||analogy-3/NN	amod||proteins-6/NNS||membrane-associated-5/JJ	prep_with||provides-2/VBZ||proteins-6/NNS	vmod||proteins-6/NNS||mediating-7/VBG	det||build-up-9/NN||the-8/DT	dobj||mediating-7/VBG||build-up-9/NN	prep_of||build-up-9/NN||â-11/NN	amod||build-up-9/NN||$-12/$	dep||$-12/$||œvirus-13/JJ	vmod||build-up-9/NN||factoriesâ-14/VBN	dobj||factoriesâ-14/VBN||$-15/$	quantmod||cells-17/CD||in-16/IN	num||$-15/$||cells-17/CD	vmod||$-15/$||infected-18/VBN	amod||viruses-23/NNS||diverse-20/JJ	amod||viruses-23/NNS||positive-strand-21/JJ	nn||viruses-23/NNS||rna-22/NN	prep_with||infected-18/VBN||viruses-23/NNS	amod||viruses-26/NNS||alpha-like-25/JJ	dep||viruses-23/NNS||viruses-26/NNS	amod||viruses-29/NNS||picorna-like-28/JJ	dep||viruses-23/NNS||viruses-29/NNS	conj_and||viruses-26/NNS||viruses-29/NNS	dep||viruses-23/NNS||flaviviruses-31/NNS	conj_and||viruses-26/NNS||flaviviruses-31/NNS	dep||viruses-23/NNS||nidoviruses-34/NNS	conj_and||viruses-26/NNS||nidoviruses-34/NNS	amod||viruses-39/NNS||negative-strand-37/JJ	nn||viruses-39/NNS||rna-38/NN	prep_with||infected-18/VBN||viruses-39/NNS	conj_and||viruses-23/NNS||viruses-39/NNS	appos||viruses-23/NNS||bunyaviruses-41/NNS	virus--1||viruses-39||no||this provides analogy with membrane-associated proteins mediating the build-up of â€œvirus factoriesâ€? in cells infected with diverse positive-strand rna viruses (alpha-like viruses, picorna-like viruses, flaviviruses, and nidoviruses) and negative-strand rna viruses (bunyaviruses).
det||agent-2/NN||this-1/DT	nsubjpass||approved-5/VBN||agent-2/NN	auxpass||approved-5/VBN||was-3/VBD	advmod||approved-5/VBN||recently-4/RB	root||ROOT-0/null||approved-5/VBN	det||treatment-8/NN||the-7/DT	prep_for||approved-5/VBN||treatment-8/NN	nsubj||failed-15/VBN||treatment-8/NN	amod||patients-12/NNS||relapsed/refractory-10/JJ	nn||patients-12/NNS||cll-11/NN	prep_of||treatment-8/NN||patients-12/NNS	aux||failed-15/VBN||have-14/VBP	rcmod||treatment-8/NN||failed-15/VBN	acomp||failed-15/VBN||fludarabine-16/JJ	acomp||failed-15/VBN||alemtuzumab-18/JJ	conj_and||fludarabine-16/JJ||alemtuzumab-18/JJ	cll-11||fludarabine-16||yes||this agent was recently approved for the treatment of relapsed/refractory cll patients who have failed fludarabine and alemtuzumab.
csubj||field-9/NN||treating-1/VBG	dobj||treating-1/VBG||cancer-2/NN	prep_with||treating-1/VBG||vaccines-4/NNS	aux||field-9/NN||has-5/VBZ	cop||field-9/NN||been-6/VBN	det||field-9/NN||a-7/DT	amod||field-9/NN||challenging-8/JJ	root||ROOT-0/null||field-9/NN	prep_of||field-9/NN||investigation-11/NN	det||1950s-14/NNS||the-13/DT	prep_since||field-9/NN||1950s-14/NNS	cancer-2||vaccines-4||no_rel||treating cancer with vaccines has been a challenging field of investigation since the 1950s.
nn||resistance-2/NN||platinum-1/NN	nsubj||cause-6/NN||resistance-2/NN	cop||cause-6/NN||is-3/VBZ	det||cause-6/NN||a-4/DT	amod||cause-6/NN||major-5/JJ	root||ROOT-0/null||cause-6/NN	nn||failure-9/NN||treatment-8/NN	prep_of||cause-6/NN||failure-9/NN	nn||cancer-12/NN||ovarian-11/NN	prep_in||failure-9/NN||cancer-12/NN	cancer-12||platinum-1||no_rel||platinum resistance is a major cause of treatment failure in ovarian cancer.
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	det||role-4/NN||the-3/DT	dobj||included-2/VBD||role-4/NN	prep_of||role-4/NN||statins-6/NNS	det||agent-10/NN||an-8/DT	amod||agent-10/NN||anti-lipid-9/JJ	appos||statins-6/NNS||agent-10/NN	prepc_in||included-2/VBD||reducing-13/VBG	amod||morbidity-15/NN||post-stroke-14/JJ	dobj||reducing-13/VBG||morbidity-15/NN	dobj||reducing-13/VBG||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prepc_in||included-2/VBD||decreasing-20/VBG	conj_and||reducing-13/VBG||decreasing-20/VBG	det||plaque-24/NN||the-21/DT	amod||plaque-24/NN||carotid-22/JJ	amod||plaque-24/NN||atherosclerotic-23/JJ	dobj||decreasing-20/VBG||plaque-24/NN	prep_in||plaque-24/NN||middle-26/NN	vmod||middle-26/NN||aged-27/VBN	dobj||aged-27/VBN||patients-28/NNS	amod||risk-31/NN||increased-30/VBN	prep_at||aged-27/VBN||risk-31/NN	prep_of||risk-31/NN||cardiovasculardisease-33/NN	amod||infusion-36/NN||glucose-potassium-insulin-35/JJ	dobj||decreasing-20/VBG||infusion-36/NN	conj_and||plaque-24/NN||infusion-36/NN	amod||acute-39/JJ||hyperglyceamic-38/JJ	amod||patients-41/NNS||acute-39/JJ	nn||patients-41/NNS||stroke-40/NN	prep_in||infusion-36/NN||patients-41/NNS	dep||infusion-36/NN||pioglitazone-43/VB	det||medication-47/NN||an-45/DT	amod||medication-47/NN||anti-diabetic-46/JJ	dobj||pioglitazone-43/VB||medication-47/NN	nsubj||reduce-50/VB||medication-47/NN	aux||reduce-50/VB||to-49/TO	xcomp||pioglitazone-43/VB||reduce-50/VB	dobj||reduce-50/VB||recurrence-51/NN	prep_of||recurrence-51/NN||stroke-53/NN	nn||patients-58/NNS||type-55/NN	num||patients-58/NNS||2-56/CD	nn||patients-58/NNS||diabetic-57/NN	prep_in||reduce-50/VB||patients-58/NNS	parataxis||pioglitazone-43/VB||administration-60/NN	amod||urokinase-63/NN||intra-arterial-62/JJ	prep_of||administration-60/NN||urokinase-63/NN	det||agent-67/NN||a-65/DT	amod||agent-67/NN||thrombolytic-66/JJ	appos||urokinase-63/NN||agent-67/NN	det||role-71/NN||the-70/DT	prep_of||administration-60/NN||role-71/NN	conj_and||urokinase-63/NN||role-71/NN	nn||therapy-74/NN||laser-73/NN	prep_of||role-71/NN||therapy-74/NN	amod||dissolution-77/NN||clot-76/JJ	prep_in||therapy-74/NN||dissolution-77/NN	dep||administration-60/NN||given-78/VBN	mark||is-83/VBZ||that-79/IN	prep_at||is-83/VBZ||present-81/JJ	expl||is-83/VBZ||there-82/EX	pcomp||given-78/VBN||is-83/VBZ	advmod||fda-86/NN||only-84/RB	num||fda-86/NN||one-85/CD	nsubj||is-83/VBZ||fda-86/NN	vmod||fda-86/NN||approved-87/VBN	amod||agent-89/NN||thrombolytic-88/JJ	dobj||approved-87/VBN||agent-89/NN	nn||tpa-92/NN||r-91/NN	dep||administration-60/NN||tpa-92/NN	parataxis||pioglitazone-43/VB||benefit-95/VB	prep_of||benefit-95/VB||warfarin-97/NN	det||anticoagulant-100/NN||an-99/DT	appos||warfarin-97/NN||anticoagulant-100/NN	amod||patients-104/NNS||elderly-103/JJ	prep_in||warfarin-97/NN||patients-104/NNS	prep_with||benefit-95/VB||atrialfibrillation-106/NN	det||community-109/NN||the-108/DT	prep_in||atrialfibrillation-106/NN||community-109/NN	parataxis||pioglitazone-43/VB||nxy-111/VB	det||agent-117/NN||a-113/DT	amod||radical-115/JJ||free-114/JJ	amod||agent-117/NN||radical-115/JJ	amod||agent-117/NN||trapping-116/JJ	dep||nxy-111/VB||agent-117/NN	parataxis||pioglitazone-43/VB||minocycline-120/VB	conj_and||nxy-111/VB||minocycline-120/VB	det||tested-122/NN||both-121/DT	dobj||nxy-111/VB||tested-122/NN	prep_as||nxy-111/VB||neuroprotectants-124/NNS	dobj||decreasing-20/VBG||zoledronate-127/NN	conj_and||plaque-24/NN||zoledronate-127/NN	det||bisphosphonate-131/NN||an-129/DT	amod||bisphosphonate-131/NN||intravenous-130/JJ	appos||zoledronate-127/NN||bisphosphonate-131/NN	aux||prevent-134/VB||to-133/TO	vmod||zoledronate-127/NN||prevent-134/VB	dobj||prevent-134/VB||loss-135/NN	nn||density-139/NN||bone-137/NN	nn||density-139/NN||mineral-138/NN	prep_of||loss-135/NN||density-139/NN	det||extremity-143/NN||the-141/DT	amod||extremity-143/NN||affected-142/VBN	prep_of||density-139/NN||extremity-143/NN	advmod||role-148/NN||finally-146/RB	det||role-148/NN||the-147/DT	prep_of||density-139/NN||role-148/NN	conj_and||extremity-143/NN||role-148/NN	prep_of||role-148/NN||nicardipine-150/NN	det||blocker-155/NN||a-152/DT	nn||blocker-155/NN||calcium-153/NN	nn||blocker-155/NN||channel-154/NN	dep||nicardipine-150/NN||blocker-155/NN	det||prevention-159/NN||the-158/DT	prep_in||nicardipine-150/NN||prevention-159/NN	prep_of||prevention-159/NN||vasospasm-161/NN	vmod||zoledronate-127/NN||hydrocortisone-164/VB	conj_and||prevent-134/VB||hydrocortisone-164/VB	aux||prevent-166/VB||to-165/TO	xcomp||hydrocortisone-164/VB||prevent-166/VB	dobj||prevent-166/VB||hyponatraemia-167/NN	amod||hemorrhage-170/NN||sub-arachnoid-169/JJ	prep_after||prevent-166/VB||hemorrhage-170/NN	stroke-53||warfarin-97||yes||these included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovasculardisease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one fda approved thrombolytic agent (r tpa); benefit of warfarin (an anticoagulant) in elderly patients with atrialfibrillation in the community; nxy (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a calcium channel blocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage.
nsubjpass||involved-3/VBN||nk-1r-1/JJ	auxpass||involved-3/VBN||is-2/VBZ	root||ROOT-0/null||involved-3/VBN	det||pathogenesis-6/NNS||the-5/DT	prep_in||involved-3/VBN||pathogenesis-6/NNS	prep_of||pathogenesis-6/NNS||asthma-8/NN	det||budesonide-11/NN||that-10/DT	nsubj||downregulate-13/VB||budesonide-11/NN	aux||downregulate-13/VB||may-12/MD	conj_and||involved-3/VBN||downregulate-13/VB	det||expression-15/NN||the-14/DT	dobj||downregulate-13/VB||expression-15/NN	prep_of||expression-15/NN||nk-1r-17/CD	det||asmcs-20/NNS||the-19/DT	prep_in||downregulate-13/VB||asmcs-20/NNS	prep_in||downregulate-13/VB||airways-22/NNS	conj_and||asmcs-20/NNS||airways-22/NNS	amod||rats-25/NNS||asthmatic-24/JJ	prep_of||asmcs-20/NNS||rats-25/NNS	nsubj||alleviate-29/VB||rats-25/NNS	aux||alleviate-29/VB||may-28/MD	rcmod||rats-25/NNS||alleviate-29/VB	amod||inflammation-32/NN||neurogenic-30/JJ	nn||inflammation-32/NN||airway-31/NN	dobj||alleviate-29/VB||inflammation-32/NN	asthmatic-24||budesonide-11||yes||nk-1r is involved in the pathogenesis of asthma and that budesonide may downregulate the expression of nk-1r in the asmcs and airways of asthmatic rats, which may alleviate neurogenic airway inflammation.
det||subjects-5/NNS||the-3/DT	num||subjects-5/NNS||513-4/CD	prep_among||associated-20/VBN||subjects-5/NNS	nn||pain-8/NN||knee-7/NN	prep_with||subjects-5/NNS||pain-8/NN	det||presence-12/NN||the-10/DT	amod||presence-12/NN||additional-11/JJ	nsubjpass||associated-20/VBN||presence-12/NN	nsubjpass||associated-20/VBN||presence-12/NN	amod||evidence-15/NN||radiographic-14/JJ	prep_of||presence-12/NN||evidence-15/NN	prep_of||evidence-15/NN||oa-17/NN	auxpass||associated-20/VBN||was-18/VBD	advmod||associated-20/VBN||significantly-19/RB	root||ROOT-0/null||associated-20/VBN	conj_and||associated-20/VBN||associated-20/VBN	amod||occasions-23/NNS||more-22/JJR	prep_with||associated-20/VBN||occasions-23/NNS	prep_of||occasions-23/NNS||unbearable-27/NN	dep||occasions-23/NNS||pain-30/NN	num||%-33/NN||59-32/CD	dep||pain-30/NN||%-33/NN	num||%-36/NN||36-35/CD	dep||pain-30/NN||%-36/NN	conj_versus||%-33/NN||%-36/NN	amod||activity-40/NN||restricted-39/VBN	dep||occasions-23/NNS||activity-40/NN	conj_and||pain-30/NN||activity-40/NN	num||%-43/NN||64-42/CD	dep||activity-40/NN||%-43/NN	num||%-46/NN||39-45/CD	dep||activity-40/NN||%-46/NN	conj_versus||%-43/NN||%-46/NN	amod||use-53/NN||increased-52/VBN	npadvmod||associated-20/VBN||use-53/NN	prep_of||use-53/NN||nonsteroidalantiinflammatorydrugs-55/NNS	appos||nonsteroidalantiinflammatorydrugs-55/NNS||nsaids-57/NNS	num||%-61/NN||88-60/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-61/NN	num||%-64/NN||78-63/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-64/NN	conj_versus||%-61/NN||%-64/NN	det||number-69/NN||the-67/DT	amod||number-69/NN||reported-68/VBN	npadvmod||associated-20/VBN||number-69/NN	conj_and||use-53/NN||number-69/NN	nn||visits-72/NNS||doctor-71/NN	prep_of||number-69/NN||visits-72/NNS	num||%-75/NN||59-74/CD	dep||visits-72/NNS||%-75/NN	num||%-78/NN||33-77/CD	dep||visits-72/NNS||%-78/NN	conj_versus||%-75/NN||%-78/NN	det||year-83/NN||the-81/DT	amod||year-83/NN||past-82/JJ	prep_in||associated-20/VBN||year-83/NN	pain-30||nonsteroidalantiinflammatorydrugs-55||no_rel||" among the 513 subjects with knee pain, the additional presence of radiographic evidence of oa was significantly associated with more occasions of ""unbearable"" pain (59% versus 36%) and restricted activity (64% versus 39%), as well as increased use of nonsteroidalantiinflammatorydrugs (nsaids) (88% versus 78%) and the reported number of doctor visits (59% versus 33%) in the past year."
det||prionprotein-2/NN||the-1/DT	nsubj||plays-6/VBZ||prionprotein-2/NN	appos||prionprotein-2/NN||prnp/prp-4/NN	root||ROOT-0/null||plays-6/VBZ	det||role-9/NN||a-7/DT	amod||role-9/NN||crucial-8/JJ	dobj||plays-6/VBZ||role-9/NN	prep_in||role-9/NN||transmissiblespongiformencephalopathies-11/NNS	appos||transmissiblespongiformencephalopathies-11/NNS||tses-13/NNS	amod||cjd-18/NN||creutzfeldt-jakobdisease-16/JJ	prep_like||plays-6/VBZ||cjd-18/NN	amod||cjd-18/NN||scrapie-21/JJ	amod||cjd-18/NN||madcowdisease-23/JJ	conj_and||scrapie-21/JJ||madcowdisease-23/JJ	madcowdisease-23||prionprotein-2||no_rel||the prionprotein (prnp/prp) plays a crucial role in transmissiblespongiformencephalopathies (tses) like creutzfeldt-jakobdisease (cjd), scrapie and madcowdisease.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	prep_of||case-4/NN||entericfever-6/NN	vmod||entericfever-6/NN||caused-7/VBN	amod||typhi-10/NNS||s-9/JJ	agent||caused-7/VBN||typhi-10/NNS	prep_in||resistant-16/JJ||typhi-10/NNS	det||isolate-14/NN||the-13/DT	nsubj||resistant-16/JJ||isolate-14/NN	nsubj||showed-22/VBD||isolate-14/NN	cop||resistant-16/JJ||was-15/VBD	rcmod||typhi-10/NNS||resistant-16/JJ	amod||acid-19/NN||nalidixic-18/JJ	prep_to||resistant-16/JJ||acid-19/NN	rcmod||typhi-10/NNS||showed-22/VBD	conj_but||resistant-16/JJ||showed-22/VBD	npadvmod||susceptibility-25/JJ||vitro-24/NN	prep_in||showed-22/VBD||susceptibility-25/JJ	prep_to||showed-22/VBD||ciprofloxacin-27/NN	entericfever-6||ciprofloxacin-27||yes||we report a case of entericfever caused by s typhi in which the isolate was resistant to nalidixic acid, but showed in vitro susceptibility to ciprofloxacin.
nn||injection-2/NN||lps-1/NN	root||ROOT-0/null||injection-2/NN	vmod||injection-2/NN||induced-3/VBN	det||increase-6/NN||a-4/DT	amod||increase-6/NN||rapid-5/JJ	dobj||induced-3/VBN||increase-6/NN	nn||concentrations-9/NNS||plasma-8/NN	prep_in||increase-6/NN||concentrations-9/NNS	amod||metabolites-12/NNS||nitricoxide-11/JJ	prep_of||concentrations-9/NNS||metabolites-12/NNS	amod||concentrations-9/NNS||nitrite-14/JJ	amod||concentrations-9/NNS||nitrate-16/JJ	conj_and||nitrite-14/JJ||nitrate-16/JJ	appos||concentrations-9/NNS||nom-18/NN	amod||acidâ-23/NNS||thiobarbituric-22/JJ	dobj||induced-3/VBN||acidâ-23/NNS	conj_and||increase-6/NN||acidâ-23/NNS	dep||acidâ-23/NNS||$-24/$	advmod||substances-27/RB||reacting-26/RB	dep||generation-41/CD||substances-27/RB	pobj||substances-27/RB||tbars-29/NN	det||increase-33/NN||an-32/DT	appos||tbars-29/NN||increase-33/NN	amod||species-37/NNS||reactive-35/JJ	nn||species-37/NNS||oxygen-36/NN	prep_in||increase-33/NN||species-37/NNS	appos||species-37/NNS||ros-39/NN	num||$-24/$||generation-41/CD	nn||leukocytes-44/NNS||polymorphonuclear-43/NN	agent||induced-3/VBN||leukocytes-44/NNS	dep||injection-2/NN||pmnls-46/NNS	amod||increases-51/NNS||marked-50/VBN	conj_and||injection-2/NN||increases-51/NNS	amod||fattyacids-55/NNS||plasma-53/JJ	amod||fattyacids-55/NNS||free-54/JJ	prep_in||increases-51/NNS||fattyacids-55/NNS	nn||necrosis-58/NNS||tumor-57/NN	appos||fattyacids-55/NNS||necrosis-58/NNS	nn||±-60/NNP||factor-î-59/NNP	dep||injection-2/NN||±-60/NNP	nn||±-63/NNP||tnf-î-62/NNP	appos||±-60/NNP||±-63/NNP	dep||injection-2/NN||interleukin-6-66/JJ	conj_and||±-60/NNP||interleukin-6-66/JJ	dep||interleukin-6-66/JJ||il-6-68/JJ	amod||protein-1-73/NN||monocyte-71/JJ	nn||protein-1-73/NN||chemoattractant-72/NN	dep||injection-2/NN||protein-1-73/NN	conj_and||±-60/NNP||protein-1-73/NN	dep||protein-1-73/NN||mcp-1-75/JJ	amod||factor-81/NN||macrophage-78/JJ	nn||factor-81/NN||migration-79/NN	nn||factor-81/NN||inhibition-80/NN	appos||protein-1-73/NN||factor-81/NN	appos||factor-81/NN||mif-83/NN	amod||protein-87/NN||c-reactive-86/JJ	appos||protein-1-73/NN||protein-87/NN	appos||protein-87/NN||resistin-89/NN	vmod||protein-1-73/NN||visfatin-91/VBN	nn||protein-95/NN||lipopolysaccharide-93/NN	amod||protein-95/NN||binding-94/VBG	appos||protein-1-73/NN||protein-95/NN	appos||protein-95/NN||lbp-97/NN	advmod||group-b1-102/JJ||high-100/RB	advmod||group-b1-102/JJ||mobility-101/RB	dep||injection-2/NN||group-b1-102/JJ	amod||±-60/NNP||group-b1-102/JJ	conj_and||±-60/NNP||group-b1-102/JJ	dep||group-b1-102/JJ||hmg-b1-104/JJ	nn||concentrations-109/NNS||myoglobin-108/NN	dep||injection-2/NN||concentrations-109/NNS	conj_and||±-60/NNP||concentrations-109/NNS	oxygen-36||tumor-57||no_rel||lps injection induced a rapid increase in plasma concentrations of nitricoxide metabolites, nitrite and nitrate (nom), and thiobarbituric acidâ€“reacting substances (tbars), an increase in reactive oxygen species (ros) generation by polymorphonuclear leukocytes (pmnls), and marked increases in plasma free fattyacids, tumor necrosis factor-î± (tnf-î±), interleukin-6 (il-6), monocyte chemoattractant protein-1 (mcp-1), macrophage migration inhibition factor (mif), c-reactive protein, resistin, visfatin, lipopolysaccharide binding protein (lbp), high mobility group-b1 (hmg-b1), and myoglobin concentrations.
nsubj||reduced-6/VBD||use-1/NN	det||test-5/NN||the-3/DT	nn||test-5/NN||mtb/rif-4/NN	prep_of||use-1/NN||test-5/NN	root||ROOT-0/null||reduced-6/VBD	amod||time-8/NN||median-7/JJ	dobj||reduced-6/VBD||time-8/NN	prep_to||reduced-6/VBD||treatment-10/NN	amod||tuberculosis-13/NNP||smear-negative-12/JJ	prep_for||treatment-10/NN||tuberculosis-13/NNP	num||days-16/NNS||56-15/CD	prep_from||reduced-6/VBD||days-16/NNS	appos||days-16/NNS||39â-18/NNP	num||39â-18/NNP||$-19/$	num||$-19/$||81-21/CD	dep||days-16/NNS||to-23/TO	num||days-25/NNS||5-24/CD	dep||days-16/NNS||days-25/NNS	appos||days-25/NNS||2â-27/NNP	num||2â-27/NNP||$-28/$	num||$-28/$||8-30/CD	tuberculosis-13||rif--1||yes||use of the mtb/rif test reduced median time to treatment for smear-negative tuberculosis from 56 days (39â€“81) to 5 days (2â€“8).
nsubj||factor-8/NN||hyperhomocysteinemia-1/NN	nsubj||develop-16/VB||hyperhomocysteinemia-1/NN	cop||factor-8/NN||is-4/VBZ	det||factor-8/NN||an-5/DT	amod||factor-8/NN||independent-6/JJ	nn||factor-8/NN||risk-7/NN	rcmod||hyperhomocysteinemia-1/NN||factor-8/NN	amod||vasculardisease-11/NN||atherosclerotic-10/JJ	prep_for||factor-8/NN||vasculardisease-11/NN	prep_for||factor-8/NN||thromboembolism-13/NN	conj_and||vasculardisease-11/NN||thromboembolism-13/NN	aux||develop-16/VB||may-15/MD	root||ROOT-0/null||develop-16/VB	amod||patients-19/NNS||hcv-infected-18/JJ	prep_in||develop-16/VB||patients-19/NNS	mark||enzyme-28/VBP||although-20/IN	amod||transferase-24/NN||altered-21/JJ	amod||transferase-24/NN||alanine-22/JJ	amod||transferase-24/NN||amino-23/JJ	nsubj||enzyme-28/VBP||transferase-24/NN	appos||transferase-24/NN||alt-26/NN	advcl||develop-16/VB||enzyme-28/VBP	nsubjpass||associated-32/VBN||levels-29/NNS	auxpass||associated-32/VBN||are-30/VBP	advmod||associated-32/VBN||generally-31/RB	ccomp||enzyme-28/VBP||associated-32/VBN	prep_with||associated-32/VBN||damage-34/NN	nn||cells-37/NNS||liver-36/NN	prep_to||associated-32/VBN||cells-37/NNS	vasculardisease-11||alanine-22||no_rel||hyperhomocysteinemia, which is an independent risk factor for atherosclerotic vasculardisease and thromboembolism , may develop in hcv-infected patients although altered alanine amino transferase (alt) enzyme levels are generally associated with damage to liver cells.
nsubj||become-3/VB||multidrug-resistance-1/NN	aux||become-3/VB||may-2/MD	root||ROOT-0/null||become-3/VB	acomp||become-3/VB||prevalent-4/JJ	prep_in||become-3/VB||salmonellainfections-6/NNS	prep_in||salmonellainfections-6/NNS||japan-8/NN	mark||shown-11/VBN||as-10/IN	advcl||become-3/VB||shown-11/VBN	det||case-15/NN||this-13/DT	amod||case-15/NN||first-14/JJ	prep_in||shown-11/VBN||case-15/NN	det||patient-18/NN||a-17/DT	prep_of||case-15/NN||patient-18/NN	vmod||patient-18/NN||infected-19/VBN	amod||salmonella-22/NN||fluoroquinolone-resistant-21/JJ	prep_with||infected-19/VBN||salmonella-22/NN	salmonellainfections-6||salmonella-22||no||multidrug-resistance may become prevalent in salmonellainfections in japan, as shown in this first case of a patient infected with fluoroquinolone-resistant salmonella .
nsubj||therapy-9/NN||chloroquine-1/NN	appos||chloroquine-1/NN||cq-3/NN	cop||therapy-9/NN||was-5/VBD	det||therapy-9/NN||the-6/DT	amod||therapy-9/NN||main-7/JJ	nn||therapy-9/NN||malaria-8/NN	root||ROOT-0/null||therapy-9/NN	advmod||therapy-9/NN||worldwide-10/RB	det||1940s-13/NNS||the-12/DT	prep_from||therapy-9/NN||1940s-13/NNS	det||1990s-16/NNS||the-15/DT	prep_until||therapy-9/NN||1990s-16/NNS	malaria-8||chloroquine-1||yes||chloroquine (cq) was the main malaria therapy worldwide from the 1940s until the 1990s.
nsubjpass||computed-10/VBN||association-1/NN	amod||survival-4/NN||overall-3/JJ	prep_between||association-1/NN||survival-4/NN	nn||levels-8/NNS||serum-6/NN	nn||levels-8/NNS||25ohd-7/NNS	prep_between||association-1/NN||levels-8/NNS	conj_and||survival-4/NN||levels-8/NNS	auxpass||computed-10/VBN||were-9/VBD	ccomp||adjuvant-49/VBD||computed-10/VBN	xcomp||computed-10/VBN||using-11/VBG	det||model-16/NN||the-12/DT	amod||model-16/NN||cox-13/JJ	amod||model-16/NN||proportional-14/JJ	nn||model-16/NN||hazard-15/NN	dobj||using-11/VBG||model-16/NN	vmod||model-16/NN||adjusted-17/VBN	prep_for||adjusted-17/VBN||month-19/NN	nn||sampling-22/NN||serum-21/NN	prep_of||month-19/NN||sampling-22/NN	dobj||using-11/VBG||age-26/NN	conj_and||model-16/NN||age-26/NN	prep_at||age-26/NN||diagnosis-28/NN	nsubj||adjuvant-49/VBD||gender-30/NN	nn||stage-33/NN||cancer-32/NN	appos||gender-30/NN||stage-33/NN	amod||tumor-36/NN||residual-35/JJ	appos||gender-30/NN||tumor-36/NN	prep_after||tumor-36/NN||surgery-38/NN	nn||period-41/NN||time-40/NN	appos||gender-30/NN||period-41/NN	prep_of||period-41/NN||surgery-43/NN	appos||gender-30/NN||location-45/NN	prep_of||location-45/NN||tumor-47/NN	root||ROOT-0/null||adjuvant-49/VBD	dobj||adjuvant-49/VBD||chemotherapy-50/NN	dobj||adjuvant-49/VBD||number-52/NN	conj_and||chemotherapy-50/NN||number-52/NN	nn||nodes-55/NNS||lymph-54/NN	prep_of||chemotherapy-50/NN||nodes-55/NNS	prep_with||adjuvant-49/VBD||metastasis-57/NNS	prep_at||metastasis-57/NNS||surgery-59/NN	cancer-32||adjuvant-49||no_rel||association between overall survival and serum 25ohd levels were computed using the cox proportional hazard model adjusted for month of serum sampling as well as age at diagnosis, gender, cancer stage, residual tumor after surgery, time period of surgery, location of tumor, adjuvant chemotherapy and number of lymph nodes with metastasis at surgery.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	aspirin--1||urticaria-43||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
det||exception-2/NN||an-1/DT	nsubj||infection-15/NN||exception-2/NN	cop||infection-15/NN||is-3/VBZ	det||treatment-6/NN||the-5/DT	prep_in||infection-15/NN||treatment-6/NN	amod||virus-9/NN||chronichepatitisc-8/JJ	prep_for||treatment-6/NN||virus-9/NN	appos||virus-9/NN||hcv-11/NN	amod||infection-15/NN||genotype-13/JJ	dep||genotype-13/JJ||1-14/CD	root||ROOT-0/null||infection-15/NN	amod||±-20/NNS||pegylated-17/JJ	nn||±-20/NNS||interferon-18/NN	nn||±-20/NNS||î-19/NN	prep_with||infection-15/NN||±-20/NNS	prep_with||infection-15/NN||ribavirin-22/NNP	conj_and||±-20/NNS||ribavirin-22/NNP	chronichepatitisc-8||hcv-11||no||an exception is in the treatment for chronichepatitisc virus (hcv) genotype 1 infection with pegylated interferon î± and ribavirin.
nsubj||received-15/VBN||janumettm-1/NN	nsubj||received-15/VBN||janumettm-1/NN	nsubj||received-15/VBN||janumettm-1/NN	det||combination-6/NN||a-3/DT	amod||combination-6/NN||fixed-4/VBN	nn||combination-6/NN||dose-5/NN	appos||janumettm-1/NN||combination-6/NN	prep_of||combination-6/NN||sitagliptin/metforminhcl-8/NN	vmod||combination-6/NN||manufactured-9/VBN	nn||pharmaceuticals-12/NNS||merck-11/NN	agent||manufactured-9/VBN||pharmaceuticals-12/NNS	aux||received-15/VBN||has-14/VBZ	root||ROOT-0/null||received-15/VBN	conj_or||received-15/VBN||received-15/VBN	conj_or||received-15/VBN||received-15/VBN	nsubj||approval-21/NN||us-16/PRP	nn||approval-21/NN||food-17/NN	conj_and||food-17/NN||drug-19/NN	nn||approval-21/NN||drug-19/NN	nn||approval-21/NN||administration-20/NN	xcomp||received-15/VBN||approval-21/NN	prep_for||approval-21/NN||treatment-23/NN	prep_of||treatment-23/NN||patients-25/NNS	prep_with||received-15/VBN||type2diabetes-27/NNS	nsubjpass||controlled-32/VBN||type2diabetes-27/NNS	auxpass||controlled-32/VBN||are-30/VBP	advmod||controlled-32/VBN||inadequately-31/RB	rcmod||type2diabetes-27/NNS||controlled-32/VBN	preconj||received-15/VBN||either-34/CC	prep_by||received-15/VBN||sitagliptin-36/NN	prep_by||received-15/VBN||metformin-38/NN	conj_or||sitagliptin-36/NN||metformin-38/NN	advmod||received-15/VBN||alone-39/RB	advmod||received-15/VBN||together-41/RB	amod||form-45/NN||free-dose-43/JJ	nn||form-45/NN||combination-44/NN	prep_in||received-15/VBN||form-45/NN	type2diabetes-27||metforminhcl--1||yes||janumettm, a fixed dose combination of sitagliptin/metforminhcl manufactured by merck pharmaceuticals, has received us food and drug administration approval for treatment of patients with type2diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form.
amod||lines-2/NNS||several-1/JJ	nsubj||support-5/VBP||lines-2/NNS	prep_of||lines-2/NNS||evidence-4/NN	root||ROOT-0/null||support-5/VBP	det||notion-7/NN||the-6/DT	dobj||support-5/VBP||notion-7/NN	mark||predispose-13/VB||that-8/IN	amod||viscosity-11/NN||elevated-9/JJ	nn||viscosity-11/NN||blood-10/NN	nsubj||predispose-13/VB||viscosity-11/NN	aux||predispose-13/VB||may-12/MD	ccomp||support-5/VBP||predispose-13/VB	prep_to||predispose-13/VB||insulinresistance-15/NN	prep_to||predispose-13/VB||type2diabetesmellitus-17/NNS	conj_and||insulinresistance-15/NN||type2diabetesmellitus-17/NNS	prepc_by||predispose-13/VB||limiting-19/VBG	dobj||limiting-19/VBG||delivery-20/NN	prep_of||delivery-20/NN||glucose-22/NN	prep_of||delivery-20/NN||insulin-24/NN	conj_and||glucose-22/NN||insulin-24/NN	prep_of||delivery-20/NN||oxygen-27/NN	conj_and||glucose-22/NN||oxygen-27/NN	advmod||active-30/JJ||metabolically-29/RB	amod||tissues-31/NNS||active-30/JJ	prep_to||glucose-22/NN||tissues-31/NNS	oxygen-27||type2diabetesmellitus-17||no_rel||several lines of evidence support the notion that elevated blood viscosity may predispose to insulinresistance and type2diabetesmellitus by limiting delivery of glucose, insulin, and oxygen to metabolically active tissues.
det||paper-2/NN||this-1/DT	nsubj||provides-3/VBZ||paper-2/NN	root||ROOT-0/null||provides-3/VBZ	det||overview-5/NN||an-4/DT	dobj||provides-3/VBZ||overview-5/NN	det||arguments-8/NNS||the-7/DT	prep_of||overview-5/NN||arguments-8/NNS	det||role-12/NN||the-10/DT	amod||role-12/NN||central-11/JJ	prep_for||arguments-8/NNS||role-12/NN	prep_of||role-12/NN||families-14/NNS	vmod||families-14/NNS||defined-16/VBN	advmod||broadly-18/RB||very-17/RB	advmod||defined-16/VBN||broadly-18/RB	nsubj||emphasise-22/VBP||we-21/PRP	conj_and||provides-3/VBZ||emphasise-22/VBP	det||importance-24/NN||the-23/DT	dobj||emphasise-22/VBP||importance-24/NN	nsubj||strengthen-28/VB||importance-24/NN	prep_of||importance-24/NN||efforts-26/NNS	aux||strengthen-28/VB||to-27/TO	xcomp||emphasise-22/VBP||strengthen-28/VB	dobj||strengthen-28/VB||families-29/NNS	nsubj||support-31/VB||families-29/NNS	aux||support-31/VB||to-30/TO	xcomp||strengthen-28/VB||support-31/VB	dobj||support-31/VB||children-32/NNS	vmod||children-32/NNS||affected-33/VBN	agent||affected-33/VBN||hiv-35/NN	agent||affected-33/VBN||aids-37/NNS	conj_and||hiv-35/NN||aids-37/NNS	aids-37||hiv-35||no||this paper provides an overview of the arguments for the central role of families, defined very broadly, and we emphasise the importance of efforts to strengthen families to support children affected by hiv and aids.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
nsubj||suggests-11/VBZ||detection-1/NN	amod||phenotype-5/NN||increased-3/VBN	amod||phenotype-5/NN||renaldisease-4/JJ	prep_of||detection-1/NN||phenotype-5/NN	amod||subjects-10/NNS||postmenopausal-7/JJ	conj_and||postmenopausal-7/JJ||ovariectomized-9/JJ	amod||subjects-10/NNS||ovariectomized-9/JJ	prep_in||phenotype-5/NN||subjects-10/NNS	root||ROOT-0/null||suggests-11/VBZ	det||role-14/NN||a-12/DT	amod||role-14/NN||protective-13/JJ	dobj||suggests-11/VBZ||role-14/NN	nn||hormones-17/NNS||ovarian-16/NN	prep_of||role-14/NN||hormones-17/NNS	renaldisease-4||hormones-17||no_rel||detection of increased renaldisease phenotype in postmenopausal and ovariectomized subjects suggests a protective role of ovarian hormones.
det||varicellazostervirus-2/NNS||the-1/DT	nsubj||alpha-herpesvirus-10/NNS||varicellazostervirus-2/NNS	appos||varicellazostervirus-2/NNS||vzv-4/NN	cop||alpha-herpesvirus-10/NNS||is-6/VBZ	det||alpha-herpesvirus-10/NNS||a-7/DT	amod||alpha-herpesvirus-10/NNS||ubiquitous-8/JJ	amod||alpha-herpesvirus-10/NNS||human-9/JJ	root||ROOT-0/null||alpha-herpesvirus-10/NNS	nsubj||agent-15/NN||alpha-herpesvirus-10/NNS	cop||agent-15/NN||is-12/VBZ	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	rcmod||alpha-herpesvirus-10/NNS||agent-15/NN	prep_of||agent-15/NN||chickenpox-17/NN	prep_of||agent-15/NN||shingles-19/NNS	conj_and||chickenpox-17/NN||shingles-19/NNS	chickenpox-17||vzv-4||no||the varicellazostervirus (vzv) is a ubiquitous human alpha-herpesvirus that is the causative agent of chickenpox and shingles.
nn||supervision-3/NN||training-1/NN	nn||mentoring-6/NN||supervision-3/NN	conj_and||supervision-3/NN||clinical-5/JJ	nn||mentoring-6/NN||clinical-5/JJ	nsubj||cornerstone-12/NN||mentoring-6/NN	nn||workers-9/NNS||health-8/NN	prep_of||mentoring-6/NN||workers-9/NNS	cop||cornerstone-12/NN||are-10/VBP	det||cornerstone-12/NN||the-11/DT	root||ROOT-0/null||cornerstone-12/NN	det||scaling-15/NN||the-14/DT	prep_of||cornerstone-12/NN||scaling-15/NN	prep_up||scaling-15/NN||process-17/NN	amod||care-20/NN||hiv/aids-19/JJ	prep_of||scaling-15/NN||care-20/NN	amod||settings-23/NNS||resource-limited-22/JJ	prep_in||scaling-15/NN||settings-23/NNS	dep||scaling-15/NN||rlss-25/VBZ	aids--1||hiv--1||no||training, supervision and clinical mentoring of health workers are the cornerstone of the scaling up process of hiv/aids care in resource-limited settings (rlss).
poss||study-2/NN||our-1/PRP$	nsubj||demonstrated-3/VBD||study-2/NN	nsubj||suggest-21/VBP||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||increased-11/VBN||that-4/IN	det||a2ars-6/NN||the-5/DT	nsubjpass||increased-11/VBN||a2ars-6/NN	det||putamen-9/NN||the-8/DT	prep_in||a2ars-6/NN||putamen-9/NN	auxpass||increased-11/VBN||were-10/VBD	ccomp||demonstrated-3/VBD||increased-11/VBN	det||patients-15/NNS||the-13/DT	nn||patients-15/NNS||pd-14/NN	prep_in||increased-11/VBN||patients-15/NNS	prep_with||increased-11/VBN||dyskinesia-17/NN	advmod||suggest-21/VBP||also-20/RB	conj_and||demonstrated-3/VBD||suggest-21/VBP	mark||compensate-28/VB||that-22/IN	det||a2ars-24/NN||the-23/DT	nsubj||compensate-28/VB||a2ars-24/NN	det||putamen-27/NN||the-26/DT	prep_in||a2ars-24/NN||putamen-27/NN	ccomp||suggest-21/VBP||compensate-28/VB	det||decrease-32/NN||the-30/DT	amod||decrease-32/NN||asymmetrical-31/JJ	prep_for||compensate-28/VB||decrease-32/NN	prep_of||decrease-32/NN||dopamine-34/NN	amod||patients-40/NNS||drug-naã-36/JJ	nn||patients-40/NNS||¯-37/NNP	nn||patients-40/NNS||ve-38/NN	nn||patients-40/NNS||pd-39/NN	prep_in||compensate-28/VB||patients-40/NNS	mark||increases-45/VBZ||that-42/IN	nn||therapy-44/NN||antiparkinsonian-43/NN	nsubj||increases-45/VBZ||therapy-44/NN	ccomp||suggest-21/VBP||increases-45/VBZ	conj_and||compensate-28/VB||increases-45/VBZ	det||a2ars-47/NN||the-46/DT	dobj||increases-45/VBZ||a2ars-47/NN	det||putamen-50/NN||the-49/DT	prep_in||a2ars-47/NN||putamen-50/NN	dyskinesia-17||dopamine-34||no_rel||our study demonstrated that the a2ars in the putamen were increased in the pd patients with dyskinesia, and also suggest that the a2ars in the putamen compensate for the asymmetrical decrease of dopamine in drug-naã¯ve pd patients and that antiparkinsonian therapy increases the a2ars in the putamen.
nsubj||reduced-10/VBD||induction-1/NN	amod||inflammation-4/NN||neurogenic-3/JJ	prep_of||induction-1/NN||inflammation-4/NN	amod||application-7/NN||topical-6/JJ	prep_by||inflammation-4/NN||application-7/NN	prep_of||application-7/NN||capsaicin-9/NN	root||ROOT-0/null||reduced-10/VBD	xcomp||reduced-10/VBD||licking-11/VBG	dobj||licking-11/VBG||events-12/NNS	amod||mice-15/NNS||skh1-hrhr-14/JJ	prep_in||licking-11/VBG||mice-15/NNS	nsubj||rescued-19/VBD||morphine-18/NN	conj_and||reduced-10/VBD||rescued-19/VBD	det||response-21/NN||this-20/DT	dobj||rescued-19/VBD||response-21/NN	capsaicin-9||inflammation-4||no_rel||induction of neurogenic inflammation by topical application of capsaicin reduced licking events in skh1-hrhr mice, and morphine rescued this response.
amod||insulinresistance-6/NNP||conclusionsâ-1/JJ	nn||insulinresistance-6/NNP||$-2/NN	amod||insulinresistance-6/NNP||selective-4/JJ	nn||insulinresistance-6/NNP||endothelial-5/NN	nsubj||sufficient-8/JJ||insulinresistance-6/NNP	nsubj||induce-10/VB||insulinresistance-6/NNP	cop||sufficient-8/JJ||is-7/VBZ	root||ROOT-0/null||sufficient-8/JJ	aux||induce-10/VB||to-9/TO	xcomp||sufficient-8/JJ||induce-10/VB	det||reduction-12/NN||a-11/DT	dobj||induce-10/VB||reduction-12/NN	neg||dysfunction-18/NN||no-14/DT	amod||dysfunction-18/NN||bioavailability-15/JJ	conj_and||bioavailability-15/JJ||endothelial-17/JJ	amod||dysfunction-18/NN||endothelial-17/JJ	prep_in||induce-10/VB||dysfunction-18/NN	nsubj||secondary-21/JJ||dysfunction-18/NN	cop||secondary-21/JJ||is-20/VBZ	rcmod||dysfunction-18/NN||secondary-21/JJ	amod||generation-24/NN||increased-23/VBN	prep_to||secondary-21/JJ||generation-24/NN	amod||species-28/NNS||reactive-26/JJ	nn||species-28/NNS||oxygen-27/NN	prep_of||generation-24/NN||species-28/NNS	oxygen-27||insulinresistance-6||no_rel||conclusionsâ€” selective endothelial insulinresistance is sufficient to induce a reduction in no bioavailability and endothelial dysfunction that is secondary to increased generation of reactive oxygen species.
amod||treatment-2/NN||current-1/JJ	nsubj||limited-11/VBN||treatment-2/NN	nsubj||costly-24/JJ||treatment-2/NN	nsubj||involves-27/VBZ||treatment-2/NN	amod||infection-9/NN||chronichepatitisc-4/JJ	nn||infection-9/NN||virus-5/NN	appos||infection-9/NN||hcv-7/NN	prep_of||treatment-2/NN||infection-9/NN	aux||limited-11/VBN||has-10/VBZ	root||ROOT-0/null||limited-11/VBN	advmod||limited-11/VBN||efficacy-12/RB	poss||patientsâˆ-20/NN||âˆ-13/NNP	amod||patientsâˆ-20/NN||especially-15/RB	amod||1-18/CD||genotype-17/JJ	prep_among||especially-15/RB||1-18/CD	amod||patientsâˆ-20/NN||infected-19/JJ	dobj||limited-11/VBN||patientsâˆ-20/NN	cop||costly-24/JJ||is-23/VBZ	conj_and||limited-11/VBN||costly-24/JJ	conj_and||limited-11/VBN||involves-27/VBZ	amod||effects-30/NNS||severe-28/JJ	nn||effects-30/NNS||side-29/NN	dobj||involves-27/VBZ||effects-30/NNS	chronichepatitisc-4||hcv-7||no||current treatment of chronichepatitisc virus (hcv) infection has limited efficacy âˆ’especially among genotype 1 infected patientsâˆ’, is costly, and involves severe side effects.
det||report-3/NN||this-1/DT	nn||report-3/NN||case-2/NN	nsubj||demonstrates-4/VBZ||report-3/NN	root||ROOT-0/null||demonstrates-4/VBZ	det||response-7/NN||a-5/DT	amod||response-7/NN||satisfying-6/JJ	nsubj||had-24/VBD||response-7/NN	nsubjpass||discontinued-27/VBN||response-7/NN	aux||topiramate-9/VB||to-8/TO	vmod||response-7/NN||topiramate-9/VB	det||patient-13/NN||a-11/DT	amod||patient-13/NN||79-year-old-12/JJ	prep_in||topiramate-9/VB||patient-13/NN	amod||essentialtremor-16/NN||disabling-15/VBG	prep_with||topiramate-9/VB||essentialtremor-16/NN	nsubj||propranolol-19/VBP||whom-18/WP	nsubj||primidone-23/VBP||whom-18/WP	prepc_in||essentialtremor-16/NN||propranolol-19/VBP	prepc_in||essentialtremor-16/NN||primidone-23/VBP	conj_and||propranolol-19/VBP||primidone-23/VBP	ccomp||demonstrates-4/VBZ||had-24/VBD	aux||discontinued-27/VBN||to-25/TO	auxpass||discontinued-27/VBN||be-26/VB	xcomp||had-24/VBD||discontinued-27/VBN	xcomp||discontinued-27/VBN||due-28/JJ	amod||effects-32/NNS||severe-30/JJ	nn||effects-32/NNS||side-31/NN	prep_to||due-28/JJ||effects-32/NNS	propranolol-19||essentialtremor-16||no_rel||this case report demonstrates a satisfying response to topiramate in a 79-year-old patient with disabling essentialtremor in whom propranolol as well as primidone had to be discontinued due to severe side effects.
nsubj||conducted-5/VBD||we-1/PRP	advmod||conducted-5/VBD||therefore-3/RB	root||ROOT-0/null||conducted-5/VBD	det||evaluation-8/NN||a-6/DT	amod||evaluation-8/NN||comprehensive-7/JJ	dobj||conducted-5/VBD||evaluation-8/NN	advmod||resistant-11/JJ||inh-10/RB	amod||levels-54/NNS||resistant-11/JJ	amod||strains-13/NNS||m.tuberculosis-12/JJ	nn||n-15/NN||strains-13/NNS	amod||n-15/NN||-lrb--14/JJ	npadvmod||resistant-11/JJ||n-15/NN	dep||-rrb--18/NNS||=-16/SYM	num||-rrb--18/NNS||224-17/CD	dep||n-15/NN||-rrb--18/NNS	npadvmod||south-21/RB||three-20/CD	advmod||countries-23/NNS||south-21/RB	amod||countries-23/NNS||american-22/JJ	prep_from||resistant-11/JJ||countries-23/NNS	amod||burden-26/NN||high-25/JJ	prep_with||resistant-11/JJ||burden-26/NN	prep_of||burden-26/NN||drug-28/NN	amod||levels-54/NNS||resistant-29/JJ	advmod||resistant-29/JJ||tb-30/RB	aux||characterize-32/VB||to-31/TO	xcomp||resistant-29/JJ||characterize-32/VB	dobj||characterize-32/VB||mutations-33/NNS	nn||g-36/NN||kat-35/NN	prep_in||characterize-32/VB||g-36/NN	xcomp||resistant-29/JJ||ahp-38/VB	conj_and||characterize-32/VB||ahp-38/VB	dep||ahp-38/VB||c-39/SYM	xcomp||resistant-29/JJ||inh-41/VB	conj_and||characterize-32/VB||inh-41/VB	det||loci-44/NN||a-42/DT	nn||loci-44/NN||gene-43/NN	dobj||inh-41/VB||loci-44/NN	conj_and||characterize-32/VB||correlate-46/VB	conj_and||inh-41/VB||correlate-46/VB	amod||concentrations-50/NNS||minimal-48/JJ	nn||concentrations-50/NNS||inhibitory-49/NN	prep_with||correlate-46/VB||concentrations-50/NNS	amod||levels-54/NNS||-lrb--51/JJ	amod||levels-54/NNS||mic-52/JJ	nn||levels-54/NNS||-rrb--53/NN	prep_of||evaluation-8/NN||levels-54/NNS	amod||family-58/NN||spoligotype-56/JJ	nn||family-58/NN||strain-57/NN	prep_of||evaluation-8/NN||family-58/NN	conj_and||levels-54/NNS||family-58/NN	tb-30||m.tuberculosis-12||no||we , therefore , conducted a comprehensive evaluation of inh resistant m.tuberculosis strains -lrb- n = 224 -rrb- from three south american countries with high burden of drug resistant tb to characterize mutations in kat g , ahp c and inh a gene loci and correlate with minimal inhibitory concentrations -lrb- mic -rrb- levels and spoligotype strain family .
det||study-2/NN||this-1/DT	nsubj||demonstrated-3/VBD||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||higher-18/JJR||that-4/IN	csubj||higher-18/JJR||circulating-5/VBG	nn||plasmablasts-8/NNS||igg-6/NN	nn||plasmablasts-8/NNS||+-7/NN	dobj||circulating-5/VBG||plasmablasts-8/NNS	amod||secretion-11/NN||spontaneous-10/JJ	dobj||circulating-5/VBG||secretion-11/NN	conj_and||plasmablasts-8/NNS||secretion-11/NN	amod||antibodies-15/NNS||bcg-specific-13/JJ	nn||antibodies-15/NNS||igg-14/NN	prep_of||secretion-11/NN||antibodies-15/NNS	cop||higher-18/JJR||were-16/VBD	advmod||higher-18/JJR||significantly-17/RB	ccomp||demonstrated-3/VBD||higher-18/JJR	prep_in||higher-18/JJR||patients-20/NNS	amod||tb-23/NN||active-22/JJ	prep_with||patients-20/NNS||tb-23/NN	prepc_compared_with||higher-18/JJR||with-25/IN	nn||cases-28/NNS||latent-26/NN	nn||cases-28/NNS||tb-27/NN	pobj||higher-18/JJR||cases-28/NNS	amod||controls-31/NNS||non-tb-30/JJ	pobj||higher-18/JJR||controls-31/NNS	conj_and||cases-28/NNS||controls-31/NNS	tb-27||bcg--1||no||this study demonstrated that circulating igg+ plasmablasts and spontaneous secretion of bcg-specific igg antibodies were significantly higher in patients with active tb compared with latent tb cases and non-tb controls.
advmod||papers-4/NNS||only-2/RB	num||papers-4/NNS||four-3/CD	prep_in||were-5/VBD||papers-4/NNS	root||ROOT-0/null||were-5/VBD	det||weights-8/NNS||the-6/DT	amod||weights-8/NNS||hrql-7/JJ	nsubj||were-5/VBD||weights-8/NNS	prep_for||weights-8/NNS||hiv/aids-10/NNS	amod||africa-13/NN||sub-saharan-12/JJ	prep_in||hiv/aids-10/NNS||africa-13/NN	vmod||africa-13/NN||estimated-14/VBN	amod||preference-17/NN||generic-16/JJ	prep_with||estimated-14/VBN||preference-17/NN	vmod||preference-17/NN||based-18/VBN	dobj||based-18/VBN||methodologies-19/NNS	nsubjpass||applied-24/VBN||methodologies-19/NNS	aux||applied-24/VBN||can-21/MD	auxpass||applied-24/VBN||be-22/VB	advmod||applied-24/VBN||directly-23/RB	rcmod||methodologies-19/NNS||applied-24/VBN	amod||evaluation-27/NN||economic-26/JJ	prep_in||applied-24/VBN||evaluation-27/NN	aids--1||hiv--1||no||in only four papers were the hrql weights for hiv/aids in sub-saharan africa estimated with generic preference based methodologies that can be directly applied in economic evaluation.
det||severity-2/NN||the-1/DT	nsubj||one-12/CD||severity-2/NN	amod||pandemic-5/NN||hiv/aids-4/JJ	prep_of||severity-2/NN||pandemic-5/NN	vmod||pandemic-5/NN||linked-6/VBN	amod||use-10/NN||injecting-8/VBG	nn||use-10/NN||drug-9/NN	prep_to||linked-6/VBN||use-10/NN	cop||one-12/CD||is-11/VBZ	root||ROOT-0/null||one-12/CD	det||most-15/JJS||the-14/DT	prep_of||one-12/CD||most-15/JJS	vmod||most-15/JJS||worrying-16/VBG	amod||problems-20/NNS||medical-17/JJ	conj_and||medical-17/JJ||social-19/JJ	amod||problems-20/NNS||social-19/JJ	dobj||worrying-16/VBG||problems-20/NNS	det||world-23/NN||the-22/DT	prep_throughout||worrying-16/VBG||world-23/NN	amod||years-26/NNS||recent-25/JJ	prep_in||world-23/NN||years-26/NNS	aids--1||hiv--1||no||the severity of hiv/aids pandemic linked to injecting drug use is one of the most worrying medical and social problems throughout the world in recent years.
amod||biopsies-2/NNS||conjunctival-1/JJ	nsubjpass||obtained-4/VBN||biopsies-2/NNS	auxpass||obtained-4/VBN||were-3/VBD	root||ROOT-0/null||obtained-4/VBN	det||fornix-8/NN||the-6/DT	amod||fornix-8/NN||inferior-7/JJ	prep_from||obtained-4/VBN||fornix-8/NN	amod||surgery-12/NN||routine-10/JJ	nn||surgery-12/NN||cataract-11/NN	prep_during||fornix-8/NN||surgery-12/NN	num||patients-15/NNS||20-14/CD	prep_from||obtained-4/VBN||patients-15/NNS	amod||open-angleglaucoma-18/NN||primary-17/JJ	prep_with||patients-15/NNS||open-angleglaucoma-18/NN	nsubj||received-22/VBN||open-angleglaucoma-18/NN	aux||received-22/VBN||had-21/VBD	rcmod||open-angleglaucoma-18/NN||received-22/VBN	det||monotherapy-24/NN||a-23/DT	dobj||received-22/VBN||monotherapy-24/NN	dobj||received-22/VBN||monotherapy-24/NN	conj_and||monotherapy-24/NN||monotherapy-24/NN	preconj||monotherapy-24/NN||either-25/CC	prep_with||monotherapy-24/NN||timolol-27/NN	prep_with||monotherapy-24/NN||latanoprost-29/NN	conj_or||timolol-27/NN||latanoprost-29/NN	prep_from||monotherapy-24/NN||10-33/CD	amod||patients-35/NNS||non-glaucomatous-34/JJ	dep||monotherapy-24/NN||patients-35/NNS	open-angleglaucoma-18||timolol-27||yes||conjunctival biopsies were obtained from the inferior fornix during routine cataract surgery from 20 patients with primary open-angleglaucoma, who had received a monotherapy either with timolol or latanoprost, and from 10 non-glaucomatous patients.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||association-7/NN||the-3/DT	amod||association-7/NN||independent-4/JJ	conj_and||independent-4/JJ||joint-6/JJ	amod||association-7/NN||joint-6/JJ	dobj||investigated-2/VBD||association-7/NN	amod||activity-12/NN||adiposity-9/JJ	conj_and||adiposity-9/JJ||physical-11/JJ	amod||activity-12/NN||physical-11/JJ	prep_of||association-7/NN||activity-12/NN	amod||glucose-16/NN||fasting-14/VBG	nn||glucose-16/NN||plasma-15/NN	prep_with||investigated-2/VBD||glucose-16/NN	amod||glucose-20/NN||impaired-18/VBN	amod||glucose-20/NN||fasting-19/JJ	prep_with||investigated-2/VBD||glucose-20/NN	conj_and||glucose-16/NN||glucose-20/NN	prep_with||investigated-2/VBD||type2diabetes-23/NNS	conj_and||glucose-16/NN||type2diabetes-23/NNS	det||population-27/NN||a-25/DT	amod||population-27/NN||chinese-26/JJ	prep_in||type2diabetes-23/NNS||population-27/NN	glucose-20||type2diabetes-23||no_rel||we investigated the independent and joint association of adiposity and physical activity with fasting plasma glucose, impaired fasting glucose, and type2diabetes in a chinese population.
det||profile-5/NN||the-1/DT	nn||profile-5/NN||safety-2/NN	conj_and||safety-2/NN||efficacy-4/NN	nn||profile-5/NN||efficacy-4/NN	nsubj||were-15/VBD||profile-5/NN	prep_of||profile-5/NN||caspofungin-7/NN	prep_of||profile-5/NN||micafungin-9/NN	conj_and||caspofungin-7/NN||micafungin-9/NN	amod||patients-12/NNS||japanese-11/JJ	prep_in||caspofungin-7/NN||patients-12/NNS	prep_with||patients-12/NNS||fungalinfections-14/NNS	root||ROOT-0/null||were-15/VBD	advmod||were-15/VBD||directly-16/RB	prep||were-15/VBD||compared-17/VBN	pcomp||compared-17/VBN||in-18/IN	det||study-25/NN||this-19/DT	amod||study-25/NN||prospective-20/JJ	amod||study-25/NN||randomized-22/JJ	amod||study-25/NN||double-blind-24/JJ	pobj||in-18/IN||study-25/NN	fungalinfections-14||micafungin-9||yes||the safety and efficacy profile of caspofungin and micafungin in japanese patients with fungalinfections were directly compared in this prospective, randomized, double-blind study.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	amod||interaction-4/NN||significant-3/JJ	nsubj||was-2/VBD||interaction-4/NN	prep_of||interaction-4/NN||location-6/NN	nn||colon-10/NN||tumor-8/NN	nn||colon-10/NN||-lrb--9/NN	prep_of||location-6/NN||colon-10/NN	amod||cancer-13/NN||rectal-12/JJ	prep_vs.||colon-10/NN||cancer-13/NN	vmod||cancer-13/NN||-rrb--14/VBN	prep_with||-rrb--14/VBN||dm-16/NN	nn||â-21/NN||os-18/NN	num||â-21/NN||-lrb--19/CD	nn||â-21/NN||p-20/NN	prep_on||dm-16/NN||â-21/NN	num||â-25/NN||$-22/$	number||=-24/CD||š-23/CD	num||$-22/$||=-24/CD	dep||cancer-13/NN||â-25/NN	num||-rrb--29/NNS||$-26/$	number||.009-28/CD||š0-27/CD	num||$-26/$||.009-28/CD	dep||cancer-13/NN||-rrb--29/NNS	nn||â-34/NN||dfs-31/NN	num||â-34/NN||-lrb--32/CD	nn||â-34/NN||p-33/NN	prep_vs.||colon-10/NN||â-34/NN	conj_and||cancer-13/NN||â-34/NN	num||-rrb--42/NNS||$-35/$	number||=-37/CD||š-36/CD	num||$-35/$||=-37/CD	amod||-rrb--42/NNS||â-38/JJ	num||-rrb--42/NNS||$-39/$	number||.007-41/CD||š0-40/CD	num||$-39/$||.007-41/CD	dep||â-34/NN||-rrb--42/NNS	tumor-8||dm-16||yes||there was significant interaction of location of tumor -lrb- colon vs. rectal cancer -rrb- with dm on os -lrb- p â $ š = â $ š0 .009 -rrb- and dfs -lrb- p â $ š = â $ š0 .007 -rrb- .
nsubj||lower-7/JJR||severity-1/NN	nn||pain-4/NN||injection-3/NN	prep_of||severity-1/NN||pain-4/NN	cop||lower-7/JJR||was-5/VBD	advmod||lower-7/JJR||significantly-6/RB	root||ROOT-0/null||lower-7/JJR	det||group-25/NN||the-9/DT	amod||group-25/NN||sufentanil-10/JJ	dep||sufentanil-10/JJ||0.3-11/CD	nn||group-25/NN||âµg-12/NN	punct||group-15/NN||/-13/:	nn||group-15/NN||kg-14/NN	dep||group-25/NN||group-15/NN	amod||saline-18/NN||normal-17/JJ	prep_than||group-15/NN||saline-18/NN	amod||âµg-22/NN||sufentanil-20/JJ	num||âµg-22/NN||0.1-21/CD	prep_than||group-15/NN||âµg-22/NN	conj_and||saline-18/NN||âµg-22/NN	punct||group-15/NN||/-23/:	amod||group-25/NN||kg-24/JJ	prep_in||lower-7/JJR||group-25/NN	pain-4||sufentanil-20||yes||severity of injection pain was significantly lower in the sufentanil 0.3 âµg/kg group than normal saline and sufentanil 0.1 âµg/kg group.
amod||hydroxyethylstarch-3/NN||hypertonic-1/JJ	nn||hydroxyethylstarch-3/NN||saline-2/NN	nsubjpass||recommended-9/VBN||hydroxyethylstarch-3/NN	appos||hydroxyethylstarch-3/NN||hh-5/NN	aux||recommended-9/VBN||has-7/VBZ	auxpass||recommended-9/VBN||been-8/VBN	root||ROOT-0/null||recommended-9/VBN	amod||treatment-13/NN||first-11/JJ	nn||treatment-13/NN||line-12/NN	prep_for||recommended-9/VBN||treatment-13/NN	prep_of||treatment-13/NN||hemorrhagicshock-15/NN	hydroxyethylstarch-3||hemorrhagicshock-15||no_rel||hypertonic saline hydroxyethylstarch (hh) has been recommended for first line treatment of hemorrhagicshock.
nsubj||spread-17/VBN||infection-1/NN	amod||avianinfluenzaviruses-6/NNS||h5n1-3/JJ	advmod||pathogenic-5/JJ||highly-4/RB	amod||avianinfluenzaviruses-6/NNS||pathogenic-5/JJ	prep_with||infection-1/NN||avianinfluenzaviruses-6/NNS	appos||avianinfluenzaviruses-6/NNS||hpaivs-8/NNS	amod||poultry-12/NN||domestic-11/JJ	prep_of||infection-1/NN||poultry-12/NN	amod||birds-15/NNS||wild-14/JJ	prep_of||infection-1/NN||birds-15/NNS	conj_and||poultry-12/NN||birds-15/NNS	aux||spread-17/VBN||has-16/VBZ	root||ROOT-0/null||spread-17/VBN	mwe||than-20/IN||more-19/JJR	quantmod||60-21/CD||than-20/IN	num||countries-22/NNS||60-21/CD	prep_to||spread-17/VBN||countries-22/NNS	prep_in||spread-17/VBN||eurasia-24/NN	prep_in||spread-17/VBN||africa-26/NN	conj_and||eurasia-24/NN||africa-26/NN	h5n1-3||influenzaviruses--1||no||infection with h5n1 highly pathogenic avianinfluenzaviruses (hpaivs) of domestic poultry and wild birds has spread to more than 60 countries in eurasia and africa.
det||effect-2/NN||this-1/DT	nsubj||results-3/VBZ||effect-2/NN	root||ROOT-0/null||results-3/VBZ	det||stimulation-7/NN||a-5/DT	amod||stimulation-7/NN||glucose-dependent-6/JJ	prep_in||results-3/VBZ||stimulation-7/NN	nn||secretion-10/NN||insulin-9/NN	prep_of||stimulation-7/NN||secretion-10/NN	det||inhibition-13/NN||an-12/DT	prep_in||results-3/VBZ||inhibition-13/NN	conj_and||stimulation-7/NN||inhibition-13/NN	nn||secretion-16/NN||glucagon-15/NN	prep_of||inhibition-13/NN||secretion-16/NN	det||risk-20/NN||an-18/DT	amod||risk-20/NN||intrinsic-19/JJ	prep_without||results-3/VBZ||risk-20/NN	prep_for||risk-20/NN||hypoglycemia-22/NN	hypoglycemia-22||glucose--1||yes||this effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia.
det||bacillusanthracis-5/NNS||the-2/DT	amod||bacillusanthracis-5/NNS||pathogenic-3/JJ	nn||bacillusanthracis-5/NNS||bacterium-4/NN	prep_in||requires-8/VBZ||bacillusanthracis-5/NNS	nsubj||requires-8/VBZ||virulence-7/NN	root||ROOT-0/null||requires-8/VBZ	amod||expression-10/NN||induced-9/JJ	dobj||requires-8/VBZ||expression-10/NN	det||toxin-14/NN||the-12/DT	nn||toxin-14/NN||anthrax-13/NN	prep_of||expression-10/NN||toxin-14/NN	amod||genes-17/NNS||capsule-16/JJ	prep_of||expression-10/NN||genes-17/NNS	conj_and||toxin-14/NN||genes-17/NNS	toxin-14||anthrax-13||no_rel||in the pathogenic bacterium bacillusanthracis , virulence requires induced expression of the anthrax toxin and capsule genes.
nsubj||alternative-5/NN||daptomycin-1/NN	cop||alternative-5/NN||was-2/VBD	det||alternative-5/NN||an-3/DT	amod||alternative-5/NN||effective-4/JJ	root||ROOT-0/null||alternative-5/NN	aux||vancomycin/gentamicin-7/VB||to-6/TO	vmod||alternative-5/NN||vancomycin/gentamicin-7/VB	nn||bacteraemia-10/NN||mrsa-9/NN	prep_for||vancomycin/gentamicin-7/VB||bacteraemia-10/NN	amod||endocarditis-13/NNS||right-sided-12/JJ	prep_for||vancomycin/gentamicin-7/VB||endocarditis-13/NNS	conj_or||bacteraemia-10/NN||endocarditis-13/NNS	endocarditis-13||daptomycin-1||no_rel||daptomycin was an effective alternative to vancomycin/gentamicin for mrsa bacteraemia or right-sided endocarditis.
num||patient-4/NN||46-1/CD	nn||patient-4/NN||year-2/NN	amod||patient-4/NN||old-3/JJ	nsubjpass||admitted-6/VBN||patient-4/NN	auxpass||admitted-6/VBN||was-5/VBD	root||ROOT-0/null||admitted-6/VBN	det||emergency-9/NN||an-8/DT	prep_as||admitted-6/VBN||emergency-9/NN	nn||cortisol-16/NN||vomiting-11/NN	conj_and||vomiting-11/NN||hypotension-13/NN	nn||cortisol-16/NN||hypotension-13/NN	conj_and||vomiting-11/NN||serum-15/NN	nn||cortisol-16/NN||serum-15/NN	prep_with||emergency-9/NN||cortisol-16/NN	number||î-19/CD||0,940-18/CD	num||indicative-26/NNS||î-19/CD	num||indicative-26/NNS||1/4-20/CD	amod||indicative-26/NNS||g/dl-21/JJ	num||nmol/l-24/NN||26-23/CD	appos||indicative-26/NNS||nmol/l-24/NN	prep_of||cortisol-16/NN||indicative-26/NNS	prep_of||cortisol-16/NN||adrenalfailure-28/NN	adrenalfailure-28||cortisol-16||yes||46 year old patient was admitted as an emergency with vomiting, hypotension and serum cortisol of 0,940 î¼g/dl (26 nmol/l) indicative of adrenalfailure.
det||perturbations-3/NNS||some-1/DT	amod||perturbations-3/NNS||minor-2/JJ	nsubj||caused-14/VBD||perturbations-3/NNS	prepc_like||perturbations-3/NNS||increasing-5/VBG	det||concentration-8/NN||the-6/DT	nn||concentration-8/NN||glucose-7/NN	dobj||increasing-5/VBG||concentration-8/NN	number||1-12/CD||0.1-10/CD	dep||1-12/CD||to-11/TO	num||g/l-13/NN||1-12/CD	prep_from||increasing-5/VBG||g/l-13/NN	root||ROOT-0/null||caused-14/VBD	det||difference-19/NN||a-15/DT	number||million-17/CD||ten-16/CD	num||difference-19/NN||million-17/CD	nn||difference-19/NN||fold-18/NN	dobj||caused-14/VBD||difference-19/NN	amod||cells-22/NNS||culturable-21/JJ	prep_in||caused-14/VBD||cells-22/NNS	det||treatment-29/NN||a-24/DT	amod||treatment-29/NN||twenty-25/CD	num||hour-27/NN||four-26/CD	dep||twenty-25/CD||hour-27/NN	amod||treatment-29/NN||antibiotic-28/JJ	prep_over||caused-14/VBD||treatment-29/NN	ten-16||antibiotic-28||no_rel||some minor perturbations like increasing the glucose concentration from 0.1 to 1 g/l caused a ten million fold difference in culturable cells over a twenty four hour antibiotic treatment.
advmod||recruited-17/VBN||moreover-1/RB	num||individuals-4/NNS||25-3/CD	nsubjpass||recruited-17/VBN||individuals-4/NNS	prep_with||individuals-4/NNS||immunity-6/NN	amod||immunity-6/NN||consistent-7/JJ	nn||m.tuberculosisinfection-10/NN||latent-9/NN	prep_with||consistent-7/JJ||m.tuberculosisinfection-10/NN	prep_with||consistent-7/JJ||bcg-vaccination-12/NN	conj_and||m.tuberculosisinfection-10/NN||bcg-vaccination-12/NN	advmod||recruited-17/VBN||respectively-14/RB	auxpass||recruited-17/VBN||were-16/VBD	root||ROOT-0/null||recruited-17/VBN	tuberculosisinfection--1||bcg--1||yes||moreover , 25 individuals with immunity consistent with latent m.tuberculosisinfection and bcg-vaccination , respectively , were recruited .
nsubj||reactions-7/NNS||contact-allergicreactions-1/NNS	prep_to||contact-allergicreactions-1/NNS||cosmetics-3/NNS	aux||reactions-7/NNS||may-4/MD	cop||reactions-7/NNS||be-5/VB	amod||reactions-7/NNS||delayed-type-6/JJ	root||ROOT-0/null||reactions-7/NNS	prep_such_as||reactions-7/NNS||allergic-10/NNS	prep_such_as||reactions-7/NNS||photo-allergiccontactdermatitis-12/NNS	conj_and||allergic-10/NNS||photo-allergiccontactdermatitis-12/NNS	advmod||reactions-19/NNS||more-15/RBR	advmod||also-17/RB||exceptionally-16/RB	amod||reactions-19/NNS||also-17/RB	amod||reactions-19/NNS||immediate-type-18/JJ	conj_and||reactions-7/NNS||reactions-19/NNS	discourse||reactions-7/NNS||that-21/DT	dep||that-21/DT||is-22/VBZ	nn||urticaria-25/NN||contact-24/NN	dobj||reactions-7/NNS||urticaria-25/NN	allergiccontactdermatitis--1||allergicreactions--1||no||contact-allergicreactions to cosmetics may be delayed-type reactions such as allergic and photo-allergiccontactdermatitis, and more exceptionally also immediate-type reactions, that is, contact urticaria.
nsubj||remain-11/VBP||diseases-1/NNS	vmod||diseases-1/NNS||linked-2/VBN	aux||thiamine-4/VB||to-3/TO	xcomp||linked-2/VBN||thiamine-4/VB	dobj||thiamine-4/VB||deficiency-5/NN	dep||diseases-1/NNS||polyneuritis-7/NNS	appos||polyneuritis-7/NNS||wernicke-korsakoffsyndrome-9/NN	root||ROOT-0/null||remain-11/VBP	acomp||remain-11/VBP||frequent-12/JJ	prep_among||remain-11/VBP||alcoholabusers-14/NNS	amod||populations-18/NNS||other-16/JJ	nn||populations-18/NNS||risk-17/NN	prep_among||remain-11/VBP||populations-18/NNS	conj_and||alcoholabusers-14/NNS||populations-18/NNS	alcohol--1||wernicke-korsakoffsyndrome-9||no_rel||diseases linked to thiamine deficiency (polyneuritis, wernicke-korsakoffsyndrome) remain frequent among alcoholabusers and other risk populations.
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||‰-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	hypertension-21||dm-44||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â€“11.0 mmol/l), diabetes (dm; p-glucose â‰¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
det||study-3/NN||this-2/DT	prep_in||found-6/VBD||study-3/NN	nsubj||found-6/VBD||we-5/PRP	root||ROOT-0/null||found-6/VBD	mark||isolates-11/VBZ||that-7/IN	amod||s.aureus-10/NNS||many-8/JJ	amod||s.aureus-10/NNS||bovine-9/JJ	nsubj||isolates-11/VBZ||s.aureus-10/NNS	ccomp||found-6/VBD||isolates-11/VBZ	dep||isolates-11/VBZ||including-13/VBG	det||strain-16/NN||the-14/DT	amod||strain-16/NN||rf122-15/JJ	pobj||including-13/VBG||strain-16/NN	dep||isolates-11/VBZ||generate-18/VB	amod||amounts-20/NNS||dramatic-19/JJ	dobj||generate-18/VB||amounts-20/NNS	nn||±-23/NNS||î-22/NN	prep_of||amounts-20/NNS||±-23/NNS	dep||amounts-20/NNS||toxin-25/NN	prep_in||toxin-25/NN||vitro-27/NNP	prepc_compared_with||generate-18/VB||with-29/IN	amod||s.aureus-32/NNS||human-30/JJ	amod||s.aureus-32/NNS||clinical-31/JJ	pobj||generate-18/VB||s.aureus-32/NNS	dep||s.aureus-32/NNS||isolates-33/VBZ	nn||wcuh29-37/NNS||mrsa-36/NN	prep_including||s.aureus-32/NNS||wcuh29-37/NNS	nn||usa300-40/NNS||mrsa-39/NN	prep_including||s.aureus-32/NNS||usa300-40/NNS	conj_and||wcuh29-37/NNS||usa300-40/NNS	mrsa-39||s.aureus-32||no||in this study , we found that many bovine s.aureus isolates , including the rf122 strain , generate dramatic amounts of î ± - toxin in vitro compared with human clinical s.aureus isolates , including mrsa wcuh29 and mrsa usa300 .
num||viruses-2/NNS||two-1/CD	nsubj||lethal-6/JJ||viruses-2/NNS	prep_with||viruses-2/NNS||g222-4/CD	cop||lethal-6/JJ||were-5/VBD	root||ROOT-0/null||lethal-6/JJ	mark||caused-15/VBD||while-7/IN	det||virus-10/NN||a-8/DT	amod||virus-10/NN||third-9/JJ	nsubj||caused-15/VBD||virus-10/NN	prep_with||virus-10/NN||g222-13/CD	advcl||lethal-6/JJ||caused-15/VBD	advmod||illness-18/NN||only-16/RB	amod||illness-18/NN||mild-17/JJ	dobj||caused-15/VBD||illness-18/NN	prep_in||caused-15/VBD||mice-20/NNS	amod||mice-20/NNS||similar-21/JJ	det||virus-25/NN||the-23/DT	amod||virus-25/NN||fourth-24/JJ	prep_to||similar-21/JJ||virus-25/NN	nsubj||contained-27/VBD||virus-25/NN	rcmod||virus-25/NN||contained-27/VBD	dobj||contained-27/VBD||d222-28/NNS	virus-25||viruses-2||no||two viruses with g222 were lethal while a third virus, with g222, caused only mild illness in mice similar to the fourth virus that contained d222.
prep||led-9/VBD||beginning-1/VBG	pcomp||beginning-1/VBG||in-2/IN	pobj||in-2/IN||1955-3/CD	det||creation-6/NN||the-5/DT	nsubj||led-9/VBD||creation-6/NN	prep_of||creation-6/NN||poliovirusvaccines-8/NNS	root||ROOT-0/null||led-9/VBD	det||reduction-13/NN||a-11/DT	amod||reduction-13/NN||stepwise-12/JJ	prep_to||led-9/VBD||reduction-13/NN	prep_in||led-9/VBD||poliomyelitis-15/NNP	xcomp||led-9/VBD||culminating-17/VBG	det||elimination-21/NN||the-19/DT	amod||elimination-21/NN||unpredicted-20/JJ	prep_in||culminating-17/VBG||elimination-21/NN	amod||polioviruses-24/NNS||wild-23/JJ	prep_of||elimination-21/NN||polioviruses-24/NNS	det||states-28/NNS||the-26/DT	amod||states-28/NNS||united-27/VBN	prep_in||culminating-17/VBG||states-28/NNS	prep_by||states-28/NNS||1972-30/CD	poliomyelitis-15||polioviruses-24||no||beginning in 1955, the creation of poliovirusvaccines led to a stepwise reduction in poliomyelitis, culminating in the unpredicted elimination of wild polioviruses in the united states by 1972.
amod||sensitivities-2/NNS||analytical-1/JJ	nsubj||reduce-10/VB||sensitivities-2/NNS	prep_for||sensitivities-2/NNS||hbsag-4/NN	number||1-7/CD||>-6/CD	num||iu/ml-8/NN||1-7/CD	prep_of||hbsag-4/NN||iu/ml-8/NN	advmod||reduce-10/VB||significantly-9/RB	root||ROOT-0/null||reduce-10/VB	det||length-12/NN||the-11/DT	dobj||reduce-10/VB||length-12/NN	det||period-17/NN||the-14/DT	amod||period-17/NN||hbsag-15/JJ	amod||period-17/NN||positive-16/JJ	prep_of||length-12/NN||period-17/NN	nsubj||renders-19/VBZ||period-17/NN	rcmod||period-17/NN||renders-19/VBZ	nsubj||reliable-22/JJ||them-20/PRP	advmod||reliable-22/JJ||less-21/RBR	xcomp||renders-19/VBZ||reliable-22/JJ	prepc_for||renders-19/VBZ||detecting-24/VBG	vmod||detecting-24/VBG||hbsag-25/VBG	amod||infections-29/NNS||asymptomatic-27/JJ	nn||infections-29/NNS||hbv-28/NN	prep_in||hbsag-25/VBG||infections-29/NNS	hbv-28||hbsag-25||yes||analytical sensitivities for hbsag of >1 iu/ml significantly reduce the length of the hbsag positive period which renders them less reliable for detecting hbsag in asymptomatic hbv infections.
poss||model-2/NN||our-1/PRP$	nsubj||addressed-21/VBD||model-2/NN	amod||care-6/NN||pediatric-4/JJ	nn||care-6/NN||hiv/aids-5/NNS	prep_of||model-2/NN||care-6/NN	vmod||model-2/NN||focused-8/VBN	det||approach-12/NN||a-10/DT	amod||approach-12/NN||child-centered-11/JJ	prep_on||focused-8/VBN||approach-12/NN	prep_with||focused-8/VBN||inclusion-14/NN	prep_of||inclusion-14/NN||caregivers-16/NNS	amod||family-19/NN||extended-18/JJ	prep_of||inclusion-14/NN||family-19/NN	conj_and||caregivers-16/NNS||family-19/NN	root||ROOT-0/null||addressed-21/VBD	det||factors-24/NNS||the-22/DT	amod||factors-24/NNS||main-23/JJ	dobj||addressed-21/VBD||factors-24/NNS	vmod||factors-24/NNS||influencing-25/VBG	nn||adherence-27/NN||treatment-26/NN	dobj||influencing-25/VBG||adherence-27/NN	aids--1||hiv--1||no||our model of pediatric hiv/aids care, focused on a child-centered approach with inclusion of caregivers and extended family, addressed the main factors influencing treatment adherence.
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBN||study-2/NN	nsubj||investigate-5/VB||study-2/NN	nsubj||determine-21/VB||study-2/NN	nsubj||spreading-32/VBG||study-2/NN	root||ROOT-0/null||aimed-3/VBN	aux||investigate-5/VB||to-4/TO	xcomp||aimed-3/VBN||investigate-5/VB	det||relationship-9/NN||the-6/DT	amod||relationship-9/NN||molecular-7/JJ	amod||relationship-9/NN||structural-8/JJ	dobj||investigate-5/VB||relationship-9/NN	nn||cd44-14/NNS||cell-11/NN	nn||cd44-14/NNS||adhesive-12/NN	nn||cd44-14/NNS||molecule-13/NN	prep_between||relationship-9/NN||cd44-14/NNS	amod||antigen-18/NN||lewis-16/JJ	nn||antigen-18/NN||y-17/NN	prep_between||relationship-9/NN||antigen-18/NN	conj_and||cd44-14/NNS||antigen-18/NN	xcomp||aimed-3/VBN||determine-21/VB	conj_and||investigate-5/VB||determine-21/VB	det||effects-23/NNS||the-22/DT	dobj||determine-21/VB||effects-23/NNS	amod||antigen-27/NN||lewis-25/JJ	nn||antigen-27/NN||y-26/NN	prep_of||effects-23/NNS||antigen-27/NN	amod||adhesion-30/NN||cd44-mediated-29/JJ	prep_on||determine-21/VB||adhesion-30/NN	conj_and||aimed-3/VBN||spreading-32/VBG	amod||rmg-i-38/NNS||ovarian-34/JJ	nn||rmg-i-38/NNS||cancer-35/NN	nn||rmg-i-38/NNS||cell-36/NN	nn||rmg-i-38/NNS||line-37/NN	prep_of||spreading-32/VBG||rmg-i-38/NNS	det||rmg-i-h-46/NN||the-40/DT	amod||rmg-i-h-46/NN||lewis-41/JJ	amod||rmg-i-h-46/NN||y-42/JJ	amod||rmg-i-h-46/NN||antigen-overexpressed-43/JJ	nn||rmg-i-h-46/NN||cell-44/NN	nn||rmg-i-h-46/NN||line-45/NN	prep_of||spreading-32/VBG||rmg-i-h-46/NN	conj_and||rmg-i-38/NNS||rmg-i-h-46/NN	i---1||adhesion-30||no_rel||this study aimed to investigate the molecular structural relationship between cell adhesive molecule cd44 and lewis y antigen, and determine the effects of lewis y antigen on cd44-mediated adhesion and spreading of ovarian cancer cell line rmg-i and the lewis y antigen-overexpressed cell line rmg-i-h.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||develop-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||develop-8/VB||to-7/TO	xcomp||was-6/VBD||develop-8/VB	det||system-12/NN||a-9/DT	amod||system-12/NN||partial-10/JJ	amod||system-12/NN||closed-loop-11/JJ	dobj||develop-8/VB||system-12/NN	aux||prevent-15/VB||to-13/TO	advmod||prevent-15/VB||safely-14/RB	vmod||develop-8/VB||prevent-15/VB	amod||hypoglycemia-17/NN||nocturnal-16/JJ	dobj||prevent-15/VB||hypoglycemia-17/NN	prepc_by||prevent-15/VB||suspending-19/VBG	nn||delivery-21/NN||insulin-20/NN	dobj||suspending-19/VBG||delivery-21/NN	tmod||predicted-25/VBN||delivery-21/NN	advmod||predicted-25/VBN||when-22/WRB	nsubjpass||predicted-25/VBN||hypoglycemia-23/NN	auxpass||predicted-25/VBN||is-24/VBZ	rcmod||delivery-21/NN||predicted-25/VBN	prep_in||predicted-25/VBN||type1diabetes-27/CD	type1diabetes-27||insulin-20||yes||the aim of this study was to develop a partial closed-loop system to safely prevent nocturnal hypoglycemia by suspending insulin delivery when hypoglycemia is predicted in type1diabetes.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	amod||lidocaine-4/NN||adjunctive-3/JJ	nsubj||decreases-6/VBZ||lidocaine-4/NN	advmod||decreases-6/VBZ||significantly-5/RB	ccomp||found-2/VBD||decreases-6/VBZ	dobj||decreases-6/VBZ||pain-7/NN	prep_during||decreases-6/VBZ||injection-9/NN	prep_during||decreases-6/VBZ||postinjection-11/NN	conj_and||injection-9/NN||postinjection-11/NN	amod||satisfaction-16/NN||corresponding-13/JJ	amod||satisfaction-16/NN||increased-14/JJ	nn||satisfaction-16/NN||patient-15/NN	prep_with||decreases-6/VBZ||satisfaction-16/NN	pain-7||lidocaine-4||yes||we found adjunctive lidocaine significantly decreases pain during injection and postinjection with corresponding increased patient satisfaction.
det||reagent-5/NN||the-1/DT	amod||reagent-5/NN||investigational-2/JJ	nn||reagent-5/NN||skin-3/NN	nn||reagent-5/NN||test-4/NN	nsubj||appeared-9/VBD||reagent-5/NN	nsubjpass||tested-25/VBN||reagent-5/NN	amod||reagent-5/NN||rdesat-6-6/JJ	amod||reagent-5/NN||cfp-10-8/JJ	conj_and||rdesat-6-6/JJ||cfp-10-8/JJ	root||ROOT-0/null||appeared-9/VBD	acomp||appeared-9/VBD||safe-10/JJ	acomp||appeared-9/VBD||non-sensitising-12/JJ	conj_and||safe-10/JJ||non-sensitising-12/JJ	det||trial-17/NN||this-14/DT	amod||trial-17/NN||first-in-man-15/JJ	amod||trial-17/NN||clinical-16/JJ	prep_in||appeared-9/VBD||trial-17/NN	amod||volunteers-20/NNS||human-19/JJ	prep_in||trial-17/NN||volunteers-20/NNS	aux||tested-25/VBN||can-22/MD	advmod||tested-25/VBN||now-23/RB	auxpass||tested-25/VBN||be-24/VB	conj_and||appeared-9/VBD||tested-25/VBN	amod||trials-29/NNS||larger-27/JJR	amod||trials-29/NNS||clinical-28/JJ	prep_in||tested-25/VBN||trials-29/NNS	vmod||trials-29/NNS||involving-30/VBG	dobj||involving-30/VBG||individuals-31/NNS	nn||m.tuberculosisinfection-34/NN||latent-33/NN	prep_with||involving-30/VBG||m.tuberculosisinfection-34/NN	amod||disease-38/NN||active-36/JJ	nn||disease-38/NN||tb-37/NN	prep_with||involving-30/VBG||disease-38/NN	conj_or||m.tuberculosisinfection-34/NN||disease-38/NN	tb-37||m.tuberculosis--1||no||the investigational skin test reagent rdesat-6 and cfp-10 appeared safe and non-sensitising in this first-in-man clinical trial in human volunteers and can now be tested in larger clinical trials involving individuals with latent m.tuberculosisinfection or active tb disease .
prep_after||observed-17/VBD||adjustment-2/NN	nn||sex-6/NN||age-4/NN	prep_for||adjustment-2/NN||sex-6/NN	nn||circumference-10/NN||waist-9/NN	prep_for||adjustment-2/NN||circumference-10/NN	conj_and||sex-6/NN||circumference-10/NN	det||ors-14/NN||the-12/DT	amod||ors-14/NN||standardized-13/JJ	nsubj||observed-17/VBD||ors-14/NN	prep_for||ors-14/NN||incident-16/NN	root||ROOT-0/null||observed-17/VBD	nsubj||identical-20/JJ||apnea-18/NN	cop||identical-20/JJ||were-19/VBD	ccomp||observed-17/VBD||identical-20/JJ	prepc_for||identical-20/JJ||fasting-22/VBG	dobj||fasting-22/VBG||insulin-23/NN	det||assessment-28/NN||the-25/DT	amod||assessment-28/NN||homeostasis-26/JJ	nn||assessment-28/NN||model-27/NN	dobj||fasting-22/VBG||assessment-28/NN	conj_and||insulin-23/NN||assessment-28/NN	prep_of||assessment-28/NN||insulinresistance-30/NN	num||insulinresistance-30/NN||1.31-31/CD	npadvmod||â-34/RB||1.13-33/CD	dep||$-35/$||â-34/RB	dep||insulinresistance-30/NN||$-35/$	num||$-35/$||1.51-37/CD	prep_of||assessment-28/NN||1.24-40/CD	conj_and||insulinresistance-30/NN||1.24-40/CD	npadvmod||â-43/RB||1.09-42/CD	dep||$-44/$||â-43/RB	dep||insulinresistance-30/NN||$-44/$	num||$-44/$||1.41-46/CD	prep_for||fasting-22/VBG||triglycerides-49/CD	prep_for||fasting-22/VBG||1.52-51/CD	conj_and||triglycerides-49/CD||1.52-51/CD	dep||triglycerides-49/CD||1.12-53/CD	dep||triglycerides-49/CD||$-55/$	conj_â||1.12-53/CD||$-55/$	num||$-55/$||2.05-57/CD	prep_for||fasting-22/VBG||smoking-60/NN	insulin-23||apnea-18||no_rel||after adjustment for age, sex, and waist circumference, the standardized ors for incident observed apnea were identical for fasting insulin and the homeostasis model assessment of insulinresistance 1.31 (1.13â€“1.51) and 1.24 (1.09â€“1.41) for triglycerides and 1.52 (1.12â€“2.05) for smoking.
nsubjpass||documented-3/VBN||hbv-seropositivity-1/NN	auxpass||documented-3/VBN||was-2/VBD	dep||positive-17/JJ||documented-3/VBN	amod||participants-10/NNS||582-5/JJ	num||%-8/NN||29-7/CD	appos||participants-10/NNS||%-8/NN	prep_in||documented-3/VBN||participants-10/NNS	nsubj||positive-17/JJ||14-11/CD	num||%-14/NN||0.7-13/CD	appos||14-11/CD||%-14/NN	cop||positive-17/JJ||were-16/VBD	root||ROOT-0/null||positive-17/JJ	prep_for||positive-17/JJ||hbsag-19/NN	appos||hbsag-19/NN||452-21/NNP	num||%-24/NN||22.6-23/CD	appos||452-21/NNP||%-24/NN	prep_for||452-21/NNP||anti-hbc-27/CD	prep_for||452-21/NNP||116-29/CD	conj_and||anti-hbc-27/CD||116-29/CD	num||%-32/NN||5.8-31/CD	appos||anti-hbc-27/CD||%-32/NN	dep||hbsag-36/JJ||both-35/DT	prep_for||positive-17/JJ||hbsag-36/JJ	prep_for||positive-17/JJ||anti-hbc-38/JJ	conj_and||hbsag-36/JJ||anti-hbc-38/JJ	hbv--1||hbsag-36||yes||hbv-seropositivity was documented in 582 (29%) participants 14 (0.7%) were positive for hbsag, 452 (22.6%) for anti-hbc and 116 (5.8%) for both hbsag and anti-hbc.
nsubjpass||associated-4/VBN||fospropofol-1/NN	aux||associated-4/VBN||has-2/VBZ	auxpass||associated-4/VBN||been-3/VBN	root||ROOT-0/null||associated-4/VBN	amod||pain-7/NN||less-6/JJR	prep_with||associated-4/VBN||pain-7/NN	nn||site-10/NN||injection-9/NN	prep_at||pain-7/NN||site-10/NN	prep_than||associated-4/VBN||propofol-12/NN	pain-7||propofol-12||yes||fospropofol has been associated with less pain at injection site than propofol.
det||data-2/NNS||these-1/DT	nsubj||suggest-4/VBP||data-2/NNS	advmod||suggest-4/VBP||also-3/RB	root||ROOT-0/null||suggest-4/VBP	mark||useful-12/JJ||that-5/IN	det||use-7/NN||the-6/DT	nsubj||useful-12/JJ||use-7/NN	prep_of||use-7/NN||fluoxetine-9/NN	aux||useful-12/JJ||may-10/MD	cop||useful-12/JJ||be-11/VB	ccomp||suggest-4/VBP||useful-12/JJ	prepc_in||useful-12/JJ||increasing-14/VBG	amod||responses-16/NNS||epinephrine-15/JJ	dobj||increasing-14/VBG||responses-16/NNS	prep_during||increasing-14/VBG||hypoglycemia-18/NN	amod||practice-21/NN||clinical-20/JJ	prep_in||hypoglycemia-18/NN||practice-21/NN	hypoglycemia-18||epinephrine-15||no_rel||these data also suggest that the use of fluoxetine may be useful in increasing epinephrine responses during hypoglycemia in clinical practice.
nsubjpass||caused-7/VBN||osteogenesisimperfecta-1/NN	appos||osteogenesisimperfecta-1/NN||oi-3/NN	auxpass||caused-7/VBN||is-5/VBZ	advmod||caused-7/VBN||generally-6/RB	root||ROOT-0/null||caused-7/VBN	det||mutation-11/NN||a-9/DT	amod||mutation-11/NN||dominant-10/JJ	agent||caused-7/VBN||mutation-11/NN	nn||i-14/FW||collagen-13/FW	prep_in||mutation-11/NN||i-14/FW	vmod||mutation-11/NN||encoded-16/VBN	det||genes-19/NNS||the-18/DT	agent||encoded-16/VBN||genes-19/NNS	amod||mutation-11/NN||col1a1-20/JJ	amod||mutation-11/NN||col1a2-22/JJ	conj_and||col1a1-20/JJ||col1a2-22/JJ	collagen-13||osteogenesisimperfecta-1||no_rel||osteogenesisimperfecta (oi) is generally caused by a dominant mutation in collagen i, encoded by the genes col1a1 and col1a2 .
det||total-2/NN||a-1/DT	root||ROOT-0/null||total-2/NN	num||subjects-5/NNS||95-4/CD	prep_of||total-2/NN||subjects-5/NNS	prep_including||subjects-5/NNS||33-8/CD	amod||hypothyroidism-11/NN||subclinical-10/JJ	prep_with||33-8/CD||hypothyroidism-11/NN	det||hormone-16/NN||an-13/DT	amod||hormone-16/NN||elevated-14/JJ	amod||hormone-16/NN||thyroid-stimulating-15/JJ	dep||hypothyroidism-11/NN||hormone-16/NN	appos||hormone-16/NN||tsh-18/NN	dep||hormone-16/NN||level-20/NN	det||thyroxin-24/NN||a-22/DT	amod||thyroxin-24/NN||normal-23/JJ	dep||hypothyroidism-11/NN||thyroxin-24/NN	conj_and||hormone-16/NN||thyroxin-24/NN	appos||thyroxin-24/NN||ft4-26/NNP	dep||thyroxin-24/NN||level-28/NN	prep_with||33-8/CD||31-31/CD	conj_and||hypothyroidism-11/NN||31-31/CD	amod||hypothyroidism-34/NN||overt-33/JJ	prep_with||31-31/CD||hypothyroidism-34/NN	amod||tsh-37/NN||elevated-36/JJ	dep||hypothyroidism-34/NN||tsh-37/NN	nn||ft4-40/NN||decreased-39/NN	dep||hypothyroidism-34/NN||ft4-40/NN	conj_and||tsh-37/NN||ft4-40/NN	num||controls-46/NNS||31-44/CD	amod||controls-46/NNS||healthy-45/JJ	prep_with||33-8/CD||controls-46/NNS	conj_and||hypothyroidism-11/NN||controls-46/NNS	hypothyroidism-34||thyroxin-24||yes||a total of 95 subjects, including 33 with subclinical hypothyroidism (an elevated thyroid-stimulating hormone (tsh) level and a normal thyroxin (ft4) level), 31 with overt hypothyroidism (elevated tsh and decreased ft4), and 31 healthy controls.
advmod||show-3/VBP||here-1/RB	nsubj||show-3/VBP||we-2/PRP	root||ROOT-0/null||show-3/VBP	mark||senses-33/VBD||that-4/IN	nsubj||senses-33/VBD||aim2-5/NNS	dep||aim2-5/NNS||absent-7/JJ	prep_in||absent-7/JJ||melanoma-9/NNP	num||melanoma-9/NNP||2-10/CD	det||member-17/NN||an-13/DT	amod||member-17/NN||interferon-inducible-14/JJ	amod||member-17/NN||hin-200-15/JJ	nn||member-17/NN||family-16/NN	appos||aim2-5/NNS||member-17/NN	nsubj||contains-19/VBZ||member-17/NN	rcmod||member-17/NN||contains-19/VBZ	det||domain-23/NN||an-20/DT	amod||domain-23/NN||amino-terminal-21/JJ	nn||domain-23/NN||pyrin-22/NN	iobj||contains-19/VBZ||domain-23/NN	det||oligonucleotide/oligosaccharide-binding-27/NN||a-25/DT	amod||oligonucleotide/oligosaccharide-binding-27/NN||carboxy-terminal-26/JJ	iobj||contains-19/VBZ||oligonucleotide/oligosaccharide-binding-27/NN	conj_and||domain-23/NN||oligonucleotide/oligosaccharide-binding-27/NN	dobj||contains-19/VBZ||domain-28/NNP	num||domain-28/NNP||2-29/CD	num||domain-28/NNP||3-31/CD	ccomp||show-3/VBP||senses-33/VBD	amod||dna-35/NN||cytoplasmic-34/JJ	dobj||senses-33/VBD||dna-35/NN	poss||domain-41/NN||its-39/PRP$	amod||domain-41/NN||oligonucleotide/oligosaccharide-binding-40/JJ	prep_by_means_of||senses-33/VBD||domain-41/NN	prep_by_means_of||senses-33/VBD||interacts-43/NNS	conj_and||domain-41/NN||interacts-43/NNS	prep_with||senses-33/VBD||asc-45/NN	amod||protein-49/NN||apoptosis-associated-47/JJ	amod||protein-49/NN||speck-like-48/JJ	nsubj||containing-50/VBG||protein-49/NN	parataxis||senses-33/VBD||containing-50/VBG	det||card-52/NN||a-51/DT	dobj||containing-50/VBG||card-52/NN	poss||domain-57/NN||its-55/PRP$	amod||domain-57/NN||pyrin-56/JJ	prep_through||senses-33/VBD||domain-57/NN	aux||activate-59/VB||to-58/TO	vmod||domain-57/NN||activate-59/VB	acomp||activate-59/VB||caspase-1-60/JJ	melanoma-9||interferon--1||yes||here we show that aim2 (absent in melanoma 2), an interferon-inducible hin-200 family member that contains an amino-terminal pyrin domain and a carboxy-terminal oligonucleotide/oligosaccharide-binding domain 2 , 3 , senses cytoplasmic dna by means of its oligonucleotide/oligosaccharide-binding domain and interacts with asc (apoptosis-associated speck-like protein containing a card) through its pyrin domain to activate caspase-1.
advmod||seen-15/VBN||irondeficiency-1/RB	nn||depletion-8/NN||anemia-3/NN	conj_and||depletion-8/NN||irondeficiencyanemia-5/NN	nsubjpass||seen-15/VBN||irondeficiencyanemia-5/NN	conj_and||depletion-8/NN||iron-7/NN	nsubjpass||seen-15/VBN||iron-7/NN	nsubjpass||seen-15/VBN||depletion-8/NN	conj_and||depletion-8/NN||lack-10/NN	nsubjpass||seen-15/VBN||lack-10/NN	nn||resources-13/NNS||iron-12/NN	prep_of||depletion-8/NN||resources-13/NNS	auxpass||seen-15/VBN||were-14/VBD	root||ROOT-0/null||seen-15/VBN	prep_in||seen-15/VBN||2.3-17/CD	prep_in||seen-15/VBN||4.08-19/CD	conj_and||2.3-17/CD||4.08-19/CD	prep_in||seen-15/VBN||2.14-21/CD	conj_and||2.3-17/CD||2.14-21/CD	prep_in||seen-15/VBN||22.76-23/NNP	conj_and||2.3-17/CD||22.76-23/NNP	amod||percent-26/NN||4.66-25/JJ	prep_in||seen-15/VBN||percent-26/NN	conj_and||2.3-17/CD||percent-26/NN	advmod||seen-15/VBN||respectively-27/RB	irondeficiencyanemia-5||iron-12||yes||irondeficiency, anemia, irondeficiencyanemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
det||paper-2/NN||this-1/DT	nsubj||describes-3/VBZ||paper-2/NN	root||ROOT-0/null||describes-3/VBZ	det||findings-6/NNS||the-4/DT	amod||findings-6/NNS||main-5/JJ	dobj||describes-3/VBZ||findings-6/NNS	det||exercises-10/NNS||the-8/DT	num||exercises-10/NNS||two-9/CD	prep_from||describes-3/VBZ||exercises-10/NNS	prep_in||exercises-10/NNS||relation-12/NN	aux||contraception-14/VB||to-13/TO	vmod||describes-3/VBZ||contraception-14/VB	prep_for||contraception-14/VB||women-16/NNS	vmod||women-16/NNS||living-17/VBG	prep_with||living-17/VBG||hiv-19/NN	prep_with||living-17/VBG||aids-21/NNS	conj_or||hiv-19/NN||aids-21/NNS	amod||care-24/NN||abortion-related-23/JJ	prep_for||contraception-14/VB||care-24/NN	conj_and||women-16/NNS||care-24/NN	amod||adoption-27/NN||legal-26/JJ	prep_for||contraception-14/VB||adoption-27/NN	conj_and||women-16/NNS||adoption-27/NN	amod||parents-30/NNS||hiv-positive-29/JJ	prep_by||adoption-27/NN||parents-30/NNS	amod||rights-34/NNS||reproductive-33/JJ	prep_for||contraception-14/VB||rights-34/NNS	conj_and||women-16/NNS||rights-34/NNS	aids-21||hiv-19||no||this paper describes the main findings from the two exercises in relation to contraception for women living with hiv or aids, abortion-related care, legal adoption by hiv-positive parents, and reproductive rights.
nsubj||heard-5/VBN||those-2/DT	prep_of||reported-16/VBD||those-2/DT	aux||heard-5/VBN||had-4/VBD	rcmod||those-2/DT||heard-5/VBN	prep_about||heard-5/VBN||hiv/aids-7/NNS	quantmod||36-10/CD||only-9/RB	num||%-13/NN||36-10/CD	num||%-13/NN||72-12/CD	nsubj||reported-16/VBD||%-13/NN	advmod||reported-16/VBD||correctly-15/RB	root||ROOT-0/null||reported-16/VBD	mark||spread-22/VBN||that-17/IN	det||virus-19/NN||the-18/DT	nsubjpass||spread-22/VBN||virus-19/NN	aux||spread-22/VBN||could-20/MD	auxpass||spread-22/VBN||be-21/VB	ccomp||reported-16/VBD||spread-22/VBN	prep_from||spread-22/VBN||mother-24/NN	prep_to||spread-22/VBN||child-26/NN	nsubj||identified-33/VBD||37-28/CD	num||%-31/NN||74-30/CD	appos||37-28/CD||%-31/NN	conj_and||reported-16/VBD||identified-33/VBD	amod||sex-35/NN||unprotected-34/JJ	dobj||identified-33/VBD||sex-35/NN	det||mode-38/NN||a-37/DT	prep_as||identified-33/VBD||mode-38/NN	prep_of||mode-38/NN||transmission-40/NN	nsubj||said-49/VBD||26-43/CD	num||%-46/NN||51-45/CD	appos||26-43/CD||%-46/NN	advmod||said-49/VBD||correctly-48/RB	conj_and||reported-16/VBD||said-49/VBD	acomp||said-49/VBD||healthy-50/JJ	dep||healthy-50/JJ||looking-51/VBG	nsubj||spread-54/VB||people-52/NNS	aux||spread-54/VB||could-53/MD	ccomp||looking-51/VBG||spread-54/VB	dobj||spread-54/VB||hiv-55/NN	aids--1||hiv-55||no||of those who had heard about hiv/aids, only 36 (72%) correctly reported that the virus could be spread from mother to child; 37 (74%) identified unprotected sex as a mode of transmission; and 26 (51%) correctly said healthy looking people could spread hiv.
det||proportions-2/NNS||the-1/DT	nsubj||%-8/NN||proportions-2/NNS	amod||resistance-5/NN||mono-drug-4/JJ	prep_of||proportions-2/NNS||resistance-5/NN	cop||%-8/NN||were-6/VBD	num||%-8/NN||28.73-7/CD	root||ROOT-0/null||%-8/NN	prep_for||%-8/NN||isoniazid-10/NN	num||%-13/NN||19.41-12/CD	conj_and||%-8/NN||%-13/NN	prep_for||%-13/NN||rifampicin-15/NN	num||%-18/NN||29.33-17/CD	conj_and||%-8/NN||%-18/NN	prep_for||%-18/NN||streptomycin-20/NN	num||%-24/NN||13.98-23/CD	conj_and||%-8/NN||%-24/NN	prep_for||%-24/NN||ethambutol-26/NN	advmod||%-8/NN||respectively-28/RB	mono--1||isoniazid-10||no_rel||the proportions of mono-drug resistance were 28.73% for isoniazid, 19.41% for rifampicin, 29.33% for streptomycin, and 13.98% for ethambutol, respectively.
nsubj||likely-16/JJ||patients-1/NNS	nsubj||have-18/VB||patients-1/NNS	amod||obstructivepulmonarydisease-4/NN||chronic-3/JJ	prep_with||patients-1/NNS||obstructivepulmonarydisease-4/NN	nsubj||received-6/VBD||obstructivepulmonarydisease-4/NN	rcmod||obstructivepulmonarydisease-4/NN||received-6/VBD	amod||oxygen-8/NN||titrated-7/JJ	dobj||received-6/VBD||oxygen-8/NN	prepc_according_to||received-6/VBD||to-10/TO	det||protocol-12/NN||the-11/DT	pobj||received-6/VBD||protocol-12/NN	cop||likely-16/JJ||were-13/VBD	advmod||likely-16/JJ||significantly-14/RB	advmod||likely-16/JJ||less-15/RBR	root||ROOT-0/null||likely-16/JJ	aux||have-18/VB||to-17/TO	xcomp||likely-16/JJ||have-18/VB	dobj||have-18/VB||respiratoryacidosis-19/NNS	dep||respiratoryacidosis-19/NNS||mean-21/VB	nsubj||n-35/VBP||difference-22/NN	number||0.12-25/CD||ph-24/CD	prep_in||difference-22/NN||0.12-25/CD	appos||0.12-25/CD||se-27/NNP	num||se-27/NNP||0.05-28/CD	vmod||difference-22/NN||p-31/VBN	dep||0.01-33/CD||=-32/SYM	ccomp||p-31/VBN||0.01-33/CD	ccomp||mean-21/VB||n-35/VBP	dep||28-37/CD||=-36/SYM	ccomp||n-35/VBP||28-37/CD	dobj||have-18/VB||hypercapnia-40/NN	conj_or||respiratoryacidosis-19/NNS||hypercapnia-40/NN	amod||difference-43/NN||mean-42/JJ	dep||hypercapnia-40/NN||difference-43/NN	amod||pressure-47/NN||arterial-45/JJ	nn||pressure-47/NN||carbondioxide-46/NN	prep_in||difference-43/NN||pressure-47/NN	poss||hg-55/NN||âˆ-48/NNP	nn||hg-55/NN||33.6-50/NNP	appos||hg-55/NN||16.3-52/CD	nn||hg-55/NN||mm-54/NN	dep||pressure-47/NN||hg-55/NN	dep||pressure-47/NN||p-57/NN	dep||0.02-59/CD||=-58/SYM	rcmod||p-57/NN||0.02-59/CD	vmod||difference-43/NN||n-61/VBN	dep||29-63/CD||=-62/SYM	ccomp||n-61/VBN||29-63/CD	mark||patients-67/NNS||than-65/IN	cop||patients-67/NNS||were-66/VBD	advcl||likely-16/JJ||patients-67/NNS	nsubj||received-69/VBD||patients-67/NNS	rcmod||patients-67/NNS||received-69/VBD	amod||oxygen-72/NN||high-70/JJ	nn||oxygen-72/NN||flow-71/NN	dobj||received-69/VBD||oxygen-72/NN	obstructivepulmonarydisease-4||oxygen-72||yes||patients with chronic obstructivepulmonarydisease who received titrated oxygen according to the protocol were significantly less likely to have respiratoryacidosis (mean difference in ph 0.12 (se 0.05); p=0.01; n=28) or hypercapnia (mean difference in arterial carbondioxide pressure âˆ’33.6 (16.3) mm hg; p=0.02; n=29) than were patients who received high flow oxygen.
nsubj||drug-7/NN||ondansetronhydrochloride-1/NN	cop||drug-7/NN||is-2/VBZ	det||drug-7/NN||an-3/DT	advmod||bitter-5/JJ||intensely-4/RB	amod||drug-7/NN||bitter-5/JJ	amod||drug-7/NN||antiemetic-6/JJ	root||ROOT-0/null||drug-7/NN	vmod||drug-7/NN||used-8/VBN	aux||treat-10/VB||to-9/TO	xcomp||used-8/VBN||treat-10/VB	dobj||treat-10/VB||nausea-11/NN	dobj||treat-10/VB||vomiting-13/NN	conj_and||nausea-11/NN||vomiting-13/NN	prep_following||nausea-11/NN||chemotherapy-15/NN	nausea-11||ondansetronhydrochloride-1||yes||ondansetronhydrochloride is an intensely bitter antiemetic drug used to treat nausea and vomiting following chemotherapy.
nsubj||combined-25/VBD||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||costs-6/NNS||the-4/DT	nn||costs-6/NNS||treatment-5/NN	dobj||compare-3/VB||costs-6/NNS	prep_of||costs-6/NNS||insulinglargine-8/NN	dep||insulinglargine-8/NN||ig-10/NN	nn||®-13/NNP||lantusâ-12/NNP	dep||ig-10/NN||®-13/NNP	aux||detemir-16/VB||to-15/TO	vmod||insulinglargine-8/NN||detemir-16/VB	dep||combined-25/VBD||id-18/NN	nn||®-21/NNP||levemirâ-20/NNP	dep||id-18/NN||®-21/NNP	nsubj||combined-25/VBD||both-24/DT	root||ROOT-0/null||combined-25/VBD	amod||insulinaspart-28/NN||bolus-27/JJ	prep_with||combined-25/VBD||insulinaspart-28/NN	nn||®-31/NNP||novorapidâ-30/NNP	appos||insulinaspart-28/NN||®-31/NNP	amod||t2d-36/NNS||type2diabetes-34/JJ	prep_in||combined-25/VBD||t2d-36/NNS	prep_in||t2d-36/NNS||germany-39/NN	type2diabetes-34||insulinaspart-28||yes||objective to compare the treatment costs of insulinglargine (ig; lantusâ®) to detemir (id; levemirâ®), both combined with bolus insulinaspart (novorapidâ®) in type2diabetes (t2d) in germany.
nn||design-2/NN||research-1/NN	nsubjpass||compared-47/VBN||design-2/NN	nsubj||detect-49/VB||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubjpass||compared-47/VBN||methods-4/NNS	nsubj||detect-49/VB||methods-4/NNS	nn||$-7/NNP||resultsâ-6/NNP	conj_and||design-2/NN||$-7/NNP	nsubjpass||compared-47/VBN||$-7/NNP	nsubj||detect-49/VB||$-7/NNP	conj_and||design-2/NN||measures-9/NNS	nsubjpass||compared-47/VBN||measures-9/NNS	nsubj||detect-49/VB||measures-9/NNS	amod||risk-12/NN||cardiovascular-11/JJ	prep_of||measures-9/NNS||risk-12/NN	nn||composition-15/NN||body-14/NN	conj_and||design-2/NN||composition-15/NN	nsubjpass||compared-47/VBN||composition-15/NN	nsubj||detect-49/VB||composition-15/NN	nn||hormones-19/NNS||serum-18/NN	conj_and||design-2/NN||hormones-19/NNS	nsubjpass||compared-47/VBN||hormones-19/NNS	nsubj||detect-49/VB||hormones-19/NNS	det||examinations-23/NNS||the-21/DT	amod||examinations-23/NNS||baseline-22/JJ	prep_from||hormones-19/NNS||examinations-23/NNS	det||study-28/NN||the-25/DT	amod||study-28/NN||insulinresistance-26/JJ	nn||study-28/NN||atherosclerosis-27/NNS	prep_of||examinations-23/NNS||study-28/NN	num||women-32/NNS||524-30/CD	amod||women-32/NNS||nondiabetic-31/JJ	prep_on||study-28/NN||women-32/NNS	amod||women-36/NNS||258-34/JJ	amod||women-36/NNS||diabetic-35/JJ	prep_on||study-28/NN||women-36/NNS	conj_and||women-32/NNS||women-36/NNS	num||men-40/NNS||421-38/CD	amod||men-40/NNS||nondiabetic-39/JJ	prep_on||study-28/NN||men-40/NNS	conj_and||women-32/NNS||men-40/NNS	num||men-45/NNS||220-43/CD	amod||men-45/NNS||diabetic-44/JJ	prep_on||study-28/NN||men-45/NNS	conj_and||women-32/NNS||men-45/NNS	auxpass||compared-47/VBN||were-46/VBD	root||ROOT-0/null||compared-47/VBN	aux||detect-49/VB||to-48/TO	xcomp||compared-47/VBN||detect-49/VB	amod||differences-52/NNS||greater-50/JJR	amod||differences-52/NNS||adverse-51/JJ	dobj||detect-49/VB||differences-52/NNS	prep_in||detect-49/VB||women-54/NNS	prep||detect-49/VB||than-55/IN	pcomp||than-55/IN||in-56/IN	pobj||in-56/IN||men-57/NNS	hormones-19||insulinresistance-26||no_rel||research design and methods and resultsâ€” measures of cardiovascular risk, body composition, and serum hormones from the baseline examinations of the insulinresistance atherosclerosis study on 524 nondiabetic women, 258 diabetic women, 421 nondiabetic men, and 220 diabetic men were compared to detect greater adverse differences in women than in men.
nsubj||compromises-2/VBZ||hyperglycemia-1/NN	nsubj||favors-7/VBZ||hyperglycemia-1/NN	root||ROOT-0/null||compromises-2/VBZ	det||response-5/NN||the-3/DT	amod||response-5/NN||immune-4/JJ	dobj||compromises-2/VBZ||response-5/NN	conj_and||compromises-2/VBZ||favors-7/VBZ	dobj||favors-7/VBZ||bacterialinfections-8/NNS	advmod||conflicting-25/JJ||however-10/RB	nsubj||conflicting-25/JJ||reports-12/NNS	nsubj||rare-29/JJ||reports-12/NNS	det||effects-15/NNS||the-14/DT	prep_on||reports-12/NNS||effects-15/NNS	prep_of||effects-15/NNS||glucose-17/NN	amod||metabolism-21/NN||neutrophil-19/JJ	nn||metabolism-21/NN||oxidative-20/NN	prep_on||glucose-17/NN||metabolism-21/NN	prep_on||glucose-17/NN||apoptosis-23/NNS	conj_and||metabolism-21/NN||apoptosis-23/NNS	cop||conflicting-25/JJ||are-24/VBP	parataxis||compromises-2/VBZ||conflicting-25/JJ	prep_in||conflicting-25/JJ||humans-27/NNS	parataxis||compromises-2/VBZ||rare-29/JJ	conj_and||conflicting-25/JJ||rare-29/JJ	prep_in||rare-29/JJ||dogs-31/NNS	hyperglycemia-1||glucose-17||no||hyperglycemia compromises the immune response and favors bacterialinfections; however, reports on the effects of glucose on neutrophil oxidative metabolism and apoptosis are conflicting in humans and rare in dogs.
nsubj||demonstrated-3/VBD||we-1/PRP	advmod||demonstrated-3/VBD||recently-2/RB	root||ROOT-0/null||demonstrated-3/VBD	mark||have-7/VBP||that-4/IN	amod||strains-6/NNS||s-5/JJ	nsubj||have-7/VBP||strains-6/NNS	ccomp||demonstrated-3/VBD||have-7/VBP	amod||systems-11/NNS||defective-8/JJ	nn||systems-11/NNS||iron-9/NN	nn||systems-11/NNS||storage-10/NN	dobj||have-7/VBP||systems-11/NNS	vmod||have-7/VBP||leading-13/VBG	dobj||leading-13/VBG||us-14/PRP	nsubj||propose-16/VB||us-14/PRP	aux||propose-16/VB||to-15/TO	xcomp||leading-13/VBG||propose-16/VB	mark||experience-21/VB||that-17/IN	det||strains-19/NNS||these-18/DT	nsubj||experience-21/VB||strains-19/NNS	aux||experience-21/VB||might-20/MD	ccomp||propose-16/VB||experience-21/VB	nn||toxicity-23/NN||iron-22/NN	dobj||experience-21/VB||toxicity-23/NN	advmod||provided-27/VBN||when-24/WRB	nsubjpass||provided-27/VBN||excessiron-25/NN	auxpass||provided-27/VBN||is-26/VBZ	advcl||experience-21/VB||provided-27/VBN	det||medium-30/NN||the-29/DT	prep_in||provided-27/VBN||medium-30/NN	excessiron-25||iron-22||no||we recently demonstrated that s strains have defective iron storage systems, leading us to propose that these strains might experience iron toxicity when excessiron is provided in the medium.
det||trial-6/NN||a-1/DT	num||trial-6/NN||72-2/CD	nn||trial-6/NN||week-3/NN	amod||trial-6/NN||non-inferiority-5/JJ	nsubj||enrolled-7/VBD||trial-6/NN	root||ROOT-0/null||enrolled-7/VBD	num||persons-13/NNS||one-8/CD	num||persons-13/NNS||hundred-9/CD	amod||persons-13/NNS||forty-10/JJ	num||persons-13/NNS||six-11/CD	nn||persons-13/NNS||hivpositive-12/NN	dobj||enrolled-7/VBD||persons-13/NNS	xcomp||enrolled-7/VBD||receiving-14/VBG	dobj||receiving-14/VBG||art-15/NN	amod||cells/mm3-25/JJ||cd4-17/JJ	amod||cells/mm3-25/JJ||+-18/JJ	npadvmod||cells/mm3-25/JJ||cell-19/NN	npadvmod||cells/mm3-25/JJ||count-20/NN	npadvmod||cells/mm3-25/JJ||â-21/NN	amod||cells/mm3-25/JJ||‰-22/NNP	amod||cells/mm3-25/JJ||¥-23/NNP	number||cells/mm3-25/JJ||125-24/CD	npadvmod||copies/ml-33/JJ||cells/mm3-25/JJ	nn||levels-30/NNS||hiv-27/NN	nn||levels-30/NNS||rna-28/NN	nn||levels-30/NNS||plasma-29/NN	conj_and||cells/mm3-25/JJ||levels-30/NNS	npadvmod||copies/ml-33/JJ||levels-30/NNS	number||50-32/CD||<-31/CD	num||cells/mm3-25/JJ||50-32/CD	dep||art-15/NN||copies/ml-33/JJ	prep_in||art-15/NN||one-36/CD	num||arms-39/NNS||three-38/CD	npadvmod||continuous-40/JJ||arms-39/NNS	dep||days-51/NNS||continuous-40/JJ	num||days-43/NNS||7-42/CD	dep||continuous-40/JJ||days-43/NNS	num||days-45/NNS||on/7-44/CD	tmod||days-43/NNS||days-45/NNS	prep||continuous-40/JJ||off-46/RP	num||days-49/NNS||5-48/CD	conj_and||continuous-40/JJ||days-49/NNS	dep||days-51/NNS||days-49/NNS	amod||days-51/NNS||on/2-50/JJ	prep_of||one-36/CD||days-51/NNS	prep_off||receiving-14/VBG||treatment-53/NN	hivpositive-12||hiv-27||no||a 72 week, non-inferiority trial enrolled one hundred forty six hivpositive persons receiving art (cd4+ cell count â‰¥125 cells/mm3 and hiv rna plasma levels <50 copies/ml) in one of three arms continuous, 7 days on/7 days off and 5 days on/2 days off treatment.
amod||isoform-3/NN||aldehyde-1/JJ	amod||isoform-3/NN||dehydrogenase-2/JJ	nsubjpass||proved-10/VBN||isoform-3/NN	num||isoform-3/NN||1-4/CD	appos||isoform-3/NN||aldh1-6/NNP	aux||proved-10/VBN||has-8/VBZ	auxpass||proved-10/VBN||been-9/VBN	root||ROOT-0/null||proved-10/VBN	acomp||proved-10/VBN||useful-11/JJ	det||identification-14/NN||the-13/DT	prep_for||proved-10/VBN||identification-14/NN	nn||cells-18/NNS||cancer-16/NN	nn||cells-18/NNS||stem-17/NN	prep_of||identification-14/NN||cells-18/NNS	cancer-16||aldehyde-1||no_rel||aldehyde dehydrogenase isoform 1 (aldh1) has been proved useful for the identification of cancer stem cells.
det||beginning-3/NN||the-2/DT	prep_since||provided-16/VBN||beginning-3/NN	det||century-7/NN||the-5/DT	amod||century-7/NN||21st-6/JJ	prep_of||beginning-3/NN||century-7/NN	nn||assistance-10/NN||development-9/NN	nsubjpass||provided-16/VBN||assistance-10/NN	prep_for||assistance-10/NN||hiv/aids-12/NNS	aux||provided-16/VBN||has-13/VBZ	advmod||provided-16/VBN||increasingly-14/RB	auxpass||provided-16/VBN||been-15/VBN	root||ROOT-0/null||provided-16/VBN	amod||initiatives-20/NNS||global-18/JJ	nn||initiatives-20/NNS||health-19/NN	prep_through||provided-16/VBN||initiatives-20/NNS	advmod||plan-28/VBP||specifically-22/RB	det||emergency-27/NN||the-23/DT	amod||emergency-27/NN||united-24/VBN	nn||emergency-27/NN||states-25/NNS	amod||emergency-27/NN||presidential-26/JJ	nsubj||plan-28/VBP||emergency-27/NN	nsubj||fight-37/VB||emergency-27/NN	parataxis||provided-16/VBN||plan-28/VBP	nn||relief-31/NN||aids-30/NNS	prep_for||plan-28/VBP||relief-31/NN	det||fund-35/NN||the-33/DT	amod||fund-35/NN||global-34/JJ	appos||relief-31/NN||fund-35/NN	aux||fight-37/VB||to-36/TO	xcomp||plan-28/VBP||fight-37/VB	dobj||fight-37/VB||hiv-38/NN	dobj||fight-37/VB||tb-40/NN	conj_and||hiv-38/NN||tb-40/NN	dobj||fight-37/VB||malaria-42/NN	conj_and||hiv-38/NN||malaria-42/NN	det||multi-country-47/NN||the-44/DT	nn||multi-country-47/NN||world-45/NN	nn||multi-country-47/NN||bank-46/NN	nsubj||aids-48/VBZ||multi-country-47/NN	conj_and||provided-16/VBN||aids-48/VBZ	dobj||aids-48/VBZ||programme-49/NN	aids-48||hiv-38||no||since the beginning of the 21st century, development assistance for hiv/aids has increasingly been provided through global health initiatives, specifically the united states presidential emergency plan for aids relief, the global fund to fight hiv, tb and malaria and the world bank multi-country aids programme.
nsubj||are-2/VBP||implications-1/NNS	root||ROOT-0/null||are-2/VBP	mark||underlie-10/VB||that-3/IN	amod||variability-5/NN||genetic-4/JJ	nsubj||underlie-10/VB||variability-5/NN	det||system-8/NN||this-7/DT	prep_in||variability-5/NN||system-8/NN	aux||underlie-10/VB||may-9/MD	ccomp||are-2/VBP||underlie-10/VB	amod||differences-12/NNS||individual-11/JJ	dobj||underlie-10/VB||differences-12/NNS	prep_in||underlie-10/VB||anxiety-14/NN	xcomp||are-2/VBP||rendering-16/VBG	amod||receptor-18/NN||cannabinoid-17/JJ	dobj||rendering-16/VBG||receptor-18/NN	prep||rendering-16/VBG||1-19/CD	det||target-22/NN||a-20/DT	amod||target-22/NN||potential-21/JJ	dep||1-19/CD||target-22/NN	amod||treatments-26/NNS||novel-24/JJ	amod||treatments-26/NNS||pharmacological-25/JJ	prep_for||target-22/NN||treatments-26/NNS	prep_of||treatments-26/NNS||anxietydisorders-28/NNS	cannabinoid-17||anxietydisorders-28||no_rel||implications are that genetic variability in this system may underlie individual differences in anxiety, rendering cannabinoid receptor 1 a potential target for novel pharmacological treatments of anxietydisorders.
det||study-3/NN||this-2/DT	prep_in||determined-6/VBD||study-3/NN	nsubj||determined-6/VBD||we-5/PRP	nsubj||assessed-36/VBD||we-5/PRP	root||ROOT-0/null||determined-6/VBD	det||percentage-8/NN||the-7/DT	nsubj||isolates-19/VBZ||percentage-8/NN	prep_of||percentage-8/NN||strains-10/NNS	vmod||strains-10/NNS||possessing-11/VBG	amod||resistance-13/NN||pyrazinamide-12/JJ	dobj||possessing-11/VBG||resistance-13/NN	amod||m.tuberculosis-16/NNS||pan-susceptible-15/JJ	prep_among||possessing-11/VBG||m.tuberculosis-16/NNS	prep_among||possessing-11/VBG||mdr-tb-18/NN	conj_and||m.tuberculosis-16/NNS||mdr-tb-18/NN	ccomp||determined-6/VBD||isolates-19/VBZ	prepc_by||isolates-19/VBZ||using-21/VBG	det||method-30/NN||the-22/DT	amod||method-30/NN||pyrazinamidase-23/JJ	amod||method-30/NN||assay-24/JJ	amod||method-30/NN||bactec-26/JJ	nn||method-30/NN||mgit-27/NN	num||method-30/NN||960-28/CD	nn||method-30/NN||pza-29/NNP	dobj||using-21/VBG||method-30/NN	nn||sequencing-33/NN||pnca-32/NN	dobj||using-21/VBG||sequencing-33/NN	conj_and||method-30/NN||sequencing-33/NN	conj_and||determined-6/VBD||assessed-36/VBD	det||correlation-38/NN||the-37/DT	dobj||assessed-36/VBD||correlation-38/NN	det||data-41/NNS||the-40/DT	prep_in||assessed-36/VBD||data-41/NNS	vmod||data-41/NNS||generated-42/VBN	xcomp||generated-42/VBN||using-43/VBG	det||methods-45/NNS||these-44/DT	dobj||using-43/VBG||methods-45/NNS	tb--1||pyrazinamide-12||yes||in this study , we determined the percentage of strains possessing pyrazinamide resistance among pan-susceptible m.tuberculosis and mdr-tb isolates by using the pyrazinamidase assay , bactec mgit 960 pza method and pnca sequencing , and assessed the correlation in the data generated using these methods .
nn||bovis-2/NNS||m.-1/NN	nsubj||bacille-3/VBP||bovis-2/NNS	root||ROOT-0/null||bacille-3/VBP	nn||-rrb--9/NNP||calmette-guã-4/NNP	nn||-rrb--9/NNP||©-5/NNP	nn||-rrb--9/NNP||rin-6/NNP	nn||-rrb--9/NNP||-lrb--7/NNP	nn||-rrb--9/NNP||bcg-8/NNP	nsubj||fails-22/VBZ||-rrb--9/NNP	nsubj||protect-25/VB||-rrb--9/NNP	advmod||vaccine-15/NN||currently-11/RB	det||vaccine-15/NN||the-12/DT	advmod||available-14/JJ||only-13/RB	amod||vaccine-15/NN||available-14/JJ	appos||-rrb--9/NNP||vaccine-15/NN	nn||-rrb--20/NNP||tuberculosis-17/NNP	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||tb-19/NNP	prep_against||vaccine-15/NN||-rrb--20/NNP	ccomp||bacille-3/VBP||fails-22/VBZ	aux||protect-25/VB||to-23/TO	advmod||protect-25/VB||adequately-24/RB	xcomp||fails-22/VBZ||protect-25/VB	dobj||protect-25/VB||individuals-26/NNS	amod||infection-32/NN||active-28/JJ	conj_and||active-28/JJ||latent-30/JJ	amod||infection-32/NN||latent-30/JJ	nn||infection-32/NN||tb-31/NN	prep_from||protect-25/VB||infection-32/NN	tb-31||bcg-8||yes||m. bovis bacille calmette-guã © rin -lrb- bcg -rrb- , currently the only available vaccine against tuberculosis -lrb- tb -rrb- , fails to adequately protect individuals from active and latent tb infection .
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||budesonide-23||no||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
prep_in||mandated-8/VBD||2006-2/CD	det||agency-7/NN||the-4/DT	nn||agency-7/NN||norwegian-5/NN	nn||agency-7/NN||medicines-6/NNS	nsubj||mandated-8/VBD||agency-7/NN	root||ROOT-0/null||mandated-8/VBD	det||switch-10/NN||a-9/DT	dobj||mandated-8/VBD||switch-10/NN	prep_from||mandated-8/VBD||desloratadine-12/NN	prep_from||mandated-8/VBD||ebastine-14/NN	conj_or||desloratadine-12/NN||ebastine-14/NN	prep_from||mandated-8/VBD||fexofenadine-17/NN	conj_or||desloratadine-12/NN||fexofenadine-17/NN	prep_to||desloratadine-12/NN||cetirizine-19/NN	prep_to||desloratadine-12/NN||loratadine-21/NN	conj_or||cetirizine-19/NN||loratadine-21/NN	prep_in||mandated-8/VBD||patients-23/NNS	amod||rhinitis-26/NNS||allergic-25/JJ	prep_with||patients-23/NNS||rhinitis-26/NNS	appos||rhinitis-26/NNS||ar-28/NN	amod||urticaria-32/NN||chronic-31/JJ	prep_with||patients-23/NNS||urticaria-32/NN	conj_or||rhinitis-26/NNS||urticaria-32/NN	appos||rhinitis-26/NNS||cu-34/NN	urticaria-32||desloratadine-12||yes||in 2006, the norwegian medicines agency mandated a switch from desloratadine, ebastine, or fexofenadine to cetirizine or loratadine in patients with allergic rhinitis (ar) or chronic urticaria (cu).
nn||subcutaneous-2/NNS||immuneglobulin-1/NN	nsubj||high-concentration-8/NN||subcutaneous-2/NNS	number||%-4/NN||20-3/CD	amod||subcutaneous-2/NNS||%-4/NN	cop||high-concentration-8/NN||is-5/VBZ	det||high-concentration-8/NN||a-6/DT	amod||high-concentration-8/NN||new-7/JJ	root||ROOT-0/null||high-concentration-8/NN	number||g/l-11/CD||200-10/CD	dep||high-concentration-8/NN||g/l-11/CD	nsubj||indicated-26/VBD||solution-13/NN	advmod||purified-16/JJ||highly-15/RB	amod||igg-18/NN||purified-16/JJ	amod||igg-18/NN||human-17/JJ	prep_of||solution-13/NN||igg-18/NN	nn||¥-22/NNP||â-20/NNP	nn||¥-22/NNP||‰-21/NNP	dep||igg-18/NN||¥-22/NNP	num||%-24/NN||98-23/CD	dep||¥-22/NNP||%-24/NN	rcmod||high-concentration-8/NN||indicated-26/VBD	det||eu-29/NN||the-28/DT	prep_in||indicated-26/VBD||eu-29/NN	det||us-32/PRP||the-31/DT	prep_in||indicated-26/VBD||us-32/PRP	conj_and||eu-29/NN||us-32/PRP	nn||therapy-36/NN||antibody-34/NN	nn||therapy-36/NN||replacement-35/NN	prep_for||indicated-26/VBD||therapy-36/NN	prep_in||therapy-36/NN||patients-38/NNS	prep_in||therapy-36/NN||patients-38/NNS	conj_and||patients-38/NNS||patients-38/NNS	amod||immunodeficiency-41/NN||primary-40/JJ	prep_with||patients-38/NNS||immunodeficiency-41/NN	nn||deficiency-44/NN||antibody-43/NN	prep_with||immunodeficiency-41/NN||deficiency-44/NN	det||eu-49/NN||the-48/DT	prep_in||patients-38/NNS||eu-49/NN	nn||therapy-52/NN||replacement-51/NN	prep_for||eu-49/NN||therapy-52/NN	amod||immunodeficiency-55/NN||humoral-54/JJ	prep_in||therapy-52/NN||immunodeficiency-55/NN	amod||immunodeficiency-55/NN||secondary-56/JJ	prep_to||indicated-26/VBD||myeloma-58/NN	prep_to||indicated-26/VBD||chroniclymphocyticleukaemia-60/NN	conj_or||myeloma-58/NN||chroniclymphocyticleukaemia-60/NN	immunodeficiency-55||immuneglobulin-1||yes||immuneglobulin subcutaneous 20% is a new high-concentration (200 g/l) solution of highly purified human igg (â‰¥98%) indicated in the eu and the us for antibody replacement therapy in patients with primary immunodeficiency with antibody deficiency, and in the eu for replacement therapy in humoral immunodeficiency secondary to myeloma or chroniclymphocyticleukaemia.
nsubj||showed-2/VBD||we-1/PRP	root||ROOT-0/null||showed-2/VBD	mark||enhanced-19/VBD||that-3/IN	det||addition-5/NN||the-4/DT	nsubj||enhanced-19/VBD||addition-5/NN	det||sericin-10/NN||the-7/DT	amod||sericin-10/NN||sticky-8/JJ	nn||sericin-10/NN||protein-9/NN	prep_of||addition-5/NN||sericin-10/NN	det||composition-13/NN||the-12/DT	prep_in||sericin-10/NN||composition-13/NN	det||sponge-18/NN||a-15/DT	amod||sponge-18/NN||classical-16/JJ	nn||sponge-18/NN||collagen-17/NN	prep_of||composition-13/NN||sponge-18/NN	ccomp||showed-2/VBD||enhanced-19/VBD	det||adhesion-21/NN||the-20/DT	dobj||enhanced-19/VBD||adhesion-21/NN	advmod||rate-26/NN||also-23/RB	det||rate-26/NN||the-24/DT	nn||rate-26/NN||proliferation-25/NN	dobj||enhanced-19/VBD||rate-26/NN	conj_and||adhesion-21/NN||rate-26/NN	det||cells-30/NNS||the-28/DT	amod||cells-30/NNS||seeded-29/JJ	prep_of||rate-26/NN||cells-30/NNS	advmod||improving-33/VBG||thus-32/RB	vmod||enhanced-19/VBD||improving-33/VBG	det||biocompatibility-35/NN||the-34/DT	dobj||improving-33/VBG||biocompatibility-35/NN	det||scaffold-39/NN||the-37/DT	nn||scaffold-39/NN||novel-38/NN	prep_of||biocompatibility-35/NN||scaffold-39/NN	collagen-17||adhesion-21||no_rel||we showed that the addition of the sticky protein sericin in the composition of a classical collagen sponge enhanced the adhesion and also the proliferation rate of the seeded cells, thus improving the biocompatibility of the novel scaffold.
csubj||increases-22/VBZ||adding-1/VBG	dobj||adding-1/VBG||snps-2/NNS	advmod||associated-4/VBN||previously-3/RB	vmod||snps-2/NNS||associated-4/VBN	prepc_with||associated-4/VBN||fasting-6/VBG	dobj||fasting-6/VBG||glucose-7/NN	dobj||fasting-6/VBG||insulin-9/NN	conj_or||glucose-7/NN||insulin-9/NN	dobj||fasting-6/VBG||lipids-11/NN	conj_or||glucose-7/NN||lipids-11/NN	dobj||fasting-6/VBG||obesity-13/NN	conj_or||glucose-7/NN||obesity-13/NN	det||score-18/NN||a-15/DT	amod||score-18/NN||genetic-16/JJ	nn||score-18/NN||risk-17/NN	prep_to||fasting-6/VBG||score-18/NN	prep_for||score-18/NN||type2diabetes-20/CD	advmod||increases-22/VBZ||significantly-21/RB	root||ROOT-0/null||increases-22/VBZ	det||power-24/NN||the-23/DT	dobj||increases-22/VBZ||power-24/NN	aux||discriminate-26/VB||to-25/TO	vmod||power-24/NN||discriminate-26/VB	vmod||power-24/NN||discriminate-26/VB	conj_and||discriminate-26/VB||discriminate-26/VB	prep_between||discriminate-26/VB||people-28/NNS	advmod||manifest-33/JJ||clinically-32/RB	amod||type2diabetes-34/NNS||manifest-33/JJ	prep_with||discriminate-26/VB||type2diabetes-34/NNS	prep_without||discriminate-26/VB||type2diabetes-34/NNS	prepc_compared_with||discriminate-26/VB||with-36/IN	det||model-38/NN||a-37/DT	pobj||discriminate-26/VB||model-38/NN	amod||loci-43/NNS||only-40/JJ	amod||loci-43/NNS||conventional-41/JJ	amod||loci-43/NNS||type2diabetes-42/JJ	prep_including||model-38/NN||loci-43/NNS	type2diabetes-42||insulin-9||yes||adding snps previously associated with fasting glucose, insulin, lipids or obesity to a genetic risk score for type2diabetes significantly increases the power to discriminate between people with and without clinically manifest type2diabetes compared with a model including only conventional type2diabetes loci.
quantmod||49.9-2/CD||only-1/RB	num||%-3/NN||49.9-2/CD	nsubj||heard-5/VBN||%-3/NN	aux||heard-5/VBN||had-4/VBD	root||ROOT-0/null||heard-5/VBN	prep_of||heard-5/VBN||hiv/aids-7/NNS	aids--1||hiv--1||no||only 49.9% had heard of hiv/aids.
det||expression-2/NN||the-1/DT	nsubjpass||analyzed-25/VBN||expression-2/NN	nn||receptor-5/NN||estrogen-4/NN	prep_of||expression-2/NN||receptor-5/NN	appos||receptor-5/NN||er-7/NN	amod||pr-13/NN||progesterone-10/JJ	nn||pr-13/NN||receptor-11/NN	prep_of||expression-2/NN||pr-13/NN	conj_and||receptor-5/NN||pr-13/NN	prep_of||expression-2/NN||her2-16/NNS	conj_and||receptor-5/NN||her2-16/NNS	prep_of||expression-2/NN||her4-18/NNS	conj_and||receptor-5/NN||her4-18/NNS	nn||m-22/NN||cystatin-21/NN	prep_of||expression-2/NN||m-22/NN	conj_and||receptor-5/NN||m-22/NN	auxpass||analyzed-25/VBN||was-23/VBD	advmod||analyzed-25/VBN||retrospectively-24/RB	root||ROOT-0/null||analyzed-25/VBN	xcomp||analyzed-25/VBN||using-26/VBG	advmod||using-26/VBG||immunohistochemistry-27/RB	num||patients-30/NNS||117-29/CD	prep_in||using-26/VBG||patients-30/NNS	amod||carcinoma-33/NN||ductal-32/JJ	prep_with||patients-30/NNS||carcinoma-33/NN	prep_in||carcinoma-33/NN||situ-35/NN	appos||situ-35/NN||dcis-37/NNS	num||patients-42/NNS||175-41/CD	prep_in||using-26/VBG||patients-42/NNS	conj_and||patients-30/NNS||patients-42/NNS	amod||cancer-46/NN||invasive-44/JJ	nn||cancer-46/NN||breast-45/NN	prep_with||patients-42/NNS||cancer-46/NN	appos||cancer-46/NN||ibc-48/NN	carcinoma-33||estrogen-4||no_rel||the expression of estrogen receptor (er), progesterone receptor (pr), her2, her4, and cystatin m was retrospectively analyzed using immunohistochemistry in 117 patients with ductal carcinoma in situ (dcis) and in 175 patients with invasive breast cancer (ibc).
nsubj||observed-2/VBD||we-1/PRP	root||ROOT-0/null||observed-2/VBD	det||interaction-4/NN||an-3/DT	dobj||observed-2/VBD||interaction-4/NN	det||polymorphism-11/NN||the-6/DT	num||polymorphism-11/NN||-164-7/CD	nn||polymorphism-11/NN||t-8/NN	nn||polymorphism-11/NN||>-9/NNP	nn||polymorphism-11/NN||c-10/NN	prep_between||interaction-4/NN||polymorphism-11/NN	amod||levels-15/NNS||total-13/JJ	nn||levels-15/NNS||cholesterol-14/NN	prep_between||interaction-4/NN||levels-15/NNS	conj_and||polymorphism-11/NN||levels-15/NNS	prep_in||observed-2/VBD||relation-17/NN	amod||cvd-20/NN||future-19/JJ	prep_to||observed-2/VBD||cvd-20/NN	cholesterol-14||cvd-20||no_rel||we observed an interaction between the -164t > c polymorphism and total cholesterol levels in relation to future cvd.
advmod||produced-5/VBD||therefore-1/RB	det||study-4/NN||this-3/DT	nsubj||produced-5/VBD||study-4/NN	root||ROOT-0/null||produced-5/VBD	amod||viruses-9/NNS||chimeric-6/JJ	amod||viruses-9/NNS||jfh1-7/JJ	amod||viruses-9/NNS||hcvcc-8/JJ	dobj||produced-5/VBD||viruses-9/NNS	vmod||viruses-9/NNS||harbouring-10/VBG	det||h77c-12/NNS||the-11/DT	dobj||harbouring-10/VBG||h77c-12/NNS	nn||hvr1-15/NNS||gla-14/NN	dobj||harbouring-10/VBG||hvr1-15/NNS	conj_or||h77c-12/NNS||hvr1-15/NNS	aux||assess-17/VB||to-16/TO	vmod||harbouring-10/VBG||assess-17/VB	det||reactivity-19/NN||the-18/DT	dobj||assess-17/VB||reactivity-19/NN	prep_of||reactivity-19/NN||antibodies-21/NNS	det||region-24/NN||this-23/DT	prep_to||assess-17/VB||region-24/NN	poss||effects-27/NNS||their-26/PRP$	prep_to||assess-17/VB||effects-27/NNS	conj_and||region-24/NN||effects-27/NNS	nn||infectivity-30/NN||virus-29/NN	prep_on||assess-17/VB||infectivity-30/NN	virus-29||viruses-9||no||therefore, this study produced chimeric jfh1 hcvcc viruses harbouring the h77c or gla hvr1 to assess the reactivity of antibodies to this region and their effects on virus infectivity.
nsubjpass||prescribed-4/VBN||furosemide-1/NN	auxpass||prescribed-4/VBN||is-2/VBZ	advmod||prescribed-4/VBN||commonly-3/RB	root||ROOT-0/null||prescribed-4/VBN	advmod||ill-7/JJ||critically-6/RB	amod||patients-8/NNS||ill-7/JJ	prep_in||prescribed-4/VBN||patients-8/NNS	prep_with||patients-8/NNS||acutekidneyinjury-10/NN	appos||acutekidneyinjury-10/NN||aki-12/NN	acutekidneyinjury-10||furosemide-1||yes||furosemide is commonly prescribed in critically ill patients with acutekidneyinjury (aki).
nsubjpass||increased-22/VBN||hypertension-1/NN	conj_and||hypertension-1/NN||triglycerides-3/NN	nsubjpass||increased-22/VBN||triglycerides-3/NN	conj_and||hypertension-1/NN||insulinresistance-5/NN	nsubjpass||increased-22/VBN||insulinresistance-5/NN	dep||hypertension-1/NN||determined-7/VBN	amod||assessment-11/NN||homeostasis-9/JJ	nn||assessment-11/NN||model-10/NN	prep_by||determined-7/VBN||assessment-11/NN	prep_of||assessment-11/NN||insulinresistance-13/NN	amod||protein-17/NN||c-reactive-16/JJ	conj_and||hypertension-1/NN||protein-17/NN	nsubjpass||increased-22/VBN||protein-17/NN	dep||protein-17/NN||crp-19/VBN	auxpass||increased-22/VBN||were-21/VBD	root||ROOT-0/null||increased-22/VBN	prep_in||increased-22/VBN||sle-24/NN	parataxis||increased-22/VBN||p-26/VB	num||0.01-28/CD||<-27/CD	dobj||p-26/VB||0.01-28/CD	mark||differ-43/VB||while-30/IN	nn||lipoprotein-37/NN||smoking-31/NN	dep||lipoprotein-37/NN||ldl-33/NN	amod||lipoprotein-37/NN||high-35/JJ	nn||lipoprotein-37/NN||density-36/NN	nsubj||differ-43/VB||lipoprotein-37/NN	appos||lipoprotein-37/NN||hdl-39/NN	aux||differ-43/VB||did-41/VBD	neg||differ-43/VB||not-42/RB	advcl||increased-22/VBN||differ-43/VB	prep_between||differ-43/VB||groups-45/NNS	triglycerides-3||insulinresistance-13||no_rel||hypertension, triglycerides and insulinresistance (determined by homeostasis model assessment of insulinresistance) and c-reactive protein (crp) were increased in sle ( p < 0.01) while smoking, ldl, high density lipoprotein (hdl) did not differ between groups.
nsubj||drug-7/NN||metronidazole-1/NN	cop||drug-7/NN||is-2/VBZ	det||drug-7/NN||the-3/DT	advmod||used-6/VBN||most-4/RBS	advmod||used-6/VBN||commonly-5/RB	amod||drug-7/NN||used-6/VBN	root||ROOT-0/null||drug-7/NN	det||treatment-10/NN||the-9/DT	prep_for||drug-7/NN||treatment-10/NN	prep_of||treatment-10/NN||giardiasis-12/NNS	prep_in||giardiasis-12/NNS||humans-14/NNS	giardiasis-12||metronidazole-1||yes||metronidazole is the most commonly used drug for the treatment of giardiasis in humans.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||formoterol--1||yes||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
det||increase-2/NN||an-1/DT	nsubj||responsible-10/JJ||increase-2/NN	det||rate-5/NN||the-4/DT	prep_in||increase-2/NN||rate-5/NN	prep_of||rate-5/NN||gluconeogenesis-7/NNS	cop||responsible-10/JJ||is-8/VBZ	advmod||responsible-10/JJ||largely-9/RB	root||ROOT-0/null||responsible-10/JJ	det||hyperglycemia-13/NN||the-12/DT	prep_for||responsible-10/JJ||hyperglycemia-13/NN	prep_in||hyperglycemia-13/NN||individuals-15/NNS	prep_with||individuals-15/NNS||type2diabetes-17/CD	det||action-22/NN||the-20/DT	amod||action-22/NN||antidiabetes-21/JJ	prep_with||responsible-10/JJ||action-22/NN	prep_of||action-22/NN||metformin-24/NN	auxpass||thought-26/VBN||being-25/VBG	vmod||metformin-24/NN||thought-26/VBN	aux||achieved-29/VBN||to-27/TO	auxpass||achieved-29/VBN||be-28/VB	xcomp||thought-26/VBN||achieved-29/VBN	advmod||achieved-29/VBN||at-30/IN	pobj||at-30/IN||least-31/JJS	prep_in||achieved-29/VBN||part-33/NN	prep_through||achieved-29/VBN||suppression-35/NN	prep_of||suppression-35/NN||gluconeogenesis-37/NNS	type2diabetes-17||metformin-24||yes||an increase in the rate of gluconeogenesis is largely responsible for the hyperglycemia in individuals with type2diabetes, with the antidiabetes action of metformin being thought to be achieved at least in part through suppression of gluconeogenesis.
det||signature-3/NN||the-1/DT	amod||signature-3/NN||bioenergetic-2/JJ	nsubj||ratio-7/NN||signature-3/NN	cop||ratio-7/NN||is-4/VBZ	det||ratio-7/NN||a-5/DT	nn||ratio-7/NN||protein-6/NN	root||ROOT-0/null||ratio-7/NN	nsubj||provides-16/VBZ||ratio-7/NN	nsubj||serves-25/VBZ||ratio-7/NN	nn||²-10/NNP||î-9/NNP	dep||ratio-7/NN||²-10/NNP	dep||²-10/NNP||f1-atpase/gapdh-12/JJ	rcmod||ratio-7/NN||provides-16/VBZ	det||estimate-18/NN||an-17/DT	dobj||provides-16/VBZ||estimate-18/NN	nn||metabolism-21/NN||glucose-20/NN	prep_of||estimate-18/NN||metabolism-21/NN	prep_in||provides-16/VBZ||tumors-23/NNS	rcmod||ratio-7/NN||serves-25/VBZ	conj_and||provides-16/VBZ||serves-25/VBZ	det||indicator-29/NN||a-27/DT	amod||indicator-29/NN||prognostic-28/JJ	prep_as||serves-25/VBZ||indicator-29/NN	nn||patients-32/NNS||cancer-31/NN	prep_for||indicator-29/NN||patients-32/NNS	cancer-31||glucose-20||no_rel||the bioenergetic signature is a protein ratio (î²-f1-atpase/gapdh), which provides an estimate of glucose metabolism in tumors and serves as a prognostic indicator for cancer patients.
amod||eruption-3/NN||pruritic-1/JJ	nn||eruption-3/NN||papular-2/NN	nsubj||conditions-17/NNS||eruption-3/NN	prep_of||eruption-3/NN||hiv/aids-5/NNS	appos||hiv/aids-5/NNS||ppe-7/NN	amod||eczema-11/NN||seborrheic-10/JJ	prep_of||eruption-3/NN||eczema-11/NN	conj_and||hiv/aids-5/NNS||eczema-11/NN	cop||conditions-17/NNS||were-12/VBD	det||conditions-17/NNS||the-13/DT	advmod||common-15/JJ||most-14/RBS	amod||conditions-17/NNS||common-15/JJ	amod||conditions-17/NNS||non-infectious-16/JJ	root||ROOT-0/null||conditions-17/NNS	det||accounting-20/NN||each-19/DT	appos||conditions-17/NNS||accounting-20/NN	num||%-23/NN||4.3-22/CD	prep_for||accounting-20/NN||%-23/NN	aids--1||hiv--1||no||pruritic papular eruption of hiv/aids (ppe) and seborrheic eczema were the most common non-infectious conditions, each accounting for 4.3%.
mark||symptomatic-5/JJ||because-1/IN	nn||chlorosis-3/NNS||foliar-2/NN	nsubj||symptomatic-5/JJ||chlorosis-3/NNS	cop||symptomatic-5/JJ||was-4/VBD	advcl||began-13/VBD||symptomatic-5/JJ	prep_of||symptomatic-5/JJ||irondeficiency-7/NN	num||days-11/NNS||130-10/CD	prep_after||symptomatic-5/JJ||days-11/NNS	nsubj||began-13/VBD||we-12/PRP	nsubj||fertilize-15/VB||we-12/PRP	root||ROOT-0/null||began-13/VBD	aux||fertilize-15/VB||to-14/TO	xcomp||began-13/VBD||fertilize-15/VB	predet||seedlings-20/NNS||half-16/PDT	det||seedlings-20/NNS||the-17/DT	amod||seedlings-20/NNS||e.-18/JJ	nn||seedlings-20/NNS||tetrodonta-19/NN	dobj||fertilize-15/VB||seedlings-20/NNS	amod||soil-23/NN||ambient-22/JJ	prep_in||fertilize-15/VB||soil-23/NN	det||solution-27/NN||an-25/DT	nn||solution-27/NN||iron-26/NN	prep_with||soil-23/NN||solution-27/NN	irondeficiency-7||iron-26||yes||because foliar chlorosis was symptomatic of irondeficiency , after 130 days we began to fertilize half the e. tetrodonta seedlings in ambient soil with an iron solution .
nsubj||drug-5/NN||lithium-1/NN	cop||drug-5/NN||is-2/VBZ	det||drug-5/NN||an-3/DT	amod||drug-5/NN||integral-4/JJ	root||ROOT-0/null||drug-5/NN	vmod||drug-5/NN||used-6/VBN	det||management-9/NN||the-8/DT	prep_in||used-6/VBN||management-9/NN	amod||depression-17/NN||acute-11/JJ	nn||depression-17/NN||mania-12/NN	conj_and||mania-12/NN||unipolar-14/NN	nn||depression-17/NN||unipolar-14/NN	conj_and||mania-12/NN||bipolar-16/NN	nn||depression-17/NN||bipolar-16/NN	prep_of||management-9/NN||depression-17/NN	prep_of||management-9/NN||prophylaxis-19/NNS	conj_and||depression-17/NN||prophylaxis-19/NNS	prep_of||prophylaxis-19/NNS||bipolardisorders-21/NNS	bipolardisorders-21||lithium-1||yes||lithium is an integral drug used in the management of acute mania, unipolar and bipolar depression and prophylaxis of bipolardisorders.
det||costs-3/NNS||the-1/DT	amod||costs-3/NNS||overall-2/JJ	nsubj||low-11/JJ||costs-3/NNS	predet||programme-7/NN||such-5/PDT	det||programme-7/NN||a-6/DT	prep_for||costs-3/NNS||programme-7/NN	aux||low-11/JJ||would-8/MD	cop||low-11/JJ||be-9/VB	advmod||low-11/JJ||quite-10/RB	root||ROOT-0/null||low-11/JJ	prepc_compared_with||low-11/JJ||with-13/IN	det||sum-16/NN||the-14/DT	amod||sum-16/NN||huge-15/JJ	pobj||low-11/JJ||sum-16/NN	prep_of||sum-16/NN||money-18/NN	vmod||money-18/NN||budgeted-19/VBN	det||year-21/NN||each-20/DT	tmod||budgeted-19/VBN||year-21/NN	nn||care-24/NN||health-23/NN	prep_for||budgeted-19/VBN||care-24/NN	prep_for||budgeted-19/VBN||hiv-27/NN	conj_and||care-24/NN||hiv-27/NN	conj_and||care-24/NN||aids-29/NNS	conj_and||hiv-27/NN||aids-29/NNS	aids-29||hiv-27||no||the overall costs for such a programme would be quite low compared with the huge sum of money budgeted each year for health care and for hiv and aids.
nsubj||antibiotics-4/VBZ||administration-1/NN	nsubj||continued-9/VBD||administration-1/NN	prep_of||administration-1/NN||iv-3/NN	root||ROOT-0/null||antibiotics-4/VBZ	nn||induction-7/NN||anesthesia-6/NN	prep_during||antibiotics-4/VBZ||induction-7/NN	conj_and||antibiotics-4/VBZ||continued-9/VBD	amod||h.-12/NN||48â-11/JJ	prep_for||continued-9/VBD||h.-12/NN	amod||technique-15/NN||meticulous-13/JJ	amod||technique-15/NN||surgical-14/JJ	dobj||antibiotics-4/VBZ||technique-15/NN	nsubj||included-17/VBD||technique-15/NN	rcmod||technique-15/NN||included-17/VBD	dobj||included-17/VBD||packing-18/NN	det||stoma-22/NN||the-20/DT	amod||stoma-22/NN||proximal-21/JJ	prep_of||packing-18/NN||stoma-22/NN	amod||drape-25/NN||plastic-24/JJ	dobj||antibiotics-4/VBZ||drape-25/NN	conj_and||technique-15/NN||drape-25/NN	nsubj||included-17/VBD||drape-25/NN	aux||immobilize-27/VB||to-26/TO	vmod||drape-25/NN||immobilize-27/VB	det||field-30/NN||the-28/DT	amod||field-30/NN||surgical-29/JJ	dobj||immobilize-27/VB||field-30/NN	amod||hemostasis-33/NNS||careful-32/JJ	appos||field-30/NN||hemostasis-33/NNS	appos||field-30/NN||emphasis-35/NN	prepc_in||emphasis-35/NN||avoiding-37/VBG	dobj||avoiding-37/VBG||contamination-38/NN	vmod||field-30/NN||cleaning-40/VBG	det||edge-42/NN||the-41/DT	dobj||cleaning-40/VBG||edge-42/NN	det||stomas-45/NNS||the-44/DT	prep_of||edge-42/NN||stomas-45/NNS	aux||allow-47/VB||to-46/TO	vmod||cleaning-40/VBG||allow-47/VB	det||anastomosis-53/NNS||a-48/DT	amod||anastomosis-53/NNS||good-49/JJ	amod||anastomosis-53/NNS||2-layer-50/JJ	amod||anastomosis-53/NNS||end-to-end-52/JJ	dobj||allow-47/VB||anastomosis-53/NNS	amod||long-term-56/JJ||separated-55/JJ	amod||sutures-58/NNS||long-term-56/JJ	nn||sutures-58/NNS||absorbable-57/NN	prep_with||anastomosis-53/NNS||sutures-58/NNS	amod||irrigation-61/NN||generous-60/JJ	dobj||antibiotics-4/VBZ||irrigation-61/NN	conj_and||technique-15/NN||irrigation-61/NN	nsubj||included-17/VBD||irrigation-61/NN	det||cavity-65/NN||the-63/DT	amod||cavity-65/NN||peritoneal-64/JJ	prep_of||irrigation-61/NN||cavity-65/NN	amod||layers-68/NNS||subsequent-67/JJ	dobj||antibiotics-4/VBZ||layers-68/NNS	conj_and||technique-15/NN||layers-68/NNS	nsubj||included-17/VBD||layers-68/NNS	amod||solution-71/NN||saline-70/JJ	prep_with||layers-68/NNS||solution-71/NN	dobj||antibiotics-4/VBZ||closure-73/NN	conj_and||technique-15/NN||closure-73/NN	nsubj||included-17/VBD||closure-73/NN	prep_by||closure-73/NN||layers-75/NNS	aux||avoid-77/VB||to-76/TO	vmod||layers-75/NNS||avoid-77/VB	amod||space-79/NN||dead-78/JJ	dobj||avoid-77/VB||space-79/NN	dobj||antibiotics-4/VBZ||avoidance-82/NN	conj_and||technique-15/NN||avoidance-82/NN	nsubj||included-17/VBD||avoidance-82/NN	prep_of||avoidance-82/NN||hematomas-84/NNS	cavity-65||antibiotics-4||no_rel||administration of iv antibiotics during anesthesia induction and continued for 48â h. meticulous surgical technique that included packing of the proximal stoma , plastic drape to immobilize the surgical field , careful hemostasis , emphasis in avoiding contamination , cleaning the edge of the stomas to allow a good 2-layer , end-to-end anastomosis with separated long-term absorbable sutures , generous irrigation of the peritoneal cavity and subsequent layers with saline solution , closure by layers to avoid dead space , and avoidance of hematomas .
num||immunoassay-4/NN||seventeen-1/CD	amod||immunoassay-4/NN||hbsag-2/JJ	nn||immunoassay-4/NN||enzyme-3/NN	nn||kits-8/NNS||immunoassay-4/NN	appos||kits-8/NNS||eia-6/NN	nsubj||had-9/VBD||kits-8/NNS	nsubj||showed-19/VBD||kits-8/NNS	nsubj||sensitive-28/JJ||kits-8/NNS	root||ROOT-0/null||had-9/VBD	amod||iu/ml-17/NN||high-10/JJ	amod||iu/ml-17/NN||analytical-11/JJ	nn||iu/ml-17/NN||sensitivity-12/NN	num||iu/ml-17/NN||<-13/CD	amod||iu/ml-17/NN||0â-14/JJ	number||13-16/CD||·-15/CD	num||iu/ml-17/NN||13-16/CD	dobj||had-9/VBD||iu/ml-17/NN	conj_and||had-9/VBD||showed-19/VBD	number||%-21/NN||100-20/CD	amod||sensitivity-23/NN||%-21/NN	amod||sensitivity-23/NN||diagnostic-22/JJ	dobj||showed-19/VBD||sensitivity-23/NN	cop||sensitive-28/JJ||were-26/VBD	advmod||sensitive-28/JJ||even-27/RB	conj_and||had-9/VBD||sensitive-28/JJ	det||variants-33/NNS||the-30/DT	amod||variants-33/NNS||various-31/JJ	nn||variants-33/NNS||hbv-32/NN	prep_for||sensitive-28/JJ||variants-33/NNS	vmod||variants-33/NNS||tested-34/VBN	hbv-32||hbsag-2||yes||seventeen hbsag enzyme immunoassay (eia) kits had high analytical sensitivity <0â·13 iu/ml, showed 100% diagnostic sensitivity, and were even sensitive for the various hbv variants tested.
amod||mutations-4/NNS||mody1-1/JJ	conj_and||mody1-1/JJ||mody3-3/JJ	amod||mutations-4/NNS||mody3-3/JJ	nsubj||interact-6/VB||mutations-4/NNS	nsubj||give-10/VB||mutations-4/NNS	aux||interact-6/VB||may-5/MD	root||ROOT-0/null||interact-6/VB	prep_by||interact-6/VB||chance-8/NN	aux||give-10/VB||to-9/TO	xcomp||interact-6/VB||give-10/VB	det||form-14/NN||a-11/DT	advmod||severe-13/JJ||more-12/RBR	amod||form-14/NN||severe-13/JJ	dobj||give-10/VB||form-14/NN	prep_of||form-14/NN||diabetes-16/NN	amod||age-19/NN||younger-18/JJR	dep||form-14/NN||age-19/NN	nn||need-24/NN||presentation-21/NN	conj_and||presentation-21/NN||early-23/JJ	nn||need-24/NN||early-23/JJ	prep_at||age-19/NN||need-24/NN	nn||therapy-27/NN||insulin-26/NN	prep_of||need-24/NN||therapy-27/NN	aux||control-29/VB||to-28/TO	vmod||age-19/NN||control-29/VB	dobj||control-29/VB||hyperglycemia-30/NN	insulin-26||hyperglycemia-30||no_rel||mody1 and mody3 mutations may interact by chance to give a more severe form of diabetes (younger age at presentation and early need of insulin therapy to control hyperglycemia).
det||number-3/NN||a-1/DT	amod||number-3/NN||large-2/JJ	nsubjpass||used-30/VBN||number-3/NN	nsubj||manage-35/VB||number-3/NN	prep_of||number-3/NN||drugs-5/NNS	amod||classes-8/NNS||various-7/JJ	prep_from||drugs-5/NNS||classes-8/NNS	nn||methods-11/NNS||novel-10/NN	prep_from||drugs-5/NNS||methods-11/NNS	conj_and||classes-8/NNS||methods-11/NNS	prep_of||classes-8/NNS||administration-13/NN	amod||route-19/NN||nasal-15/JJ	conj_and||nasal-15/JJ||transmucosal-17/JJ	amod||route-19/NN||transmucosal-17/JJ	amod||route-19/NN||buccal-18/JJ	prep_like||administration-13/NN||route-19/NN	advmod||used-30/VBN||as-21/RB	det||case-24/NN||the-23/DT	prep_in||as-21/RB||case-24/NN	prep_of||case-24/NN||fentanyl-26/NN	aux||used-30/VBN||have-28/VBP	auxpass||used-30/VBN||been-29/VBN	root||ROOT-0/null||used-30/VBN	det||studies-33/NNS||these-32/DT	prep_in||used-30/VBN||studies-33/NNS	aux||manage-35/VB||to-34/TO	xcomp||used-30/VBN||manage-35/VB	det||type-37/NN||this-36/DT	dobj||manage-35/VB||type-37/NN	prep_of||type-37/NN||pain-39/NN	pain-39||fentanyl-26||yes||a large number of drugs from various classes and novel methods of administration like nasal and transmucosal buccal route, as in the case of fentanyl, have been used in these studies to manage this type of pain.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
amod||treatment-5/NN||growthhormone-1/JJ	dep||growthhormone-1/JJ||gh-3/NN	nsubj||improves-6/VBZ||treatment-5/NN	root||ROOT-0/null||improves-6/VBZ	det||growth-8/NN||the-7/DT	dobj||improves-6/VBZ||growth-8/NN	amod||phenotype-11/NN||physical-10/JJ	dobj||improves-6/VBZ||phenotype-11/NN	conj_and||growth-8/NN||phenotype-11/NN	nn||composition-15/NN||body-14/NN	dobj||improves-6/VBZ||composition-15/NN	conj_and||growth-8/NN||composition-15/NN	prep_of||composition-15/NN||patients-17/NNS	prep_with||patients-17/NNS||pws-19/NN	pws-19||growthhormone-1||yes||growthhormone (gh) treatment improves the growth, physical phenotype, and body composition of patients with pws.
det||best-3/JJS||the-2/DT	prep_to||report-9/VBP||best-3/JJS	poss||knowledge-6/NN||our-5/PRP$	prep_of||best-3/JJS||knowledge-6/NN	nsubj||report-9/VBP||we-8/PRP	root||ROOT-0/null||report-9/VBP	advmod||report-9/VBP||here-10/RB	det||dose-14/NN||the-12/DT	amod||dose-14/NN||highest-13/JJS	prep_on||report-9/VBP||dose-14/NN	nsubjpass||used-22/VBN||dose-14/NN	amod||fentanyl-17/NN||transdermal-16/JJ	prep_of||dose-14/NN||fentanyl-17/NN	aux||used-22/VBN||has-19/VBZ	auxpass||used-22/VBN||been-20/VBN	advmod||used-22/VBN||successfully-21/RB	rcmod||dose-14/NN||used-22/VBN	prepc_for||used-22/VBN||treating-24/VBG	det||suffering-27/NN||a-25/DT	amod||suffering-27/NN||patient-26/JJ	dobj||treating-24/VBG||suffering-27/NN	amod||pain-31/NN||visceral-29/JJ	nn||pain-31/NN||cancer-30/NN	prep_from||treating-24/VBG||pain-31/NN	pain-31||fentanyl-17||yes||to the best of our knowledge, we report here on the highest dose of transdermal fentanyl that has been successfully used for treating a patient suffering from visceral cancer pain.
aux||evaluate-2/VB||to-1/TO	advcl||generated-15/VBD||evaluate-2/VB	det||implication-4/NN||the-3/DT	dobj||evaluate-2/VB||implication-4/NN	amod||cells-7/NNS||treg-6/VBG	prep_of||implication-4/NN||cells-7/NNS	det||development-10/NN||the-9/DT	prep_in||cells-7/NNS||development-10/NN	prep_of||development-10/NN||silicosis-12/NNS	nsubj||generated-15/VBD||we-14/PRP	root||ROOT-0/null||generated-15/VBD	det||model-19/NN||the-16/DT	amod||model-19/NN||treg-depleted-17/JJ	nn||model-19/NN||mice-18/NNS	nsubjpass||exposed-28/VBN||model-19/NN	nsubj||establish-35/VB||model-19/NN	prep_by||model-19/NN||administration-21/NN	amod||mabs-24/NNS||anti-cd25-23/JJ	prep_of||administration-21/NN||mabs-24/NNS	prep_of||administration-21/NN||mice-26/NNS	conj_and||mabs-24/NNS||mice-26/NNS	auxpass||exposed-28/VBN||were-27/VBD	ccomp||generated-15/VBD||exposed-28/VBN	prep_to||exposed-28/VBN||silica-30/NN	amod||instillation-33/NN||intratracheal-32/JJ	agent||exposed-28/VBN||instillation-33/NN	aux||establish-35/VB||to-34/TO	xcomp||exposed-28/VBN||establish-35/VB	amod||model-37/NN||experimental-36/JJ	dobj||establish-35/VB||model-37/NN	amod||fibrosis-41/NN||silica-induced-39/JJ	nn||fibrosis-41/NN||lung-40/NN	prep_of||model-37/NN||fibrosis-41/NN	silicosis-12||silica-30||no||to evaluate the implication of treg cells in the development of silicosis, we generated the treg-depleted mice model by administration of anti-cd25 mabs and mice were exposed to silica by intratracheal instillation to establish experimental model of silica-induced lung fibrosis.
advmod||emphasized-7/VBD||recently-1/RB	det||organization-6/NN||the-3/DT	nn||organization-6/NN||world-4/NN	nn||organization-6/NN||health-5/NN	nsubj||emphasized-7/VBD||organization-6/NN	nsubj||recommended-25/VBD||organization-6/NN	root||ROOT-0/null||emphasized-7/VBD	det||benefit-10/NN||the-8/DT	amod||benefit-10/NN||potential-9/JJ	dobj||emphasized-7/VBD||benefit-10/NN	amod||treatment-14/NN||intermittent-12/JJ	nn||treatment-14/NN||preventive-13/NN	prep_of||benefit-10/NN||treatment-14/NN	prep_in||treatment-14/NN||infants-16/NNS	appos||infants-16/NNS||ipti-18/NNP	nn||malaria-22/NN||control-21/NN	prep_to||emphasized-7/VBD||malaria-22/NN	advmod||recommended-25/VBD||officially-24/RB	conj_and||emphasized-7/VBD||recommended-25/VBD	dobj||recommended-25/VBD||implementation-26/NN	prep_of||implementation-26/NN||ipti-28/NNS	amod||sp-32/NN||sulfadoxine-pyrimethamine-30/JJ	prep_with||ipti-28/NNS||sp-32/NN	prep_in||sp-32/NN||areas-35/NNS	amod||transmission-40/NN||moderate-37/JJ	conj_and||moderate-37/JJ||high-39/JJ	amod||transmission-40/NN||high-39/JJ	prep_with||areas-35/NNS||transmission-40/NN	advmod||high-47/JJ||where-42/WRB	nn||resistance-44/NN||sp-43/NN	nsubj||high-47/JJ||resistance-44/NN	cop||high-47/JJ||is-45/VBZ	neg||high-47/JJ||not-46/RB	rcmod||transmission-40/NN||high-47/JJ	malaria-22||pyrimethamine--1||yes||recently, the world health organization emphasized the potential benefit of intermittent preventive treatment in infants (ipti) to control malaria and officially recommended implementation of ipti with sulfadoxine-pyrimethamine (sp) in areas with moderate and high transmission, where sp resistance is not high.
amod||protein-3/NN||pneumococcal-1/JJ	nn||protein-3/NN||surface-2/NN	nsubj||is-8/VBZ||protein-3/NN	det||pspa-6/NN||a-4/DT	dep||protein-3/NN||pspa-6/NN	root||ROOT-0/null||is-8/VBZ	det||antigens-13/NNS||the-10/DT	amod||antigens-13/NNS||best-characterized-11/JJ	amod||antigens-13/NNS||pneumococcal-12/JJ	prep_among||is-8/VBZ||antigens-13/NNS	nsubj||confer-15/VBP||antigens-13/NNS	rcmod||antigens-13/NNS||confer-15/VBP	dobj||confer-15/VBP||protection-16/NN	nn||models-19/NNS||animal-18/NN	prep_in||confer-15/VBP||models-19/NNS	prep_of||models-19/NNS||pneumococcalinfections-21/NNS	mark||such-25/JJ||as-24/IN	parataxis||confer-15/VBP||such-25/JJ	parataxis||alternative-30/NN||such-25/JJ	cop||alternative-30/NN||is-27/VBZ	det||alternative-30/NN||a-28/DT	amod||alternative-30/NN||good-29/JJ	rcmod||antigens-13/NNS||alternative-30/NN	conj_and||confer-15/VBP||alternative-30/NN	det||vaccines-36/NNS||the-32/DT	advmod||available-34/JJ||currently-33/RB	amod||vaccines-36/NNS||available-34/JJ	amod||vaccines-36/NNS||conjugated-35/JJ	prep_for||alternative-30/NN||vaccines-36/NNS	pneumococcalinfections-21||pneumococcal-12||no||pneumococcal surface protein a (pspa) is among the best-characterized pneumococcal antigens that confer protection in animal models of pneumococcalinfections and, as such, is a good alternative for the currently available conjugated vaccines.
prep_in||produced-43/VBN||particular-2/JJ	amod||proteins-5/NNS||several-4/JJ	nsubjpass||produced-43/VBN||proteins-5/NNS	amod||protein-9/NN||green-7/JJ	amod||protein-9/NN||fluorescent-8/JJ	prep_including||proteins-5/NNS||protein-9/NN	appos||protein-9/NN||î-11/NN	appos||î-11/NN||²-12/NNP	dep||î-11/NN||galactosidase-14/NN	nn||²-17/NNS||î-16/NN	appos||galactosidase-14/NN||²-17/NNS	amod||phosphatase-22/NN||lactamase-19/JJ	amod||phosphatase-22/NN||alkaline-21/JJ	dep||î-11/NN||phosphatase-22/NN	appos||phosphatase-22/NN||d-24/SYM	amod||oxidase-27/NN||aminoacid-26/JJ	dep||î-11/NN||oxidase-27/NN	amod||kinase-30/NN||polyphosphate-29/JJ	dep||î-11/NN||kinase-30/NN	conj_and||oxidase-27/NN||kinase-30/NN	num||kinase-30/NN||3-31/CD	nn||phosphorylase-34/NN||maltodextrin-33/NN	dep||î-11/NN||phosphorylase-34/NN	conj_and||oxidase-27/NN||phosphorylase-34/NN	amod||aldolase-39/NN||sialic-37/JJ	amod||aldolase-39/NN||acid-38/JJ	dep||î-11/NN||aldolase-39/NN	conj_and||oxidase-27/NN||aldolase-39/NN	aux||produced-43/VBN||have-40/VBP	auxpass||produced-43/VBN||been-41/VBN	advmod||produced-43/VBN||successfully-42/RB	root||ROOT-0/null||produced-43/VBN	amod||ibs-46/NN||active-45/JJ	prep_as||produced-43/VBN||ibs-46/NN	tmod||amyloid-68/VBD||ibs-46/NN	advmod||amyloid-68/VBD||when-47/WRB	amod||vp1-60/NNS||fused-48/JJ	det||partner-52/NN||an-50/DT	amod||partner-52/NN||appropriate-51/JJ	prep_to||fused-48/JJ||partner-52/NN	det||virus-57/NN||the-55/DT	amod||virus-57/NN||foot-and-mouthdisease-56/JJ	prep_such_as||partner-52/NN||virus-57/NN	amod||vp1-60/NNS||capsid-58/JJ	nn||vp1-60/NNS||protein-59/NN	nsubj||amyloid-68/VBD||vp1-60/NNS	det||²-66/NN||the-63/DT	amod||²-66/NN||human-64/JJ	nn||²-66/NN||î-65/NN	conj_or||vp1-60/NNS||²-66/NN	nsubj||amyloid-68/VBD||²-66/NN	rcmod||ibs-46/NN||amyloid-68/VBD	amod||aî-70/NN||peptide-69/JJ	dobj||amyloid-68/VBD||aî-70/NN	amod||aî-70/NN||²-71/JJ	dep||²-71/JJ||42-72/CD	appos||aî-70/NN||f19d-74/NNP	aminoacid-26||ibs-46||no_rel||in particular, several proteins including green fluorescent protein, î²-galactosidase, î²-lactamase, alkaline phosphatase, d -aminoacid oxidase, polyphosphate kinase 3, maltodextrin phosphorylase, and sialic acid aldolase have been successfully produced as active ibs when fused to an appropriate partner such as the foot-and-mouthdisease virus capsid protein vp1, or the human î²-amyloid peptide aî²42(f19d).
poss||knowledge-3/NN||our-2/PRP$	prep_to||report-9/NN||knowledge-3/NN	nsubj||report-9/NN||this-5/DT	cop||report-9/NN||is-6/VBZ	det||report-9/NN||the-7/DT	amod||report-9/NN||first-8/JJ	root||ROOT-0/null||report-9/NN	nsubjpass||used-26/VBN||report-9/NN	nsubj||treat-28/VB||report-9/NN	det||isolation-12/NN||the-11/DT	prep_on||report-9/NN||isolation-12/NN	det||protein-19/NN||a-14/DT	amod||protein-19/NN||promising-15/JJ	amod||protein-19/NN||non-haemolytic-16/JJ	amod||protein-19/NN||anti--17/JJ	nn||protein-19/NN||candida-18/NN	prep_of||isolation-12/NN||protein-19/NN	nn||faecalis-22/NNS||e.-21/NN	prep_from||protein-19/NN||faecalis-22/NNS	aux||used-26/VBN||might-24/MD	auxpass||used-26/VBN||be-25/VB	rcmod||report-9/NN||used-26/VBN	aux||treat-28/VB||to-27/TO	xcomp||used-26/VBN||treat-28/VB	dobj||treat-28/VB||candidiasis-29/NNS	advmod||treat-28/VB||especially-30/RB	amod||patients-33/NNS||immunocompromised-32/JJ	prep_in||treat-28/VB||patients-33/NNS	candidiasis-29||candida-18||no||to our knowledge , this is the first report on the isolation of a promising non-haemolytic anti- candida protein from e. faecalis that might be used to treat candidiasis especially in immunocompromised patients .
nsubj||pathogen-19/NN||mycobacteriumtuberculosis-1/NNS	appos||mycobacteriumtuberculosis-1/NNS||mtb-3/NN	det||agent-8/NN||the-6/DT	amod||agent-8/NN||causative-7/JJ	appos||mycobacteriumtuberculosis-1/NNS||agent-8/NN	prep_of||agent-8/NN||tuberculosis-10/NNP	appos||tuberculosis-10/NNP||tb-12/NN	cop||pathogen-19/NN||is-15/VBZ	det||pathogen-19/NN||a-16/DT	amod||pathogen-19/NN||facultative-17/JJ	nn||pathogen-19/NN||intracellular-18/NN	root||ROOT-0/null||pathogen-19/NN	nsubj||persist-22/VB||pathogen-19/NN	aux||persist-22/VB||can-21/MD	rcmod||pathogen-19/NN||persist-22/VB	det||host-25/NN||the-24/DT	prep_within||persist-22/VB||host-25/NN	tuberculosis-10||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis ( mtb ), the causative agent of tuberculosis (tb), is a facultative intracellular pathogen that can persist within the host.
num||rhesus-2/NNS||six-1/CD	root||ROOT-0/null||rhesus-2/NNS	nsubjpass||selected-5/VBN||macaques-3/NNS	auxpass||selected-5/VBN||were-4/VBD	rcmod||rhesus-2/NNS||selected-5/VBN	prep_for||selected-5/VBN||study-7/NN	det||pool-10/NN||a-9/DT	prep_from||selected-5/VBN||pool-10/NN	prep_of||pool-10/NN||500-12/CD	prep||selected-5/VBN||including-14/VBG	num||controls-17/NNS||two-15/CD	amod||controls-17/NNS||healthy-16/JJ	npadvmod||with-22/IN||controls-17/NNS	num||animals-21/NNS||four-19/CD	amod||animals-21/NNS||gluten-sensitive-20/JJ	conj_and||controls-17/NNS||animals-21/NNS	npadvmod||with-22/IN||animals-21/NNS	pcomp||including-14/VBG||with-22/IN	amod||antibodies-27/NNS||elevated-23/JJ	amod||antibodies-27/NNS||anti-gliadin-24/JJ	conj_or||anti-gliadin-24/JJ||anti-tg2-26/JJ	amod||antibodies-27/NNS||anti-tg2-26/JJ	pobj||with-22/IN||antibodies-27/NNS	conj_and||rhesus-2/NNS||history-31/NN	amod||diarrhea-35/NN||non-infectious-33/JJ	amod||diarrhea-35/NN||chronic-34/JJ	prep_of||history-31/NN||diarrhea-35/NN	gluten--1||diarrhea-35||no_rel||six rhesus macaques were selected for study from a pool of 500, including two healthy controls and four gluten-sensitive animals with elevated anti-gliadin or anti-tg2 antibodies as well as history of non-infectious chronic diarrhea.
mark||understand-4/VB||in-1/IN	dep||understand-4/VB||order-2/NN	aux||understand-4/VB||to-3/TO	advcl||characterized-24/VBN||understand-4/VB	poss||mechanism-6/NN||its-5/PRP$	dobj||understand-4/VB||mechanism-6/NN	prep_of||mechanism-6/NN||pathogenesis-8/NNS	prep_in||pathogenesis-8/NNS||humans-10/NNS	aux||help-13/VB||to-12/TO	conj_and||understand-4/VB||help-13/VB	advcl||characterized-24/VBN||help-13/VB	nn||tuberculosis-15/NNS||control-14/NN	dobj||help-13/VB||tuberculosis-15/NNS	nsubjpass||characterized-24/VBN||functions-17/NNS	amod||genes-21/NNS||numerous-19/JJ	nn||genes-21/NNS||mycobacteriumtuberculosis-20/NNS	prep_of||functions-17/NNS||genes-21/NNS	aux||characterized-24/VBN||are-22/VBP	auxpass||characterized-24/VBN||being-23/VBG	root||ROOT-0/null||characterized-24/VBN	tuberculosis-15||mycobacteriumtuberculosis-20||no||in order to understand its mechanism of pathogenesis in humans and to help control tuberculosis, functions of numerous mycobacteriumtuberculosis genes are being characterized.
advmod||report-15/VBP||here-1/RB	det||coexistence-6/NN||a-4/DT	amod||coexistence-6/NN||unique-5/JJ	prep_as||report-15/VBP||coexistence-6/NN	det||entities-12/NNS||these-8/DT	num||entities-12/NNS||two-9/CD	amod||entities-12/NNS||seperated-10/JJ	amod||entities-12/NNS||clinical-11/JJ	prep_of||coexistence-6/NN||entities-12/NNS	nsubj||report-15/VBP||we-14/PRP	root||ROOT-0/null||report-15/VBP	det||woman-18/NN||a-16/DT	amod||woman-18/NN||30-yr-old-17/JJ	dobj||report-15/VBP||woman-18/NN	vmod||woman-18/NN||presenting-19/VBG	amod||spasm-22/NN||carpal-21/JJ	prep_with||presenting-19/VBG||spasm-22/NN	vmod||spasm-22/NN||related-23/VBN	amod||preparation-43/NN||hypocalcemia-25/JJ	amod||calcium-28/NN||ionized-27/JJ	dep||preparation-43/NN||calcium-28/NN	num||mm/l-31/NN||1.90-30/CD	prep_of||calcium-28/NN||mm/l-31/NN	amod||preparation-43/NN||due-33/JJ	aux||acute-35/VB||to-34/TO	xcomp||due-33/JJ||acute-35/VB	amod||poisoning-37/NN||phosphate-36/JJ	dobj||acute-35/VB||poisoning-37/NN	amod||bowel-42/NN||oral-39/JJ	nn||bowel-42/NN||sodium-40/NN	nn||bowel-42/NN||phosphate-41/NN	prep_after||acute-35/VB||bowel-42/NN	prep_to||related-23/VBN||preparation-43/NN	nsubj||resolved-46/VBN||preparation-43/NN	rcmod||preparation-43/NN||resolved-46/VBN	advmod||resolved-46/VBN||rapidly-47/RB	amod||intravenously-50/NN||calciumgluconate-49/JJ	prep_after||resolved-46/VBN||intravenously-50/NN	hypocalcemia-25||calciumgluconate-49||no_rel||here, as a unique coexistence of these two seperated clinical entities, we report a 30-yr-old woman presenting with carpal spasm related to hypocalcemia (ionized calcium of 1.90 mm/l) due to acute phosphate poisoning after oral sodium phosphate bowel preparation, which resolved rapidly after calciumgluconate intravenously.
nsubjpass||approved-14/VBN||levofloxacin-1/NN	det||fluoroquinolone-4/NN||a-3/DT	appos||levofloxacin-1/NN||fluoroquinolone-4/NN	appos||levofloxacin-1/NN||l-isomer-6/NN	conj_and||fluoroquinolone-4/NN||l-isomer-6/NN	det||ofloxacin-10/NN||the-8/DT	amod||ofloxacin-10/NN||racemate-9/JJ	prep_of||fluoroquinolone-4/NN||ofloxacin-10/NN	aux||approved-14/VBN||has-12/VBZ	auxpass||approved-14/VBN||been-13/VBN	root||ROOT-0/null||approved-14/VBN	det||treatment-17/NN||the-16/DT	prep_for||approved-14/VBN||treatment-17/NN	amod||bacterialinfections-22/NNS||acute-19/JJ	conj_and||acute-19/JJ||chronic-21/JJ	amod||bacterialinfections-22/NNS||chronic-21/JJ	prep_of||treatment-17/NN||bacterialinfections-22/NNS	bacterialinfections-22||ofloxacin-10||yes||levofloxacin, a fluoroquinolone and l-isomer of the racemate ofloxacin, has been approved for the treatment of acute and chronic bacterialinfections.
nsubj||led-5/VBD||investigation-1/NN	amod||incidentalomas-4/NNS||adrenal-3/JJ	prep_of||investigation-1/NN||incidentalomas-4/NNS	root||ROOT-0/null||led-5/VBD	det||discovery-8/NN||the-7/DT	prep_to||led-5/VBD||discovery-8/NN	det||family-11/NN||a-10/DT	prep_of||led-5/VBD||family-11/NN	num||individuals-15/NNS||eight-13/CD	amod||individuals-15/NNS||affected-14/JJ	nsubj||spanning-16/VBG||individuals-15/NNS	parataxis||led-5/VBD||spanning-16/VBG	num||generations-18/NNS||three-17/CD	dobj||spanning-16/VBG||generations-18/NNS	acomp||led-5/VBD||prone-21/JJ	aux||cortisol-23/VB||to-22/TO	xcomp||prone-21/JJ||cortisol-23/VB	nn||adrenalhyperplasia-27/NN||resistance-24/NN	dobj||cortisol-23/VB||bilateral-26/JJ	amod||adrenalhyperplasia-27/NN||bilateral-26/JJ	conj_and||adrenalhyperplasia-27/NN||bilateral-26/JJ	dobj||cortisol-23/VB||adrenalhyperplasia-27/NN	dobj||cortisol-23/VB||arterialhypertension-29/NN	conj_and||adrenalhyperplasia-27/NN||arterialhypertension-29/NN	dobj||cortisol-23/VB||hypokalemia-31/NN	conj_and||adrenalhyperplasia-27/NN||hypokalemia-31/NN	adrenalhyperplasia-27||cortisol-23||yes||investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to cortisol resistance, bilateral adrenalhyperplasia, arterialhypertension and hypokalemia.
amod||feâˆ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâˆ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâˆ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâˆ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	irondeficiency-40||iron-31||yes||defective feâˆ’s cluster synthesis not only affects activities of many ironâˆ’sulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
amod||prophylaxis-8/NNS||mefloquine-1/JJ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||marketed-4/JJ	nn||drug-6/NN||anti-malaria-5/NN	appos||prophylaxis-8/NNS||drug-6/NN	nsubj||has-9/VBZ||prophylaxis-8/NNS	root||ROOT-0/null||has-9/VBZ	det||risk-12/NN||a-10/DT	amod||risk-12/NN||high-11/JJ	dobj||has-9/VBZ||risk-12/NN	prepc_of||risk-12/NN||causing-14/VBG	amod||events-16/NNS||adverse-15/JJ	dobj||causing-14/VBG||events-16/NNS	malaria--1||mefloquine-1||yes||mefloquine (a marketed anti-malaria drug) prophylaxis has a high risk of causing adverse events.
nsubj||has-2/VBZ||insulin-1/NN	root||ROOT-0/null||has-2/VBZ	amod||effects-4/NNS||mitogenic-3/JJ	dobj||has-2/VBZ||effects-4/NNS	mark||factor-12/NN||although-6/IN	nsubj||factor-12/NN||hyperglycemia-7/NN	aux||factor-12/NN||may-8/MD	cop||factor-12/NN||be-9/VB	det||factor-12/NN||a-10/DT	nn||factor-12/NN||risk-11/NN	advcl||has-2/VBZ||factor-12/NN	prep_for||factor-12/NN||cancer-14/NN	prep_in||cancer-14/NN||type2diabetes-16/CD	insulin-1||type2diabetes-16||no_rel||insulin has mitogenic effects, although hyperglycemia may be a risk factor for cancer in type2diabetes.
nsubj||searched-2/VBD||we-1/PRP	root||ROOT-0/null||searched-2/VBD	ccomp||searched-2/VBD||medline-3/VB	ccomp||searched-2/VBD||pubmed-5/VB	conj_and||medline-3/VB||pubmed-5/VB	dobj||medline-3/VB||terms-6/NNS	nn||stage-9/NN||labour-8/NN	dep||terms-6/NNS||stage-9/NN	dep||stage-9/NN||third-11/JJ	dep||ergonovine-17/NN||ergonovine-15/JJ	dep||medline-3/VB||ergonovine-17/NN	amod||ergonovine-17/NN||tartrate-18/JJ	amod||ergonovine-17/NN||methylergonovine-20/JJ	conj_or||tartrate-18/JJ||methylergonovine-20/JJ	amod||ergonovine-17/NN||oxytocin-22/JJ	conj_or||tartrate-18/JJ||oxytocin-22/JJ	amod||ergonovine-17/NN||oxytocics-24/JJ	conj_or||tartrate-18/JJ||oxytocics-24/JJ	amod||ergonovine-17/NN||misoprostol-26/JJ	conj_or||tartrate-18/JJ||misoprostol-26/JJ	ccomp||searched-2/VBD||and-28/VB	conj_and||medline-3/VB||and-28/VB	parataxis||and-28/VB||postpartumhaemorrhage-30/VB	parataxis||and-28/VB||haemorrhage-32/VB	conj_or||postpartumhaemorrhage-30/VB||haemorrhage-32/VB	conj_and||medline-3/VB||cochrane-35/VB	conj_and||and-28/VB||cochrane-35/VB	dobj||and-28/VB||reviews-36/NNS	det||restriction-40/NN||any-38/DT	nn||restriction-40/NN||language-39/NN	prep_without||and-28/VB||restriction-40/NN	postpartumhaemorrhage-30||methylergonovine-20||yes||we searched medline and pubmed terms (labour stage, third) and (ergonovine, ergonovine tartrate, methylergonovine, oxytocin, oxytocics or misoprostol) and (postpartumhaemorrhage or haemorrhage) and cochrane reviews without any language restriction.
quantmod||99-2/CD||almost-1/RB	num||%-3/NN||99-2/CD	nsubj||heard-8/VBN||%-3/NN	det||respondents-6/NNS||the-5/DT	prep_of||%-3/NN||respondents-6/NNS	aux||heard-8/VBN||had-7/VBD	root||ROOT-0/null||heard-8/VBN	prep_of||heard-8/VBN||hiv/aids-10/NNS	num||%-14/NN||89-13/CD	nsubj||identify-16/VB||%-14/NN	aux||identify-16/VB||could-15/MD	conj_and||heard-8/VBN||identify-16/VB	dobj||identify-16/VB||ways-17/NNS	nsubj||protect-19/VB||ways-17/NNS	aux||protect-19/VB||to-18/TO	xcomp||identify-16/VB||protect-19/VB	dobj||protect-19/VB||oneself-20/PRP	advmod||hiv/aids-24/NNS||sexually-22/RB	amod||hiv/aids-24/NNS||transmitted-23/JJ	prep_against||protect-19/VB||hiv/aids-24/NNS	aids--1||hiv--1||no||almost 99% of the respondents had heard of hiv/aids, and 89% could identify ways to protect oneself against sexually transmitted hiv/aids.
mark||enhance-4/VB||because-1/IN	nsubj||enhance-4/VB||iron-2/NN	aux||enhance-4/VB||can-3/MD	advcl||examined-12/VBD||enhance-4/VB	det||effects-7/NNS||the-5/DT	amod||effects-7/NNS||oxidative-6/JJ	dobj||enhance-4/VB||effects-7/NNS	prep_of||effects-7/NNS||lead-9/NN	nsubj||examined-12/VBD||we-11/PRP	root||ROOT-0/null||examined-12/VBD	mark||-LSB--19/VB||whether-13/IN	nsubj||-LSB--19/VB||polymorphisms-14/NNS	nsubj||transferrin-25/VB||polymorphisms-14/NNS	nsubj||heme-32/VB||polymorphisms-14/NNS	nn||genes-18/NNS||iron-16/NN	nn||genes-18/NNS||metabolism-17/NN	prep_in||polymorphisms-14/NNS||genes-18/NNS	ccomp||examined-12/VBD||-LSB--19/VB	dobj||-LSB--19/VB||hemochromatosis-20/NNS	appos||hemochromatosis-20/NNS||hfe-22/NN	ccomp||examined-12/VBD||transferrin-25/VB	conj_and||-LSB--19/VB||transferrin-25/VB	appos||c2-29/NNS||tf-27/NN	dobj||transferrin-25/VB||c2-29/NNS	ccomp||examined-12/VBD||heme-32/VB	conj_and||-LSB--19/VB||heme-32/VB	amod||susceptibility-39/NN||oxygenase-1-33/JJ	dep||oxygenase-1-33/JJ||hmox-1-35/JJ	amod||susceptibility-39/NN||-RSB--37/JJ	nn||susceptibility-39/NN||increase-38/NN	dobj||heme-32/VB||susceptibility-39/NN	det||effects-42/NNS||the-41/DT	prep_to||heme-32/VB||effects-42/NNS	prep_of||effects-42/NNS||lead-44/NN	nn||interval-47/NN||qt-46/NN	nsubj||community-dwelling-50/VBG||interval-47/NN	prep_in||interval-47/NN||613-49/CD	prepc_on||heme-32/VB||community-dwelling-50/VBG	amod||men-52/NNS||older-51/JJR	dobj||community-dwelling-50/VBG||men-52/NNS	hemochromatosis-20||iron-16||no||because iron can enhance the oxidative effects of lead, we examined whether polymorphisms in iron metabolism genes [hemochromatosis ( hfe ), transferrin ( tf ) c2, and heme oxygenase-1 ( hmox-1 )] increase susceptibility to the effects of lead on qt interval in 613 community-dwelling older men.
advmod||pronounced-13/JJ||overall-1/RB	advmod||signs-5/NNS||most-3/RBS	amod||signs-5/NNS||clinical-4/JJ	nsubj||pronounced-13/JJ||signs-5/NNS	conj_and||signs-5/NNS||symptoms-7/NNS	nsubj||pronounced-13/JJ||symptoms-7/NNS	prep_of||symptoms-7/NNS||urti-9/NNS	cop||pronounced-13/JJ||were-10/VBD	advmod||pronounced-13/JJ||notably-11/RB	advmod||pronounced-13/JJ||less-12/RBR	root||ROOT-0/null||pronounced-13/JJ	prep_in||pronounced-13/JJ||patients-15/NNS	vmod||patients-15/NNS||treated-16/VBN	prep_with||treated-16/VBN||antipyretics-18/NNS	urti-9||antipyretics-18||no_rel||overall, most clinical signs and symptoms of urti were notably less pronounced in patients treated with antipyretics.
amod||protocol-3/NN||post-transplant-1/JJ	nn||protocol-3/NN||prophylaxis-2/NNS	nsubjpass||based-8/VBN||protocol-3/NN	nsubj||keep-28/VB||protocol-3/NN	nn||recurrence-6/NN||hbv-5/NN	prep_against||protocol-3/NN||recurrence-6/NN	auxpass||based-8/VBN||was-7/VBD	root||ROOT-0/null||based-8/VBN	det||milligrams-12/NNS||a-10/DT	num||milligrams-12/NNS||hundred-11/CD	prep_on||based-8/VBN||milligrams-12/NNS	prep_of||milligrams-12/NNS||lamivudine-14/NN	amod||lamivudine-14/NN||daily-15/JJ	amod||lamivudine-14/NN||plus-16/IN	nn||injections-18/NNS||intramuscular-17/NN	dep||lamivudine-14/NN||injections-18/NNS	prep_of||injections-18/NNS||hepatitisbimmuneglobulin-20/NN	appos||injections-18/NNS||hbig-22/NN	amod||dosage-26/NN||appropriate-25/JJ	prep_with||based-8/VBN||dosage-26/NN	aux||keep-28/VB||to-27/TO	xcomp||based-8/VBN||keep-28/VB	amod||titer-31/NN||anti-hbs-29/JJ	nn||titer-31/NN||antibody-30/NN	dobj||keep-28/VB||titer-31/NN	num||iu/l-34/NN||300-33/CD	prep_above||titer-31/NN||iu/l-34/NN	num||iu/l-37/NN||100-36/CD	prep_above||titer-31/NN||iu/l-37/NN	conj_and||iu/l-34/NN||iu/l-37/NN	prep||keep-28/VB||in-38/IN	det||months-42/NNS||the-39/DT	amod||months-42/NNS||first-40/JJ	num||months-42/NNS||six-41/CD	pobj||in-38/IN||months-42/NNS	prep||keep-28/VB||afterwards-44/RB	conj_and||in-38/IN||afterwards-44/RB	prep||keep-28/VB||respectively-46/RB	conj_and||in-38/IN||respectively-46/RB	hbv-5||hepatitisbimmuneglobulin-20||yes||post-transplant prophylaxis protocol against hbv recurrence was based on a hundred milligrams of lamivudine daily plus intramuscular injections of hepatitisbimmuneglobulin (hbig) with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l and 100 iu/l in the first six months and afterwards, respectively.
det||combination-2/NN||a-1/DT	nsubj||reduced-9/VBD||combination-2/NN	nn||exercise-7/NN||cr-4/NN	conj_and||cr-4/NN||endurance-6/JJ	nn||exercise-7/NN||endurance-6/JJ	prep_of||combination-2/NN||exercise-7/NN	advmod||reduced-9/VBD||further-8/RB	root||ROOT-0/null||reduced-9/VBD	acomp||reduced-9/VBD||obesity-10/JJ	acomp||reduced-9/VBD||insulinresistance-12/JJ	conj_and||obesity-10/JJ||insulinresistance-12/JJ	det||condition-15/NN||the-14/DT	prep_under||reduced-9/VBD||condition-15/NN	amod||diet-18/NN||high-fat-17/JJ	prep_of||condition-15/NN||diet-18/NN	cr-4||obesity-10||no_rel||a combination of cr and endurance exercise further reduced obesity and insulinresistance under the condition of high-fat diet.
det||study-5/NN||a-2/DT	amod||study-5/NN||randomized-3/JJ	amod||study-5/NN||prospective-4/JJ	prep_in||enrolled-19/VBN||study-5/NN	num||patients-8/NNS||60-7/CD	nsubjpass||enrolled-19/VBN||patients-8/NNS	nsubj||determine-21/VB||patients-8/NNS	nn||i-ii-11/NN||asa-10/NN	dep||patients-8/NNS||i-ii-11/NN	appos||i-ii-11/NN||elder-13/JJR	num||years-16/NNS||65-15/CD	prep_than||elder-13/JJR||years-16/NNS	auxpass||enrolled-19/VBN||were-18/VBD	root||ROOT-0/null||enrolled-19/VBN	aux||determine-21/VB||to-20/TO	xcomp||enrolled-19/VBN||determine-21/VB	dobj||required-37/VBN||which-22/WDT	num||target-25/NN||two-24/CD	prep_of||required-37/VBN||target-25/NN	amod||concentrations-28/NNS||remifentanil-26/JJ	nn||concentrations-28/NNS||blood-27/NN	nsubjpass||required-37/VBN||concentrations-28/NNS	num||ng/ml-31/NN||3-30/CD	dep||concentrations-28/NNS||ng/ml-31/NN	num||ng/ml-34/NN||5-33/CD	appos||ng/ml-31/NN||ng/ml-34/NN	auxpass||required-37/VBN||was-36/VBD	ccomp||determine-21/VB||required-37/VBN	aux||blunt-39/VB||to-38/TO	ccomp||required-37/VBN||blunt-39/VB	amod||changes-41/NNS||hemodynamic-40/JJ	dobj||blunt-39/VB||changes-41/NNS	prep_during||blunt-39/VB||intubation-43/NN	aux||reduce-46/VB||to-45/TO	ccomp||required-37/VBN||reduce-46/VB	conj_and||blunt-39/VB||reduce-46/VB	amod||pain-48/NN||propofol-induced-47/JJ	dobj||reduce-46/VB||pain-48/NN	pain-48||asa-10||yes||in a randomized prospective study, 60 patients (asa i-ii, elder than 65 years) were enrolled to determine which of two target remifentanil blood concentrations (3 ng/ml, 5 ng/ml) was required to blunt hemodynamic changes during intubation and to reduce propofol-induced pain.
amod||v-4/NN||non-obese-2/JJ	nn||v-4/NN||subjects-3/NNS	prep_in||cav-1-6/JJ||v-4/NN	root||ROOT-0/null||cav-1-6/JJ	advmod||correlated-8/VBN||also-7/RB	vmod||cav-1-6/JJ||correlated-8/VBN	amod||synthase-11/NN||fattyacid-10/JJ	prep_with||correlated-8/VBN||synthase-11/NN	nsubj||p-19/VBP||fas-13/NN	appos||fas-13/NN||r-15/SYM	dep||0.60-17/CD||=-16/SYM	rcmod||r-15/SYM||0.60-17/CD	dep||synthase-11/NN||p-19/VBP	number||0.0001-21/CD||<-20/CD	dobj||p-19/VBP||0.0001-21/CD	obese--1||fattyacid-10||no_rel||in non-obese subjects v- cav-1 also correlated with fattyacid synthase ( fas , r = 0.60, p < 0.0001).
num||trials-3/NNS||three-1/CD	amod||trials-3/NNS||quasi-experimental-2/JJ	nsubj||matched-4/VBD||trials-3/NNS	root||ROOT-0/null||matched-4/VBD	det||criteria-7/NNS||the-5/DT	nn||criteria-7/NNS||inclusion-6/NN	nsubj||found-10/VBD||criteria-7/NNS	num||trials-9/NNS||two-8/CD	dep||criteria-7/NNS||trials-9/NNS	ccomp||matched-4/VBD||found-10/VBD	det||reduction-12/NN||a-11/DT	dobj||found-10/VBD||reduction-12/NN	prep_in||found-10/VBD||pain-14/NN	det||use-17/NN||the-16/DT	prep_for||found-10/VBD||use-17/NN	nn||needling-22/NN||trigger-19/NN	nn||needling-22/NN||point-20/NN	amod||needling-22/NN||dry-21/JJ	prep_of||use-17/NN||needling-22/NN	advmod||found-30/VBD||when-23/WRB	csubj||found-30/VBD||combined-24/VBN	prep_with||combined-24/VBN||acupuncture-26/NN	det||third-29/JJ||the-28/DT	prep_with||combined-24/VBN||third-29/JJ	conj_and||acupuncture-26/NN||third-29/JJ	advcl||found-10/VBD||found-30/VBD	det||reduction-32/NN||a-31/DT	dobj||found-30/VBD||reduction-32/NN	prep_in||found-30/VBD||pain-34/NN	xcomp||found-30/VBD||using-35/VBG	number||%-37/NN||1-36/CD	amod||injections-39/NNS||%-37/NN	amod||injections-39/NNS||lidocaine-38/JJ	dobj||using-35/VBG||injections-39/NNS	advmod||combined-41/VBN||when-40/WRB	advcl||using-35/VBG||combined-41/VBN	amod||therapy-44/NN||physical-43/JJ	prep_with||combined-41/VBN||therapy-44/NN	pain-34||lidocaine-38||yes||three quasi-experimental trials matched the inclusion criteria  two trials found a reduction in pain for the use of trigger point dry needling when combined with acupuncture and the third found a reduction in pain using 1% lidocaine injections when combined with physical therapy.
amod||hyperglycemia-2/NN||postprandial-1/JJ	nsubjpass||characterized-6/VBN||hyperglycemia-2/NN	prep_in||hyperglycemia-2/NN||type2diabetes-4/CD	auxpass||characterized-6/VBN||is-5/VBZ	root||ROOT-0/null||characterized-6/VBN	amod||secretion-10/NN||impaired-8/VBN	nn||secretion-10/NN||insulin-9/NN	agent||characterized-6/VBN||secretion-10/NN	agent||characterized-6/VBN||action-12/NN	conj_and||secretion-10/NN||action-12/NN	amod||effectiveness-16/NN||decreased-14/VBN	nn||effectiveness-16/NN||glucose-15/NN	appos||action-12/NN||effectiveness-16/NN	amod||suppression-19/NN||defective-18/JJ	appos||action-12/NN||suppression-19/NN	conj_and||effectiveness-16/NN||suppression-19/NN	nn||secretion-22/NN||glucagon-21/NN	prep_of||suppression-19/NN||secretion-22/NN	hyperglycemia-2||glucose-15||no||postprandial hyperglycemia in type2diabetes is characterized by impaired insulin secretion and action, decreased glucose effectiveness and defective suppression of glucagon secretion.
amod||infection-7/NN||posttransfusion-1/JJ	amod||infection-7/NN||hepatitisb-2/JJ	nn||infection-7/NN||virus-3/NN	appos||infection-7/NN||hbv-5/NN	nsubj||occurs-9/VBZ||infection-7/NN	advmod||occurs-9/VBZ||still-8/RB	root||ROOT-0/null||occurs-9/VBZ	mark||reduced-16/VBN||although-10/IN	poss||incidence-12/NN||its-11/PRP$	nsubjpass||reduced-16/VBN||incidence-12/NN	aux||reduced-16/VBN||has-13/VBZ	auxpass||reduced-16/VBN||been-14/VBN	advmod||reduced-16/VBN||substantially-15/RB	advcl||occurs-9/VBZ||reduced-16/VBN	det||introduction-19/NN||the-18/DT	prep_since||reduced-16/VBN||introduction-19/NN	prep_of||introduction-19/NN||screening-21/NN	prep_of||screening-21/NN||hepatitisbsurfaceantigen-23/NN	appos||hepatitisbsurfaceantigen-23/NN||hbsag-25/NN	nn||donors-29/NNS||blood-28/NN	prep_in||hepatitisbsurfaceantigen-23/NN||donors-29/NNS	hbv-5||hepatitisbsurfaceantigen-23||yes||posttransfusion hepatitisb virus (hbv) infection still occurs although its incidence has been substantially reduced since the introduction of screening of hepatitisbsurfaceantigen (hbsag) in blood donors.
nsubj||agent-5/NN||yersiniapestis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiologic-4/JJ	root||ROOT-0/null||agent-5/NN	nsubj||killed-10/VBN||agent-5/NN	prep_of||agent-5/NN||plague-7/NNP	aux||killed-10/VBN||has-9/VBZ	rcmod||agent-5/NN||killed-10/VBN	mwe||than-12/IN||more-11/JJR	quantmod||million-14/CD||than-12/IN	number||million-14/CD||200-13/CD	num||people-15/NNS||million-14/CD	dobj||killed-10/VBN||people-15/NNS	det||history-19/NN||the-17/DT	amod||history-19/NN||recorded-18/VBN	prep_throughout||killed-10/VBN||history-19/NN	prep_of||history-19/NN||mankind-21/NN	plague-7||yersiniapestis-1||no||yersiniapestis is the etiologic agent of plague that has killed more than 200 million people throughout the recorded history of mankind.
amod||disinfections-3/NNS||repeated-1/VBN	amod||disinfections-3/NNS||simulated-2/JJ	nsubj||cause-9/VB||disinfections-3/NNS	nn||energy-6/NN||microwave-5/NN	prep_by||disinfections-3/NNS||energy-6/NN	aux||cause-9/VB||did-7/VBD	neg||cause-9/VB||not-8/RB	root||ROOT-0/null||cause-9/VB	amod||effect-11/NN||deleterious-10/JJ	dobj||cause-9/VB||effect-11/NN	det||adaptation-15/NN||the-13/DT	nn||adaptation-15/NN||base-14/NN	prep_on||cause-9/VB||adaptation-15/NN	tmod||flask-24/VBP||adaptation-15/NN	advmod||flask-24/VBP||when-17/WRB	det||cramp-20/NN||the-18/DT	amod||cramp-20/NN||traditional-19/JJ	nsubj||flask-24/VBP||cramp-20/NN	nn||system-23/NN||rs-22/NN	conj_and||cramp-20/NN||system-23/NN	nsubj||flask-24/VBP||system-23/NN	rcmod||adaptation-15/NN||flask-24/VBP	nn||methods-26/NNS||closure-25/NN	nsubjpass||compared-28/VBN||methods-26/NNS	auxpass||compared-28/VBN||were-27/VBD	ccomp||flask-24/VBP||compared-28/VBN	base-14||cramp-20||no_rel||repeated simulated disinfections by microwave energy did not cause deleterious effect on the base adaptation, when the traditional cramp and rs system flask closure methods were compared.
prep_in||involved-9/VBN||tanzania-2/NN	conj_and||tanzania-2/NN||uganda-4/NN	prep_in||involved-9/VBN||uganda-4/NN	det||rtrc-6/NN||the-5/DT	nsubjpass||involved-9/VBN||rtrc-6/NN	aux||involved-9/VBN||has-7/VBZ	auxpass||involved-9/VBN||been-8/VBN	root||ROOT-0/null||involved-9/VBN	det||training-12/NN||the-11/DT	prep_with||involved-9/VBN||training-12/NN	nn||workers-16/NNS||health-14/NN	nn||workers-16/NNS||care-15/NN	prep_of||training-12/NN||workers-16/NNS	amod||management-20/NN||hiv/aids-18/JJ	amod||management-20/NN||pharmaceutical-19/JJ	prep_in||involved-9/VBN||management-20/NN	aids--1||hiv--1||no||in tanzania and uganda the rtrc has been involved with the training of health care workers in hiv/aids pharmaceutical management.
nsubjpass||shown-3/VBN||fondaparinux-1/NN	nsubj||efficacious-6/JJ||fondaparinux-1/NN	auxpass||shown-3/VBN||was-2/VBD	root||ROOT-0/null||shown-3/VBN	aux||efficacious-6/JJ||to-4/TO	cop||efficacious-6/JJ||be-5/VB	xcomp||shown-3/VBN||efficacious-6/JJ	det||prevention-9/NN||the-8/DT	prep_in||efficacious-6/JJ||prevention-9/NN	amod||heparins-15/NNS||deep-11/JJ	nn||heparins-15/NNS||veinthrombosis-12/NN	nn||heparins-15/NNS||vs-13/NN	amod||heparins-15/NNS||low-molecular-weight-14/JJ	prep_of||prevention-9/NN||heparins-15/NNS	mark||shown-28/VBN||while-17/IN	det||setting-20/NN||the-19/DT	prep_in||shown-28/VBN||setting-20/NN	amod||disease-24/NN||venous-22/JJ	amod||disease-24/NN||thrombo-embolic-23/JJ	prep_of||setting-20/NN||disease-24/NN	nsubjpass||shown-28/VBN||it-26/PRP	nsubj||noninferior-31/JJ||it-26/PRP	auxpass||shown-28/VBN||was-27/VBD	advcl||efficacious-6/JJ||shown-28/VBN	aux||noninferior-31/JJ||to-29/TO	cop||noninferior-31/JJ||be-30/VB	xcomp||shown-28/VBN||noninferior-31/JJ	prep_to||noninferior-31/JJ||enoxaparin-33/NN	prep_to||noninferior-31/JJ||ufh-35/NN	conj_and||enoxaparin-33/NN||ufh-35/NN	veinthrombosis-12||enoxaparin-33||yes||fondaparinux was shown to be efficacious in the prevention of deep veinthrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and ufh.
amod||herpesvirus-2/NNS||bovine-1/JJ	nsubj||pathogen-10/NN||herpesvirus-2/NNS	amod||herpesvirus-2/NNS||type-1-3/JJ	dep||type-1-3/JJ||bhv-1-5/JJ	cop||pathogen-10/NN||is-7/VBZ	det||pathogen-10/NN||an-8/DT	amod||pathogen-10/NN||important-9/JJ	root||ROOT-0/null||pathogen-10/NN	prep_of||pathogen-10/NN||cattle-12/NNS	nsubj||presents-14/VBZ||cattle-12/NNS	rcmod||cattle-12/NNS||presents-14/VBZ	det||variety-17/NN||a-16/DT	prep_with||presents-14/VBZ||variety-17/NN	amod||signs-20/NNS||clinical-19/JJ	prep_of||variety-17/NN||signs-20/NNS	det||infectiousbovinerhinotracheitis-28/NNS||the-23/DT	amod||infectiousbovinerhinotracheitis-28/NNS||upper-24/JJ	amod||infectiousbovinerhinotracheitis-28/NNS||respiratory-25/JJ	nn||infectiousbovinerhinotracheitis-28/NNS||tract-26/NN	nn||infectiousbovinerhinotracheitis-28/NNS||infection-27/NN	prep_including||variety-17/NN||infectiousbovinerhinotracheitis-28/NNS	appos||cattle-12/NNS||ibr-30/NN	infectiousbovinerhinotracheitis-28||bhv-1-5||no||bovine herpesvirus type-1 (bhv-1) is an important pathogen of cattle that presents with a variety of clinical signs, including the upper respiratory tract infection infectiousbovinerhinotracheitis (ibr).
aux||understand-2/VB||to-1/TO	ccomp||studied-30/VBD||understand-2/VB	det||mechanism-5/NN||the-3/DT	amod||mechanism-5/NN||molecular-4/JJ	dobj||understand-2/VB||mechanism-5/NN	nn||responses-8/NNS||host-7/NN	prep_of||mechanism-5/NN||responses-8/NNS	advmod||pathogenic-11/JJ||highly-10/RB	amod||avianinfluenzavirusinfection-12/NN||pathogenic-11/JJ	prep_to||understand-2/VB||avianinfluenzavirusinfection-12/NN	aux||get-15/VB||to-14/TO	conj_and||understand-2/VB||get-15/VB	ccomp||studied-30/VBD||get-15/VB	det||insight-17/NN||an-16/DT	dobj||get-15/VB||insight-17/NN	det||means-20/NN||the-19/DT	prep_into||get-15/VB||means-20/NN	prep_through||overcomes-24/VBZ||means-20/NN	nsubj||overcomes-24/VBZ||virus-23/NN	rcmod||means-20/NN||overcomes-24/VBZ	nn||mechanism-27/NN||host-25/NN	nn||mechanism-27/NN||defense-26/NN	dobj||overcomes-24/VBZ||mechanism-27/NN	nsubj||studied-30/VBD||we-29/PRP	nsubj||compared-60/VBD||we-29/PRP	root||ROOT-0/null||studied-30/VBD	amod||response-34/NN||global-31/JJ	nn||response-34/NN||gene-32/NN	nn||response-34/NN||expression-33/NN	nsubj||virus-58/NN||response-34/NN	amod||cells-39/NNS||human-36/JJ	nn||cells-39/NNS||lung-37/NN	nn||cells-39/NNS||carcinoma-38/NN	prep_of||response-34/NN||cells-39/NNS	appos||cells-39/NNS||a549-41/NNP	amod||stages-47/NNS||early-44/JJ	conj_and||early-44/JJ||late-46/JJ	amod||stages-47/NNS||late-46/JJ	prep_at||cells-39/NNS||stages-47/NNS	prep_of||cells-39/NNS||infection-49/NN	advmod||pathogenic-52/JJ||highly-51/RB	amod||avianinfluenza-53/NN||pathogenic-52/JJ	prep_with||infection-49/NN||avianinfluenza-53/NN	det||virus-58/NN||a-54/DT	nn||virus-58/NN||h5n1-56/NN	xcomp||studied-30/VBD||virus-58/NN	conj_and||studied-30/VBD||compared-60/VBD	dobj||compared-60/VBD||it-61/PRP	det||genetics-65/NNS||a-63/DT	amod||genetics-65/NNS||reverse-64/JJ	prep_with||compared-60/VBD||genetics-65/NNS	vmod||genetics-65/NNS||modified-66/VBN	xcomp||modified-66/VBN||recombinant-67/VBG	det||virus-73/NN||a-68/DT	appos||virus-73/NN||h5n1-70/NNP	nn||virus-73/NN||vaccine-72/NN	dobj||recombinant-67/VBG||virus-73/NN	vmod||virus-73/NN||using-74/VBG	amod||platform-76/NN||microarray-75/JJ	dobj||using-74/VBG||platform-76/NN	avianinfluenza-53||avianinfluenzavirus--1||no||to understand the molecular mechanism of host responses to highly pathogenic avianinfluenzavirusinfection and to get an insight into the means through which virus overcomes host defense mechanism, we studied global gene expression response of human lung carcinoma cells (a549) at early and late stages of infection with highly pathogenic avianinfluenza a (h5n1) virus and compared it with a reverse genetics modified recombinant a (h5n1) vaccine virus using microarray platform.
nsubj||reported-3/VBD||we-1/PRP	advmod||reported-3/VBD||earlier-2/RB	root||ROOT-0/null||reported-3/VBD	mark||resulted-20/VBD||that-4/IN	nsubj||resulted-20/VBD||treatment-5/NN	amod||cultures-8/NNS||astrocyte-7/JJ	prep_of||treatment-5/NN||cultures-8/NNS	det||concentration-12/NN||a-10/DT	amod||concentration-12/NN||pathophysiological-11/JJ	prep_with||cultures-8/NNS||concentration-12/NN	prep_of||concentration-12/NN||ammonia-14/NN	num||nh4cl-18/NNS||5-16/CD	nn||nh4cl-18/NNS||mm-17/NNP	appos||ammonia-14/NN||nh4cl-18/NNS	ccomp||reported-3/VBD||resulted-20/VBD	det||activation-23/NN||the-22/DT	prep_in||resulted-20/VBD||activation-23/NN	amod||factor-kappab-26/NN||nuclear-25/JJ	prep_of||activation-23/NN||factor-kappab-26/NN	appos||factor-kappab-26/NN||nf-îºb-28/NNP	mark||diminished-36/VBN||that-31/IN	nsubj||diminished-36/VBN||inhibition-32/NN	amod||activation-35/NN||such-34/JJ	prep_of||inhibition-32/NN||activation-35/NN	ccomp||reported-3/VBD||diminished-36/VBN	conj_and||resulted-20/VBD||diminished-36/VBN	dobj||diminished-36/VBN||astrocyte-37/NN	amod||astrocyte-37/NN||swelling-38/VBG	vmod||diminished-36/VBN||suggesting-40/VBG	det||role-43/NN||a-41/DT	amod||role-43/NN||key-42/JJ	dobj||suggesting-40/VBG||role-43/NN	prep_of||role-43/NN||nf-îºb-45/NN	det||mechanism-48/NN||the-47/DT	prep_in||suggesting-40/VBG||mechanism-48/NN	amod||astrocyte-51/NN||ammonia-induced-50/JJ	prep_of||mechanism-48/NN||astrocyte-51/NN	amod||astrocyte-51/NN||swelling-52/VBG	ammonia-14||swelling-52||no_rel||we earlier reported that treatment of astrocyte cultures with a pathophysiological concentration of ammonia (5 mm nh4cl) resulted in the activation of nuclear factor-kappab (nf-îºb) and that inhibition of such activation diminished astrocyte swelling, suggesting a key role of nf-îºb in the mechanism of ammonia-induced astrocyte swelling.
advmod||suppressed-5/VBD||additionally-1/RB	amod||nac-5-htr4-4/NNS||inactivating-3/VBG	nsubj||suppressed-5/VBD||nac-5-htr4-4/NNS	root||ROOT-0/null||suppressed-5/VBD	poss||preference-8/NN||ecstasy-6/NN	dobj||suppressed-5/VBD||preference-8/NN	vmod||suppressed-5/VBD||strengthening-10/VBG	det||facet-13/NN||the-11/DT	amod||facet-13/NN||rewarding-12/JJ	dobj||strengthening-10/VBG||facet-13/NN	prep_of||facet-13/NN||anorexia-15/NNP	nac--1||anorexia-15||no_rel||additionally, inactivating nac-5-htr4 suppressed ecstasy's preference, strengthening the rewarding facet of anorexia.
nsubj||achieved-2/VBD||she-1/PRP	root||ROOT-0/null||achieved-2/VBD	det||improvement-6/NN||a-3/DT	advmod||dramatic-5/JJ||rather-4/RB	amod||improvement-6/NN||dramatic-5/JJ	dobj||achieved-2/VBD||improvement-6/NN	nn||control-9/NN||pain-8/NN	prep_of||improvement-6/NN||control-9/NN	det||response-14/NN||a-11/DT	amod||response-14/NN||significant-12/JJ	amod||response-14/NN||biochemical-13/JJ	dobj||achieved-2/VBD||response-14/NN	conj_but||improvement-6/NN||response-14/NN	number||%-17/NN||75-16/CD	amod||reduction-18/NN||%-17/NN	prep_with||response-14/NN||reduction-18/NN	det||level-23/NN||the-20/DT	amod||level-23/NN||ca-125-21/JJ	nn||level-23/NN||antigen-22/NN	prep_of||reduction-18/NN||level-23/NN	amod||regression-30/NN||limited-27/JJ	amod||regression-30/NN||radiographic-28/JJ	nn||regression-30/NN||tumor-29/NN	dobj||achieved-2/VBD||regression-30/NN	conj_but||improvement-6/NN||regression-30/NN	pain-8||ca--1||no_rel||she achieved a rather dramatic improvement of pain control, a significant biochemical response with 75% reduction of the ca-125 antigen level, but only limited radiographic tumor regression.
det||female-4/NN||a-1/DT	amod||female-4/NN||48-year-old-2/JJ	nn||female-4/NN||chinese-3/NN	nsubjpass||found-13/VBN||female-4/NN	nsubj||have-15/VB||female-4/NN	amod||hepatitisbvirus-7/NNS||underlying-6/VBG	prep_with||female-4/NN||hepatitisbvirus-7/NNS	dep||found-13/VBN||hbv-9/NN	nsubjpass||found-13/VBN||infection-11/NN	nsubj||have-15/VB||infection-11/NN	auxpass||found-13/VBN||was-12/VBD	root||ROOT-0/null||found-13/VBN	aux||have-15/VB||to-14/TO	xcomp||found-13/VBN||have-15/VB	det||nodule-20/NN||a-16/DT	amod||nodule-20/NN||low-17/JJ	amod||nodule-20/NN||echoic-18/JJ	amod||nodule-20/NN||hepatic-19/JJ	dobj||have-15/VB||nodule-20/NN	amod||ultrasound-23/NN||abdominal-22/JJ	prep_by||have-15/VB||ultrasound-23/NN	hbv-9||hepatitisbvirus-7||no||a 48-year-old chinese female with underlying hepatitisbvirus (hbv) infection was found to have a low echoic hepatic nodule by abdominal ultrasound.
det||compound-3/NN||the-1/DT	nn||compound-3/NN||title-2/NN	nsubj||contains-12/VBZ||compound-3/NN	nn||-RSB--10/NNP||-LSB--5/NNP	nn||-RSB--10/NNP||zni2-6/NNP	appos||-RSB--10/NNP||c10h8n2s-8/NNP	appos||compound-3/NN||-RSB--10/NNP	root||ROOT-0/null||contains-12/VBZ	det||ring-16/NN||a-13/DT	amod||ring-16/NN||six-membered-14/JJ	nn||ring-16/NN||chelate-15/NN	dobj||contains-12/VBZ||ring-16/NN	vmod||ring-16/NN||adopting-17/VBG	vmod||ring-16/NN||adopting-17/VBG	conj_and||adopting-17/VBG||adopting-17/VBG	det||conformation-20/NN||a-18/DT	nn||conformation-20/NN||boat-19/NN	dobj||adopting-17/VBG||conformation-20/NN	dobj||coordinated-27/VBN||which-22/WDT	det||atom-25/NN||the-23/DT	nn||atom-25/NN||zn-24/NN	nsubjpass||coordinated-27/VBN||atom-25/NN	auxpass||coordinated-27/VBN||is-26/VBZ	prepc_in||adopting-17/VBG||coordinated-27/VBN	num||ions-31/NNS||two-29/CD	amod||ions-31/NNS||iodide-30/JJ	agent||coordinated-27/VBN||ions-31/NNS	det||atoms-38/NNS||the-34/DT	num||atoms-38/NNS||two-35/CD	amod||atoms-38/NNS||pyridyl-36/JJ	nn||atoms-38/NNS||n-37/NN	agent||adopting-17/VBG||atoms-38/NNS	det||sulfide-43/NN||a-40/DT	amod||sulfide-43/NN||single-41/JJ	amod||sulfide-43/NN||di-2-pyridyl-42/JJ	prep_of||atoms-38/NNS||sulfide-43/NN	vmod||sulfide-43/NN||ligand-44/VBN	det||tetraâhedron-49/NN||a-46/DT	advmod||distorted-48/JJ||slightly-47/RB	amod||tetraâhedron-49/NN||distorted-48/JJ	prep_within||ligand-44/VBN||tetraâhedron-49/NN	tetra--1||di--1||no_rel||the title compound, [zni2(c10h8n2s)], contains a six-membered chelate ring adopting a boat conformation in which the zn atom is coordinated by two iodide ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand within a slightly distorted tetraâ­hedron.
nsubj||affect-6/VB||mutation-1/NN	nsubj||affects-17/VBZ||mutation-1/NN	prep_of||mutation-1/NN||gapa-1-3/CD	aux||affect-6/VB||does-4/VBZ	neg||affect-6/VB||not-5/RB	root||ROOT-0/null||affect-6/VB	det||rate-11/NN||the-7/DT	dep||vitro-9/NN||in-8/IN	amod||rate-11/NN||vitro-9/NN	nn||rate-11/NN||growth-10/NN	dobj||affect-6/VB||rate-11/NN	prep_of||rate-11/NN||n.meningitidis-13/NNS	advmod||affects-17/VBZ||significantly-16/RB	conj_but||affect-6/VB||affects-17/VBZ	det||ability-19/NN||the-18/DT	dobj||affects-17/VBZ||ability-19/NN	det||organism-22/NN||the-21/DT	prep_of||ability-19/NN||organism-22/NN	aux||adhere-24/VB||to-23/TO	vmod||organism-22/NN||adhere-24/VB	amod||cells-30/NNS||human-26/JJ	amod||cells-30/NNS||epithelial-27/JJ	conj_and||epithelial-27/JJ||endothelial-29/JJ	amod||cells-30/NNS||endothelial-29/JJ	prep_to||adhere-24/VB||cells-30/NNS	det||process-34/NN||a-32/DT	amod||process-34/NN||capsule-independent-33/JJ	prep_in||adhere-24/VB||process-34/NN	vmod||process-34/NN||suggesting-35/VBG	det||role-37/NN||a-36/DT	dobj||suggesting-35/VBG||role-37/NN	det||pathogenesis-40/NNS||the-39/DT	prep_in||suggesting-35/VBG||pathogenesis-40/NNS	prep_of||pathogenesis-40/NNS||meningococcalinfection-42/NN	meningococcalinfection-42||n.meningitidis-13||no||mutation of gapa-1 does not affect the in vitro growth rate of n.meningitidis , but significantly affects the ability of the organism to adhere to human epithelial and endothelial cells in a capsule-independent process suggesting a role in the pathogenesis of meningococcalinfection .
det||observations-2/NNS||these-1/DT	nsubj||suggest-3/VBP||observations-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||complex-17/JJ||that-4/IN	det||pathogenesis-6/NNS||the-5/DT	nsubj||complex-17/JJ||pathogenesis-6/NNS	amod||hypertension-9/NN||postmenopausal-8/JJ	prep_of||pathogenesis-6/NNS||hypertension-9/NN	poss||complications-14/NNS||its-11/PRP$	nn||complications-14/NNS||target-12/NN	nn||complications-14/NNS||organ-13/NN	prep_of||pathogenesis-6/NNS||complications-14/NNS	conj_and||hypertension-9/NN||complications-14/NNS	cop||complex-17/JJ||is-15/VBZ	advmod||complex-17/JJ||more-16/RBR	ccomp||suggest-3/VBP||complex-17/JJ	mark||projected-19/VBD||than-18/IN	advcl||complex-17/JJ||projected-19/VBD	ccomp||complex-17/JJ||projected-19/VBD	mark||induces-27/VBZ||that-22/IN	nsubj||induces-27/VBZ||loss-23/NN	amod||estrogens-26/NNS||endogenous-25/JJ	prep_of||loss-23/NN||estrogens-26/NNS	advcl||complex-17/JJ||induces-27/VBZ	ccomp||complex-17/JJ||induces-27/VBZ	conj_and||projected-19/VBD||induces-27/VBZ	amod||changes-29/NNS||epigenetic-28/JJ	dobj||induces-27/VBZ||changes-29/NNS	nsubj||alter-31/VBP||changes-29/NNS	rcmod||changes-29/NNS||alter-31/VBP	amod||susceptibility-33/NN||genetic-32/JJ	dobj||alter-31/VBP||susceptibility-33/NN	amod||complications-36/NNS||end-organ-35/JJ	prep_to||alter-31/VBP||complications-36/NNS	nn||se-38/FW||per-37/FW	advmod||resulting-39/VBG||se-38/FW	xcomp||alter-31/VBP||resulting-39/VBG	amod||mechanisms-42/NNS||pathogenetic-41/JJ	prep_in||resulting-39/VBG||mechanisms-42/NNS	prep_beyond||resulting-39/VBG||correction-44/NN	nn||replacement-47/NN||hormone-46/NN	prep_by||resulting-39/VBG||replacement-47/NN	hypertension-9||hormone-46||no_rel||these observations suggest that the pathogenesis of postmenopausal hypertension and its target organ complications is more complex than projected, and that loss of endogenous estrogens induces epigenetic changes that alter genetic susceptibility to end-organ complications per se resulting in pathogenetic mechanisms beyond correction by hormone replacement.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||œsix-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||nvp-23||yes||we assessed nvp-resistance in indian infants enrolled in the â€œsix-week extended-dose nevirapineâ€? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
det||proof-3/NN||this-2/DT	prep_for||compared-9/VBD||proof-3/NN	amod||study-6/NN||principal-5/JJ	prep_of||proof-3/NN||study-6/NN	nsubj||compared-9/VBD||we-8/PRP	root||ROOT-0/null||compared-9/VBD	amod||clearance-11/NN||bacillary-10/JJ	dobj||compared-9/VBD||clearance-11/NN	det||lungs-14/NNS||the-13/DT	prep_from||compared-9/VBD||lungs-14/NNS	prep_of||lungs-14/NNS||mtb-16/NN	amod||mice-19/NNS||infected-18/JJ	nsubj||treated-20/VBN||mice-19/NNS	parataxis||compared-9/VBD||treated-20/VBN	det||isoniazid-25/NN||the-22/DT	amod||isoniazid-25/NN||anti-tb-23/JJ	nn||isoniazid-25/NN||drug-24/NN	prep_with||treated-20/VBN||isoniazid-25/NN	appos||isoniazid-25/NN||inh-27/NN	det||presence-31/NN||the-30/DT	prep_in||treated-20/VBN||presence-31/NN	prep_in||treated-20/VBN||absence-33/NN	conj_and||presence-31/NN||absence-33/NN	det||inhibitor-39/NN||an-35/DT	amod||inhibitor-39/NN||immunomodulatory-36/JJ	amod||inhibitor-39/NN||phosphodiesterase-37/JJ	dep||phosphodiesterase-37/JJ||4-38/CD	prep_of||presence-31/NN||inhibitor-39/NN	appos||inhibitor-39/NN||pde4i-41/NNP	dep||treated-20/VBN||cc-3052-44/JJ	tb--1||isoniazid-25||yes||for this proof of principal study, we compared bacillary clearance from the lungs of mtb -infected mice treated with the anti-tb drug isoniazid (inh) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (pde4i), cc-3052.
det||profile-3/NN||the-1/DT	nn||profile-3/NN||search-2/NN	nsubj||consisted-4/VBD||profile-3/NN	root||ROOT-0/null||consisted-4/VBD	prep_of||consisted-4/VBD||terms-6/NNS	vmod||terms-6/NNS||referring-7/VBG	amod||deficiency-12/NN||vitamind-9/JJ	conj_or||vitamind-9/JJ||vitamind-11/JJ	amod||deficiency-12/NN||vitamind-11/JJ	prep_to||referring-7/VBG||deficiency-12/NN	amod||studies-17/NNS||prevalence-14/JJ	conj_or||prevalence-14/JJ||cross-sectional-16/JJ	amod||studies-17/NNS||cross-sectional-16/JJ	prep_to||referring-7/VBG||studies-17/NNS	conj_and||deficiency-12/NN||studies-17/NNS	prep_to||referring-7/VBG||countries-20/NNS	conj_and||deficiency-12/NN||countries-20/NNS	conj_and||deficiency-12/NN||ethnicity-22/NN	conj_or||countries-20/NNS||ethnicity-22/NN	vitamind-11||vitaminddeficiency--1||no_rel||the search profile consisted of terms referring to vitamind or vitamind deficiency, prevalence or cross-sectional studies, and countries or ethnicity.
nsubj||associated-28/VBN||ii-2/NN	nsubj||had-5/VBD||they-4/PRP	rcmod||ii-2/NN||had-5/VBD	amod||profiles-9/NNS||distinctive-6/JJ	amod||profiles-9/NNS||kinetic-7/JJ	nn||profiles-9/NNS||expression-8/NN	dobj||had-5/VBD||profiles-9/NNS	nn||receptor-14/NN||type-11/FW	nn||receptor-14/NN||i-12/FW	nn||receptor-14/NN||interferon-13/NN	prep_in||profiles-9/NNS||receptor-14/NN	amod||mice-18/NNS||stat1-16/JJ	nn||mice-18/NNS||knockout-17/NN	prep_in||profiles-9/NNS||mice-18/NNS	conj_and||receptor-14/NN||mice-18/NNS	prep_during||had-5/VBD||sars-covinfection-20/NN	amod||signatures-24/NNS||unique-23/JJ	prep_including||had-5/VBD||signatures-24/NNS	nn||expression-27/NN||ncrna-26/NN	prep_of||signatures-24/NNS||expression-27/NN	root||ROOT-0/null||associated-28/VBN	amod||infection-31/NN||lethal-30/JJ	prep_with||associated-28/VBN||infection-31/NN	interferon-13||sars-covinfection-20||no_rel||(ii) they had distinctive kinetic expression profiles in type i interferon receptor and stat1 knockout mice during sars-covinfection, including unique signatures of ncrna expression associated with lethal infection.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	nsubj||ketamine-21/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||combination-10/NN||a-9/DT	dobj||compare-8/VB||combination-10/NN	prep_of||combination-10/NN||lidocaine-12/NN	prep_of||combination-10/NN||ketamine-14/NN	conj_and||lidocaine-12/NN||ketamine-14/NN	amod||pain-17/NN||aquafol-induced-16/JJ	prep_on||compare-8/VB||pain-17/NN	prep_with||compare-8/VB||lidocaine-19/NN	xcomp||was-6/VBD||ketamine-21/VB	conj_or||compare-8/VB||ketamine-21/VB	advmod||ketamine-21/VB||alone-22/RB	det||induction-25/NN||the-24/DT	prep_during||ketamine-21/VB||induction-25/NN	prep_of||induction-25/NN||anesthesia-27/NN	pain-17||lidocaine-19||yes||the purpose of this study was to compare a combination of lidocaine and ketamine on aquafol-induced pain with lidocaine or ketamine alone during the induction of anesthesia.
amod||measures-3/NNS||secondary-1/JJ	nn||measures-3/NNS||outcome-2/NN	nsubj||included-4/VBD||measures-3/NNS	root||ROOT-0/null||included-4/VBD	dobj||included-4/VBD||opioids-5/NNS	nn||use-8/NN||alcohol-7/NN	dobj||included-4/VBD||use-8/NN	conj_and||opioids-5/NNS||use-8/NN	prepc_according_to||included-4/VBD||to-10/TO	pobj||included-4/VBD||urinalysis-11/NNS	amod||ratings-14/NNS||self-report-13/JJ	nsubj||measured-30/VBN||ratings-14/NNS	appos||ratings-14/NNS||intensity-16/NN	amod||craving-19/NN||opioid-18/JJ	prep_of||intensity-16/NN||craving-19/NN	vmod||craving-19/NN||assessed-20/VBN	det||scale-25/NN||a-22/DT	amod||scale-25/NN||visual-23/JJ	amod||scale-25/NN||analogue-24/JJ	prep_with||assessed-20/VBN||scale-25/NN	amod||symptoms-28/NNS||opioidwithdrawal-27/JJ	npadvmod||as-29/RB||symptoms-28/NNS	advmod||measured-30/VBN||as-29/RB	conj_and||included-4/VBD||measured-30/VBN	det||scale-36/NN||the-32/DT	amod||scale-36/NN||short-33/JJ	amod||scale-36/NN||opiate-34/JJ	nn||scale-36/NN||withdrawal-35/NN	prep_by||measured-30/VBN||scale-36/NN	nn||scores-39/NNS||depression-38/NN	prep_by||measured-30/VBN||scores-39/NNS	conj_and||scale-36/NN||scores-39/NNS	det||inventory-43/NN||the-41/DT	nn||inventory-43/NN||hamilton-42/NN	prep_on||measured-30/VBN||inventory-43/NN	opioidwithdrawal-27||opioid-18||no||secondary outcome measures included opioids and alcohol use according to urinalysis and self-report ratings, intensity of opioid craving assessed with a visual analogue scale, opioidwithdrawal symptoms as measured by the short opiate withdrawal scale and depression scores on the hamilton inventory.
nsubj||inhibitor-6/NN||sodiumphenylbutyrate-1/NN	cop||inhibitor-6/NN||is-2/VBZ	det||inhibitor-6/NN||a-3/DT	amod||inhibitor-6/NN||histone-4/JJ	nn||inhibitor-6/NN||deacetylase-5/NN	root||ROOT-0/null||inhibitor-6/NN	nsubjpass||approved-10/VBN||inhibitor-6/NN	nsubj||is-18/VBZ||inhibitor-6/NN	aux||approved-10/VBN||has-8/VBZ	auxpass||approved-10/VBN||been-9/VBN	rcmod||inhibitor-6/NN||approved-10/VBN	prep_for||approved-10/VBN||treatement-12/NN	nn||disorders-16/NNS||urea-14/NN	nn||disorders-16/NNS||cycle-15/NN	prep_of||treatement-12/NN||disorders-16/NNS	rcmod||inhibitor-6/NN||is-18/VBZ	conj_and||approved-10/VBN||is-18/VBZ	prep_under||is-18/VBZ||investigation-20/NN	prep_in||investigation-20/NN||cancer-22/NN	prep_in||investigation-20/NN||hemoglobinopathies-24/NNS	conj_and||cancer-22/NN||hemoglobinopathies-24/NNS	nn||diseases-28/NNS||motor-26/NN	nn||diseases-28/NNS||neuron-27/NN	prep_in||investigation-20/NN||diseases-28/NNS	conj_and||cancer-22/NN||diseases-28/NNS	amod||trials-33/NNS||cysticfibrosis-31/JJ	amod||trials-33/NNS||clinical-32/JJ	prep_in||investigation-20/NN||trials-33/NNS	conj_and||cancer-22/NN||trials-33/NNS	cysticfibrosis-31||sodiumphenylbutyrate-1||yes||sodiumphenylbutyrate is a histone deacetylase inhibitor that has been approved for treatement of urea cycle disorders and is under investigation in cancer, hemoglobinopathies, motor neuron diseases, and cysticfibrosis clinical trials.
nsubj||conducted-3/VBN||we-1/PRP	aux||conducted-3/VBN||have-2/VBP	root||ROOT-0/null||conducted-3/VBN	det||screening-6/NN||a-4/DT	amod||screening-6/NN||phenotypic-5/JJ	dobj||conducted-3/VBN||screening-6/NN	amod||cells-9/NNS||endothelial-8/JJ	prep_in||conducted-3/VBN||cells-9/NNS	vmod||cells-9/NNS||exposed-10/VBN	amod||glucose-14/NN||elevated-12/JJ	nn||glucose-14/NN||extracellular-13/NN	prep_to||exposed-10/VBN||glucose-14/NN	det||model-19/NN||an-16/DT	dep||vitro-18/NN||in-17/IN	amod||model-19/NN||vitro-18/NN	dep||glucose-14/NN||model-19/NN	prep_of||model-19/NN||hyperglycemia-21/NN	aux||identify-24/VB||to-23/TO	xcomp||exposed-10/VBN||identify-24/VB	dobj||identify-24/VB||compounds-25/NNS	dep||identify-24/VB||that-26/IN	dep||identify-24/VB||prevent-27/VB	amod||species-31/NNS||hyperglycemia-induced-28/JJ	amod||species-31/NNS||reactive-29/JJ	nn||species-31/NNS||oxygen-30/NN	dobj||prevent-27/VB||species-31/NNS	appos||species-31/NNS||ros-33/NN	dobj||identify-24/VB||formation-35/NN	advmod||affecting-38/VBG||adversely-37/RB	prepc_without||identify-24/VB||affecting-38/VBG	nn||viability-40/NN||cell-39/NN	dobj||affecting-38/VBG||viability-40/NN	hyperglycemia-21||glucose-14||no||we have conducted a phenotypic screening in endothelial cells exposed to elevated extracellular glucose (an in vitro model of hyperglycemia) to identify compounds that prevent hyperglycemia-induced reactive oxygen species (ros) formation without adversely affecting cell viability.
nsubj||atypicalantipsychoticdrug-4/NN||aripiprazole-1/NN	cop||atypicalantipsychoticdrug-4/NN||is-2/VBZ	det||atypicalantipsychoticdrug-4/NN||an-3/DT	root||ROOT-0/null||atypicalantipsychoticdrug-4/NN	vmod||atypicalantipsychoticdrug-4/NN||approved-5/VBN	det||treatment-8/NN||the-7/DT	prep_for||approved-5/VBN||treatment-8/NN	amod||disorders-11/NNS||psychiatric-10/JJ	prep_of||treatment-8/NN||disorders-11/NNS	nn||depressivedisorder-19/NN||schizophrenia-14/NN	prep_such_as||disorders-11/NNS||bipolardisorder-16/NN	conj_and||depressivedisorder-19/NN||bipolardisorder-16/NN	prep_such_as||disorders-11/NNS||major-18/JJ	amod||depressivedisorder-19/NN||major-18/JJ	conj_and||depressivedisorder-19/NN||major-18/JJ	prep_such_as||disorders-11/NNS||depressivedisorder-19/NN	prep_such_as||disorders-11/NNS||autism-21/NN	conj_and||depressivedisorder-19/NN||autism-21/NN	bipolardisorder-16||aripiprazole-1||no_rel||aripiprazole is an atypicalantipsychoticdrug approved for the treatment of psychiatric disorders such as schizophrenia, bipolardisorder, major depressivedisorder and autism.
num||cities-5/NNS||two-2/CD	amod||cities-5/NNS||neighboring-3/JJ	nn||cities-5/NNS||german-4/NN	prep_in||recorded-23/VBN||cities-5/NNS	amod||factors-10/NNS||prevalence-7/JJ	conj_and||prevalence-7/JJ||additional-9/JJ	amod||factors-10/NNS||additional-9/JJ	nsubjpass||recorded-23/VBN||factors-10/NNS	det||development-13/NN||the-12/DT	prep_of||factors-10/NNS||development-13/NN	prep_of||development-13/NN||bp-onj-15/NNP	nn||patients-18/NNS||multiplemyeloma-17/NN	prep_in||bp-onj-15/NNP||patients-18/NNS	amod||therapy-21/NN||bisphosphonates-20/JJ	prep_with||patients-18/NNS||therapy-21/NN	auxpass||recorded-23/VBN||were-22/VBD	root||ROOT-0/null||recorded-23/VBN	xcomp||recorded-23/VBN||using-24/VBG	det||retrospective-26/NN||a-25/DT	dobj||using-24/VBG||retrospective-26/NN	appos||retrospective-26/NN||rs-28/NN	amod||study-32/NN||cross-sectional-31/JJ	dobj||using-24/VBG||study-32/NN	conj_and||retrospective-26/NN||study-32/NN	appos||study-32/NN||css-34/NN	dep||retrospective-26/NN||design-36/NN	bisphosphonates-20||multiplemyeloma-17||no_rel||in two neighboring german cities, prevalence and additional factors of the development of bp-onj in multiplemyeloma patients with bisphosphonates therapy were recorded using a retrospective (rs) and cross-sectional study (css) design.
advmod||driven-2/JJ||chemically-1/RB	amod||interactions-3/NNS||driven-2/JJ	nsubj||important-6/JJ||interactions-3/NNS	cop||important-6/JJ||are-4/VBP	advmod||important-6/JJ||also-5/RB	root||ROOT-0/null||important-6/JJ	det||establishment-9/NN||the-8/DT	prep_for||important-6/JJ||establishment-9/NN	prep_in||protect-33/VB||establishment-9/NN	prep_of||establishment-9/NN||cross-relationships-11/NNS	prep_between||cross-relationships-11/NNS||microbes-13/NNS	poss||hosts-17/NNS||their-15/PRP$	amod||hosts-17/NNS||eukaryotic-16/JJ	prep_between||cross-relationships-11/NNS||hosts-17/NNS	conj_and||microbes-13/NNS||hosts-17/NNS	nsubj||protect-33/VB||organisms-21/NNS	vmod||organisms-21/NNS||producing-22/VBG	amod||compounds-24/NNS||antimicrobial-23/JJ	dobj||producing-22/VBG||compounds-24/NNS	quantmod||$-27/$||â-26/RB	dep||compounds-24/NNS||$-27/$	number||$-29/CD||œantimicrobialsâ-28/CD	num||$-27/$||$-29/CD	aux||protect-33/VB||may-32/MD	rcmod||establishment-9/NN||protect-33/VB	det||surface-36/NN||the-34/DT	nn||surface-36/NN||host-35/NN	dobj||protect-33/VB||surface-36/NN	dep||protect-33/VB||against-37/IN	prep_over||protect-33/VB||colonisation-39/NN	prep_in||colonisation-39/NN||return-41/NN	det||environment-46/NN||a-43/DT	amod||environment-46/NN||nutrient-44/JJ	amod||environment-46/NN||rich-45/JJ	prep_for||return-41/NN||environment-46/NN	cross--1||chemically-1||no_rel||chemically driven interactions are also important for the establishment of cross-relationships between microbes and their eukaryotic hosts, in which organisms producing antimicrobial compounds (â€œantimicrobialsâ€?), may protect the host surface against over colonisation in return for a nutrient rich environment.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	chf-60||oil--1||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
amod||women-2/NNS||postmenopausal-1/JJ	nsubj||experience-3/VBP||women-2/NNS	root||ROOT-0/null||experience-3/VBP	amod||symptoms-7/NNS||estrogen-4/JJ	amod||symptoms-7/NNS||deficiency-related-5/JJ	amod||symptoms-7/NNS||menopausal-6/JJ	dobj||experience-3/VBP||symptoms-7/NNS	dep||symptoms-7/NNS||e.g.-9/NNP	dep||symptoms-7/NNS||hotflashes-11/NNS	conj_and||e.g.-9/NNP||hotflashes-11/NNS	nn||swings-14/NNS||mood-13/NN	dep||symptoms-7/NNS||swings-14/NNS	conj_and||e.g.-9/NNP||swings-14/NNS	det||increase-19/NN||a-17/DT	amod||increase-19/NN||dramatic-18/JJ	dobj||experience-3/VBP||increase-19/NN	conj_and||symptoms-7/NNS||increase-19/NN	det||incidence-22/NN||the-21/DT	prep_in||increase-19/NN||incidence-22/NN	prep_of||incidence-22/NN||chronicdiseases-24/NNS	hotflashes-11||estrogen-4||yes||postmenopausal women experience estrogen deficiency-related menopausal symptoms (e.g., hotflashes and mood swings) and a dramatic increase in the incidence of chronicdiseases.
advmod||suppressed-10/VBD||additionally-1/RB	nsubj||suppressed-10/VBD||asa-3/NN	amod||acid-8/NN||salicylic-7/JJ	conj_negcc||asa-3/NN||acid-8/NN	nsubj||suppressed-10/VBD||acid-8/NN	root||ROOT-0/null||suppressed-10/VBD	amod||inflammation-13/NN||th17-11/JJ	nn||inflammation-13/NN||airway-12/NN	dobj||suppressed-10/VBD||inflammation-13/NN	nsubjpass||associated-17/VBN||inflammation-13/NN	auxpass||associated-17/VBN||was-16/VBD	rcmod||inflammation-13/NN||associated-17/VBN	amod||expression-20/NN||decreased-19/VBN	prep_with||associated-17/VBN||expression-20/NN	prep_of||expression-20/NN||acetyl-stat3-22/CD	dep||expression-20/NN||downstream-24/JJ	dep||downstream-24/JJ||signaling-25/VBG	prep_of||signaling-25/VBG||il-6-27/JJ	det||lung-31/NN||the-30/DT	prep_in||expression-20/NN||lung-31/NN	inflammation-13||asa-3||yes||additionally, asa, but not salicylic acid, suppressed th17 airway inflammation, which was associated with decreased expression of acetyl-stat3 (downstream signaling of il-6) in the lung.
num||patients-2/NNS||twelve-1/CD	nsubjpass||treated-8/VBN||patients-2/NNS	nn||sdiseaseofbone-6/NN||paget-4/NN	prep_with||patients-2/NNS||sdiseaseofbone-6/NN	auxpass||treated-8/VBN||were-7/VBD	root||ROOT-0/null||treated-8/VBN	amod||calcitonin-12/NN||synthetic-10/JJ	amod||calcitonin-12/NN||human-11/JJ	prep_with||treated-8/VBN||calcitonin-12/NN	number||26-16/CD||seven-14/CD	dep||26-16/CD||to-15/TO	num||months-17/NNS||26-16/CD	prep_for||calcitonin-12/NN||months-17/NNS	dep||months-17/NNS||mean-19/VB	num||months-21/NNS||15.3-20/CD	tmod||mean-19/VB||months-21/NNS	paget'sdiseaseofbone--1||calcitonin-12||yes||twelve patients with paget'sdiseaseofbone were treated with synthetic human calcitonin for seven to 26 months (mean 15.3 months).
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||vasculitis-11/NNS||hydralazine-induced-7/JJ	amod||vasculitis-11/NNS||anti-neutrophil-8/JJ	amod||vasculitis-11/NNS||cytoplasmic-9/JJ	amod||vasculitis-11/NNS||antibody-associated-10/JJ	prep_of||case-5/NN||vasculitis-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||62-year-old-14/JJ	amod||woman-16/NN||caucasian-15/JJ	prep_in||vasculitis-11/NNS||woman-16/NN	nsubj||presented-18/VBN||woman-16/NN	rcmod||woman-16/NN||presented-18/VBN	det||syndrome-22/NN||a-20/DT	amod||syndrome-22/NN||vasculitic-21/JJ	prep_with||presented-18/VBN||syndrome-22/NN	det||throat-26/NN||a-24/DT	amod||throat-26/NN||sore-25/JJ	prep_with||presented-18/VBN||throat-26/NN	prep_with||presented-18/VBN||mouthulcers-28/NNS	conj_and||throat-26/NN||mouthulcers-28/NNS	prep_with||presented-18/VBN||otalgia-30/NN	conj_and||throat-26/NN||otalgia-30/NN	amod||months-33/NNS||several-32/JJ	prep_after||presented-18/VBN||months-33/NNS	amod||symptoms-36/NNS||constitutional-35/JJ	prep_of||months-33/NNS||symptoms-36/NNS	hydralazine--1||mouthulcers-28||no_rel||we report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis in a 62-year-old caucasian woman who presented with a vasculitic syndrome with a sore throat, mouthulcers and otalgia after several months of constitutional symptoms.
nsubjpass||established-12/VBN||chronichepatitisbvirus-1/NNS	appos||chronichepatitisbvirus-1/NNS||hbv-3/NN	amod||virus-7/NN||hepatitisc-6/JJ	conj_and||chronichepatitisbvirus-1/NNS||virus-7/NN	nsubjpass||established-12/VBN||virus-7/NN	appos||virus-7/NN||hcv-9/NN	auxpass||established-12/VBN||are-11/VBP	root||ROOT-0/null||established-12/VBN	dobj||established-12/VBN||causes-13/NNS	prep_of||causes-13/NNS||hcc-15/NN	hbv-3||hepatitisbvirus--1||no||chronichepatitisbvirus (hbv) and hepatitisc virus (hcv) are established causes of hcc.
det||efficacy-2/NN||the-1/DT	nsubj||shows-27/VBZ||efficacy-2/NN	conj_and||efficacy-2/NN||safety-4/NN	nsubj||shows-27/VBZ||safety-4/NN	prep_of||efficacy-2/NN||staloral-6/NN	mark||demonstrated-9/VBD||as-8/IN	dep||efficacy-2/NN||demonstrated-9/VBD	prep_by||demonstrated-9/VBD||review-11/NN	amod||studies-14/NNS||published-13/VBN	prep_of||review-11/NN||studies-14/NNS	nsubj||used-16/VBD||studies-14/NNS	rcmod||studies-14/NNS||used-16/VBD	dobj||used-16/VBD||doses-17/NNS	prt||used-16/VBD||up-18/RP	number||times-21/NNS||1125-20/CD	prep_to||used-16/VBD||times-21/NNS	dobj||demonstrated-9/VBD||those-22/DT	vmod||those-22/DT||administered-23/VBN	prep_with||administered-23/VBN||scit-25/NN	root||ROOT-0/null||shows-27/VBZ	mark||has-32/VBZ||that-28/IN	det||extract-31/NN||this-29/DT	nn||extract-31/NN||allergen-30/NN	nsubj||has-32/VBZ||extract-31/NN	ccomp||shows-27/VBZ||has-32/VBZ	amod||characteristics-34/NNS||optimal-33/JJ	dobj||has-32/VBZ||characteristics-34/NNS	prepc_for||characteristics-34/NNS||treating-36/VBG	dobj||treating-36/VBG||patients-37/NNS	prep_with||treating-36/VBG||seasonalallergies-39/NNS	nn||pollens-43/NNS||grass-42/NN	prep_due_to||seasonalallergies-39/NNS||pollens-43/NNS	seasonalallergies-39||pollens-43||no||the efficacy and safety of staloral, as demonstrated by review of published studies which used doses up to 1125 times those administered with scit, shows that this allergen extract has optimal characteristics for treating patients with seasonalallergies due to grass pollens.
aux||investigate-2/VB||to-1/TO	advcl||determined-7/VBD||investigate-2/VB	det||hypothesis-4/NNS||this-3/DT	dobj||investigate-2/VB||hypothesis-4/NNS	nsubj||determined-7/VBD||we-6/PRP	root||ROOT-0/null||determined-7/VBD	det||activities-9/NNS||the-8/DT	dobj||determined-7/VBD||activities-9/NNS	det||enzymes-14/NNS||the-11/DT	amod||enzymes-14/NNS||key-12/JJ	amod||enzymes-14/NNS||mitochondrial-13/JJ	prep_of||activities-9/NNS||enzymes-14/NNS	amod||synthase-17/NN||citrate-16/JJ	prep_of||activities-9/NNS||synthase-17/NN	conj_and||enzymes-14/NNS||synthase-17/NN	amod||dehydrogenase-20/NN||malate-19/JJ	prep_of||activities-9/NNS||dehydrogenase-20/NN	conj_and||enzymes-14/NNS||dehydrogenase-20/NN	amod||cells-25/NNS||astrocytoma-23/JJ	amod||cells-25/NNS||u87-24/JJ	prep_in||determined-7/VBD||cells-25/NNS	vmod||cells-25/NNS||treated-26/VBN	amod||nanoparticles-29/NNS||silicondioxide-28/JJ	prep_with||treated-26/VBN||nanoparticles-29/NNS	astrocytoma-23||silicondioxide-28||no_rel||to investigate this hypothesis, we determined the activities of the key mitochondrial enzymes, citrate synthase and malate dehydrogenase, in astrocytoma u87 cells treated with silicondioxide nanoparticles.
aux||determine-2/VB||to-1/TO	root||ROOT-0/null||determine-2/VB	det||effects-4/NNS||the-3/DT	dobj||determine-2/VB||effects-4/NNS	amod||supplementation-7/NN||combined-6/JJ	prep_of||determine-2/VB||supplementation-7/NN	prep_with||determine-2/VB||chromium-9/NN	appos||chromium-9/NN||cr-11/NN	prep_with||determine-2/VB||vitamins-14/NNS	conj_and||chromium-9/NN||vitamins-14/NNS	dep||determine-2/VB||c-15/SYM	dep||>-28/VBZ||e-17/SYM	amod||stress-20/NN||oxidative-19/JJ	prep_on||>-28/VBZ||stress-20/NN	prep_in||stress-20/NN||type2diabetes-22/CD	amod||subjects-25/NNS||adult-24/JJ	nsubj||>-28/VBZ||subjects-25/NNS	prep_with||subjects-25/NNS||hba1c-27/CD	conj_and||determine-2/VB||>-28/VBZ	num||%-30/NN||8.5-29/CD	dobj||>-28/VBZ||%-30/NN	cr-11||type2diabetes-22||no_rel||to determine the effects of combined supplementation with chromium (cr) and vitamins c and e on oxidative stress in type2diabetes, adult subjects with hba1c >8.5%.
aux||investigate-2/VB||to-1/TO	advcl||compared-12/VBD||investigate-2/VB	det||relationship-4/NN||the-3/DT	dobj||investigate-2/VB||relationship-4/NN	nn||expression-7/NN||microrna-6/NN	prep_between||relationship-4/NN||expression-7/NN	prep_between||relationship-4/NN||type2diabetes-9/NN	conj_and||expression-7/NN||type2diabetes-9/NN	nsubj||compared-12/VBD||we-11/PRP	root||ROOT-0/null||compared-12/VBD	amod||expression-15/NN||global-13/JJ	nn||expression-15/NN||microrna-14/NN	dobj||compared-12/VBD||expression-15/NN	nn||tissues-19/NNS||insulin-17/NN	nn||tissues-19/NNS||target-18/NN	prep_in||compared-12/VBD||tissues-19/NNS	num||strains-24/NNS||three-21/CD	amod||strains-24/NNS||inbred-22/JJ	nn||strains-24/NNS||rat-23/NN	prep_from||compared-12/VBD||strains-24/NNS	nsubj||differ-26/VBP||strains-24/NNS	rcmod||strains-24/NNS||differ-26/VBP	nn||susceptibility-29/NN||diabetes-28/NN	prep_in||differ-26/VBP||susceptibility-29/NN	type2diabetes-9||insulin-17||yes||to investigate the relationship between microrna expression and type2diabetes, we compared global microrna expression in insulin target tissues from three inbred rat strains that differ in diabetes susceptibility.
det||risk-3/NN||an-1/DT	amod||risk-3/NN||increased-2/VBN	nsubjpass||described-18/VBN||risk-3/NN	amod||gastrointestinalbleeding-6/NN||upper-5/JJ	prep_for||risk-3/NN||gastrointestinalbleeding-6/NN	prep_with||gastrointestinalbleeding-6/NN||nsaids-8/NNS	advmod||gastrointestinalbleeding-6/NN||alone-9/RB	advmod||combined-12/JJ||when-11/WRB	advmod||gastrointestinalbleeding-6/NN||combined-12/JJ	conj_and||alone-9/RB||combined-12/JJ	amod||aspirin-15/NN||low-dose-14/JJ	prep_with||risk-3/NN||aspirin-15/NN	aux||described-18/VBN||has-16/VBZ	auxpass||described-18/VBN||been-17/VBN	root||ROOT-0/null||described-18/VBN	amod||studies-21/NNS||numerous-20/JJ	prep_in||described-18/VBN||studies-21/NNS	gastrointestinalbleeding-6||nsaids-8||no_rel||an increased risk for upper gastrointestinalbleeding with nsaids alone and when combined with low-dose aspirin has been described in numerous studies.
nsubj||likely-16/JJ||patients-1/NNS	nsubj||have-18/VB||patients-1/NNS	amod||obstructivepulmonarydisease-4/NN||chronic-3/JJ	prep_with||patients-1/NNS||obstructivepulmonarydisease-4/NN	nsubj||received-6/VBD||obstructivepulmonarydisease-4/NN	rcmod||obstructivepulmonarydisease-4/NN||received-6/VBD	amod||oxygen-8/NN||titrated-7/JJ	dobj||received-6/VBD||oxygen-8/NN	prepc_according_to||received-6/VBD||to-10/TO	det||protocol-12/NN||the-11/DT	pobj||received-6/VBD||protocol-12/NN	cop||likely-16/JJ||were-13/VBD	advmod||likely-16/JJ||significantly-14/RB	advmod||likely-16/JJ||less-15/RBR	root||ROOT-0/null||likely-16/JJ	aux||have-18/VB||to-17/TO	xcomp||likely-16/JJ||have-18/VB	dobj||have-18/VB||respiratoryacidosis-19/NNS	dep||respiratoryacidosis-19/NNS||mean-21/VB	nsubj||n-35/VBP||difference-22/NN	number||0.12-25/CD||ph-24/CD	prep_in||difference-22/NN||0.12-25/CD	appos||0.12-25/CD||se-27/NNP	num||se-27/NNP||0.05-28/CD	vmod||difference-22/NN||p-31/VBN	dep||0.01-33/CD||=-32/SYM	ccomp||p-31/VBN||0.01-33/CD	ccomp||mean-21/VB||n-35/VBP	dep||28-37/CD||=-36/SYM	ccomp||n-35/VBP||28-37/CD	dobj||have-18/VB||hypercapnia-40/NN	conj_or||respiratoryacidosis-19/NNS||hypercapnia-40/NN	amod||difference-43/NN||mean-42/JJ	dep||hypercapnia-40/NN||difference-43/NN	amod||pressure-47/NN||arterial-45/JJ	nn||pressure-47/NN||carbondioxide-46/NN	prep_in||difference-43/NN||pressure-47/NN	poss||hg-55/NN||âˆ-48/NNP	nn||hg-55/NN||33.6-50/NNP	appos||hg-55/NN||16.3-52/CD	nn||hg-55/NN||mm-54/NN	dep||pressure-47/NN||hg-55/NN	dep||pressure-47/NN||p-57/NN	dep||0.02-59/CD||=-58/SYM	rcmod||p-57/NN||0.02-59/CD	vmod||difference-43/NN||n-61/VBN	dep||29-63/CD||=-62/SYM	ccomp||n-61/VBN||29-63/CD	mark||patients-67/NNS||than-65/IN	cop||patients-67/NNS||were-66/VBD	advcl||likely-16/JJ||patients-67/NNS	nsubj||received-69/VBD||patients-67/NNS	rcmod||patients-67/NNS||received-69/VBD	amod||oxygen-72/NN||high-70/JJ	nn||oxygen-72/NN||flow-71/NN	dobj||received-69/VBD||oxygen-72/NN	respiratoryacidosis-19||carbondioxide-46||no||patients with chronic obstructivepulmonarydisease who received titrated oxygen according to the protocol were significantly less likely to have respiratoryacidosis (mean difference in ph 0.12 (se 0.05); p=0.01; n=28) or hypercapnia (mean difference in arterial carbondioxide pressure âˆ’33.6 (16.3) mm hg; p=0.02; n=29) than were patients who received high flow oxygen.
nsubjpass||used-13/VBN||conclusions-1/NNS	nsubj||identify-15/VB||conclusions-1/NNS	amod||conclusions-1/NNS||independent-2/JJ	det||seasonality-6/NN||the-4/DT	nn||seasonality-6/NN||rsv-5/NN	prep_from||independent-2/JJ||seasonality-6/NN	amod||factors-10/NNS||specific-8/JJ	amod||factors-10/NNS||host/environmental-9/JJ	appos||seasonality-6/NN||factors-10/NNS	aux||used-13/VBN||can-11/MD	auxpass||used-13/VBN||be-12/VB	root||ROOT-0/null||used-13/VBN	aux||identify-15/VB||to-14/TO	xcomp||used-13/VBN||identify-15/VB	dobj||identify-15/VB||children-16/NNS	amod||risk-19/NN||greatest-18/JJS	prep_at||identify-15/VB||risk-19/NN	prep_for||identify-15/VB||hospitalization-21/NN	prep_for||hospitalization-21/NN||rsvinfection-23/NN	rsvinfection-23||rsv-5||no||conclusions independent from the rsv seasonality, specific host/environmental factors can be used to identify children at greatest risk for hospitalization for rsvinfection.
det||understanding-3/NN||a-1/DT	amod||understanding-3/NN||better-2/JJR	nsubj||help-12/VB||understanding-3/NN	nsubj||develop-14/VB||understanding-3/NN	det||anorexia-10/NN||the-5/DT	amod||anorexia-10/NN||neurobiological-6/JJ	nn||anorexia-10/NN||mechanisms-7/NNP	amod||anorexia-10/NN||underlying-8/JJ	amod||anorexia-10/NN||inflammation-associated-9/JJ	prep_of||understanding-3/NN||anorexia-10/NN	aux||help-12/VB||will-11/MD	root||ROOT-0/null||help-12/VB	aux||develop-14/VB||to-13/TO	xcomp||help-12/VB||develop-14/VB	nn||stimulants-16/NNS||appetite-15/NN	dobj||develop-14/VB||stimulants-16/NNS	nn||patients-21/NNS||cancer-18/NN	conj_and||cancer-18/NN||aids-20/NNS	nn||patients-21/NNS||aids-20/NNS	prep_for||develop-14/VB||patients-21/NNS	stimulants-16||aids-20||no_rel||a better understanding of the neurobiological mechanisms underlying inflammation-associated anorexia will help to develop appetite stimulants for cancer and aids patients.
prep||undertaken-7/VBN||given-1/VBN	det||scenario-3/NN||these-2/DT	pobj||given-1/VBN||scenario-3/NN	det||study-5/NN||the-4/DT	nsubjpass||undertaken-7/VBN||study-5/NN	nsubj||examine-9/VB||study-5/NN	nsubj||aids-14/VBZ||study-5/NN	nsubj||identify-18/VB||study-5/NN	auxpass||undertaken-7/VBN||was-6/VBD	root||ROOT-0/null||undertaken-7/VBN	aux||examine-9/VB||to-8/TO	xcomp||undertaken-7/VBN||examine-9/VB	dobj||examine-9/VB||trends-10/NNS	prep_in||examine-9/VB||hiv-12/NN	xcomp||undertaken-7/VBN||aids-14/VBZ	conj_and||examine-9/VB||aids-14/VBZ	amod||knowledge-16/NN||comprehensive-15/JJ	dobj||aids-14/VBZ||knowledge-16/NN	xcomp||undertaken-7/VBN||identify-18/VB	conj_and||examine-9/VB||identify-18/VB	det||correlates-21/NNS||the-19/DT	amod||correlates-21/NNS||main-20/JJ	dobj||identify-18/VB||correlates-21/NNS	amod||hiv-24/NN||comprehensive-23/JJ	prep_of||correlates-21/NNS||hiv-24/NN	nn||knowledge-27/NN||aids-26/NNS	prep_of||correlates-21/NNS||knowledge-27/NN	conj_and||hiv-24/NN||knowledge-27/NN	amod||women-32/NNS||kenyan-29/JJ	amod||women-32/NNS||urban-30/JJ	amod||women-32/NNS||young-31/JJ	prep_among||identify-18/VB||women-32/NNS	aids-26||hiv-24||no||given these scenario the study was undertaken to examine trends in hiv and aids comprehensive knowledge and identify the main correlates of comprehensive hiv and aids knowledge among kenyan urban young women.
amod||fatigue-4/NN||such-2/JJ	amod||fatigue-4/NN||mental-3/JJ	prep_during||showed-31/VBD||fatigue-4/NN	dep||fatigue-4/NN||indicated-6/VBN	amod||errors-9/NNS||increased-8/VBN	prep_by||indicated-6/VBN||errors-9/NNS	amod||post-error-13/NN||decreased-12/VBN	prep_by||indicated-6/VBN||post-error-13/NN	conj_and||errors-9/NNS||post-error-13/NN	amod||post-error-13/NN||slowing-14/VBG	amod||response-19/NN||dorsal-16/JJ	nn||response-19/NN||anterior-17/NN	nn||response-19/NN||cingulate-18/NN	dep||fatigue-4/NN||response-19/NN	conj_and||indicated-6/VBN||response-19/NN	prep_to||response-19/NN||error-21/NN	det||function-24/NN||a-23/DT	prep_as||response-19/NN||function-24/NN	prep_of||function-24/NN||time-on-task-26/NN	amod||individuals-30/NNS||healthy-29/JJ	nsubj||showed-31/VBD||individuals-30/NNS	root||ROOT-0/null||showed-31/VBD	amod||activity-33/NN||increased-32/JJ	dobj||showed-31/VBD||activity-33/NN	det||midbrain-37/NN||the-35/DT	amod||midbrain-37/NN||dopaminergic-36/JJ	prep_in||showed-31/VBD||midbrain-37/NN	prep_to||showed-31/VBD||error-39/NN	fatigue-4||dopaminergic-36||no_rel||during such mental fatigue (indicated by increased errors, and decreased post-error slowing and dorsal anterior cingulate response to error as a function of time-on-task), healthy individuals showed increased activity in the dopaminergic midbrain to error.
det||epidemic-7/NN||the-1/DT	amod||epidemic-7/NN||global-2/JJ	nn||epidemic-7/NN||humanimmunodeficiencyvirusinfection/acquiredimmuno-deficiencysyndrome-3/NN	appos||epidemic-7/NN||hiv/aids-5/NNS	nsubj||one-9/CD||epidemic-7/NN	cop||one-9/CD||is-8/VBZ	root||ROOT-0/null||one-9/CD	det||threats-13/NNS||the-11/DT	amod||threats-13/NNS||biggest-12/JJS	prep_of||one-9/CD||threats-13/NNS	amod||life-16/NN||human-15/JJ	prep_to||threats-13/NNS||life-16/NN	aids--1||hiv--1||no||the global humanimmunodeficiencyvirusinfection/acquiredimmuno-deficiencysyndrome (hiv/aids) epidemic is one of the biggest threats to human life.
det||trial-12/NN||a-2/DT	amod||trial-12/NN||prospective-3/JJ	amod||trial-12/NN||open-label-5/JJ	amod||trial-12/NN||15-center-7/JJ	amod||trial-12/NN||randomized-9/JJ	amod||trial-12/NN||controlled-10/JJ	amod||trial-12/NN||clinical-11/JJ	prep_in||randomized-26/VBN||trial-12/NN	amod||outpatients-15/NNS||consecutive-14/JJ	nsubjpass||randomized-26/VBN||outpatients-15/NNS	vmod||outpatients-15/NNS||diagnosed-16/VBN	amod||depressivedisorder-19/NN||major-18/JJ	prep_with||diagnosed-16/VBN||depressivedisorder-19/NN	advmod||severity-24/NN||at-21/IN	pobj||at-21/IN||least-22/JJS	amod||severity-24/NN||moderate-23/JJ	prep_of||depressivedisorder-19/NN||severity-24/NN	auxpass||randomized-26/VBN||were-25/VBD	root||ROOT-0/null||randomized-26/VBN	dobj||randomized-26/VBN||11-27/CD	aux||receive-29/VB||to-28/TO	vmod||randomized-26/VBN||receive-29/VB	amod||doses-31/NNS||flexible-30/JJ	dobj||receive-29/VB||doses-31/NNS	det||pb-34/NN||either-33/DT	prep_of||doses-31/NNS||pb-34/NN	vmod||randomized-26/VBN||sertraline-36/VB	conj_or||receive-29/VB||sertraline-36/VB	advmod||sertraline-36/VB||once-37/RB	det||morning-39/NN||each-38/DT	tmod||sertraline-36/VB||morning-39/NN	depressivedisorder-19||sertraline-36||yes||in a prospective, open-label, 15-center, randomized controlled clinical trial, consecutive outpatients diagnosed with major depressivedisorder of at least moderate severity were randomized 11 to receive flexible doses of either pb or sertraline once each morning.
mark||reduced-12/VBD||although-1/IN	nsubj||reduced-12/VBD||glibenclamide-2/NN	conj_or||glibenclamide-2/NN||metformin-4/NN	nsubj||reduced-12/VBD||metformin-4/NN	advmod||significantly-6/RB||alone-5/RB	advmod||reduced-12/VBD||significantly-6/RB	dep||<-9/JJ||p-8/RB	dep||significantly-6/RB||<-9/JJ	dep||<-9/JJ||0.05-10/CD	csubj||produced-21/VBD||reduced-12/VBD	csubj||metformin-45/VBN||reduced-12/VBD	dobj||reduced-12/VBD||hyperglycemia-13/NN	dobj||reduced-12/VBD||glibenclamide-15/NN	conj_or||hyperglycemia-13/NN||glibenclamide-15/NN	dobj||reduced-12/VBD||metformin-17/NN	conj_or||hyperglycemia-13/NN||metformin-17/NN	prep||reduced-12/VBD||combined-18/VBN	pcomp||combined-18/VBN||with-19/IN	pobj||with-19/IN||honey-20/NN	root||ROOT-0/null||produced-21/VBD	advmod||produced-21/VBD||significantly-22/RB	advmod||lower-24/JJR||much-23/RB	amod||glucose-26/NN||lower-24/JJR	nn||glucose-26/NN||blood-25/NN	dobj||produced-21/VBD||glucose-26/NN	num||â-29/NN||8.8-28/CD	dep||glucose-26/NN||â-29/NN	num||2.9-31/CD||±-30/CD	num||mmol/l-37/NN||2.9-31/CD	num||3.3-36/CD||9.9-33/CD	num||3.3-36/CD||â-34/CD	num||3.3-36/CD||±-35/CD	conj_or||2.9-31/CD||3.3-36/CD	num||mmol/l-37/NN||3.3-36/CD	dep||â-29/NN||mmol/l-37/NN	advmod||â-29/NN||respectively-39/RB	prepc_compared_to||produced-21/VBD||to-42/TO	pobj||produced-21/VBD||glibenclamide-43/NN	conj_or||produced-21/VBD||metformin-45/VBN	advmod||metformin-45/VBN||alone-46/RB	nn||±-50/NNP||13.9-48/NNP	nn||±-50/NNP||â-49/NNP	dep||metformin-45/VBN||±-50/NNP	num||mmol/l-57/NN||3.4-51/CD	conj_or||3.4-51/CD||13.2-53/CD	num||mmol/l-57/NN||13.2-53/CD	nn||mmol/l-57/NN||â-54/NN	nn||mmol/l-57/NN||±-55/NN	num||mmol/l-57/NN||2.9-56/CD	dep||±-50/NNP||mmol/l-57/NN	advmod||±-50/NNP||respectively-59/RB	hyperglycemia-13||glucose-26||no||although glibenclamide or metformin alone significantly (p < 0.05) reduced hyperglycemia, glibenclamide or metformin combined with honey produced significantly much lower blood glucose (8.8 â± 2.9 or 9.9 â± 3.3 mmol/l, respectively) compared to glibenclamide or metformin alone (13.9 â± 3.4 or 13.2 â± 2.9 mmol/l, respectively).
amod||treatment-3/NN||hdsd-1/JJ	nn||treatment-3/NN||enrofloxacin-2/NN	nsubj||inferior-6/JJ||treatment-3/NN	cop||inferior-6/JJ||was-4/VBD	neg||inferior-6/JJ||not-5/RB	root||ROOT-0/null||inferior-6/JJ	det||protocol-11/NN||a-8/DT	amod||protocol-11/NN||conventional-9/JJ	amod||protocol-11/NN||amoxicillin-clavulanicacid-10/JJ	prep_to||inferior-6/JJ||protocol-11/NN	det||treatment-14/NN||the-13/DT	prep_for||protocol-11/NN||treatment-14/NN	amod||uti-18/NN||uncomplicated-16/JJ	amod||uti-18/NN||bacterial-17/JJ	prep_of||treatment-14/NN||uti-18/NN	prep_in||uti-18/NN||dogs-20/NNS	amoxicillin-clavulanicacid-10||uti-18||no_rel||hdsd enrofloxacin treatment was not inferior to a conventional amoxicillin-clavulanicacid protocol for the treatment of uncomplicated bacterial uti in dogs.
mark||analyze-4/VB||in-1/IN	dep||analyze-4/VB||order-2/NN	aux||analyze-4/VB||to-3/TO	advcl||studied-19/VBD||analyze-4/VB	amod||cells-6/NNS||dendritic-5/JJ	dobj||analyze-4/VB||cells-6/NNS	appos||cells-6/NNS||dcs-8/NN	vmod||cells-6/NNS||activation-10/VBN	prep_following||activation-10/VBN||infection-12/NN	amod||strains-16/NNS||different-14/JJ	amod||strains-16/NNS||mycobacterial-15/JJ	prep_with||infection-12/NN||strains-16/NNS	nsubj||studied-19/VBD||we-18/PRP	ccomp||mycobacteriumtuberculosis-36/VBZ||studied-19/VBD	det||profiles-22/NNS||the-20/DT	nn||profiles-22/NNS||expression-21/NN	dobj||studied-19/VBD||profiles-22/NNS	num||genes-25/NNS||165-24/CD	prep_of||profiles-22/NNS||genes-25/NNS	amod||dcs-29/NN||human-27/JJ	amod||dcs-29/NN||monocyte-derived-28/JJ	prep_of||genes-25/NNS||dcs-29/NN	vmod||dcs-29/NN||infected-30/VBN	prep_with||infected-30/VBN||h37rv-32/CD	det||virulent-35/NN||a-34/DT	nsubj||mycobacteriumtuberculosis-36/VBZ||virulent-35/NN	root||ROOT-0/null||mycobacteriumtuberculosis-36/VBZ	dep||mycobacteriumtuberculosis-36/VBZ||mtb-38/NN	nn||strain-41/NN||laboratory-40/NN	dobj||mycobacteriumtuberculosis-36/VBZ||strain-41/NN	dobj||mycobacteriumtuberculosis-36/VBZ||cmt97-43/NNS	conj_and||strain-41/NN||cmt97-43/NNS	det||isolate-48/NN||a-45/DT	amod||isolate-48/NN||clinical-46/JJ	nn||isolate-48/NN||mtb-47/NN	dobj||mycobacteriumtuberculosis-36/VBZ||isolate-48/NN	conj_and||strain-41/NN||isolate-48/NN	amod||bacillus-51/NNS||mycobacteriumbovis-50/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||bacillus-51/NNS	conj_and||strain-41/NN||bacillus-51/NNS	nn||rin-54/NNP||calmette-guã-52/NNP	nn||rin-54/NNP||©-53/NNP	dep||bacillus-51/NNS||rin-54/NNP	appos||rin-54/NNP||bcg-56/NN	amod||pasteur-60/NN||aventis-59/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||pasteur-60/NN	conj_and||strain-41/NN||pasteur-60/NN	nn||japan-64/NN||bcg-63/NN	dobj||mycobacteriumtuberculosis-36/VBZ||japan-64/NN	conj_and||strain-41/NN||japan-64/NN	nsubj||employed-67/VBN||both-66/DT	rcmod||japan-64/NN||employed-67/VBN	prep_as||employed-67/VBN||vaccine-69/NN	prep_against||vaccine-69/NN||tuberculosis-71/NNP	tuberculosis-71||bcg-63||no||in order to analyze dendritic cells (dcs) activation following infection with different mycobacterial strains, we studied the expression profiles of 165 genes of human monocyte-derived dcs infected with h37rv, a virulent mycobacteriumtuberculosis (mtb) laboratory strain, cmt97, a clinical mtb isolate, mycobacteriumbovis bacillus calmette-guã©rin (bcg), aventis pasteur, and bcg japan, both employed as vaccine against tuberculosis.
nsubj||revealed-2/VBD||msp-1/NN	nsubj||identified-21/VBD||msp-1/NN	root||ROOT-0/null||revealed-2/VBD	num||viruses-6/NNS||two-3/CD	amod||viruses-6/NNS||unreported-4/JJ	nn||viruses-6/NNS||rna-5/NN	dobj||revealed-2/VBD||viruses-6/NNS	nn||bees-11/NNS||north-8/NN	nn||bees-11/NNS||american-9/NN	nn||bees-11/NNS||honey-10/NN	prep_in||revealed-2/VBD||bees-11/NNS	amod||virus-15/NN||varroa-13/JJ	amod||virus-15/NN||destructor-1-14/JJ	prep_in||revealed-2/VBD||virus-15/NN	conj_and||bees-11/NNS||virus-15/NN	nn||virus-18/NN||kakugo-17/NN	prep_in||revealed-2/VBD||virus-18/NN	conj_and||bees-11/NNS||virus-18/NN	conj_and||revealed-2/VBD||identified-21/VBD	det||virus-25/NN||an-22/DT	amod||virus-25/NN||invertebrate-23/JJ	nn||virus-25/NN||iridescent-24/NN	dobj||identified-21/VBD||virus-25/NN	dep||virus-25/NN||iiv-27/NN	amod||virus-25/NN||iridoviridae-30/JJ	vmod||virus-25/NN||associated-32/VBN	nn||colonies-35/NNS||ccd-34/NN	prep_with||associated-32/VBN||colonies-35/NNS	virus-25||viruses-6||no||msp revealed two unreported rna viruses in north american honey bees, varroa destructor-1 virus and kakugo virus, and identified an invertebrate iridescent virus (iiv) ( iridoviridae ) associated with ccd colonies.
nsubjpass||mentioned-4/VBN||it-1/PRP	nsubjpass||divided-23/VBN||it-1/PRP	auxpass||mentioned-4/VBN||was-2/VBD	advmod||mentioned-4/VBN||first-3/RB	root||ROOT-0/null||mentioned-4/VBN	agent||mentioned-4/VBN||maurice-6/NN	vmod||maurice-6/NN||raynaud-7/VBN	prep_in||raynaud-7/VBN||1862-9/CD	xcomp||raynaud-7/VBN||describing-10/VBG	quantmod||$-12/$||â-11/RB	num||asphyxia-15/FW||$-12/$	num||$-12/$||œa-13/CD	amod||asphyxia-15/FW||local-14/JJ	dobj||describing-10/VBG||asphyxia-15/FW	det||$-19/NN||the-17/DT	amod||$-19/NN||extremitiesâ-18/JJ	prep_of||asphyxia-15/FW||$-19/NN	auxpass||divided-23/VBN||was-21/VBD	advmod||divided-23/VBN||further-22/RBR	conj_and||mentioned-4/VBN||divided-23/VBN	amod||raynaudâ-26/NNS||primary-25/JJ	prep_into||divided-23/VBN||raynaudâ-26/NNS	nsubjpass||related-42/VBN||raynaudâ-26/NNS	nsubj||connective-44/VB||raynaudâ-26/NNS	num||disease-30/NN||$-27/$	number||s-29/CD||™-28/CD	num||$-27/$||s-29/CD	nsubj||phenomenon-37/NN||disease-30/NN	amod||raynaudâ-33/NNS||secondary-32/JJ	conj_and||disease-30/NN||raynaudâ-33/NNS	nsubj||phenomenon-37/NN||raynaudâ-33/NNS	amod||disease-30/NN||$-34/$	number||$-34/$||™-35/CD	cop||phenomenon-37/NN||s-36/VBZ	rcmod||raynaudâ-26/NNS||phenomenon-37/NN	auxpass||related-42/VBN||is-40/VBZ	advmod||related-42/VBN||often-41/RB	rcmod||phenomenon-37/NN||related-42/VBN	aux||connective-44/VB||to-43/TO	xcomp||related-42/VBN||connective-44/VB	nn||diseases-46/NNS||tissue-45/NN	dobj||connective-44/VB||diseases-46/NNS	amod||strain-53/NN||physical-50/NN	conj_or||physical-50/NN||chemical-52/NN	amod||strain-53/NN||chemical-52/NN	rcmod||raynaudâ-26/NNS||strain-53/NN	conj_and||phenomenon-37/NN||strain-53/NN	chemical-52||raynaud-7||no_rel||it was first mentioned by maurice raynaud in 1862 describing â€œa local asphyxia of the extremitiesâ€? and was further divided into primary raynaudâ€™s disease and secondary raynaudâ€™s phenomenon, which is often related to connective tissue diseases, but also physical or chemical strain.
det||data-2/NNS||these-1/DT	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||play-23/VB||that-4/IN	amod||clusterin-6/NN||secretory-5/JJ	nsubjpass||up-regulated-11/VBN||clusterin-6/NN	nsubj||play-23/VB||clusterin-6/NN	auxpass||up-regulated-11/VBN||is-9/VBZ	advmod||up-regulated-11/VBN||frequently-10/RB	rcmod||clusterin-6/NN||up-regulated-11/VBN	nn||cancers-14/NNS||breast-13/NN	prep_in||up-regulated-11/VBN||cancers-14/NNS	amod||therapies-17/NNS||common-16/JJ	agent||up-regulated-11/VBN||therapies-17/NNS	prep_including||up-regulated-11/VBN||anti-estrogens-20/NNS	aux||play-23/VB||may-22/MD	ccomp||suggest-3/VBP||play-23/VB	det||role-26/NN||a-24/DT	amod||role-26/NN||significant-25/JJ	dobj||play-23/VB||role-26/NN	nn||growth-29/NN||tumor-28/NN	prep_in||role-26/NN||growth-29/NN	amod||progression-32/NN||metastatic-31/JJ	prep_in||role-26/NN||progression-32/NN	conj_and||growth-29/NN||progression-32/NN	amod||resistance-36/NN||subsequent-34/JJ	nn||resistance-36/NN||drug-35/NN	prep_in||role-26/NN||resistance-36/NN	conj_and||growth-29/NN||resistance-36/NN	amod||cells-39/NNS||surviving-38/VBG	prep_in||play-23/VB||cells-39/NNS	tumor-28||anti-estrogens-20||no_rel||these data suggest that secretory clusterin, which is frequently up-regulated in breast cancers by common therapies, including anti-estrogens, may play a significant role in tumor growth, metastatic progression and subsequent drug resistance in surviving cells.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effects-10/NNS||the-9/DT	dobj||evaluate-8/VB||effects-10/NNS	prepc_of||effects-10/NNS||adding-12/VBG	dobj||adding-12/VBG||theophylline-13/NN	prepc_compared_with||adding-12/VBG||with-15/IN	pcomp||adding-12/VBG||increasing-16/VBG	det||dose-18/NN||the-17/DT	dobj||increasing-16/VBG||dose-18/NN	amod||corticosteroid-21/NN||inhaled-20/JJ	prep_of||dose-18/NN||corticosteroid-21/NN	appos||corticosteroid-21/NN||ics-23/NN	amod||asthma-27/NN||symptomatic-26/JJ	prep_on||increasing-16/VBG||asthma-27/NN	asthma-27||theophylline-13||yes||the aim of this study was to evaluate the effects of adding theophylline compared with increasing the dose of inhaled corticosteroid (ics) on symptomatic asthma.
det||study-2/NN||the-1/DT	nsubj||indicated-3/VBD||study-2/NN	nsubj||highlights-14/VBZ||study-2/NN	root||ROOT-0/null||indicated-3/VBD	det||prevalence-6/NN||a-4/DT	amod||prevalence-6/NN||high-5/JJ	dobj||indicated-3/VBD||prevalence-6/NN	amod||deficiency-9/NN||g6pd-8/JJ	prep_of||prevalence-6/NN||deficiency-9/NN	amod||province-12/NN||isabel-11/JJ	prep_in||indicated-3/VBD||province-12/NN	conj_and||indicated-3/VBD||highlights-14/VBZ	det||need-17/NN||the-15/DT	amod||need-17/NN||critical-16/JJ	dobj||highlights-14/VBZ||need-17/NN	aux||consider-19/VB||to-18/TO	vmod||need-17/NN||consider-19/VB	amod||deficiency-21/NN||g6pd-20/JJ	dobj||consider-19/VB||deficiency-21/NN	det||context-24/NN||the-23/DT	prep_in||consider-19/VB||context-24/NN	nn||strategies-29/NNS||p.-26/NN	nn||strategies-29/NNS||vivaxmalaria-27/NN	nn||strategies-29/NNS||elimination-28/NN	prep_of||context-24/NN||strategies-29/NNS	nn||islands-32/NNS||solomon-31/NN	prep_in||strategies-29/NNS||islands-32/NNS	advmod||consider-19/VB||particularly-34/RB	prep_in||consider-19/VB||light-36/NN	det||role-40/NN||the-38/DT	amod||role-40/NN||potential-39/JJ	prep_of||light-36/NN||role-40/NN	amod||administration-45/NN||primaquine-42/JJ	nn||administration-45/NN||mass-43/NN	nn||administration-45/NN||drug-44/NN	prep_of||role-40/NN||administration-45/NN	vivaxmalaria-27||primaquine-42||yes||the study indicated a high prevalence of g6pd deficiency in isabel province and highlights the critical need to consider g6pd deficiency in the context of p. vivaxmalaria elimination strategies in solomon islands , particularly in light of the potential role of primaquine mass drug administration .
nsubj||analog-6/NN||lamivudine-1/NN	cop||analog-6/NN||is-2/VBZ	det||analog-6/NN||a-3/DT	amod||analog-6/NN||synthetic-4/JJ	nn||analog-6/NN||nucleoside-5/NN	root||ROOT-0/null||analog-6/NN	det||action-10/NN||a-8/DT	amod||action-10/NN||potent-9/JJ	prep_with||analog-6/NN||action-10/NN	nn||replication-13/NN||hbv-12/NN	prep_on||action-10/NN||replication-13/NN	hbv-12||lamivudine-1||yes||lamivudine is a synthetic nucleoside analog with a potent action on hbv replication.
amod||evidence-2/NN||converging-1/VBG	nsubj||leaves-3/VBZ||evidence-2/NN	root||ROOT-0/null||leaves-3/VBZ	advmod||event-39/NN||little-4/JJ	dep||little-4/JJ||doubt-5/NN	mark||event-39/NN||that-6/IN	det||form-35/NN||a-7/DT	dep||form-35/NN||change-8/NN	det||conformation-11/NN||the-10/DT	prep_in||change-8/NN||conformation-11/NN	prep_of||conformation-11/NN||prionprotein-13/NN	dep||prionprotein-13/NN||prpc-15/JJ	det||sheet-29/NN||a-18/DT	advmod||î-20/JJ||mainly-19/RB	amod||sheet-29/NN||î-20/JJ	nn||sheet-29/NN||±-21/NN	dep||sheet-29/NN||helical-23/JJ	det||²-27/NN||a-25/DT	nn||²-27/NN||î-26/NN	prep_to||helical-23/JJ||²-27/NN	prep_from||prionprotein-13/NN||sheet-29/NN	amod||form-35/NN||rich-30/JJ	nn||form-35/NN||prp-scrapie-31/NN	dep||form-35/NN||prpsc-33/JJ	nsubj||event-39/NN||form-35/NN	cop||event-39/NN||is-36/VBZ	det||event-39/NN||the-37/DT	amod||event-39/NN||main-38/JJ	dep||leaves-3/VBZ||event-39/NN	amod||event-39/NN||responsible-40/JJ	prep_for||responsible-40/JJ||priondisease-42/NN	vmod||priondisease-42/NN||associated-43/VBN	advmod||associated-43/VBN||neurotoxicity-44/RB	priondisease-42||prionprotein-13||no||converging evidence leaves little doubt that a change in the conformation of prionprotein (prpc) from a mainly î±-helical to a î²-sheet rich prp-scrapie (prpsc) form is the main event responsible for priondisease associated neurotoxicity.
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tuberculosis--1||pyrazinamide-29||yes||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
nsubj||likely-9/JJ||persons-1/NNS	nsubjpass||older-16/JJR||persons-1/NNS	nsubjpass||admitted-18/VBN||persons-1/NNS	prep_without||persons-1/NNS||hiv/aids-3/NNS	vmod||hiv/aids-3/NNS||hospitalized-4/VBN	prep_with||hospitalized-4/VBN||cryptococcosis-6/NNS	cop||likely-9/JJ||were-7/VBD	advmod||likely-9/JJ||more-8/RBR	root||ROOT-0/null||likely-9/JJ	prep_than||likely-9/JJ||those-11/DT	prep_with||those-11/DT||hiv/aids-13/NNS	aux||older-16/JJR||to-14/TO	auxpass||older-16/JJR||be-15/VB	cop||older-16/JJR||be-15/VB	xcomp||likely-9/JJ||older-16/JJR	xcomp||likely-9/JJ||admitted-18/VBN	conj_and||older-16/JJR||admitted-18/VBN	prep_for||admitted-18/VBN||pulmonarycryptococcosis-20/NNS	aids--1||hiv--1||no||persons without hiv/aids hospitalized with cryptococcosis were more likely than those with hiv/aids to be older and admitted for pulmonarycryptococcosis.
det||study-9/NN||a-1/DT	amod||double-blind-8/JJ||4-week-2/JJ	amod||double-blind-8/JJ||multicentre-4/JJ	amod||double-blind-8/JJ||randomised-6/JJ	amod||study-9/NN||double-blind-8/JJ	nsubj||compared-11/VBN||study-9/NN	aux||compared-11/VBN||has-10/VBZ	root||ROOT-0/null||compared-11/VBN	det||effects-13/NNS||the-12/DT	dobj||compared-11/VBN||effects-13/NNS	nn||mg-17/NN||lumiracoxib-15/NN	num||mg-17/NN||100-16/CD	prep_of||effects-13/NNS||mg-17/NN	advmod||od-21/NN||once-18/RB	amod||od-21/NN||daily-19/JJ	dep||mg-17/NN||od-21/NN	dep||mg-17/NN||n-24/VBN	dep||394-26/NNS||=-25/SYM	ccomp||n-24/VBN||394-26/NNS	prep_of||effects-13/NNS||ibuprofen-29/NN	conj_and||mg-17/NN||ibuprofen-29/NN	num||ibuprofen-29/NN||600-30/CD	vmod||ibuprofen-29/NN||mg-31/VBN	num||times-33/NNS||three-32/CD	dobj||mg-31/VBN||times-33/NNS	advmod||times-33/NNS||daily-34/RB	appos||ibuprofen-29/NN||tid-36/NN	dep||effects-13/NNS||n-39/VBN	dep||393-41/CD||=-40/SYM	ccomp||n-39/VBN||393-41/CD	amod||bp-45/NN||ambulatory-44/JJ	prep_on||compared-11/VBN||bp-45/NN	amod||patients-51/NNS||osteoarthritis-47/JJ	appos||patients-51/NNS||oa-49/NN	prep_in||bp-45/NN||patients-51/NNS	amod||hypertension-54/NN||controlled-53/JJ	prep_with||bp-45/NN||hypertension-54/NN	osteoarthritis-47||ibuprofen-29||yes||a 4-week, multicentre, randomised, double-blind study has compared the effects of lumiracoxib 100 mg once daily (od) ( n = 394) and ibuprofen 600 mg three times daily (tid) ( n = 393) on ambulatory bp in osteoarthritis (oa) patients with controlled hypertension.
nsubj||has-3/VBZ||enoxaparin-1/NN	nsubjpass||used-23/VBN||enoxaparin-1/NN	advmod||has-3/VBZ||also-2/RB	root||ROOT-0/null||has-3/VBZ	det||body-6/NN||the-4/DT	amod||body-6/NN||largest-5/JJS	dobj||has-3/VBZ||body-6/NN	amod||evidence-9/NN||clinical-8/JJ	prep_of||body-6/NN||evidence-9/NN	vmod||evidence-9/NN||supporting-10/VBG	poss||use-12/NN||its-11/PRP$	dobj||supporting-10/VBG||use-12/NN	det||spectrum-15/NN||the-14/DT	prep_across||supporting-10/VBG||spectrum-15/NN	amod||management-19/NN||venous-17/JJ	nn||management-19/NN||thromboembolism-18/NN	prep_of||spectrum-15/NN||management-19/NN	aux||used-23/VBN||has-21/VBZ	auxpass||used-23/VBN||been-22/VBN	conj_and||has-3/VBZ||used-23/VBN	det||anticoagulant-29/NN||the-25/DT	nn||anticoagulant-29/NN||reference-26/NN	amod||anticoagulant-29/NN||standard-27/JJ	nn||anticoagulant-29/NN||comparator-28/NN	prep_as||used-23/VBN||anticoagulant-29/NN	prep_in||used-23/VBN||trials-31/NNS	amod||anticoagulants-34/NNS||new-33/JJ	prep_of||trials-31/NNS||anticoagulants-34/NNS	thromboembolism-18||enoxaparin-1||yes||enoxaparin also has the largest body of clinical evidence supporting its use across the spectrum of venous thromboembolism management and has been used as the reference standard comparator anticoagulant in trials of new anticoagulants.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||âˆ-14/VB	num||±-17/NN||’14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||âˆ-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||âˆ-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||âˆ-37/NN	num||±-40/NN||’14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||âˆ-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||âˆ-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||âˆ-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	insulin-82||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (âˆ’14 â± 3 pg/ml [âˆ’4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (âˆ’14 â± 2 pg/ml [âˆ’4.0 â± 0.6 pmol/l]) but increased to âˆ’3 â± 3 pg/ml (âˆ’0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
nsubj||herpesvirus-17/NNS||varicella-zostervirus-1/NNS	nsubj||first-24/JJ||varicella-zostervirus-1/NNS	appos||varicella-zostervirus-1/NNS||vzv-3/NN	det||cause-7/NN||the-6/DT	appos||varicella-zostervirus-1/NNS||cause-7/NN	prep_of||cause-7/NN||chickenpox-9/NN	prep_of||cause-7/NN||zoster-11/NN	conj_and||chickenpox-9/NN||zoster-11/NN	cop||herpesvirus-17/NNS||was-13/VBD	det||herpesvirus-17/NNS||the-14/DT	amod||herpesvirus-17/NNS||first-15/JJ	amod||herpesvirus-17/NNS||human-16/JJ	root||ROOT-0/null||herpesvirus-17/NNS	aux||sequenced-20/VBN||to-18/TO	auxpass||sequenced-20/VBN||be-19/VB	vmod||herpesvirus-17/NNS||sequenced-20/VBN	advmod||sequenced-20/VBN||fully-21/RB	det||first-24/JJ||the-23/DT	conj_and||herpesvirus-17/NNS||first-24/JJ	prep_for||licensed-30/VBN||first-24/JJ	nsubjpass||licensed-30/VBN||vaccines-27/NNS	nsubjpass||used-33/VBN||vaccines-27/NNS	aux||licensed-30/VBN||have-28/VBP	auxpass||licensed-30/VBN||been-29/VBN	rcmod||first-24/JJ||licensed-30/VBN	advmod||used-33/VBN||widely-32/RB	rcmod||first-24/JJ||used-33/VBN	conj_and||licensed-30/VBN||used-33/VBN	zoster-11||varicella-zostervirus-1||no||varicella-zostervirus (vzv), the cause of chickenpox and zoster, was the first human herpesvirus to be sequenced fully and the first for which vaccines have been licensed and widely used.
advmod||recognized-16/VBN||currently-1/RB	amod||5-fluorouracil-3/NN||definitive-2/JJ	nsubjpass||recognized-16/VBN||5-fluorouracil-3/NN	dep||5-fluorouracil-3/NN||5-fu-5/JJ	punct||cisplatin-8/NN||/-7/:	dep||5-fluorouracil-3/NN||cisplatin-8/NN	appos||cisplatin-8/NN||cddp-10/NN	vmod||5-fluorouracil-3/NN||based-13/VBN	advmod||recognized-16/VBN||chemotherapy-14/RB	auxpass||recognized-16/VBN||is-15/VBZ	root||ROOT-0/null||recognized-16/VBN	prep_as||recognized-16/VBN||one-18/CD	det||treatments-23/NNS||the-20/DT	advmod||treatments-23/NNS||most-21/RBS	amod||treatments-23/NNS||promising-22/JJ	prep_of||one-18/CD||treatments-23/NNS	prep_for||treatments-23/NNS||esophagealcancer-25/NN	esophagealcancer-25||cisplatin-8||yes||currently definitive 5-fluorouracil (5-fu)/cisplatin (cddp) -based chemotherapy is recognized as one of the most promising treatments for esophagealcancer.
amod||efficacy-4/NN||limited-2/JJ	amod||efficacy-4/NN||clinical-3/JJ	prep_despite||remains-14/VBZ||efficacy-4/NN	nsubj||remains-14/VBZ||treatment-6/NN	prep_with||treatment-6/NN||dacarbazine-8/NN	prep_with||treatment-6/NN||temozolomide-10/NN	conj_or||dacarbazine-8/NN||temozolomide-10/NN	appos||treatment-6/NN||tmz-12/NN	root||ROOT-0/null||remains-14/VBZ	det||therapy-17/NN||the-15/DT	amod||therapy-17/NN||standard-16/JJ	xcomp||remains-14/VBZ||therapy-17/NN	amod||melanoma-20/NN||metastatic-19/JJ	prep_for||therapy-17/NN||melanoma-20/NN	melanoma-20||dacarbazine-8||yes||despite limited clinical efficacy, treatment with dacarbazine or temozolomide (tmz) remains the standard therapy for metastatic melanoma.
nsubj||seems-3/VBZ||it-1/PRP	advmod||seems-3/VBZ||also-2/RB	root||ROOT-0/null||seems-3/VBZ	mark||better-12/JJR||that-4/IN	det||properties-7/NNS||some-5/DT	amod||properties-7/NNS||pharmacologic-6/JJ	nsubj||better-12/JJR||properties-7/NNS	prep_of||properties-7/NNS||esomeprazole-9/NN	cop||better-12/JJR||are-10/VBP	advmod||better-12/JJR||actually-11/RB	ccomp||seems-3/VBZ||better-12/JJR	det||treatment-15/NN||the-14/DT	prep_for||better-12/JJR||treatment-15/NN	prep_of||treatment-15/NN||gerd-17/NN	gerd-17||esomeprazole-9||yes||it also seems that some pharmacologic properties of esomeprazole are actually better for the treatment of gerd.
nsubjpass||reported-4/VBN||dieldrin-1/NN	nsubj||one-7/CD||dieldrin-1/NN	nsubj||destroy-20/VB||dieldrin-1/NN	aux||reported-4/VBN||has-2/VBZ	auxpass||reported-4/VBN||been-3/VBN	root||ROOT-0/null||reported-4/VBN	aux||one-7/CD||to-5/TO	cop||one-7/CD||be-6/VB	xcomp||reported-4/VBN||one-7/CD	det||factors-11/NNS||the-9/DT	amod||factors-11/NNS||environmental-10/JJ	prep_of||one-7/CD||factors-11/NNS	vmod||factors-11/NNS||correlated-12/VBN	nn||sdisease-16/NN||parkinson-14/NN	prep_with||correlated-12/VBN||sdisease-16/NN	aux||destroy-20/VB||may-18/MD	advmod||destroy-20/VB||selectively-19/RB	conj_and||reported-4/VBN||destroy-20/VB	amod||neurons-22/NNS||dopaminergic-21/JJ	dobj||destroy-20/VB||neurons-22/NNS	dopaminergic-21||parkinson'sdisease--1||no_rel||dieldrin has been reported to be one of the environmental factors correlated with parkinson'sdisease and may selectively destroy dopaminergic neurons.
det||imbalance-2/NN||this-1/DT	nsubj||have-10/VB||imbalance-2/NN	prepc_of||imbalance-2/NN||treg-4/VBG	dobj||treg-4/VBG||cells-5/NNS	amod||cells-8/NNS||th17-7/JJ	prep_to||treg-4/VBG||cells-8/NNS	aux||have-10/VB||might-9/MD	root||ROOT-0/null||have-10/VB	det||role-13/NN||an-11/DT	amod||role-13/NN||important-12/JJ	dobj||have-10/VB||role-13/NN	nn||persistence-16/NN||hbv-15/NN	prep_in||role-13/NN||persistence-16/NN	nn||treatment-19/NN||entecavir-18/NN	prep_during||have-10/VB||treatment-19/NN	hbv-15||entecavir-18||yes||this imbalance of treg cells to th17 cells might have an important role in hbv persistence during entecavir treatment.
det||article-2/NN||this-1/DT	nsubj||focuses-3/VBZ||article-2/NN	root||ROOT-0/null||focuses-3/VBZ	det||determination-6/NN||the-5/DT	prep_on||focuses-3/VBZ||determination-6/NN	nn||species-9/NNS||arsenic-8/NN	prep_of||determination-6/NN||species-9/NNS	nn||samples-12/NNS||saliva-11/NN	prep_in||species-9/NNS||samples-12/NNS	nn||patients-15/NNS||apl-14/NN	prep_from||focuses-3/VBZ||patients-15/NNS	vmod||patients-15/NNS||undergoing-16/VBG	nn||treatment-18/NN||arsenic-17/NN	dobj||undergoing-16/VBG||treatment-18/NN	arsenic-17||apl-14||no_rel||this article focuses on the determination of arsenic species in saliva samples from apl patients undergoing arsenic treatment.
nsubjpass||recommended-6/VBN||surgery-2/NN	prep_besides||therapy-24/NN||surgery-2/NN	auxpass||recommended-6/VBN||is-5/VBZ	rcmod||surgery-2/NN||recommended-6/VBN	amod||goitres-9/NNS||large-8/JJ	prep_for||recommended-6/VBN||goitres-9/NNS	advmod||excluded-16/VBN||when-11/WRB	nsubjpass||excluded-16/VBN||malignancy-12/NN	aux||excluded-16/VBN||can-13/MD	neg||excluded-16/VBN||not-14/RB	auxpass||excluded-16/VBN||be-15/VB	rcmod||surgery-2/NN||excluded-16/VBN	conj_or||recommended-6/VBN||excluded-16/VBN	det||options-21/NNS||the-18/DT	amod||options-21/NNS||non-surgical-19/JJ	nn||options-21/NNS||treatment-20/NN	nsubj||therapy-24/NN||options-21/NNS	cop||therapy-24/NN||are-22/VBP	amod||therapy-24/NN||levothyroxine-23/JJ	root||ROOT-0/null||therapy-24/NN	amod||therapy-30/NN||radioiodine-26/JJ	appos||therapy-30/NN||131i-28/NNP	conj_and||therapy-24/NN||therapy-30/NN	goitres-9||levothyroxine-23||yes||besides surgery, which is recommended for large goitres or when malignancy cannot be excluded, the non-surgical treatment options are levothyroxine therapy and radioiodine (131i) therapy.
nsubj||diagnosed-2/VBD||patients-1/NNS	root||ROOT-0/null||diagnosed-2/VBD	nn||expression-7/NN||ham/tsp-4/NN	amod||expression-7/NN||down-regulated-5/JJ	amod||expression-7/NN||tim-3-6/JJ	prep_with||diagnosed-2/VBD||expression-7/NN	det||+-11/NN||both-9/DT	amod||+-11/NN||cd8-10/JJ	prep_on||diagnosed-2/VBD||+-11/NN	amod||cells-16/NNS||cd4-13/JJ	amod||cells-16/NNS||+-14/JJ	nn||cells-16/NNS||t-15/NN	prep_on||diagnosed-2/VBD||cells-16/NNS	conj_and||+-11/NN||cells-16/NNS	prepc_compared_to||diagnosed-2/VBD||to-18/TO	amod||patients-20/NNS||asymptomatic-19/JJ	pobj||diagnosed-2/VBD||patients-20/NNS	amod||controls-24/NNS||htlv-1-22/JJ	nn||controls-24/NNS||seronegative-23/NN	pobj||diagnosed-2/VBD||controls-24/NNS	conj_and||patients-20/NNS||controls-24/NNS	ham--1||htlv-1-22||no||patients diagnosed with ham/tsp down-regulated tim-3 expression on both cd8+ and cd4+ t cells compared to asymptomatic patients and htlv-1 seronegative controls.
det||anthracycline-9/NN||all-1/DT	dep||anthracycline-9/NN||trans-3/NNS	amod||atra-6/NN||retinoicacid-4/JJ	dep||trans-3/NNS||atra-6/NN	punct||trans-3/NNS||/-8/:	nsubj||beneficial-12/JJ||anthracycline-9/NN	advmod||beneficial-12/JJ||chemotherapy-10/RB	cop||beneficial-12/JJ||is-11/VBZ	root||ROOT-0/null||beneficial-12/JJ	advmod||diagnosed-15/JJ||newly-14/RB	amod||acutepromyelocyticleukemia-16/NN||diagnosed-15/JJ	prep_in||beneficial-12/JJ||acutepromyelocyticleukemia-16/NN	appos||acutepromyelocyticleukemia-16/NN||apl-18/NN	advmod||important-25/JJ||however-21/RB	nsubj||important-25/JJ||it-23/PRP	nsubj||identify-27/VB||it-23/PRP	cop||important-25/JJ||is-24/VBZ	parataxis||beneficial-12/JJ||important-25/JJ	aux||identify-27/VB||to-26/TO	xcomp||important-25/JJ||identify-27/VB	dobj||identify-27/VB||patients-28/NNS	amod||disease-31/NN||high-risk-30/JJ	prep_with||patients-28/NNS||disease-31/NN	aux||increase-33/VB||to-32/TO	vmod||identify-27/VB||increase-33/VB	det||rate-36/NN||the-34/DT	nn||rate-36/NN||cure-35/NN	dobj||increase-33/VB||rate-36/NN	acutepromyelocyticleukemia-16||atra-6||yes||all- trans retinoicacid (atra)/anthracycline chemotherapy is beneficial in newly diagnosed acutepromyelocyticleukemia (apl); however, it is important to identify patients with high-risk disease to increase the cure rate.
amod||administration-2/NN||oral-1/JJ	nsubj||led-14/VBD||administration-2/NN	prep_of||administration-2/NN||pde5inhibitor-4/NNS	appos||pde5inhibitor-4/NNS||vardenafil-6/NN	prep_to||pde5inhibitor-4/NNS||mice-9/NNS	amod||lungtumors-13/NNS||her2-positive-11/JJ	amod||lungtumors-13/NNS||intracranial-12/JJ	prep_with||mice-9/NNS||lungtumors-13/NNS	root||ROOT-0/null||led-14/VBD	det||permeability-19/NN||an-16/DT	amod||permeability-19/NN||increased-17/VBN	nn||permeability-19/NN||tumor-18/NN	prep_to||led-14/VBD||permeability-19/NN	amod||dextran-27/NNS||high-21/JJ	amod||dextran-27/NNS||molecular-22/JJ	nn||dextran-27/NNS||weight-23/NN	amod||dextran-27/NNS||-LSB--24/JJ	amod||dextran-27/NNS||14c-25/JJ	nn||dextran-27/NNS||-RSB--26/NN	prep_to||permeability-19/NN||dextran-27/NNS	amod||increase-30/NN||2.6-fold-29/JJ	appos||dextran-27/NNS||increase-30/NN	prep_to||permeability-19/NN||herceptin-34/NN	conj_and||dextran-27/NNS||herceptin-34/NN	amod||increase-37/NN||2-fold-36/JJ	appos||herceptin-34/NN||increase-37/NN	lungtumors-13||pde5inhibitor-4||no_rel||oral administration of pde5inhibitor, vardenafil, to mice with her2-positive intracranial lungtumors led to an increased tumor permeability to high molecular weight [14c]dextran (2.6-fold increase) and to herceptin (2-fold increase).
amod||patients-2/NNS||forty-five-1/JJ	nsubjpass||treated-7/VBN||patients-2/NNS	amod||aml-5/NN||relapsed-4/JJ	prep_with||patients-2/NNS||aml-5/NN	auxpass||treated-7/VBN||were-6/VBD	root||ROOT-0/null||treated-7/VBN	det||regimen-11/NN||the-9/DT	amod||regimen-11/NN||mito-flag-10/JJ	prep_with||treated-7/VBN||regimen-11/NN	vmod||regimen-11/NN||consisting-12/VBG	prep_of||consisting-12/VBG||mitoxantrone-14/NN	num||mg/m2-17/NNS||7-16/CD	dep||mitoxantrone-14/NN||mg/m2-17/NNS	appos||mg/m2-17/NNS||day-19/NNP	num||day-19/NNP||1-20/CD	num||day-19/NNP||3-22/CD	appos||mg/m2-17/NNS||5-24/CD	conj_and||day-19/NNP||5-24/CD	prep_of||consisting-12/VBG||fludarabine-27/NN	conj_and||mitoxantrone-14/NN||fludarabine-27/NN	num||mg/m2-30/NNS||30-29/CD	dep||fludarabine-27/NN||mg/m2-30/NNS	nn||1â-33/NNS||days-32/NNS	appos||mg/m2-30/NNS||1â-33/NNS	dep||1â-33/NNS||$-34/$	num||$-34/$||5-36/CD	prep_of||consisting-12/VBG||ara-c-39/JJ	conj_and||mitoxantrone-14/NN||ara-c-39/JJ	num||g/m2-42/NNS||1-41/CD	dep||ara-c-39/JJ||g/m2-42/NNS	num||h-46/NN||3-45/CD	prep_over||g/m2-42/NNS||h-46/NN	det||h-49/NN||every-47/DT	num||h-49/NN||12-48/CD	dep||h-46/NN||h-49/NN	nn||1â-52/NNS||days-51/NNS	appos||h-46/NN||1â-52/NNS	dep||1â-52/NNS||$-53/$	num||$-53/$||5-55/CD	amod||î-61/NN||g-csf-58/JJ	dep||g-csf-58/JJ||-LSB--59/NNP	num||-LSB--59/NNP||5-60/CD	prep_of||consisting-12/VBG||î-61/NN	conj_and||mitoxantrone-14/NN||î-61/NN	num||g/kg/day-63/NN||1/4-62/CD	npadvmod||subcutaneously-64/RB||g/kg/day-63/NN	advmod||consisting-12/VBG||subcutaneously-64/RB	prep_from||subcutaneously-64/RB||day-66/NN	num||day-66/NN||0-67/CD	mark||20ã-78/NNS||until-68/IN	det||count-72/NN||the-69/DT	amod||count-72/NN||white-70/JJ	nn||count-72/NN||blood-71/NN	nsubj||20ã-78/NNS||count-72/NN	discourse||count-72/NN||wbc-74/UH	cop||20ã-78/NNS||was-76/VBD	punct||20ã-78/NNS||>-77/``	advcl||subcutaneously-64/RB||20ã-78/NNS	amod||-RSB--81/NNS||109/l-80/JJ	dep||20ã-78/NNS||-RSB--81/NNS	aml-5||mitoxantrone-14||yes||forty-five patients with relapsed aml were treated with the mito-flag regimen consisting of mitoxantrone (7 mg/m2, day 1, 3 and 5), fludarabine (30 mg/m2, days 1â€“5), ara-c (1 g/m2, over 3 h every 12 h, days 1â€“5) and g-csf [5 î¼ g/kg/day subcutaneously from day 0 until the white blood count (wbc) was >20ã—109/l].
det||targets-3/NNS||the-1/DT	amod||targets-3/NNS||putative-2/JJ	nsubjpass||found-17/VBN||targets-3/NNS	nsubjpass||enriched-20/VBN||targets-3/NNS	amod||mirnas-6/NNS||upregulated-5/JJ	prep_of||targets-3/NNS||mirnas-6/NNS	det||gk-9/NN||the-8/DT	prep_in||mirnas-6/NNS||gk-9/NN	vmod||targets-3/NNS||filtered-11/VBN	amod||mrnas-14/NNS||glucose-regulated-13/JJ	prep_with||filtered-11/VBN||mrnas-14/NNS	auxpass||found-17/VBN||were-16/VBD	root||ROOT-0/null||found-17/VBN	aux||enriched-20/VBN||to-18/TO	auxpass||enriched-20/VBN||be-19/VB	xcomp||found-17/VBN||enriched-20/VBN	amod||genes-23/NNS||insulin-secretion-22/JJ	prep_for||enriched-20/VBN||genes-23/NNS	vmod||genes-23/NNS||known-24/VBN	aux||downregulated-27/VBN||to-25/TO	auxpass||downregulated-27/VBN||be-26/VB	xcomp||known-24/VBN||downregulated-27/VBN	amod||patients-30/NNS||t2d-29/JJ	prep_in||downregulated-27/VBN||patients-30/NNS	t2d-29||insulin--1||yes||the putative targets of upregulated mirnas in the gk, filtered with glucose-regulated mrnas, were found to be enriched for insulin-secretion genes known to be downregulated in t2d patients.
amod||model-5/NN||castoroil-2/JJ	amod||model-5/NN||induced-3/JJ	nn||model-5/NN||diarrhea-4/NN	prep_in||reduced-33/VBD||model-5/NN	det||extract-12/NN||the-7/DT	number||%-9/NN||80-8/CD	amod||extract-12/NN||%-9/NN	nn||extract-12/NN||methanol-10/NN	nn||extract-12/NN||leaf-11/NN	nsubj||reduced-33/VBD||extract-12/NN	nn||aurea-15/NN||c.-14/NN	prep_of||extract-12/NN||aurea-15/NN	prep_at||aurea-15/NN||100-17/CD	num||100-17/CD||200-19/CD	prep_at||aurea-15/NN||400-21/CD	conj_and||100-17/CD||400-21/CD	amod||aurea-15/NN||mg/kg-22/JJ	det||drug-26/NN||the-24/DT	amod||drug-26/NN||standard-25/JJ	amod||aurea-15/NN||drug-26/NN	conj_and||mg/kg-22/JJ||drug-26/NN	advmod||drug-26/NN||loperamide-27/RB	number||3-29/CD||-lrb--28/CD	num||-rrb--31/NNS||3-29/CD	amod||-rrb--31/NNS||mg/kg-30/JJ	dep||mg/kg-22/JJ||-rrb--31/NNS	advmod||reduced-33/VBD||significantly-32/RB	root||ROOT-0/null||reduced-33/VBD	det||time-35/NN||the-34/DT	dobj||reduced-33/VBD||time-35/NN	prep_of||time-35/NN||onset-37/NN	prep_of||onset-37/NN||diarrhea-39/NN	det||frequency-42/NN||the-41/DT	prep_of||time-35/NN||frequency-42/NN	conj_and||onset-37/NN||frequency-42/NN	nn||number-47/NN||defecation-44/NN	nn||number-47/NN||-lrb--45/NNP	amod||number-47/NN||total-46/JJ	prep_of||frequency-42/NN||number-47/NN	amod||-rrb--51/NNS||faecal-49/JJ	nn||-rrb--51/NNS||output-50/NN	prep_of||frequency-42/NN||-rrb--51/NNS	prep_of||time-35/NN||weight-53/NN	conj_and||onset-37/NN||weight-53/NN	prep_of||weight-53/NN||faeces-55/NNS	diarrhea-39||methanol-10||no_rel||in castoroil induced diarrhea model , the 80 % methanol leaf extract of c. aurea at 100 , 200 and 400 mg/kg and the standard drug loperamide -lrb- 3 mg/kg -rrb- significantly reduced the time of onset of diarrhea , the frequency of defecation -lrb- total number of faecal output -rrb- and weight of faeces .
mark||reached-11/VBN||after-1/IN	det||concentration-6/NN||the-2/DT	nn||concentration-6/NN||target-3/NN	nn||concentration-6/NN||effect-4/NN	nn||concentration-6/NN||site-5/NN	nsubjpass||reached-11/VBN||concentration-6/NN	prep_of||concentration-6/NN||remifentanil-8/NN	aux||reached-11/VBN||had-9/VBD	auxpass||reached-11/VBN||been-10/VBN	advcl||controlled-15/VBD||reached-11/VBN	det||target-14/NN||the-13/DT	nsubj||controlled-15/VBD||target-14/NN	root||ROOT-0/null||controlled-15/VBD	nsubjpass||started-20/VBN||infusion-16/NN	prep_of||infusion-16/NN||propofol-18/NN	auxpass||started-20/VBN||was-19/VBD	dep||controlled-15/VBD||started-20/VBN	amod||pain-23/NN||propofol-induced-22/JJ	nsubjpass||recorded-25/VBN||pain-23/NN	auxpass||recorded-25/VBN||was-24/VBD	dep||controlled-15/VBD||recorded-25/VBN	conj_and||started-20/VBN||recorded-25/VBN	pain-23||propofol-18||yes||after the target effect site concentration of remifentanil had been reached, the target controlled infusion of propofol was started and propofol-induced pain was recorded.
det||vaccine-7/NN||the-1/DT	amod||vaccine-7/NN||only-2/JJ	nn||vaccine-7/NN||tuberculosis-3/NNP	appos||vaccine-7/NN||tb-5/NN	nsubj||rin-14/NN||vaccine-7/NN	advmod||available-9/JJ||currently-8/RB	amod||vaccine-7/NN||available-9/JJ	cop||rin-14/NN||is-10/VBZ	amod||calmette-guã-12/JJ||bacillus-11/JJ	amod||rin-14/NN||calmette-guã-12/JJ	amod||rin-14/NN||©-13/JJ	root||ROOT-0/null||rin-14/NN	appos||rin-14/NN||bcg-16/NN	mark||has-21/VBZ||although-19/IN	nsubj||has-21/VBZ||it-20/PRP	advcl||rin-14/NN||has-21/VBZ	neg||efficacy-23/NN||no-22/DT	dobj||has-21/VBZ||efficacy-23/NN	prep_in||efficacy-23/NN||adults-25/NNS	tuberculosis-3||bcg-16||yes||the only tuberculosis (tb) vaccine currently available is bacillus calmette-guã©rin (bcg), although it has no efficacy in adults.
det||results-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	det||detection-8/NN||that-4/DT	amod||detection-8/NN||hrp-ld5-5/JJ	amod||detection-8/NN||improved-6/VBN	amod||detection-8/NN||anti-hcv-7/JJ	dobj||demonstrate-3/VBP||detection-8/NN	prepc_by||demonstrate-3/VBP||enhancing-10/VBG	det||detection-12/NN||the-11/DT	dobj||enhancing-10/VBG||detection-12/NN	amod||igm-15/NN||anti-hcv-14/JJ	prep_of||detection-12/NN||igm-15/NN	nsubj||have-19/VB||igm-15/NN	aux||have-19/VB||may-18/MD	rcmod||igm-15/NN||have-19/VB	amod||value-21/NN||potential-20/JJ	dobj||have-19/VB||value-21/NN	det||diagnosis-25/NN||the-23/DT	amod||diagnosis-25/NN||early-24/JJ	prep_for||value-21/NN||diagnosis-25/NN	prep_for||value-21/NN||screening-27/NN	conj_and||diagnosis-25/NN||screening-27/NN	amod||diseases-33/NNS||hepatitisc-29/JJ	conj_and||hepatitisc-29/JJ||other-31/JJ	amod||diseases-33/NNS||other-31/JJ	amod||diseases-33/NNS||infectious-32/JJ	prep_of||diagnosis-25/NN||diseases-33/NNS	hepatitisc-29||hcv--1||no||these results demonstrate that hrp-ld5 improved anti-hcv detection by enhancing the detection of anti-hcv igm, which may have potential value for the early diagnosis and screening of hepatitisc and other infectious diseases.
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBD||study-2/NN	nsubj||examine-5/VB||study-2/NN	root||ROOT-0/null||aimed-3/VBD	aux||examine-5/VB||to-4/TO	xcomp||aimed-3/VBD||examine-5/VB	det||effect-7/NN||the-6/DT	dobj||examine-5/VB||effect-7/NN	prep_of||effect-7/NN||chemerin-9/NN	nn||metabolism-16/NNS||weight-11/NN	conj_and||weight-11/NN||glucose-13/NN	nn||metabolism-16/NNS||glucose-13/NN	conj_and||weight-11/NN||lipid-15/NN	nn||metabolism-16/NNS||lipid-15/NN	prep_on||chemerin-9/NN||metabolism-16/NNS	prep_of||effect-7/NN||atherosclerosis-21/NNS	conj_and||chemerin-9/NN||atherosclerosis-21/NNS	prep_in||atherosclerosis-21/NNS||vivo-23/NN	atherosclerosis-21||lipid-15||no_rel||this study aimed to examine the effect of chemerin on weight, glucose and lipid metabolism, as well as atherosclerosis in vivo.
det||study-3/NN||this-2/DT	prep_in||focused-6/VBD||study-3/NN	nsubj||focused-6/VBD||we-5/PRP	nsubj||define-11/VB||we-5/PRP	root||ROOT-0/null||focused-6/VBD	amod||dcs-9/NN||dermal-8/JJ	prep_on||focused-6/VBD||dcs-9/NN	aux||define-11/VB||to-10/TO	xcomp||focused-6/VBD||define-11/VB	det||model-28/NN||the-12/DT	amod||model-28/NN||in-13/IN	nn||mechanisms-15/NNS||vivo-14/NN	dep||in-13/IN||mechanisms-15/NNS	nn||pathogenesis-19/NNS||metal-17/NN	nn||pathogenesis-19/NNS||allergy-18/NN	prep_of||mechanisms-15/NNS||pathogenesis-19/NNS	det||nickel-23/NN||a-21/DT	nn||nickel-23/NN||mouse-22/NN	prep_in||pathogenesis-19/NNS||nickel-23/NN	appos||nickel-23/NN||ni-25/NN	nn||model-28/NN||allergy-27/NN	dobj||define-11/VB||model-28/NN	allergy-27||allergy-27||no||in this study, we focused on dermal dcs to define the in vivo mechanisms of metal allergy pathogenesis in a mouse nickel (ni) allergy model.
nsubj||revealed-2/VBD||they-1/PRP	root||ROOT-0/null||revealed-2/VBD	mark||proportional-33/JJ||that-3/IN	amod||times-6/NNS||relative-4/JJ	nn||times-6/NNS||divergence-5/NN	nsubj||proportional-33/JJ||times-6/NNS	det||wdv-10/NN||the-8/DT	amod||wdv-10/NN||viruses-9/JJ	prep_for||times-6/NNS||wdv-10/NN	nn||virus-14/NN||barley-12/NN	nn||virus-14/NN||dwarf-13/NN	appos||wdv-10/NN||virus-14/NN	appos||virus-14/NN||bdv-16/NN	nn||virus-21/NN||oat-19/NN	nn||virus-21/NN||dwarf-20/NN	appos||wdv-10/NN||virus-21/NN	conj_and||virus-14/NN||virus-21/NN	appos||virus-21/NN||odv-23/NN	amod||virus-28/NN||maize-26/JJ	nn||virus-28/NN||streak-27/NN	appos||wdv-10/NN||virus-28/NN	conj_and||virus-14/NN||virus-28/NN	appos||virus-28/NN||msv-30/NN	cop||proportional-33/JJ||are-32/VBP	ccomp||revealed-2/VBD||proportional-33/JJ	nn||times-36/NNS||divergence-35/NN	prep_to||proportional-33/JJ||times-36/NNS	poss||hosts-39/NNS||their-38/PRP$	prep_of||times-36/NNS||hosts-39/NNS	xcomp||proportional-33/JJ||suggesting-41/VBG	dobj||suggesting-41/VBG||codivergence-42/NN	virus-28||viruses-9||no||they revealed that relative divergence times for the viruses wdv, barley dwarf virus (bdv), oat dwarf virus (odv) and maize streak virus (msv) are proportional to divergence times of their hosts, suggesting codivergence.
amod||agents-4/NNS||recommended-1/VBN	amod||agents-4/NNS||parenteral-2/JJ	nn||agents-4/NNS||anticoagulant-3/NN	nsubj||include-16/VBP||agents-4/NNS	amod||indications-7/NNS||different-6/JJ	prep_with||agents-4/NNS||indications-7/NNS	det||prevention-10/NN||the-9/DT	prep_for||indications-7/NNS||prevention-10/NN	prep_for||indications-7/NNS||treatment-12/NN	conj_and||prevention-10/NN||treatment-12/NN	amod||thromboembolism-15/NN||venous-14/JJ	prep_of||prevention-10/NN||thromboembolism-15/NN	root||ROOT-0/null||include-16/VBP	dobj||include-16/VBP||unfractionatedheparin-17/NN	amod||heparins-20/NNS||low-molecular-weight-19/JJ	dobj||include-16/VBP||heparins-20/NNS	conj_and||unfractionatedheparin-17/NN||heparins-20/NNS	dobj||include-16/VBP||fondaparinux-22/NN	conj_and||unfractionatedheparin-17/NN||fondaparinux-22/NN	thromboembolism-15||heparins-20||yes||recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include unfractionatedheparin, low-molecular-weight heparins and fondaparinux.
aux||investigate-2/VB||to-1/TO	advcl||generated-28/VBN||investigate-2/VB	det||mechanism-4/NN||the-3/DT	dobj||investigate-2/VB||mechanism-4/NN	dep||mechanism-4/NN||s-6/PRP	det||effect-11/NN||the-9/DT	amod||effect-11/NN||inhibitory-10/JJ	prep_of||mechanism-4/NN||effect-11/NN	prep_of||effect-11/NN||asa-13/NN	det||development-16/NN||the-15/DT	prep_on||investigate-2/VB||development-16/NN	amod||inflammation-20/NN||th17-18/JJ	amod||inflammation-20/NN||airway-19/JJ	prep_of||development-16/NN||inflammation-20/NN	det||model-26/NN||a-22/DT	amod||model-26/NN||neutrophilic-23/JJ	nn||model-26/NN||asthma-24/NN	nn||model-26/NN||mouse-25/NN	nsubjpass||generated-28/VBN||model-26/NN	nsubjpass||challenged-41/VBN||model-26/NN	auxpass||generated-28/VBN||was-27/VBD	root||ROOT-0/null||generated-28/VBN	amod||sensitization-31/NN||intranasal-30/JJ	agent||generated-28/VBN||sensitization-31/NN	prep_with||generated-28/VBN||lps-33/NNP	prep_with||generated-28/VBN||ovalbumin-35/NNP	conj_plus||lps-33/NNP||ovalbumin-35/NNP	appos||lps-33/NNP||ova-37/NN	advmod||challenged-41/VBN||then-40/RB	conj_and||generated-28/VBN||challenged-41/VBN	prep_with||challenged-41/VBN||ova-43/NN	advmod||challenged-41/VBN||alone-44/RB	asthma-24||asa-13||no||to investigate the mechanism(s) of the inhibitory effect of asa on the development of th17 airway inflammation, a neutrophilic asthma mouse model was generated by intranasal sensitization with lps plus ovalbumin (ova) and then challenged with ova alone.
nn||cytokines-4/NNS||objectiveâ-1/NNP	nn||cytokines-4/NNS||$-2/NNP	nsubjpass||elevated-6/VBN||cytokines-4/NNS	auxpass||elevated-6/VBN||are-5/VBP	root||ROOT-0/null||elevated-6/VBN	amod||states-10/NNS||various-8/JJ	amod||states-10/NNS||insulin-resistant-9/JJ	prep_in||elevated-6/VBN||states-10/NNS	prep_including||elevated-6/VBN||type2diabetes-13/NNS	prep_including||elevated-6/VBN||obesity-15/NN	conj_and||type2diabetes-13/NNS||obesity-15/NN	mark||controversial-32/JJ||although-17/IN	det||contribution-19/NN||the-18/DT	nsubj||controversial-32/JJ||contribution-19/NN	prep_of||contribution-19/NN||interleukin-6-21/JJ	dep||interleukin-6-21/JJ||il-6-23/JJ	det||induction-27/NN||the-26/DT	prep_in||interleukin-6-21/JJ||induction-27/NN	det||diseases-30/NNS||these-29/DT	prep_of||induction-27/NN||diseases-30/NNS	cop||controversial-32/JJ||is-31/VBZ	advcl||elevated-6/VBN||controversial-32/JJ	insulin--1||obesity-15||no_rel||objectiveâ€” cytokines are elevated in various insulin-resistant states, including type2diabetes and obesity, although the contribution of interleukin-6 (il-6) in the induction of these diseases is controversial.
nsubj||is-9/VBZ||epratuzumab-1/NN	det||antibody-7/NN||a-3/DT	amod||antibody-7/NN||humanized-4/JJ	amod||antibody-7/NN||anti-cd22-5/JJ	nn||antibody-7/NN||monoclonal-6/NN	appos||epratuzumab-1/NN||antibody-7/NN	root||ROOT-0/null||is-9/VBZ	prep_under||is-9/VBZ||investigation-11/NN	det||antibody-15/NN||a-13/DT	amod||antibody-15/NN||therapeutic-14/JJ	prep_as||investigation-11/NN||antibody-15/NN	amod||slymphoma-19/NN||non-hodgkin-17/JJ	prep_in||antibody-15/NN||slymphoma-19/NN	amod||lupuserythematosus-22/NNS||systemic-21/JJ	prep_in||antibody-15/NN||lupuserythematosus-22/NNS	conj_and||slymphoma-19/NN||lupuserythematosus-22/NNS	appos||slymphoma-19/NN||sle-24/NN	poss||mechanism-29/NN||its-28/PRP$	nsubj||remains-34/VBZ||mechanism-29/NN	prep_of||mechanism-29/NN||action-31/NN	prep_on||action-31/NN||b-cells-33/NNS	conj_but||is-9/VBZ||remains-34/VBZ	acomp||remains-34/VBZ||elusive-35/JJ	non-hodgkin'slymphoma--1||antibody-15||no_rel||epratuzumab, a humanized anti-cd22 monoclonal antibody, is under investigation as a therapeutic antibody in non-hodgkin'slymphoma and systemic lupuserythematosus (sle), but its mechanism of action on b-cells remains elusive.
det||finding-2/NN||the-1/DT	nsubj||has-18/VBZ||finding-2/NN	nsubj||provides-30/VBZ||finding-2/NN	mark||has-6/VBZ||that-3/IN	nn||infection-5/NN||helminth-4/NN	nsubj||has-6/VBZ||infection-5/NN	dep||finding-2/NN||has-6/VBZ	det||association-9/NN||a-7/DT	amod||association-9/NN||profound-8/JJ	dobj||has-6/VBZ||association-9/NN	det||response-15/NN||the-11/DT	amod||response-15/NN||mucosal-12/JJ	amod||response-15/NN||humoral-13/JJ	amod||response-15/NN||immune-14/JJ	prep_with||association-9/NN||response-15/NN	aux||v.cholerae-17/VB||to-16/TO	vmod||response-15/NN||v.cholerae-17/VB	root||ROOT-0/null||has-18/VBZ	dobj||has-18/VBZ||implications-19/NNS	det||development-22/NN||the-21/DT	prep_for||implications-19/NNS||development-22/NN	amod||immunity-25/NN||protective-24/JJ	prep_of||development-22/NN||immunity-25/NN	amod||areas-28/NNS||cholera-endemic-27/JJ	prep_in||immunity-25/NN||areas-28/NNS	conj_and||has-18/VBZ||provides-30/VBZ	det||basis-33/NN||an-31/DT	amod||basis-33/NN||additional-32/JJ	dobj||provides-30/VBZ||basis-33/NN	prepc_for||provides-30/VBZ||deworming-35/VBG	dobj||deworming-35/VBG||programs-36/NNS	amod||areas-39/NNS||cholera-endemic-38/JJ	prep_in||deworming-35/VBG||areas-39/NNS	cholera--1||v.cholerae-17||no||the finding that helminth infection has a profound association with the mucosal humoral immune response to v.cholerae has implications for the development of protective immunity in cholera-endemic areas and provides an additional basis for deworming programs in cholera-endemic areas .
amod||tuberculosis-2/NNS||multidrug-resistant-1/JJ	nsubj||is-6/VBZ||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||mdr-tb-4/NNP	root||ROOT-0/null||is-6/VBZ	dep||resistant-9/NN||vitro-8/NN	prep_in||is-6/VBZ||resistant-9/NN	prep_to||is-6/VBZ||isoniazid-11/NN	appos||isoniazid-11/NN||h-13/NN	prep_to||is-6/VBZ||rifampicin-16/NN	conj_and||isoniazid-11/NN||rifampicin-16/NN	appos||isoniazid-11/NN||r-18/NN	tb--1||isoniazid-11||yes||multidrug-resistant tuberculosis (mdr-tb) is in vitro resistant to isoniazid (h) and rifampicin (r).
det||year-2/NN||each-1/DT	nsubjpass||collected-21/VBN||year-2/NN	tmod||collected-21/VBN||year-2/NN	prep_between||collected-21/VBN||july-5/NNP	conj_and||july-5/NNP||december-7/NNP	prep_between||collected-21/VBN||december-7/NNP	amod||july-5/NNP||inclusive-8/JJ	nsubjpass||collected-21/VBN||fevers-10/NNS	vmod||fevers-10/NNS||treated-11/VBN	prep_with||treated-11/VBN||antimalarials-13/NNS	amod||cases-19/NNS||slide-proven-15/JJ	amod||cases-19/NNS||uncomplicated-17/JJ	nn||cases-19/NNS||malaria-18/NN	prep_with||treated-11/VBN||cases-19/NNS	conj_and||antimalarials-13/NNS||cases-19/NNS	auxpass||collected-21/VBN||were-20/VBD	root||ROOT-0/null||collected-21/VBN	amod||records-25/NNS||dispensary-23/JJ	nn||records-25/NNS||health-24/NN	prep_from||collected-21/VBN||records-25/NNS	antimalarials-13||malaria-18||no_rel||each year, between july and december inclusive, fevers treated with antimalarials and slide-proven, uncomplicated malaria cases were collected from dispensary health records.
nn||toxin-2/NN||anthrax-1/NN	nsubjpass||released-6/VBN||toxin-2/NN	nsubjpass||composed-13/VBN||toxin-2/NN	auxpass||released-6/VBN||is-5/VBZ	rcmod||toxin-2/NN||released-6/VBN	det||bacillusanthracis-10/NNS||the-8/DT	amod||bacillusanthracis-10/NNS||gram-positivebacterium-9/JJ	prep_from||released-6/VBN||bacillusanthracis-10/NNS	auxpass||composed-13/VBN||is-12/VBZ	root||ROOT-0/null||composed-13/VBN	num||proteins-16/NNS||three-15/CD	prep_of||composed-13/VBN||proteins-16/NNS	amod||antigen-18/NN||protective-17/JJ	dep||proteins-16/NNS||antigen-18/NN	appos||antigen-18/NN||pa-20/NN	amod||factor-24/NN||lethal-23/JJ	dep||proteins-16/NNS||factor-24/NN	conj_and||antigen-18/NN||factor-24/NN	appos||factor-24/NN||lf-26/NN	nn||factor-31/NN||edema-30/NN	dep||proteins-16/NNS||factor-31/NN	conj_and||antigen-18/NN||factor-31/NN	appos||factor-31/NN||ef-33/NN	anthrax-1||bacillusanthracis-10||no||anthrax toxin, which is released from the gram-positivebacterium bacillusanthracis , is composed of three proteins protective antigen (pa), lethal factor (lf), and edema factor (ef).
prep_in||displayed-9/VBD||vietnam-2/NN	det||population-8/NN||the-4/DT	advmod||diversified-6/VBN||highly-5/RB	amod||population-8/NN||diversified-6/VBN	nn||population-8/NN||gonococcal-7/NN	nsubj||displayed-9/VBD||population-8/NN	root||ROOT-0/null||displayed-9/VBD	amod||resistance-13/NN||high-10/JJ	dep||vitro-12/NN||in-11/IN	amod||resistance-13/NN||vitro-12/NN	dobj||displayed-9/VBD||resistance-13/NN	prep_to||displayed-9/VBD||antimicrobials-15/NNS	advmod||recommended-17/VBN||previously-16/RB	vmod||antimicrobials-15/NNS||recommended-17/VBN	nn||treatment-20/NN||gonorrhoea-19/NN	prep_for||recommended-17/VBN||treatment-20/NN	prep_with||treatment-20/NN||exception-23/NN	prep_of||exception-23/NN||spectinomycin-25/NN	nsubjpass||found-37/VBN||resistance-29/NN	advmod||resistance-29/NN||also-30/RB	det||escs-35/NN||the-32/DT	advmod||escs-35/NN||currently-33/RB	amod||escs-35/NN||recommended-34/VBN	prep_to||resistance-29/NN||escs-35/NN	auxpass||found-37/VBN||were-36/VBD	conj_but||displayed-9/VBD||found-37/VBN	gonorrhoea-19||spectinomycin-25||yes||in vietnam, the highly diversified gonococcal population displayed high in vitro resistance to antimicrobials previously recommended for gonorrhoea treatment (with exception of spectinomycin), but resistance also to the currently recommended escs were found.
advmod||isolates-5/VBZ||overall-1/RB	num||m.tuberculosis-4/NNS||150-3/CD	nsubj||isolates-5/VBZ||m.tuberculosis-4/NNS	ccomp||tested-17/VBN||isolates-5/VBZ	xcomp||isolates-5/VBZ||consisting-7/VBG	num||susceptible-10/NNS||50-9/CD	prep_of||consisting-7/VBG||susceptible-10/NNS	num||isolates-14/NNS||100-12/CD	amod||isolates-14/NNS||mdr-tb-13/JJ	prep_of||consisting-7/VBG||isolates-14/NNS	conj_and||susceptible-10/NNS||isolates-14/NNS	auxpass||tested-17/VBN||were-16/VBD	root||ROOT-0/null||tested-17/VBN	nn||susceptibility-20/NN||pza-19/NN	prep_for||tested-17/VBN||susceptibility-20/NN	amod||mgit-23/NN||bactec-22/JJ	agent||tested-17/VBN||mgit-23/NN	num||pza-25/NN||960-24/CD	nsubjpass||tested-17/VBN||pza-25/NN	det||assay-29/NN||the-27/DT	amod||assay-29/NN||pyrazinamidase-28/JJ	appos||pza-25/NN||assay-29/NN	nn||sequencing-32/NN||pnca-31/NN	appos||pza-25/NN||sequencing-32/NN	conj_and||assay-29/NN||sequencing-32/NN	tb--1||m.tuberculosis-4||no||overall , 150 m.tuberculosis isolates , consisting of 50 susceptible and 100 mdr-tb isolates , were tested for pza susceptibility by bactec mgit 960 pza , the pyrazinamidase assay and pnca sequencing .
advmod||present-3/VBP||here-1/RB	nsubj||present-3/VBP||we-2/PRP	root||ROOT-0/null||present-3/VBP	det||overview-5/NN||an-4/DT	dobj||present-3/VBP||overview-5/NN	poss||studies-9/NNS||our-7/PRP$	amod||studies-9/NNS||published-8/JJ	prep_of||overview-5/NN||studies-9/NNS	det||data-13/NNS||some-11/DT	amod||data-13/NNS||original-12/JJ	dobj||present-3/VBP||data-13/NNS	conj_and||overview-5/NN||data-13/NNS	det||effects-16/NNS||the-15/DT	prep_on||data-13/NNS||effects-16/NNS	appos||stress-22/NN||1-19/CD	amod||stress-22/NN||prenatal-21/JJ	prep_of||effects-16/NNS||stress-22/NN	prepc_on||present-3/VBP||hypothalamicâ-24/VBG	dobj||hypothalamicâ-24/VBG||$-25/$	npadvmod||in-86/RB||pituitaryâ-27/NNS	npadvmod||stress-72/JJ||$-28/$	amod||hpa-32/NNS||adrenal-30/JJ	npadvmod||neuroanatomy-37/JJ||hpa-32/NNS	amod||hpa-32/NNS||re/activity-34/JJ	amod||hpa-32/NNS||hippocampus-36/JJ	conj_and||re/activity-34/JJ||hippocampus-36/JJ	amod||postnatal-68/NNS||neuroanatomy-37/JJ	amod||macaques-41/NNS||juvenile-adolescent-39/JJ	nn||macaques-41/NNS||rhesus-40/NNS	prep_in||neuroanatomy-37/JJ||macaques-41/NNS	dep||dex-49/NN||2-44/LS	amod||dex-49/NN||prenatal-46/JJ	nn||dex-49/NN||dexamethasone-47/NN	dep||macaques-41/NNS||dex-49/NN	amod||neuroanatomy-59/NN||hpa-52/JJ	nn||behaviour-55/NN||activity-53/NN	nn||neuroanatomy-59/NN||behaviour-55/NN	conj_and||behaviour-55/NN||prefrontal-57/JJ	nn||neuroanatomy-59/NN||prefrontal-57/JJ	nn||neuroanatomy-59/NN||cortex-58/NN	prep_on||dex-49/NN||neuroanatomy-59/NN	amod||marmosets-63/NNS||infant-adolescent-61/JJ	amod||marmosets-63/NNS||common-62/JJ	prep_in||neuroanatomy-59/NN||marmosets-63/NNS	dep||neuroanatomy-37/JJ||3-66/CD	npadvmod||daily-69/RB||postnatal-68/NNS	dep||parental-70/CD||daily-69/RB	num||$-28/$||parental-70/CD	num||$-28/$||separation-71/CD	advmod||pituitaryâ-27/NNS||stress-72/JJ	amod||re/activity-75/NN||hpa-74/JJ	prep_on||stress-72/JJ||re/activity-75/NN	prep_on||stress-72/JJ||behaviour-77/NN	conj_and||re/activity-75/NN||behaviour-77/NN	prep_on||stress-72/JJ||sleep-79/NN	conj_and||re/activity-75/NN||sleep-79/NN	prep_on||stress-72/JJ||hippocampus-81/NNS	conj_and||re/activity-75/NN||hippocampus-81/NNS	amod||neuroanatomy-85/NN||prefrontal-83/JJ	nn||neuroanatomy-85/NN||cortex-84/NN	prep_on||stress-72/JJ||neuroanatomy-85/NN	conj_and||re/activity-75/NN||neuroanatomy-85/NN	dep||infant-adolescent-87/CD||in-86/RB	num||$-25/$||infant-adolescent-87/CD	amod||marmoset-89/JJ||common-88/JJ	amod||$-25/$||marmoset-89/JJ	pituitary--1||dexamethasone-47||no_rel||here we present an overview of our published studies and some original data on the effects of (1) prenatal stress on hypothalamicâ€“pituitaryâ€“adrenal (hpa) re/activity and hippocampus neuroanatomy in juvenile-adolescent rhesus macaques; (2) prenatal dexamethasone (dex) on hpa activity, behaviour and prefrontal cortex neuroanatomy in infant-adolescent common marmosets; (3) postnatal daily parental separation stress on hpa re/activity, behaviour, sleep and hippocampus and prefrontal cortex neuroanatomy in infant-adolescent common marmoset.
preconj||mos-hiv-3/NN||both-1/CC	det||mos-hiv-3/NN||the-2/DT	nsubjpass||adapted-10/VBN||mos-hiv-3/NN	nsubjpass||showed-20/VBD||mos-hiv-3/NN	det||sf-12-7/NN||the-5/DT	amod||sf-12-7/NN||shorter-6/JJR	conj_and||mos-hiv-3/NN||sf-12-7/NN	nsubjpass||adapted-10/VBN||sf-12-7/NN	auxpass||adapted-10/VBN||were-8/VBD	advmod||adapted-10/VBN||successfully-9/RB	root||ROOT-0/null||adapted-10/VBN	prep_for||adapted-10/VBN||people-12/NNS	prep_with||people-12/NNS||hiv/aids-14/NNS	amod||thailand-17/NN||northern-16/JJ	prep_in||hiv/aids-14/NNS||thailand-17/NN	conj_and||adapted-10/VBN||showed-20/VBD	amod||evidence-22/NN||encouraging-21/JJ	dobj||showed-20/VBD||evidence-22/NN	prep_for||showed-20/VBD||reliability-24/NN	prep_for||showed-20/VBD||validity-26/NN	conj_and||reliability-24/NN||validity-26/NN	aids--1||hiv--1||no||both the mos-hiv and the shorter sf-12 were successfully adapted for people with hiv/aids in northern thailand, and showed encouraging evidence for reliability and validity.
amod||differences-2/NNS||regional-1/JJ	nsubj||depots-5/VBZ||differences-2/NNS	prep_among||differences-2/NNS||adipose-4/NN	root||ROOT-0/null||depots-5/VBZ	prep_in||depots-5/VBZ||capacities-7/NNS	amod||storage-10/NN||fattyacid-9/JJ	prep_for||capacities-7/NNS||storage-10/NN	advmod||depots-5/VBZ||susceptibility-12/RB	prep_to||depots-5/VBZ||hypoxia-14/NN	nsubj||contribute-19/VBP||inflammation-17/NN	advmod||contribute-19/VBP||likely-18/RB	conj_and||depots-5/VBZ||contribute-19/VBP	prep_to||contribute-19/VBP||complications-21/NNS	prep_of||complications-21/NNS||obesity-23/NN	obesity-23||fattyacid-9||no_rel||regional differences among adipose depots in capacities for fattyacid storage, susceptibility to hypoxia, and inflammation likely contribute to complications of obesity.
det||ipp-5/NN||the-1/DT	amod||ipp-5/NN||meanâ-2/JJ	amod||ipp-5/NN||±-3/JJ	nn||ipp-5/NN||sd-4/NN	nsubj||±-27/NNS||ipp-5/NN	nn||volume-8/NN||prostate-7/NN	appos||ipp-5/NN||volume-8/NN	appos||volume-8/NN||pv-10/NN	nn||volume-16/NN||transition-14/NN	nn||volume-16/NN||zone-15/NN	appos||ipp-5/NN||volume-16/NN	conj_and||volume-8/NN||volume-16/NN	det||trilobar-19/NN||the-18/DT	prep_of||volume-16/NN||trilobar-19/NN	nn||groups-23/NNS||bilobar-21/NN	nn||groups-23/NNS||adenoma-22/NN	prep_of||volume-16/NN||groups-23/NNS	conj_and||trilobar-19/NN||groups-23/NNS	cop||±-27/NNS||were-24/VBD	number||â-26/CD||11.8-25/CD	num||±-27/NNS||â-26/CD	root||ROOT-0/null||±-27/NNS	num||mm-29/NN||5.2-28/CD	dep||±-27/NNS||mm-29/NN	num||â-32/NN||9.0-31/CD	conj_and||±-27/NNS||â-32/NN	number||3.8-34/CD||±-33/CD	num||mm-35/NN||3.8-34/CD	dep||â-32/NN||mm-35/NN	dep||±-27/NNS||p-37/VBN	dep||0.014-39/CD||=-38/SYM	ccomp||p-37/VBN||0.014-39/CD	num||±-44/NNS||81.1-42/CD	nn||±-44/NNS||â-43/NN	conj_and||±-27/NNS||±-44/NNS	num||g-46/CD||25.8-45/CD	num||g-52/NN||g-46/CD	num||22.5-51/CD||59.3-48/CD	num||22.5-51/CD||â-49/CD	num||22.5-51/CD||±-50/CD	conj_and||g-46/CD||22.5-51/CD	num||g-52/NN||22.5-51/CD	dep||±-44/NNS||g-52/NN	dep||±-27/NNS||p-54/VB	number||0.001-56/CD||<-55/CD	dobj||p-54/VB||0.001-56/CD	num||±-62/NNS||49.6-60/CD	nn||±-62/NNS||â-61/NN	conj_and||±-27/NNS||±-62/NNS	num||g-64/CD||20.6-63/CD	num||g-70/NN||g-64/CD	num||19.4-69/CD||34.8-66/CD	num||19.4-69/CD||â-67/CD	num||19.4-69/CD||±-68/CD	conj_and||g-64/CD||19.4-69/CD	num||g-70/NN||19.4-69/CD	dep||±-62/NNS||g-70/NN	dep||±-62/NNS||p-72/VBN	dep||0.003-74/CD||=-73/SYM	ccomp||p-72/VBN||0.003-74/CD	advmod||±-27/NNS||respectively-77/RB	ipp-5||adenoma-22||no_rel||the meanâ±sd ipp, prostate volume (pv), and transition zone volume of the trilobar and bilobar adenoma groups were 11.8â±5.2 mm and 9.0â±3.8 mm (p=0.014), 81.1â±25.8 g and 59.3â±22.5 g (p<0.001), and 49.6â±20.6 g and 34.8â±19.4 g (p=0.003), respectively.
nsubj||discovered-3/VBD||we-1/PRP	advmod||discovered-3/VBD||previously-2/RB	root||ROOT-0/null||discovered-3/VBD	det||facet-7/NN||an-4/DT	amod||facet-7/NN||addictive-5/JJ	amod||facet-7/NN||molecular-6/JJ	dobj||discovered-3/VBD||facet-7/NN	prep_of||facet-7/NN||anorexia-9/NNP	vmod||discovered-3/VBD||involving-11/VBG	dobj||involving-11/VBG||production-12/NN	det||accumbens-17/NNS||the-15/DT	nn||accumbens-17/NNS||nucleus-16/NN	prep_in||discovered-3/VBD||accumbens-17/NNS	appos||accumbens-17/NNS||nac-19/NN	det||transcripts-25/NNS||the-23/DT	amod||transcripts-25/NNS||same-24/JJ	prep_of||accumbens-17/NNS||transcripts-25/NNS	vmod||transcripts-25/NNS||stimulated-26/VBN	prep_in||stimulated-26/VBN||response-28/NN	prep_to||stimulated-26/VBN||cocaine-30/NN	prep_to||stimulated-26/VBN||amphetamine-32/NN	conj_and||cocaine-30/NN||amphetamine-32/NN	appos||cocaine-30/NN||cart-34/NN	prep_upon||stimulated-26/VBN||stimulation-37/NN	det||receptors-41/NNS||the-39/DT	amod||receptors-41/NNS||5-ht4-40/JJ	prep_of||stimulation-37/NN||receptors-41/NNS	dep||receptors-41/NNS||5-htr4-43/JJ	prep_of||stimulation-37/NN||mdma-46/NN	conj_or||receptors-41/NNS||mdma-46/NN	appos||receptors-41/NNS||ecstasy-48/NN	mdma-46||anorexia-9||no_rel||we previously discovered an addictive molecular facet of anorexia, involving production, in the nucleus accumbens (nac), of the same transcripts stimulated in response to cocaine and amphetamine (cart) upon stimulation of the 5-ht4 receptors (5-htr4) or mdma (ecstasy).
nn||specimens-4/NNS||stool-1/NN	conj_and||stool-1/NN||blood-3/NN	nn||specimens-4/NNS||blood-3/NN	nsubjpass||screened-12/VBN||specimens-4/NNS	amod||patients-7/NNS||hiv/aids-6/JJ	prep_from||specimens-4/NNS||patients-7/NNS	nn||group-10/NN||control-9/NN	prep_from||specimens-4/NNS||group-10/NN	conj_and||patients-7/NNS||group-10/NN	auxpass||screened-12/VBN||were-11/VBD	root||ROOT-0/null||screened-12/VBN	advmod||screened-12/VBN||respectively-13/RB	amod||parasites-16/NNS||intestinal-15/JJ	prep_for||screened-12/VBN||parasites-16/NNS	nn||antibodies-20/NNS||hiv-19/NN	prep_for||screened-12/VBN||antibodies-20/NNS	conj_and||parasites-16/NNS||antibodies-20/NNS	aids--1||hiv-19||no||stool and blood specimens from hiv/aids patients and control group were screened respectively for intestinal parasites and for hiv antibodies.
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||provides-11/VBZ||that-4/IN	det||combination-6/NN||the-5/DT	nsubj||provides-11/VBZ||combination-6/NN	amod||olmesartanmedoxomil-10/NN||amlodipine-8/JJ	amod||olmesartanmedoxomil-10/NN||+-9/JJ	prep_of||combination-6/NN||olmesartanmedoxomil-10/NN	ccomp||suggest-3/VBP||provides-11/VBZ	det||option-16/NN||a-12/DT	amod||option-16/NN||safe-13/JJ	conj_and||safe-13/JJ||effective-15/JJ	amod||option-16/NN||effective-15/JJ	dobj||provides-11/VBZ||option-16/NN	det||treatment-19/NN||the-18/DT	prep_for||option-16/NN||treatment-19/NN	prep_of||treatment-19/NN||hypertension-21/NN	prepc_in||provides-11/VBZ||challenging-23/VBG	amod||populations-25/NNS||patient-24/JJ	dobj||challenging-23/VBG||populations-25/NNS	hypertension-21||olmesartanmedoxomil-10||yes||these results suggest that the combination of amlodipine+olmesartanmedoxomil provides a safe and effective option for the treatment of hypertension in challenging patient populations.
advmod||tested-3/VBD||here-1/RB	nsubj||tested-3/VBD||we-2/PRP	root||ROOT-0/null||tested-3/VBD	mark||express-10/VBP||whether-4/IN	amod||mice-9/NNS||nk1r-5/JJ	dep||mice-9/NNS||/-7/NNP	nsubj||express-10/VBP||mice-9/NNS	ccomp||tested-3/VBD||express-10/VBP	amod||features-13/NNS||other-11/JJ	nn||features-13/NNS||core-12/NN	dobj||express-10/VBP||features-13/NNS	prep_of||features-13/NNS||adhd-15/NN	appos||adhd-15/NN||impulsivity-17/NN	appos||adhd-15/NN||inattentiveness-19/NNS	conj_and||impulsivity-17/NN||inattentiveness-19/NNS	ccomp||tested-3/VBD||if-23/IN	conj_and||express-10/VBP||if-23/IN	advmod||if-23/IN||so-24/RB	mark||diminished-29/VBN||whether-26/IN	nsubjpass||diminished-29/VBN||they-27/PRP	auxpass||diminished-29/VBN||are-28/VBP	ccomp||if-23/IN||diminished-29/VBN	agent||diminished-29/VBN||d-31/SYM	dep||d-31/SYM||amphetamine-33/NN	advmod||amphetamine-33/NN||as-35/RB	prep_in||as-35/RB||adhd-37/JJ	adhd-37||amphetamine-33||yes||here we tested whether nk1r-/- mice express other core features of adhd (impulsivity and inattentiveness) and, if so, whether they are diminished by d -amphetamine, as in adhd.
advmod||diagnosed-4/VBN||when-1/WRB	nsubjpass||diagnosed-4/VBN||retinitis-2/NNS	auxpass||diagnosed-4/VBN||is-3/VBZ	advcl||started-10/VBN||diagnosed-4/VBN	nn||therapy-7/NN||haart-6/NN	nsubjpass||started-10/VBN||therapy-7/NN	nsubjpass||improved-12/VBN||therapy-7/NN	aux||started-10/VBN||should-8/MD	auxpass||started-10/VBN||be-9/VB	root||ROOT-0/null||started-10/VBN	conj_or||started-10/VBN||improved-12/VBN	amod||therapy-16/NN||anti-cmv-15/JJ	nsubjpass||administered-30/VBN||therapy-16/NN	amod||valganciclovir-19/NN||oral-18/JJ	prep_with||therapy-16/NN||valganciclovir-19/NN	amod||ganciclovir-22/NN||intravenous-21/JJ	prep_with||therapy-16/NN||ganciclovir-22/NN	conj_or||valganciclovir-19/NN||ganciclovir-22/NN	prep_with||therapy-16/NN||foscarnet-24/NN	conj_or||valganciclovir-19/NN||foscarnet-24/NN	prep_with||therapy-16/NN||cidofovir-27/NN	conj_or||valganciclovir-19/NN||cidofovir-27/NN	aux||administered-30/VBN||should-28/MD	auxpass||administered-30/VBN||be-29/VB	conj_and||started-10/VBN||administered-30/VBN	cmv--1||foscarnet-24||yes||when retinitis is diagnosed, haart therapy should be started or improved, and anti-cmv therapy with oral valganciclovir, intravenous ganciclovir, foscarnet, or cidofovir should be administered.
amod||studies-3/NNS||previous-2/JJ	prep_in||shown-7/VBN||studies-3/NNS	poss||group-5/NN||our-4/PRP$	nsubj||shown-7/VBN||group-5/NN	aux||shown-7/VBN||has-6/VBZ	root||ROOT-0/null||shown-7/VBN	mark||albicans-12/VBZ||that-8/IN	nsubj||albicans-12/VBZ||adhesion-9/NN	prep_of||adhesion-9/NN||c.-11/NN	ccomp||shown-7/VBN||albicans-12/VBZ	nn||tubes-14/NNS||germ-13/NN	nsubjpass||decreased-18/VBN||tubes-14/NNS	prep_to||tubes-14/NNS||polystyrene-16/NN	auxpass||decreased-18/VBN||is-17/VBZ	ccomp||albicans-12/VBZ||decreased-18/VBN	agent||decreased-18/VBN||saliva-20/NN	mark||enhanced-32/VBN||whereas-21/IN	amod||cells-25/NNS||c.-22/JJ	amod||cells-25/NNS||albicans-23/JJ	nn||cells-25/NNS||yeast-24/NN	nsubjpass||enhanced-32/VBN||cells-25/NNS	vmod||cells-25/NNS||adhesion-26/VBN	det||material-30/NN||the-28/DT	amod||material-30/NN||same-29/JJ	prep_to||adhesion-26/VBN||material-30/NN	auxpass||enhanced-32/VBN||is-31/VBZ	advcl||decreased-18/VBN||enhanced-32/VBN	adhesion-26||polystyrene-16||no_rel||in previous studies our group has shown that adhesion of c. albicans germ tubes to polystyrene is decreased by saliva whereas c. albicans yeast cells adhesion to the same material is enhanced .
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	viremia-7||doxorubicin-40||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
det||search-3/NN||a-1/DT	num||search-3/NN||2007-2/CD	nsubj||identified-25/VBD||search-3/NN	det||evidence-6/NN||the-5/DT	prep_for||search-3/NN||evidence-6/NN	amod||settings-10/NNS||low-8/JJ	nn||settings-10/NNS||prevalence-9/NN	prep_in||evidence-6/NN||settings-10/NNS	amod||challenges-13/NNS||situational-12/JJ	prep_on||settings-10/NNS||challenges-13/NNS	nn||children-18/NNS||hiv-15/NN	conj_and||hiv-15/NN||aids-affected-17/JJ	nn||children-18/NNS||aids-affected-17/JJ	prep_of||challenges-13/NNS||children-18/NNS	prep_of||challenges-13/NNS||interventions-20/NNS	conj_and||children-18/NNS||interventions-20/NNS	aux||address-22/VB||to-21/TO	vmod||evidence-6/NN||address-22/VB	det||challenges-24/NNS||these-23/DT	dobj||address-22/VB||challenges-24/NNS	root||ROOT-0/null||identified-25/VBD	amod||documents-27/NNS||413-26/JJ	dobj||identified-25/VBD||documents-27/NNS	aids--1||hiv-15||no||a 2007 search for the evidence in low prevalence settings on situational challenges of hiv and aids-affected children and interventions to address these challenges identified 413 documents.
det||subset-2/NN||a-1/DT	nsubj||showed-9/VBD||subset-2/NN	nn||women-5/NNS||aa-4/NN	prep_of||subset-2/NN||women-5/NNS	nn||therapy-8/NN||dhea-7/NN	prep_on||women-5/NNS||therapy-8/NN	root||ROOT-0/null||showed-9/VBD	det||decrease-12/NN||a-10/DT	amod||decrease-12/NN||significant-11/JJ	dobj||showed-9/VBD||decrease-12/NN	nn||â-15/NN||p-14/NN	dep||decrease-12/NN||â-15/NN	num||â-19/NN||$-16/$	number||<-18/CD||‰-17/CD	num||$-16/$||<-18/CD	dep||â-15/NN||â-19/NN	dep||â-19/NN||$-20/$	num||$-20/$||‰-21/CD	num||$-20/$||0.05-22/CD	amod||expression-26/NN||dnmt3a-25/JJ	prep_in||showed-9/VBD||expression-26/NN	prep_in||expression-26/NN||comparison-28/NN	amod||patients-31/NNS||lupus-30/JJ	prep_to||showed-9/VBD||patients-31/NNS	neg||showed-9/VBD||not-32/RB	det||therapy-35/NN||the-34/DT	prep_on||showed-9/VBD||therapy-35/NN	lupus-30||dhea-7||yes||a subset of aa women on dhea therapy showed a significant decrease ( p â€‰<â€‰0.05) in dnmt3a expression in comparison to lupus patients not on the therapy.
amod||effects-2/NNS||direct-1/JJ	nsubjpass||evaluated-9/VBN||effects-2/NNS	prep_of||effects-2/NNS||calcitonin-4/NN	nn||cartilage-7/NN||articular-6/NN	prep_on||calcitonin-4/NN||cartilage-7/NN	auxpass||evaluated-9/VBN||were-8/VBD	root||ROOT-0/null||evaluated-9/VBN	dep||measurement-13/NN||1-11/LS	agent||evaluated-9/VBN||measurement-13/NN	nn||synthesis-16/NN||proteoglycan-15/NN	prep_of||measurement-13/NN||synthesis-16/NN	prep_by||synthesis-16/NN||incorporation-18/NN	prep_of||incorporation-18/NN||radioactive-20/NN	vmod||radioactive-20/NN||labeled-21/VBN	amod||ci-27/NN||35so4-22/JJ	amod||ci-27/NN||-LSB--23/JJ	num||ci-27/NN||5-24/CD	nn||ci-27/NN||î-25/NN	num||ci-27/NN||1/4-26/CD	dobj||labeled-21/VBN||ci-27/NN	xcomp||labeled-21/VBN||-RSB--28/VBG	dep||quantification-31/NN||2-29/LS	dobj||-RSB--28/VBG||quantification-31/NN	nn||formation-34/NN||collagen-type-ii-33/NN	prep_of||quantification-31/NN||formation-34/NN	prep_by||formation-34/NN||pro-peptides-36/NNS	nn||elisa-44/NN||collagen-38/NN	nn||elisa-44/NN||type-39/NN	nn||elisa-44/NN||ii-40/NN	nn||elisa-44/NN||piinp-42/NN	prep_of||pro-peptides-36/NNS||elisa-44/NN	dep||expression-49/NN||3-46/LS	nn||expression-49/NN||qpcr-48/NN	appos||elisa-44/NN||expression-49/NN	det||receptor-53/NN||the-51/DT	nn||receptor-53/NN||calcitonin-52/NN	prep_of||expression-49/NN||receptor-53/NN	nn||chondrocytes-56/NNS||oa-55/NN	prep_in||receptor-53/NN||chondrocytes-56/NNS	vmod||chondrocytes-56/NNS||using-57/VBG	num||pairs-61/NNS||four-58/CD	amod||pairs-61/NNS||individual-59/JJ	nn||pairs-61/NNS||primer-60/NN	dobj||using-57/VBG||pairs-61/NNS	dep||activation-65/NN||4-63/LS	appos||quantification-31/NN||activation-65/NN	det||camp-68/NN||the-67/DT	prep_of||activation-65/NN||camp-68/NN	vmod||camp-68/NN||signaling-69/VBG	advmod||signaling-69/VBG||pathway-70/RB	agent||signaling-69/VBG||eia-72/NN	dep||investigations-77/NNS||5-75/CD	agent||evaluated-9/VBN||investigations-77/NNS	conj_and||measurement-13/NN||investigations-77/NNS	amod||activity-80/NN||metabolic-79/JJ	prep_of||investigations-77/NNS||activity-80/NN	prep_by||activity-80/NN||alamarblue-82/NN	calcitonin-52||oa-55||no_rel||direct effects of calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of radioactive labeled 35so4 [5 î¼ci] 2) quantification of collagen-type-ii formation by pro-peptides of collagen type ii (piinp) elisa, 3) qpcr expression of the calcitonin receptor in oa chondrocytes using four individual primer pairs, 4) activation of the camp signaling pathway by eia and, 5) investigations of metabolic activity by alamarblue.
det||male-3/NN||a-1/DT	amod||male-3/NN||33-year-old-2/JJ	nsubjpass||diagnosed-8/VBN||male-3/NN	nsubjpass||given-12/VBN||male-3/NN	nsubjpass||discovered-19/VBN||male-3/NN	aux||diagnosed-8/VBN||had-6/VBD	auxpass||diagnosed-8/VBN||been-7/VBN	rcmod||male-3/NN||diagnosed-8/VBN	prep_with||diagnosed-8/VBN||schizophrenia-10/NN	rcmod||male-3/NN||given-12/VBN	conj_and||diagnosed-8/VBN||given-12/VBN	det||prescription-14/NN||a-13/DT	dobj||given-12/VBN||prescription-14/NN	prep_for||prescription-14/NN||olanzapine-16/NN	auxpass||discovered-19/VBN||was-18/VBD	root||ROOT-0/null||discovered-19/VBN	amod||cuts-24/NNS||multiple-21/JJ	amod||cuts-24/NNS||self-inflicted-22/JJ	nn||cuts-24/NNS||bleeding-23/NN	prep_with||discovered-19/VBN||cuts-24/NNS	poss||wrist-27/NN||his-26/PRP$	prep_on||cuts-24/NNS||wrist-27/NN	schizophrenia-10||olanzapine-16||yes||a 33-year-old male, who had been diagnosed with schizophrenia and given a prescription for olanzapine, was discovered with multiple self-inflicted bleeding cuts on his wrist.
det||procedures-3/NNS||the-2/DT	nsubj||eliminated-13/VBD||procedures-3/NNS	nsubj||vaccinated-75/VBD||procedures-3/NNS	prep_by||eliminated-13/VBD||which-5/WDT	amod||vaccine-8/NN||oral-6/JJ	amod||vaccine-8/NN||polio-7/JJ	npadvmod||rapidly-12/RB||vaccine-8/NN	appos||vaccine-8/NN||opv-10/NN	advmod||eliminated-13/VBD||rapidly-12/RB	root||ROOT-0/null||eliminated-13/VBD	dobj||eliminated-13/VBD||all-14/DT	dobj||eliminated-13/VBD||almost-16/RB	advmod||all-14/DT||almost-16/RB	conj_or||all-14/DT||almost-16/RB	det||disease-19/NN||all-17/DT	amod||disease-19/NN||paralytic-18/JJ	dep||all-14/DT||disease-19/NN	vmod||disease-19/NN||caused-20/VBN	agent||caused-20/VBN||polioviruses-22/NNS	det||temperate-27/NN||the-24/DT	advmod||developed-26/JJ||economically-25/RB	amod||temperate-27/NN||developed-26/JJ	prep_from||caused-20/VBN||temperate-27/NN	nn||countries-29/NNS||climate-28/NN	nsubj||inadequate-32/JJ||countries-29/NNS	aux||inadequate-32/JJ||have-30/VBP	cop||inadequate-32/JJ||been-31/VBN	rcmod||temperate-27/NN||inadequate-32/JJ	amod||countries-37/NNS||tropical-34/JJ	conj_and||tropical-34/JJ||subtropical-36/JJ	amod||countries-37/NNS||subtropical-36/JJ	prep_in||inadequate-32/JJ||countries-37/NNS	dep||inadequate-32/JJ||except-39/IN	det||countries-43/NNS||some-41/DT	amod||countries-43/NNS||small-42/JJ	prep_in||inadequate-32/JJ||countries-43/NNS	amod||services-47/NNS||good-45/JJ	nn||services-47/NNS||health-46/NN	prep_with||countries-43/NNS||services-47/NNS	advmod||is-52/VBZ||largely-49/RB	mark||is-52/VBZ||because-50/IN	expl||is-52/VBZ||there-51/EX	advcl||inadequate-32/JJ||is-52/VBZ	advmod||more-54/JJR||much-53/RB	amod||circulation-56/NN||more-54/JJR	amod||circulation-56/NN||year-round-55/JJ	iobj||is-52/VBZ||circulation-56/NN	nsubj||is-52/VBZ||circulation-56/NN	prep_of||circulation-56/NN||wild-60/NN	dep||circulation-56/NN||polioviruses-63/NNS	nsubj||continue-65/VBP||polioviruses-63/NNS	nsubj||produce-67/VB||polioviruses-63/NNS	rcmod||polioviruses-63/NNS||continue-65/VBP	aux||produce-67/VB||to-66/TO	xcomp||continue-65/VBP||produce-67/VB	det||disease-69/NN||the-68/DT	dobj||produce-67/VB||disease-69/NN	det||unvaccinated-72/NN||the-71/DT	prep_in||disease-69/NN||unvaccinated-72/NN	advmod||vaccinated-75/VBD||incompletely-74/RB	conj_and||eliminated-13/VBD||vaccinated-75/VBD	dobj||vaccinated-75/VBD||children-76/NNS	polio-7||polioviruses-63||no||" the procedures by which oral polio vaccine (opv) rapidly eliminated all or almost all paralytic disease caused by polioviruses from the economically developed temperate climate countries have been inadequate in tropical and subtropical countries, except in some small countries with good health services, largely because there is much more year-round circulation of ""wild"" polioviruses which continue to produce the disease in the unvaccinated and incompletely vaccinated children."
nsubj||has-6/VBZ||addition-1/NN	prep_of||addition-1/NN||theophylline-3/NN	prep_to||theophylline-3/NN||ics-5/NN	root||ROOT-0/null||has-6/VBZ	amod||effects-9/NNS||similar-7/JJ	amod||effects-9/NNS||therapeutic-8/JJ	dobj||has-6/VBZ||effects-9/NNS	prepc_on||effects-9/NNS||improving-11/VBG	nn||function-13/NN||lung-12/NN	dobj||improving-11/VBG||function-13/NN	prepc_as||improving-11/VBG||increasing-15/VBG	det||dose-17/NN||the-16/DT	dobj||increasing-15/VBG||dose-17/NN	prep_of||dose-17/NN||ics-19/NN	det||treatment-22/NN||the-21/DT	prep_in||increasing-15/VBG||treatment-22/NN	amod||asthma-25/NN||symptomatic-24/JJ	prep_of||treatment-22/NN||asthma-25/NN	asthma-25||theophylline-3||yes||addition of theophylline to ics has similar therapeutic effects on improving lung function as increasing the dose of ics in the treatment of symptomatic asthma.
mark||occur-10/VB||although-1/IN	amod||deposits-5/NNS||renal-2/JJ	nn||deposits-5/NNS||calcium-3/NN	nn||deposits-5/NNS||crystal-4/NN	nsubj||occur-10/VB||deposits-5/NNS	appos||deposits-5/NNS||nephrocalcinosis-7/NNS	aux||occur-10/VB||may-9/MD	advcl||common-28/JJ||occur-10/VB	amod||poisoning-14/NN||acute-12/JJ	nn||poisoning-14/NN||phosphate-13/NN	prep_in||occur-10/VB||poisoning-14/NN	prep_in||occur-10/VB||type-18/NN	conj_and||poisoning-14/NN||type-18/NN	num||renaltubularacidosis-20/NNS||1-19/CD	dep||type-18/NN||renaltubularacidosis-20/NNS	appos||renaltubularacidosis-20/NNS||rta-22/NN	amod||hypocalcemia-26/NN||hyperphosphatemic-25/JJ	nsubj||common-28/JJ||hypocalcemia-26/NN	cop||common-28/JJ||is-27/VBZ	root||ROOT-0/null||common-28/JJ	det||former-31/JJ||the-30/DT	prep_in||common-28/JJ||former-31/JJ	mark||typical-36/JJ||while-32/IN	amod||hypokalemia-34/NN||normocalcemic-33/JJ	nsubj||typical-36/JJ||hypokalemia-34/NN	cop||typical-36/JJ||is-35/VBZ	advcl||common-28/JJ||typical-36/JJ	det||latter-39/NN||the-38/DT	prep_in||typical-36/JJ||latter-39/NN	calcium-3||renaltubularacidosis-20||no_rel||although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renaltubularacidosis (rta), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter.
det||model-4/NN||a-1/DT	amod||model-4/NN||polarized-2/JJ	nn||model-4/NN||cell-3/NN	nsubj||demonstrated-8/VBN||model-4/NN	prep_of||model-4/NN||chlamydialinfection-6/NN	aux||demonstrated-8/VBN||has-7/VBZ	root||ROOT-0/null||demonstrated-8/VBN	mark||directed-14/VBD||that-9/IN	amod||intercept-12/NN||chlamydiae-10/JJ	nn||intercept-12/NN||preferentially-11/NN	nsubj||directed-14/VBD||intercept-12/NN	advmod||directed-14/VBD||basolaterally-13/RB	ccomp||demonstrated-8/VBN||directed-14/VBD	xcomp||directed-14/VBD||sphingomyelin-containing-16/VBG	amod||vesicles-18/NNS||exocytic-17/JJ	dobj||sphingomyelin-containing-16/VBG||vesicles-18/NNS	chlamydialinfection-6||chlamydiae-10||no||a polarized cell model of chlamydialinfection has demonstrated that chlamydiae preferentially intercept basolaterally directed, sphingomyelin-containing exocytic vesicles.
nsubjpass||adjusted-5/VBN||doses-1/NNS	nsubj||obtain-7/VB||doses-1/NNS	nsubj||obtain-7/VB||doses-1/NNS	prep_of||doses-1/NNS||insulin-3/NN	auxpass||adjusted-5/VBN||were-4/VBD	root||ROOT-0/null||adjusted-5/VBN	aux||obtain-7/VB||to-6/TO	xcomp||adjusted-5/VBN||obtain-7/VB	xcomp||adjusted-5/VBN||obtain-7/VB	conj_and||obtain-7/VB||obtain-7/VB	nn||concentrations-11/NNS||target-8/NN	nn||concentrations-11/NNS||blood-9/NN	nn||concentrations-11/NNS||glucose-10/NN	dobj||obtain-7/VB||concentrations-11/NNS	number||130-14/CD||<-13/CD	num||mg/dl-15/NN||130-14/CD	prep_of||concentrations-11/NNS||mg/dl-15/NN	prep_before||obtain-7/VB||meals-17/NNS	amod||while-21/NN||bedtime-20/JJ	prep_at||obtain-7/VB||while-21/NN	vmod||while-21/NN||avoiding-22/VBG	dobj||avoiding-22/VBG||hypoglycemia-23/NN	hypoglycemia-23||glucose-10||yes||doses of insulin were adjusted to obtain target blood glucose concentrations of <130 mg/dl before meals and at bedtime while avoiding hypoglycemia.
poss||studies-2/NNS||our-1/PRP$	nsubj||demonstrated-11/VBD||studies-2/NNS	nn||effects-5/NNS||nm-4/NN	prep_on||studies-2/NNS||effects-5/NNS	amod||metastasis-10/NNS||hepatic-7/JJ	conj_and||hepatic-7/JJ||pulmonary-9/JJ	amod||metastasis-10/NNS||pulmonary-9/JJ	prep_on||effects-5/NNS||metastasis-10/NNS	root||ROOT-0/null||demonstrated-11/VBD	amod||suppression-15/NN||profound-12/JJ	amod||suppression-15/NN||significant-14/JJ	dobj||demonstrated-11/VBD||suppression-15/NN	prep_of||suppression-15/NN||metastasis-17/NNS	det||model-21/NN||a-19/DT	amod||model-21/NN||murine-20/JJ	prep_in||demonstrated-11/VBD||model-21/NN	metastasis-17||nm-4||yes||our studies on nm effects on hepatic and pulmonary metastasis demonstrated profound, significant suppression of metastasis in a murine model.
nn||replacement-2/NN||androgen-1/NN	nsubjpass||indicated-4/VBN||replacement-2/NN	auxpass||indicated-4/VBN||is-3/VBZ	root||ROOT-0/null||indicated-4/VBN	prep_for||indicated-4/VBN||men-6/NNS	nsubj||have-9/VBP||men-6/NNS	nsubj||have-12/VBP||men-6/NNS	advmod||have-9/VBP||already-8/RB	rcmod||men-6/NNS||have-9/VBP	dobj||have-9/VBP||children-10/NNS	rcmod||men-6/NNS||have-12/VBP	conj_or||have-9/VBP||have-12/VBP	neg||desire-14/NN||no-13/DT	dobj||have-12/VBP||desire-14/NN	aux||induce-16/VB||to-15/TO	vmod||desire-14/NN||induce-16/VB	dobj||induce-16/VB||pregnancy-17/NN	amod||therapy-21/NN||testosterone-20/JJ	nsubjpass||used-23/VBN||therapy-21/NN	nsubj||reverse-25/VB||therapy-21/NN	auxpass||used-23/VBN||is-22/VBZ	conj_and||indicated-4/VBN||used-23/VBN	aux||reverse-25/VB||to-24/TO	xcomp||used-23/VBN||reverse-25/VB	det||symptoms-27/NNS||the-26/DT	dobj||reverse-25/VB||symptoms-27/NNS	dobj||reverse-25/VB||signs-29/NNS	conj_and||symptoms-27/NNS||signs-29/NNS	prep_of||symptoms-27/NNS||hypogonadism-31/NN	hypogonadism-31||testosterone-20||yes||androgen replacement is indicated for men who already have children or have no desire to induce pregnancy, and testosterone therapy is used to reverse the symptoms and signs of hypogonadism.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||preserved-7/VBN||that-4/IN	nsubjpass||preserved-7/VBN||bmd/bmc-5/NN	auxpass||preserved-7/VBN||is-6/VBZ	ccomp||suggest-3/VBP||preserved-7/VBN	amod||patients-11/NNS||glucocorticoid-treated-9/JJ	nn||patients-11/NNS||sle-10/NN	prep_in||preserved-7/VBN||patients-11/NNS	amod||turnover-15/NN||accelerated-13/VBN	nn||turnover-15/NN||bone-14/NN	prep_despite||preserved-7/VBN||turnover-15/NN	sle-10||glucocorticoid--1||no_rel||our results suggest that bmd/bmc is preserved in glucocorticoid-treated sle patients despite accelerated bone turnover.
amod||influenzavirus-2/NNS||viable-1/JJ	nsubjpass||detected-4/VBN||influenzavirus-2/NNS	auxpass||detected-4/VBN||was-3/VBD	root||ROOT-0/null||detected-4/VBN	det||aerosols-8/NNS||the-6/DT	nn||aerosols-8/NNS||cough-7/NN	prep_in||detected-4/VBN||aerosols-8/NNS	prep_from||detected-4/VBN||2-10/CD	num||subjects-13/NNS||21-12/CD	prep_of||2-10/CD||subjects-13/NNS	prep_with||subjects-13/NNS||influenza-15/NN	influenza-15||influenzavirus-2||no||viable influenzavirus was detected in the cough aerosols from 2 of 21 subjects with influenza.
nsubj||vaccinated-13/VBD||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||incidence-5/NN||the-4/DT	dobj||compare-3/VB||incidence-5/NN	prep_of||incidence-5/NN||tuberculosis-7/NNP	num||years-10/NNS||two-9/CD	prep_over||compare-3/VB||years-10/NNS	prep_in||years-10/NNS||infants-12/NNS	root||ROOT-0/null||vaccinated-13/VBD	prep_at||vaccinated-13/VBD||birth-15/NN	amod||bcg-18/NN||intradermal-17/JJ	prep_with||vaccinated-13/VBD||bcg-18/NN	amod||bcg-22/NN||percutaneous-21/JJ	prep_with||vaccinated-13/VBD||bcg-22/NN	conj_or||bcg-18/NN||bcg-22/NN	tuberculosis-7||bcg-22||no||objective to compare the incidence of tuberculosis over two years in infants vaccinated at birth with intradermal bcg or with percutaneous bcg.
amod||h5n1-3/NNS||avianinfluenzavirus-1/JJ	nn||h5n1-3/NNS||subtype-2/NN	nsubj||threat-8/NN||h5n1-3/NNS	cop||threat-8/NN||is-4/VBZ	det||threat-8/NN||a-5/DT	amod||threat-8/NN||potential-6/JJ	amod||threat-8/NN||pandemic-7/JJ	root||ROOT-0/null||threat-8/NN	amod||strains-11/NNS||human-adapted-10/JJ	prep_with||threat-8/NN||strains-11/NNS	amod||strains-11/NNS||resistant-12/JJ	amod||drugs-15/NNS||antiviral-14/JJ	prep_to||resistant-12/JJ||drugs-15/NNS	h5n1-3||avianinfluenzavirus-1||no||avianinfluenzavirus subtype h5n1 is a potential pandemic threat with human-adapted strains resistant to antiviral drugs.
det||health-4/NN||the-2/DT	amod||health-4/NN||known-3/VBN	prep_despite||are-39/VBP||health-4/NN	nn||costs-7/NNS||healthcare-6/NN	conj_and||health-4/NN||costs-7/NNS	prep_despite||are-39/VBP||costs-7/NNS	amod||chlamydiainfection-10/NN||untreated-9/JJ	prep_of||health-4/NN||chlamydiainfection-10/NN	det||efforts-13/NNS||the-12/DT	conj_and||health-4/NN||efforts-13/NNS	prep_despite||are-39/VBP||efforts-13/NNS	det||programme-19/NN||the-15/DT	amod||programme-19/NN||national-16/JJ	nn||programme-19/NN||chlamydia-17/NN	nn||programme-19/NN||screening-18/NN	prep_of||efforts-13/NNS||programme-19/NN	appos||programme-19/NN||ncsp-21/NN	aux||control-24/VB||to-23/TO	vmod||efforts-13/NNS||control-24/VB	dobj||control-24/VB||chlamydia-25/NN	advmod||detection-28/NN||early-27/RB	prep_through||control-24/VB||detection-28/NN	prep_through||control-24/VB||treatment-30/NN	conj_and||detection-28/NN||treatment-30/NN	amod||infection-33/NN||asymptomatic-32/JJ	prep_of||detection-28/NN||infection-33/NN	det||rates-36/NNS||the-35/DT	nsubj||are-39/VBP||rates-36/NNS	prep_of||rates-36/NNS||screening-38/NN	root||ROOT-0/null||are-39/VBP	advmod||are-39/VBP||well-40/RB	det||rate-45/NN||the-42/DT	amod||rate-45/NN||2010-2011-43/JJ	nn||rate-45/NN||target-44/NN	prep_below||are-39/VBP||rate-45/NN	num||%-48/NN||35-47/CD	prep_of||rate-45/NN||%-48/NN	chlamydiainfection-10||chlamydia-25||no||despite the known health and healthcare costs of untreated chlamydiainfection and the efforts of the national chlamydia screening programme (ncsp) to control chlamydia through early detection and treatment of asymptomatic infection, the rates of screening are well below the 2010-2011 target rate of 35%.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	dobj||assess-2/VB||mortality-3/NN	amod||workers-7/NNS||vermont-5/JJ	nn||workers-7/NNS||granite-6/NN	prep_in||assess-2/VB||workers-7/NNS	conj_and||assess-2/VB||examine-9/VB	dobj||examine-9/VB||relationships-10/NNS	nn||exposure-13/NN||silica-12/NN	prep_between||relationships-10/NNS||exposure-13/NN	prep_between||relationships-10/NNS||mortality-15/NN	conj_and||exposure-13/NN||mortality-15/NN	nn||cancer-18/NN||lung-17/NN	prep_from||examine-9/VB||cancer-18/NN	nn||cancer-21/NN||kidney-20/NN	prep_from||examine-9/VB||cancer-21/NN	conj_and||cancer-18/NN||cancer-21/NN	amod||kidneydisease-24/NN||non-malignant-23/JJ	prep_from||examine-9/VB||kidneydisease-24/NN	conj_and||cancer-18/NN||kidneydisease-24/NN	prep_from||examine-9/VB||silicosis-26/NNS	conj_and||cancer-18/NN||silicosis-26/NNS	amod||disease-31/NN||other-28/JJ	amod||disease-31/NN||non-malignant-29/JJ	nn||disease-31/NN||respiratory-30/NN	prep_from||examine-9/VB||disease-31/NN	conj_and||cancer-18/NN||disease-31/NN	silicosis-26||silica-12||no||to assess mortality in vermont granite workers and examine relationships between silica exposure and mortality from lung cancer, kidney cancer, non-malignant kidneydisease, silicosis and other non-malignant respiratory disease.
prep_in||seen-15/VBN||mexico-2/NN	conj_and||mexico-2/NN||texas-4/NNS	prep_in||seen-15/VBN||texas-4/NNS	amod||mexico-7/NN||new-6/JJ	conj_and||mexico-2/NN||mexico-7/NN	prep_in||seen-15/VBN||mexico-7/NN	amod||hepatitisbvirus-10/NNS||respectively-9/RB	nsubjpass||seen-15/VBN||hepatitisbvirus-10/NNS	appos||hepatitisbvirus-10/NNS||hbv-12/NN	auxpass||seen-15/VBN||was-14/VBD	root||ROOT-0/null||seen-15/VBN	num||%-18/NN||88.3-17/CD	prep_in||seen-15/VBN||%-18/NN	num||%-21/NN||48.6-20/CD	appos||%-18/NN||%-21/NN	num||%-24/NN||59.6-23/CD	appos||%-18/NN||%-24/NN	conj_and||%-21/NN||%-24/NN	prep_of||%-21/NN||participants-26/NNS	amod||virus-29/NN||hepatitisc-28/JJ	appos||%-18/NN||virus-29/NN	conj_and||%-21/NN||virus-29/NN	appos||virus-29/NN||hcv-31/NN	num||%-35/NN||98.7-34/CD	prep_in||virus-29/NN||%-35/NN	num||%-38/NN||76.4-37/CD	prep_in||virus-29/NN||%-38/NN	conj_and||%-35/NN||%-38/NN	num||%-41/NN||80.0-40/CD	prep_in||virus-29/NN||%-41/NN	conj_and||%-35/NN||%-41/NN	appos||%-18/NN||humanimmunodeficiencyvirus-43/NNS	conj_and||%-21/NN||humanimmunodeficiencyvirus-43/NNS	appos||humanimmunodeficiencyvirus-43/NNS||hiv-45/NN	num||%-49/NN||2.1-48/CD	prep_in||humanimmunodeficiencyvirus-43/NNS||%-49/NN	num||%-52/NN||10.0-51/CD	prep_in||humanimmunodeficiencyvirus-43/NNS||%-52/NN	conj_and||%-49/NN||%-52/NN	num||%-55/NN||1.0-54/CD	prep_in||humanimmunodeficiencyvirus-43/NNS||%-55/NN	conj_and||%-49/NN||%-55/NN	appos||%-18/NN||syphilis-58/NNS	conj_and||%-21/NN||syphilis-58/NNS	num||%-61/NN||4.0-60/CD	prep_in||syphilis-58/NNS||%-61/NN	num||%-64/NN||9.9-63/CD	prep_in||syphilis-58/NNS||%-64/NN	conj_and||%-61/NN||%-64/NN	num||%-67/NN||3.0-66/CD	prep_in||syphilis-58/NNS||%-67/NN	conj_and||%-61/NN||%-67/NN	hbv-12||hepatitisbvirus-10||no||in mexico, texas and new mexico, respectively hepatitisbvirus (hbv) was seen in 88.3%, 48.6% and 59.6% of participants; hepatitisc virus (hcv) in 98.7%, 76.4% and 80.0%; humanimmunodeficiencyvirus (hiv) in 2.1%, 10.0% and 1.0%; and syphilis in 4.0%, 9.9% and 3.0%.
nsubj||persists-2/VBZ||hepatitisb-1/NN	root||ROOT-0/null||persists-2/VBZ	det||disease-7/NN||a-4/DT	amod||disease-7/NN||common-5/JJ	amod||disease-7/NN||human-6/JJ	prep_as||persists-2/VBZ||disease-7/NN	amod||vaccines-10/NNS||effective-9/JJ	nsubjpass||employed-13/VBN||vaccines-10/NNS	aux||employed-13/VBN||having-11/VBG	auxpass||employed-13/VBN||been-12/VBN	prepc_despite||persists-2/VBZ||employed-13/VBN	advmod||years-17/NNS||almost-15/RB	num||years-17/NNS||30-16/CD	prep_for||employed-13/VBN||years-17/NNS	hepatitisb-1||vaccines-10||no_rel||hepatitisb persists as a common human disease despite effective vaccines having been employed for almost 30 years.
amod||analysis-3/NN||logistic-1/JJ	nn||analysis-3/NN||regression-2/NN	nsubj||revealed-4/VBD||analysis-3/NN	root||ROOT-0/null||revealed-4/VBD	mark||significant-9/JJ||that-5/IN	nn||time-7/NN||infusion-6/NN	nsubj||significant-9/JJ||time-7/NN	cop||significant-9/JJ||was-8/VBD	ccomp||revealed-4/VBD||significant-9/JJ	dep||revealed-4/VBD||p-11/VB	number||0.0004-13/CD||=-12/CD	dobj||p-11/VB||0.0004-13/CD	nn||ratio-16/NN||odds-15/NNS	dep||0.0004-13/CD||ratio-16/NN	dep||0.974-18/CD||=-17/SYM	rcmod||ratio-16/NN||0.974-18/CD	csubjpass||associated-31/VBN||increasing-21/VBG	det||time-25/NN||the-22/DT	nn||time-25/NN||ip-23/NN	nn||time-25/NN||infusion-24/NN	dobj||increasing-21/VBG||time-25/NN	amod||mg/kg-29/NN||bupropionhcl-27/JJ	dep||bupropionhcl-27/JJ||120-28/CD	prep_of||time-25/NN||mg/kg-29/NN	auxpass||associated-31/VBN||was-30/VBD	conj_and||revealed-4/VBD||associated-31/VBN	det||odds-37/NNS||a-33/DT	number||%-35/NN||91-34/CD	amod||odds-37/NNS||%-35/NN	amod||odds-37/NNS||reduced-36/JJ	prep_with||associated-31/VBN||odds-37/NNS	prep_of||odds-37/NNS||convulsions-39/NNS	nn||times-42/NNS||infusion-41/NN	prep_at||convulsions-39/NNS||times-42/NNS	number||90-46/CD||15-44/CD	dep||90-46/CD||to-45/TO	num||min-47/NN||90-46/CD	prep_of||times-42/NNS||min-47/NN	prepc_compared_to||associated-31/VBN||to-49/TO	amod||injection-51/NN||bolus-50/JJ	pobj||associated-31/VBN||injection-51/NN	convulsions-39||bupropionhcl-27||no||logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the ip infusion time of bupropionhcl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.
nsubj||have-8/VBP||fsw-1/NN	conj_and||fsw-1/NN||msm-3/NN	nsubj||have-8/VBP||msm-3/NN	conj_and||fsw-1/NN||du-5/NN	nsubj||have-8/VBP||du-5/NN	prep_from||fsw-1/NN||brazil-7/NN	root||ROOT-0/null||have-8/VBP	det||risk-11/NN||a-9/DT	amod||risk-11/NN||much-10/JJ	dobj||have-8/VBP||risk-11/NN	prepc_of||risk-11/NN||acquiring-13/VBG	dobj||acquiring-13/VBG||hivinfection-14/NN	prepc_compared_to||acquiring-13/VBG||to-16/TO	det||population-19/NN||the-17/DT	amod||population-19/NN||general-18/JJ	pobj||acquiring-13/VBG||population-19/NN	dobj||low-28/JJ||which-22/WDT	nn||prevalence-24/NN||hiv-23/NN	nsubj||low-28/JJ||prevalence-24/NN	aux||low-28/JJ||has-25/VBZ	cop||low-28/JJ||been-26/VBN	advmod||low-28/JJ||relatively-27/RB	prepc_among||acquiring-13/VBG||low-28/JJ	dep||risk-11/NN||~-30/VBN	num||%-32/NN||0.6-31/CD	dobj||~-30/VBN||%-32/NN	hivinfection-14||hiv-23||no||fsw, msm and du from brazil have a much risk of acquiring hivinfection compared to the general population, among which hiv prevalence has been relatively low (~0.6%).
det||study-2/NN||the-1/DT	nsubj||identified-4/VBN||study-2/NN	nsubj||revealed-16/VBN||study-2/NN	nsubj||vis-25/VBN||study-2/NN	aux||identified-4/VBN||has-3/VBZ	root||ROOT-0/null||identified-4/VBN	dobj||identified-4/VBN||criteria-5/NNS	nn||setting-8/NN||priority-7/NN	prep_for||criteria-5/NNS||setting-8/NN	amod||interventions-11/NNS||hiv/aids-10/JJ	prep_of||setting-8/NN||interventions-11/NNS	prep_in||identified-4/VBN||thailand-13/NN	conj_and||identified-4/VBN||revealed-16/VBN	mark||have-20/VBP||that-17/IN	amod||stakeholders-19/NNS||different-18/JJ	nsubj||have-20/VBP||stakeholders-19/NNS	ccomp||revealed-16/VBN||have-20/VBP	amod||vis-ã-23/NNS||different-21/JJ	nn||vis-ã-23/NNS||preferences-22/NNS	dobj||have-20/VBP||vis-ã-23/NNS	conj_and||identified-4/VBN||vis-25/VBN	det||criteria-27/NNS||these-26/DT	dobj||identified-4/VBN||criteria-27/NNS	aids--1||hiv--1||no||the study has identified criteria for priority setting of hiv/aids interventions in thailand, and revealed that different stakeholders have different preferences vis-ã -vis these criteria.
det||pressure-6/NN||the-1/DT	amod||pressure-6/NN||powerful-2/JJ	conj_and||powerful-2/JJ||sustained-4/VBN	amod||pressure-6/NN||sustained-4/VBN	nn||pressure-6/NN||blood-5/NN	nsubj||control-7/VBP||pressure-6/NN	root||ROOT-0/null||control-7/VBP	acomp||control-7/VBP||apparent-8/JJ	amod||trials-11/NNS||clinical-10/JJ	prep_in||control-7/VBP||trials-11/NNS	amod||protection-16/NN||cardiovascular-15/JJ	prep_together_with||control-7/VBP||protection-16/NN	prep_together_with||control-7/VBP||tolerability-18/NN	conj_and||protection-16/NN||tolerability-18/NN	vmod||protection-16/NN||demonstrated-19/VBN	amod||means-23/NNS||ontargetâ-21/JJ	amod||means-23/NNS||®-22/JJ	prep_in||demonstrated-19/VBN||means-23/NNS	mark||option-30/NN||that-24/IN	nsubj||option-30/NN||telmisartan-25/NN	aux||option-30/NN||may-26/MD	cop||option-30/NN||be-27/VB	det||option-30/NN||a-28/DT	amod||option-30/NN||preferred-29/JJ	ccomp||demonstrated-19/VBN||option-30/NN	prep_for||option-30/NN||patients-32/NNS	prep_with||patients-32/NNS||hypertension-34/NN	hypertension-34||telmisartan-25||yes||the powerful and sustained blood pressure control apparent in clinical trials, together with cardiovascular protection and tolerability demonstrated in ontargetâ® means that telmisartan may be a preferred option for patients with hypertension.
det||study-5/NN||a-2/DT	amod||study-5/NN||one-year-3/JJ	nn||study-5/NN||follow-up-4/NN	prep_in||tb-70/VBP||study-5/NN	nsubj||tb-70/VBP||11-7/CD	num||%-10/NN||19.3-9/CD	appos||11-7/CD||%-10/NN	num||test-16/NN||57-13/CD	nn||test-16/NN||tuberculin-14/NN	nn||test-16/NN||skin-15/NN	prep_of||11-7/CD||test-16/NN	appos||test-16/NN||tst-18/NN	amod||inmates-23/NNS||hiv-negative-22/JJ	conj_and||11-7/CD||inmates-23/NNS	nsubj||tb-70/VBP||inmates-23/NNS	vmod||inmates-23/NNS||became-24/VBD	nsubj||hiv-positive-32/JJ||tst-positive-25/NN	conj_and||tst-positive-25/NN||one-27/NN	nsubj||hiv-positive-32/JJ||one-27/NN	num||%-30/NN||1.8-29/CD	appos||tst-positive-25/NN||%-30/NN	xcomp||became-24/VBD||hiv-positive-32/JJ	conj_and||11-7/CD||eight-34/CD	conj_and||inmates-23/NNS||eight-34/CD	num||%-37/NN||13.8-36/CD	appos||eight-34/CD||%-37/NN	det||inmates-45/NNS||the-40/DT	num||inmates-45/NNS||58-41/CD	amod||inmates-45/NNS||tst-positive-42/JJ	conj_but||tst-positive-42/JJ||hiv-negative-44/JJ	amod||inmates-45/NNS||hiv-negative-44/JJ	prep_of||eight-34/CD||inmates-45/NNS	vmod||inmates-45/NNS||developed-46/VBN	dobj||developed-46/VBN||tb-47/NN	conj_and||11-7/CD||one-50/CD	conj_and||inmates-23/NNS||one-50/CD	num||%-53/NN||1.7-52/CD	appos||one-50/CD||%-53/NN	rcmod||one-50/CD||became-55/VBD	amod||six-57/CD||hiv-infected-56/JJ	xcomp||became-55/VBD||six-57/CD	num||%-60/NN||24.0-59/CD	appos||six-57/CD||%-60/NN	num||tst-64/NN||25-63/CD	prep_of||six-57/CD||tst-64/NN	amod||inmates-68/NNS||hiv-positive-67/JJ	conj_and||inmates-23/NNS||inmates-68/NNS	conj_and||one-50/CD||inmates-68/NNS	vmod||inmates-68/NNS||developed-69/VBN	root||ROOT-0/null||tb-70/VBP	mark||became-83/VBD||while-71/IN	nsubj||became-83/VBD||five-72/CD	num||%-75/NN||33.3-74/CD	appos||five-72/CD||%-75/NN	num||inmates-82/NNS||15-78/CD	amod||inmates-82/NNS||tst-negative-79/JJ	conj_but||tst-negative-79/JJ||hiv-positive-81/JJ	amod||inmates-82/NNS||hiv-positive-81/JJ	prep_of||five-72/CD||inmates-82/NNS	advcl||tb-70/VBP||became-83/VBD	acomp||became-83/VBD||tst-positive-84/JJ	nsubj||progressed-92/VBD||one-87/CD	num||%-90/NN||6.7-89/CD	appos||one-87/CD||%-90/NN	conj_and||tb-70/VBP||progressed-92/VBD	prep_to||progressed-92/VBD||aids-94/NNS	aids-94||hiv--1||no||in a one-year follow-up study, 11 (19.3%) of 57 tuberculin skin test (tst)- and hiv-negative inmates became tst-positive and one (1.8%) hiv-positive, eight (13.8%) of the 58 tst-positive but hiv-negative inmates developed tb, and one (1.7%) became hiv-infected six (24.0%) of 25 tst- and hiv-positive inmates developed tb while five (33.3%) of 15 tst-negative but hiv-positive inmates became tst-positive, and one (6.7%) progressed to aids.
nsubj||zoonoticdisease-4/NN||qfever-1/NN	cop||zoonoticdisease-4/NN||is-2/VBZ	det||zoonoticdisease-4/NN||a-3/DT	root||ROOT-0/null||zoonoticdisease-4/NN	vmod||zoonoticdisease-4/NN||caused-5/VBN	agent||caused-5/VBN||coxiellaburnetii-7/NNS	qfever-1||coxiellaburnetii-7||no||qfever is a zoonoticdisease caused by coxiellaburnetii.
det||study-3/NN||this-2/DT	prep_in||shown-7/VBN||study-3/NN	nsubj||shown-7/VBN||we-5/PRP	aux||shown-7/VBN||have-6/VBP	root||ROOT-0/null||shown-7/VBN	det||vaccination-11/NN||that-8/DT	amod||vaccination-11/NN||heterologous-9/JJ	amod||vaccination-11/NN||prime-boost-10/JJ	dobj||shown-7/VBN||vaccination-11/NN	nn||tb-15/NN||tuberculosis-13/NNP	prep_against||shown-7/VBN||tb-15/NN	vmod||tb-15/NN||using-17/VBG	amod||priming/dna-hsp-20/NN||intranasal-18/JJ	nn||priming/dna-hsp-20/NN||bcg-19/NN	dobj||using-17/VBG||priming/dna-hsp-20/NN	prep_than||provided-26/VBD||priming/dna-hsp-20/NN	num||boosting-22/NNS||65-21/CD	nsubj||provided-26/VBD||boosting-22/NNS	appos||boosting-22/NNS||bcgin/dna-24/NNP	rcmod||priming/dna-hsp-20/NN||provided-26/VBD	advmod||greater-28/JJR||significantly-27/RB	amod||protection-29/NN||greater-28/JJR	dobj||provided-26/VBD||protection-29/NN	vmod||that-31/DT||afforded-32/VBN	det||subcutaneous-36/NNS||a-34/DT	amod||subcutaneous-36/NNS||single-35/JJ	agent||afforded-32/VBN||subcutaneous-36/NNS	nn||dose-39/NN||intranasal-38/NN	agent||afforded-32/VBN||dose-39/NN	conj_or||subcutaneous-36/NNS||dose-39/NN	prep_of||subcutaneous-36/NNS||bcg-41/NN	tb-15||bcg-41||no||in this study, we have shown that heterologous prime-boost vaccination against tuberculosis (tb) using intranasal bcg priming/dna-hsp65 boosting (bcgin/dna) provided significantly greater protection than that afforded by a single subcutaneous or intranasal dose of bcg.
csubj||increases-22/VBZ||adding-1/VBG	dobj||adding-1/VBG||snps-2/NNS	advmod||associated-4/VBN||previously-3/RB	vmod||snps-2/NNS||associated-4/VBN	prepc_with||associated-4/VBN||fasting-6/VBG	dobj||fasting-6/VBG||glucose-7/NN	dobj||fasting-6/VBG||insulin-9/NN	conj_or||glucose-7/NN||insulin-9/NN	dobj||fasting-6/VBG||lipids-11/NN	conj_or||glucose-7/NN||lipids-11/NN	dobj||fasting-6/VBG||obesity-13/NN	conj_or||glucose-7/NN||obesity-13/NN	det||score-18/NN||a-15/DT	amod||score-18/NN||genetic-16/JJ	nn||score-18/NN||risk-17/NN	prep_to||fasting-6/VBG||score-18/NN	prep_for||score-18/NN||type2diabetes-20/CD	advmod||increases-22/VBZ||significantly-21/RB	root||ROOT-0/null||increases-22/VBZ	det||power-24/NN||the-23/DT	dobj||increases-22/VBZ||power-24/NN	aux||discriminate-26/VB||to-25/TO	vmod||power-24/NN||discriminate-26/VB	vmod||power-24/NN||discriminate-26/VB	conj_and||discriminate-26/VB||discriminate-26/VB	prep_between||discriminate-26/VB||people-28/NNS	advmod||manifest-33/JJ||clinically-32/RB	amod||type2diabetes-34/NNS||manifest-33/JJ	prep_with||discriminate-26/VB||type2diabetes-34/NNS	prep_without||discriminate-26/VB||type2diabetes-34/NNS	prepc_compared_with||discriminate-26/VB||with-36/IN	det||model-38/NN||a-37/DT	pobj||discriminate-26/VB||model-38/NN	amod||loci-43/NNS||only-40/JJ	amod||loci-43/NNS||conventional-41/JJ	amod||loci-43/NNS||type2diabetes-42/JJ	prep_including||model-38/NN||loci-43/NNS	type2diabetes-42||insulin-9||yes||adding snps previously associated with fasting glucose, insulin, lipids or obesity to a genetic risk score for type2diabetes significantly increases the power to discriminate between people with and without clinically manifest type2diabetes compared with a model including only conventional type2diabetes loci.
poss||objective-2/NN||our-1/PRP$	nsubj||was-3/VBD||objective-2/NN	nsubj||estimate-5/VB||objective-2/NN	nsubj||determine-26/VB||objective-2/NN	root||ROOT-0/null||was-3/VBD	aux||estimate-5/VB||to-4/TO	xcomp||was-3/VBD||estimate-5/VB	det||proportion-7/NN||the-6/DT	dobj||estimate-5/VB||proportion-7/NN	prep_of||proportion-7/NN||idus-9/NNS	det||diagnosis-14/NN||a-11/DT	amod||diagnosis-14/NN||late-12/JJ	nn||diagnosis-14/NN||hiv-13/NN	prep_with||idus-9/NNS||diagnosis-14/NN	dep||idus-9/NNS||aids-16/VBZ	dobj||aids-16/VBZ||diagnosis-17/NN	num||months-20/NNS||12-19/CD	prep_within||aids-16/VBZ||months-20/NNS	nn||diagnosis-23/NN||hiv-22/NN	prep_of||months-20/NNS||diagnosis-23/NN	xcomp||was-3/VBD||determine-26/VB	conj_and||estimate-5/VB||determine-26/VB	det||factors-28/NNS||the-27/DT	dobj||determine-26/VB||factors-28/NNS	vmod||factors-28/NNS||associated-29/VBN	nn||progression-32/NN||disease-31/NN	prep_with||associated-29/VBN||progression-32/NN	nn||diagnosis-35/NN||hiv-34/NN	prep_after||associated-29/VBN||diagnosis-35/NN	aids-16||hiv-34||no||our objective was to estimate the proportion of idus with a late hiv diagnosis (aids diagnosis within 12 months of hiv diagnosis) and determine the factors associated with disease progression after hiv diagnosis.
det||time-2/NN||the-1/DT	nsubj||shorter-17/JJR||time-2/NN	nsubj||aldrete-25/JJ||time-2/NN	prep_to||time-2/NN||response-4/NN	amod||stimuli-7/NNS||painful-6/JJ	prep_to||time-2/NN||stimuli-7/NNS	amod||commands-11/NNS||obeying-9/JJ	amod||commands-11/NNS||verbal-10/JJ	prep_to||time-2/NN||commands-11/NNS	conj_and||stimuli-7/NNS||commands-11/NNS	amod||opening-15/NN||spontaneous-13/JJ	nn||opening-15/NN||eye-14/NN	prep_to||time-2/NN||opening-15/NN	conj_and||stimuli-7/NNS||opening-15/NN	cop||shorter-17/JJR||was-16/VBD	root||ROOT-0/null||shorter-17/JJR	dep||shorter-17/JJR||p-19/VBN	dep||0.001-21/CD||=-20/SYM	ccomp||p-19/VBN||0.001-21/CD	advmod||aldrete-25/JJ||modified-24/RB	conj_and||shorter-17/JJR||aldrete-25/JJ	nsubj||higher-28/JJR||score-26/NN	cop||higher-28/JJR||was-27/VBD	ccomp||aldrete-25/JJ||higher-28/JJR	amod||anesthesia-31/NN||desflurane-30/JJ	prep_after||higher-28/JJR||anesthesia-31/NN	prep||higher-28/JJR||than-32/IN	pcomp||than-32/IN||after-33/IN	amod||anesthesia-35/NN||sevoflurane-34/JJ	pobj||after-33/IN||anesthesia-35/NN	dep||shorter-17/JJR||p-37/VBN	dep||0.049-39/CD||=-38/SYM	ccomp||p-37/VBN||0.049-39/CD	painful-6||desflurane-30||yes||the time to response to painful stimuli, obeying verbal commands and spontaneous eye opening was shorter ( p = 0.001) and modified aldrete score was higher after desflurane anesthesia than after sevoflurane anesthesia ( p = 0.049).
amod||budesonide-2/NN||inhaled-1/JJ	nsubj||suppressed-3/VBD||budesonide-2/NN	root||ROOT-0/null||suppressed-3/VBD	amod||defense-7/NN||pulmonary-4/JJ	amod||defense-7/NN||antibacterial-5/JJ	nn||defense-7/NN||host-6/NN	dobj||suppressed-3/VBD||defense-7/NN	det||model-12/NN||an-9/DT	amod||model-12/NN||asthmatic-10/JJ	nn||model-12/NN||mouse-11/NN	prep_in||suppressed-3/VBD||model-12/NN	nn||cells-17/NNS||lung-15/NN	nn||cells-17/NNS||epithelium-16/NN	prep_in||suppressed-3/VBD||cells-17/NNS	conj_and||model-12/NN||cells-17/NNS	prep_in||suppressed-3/VBD||vitro-19/NN	asthmatic-10||budesonide-2||yes||inhaled budesonide suppressed pulmonary antibacterial host defense in an asthmatic mouse model and in lung epithelium cells in vitro .
amod||patients-5/NNS||atrialfibrillation-1/JJ	amod||patients-5/NNS||af-3/JJ	nsubj||anticoagulation-14/NN||patients-5/NNS	det||risk-9/NN||a-7/DT	amod||risk-9/NN||high-8/JJ	prep_with||patients-5/NNS||risk-9/NN	prep_of||risk-9/NN||stroke-11/NN	cop||anticoagulation-14/NN||are-12/VBP	amod||anticoagulation-14/NN||recommended-13/VBN	root||ROOT-0/null||anticoagulation-14/NN	prep_with||anticoagulation-14/NN||warfarin-16/NN	atrialfibrillation-1||warfarin-16||yes||atrialfibrillation (af) patients with a high risk of stroke are recommended anticoagulation with warfarin.
nsubj||disease-5/NN||leprosy-1/NNP	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||an-3/DT	amod||disease-5/NN||infectious-4/JJ	root||ROOT-0/null||disease-5/NN	dep||disease-5/NN||caused-6/VBN	det||mycobacteriumleprae-12/NN||the-8/DT	amod||mycobacteriumleprae-12/NN||obligate-9/JJ	nn||mycobacteriumleprae-12/NN||intracellular-10/NN	nn||mycobacteriumleprae-12/NN||pathogen-11/NN	prep_by||caused-6/VBN||mycobacteriumleprae-12/NN	dep||disease-5/NN||remains-14/VBZ	conj_and||caused-6/VBN||remains-14/VBZ	acomp||remains-14/VBZ||endemic-15/JJ	amod||parts-18/NNS||many-17/JJ	prep_in||remains-14/VBZ||parts-18/NNS	det||world-21/NN||the-20/DT	prep_of||parts-18/NNS||world-21/NN	leprosy-1||mycobacteriumleprae-12||no||leprosy is an infectious disease caused by the obligate intracellular pathogen mycobacteriumleprae and remains endemic in many parts of the world.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	type2diabetes-33||exenatide-5||yes||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
poss||studies-2/NNS||our-1/PRP$	nsubj||show-3/VBP||studies-2/NNS	root||ROOT-0/null||show-3/VBP	mark||induced-7/VBN||that-4/IN	amod||viruses-6/NNS||bac-derived-5/JJ	nsubj||induced-7/VBN||viruses-6/NNS	ccomp||show-3/VBP||induced-7/VBN	nsubj||similar-9/JJ||disease-8/NN	xcomp||induced-7/VBN||similar-9/JJ	det||virus-13/NN||the-11/DT	amod||virus-13/NN||wild-type-12/JJ	prep_to||induced-7/VBN||virus-13/NN	mark||were-17/VBD||though-15/IN	expl||were-17/VBD||there-16/EX	dep||virus-13/NN||were-17/VBD	nsubj||were-17/VBD||differences-18/NNS	det||levels-21/NNS||the-20/DT	prep_in||differences-18/NNS||levels-21/NNS	prep_of||levels-21/NNS||pathogenicity-23/NN	amod||viruses-26/NNS||individual-25/JJ	prep_between||pathogenicity-23/NN||viruses-26/NNS	virus-13||viruses-26||no||our studies show that bac-derived viruses induced disease similar to the wild-type virus, though there were differences in the levels of pathogenicity between individual viruses.
amod||analysis-2/NN||immunohistological-1/JJ	nsubj||confirmed-6/VBD||analysis-2/NN	det||granulomas-5/NNS||these-4/DT	prep_of||analysis-2/NN||granulomas-5/NNS	root||ROOT-0/null||confirmed-6/VBD	det||abundance-9/NN||the-7/DT	amod||abundance-9/NN||disproportionate-8/JJ	dobj||confirmed-6/VBD||abundance-9/NN	det||proteins-12/NNS||the-11/DT	prep_of||abundance-9/NN||proteins-12/NNS	vmod||proteins-12/NNS||involved-13/VBN	nn||metabolism-16/NN||lipid-15/NN	prep_in||involved-13/VBN||metabolism-16/NN	prep_in||involved-13/VBN||cells-18/NNS	vmod||cells-18/NNS||surrounding-19/VBG	det||caseum-21/NN||the-20/DT	dobj||surrounding-19/VBG||caseum-21/NN	advmod||biochemical-36/VBP||namely-23/RB	nn||member-31/NN||adipophilin-25/NN	amod||member-31/NN||acyl-coa-27/JJ	nn||member-31/NN||synthetase-28/NN	amod||member-31/NN||long-chain-29/JJ	nn||member-31/NN||family-30/NN	nsubj||biochemical-36/VBP||member-31/NN	num||member-31/NN||1-32/CD	amod||c.-35/NN||saposin-34/JJ	conj_and||member-31/NN||c.-35/NN	nsubj||biochemical-36/VBP||c.-35/NN	parataxis||confirmed-6/VBD||biochemical-36/VBP	dobj||biochemical-36/VBP||analysis-37/NN	det||species-41/NN||the-39/DT	nn||species-41/NN||lipid-40/NN	prep_of||analysis-37/NN||species-41/NN	det||caseum-44/NN||the-43/DT	prep_within||biochemical-36/VBP||caseum-44/NN	nsubj||implicated-56/VBN||caseum-44/NN	vmod||caseum-44/NN||identified-45/VBN	dobj||identified-45/VBN||cholesterol-46/NN	amod||esters-49/NNS||cholesteryl-48/JJ	dobj||identified-45/VBN||esters-49/NNS	conj_and||cholesterol-46/NN||esters-49/NNS	dobj||identified-45/VBN||triacylglycerols-51/NNS	conj_and||cholesterol-46/NN||triacylglycerols-51/NNS	dobj||identified-45/VBN||lactosylceramide-53/NN	conj_and||cholesterol-46/NN||lactosylceramide-53/NN	rcmod||caseum-44/NN||implicated-56/VBN	amod||lipids-59/NNS||low-density-57/JJ	amod||lipids-59/NNS||lipoprotein-derived-58/JJ	dobj||implicated-56/VBN||lipids-59/NNS	det||source-64/NN||the-61/DT	advmod||likely-63/JJ||most-62/RBS	amod||source-64/NN||likely-63/JJ	prep_as||implicated-56/VBN||source-64/NN	granulomas-5||lipid-40||no_rel||immunohistological analysis of these granulomas confirmed the disproportionate abundance of the proteins involved in lipid metabolism in cells surrounding the caseum ; namely , adipophilin , acyl-coa synthetase long-chain family member 1 and saposin c. biochemical analysis of the lipid species within the caseum identified cholesterol , cholesteryl esters , triacylglycerols and lactosylceramide , which implicated low-density lipoprotein-derived lipids as the most likely source .
det||paper-3/NN||this-2/DT	prep_in||compile-6/VB||paper-3/NN	nsubj||compile-6/VB||we-5/PRP	root||ROOT-0/null||compile-6/VB	det||data-10/NNS||the-7/DT	advmod||data-10/NNS||most-8/RBS	amod||data-10/NNS||significant-9/JJ	nsubj||available-11/JJ||data-10/NNS	xcomp||compile-6/VB||available-11/JJ	amod||properties-16/NNS||biochemical-13/JJ	conj_and||biochemical-13/JJ||biological-15/JJ	amod||properties-16/NNS||biological-15/JJ	prep_about||available-11/JJ||properties-16/NNS	nn||transporters-19/NNS||sugar-18/NN	prep_of||properties-16/NNS||transporters-19/NNS	amod||tissues-22/NNS||normal-21/JJ	prep_in||transporters-19/NNS||tissues-22/NNS	nsubj||review-25/VBP||we-24/PRP	conj_and||compile-6/VB||review-25/VBP	det||information-28/NN||the-26/DT	amod||information-28/NN||available-27/JJ	dobj||review-25/VBP||information-28/NN	nn||expression-32/NN||sugar-30/NN	nn||expression-32/NN||carrier-31/NN	prep_about||review-25/VBP||expression-32/NN	amod||types-35/NNS||different-34/JJ	prep_in||expression-32/NN||types-35/NNS	prep_of||types-35/NNS||cancer-37/NN	sugar-30||cancer-37||no_rel||in this paper, we compile the most significant data available about biochemical and biological properties of sugar transporters in normal tissues and we review the available information about sugar carrier expression in different types of cancer.
amod||enzyme-2/NN||insulin-degrading-1/JJ	nsubj||ubiquitously-8/NN||enzyme-2/NN	appos||enzyme-2/NN||ide-4/NN	cop||ubiquitously-8/NN||is-6/VBZ	det||ubiquitously-8/NN||a-7/DT	root||ROOT-0/null||ubiquitously-8/NN	nsubj||degrades-12/VBZ||ubiquitously-8/NN	vmod||ubiquitously-8/NN||expressed-9/VBN	acomp||expressed-9/VBN||zinc-metalloprotease-10/JJ	rcmod||ubiquitously-8/NN||degrades-12/VBZ	amod||substrates-17/NNS||several-13/JJ	amod||substrates-17/NNS||pathophysiologically-14/JJ	amod||substrates-17/NNS||significant-15/JJ	nn||substrates-17/NNS||extracellular-16/NN	dobj||degrades-12/VBZ||substrates-17/NNS	prep_including||substrates-17/NNS||insulin-20/NN	det||²-25/NN||the-22/DT	amod||²-25/NN||amyloid-23/JJ	nn||²-25/NN||î-24/NN	prep_including||substrates-17/NNS||²-25/NN	conj_and||insulin-20/NN||²-25/NN	dep||²-25/NN||protein-27/NN	nn||²-30/NNP||aî-29/NNP	appos||protein-27/NN||²-30/NNP	csubj||suggests-36/VBZ||accumulating-34/VBG	dobj||accumulating-34/VBG||evidence-35/NN	conj_and||ubiquitously-8/NN||suggests-36/VBZ	nsubj||degrades-12/VBZ||suggests-36/VBZ	mark||operative-42/VBN||that-37/IN	nn||dysfunction-39/NN||ide-38/NN	nsubjpass||operative-42/VBN||dysfunction-39/NN	aux||operative-42/VBN||may-40/MD	auxpass||operative-42/VBN||be-41/VB	ccomp||suggests-36/VBZ||operative-42/VBN	det||disease-48/NN||both-44/DT	amod||disease-48/NN||type2diabetesmellitus-45/JJ	conj_and||type2diabetesmellitus-45/JJ||alzheimer-47/JJ	amod||disease-48/NN||alzheimer-47/JJ	prep_in||operative-42/VBN||disease-48/NN	appos||disease-48/NN||ad-50/NN	type2diabetesmellitus-45||insulin-20||yes||insulin-degrading enzyme (ide) is a ubiquitously expressed zinc-metalloprotease that degrades several pathophysiologically significant extracellular substrates, including insulin and the amyloid î²-protein (aî²), and accumulating evidence suggests that ide dysfunction may be operative in both type2diabetesmellitus and alzheimer disease (ad).
det||objective-3/NN||the-1/DT	amod||objective-3/NN||main-2/JJ	nsubj||is-8/VBZ||objective-3/NN	nsubj||monitor-10/VB||objective-3/NN	det||study-7/NN||the-5/DT	amod||study-7/NN||current-6/JJ	prep_of||objective-3/NN||study-7/NN	ccomp||â-36/VBP||is-8/VBZ	aux||monitor-10/VB||to-9/TO	xcomp||is-8/VBZ||monitor-10/VB	det||status-13/NN||the-11/DT	amod||status-13/NN||auditory-12/JJ	dobj||monitor-10/VB||status-13/NN	det||group-16/NN||a-15/DT	prep_in||status-13/NN||group-16/NN	prep_of||group-16/NN||adults-18/NNS	prep_with||monitor-10/VB||aids-20/NNS	vmod||monitor-10/VB||receiving-22/VBG	advmod||active-24/JJ||highly-23/RB	amod||therapy-26/NN||active-24/JJ	amod||therapy-26/NN||antiretroviral-25/JJ	dobj||receiving-22/VBG||therapy-26/NN	appos||therapy-26/NN||haart-28/NN	dep||therapy-26/NN||3tc-31/NNP	dep||3tc-31/NNP||lamivudine-33/NN	nsubj||â-36/VBP||d4t-35/NNS	root||ROOT-0/null||â-36/VBP	dobj||â-36/VBP||$-37/$	npadvmod||outpatient-47/JJ||stavudine-39/NN	conj_and||stavudine-39/NN||efavirenz-42/NN	npadvmod||outpatient-47/JJ||efavirenz-42/NN	quantmod||hospital-46/NN||in-44/IN	quantmod||hospital-46/NN||a-45/DT	num||stavudine-39/NN||hospital-46/NN	amod||clinic-48/NNS||outpatient-47/JJ	npadvmod||in-49/RB||clinic-48/NNS	dep||gauteng-50/CD||in-49/RB	num||$-37/$||gauteng-50/CD	aids-20||efavirenz-42||yes||the main objective of the current study is to monitor the auditory status in a group of adults with aids, receiving highly active antiretroviral therapy (haart) (3tc -lamivudine, d4t â€“ stavudine, and efavirenz) in a hospital outpatient clinic in gauteng.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubjpass||carried-5/VBN||study-3/NN	nsubj||investigate-8/VB||study-3/NN	nsubj||methicillin-26/VB||study-3/NN	auxpass||carried-5/VBN||was-4/VBD	root||ROOT-0/null||carried-5/VBN	prt||carried-5/VBN||out-6/RP	aux||investigate-8/VB||to-7/TO	xcomp||carried-5/VBN||investigate-8/VB	amod||activity-12/NN||vitro-11/JJ	prep_in||investigate-8/VB||activity-12/NN	amod||antibiotics-15/NNS||conventional-14/JJ	prep_of||activity-12/NN||antibiotics-15/NNS	advmod||prescribed-17/VBN||routinely-16/RB	vmod||antibiotics-15/NNS||prescribed-17/VBN	amod||resistant-20/JJ||methicillin-19/JJ	amod||-rrb--24/NNS||resistant-20/JJ	amod||-rrb--24/NNS||s.aureus-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||mrsa-23/NN	prep_for||prescribed-17/VBN||-rrb--24/NNS	xcomp||carried-5/VBN||methicillin-26/VB	conj_and||investigate-8/VB||methicillin-26/VB	amod||s.aureus-28/JJ||sensitive-27/JJ	amod||infections-32/NNS||s.aureus-28/JJ	amod||infections-32/NNS||-lrb--29/JJ	nn||infections-32/NNS||mssa-30/NN	nn||infections-32/NNS||-rrb--31/NN	dobj||methicillin-26/VB||infections-32/NNS	det||northwest-35/NN||the-34/DT	prep_in||methicillin-26/VB||northwest-35/NN	nsubjpass||recommended-45/VBN||northwest-35/NN	nn||agents-42/NNS||iran-37/NN	conj_and||iran-37/NN||other-39/JJ	nn||agents-42/NNS||other-39/JJ	num||agents-42/NNS||alternating-40/CD	amod||agents-42/NNS||therapeutic-41/JJ	prep_of||northwest-35/NN||agents-42/NNS	auxpass||recommended-45/VBN||are-44/VBP	rcmod||northwest-35/NN||recommended-45/VBN	nn||organisms-49/NNS||gram-47/NN	amod||organisms-49/NNS||positive-48/JJ	prep_for||recommended-45/VBN||organisms-49/NNS	mrsa-23||s.aureus-28||no||the present study was carried out to investigate in - vitro activity of conventional antibiotics routinely prescribed for methicillin resistant s.aureus -lrb- mrsa -rrb- and methicillin sensitive s.aureus -lrb- mssa -rrb- infections in the northwest of iran and other alternating therapeutic agents which are recommended for gram positive organisms .
nsubj||important-14/JJ||diagnosis-1/NN	prep_of||diagnosis-1/NN||hiv/aids-3/NNS	amod||testing-6/NN||early-5/JJ	prep_via||hiv/aids-3/NNS||testing-6/NN	nn||counseling-12/NN||pretest-9/NN	conj_and||pretest-9/NN||post-test-11/NN	nn||counseling-12/NN||post-test-11/NN	prep_along_with||important-14/JJ||counseling-12/NN	cop||important-14/JJ||is-13/VBZ	root||ROOT-0/null||important-14/JJ	amod||stabilization-17/NN||psychosocial-16/JJ	prep_for||important-14/JJ||stabilization-17/NN	prep_for||important-14/JJ||destigmatization-19/NN	conj_and||stabilization-17/NN||destigmatization-19/NN	aids--1||hiv--1||no||diagnosis of hiv/aids via early testing along with pretest and post-test counseling is important for psychosocial stabilization and destigmatization.
det||viruses-2/NNS||the-1/DT	nsubj||detected-3/VBD||viruses-2/NNS	root||ROOT-0/null||detected-3/VBD	cop||virus-8/NN||were-4/VBD	det||virus-8/NN||all-5/DT	nn||virus-8/NN||chlorella-6/NN	nn||virus-8/NN||variabilis-7/NNS	ccomp||detected-3/VBD||virus-8/NN	dep||virus-8/NN||cvv-10/VBN	dep||virus-13/NN||=-11/SYM	amod||virus-13/NN||nc64a-12/JJ	ccomp||cvv-10/VBN||virus-13/NN	virus-13||viruses-2||no||the viruses detected were all chlorella variabilis virus (cvv = nc64a virus).
nsubjpass||tested-3/VBN||replication-1/NN	auxpass||tested-3/VBN||was-2/VBD	root||ROOT-0/null||tested-3/VBN	num||patients-8/NNS||390-5/CD	amod||patients-8/NNS||white-6/JJ	nn||patients-8/NNS||canadian-7/NN	prep_in||tested-3/VBN||patients-8/NNS	prep_with||patients-8/NNS||peanutallergy-10/NN	dep||patients-8/NNS||defined-12/VBN	prep||defined-12/VBN||by-13/IN	nn||challenge-15/NN||food-14/NN	pobj||by-13/IN||challenge-15/NN	amod||history-19/NN||clinical-18/JJ	prep||defined-12/VBN||history-19/NN	conj_or||by-13/IN||history-19/NN	pobj||by-13/IN||history-19/NN	nn||test-23/NN||skin-21/NN	nn||test-23/NN||prick-22/NN	conj_or||by-13/IN||test-23/NN	pobj||by-13/IN||test-23/NN	conj_and||history-19/NN||test-23/NN	amod||history-19/NN||wheal-24/JJ	nn||kulâˆ-39/NNS||peanut-26/NN	nn||kulâˆ-39/NNS||â-27/NN	nn||kulâˆ-39/NNS||‰-28/NNP	nn||kulâˆ-39/NNS||¥-29/NNP	num||kulâˆ-39/NNS||8-30/CD	nn||kulâˆ-39/NNS||mm-31/NN	nn||kulâˆ-39/NNS||and/or-32/NN	nn||kulâˆ-39/NNS||peanut-specific-33/NN	nn||kulâˆ-39/NNS||ige-34/NN	nn||kulâˆ-39/NNS||â-35/NN	nn||kulâˆ-39/NNS||‰-36/NNP	nn||kulâˆ-39/NNS||¥-37/NNP	num||kulâˆ-39/NNS||15-38/CD	prep_to||wheal-24/JJ||kulâˆ-39/NNS	dobj||defined-12/VBN||1-41/CD	num||controls-48/NNS||891-44/CD	amod||controls-48/NNS||white-45/JJ	nn||controls-48/NNS||canadian-46/NN	nn||controls-48/NNS||population-47/NN	prep_in||tested-3/VBN||controls-48/NNS	conj_and||patients-8/NNS||controls-48/NNS	peanutallergy-10||peanut-26||no||replication was tested in 390 white canadian patients with peanutallergy (defined by food challenge, or clinical history and skin prick test wheal to peanut â‰¥8 mm and/or peanut-specific ige â‰¥15 kulâˆ’1) and 891 white canadian population controls.
det||interference-4/NN||the-1/DT	amod||interference-4/NN||exogenous-2/JJ	nn||interference-4/NN||rna-3/NN	nsubj||defense-13/NN||interference-4/NN	appos||interference-4/NN||rnai-6/NNP	advmod||defense-13/NN||pathway-8/RB	cop||defense-13/NN||is-9/VBZ	det||defense-13/NN||an-10/DT	amod||defense-13/NN||important-11/JJ	amod||defense-13/NN||antiviral-12/JJ	root||ROOT-0/null||defense-13/NN	prep_against||defense-13/NN||arboviruses-15/NNS	prep_in||arboviruses-15/NNS||mosquitoes-17/NNS	amod||interfering-22/NNS||virus-specific-20/JJ	amod||interfering-22/NNS||small-21/JJ	nn||rnas-26/NNS||interfering-22/NNS	appos||rnas-26/NNS||si-24/NN	nsubj||components-29/NNS||rnas-26/NNS	cop||components-29/NNS||are-27/VBP	amod||components-29/NNS||key-28/JJ	conj_and||defense-13/NN||components-29/NNS	det||pathway-32/NN||this-31/DT	prep_of||components-29/NNS||pathway-32/NN	antiviral-12||virus--1||no_rel||the exogenous rna interference (rnai) pathway is an important antiviral defense against arboviruses in mosquitoes, and virus-specific small interfering (si)rnas are key components of this pathway.
amod||attachments-5/NNS||multipoint-1/JJ	conj_and||multipoint-1/JJ||multisubunit-3/JJ	amod||attachments-5/NNS||multisubunit-3/JJ	nn||attachments-5/NNS||covalent-4/NN	nsubj||provide-14/VBP||attachments-5/NNS	prep_of||attachments-5/NNS||enzymes-7/NNS	advmod||functionalized-10/JJ||appropriately-9/RB	amod||supports-11/NNS||functionalized-10/JJ	prep_on||enzymes-7/NNS||supports-11/NNS	prep_via||supports-11/NNS||linkers-13/NNS	root||ROOT-0/null||provide-14/VBP	acomp||provide-14/VBP||rigidity-15/JJ	det||structure-20/NN||the-17/DT	amod||structure-20/NN||immobilized-18/JJ	nn||structure-20/NN||enzyme-19/NN	prep_to||rigidity-15/JJ||structure-20/NN	advmod||resulting-23/VBG||ultimately-22/RB	xcomp||provide-14/VBP||resulting-23/VBG	amod||stability-27/NN||improved-25/VBN	nn||stability-27/NN||enzyme-26/NN	prep_in||resulting-23/VBG||stability-27/NN	enzymes-7||rigidity-15||no_rel||multipoint and multisubunit covalent attachments of enzymes on appropriately functionalized supports via linkers provide rigidity to the immobilized enzyme structure, ultimately resulting in improved enzyme stability.
amod||infection-5/NNS||humantcelllymphotropicvirustype1-1/JJ	dep||infection-5/NNS||htlv-1-3/JJ	nsubj||lead-7/VB||infection-5/NNS	aux||lead-7/VB||can-6/MD	root||ROOT-0/null||lead-7/VB	prep_to||lead-7/VB||development-9/NN	amod||leukemia/lymphoma-14/NN||adult-11/JJ	nn||leukemia/lymphoma-14/NN||t-12/NN	nn||leukemia/lymphoma-14/NN||cell-13/NN	prep_of||development-9/NN||leukemia/lymphoma-14/NN	appos||leukemia/lymphoma-14/NN||atl-16/NN	amod||tropicalspasticparaparesis-21/NNS||htlv-1-associatedmyelopathy-19/JJ	amod||tropicalspasticparaparesis-21/NNS||/-20/JJ	prep_of||development-9/NN||tropicalspasticparaparesis-21/NNS	conj_or||leukemia/lymphoma-14/NN||tropicalspasticparaparesis-21/NNS	appos||leukemia/lymphoma-14/NN||ham/tsp-23/NN	det||subset-27/NN||a-26/DT	prep_in||lead-7/VB||subset-27/NN	amod||subjects-30/NNS||infected-29/JJ	prep_of||subset-27/NN||subjects-30/NNS	tropicalspasticparaparesis-21||htlv-1-3||no||humantcelllymphotropicvirustype1 (htlv-1) infection can lead to development of adult t cell leukemia/lymphoma (atl) or htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) in a subset of infected subjects.
det||results-2/NNS||these-1/DT	nsubj||have-3/VBP||results-2/NNS	root||ROOT-0/null||have-3/VBP	dobj||have-3/VBP||implications-4/NNS	prepc_for||implications-4/NNS||defining-6/VBG	ccomp||defining-6/VBG||plague-7/VB	dobj||plague-7/VB||foci-8/NN	dobj||plague-7/VB||persistence-10/NN	conj_and||foci-8/NN||persistence-10/NN	dobj||plague-7/VB||transmission-12/NN	conj_and||foci-8/NN||transmission-12/NN	dobj||plague-7/VB||bioremediation-15/NN	conj_and||foci-8/NN||bioremediation-15/NN	det||exposure-21/NN||a-17/DT	amod||exposure-21/NN||natural-18/JJ	conj_or||natural-18/JJ||intentional-20/JJ	amod||exposure-21/NN||intentional-20/JJ	prep_after||foci-8/NN||exposure-21/NN	prep_to||exposure-21/NN||y.pestis-23/NNS	plague-7||y.pestis-23||no||these results have implications for defining plague foci , persistence , transmission , and bioremediation after a natural or intentional exposure to y.pestis .
nsubj||observed-27/VBD||dyspnoea-1/NN	vmod||dyspnoea-1/NN||developed-2/VBN	mark||progressed-6/VBD||as-3/IN	nn||injury-5/NN||liver-4/NN	nsubj||progressed-6/VBD||injury-5/NN	advcl||developed-2/VBN||progressed-6/VBD	det||resistance-12/NN||the-8/DT	amod||resistance-12/NN||increased-9/VBN	amod||resistance-12/NN||pulmonary-10/JJ	nn||resistance-12/NN||vascular-11/NN	conj_and||dyspnoea-1/NN||resistance-12/NN	nsubj||observed-27/VBD||resistance-12/NN	npadvmod||+-15/JJ||636-14/CD	dep||resistance-12/NN||+-15/JJ	punct||+-15/JJ||/-16/:	num||vs-19/NN||95-18/CD	dep||+-15/JJ||vs-19/NN	num||/-22/NNS||301-20/CD	amod||/-22/NNS||+-21/JJ	dep||vs-19/NN||/-22/NNS	amod||mpa/s/m3-25/NNS||26.9-24/JJ	dep||/-22/NNS||mpa/s/m3-25/NNS	root||ROOT-0/null||observed-27/VBD	aux||reflect-29/VB||may-28/MD	ccomp||observed-27/VBD||reflect-29/VB	det||development-31/NN||the-30/DT	dobj||reflect-29/VB||development-31/NN	prep_of||development-31/NN||respiratorydistresssyndrome-33/NN	mpa--1||dyspnoea-1||no_rel||dyspnoea developed as liver injury progressed and the increased pulmonary vascular resistance (636 +/- 95 vs 301 +/- 26.9 mpa/s/m3) observed may reflect the development of respiratorydistresssyndrome.
det||study-3/NN||this-2/DT	prep_in||translated-6/VBN||study-3/NN	nsubj||translated-6/VBN||we-5/PRP	root||ROOT-0/null||translated-6/VBN	advmod||adapted-9/VBN||culturally-8/RB	dep||translated-6/VBN||adapted-9/VBN	dep||translated-6/VBN||tested-11/VBN	conj_and||adapted-9/VBN||tested-11/VBN	det||reliability-13/NN||the-12/DT	dobj||adapted-9/VBN||reliability-13/NN	dobj||adapted-9/VBN||validity-15/NN	conj_and||reliability-13/NN||validity-15/NN	num||quality-20/NN||two-17/CD	amod||quality-20/NN||widely-used-18/JJ	amod||quality-20/NN||health-related-19/JJ	prep_of||validity-15/NN||quality-20/NN	nn||questionnaires-23/NNS||life-22/NN	prep_of||quality-20/NN||questionnaires-23/NNS	det||survey-28/NN||the-25/DT	amod||survey-28/NN||mos-hiv-26/JJ	nn||survey-28/NN||health-27/NN	dobj||adapted-9/VBN||survey-28/NN	conj_and||reliability-13/NN||survey-28/NN	det||sf-12-31/NN||the-30/DT	conj_and||reliability-13/NN||sf-12-31/NN	conj_and||survey-28/NN||sf-12-31/NN	dobj||adapted-9/VBN||in-33/IN	conj_and||reliability-13/NN||in-33/IN	prep_in||reliability-13/NN||people-34/NNS	xcomp||translated-6/VBN||living-35/VBG	prep_with||living-35/VBG||hiv/aids-37/NNS	amod||thailand-40/NN||northern-39/JJ	prep_in||hiv/aids-37/NNS||thailand-40/NN	aids--1||hiv--1||no||in this study, we translated, culturally adapted and tested the reliability and validity of two widely-used health-related quality of life questionnaires - the mos-hiv health survey and the sf-12 - in people living with hiv/aids in northern thailand.
mark||drug-11/NN||although-1/IN	nsubj||drug-11/NN||warfarin-2/NN	cop||drug-11/NN||is-3/VBZ	det||drug-11/NN||an-4/DT	amod||drug-11/NN||effective-5/JJ	amod||drug-11/NN||oral-6/JJ	nn||drug-11/NN||anticoagulation-7/NN	appos||drug-11/NN||oac-9/NN	advcl||scarce-32/JJ||drug-11/NN	aux||reduce-13/VB||to-12/TO	vmod||drug-11/NN||reduce-13/VB	det||risk-15/NN||the-14/DT	dobj||reduce-13/VB||risk-15/NN	prep_of||risk-15/NN||thromboembolism-17/NN	prep_in||reduce-13/VB||patients-19/NNS	amod||atrialfibrillation-22/NN||non-valvular-21/JJ	prep_with||patients-19/NNS||atrialfibrillation-22/NN	appos||atrialfibrillation-22/NN||nvaf-24/NN	amod||data-30/NNS||long-27/JJ	nn||data-30/NNS||term-28/NN	nn||data-30/NNS||follow-up-29/NN	nsubj||scarce-32/JJ||data-30/NNS	nsubj||certain-35/JJ||data-30/NNS	cop||scarce-32/JJ||are-31/VBP	root||ROOT-0/null||scarce-32/JJ	aux||certain-35/JJ||to-33/TO	cop||certain-35/JJ||be-34/VB	xcomp||scarce-32/JJ||certain-35/JJ	mark||maintained-42/VBN||whether-36/IN	det||level-40/NN||the-37/DT	nn||level-40/NN||target-38/NN	nn||level-40/NN||inr-39/NN	nsubjpass||maintained-42/VBN||level-40/NN	auxpass||maintained-42/VBN||is-41/VBZ	ccomp||certain-35/JJ||maintained-42/VBN	amod||patients-45/NNS||warfarin-treated-44/JJ	prep_in||maintained-42/VBN||patients-45/NNS	prep_in||patients-45/NNS||korea-47/NN	atrialfibrillation-22||warfarin-2||yes||although warfarin is an effective oral anticoagulation (oac) drug to reduce the risk of thromboembolism in patients with non-valvular atrialfibrillation (nvaf), long term follow-up data are scarce to be certain whether the target inr level is maintained in warfarin-treated patients in korea.
num||percent-2/NN||seventeen-1/CD	nsubj||resistant-8/JJ||percent-2/NN	det||cultures-6/NNS||all-4/DT	amod||cultures-6/NNS||positive-5/JJ	prep_of||percent-2/NN||cultures-6/NNS	cop||resistant-8/JJ||were-7/VBD	root||ROOT-0/null||resistant-8/JJ	preconj||isoniazid-11/NN||both-10/DT	prep_to||resistant-8/JJ||isoniazid-11/NN	prep_to||resistant-8/JJ||rifampin-13/NN	conj_and||isoniazid-11/NN||rifampin-13/NN	dep||resistant-18/NN||i.e.-15/FW	dep||resistant-18/NN||multidrug-17/JJ	dep||isoniazid-11/NN||resistant-18/NN	num||%-22/NN||16-21/CD	nsubjpass||infected-39/VBN||%-22/NN	prep_of||%-22/NN||patients-24/NNS	vmod||patients-24/NNS||dying-25/VBG	det||phase-29/NN||the-27/DT	nn||phase-29/NN||initiation-28/NN	prep_during||dying-25/VBG||phase-29/NN	poss||course-34/NN||their-31/PRP$	amod||course-34/NN||first-32/JJ	advmod||first-32/JJ||ever-33/RB	prep_of||phase-29/NN||course-34/NN	nn||treatment-37/NN||tuberculosis-36/NNP	prep_of||course-34/NN||treatment-37/NN	auxpass||infected-39/VBN||were-38/VBD	parataxis||resistant-8/JJ||infected-39/VBN	amod||bacilli-42/NNS||multidrug-resistant-41/JJ	prep_with||infected-39/VBN||bacilli-42/NNS	tuberculosis-36||isoniazid-11||yes||seventeen percent of all positive cultures were resistant to both isoniazid and rifampin (i.e., multidrug resistant); 16% of patients dying during the initiation phase of their first ever course of tuberculosis treatment were infected with multidrug-resistant bacilli.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	prednisolone-58||cytomegalovirus-6||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
nsubjpass||associated-15/VBN||isotretinoin-1/NN	det||drug-4/NN||a-3/DT	appos||isotretinoin-1/NN||drug-4/NN	vmod||drug-4/NN||used-5/VBN	amod||severe-9/JJ||moderate-7/JJ	dep||severe-9/JJ||to-8/TO	amod||acne-10/NN||severe-9/JJ	prep_for||used-5/VBN||acne-10/NN	aux||associated-15/VBN||has-12/VBZ	auxpass||associated-15/VBN||been-13/VBN	advmod||associated-15/VBN||repeatedly-14/RB	root||ROOT-0/null||associated-15/VBN	amod||complications-19/NNS||various-17/JJ	amod||complications-19/NNS||psychiatric-18/JJ	prep_with||associated-15/VBN||complications-19/NNS	mark||established-29/VBN||although-21/IN	det||relationship-25/NN||a-22/DT	amod||relationship-25/NN||definitive-23/JJ	amod||relationship-25/NN||causal-24/JJ	nsubjpass||established-29/VBN||relationship-25/NN	aux||established-29/VBN||has-26/VBZ	neg||established-29/VBN||not-27/RB	auxpass||established-29/VBN||been-28/VBN	advcl||associated-15/VBN||established-29/VBN	prep_to||established-29/VBN||date-31/NN	acne-10||isotretinoin-1||yes||isotretinoin, a drug used for moderate to severe acne, has been repeatedly associated with various psychiatric complications, although a definitive causal relationship has not been established to date.
amod||2b-3/NNS||high-dose-1/JJ	amod||2b-3/NNS||interferon-alpha-2/JJ	nsubj||therapy-14/NN||2b-3/NNS	num||2b-7/NNS||ifn-î-5/CD	nn||2b-7/NNS||±-6/NNP	appos||2b-3/NNS||2b-7/NNS	cop||therapy-14/NN||is-9/VBZ	det||therapy-14/NN||the-10/DT	advmod||therapy-14/NN||only-11/RB	amod||therapy-14/NN||approved-12/VBN	amod||therapy-14/NN||systemic-13/JJ	root||ROOT-0/null||therapy-14/NN	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_in||therapy-14/NN||states-18/NNS	det||treatment-22/NN||the-20/DT	amod||treatment-22/NN||adjuvant-21/JJ	prep_for||states-18/NNS||treatment-22/NN	prep_of||treatment-22/NN||melanoma-24/NN	melanoma-24||ifn--1||yes||high-dose interferon-alpha 2b (ifn-î± 2b) is the only approved systemic therapy in the united states for the adjuvant treatment of melanoma.
det||basis-3/NN||the-2/DT	prep_on||updated-62/VBN||basis-3/NN	det||results-8/NNS||the-5/DT	advmod||published-7/VBN||recently-6/RB	amod||results-8/NNS||published-7/VBN	prep_of||basis-3/NN||results-8/NNS	det||trial-12/NN||a-10/DT	amod||trial-12/NN||clinical-11/JJ	prep_of||results-8/NNS||trial-12/NN	vmod||trial-12/NN||comparing-13/VBG	nn||months-17/NNS||12-14/CD	conj_and||12-14/CD||36â-16/CD	nn||months-17/NNS||36â-16/CD	dobj||comparing-13/VBG||months-17/NNS	prep_of||months-17/NNS||imatinib-19/NN	amod||therapy-22/NN||adjuvant-21/JJ	prep_in||comparing-13/VBG||therapy-22/NN	amod||tumors-26/NNS||gastrointestinal-24/JJ	amod||tumors-26/NNS||stromal-25/JJ	prep_for||therapy-22/NN||tumors-26/NNS	nsubj||demonstrated-32/VBD||tumors-26/NNS	appos||tumors-26/NNS||gists-28/NNS	rcmod||tumors-26/NNS||demonstrated-32/VBD	amod||benefit-34/NN||clinical-33/JJ	dobj||demonstrated-32/VBD||benefit-34/NN	amod||treatment-38/NN||longer-36/JJR	nn||treatment-38/NN||imatinib-37/NN	prep_of||benefit-34/NN||treatment-38/NN	prep_in||treatment-38/NN||terms-40/NNS	prepc_of||terms-40/NNS||delaying-42/VBG	dobj||delaying-42/VBG||recurrences-43/NNS	prepc_of||terms-40/NNS||improving-45/VBG	conj_and||delaying-42/VBG||improving-45/VBG	amod||survival-47/NN||overall-46/JJ	dobj||improving-45/VBG||survival-47/NN	dep||survival-47/NN||both-49/CC	det||us-51/PRP||the-50/DT	conj||survival-47/NN||us-51/PRP	nn||administration-55/NN||food-52/NN	conj_and||food-52/NN||drug-54/NN	nn||administration-55/NN||drug-54/NN	nsubj||updated-62/VBN||administration-55/NN	nsubj||approved-66/VBN||administration-55/NN	det||agency-60/NN||the-57/DT	nn||agency-60/NN||european-58/NN	nn||agency-60/NN||medicines-59/NNS	conj_and||administration-55/NN||agency-60/NN	nsubj||updated-62/VBN||agency-60/NN	aux||updated-62/VBN||have-61/VBP	root||ROOT-0/null||updated-62/VBN	poss||recommendations-64/NNS||their-63/PRP$	dobj||updated-62/VBN||recommendations-64/NNS	conj_and||updated-62/VBN||approved-66/VBN	amod||months-68/NNS||36â-67/JJ	dobj||approved-66/VBN||months-68/NNS	amod||treatment-71/NN||imatinib-70/JJ	prep_of||months-68/NNS||treatment-71/NN	prep_in||approved-66/VBN||patients-73/NNS	amod||homolog-82/NN||v-kit-75/JJ	amod||homolog-82/NN||hardy-zuckerman-76/JJ	dep||hardy-zuckerman-76/JJ||4-77/CD	nn||homolog-82/NN||feline-78/NN	nn||homolog-82/NN||sarcoma-79/NN	amod||homolog-82/NN||viral-80/JJ	nn||homolog-82/NN||oncogene-81/NN	prep_with||patients-73/NNS||homolog-82/NN	appos||homolog-82/NN||kit-84/NN	amod||gists-88/NNS||positive-87/JJ	parataxis||approved-66/VBN||gists-88/NNS	advmod||known-91/VBN||also-90/RB	dep||gists-88/NNS||known-91/VBN	amod||gists-94/NNS||cd117-positive-93/JJ	prep_as||known-91/VBN||gists-94/NNS	amod||risk-98/NN||high-97/JJ	prep_at||gists-88/NNS||risk-98/NN	prep_of||risk-98/NN||recurrence-100/NN	amod||resection-103/NN||surgical-102/JJ	prep_after||updated-62/VBN||resection-103/NN	det||tumor-107/NN||a-105/DT	amod||tumor-107/NN||primary-106/JJ	prep_of||resection-103/NN||tumor-107/NN	tumors-26||adjuvant-21||no_rel||on the basis of the recently published results of a clinical trial comparing 12 and 36â months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (gists), which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall survival, both the us food and drug administration and the european medicines agency have updated their recommendations and approved 36â months of imatinib treatment in patients with v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homolog (kit)-positive gists (also known as cd117-positive gists) at high risk of recurrence after surgical resection of a primary tumor.
nsubj||accounted-7/VBN||results-1/NNS	vmod||results-1/NNS||funding-2/VBG	amod||projects-5/NNS||international-4/JJ	prep_from||funding-2/VBG||projects-5/NNS	aux||accounted-7/VBN||has-6/VBZ	root||ROOT-0/null||accounted-7/VBN	prep_for||accounted-7/VBN||one-third-9/NN	det||resources-12/NNS||the-11/DT	prep_of||one-third-9/NN||resources-12/NNS	vmod||resources-12/NNS||provided-13/VBN	det||response-17/NN||the-15/DT	amod||response-17/NN||hiv/aids-16/JJ	prep_for||provided-13/VBN||response-17/NN	prep_in||response-17/NN||china-19/NN	aids--1||hiv--1||no||results funding from international projects has accounted for one-third of the resources provided for the hiv/aids response in china.
det||data-2/NNS||the-1/DT	nsubj||show-3/VBP||data-2/NNS	root||ROOT-0/null||show-3/VBP	mark||increased-10/VBD||that-4/IN	amod||animals-7/NNS||fed-6/VBN	prep_in||increased-10/VBD||animals-7/NNS	nsubj||increased-10/VBD||injury-9/NN	nsubj||impacted-19/VBD||injury-9/NN	ccomp||show-3/VBP||increased-10/VBD	nn||output-12/NN||glucose-11/NN	dobj||increased-10/VBD||output-12/NN	advmod||increased-10/VBD||mainly-13/RB	nn||breakdown-16/NN||glycogen-15/NN	prep_from||increased-10/VBD||breakdown-16/NN	advmod||impacted-19/VBD||minimally-18/RB	ccomp||show-3/VBP||impacted-19/VBD	conj_and||increased-10/VBD||impacted-19/VBD	amod||metabolism-21/NN||aminoacid-20/JJ	dobj||impacted-19/VBD||metabolism-21/NN	aminoacid-20||impacted-19||no_rel||the data show that in fed animals, injury increased glucose output mainly from glycogen breakdown and minimally impacted aminoacid metabolism.
mark||phenotype-9/NN||as-1/IN	nsubj||phenotype-9/NN||type2diabetesmellitus-2/NNS	appos||type2diabetesmellitus-2/NNS||t2dm-4/NNP	cop||phenotype-9/NN||is-6/VBZ	det||phenotype-9/NN||a-7/DT	amod||phenotype-9/NN||complex-8/JJ	advcl||applied-17/VBD||phenotype-9/NN	advmod||influenced-11/VBN||likely-10/RB	vmod||phenotype-9/NN||influenced-11/VBN	amod||interactions-14/NNS||gene-gene-13/JJ	agent||influenced-11/VBN||interactions-14/NNS	nsubj||applied-17/VBD||we-16/PRP	root||ROOT-0/null||applied-17/VBD	dobj||applied-17/VBD||fam-mdr-18/NN	aux||examine-20/VB||to-19/TO	vmod||applied-17/VBD||examine-20/VB	dobj||examine-20/VB||data-21/NNS	nn||area-under-the-curve-24/NN||glucose-23/NN	prep_on||examine-20/VB||area-under-the-curve-24/NN	dep||area-under-the-curve-24/NN||gauc-26/JJ	det||endophenotype-30/NN||an-29/DT	appos||area-under-the-curve-24/NN||endophenotype-30/NN	prep_for||observed-41/JJ||endophenotype-30/NN	prep_of||endophenotype-30/NN||t2dm-32/CD	amod||associations-38/NNS||multiple-35/JJ	amod||associations-38/NNS||independent-36/JJ	amod||associations-38/NNS||genetic-37/JJ	nsubj||observed-41/JJ||associations-38/NNS	aux||observed-41/JJ||have-39/VBP	cop||observed-41/JJ||been-40/VBN	rcmod||endophenotype-30/NN||observed-41/JJ	det||study-48/NN||the-44/DT	amod||study-48/NN||amish-45/JJ	nn||study-48/NN||family-46/NN	nn||study-48/NN||diabetes-47/NN	prep_in||observed-41/JJ||study-48/NN	appos||study-48/NN||afds-50/NNS	type2diabetesmellitus-2||glucose-23||no_rel||as type2diabetesmellitus (t2dm) is a complex phenotype likely influenced by gene-gene interactions, we applied fam-mdr to examine data on glucose area-under-the-curve (gauc), an endophenotype of t2dm for which multiple independent genetic associations have been observed, in the amish family diabetes study (afds).
advmod||reported-15/VBN||however-1/RB	amod||lymphoma-5/NN||primary-3/JJ	nn||lymphoma-5/NN||breast-4/NN	nsubjpass||reported-15/VBN||lymphoma-5/NN	vmod||lymphoma-5/NN||occurring-6/VBG	det||patient-9/NN||a-8/DT	prep_in||occurring-6/VBG||patient-9/NN	prep_with||patient-9/NN||hiv-11/NN	aux||reported-15/VBN||has-12/VBZ	advmod||reported-15/VBN||rarely-13/RB	auxpass||reported-15/VBN||been-14/VBN	root||ROOT-0/null||reported-15/VBN	det||fact-18/NN||the-17/DT	prep_despite||reported-15/VBN||fact-18/NN	mark||known-22/VBN||that-19/IN	nsubjpass||known-22/VBN||hivinfection-20/NN	nsubj||increase-24/VB||hivinfection-20/NN	auxpass||known-22/VBN||is-21/VBZ	ccomp||reported-15/VBN||known-22/VBN	aux||increase-24/VB||to-23/TO	xcomp||known-22/VBN||increase-24/VB	det||propensity-26/NN||the-25/DT	dobj||increase-24/VB||propensity-26/NN	aux||develop-28/VB||to-27/TO	vmod||propensity-26/NN||develop-28/VB	amod||types-30/NNS||certain-29/JJ	dobj||develop-28/VB||types-30/NNS	prep_of||types-30/NNS||lymphoma-32/NN	hivinfection-20||hiv-11||no||however, primary breast lymphoma occurring in a patient with hiv has rarely been reported despite the fact that hivinfection is known to increase the propensity to develop certain types of lymphoma.
nsubj||identified-12/VBD||analyses-1/NNS	amod||data-4/NNS||phosphoproteomic-3/JJ	prep_of||analyses-1/NNS||data-4/NNS	nn||samples-11/NNS||breast-6/NN	conj_and||breast-6/NN||lung-8/NN	nn||samples-11/NNS||lung-8/NN	nn||samples-11/NNS||cancer-9/NN	amod||samples-11/NNS||patient-10/JJ	prep_from||data-4/NNS||samples-11/NNS	root||ROOT-0/null||identified-12/VBD	det||subset-14/NN||a-13/DT	dobj||identified-12/VBD||subset-14/NN	det||sites-19/NNS||the-16/DT	amod||sites-19/NNS||src-dependent-17/JJ	nn||sites-19/NNS||phosphorylation-18/NN	prep_of||subset-14/NN||sites-19/NNS	auxpass||correlated-23/VBN||being-21/VBG	advmod||correlated-23/VBN||strongly-22/RB	prepc_as||identified-12/VBD||correlated-23/VBN	nn||activation-26/NN||src-25/NN	prep_with||correlated-23/VBN||activation-26/NN	nsubj||represent-29/VBP||activation-26/NN	rcmod||activation-26/NN||represent-29/VBP	nn||markers-31/NNS||candidate-30/NN	dobj||represent-29/VBP||markers-31/NNS	nn||downstream-35/NNS||src-33/NN	nn||downstream-35/NNS||activation-34/NN	prep_of||markers-31/NNS||downstream-35/NNS	nn||kinases-39/NNS||receptor-37/NN	nn||kinases-39/NNS||tyrosine-38/NN	prep_of||downstream-35/NNS||kinases-39/NNS	amod||tumors-42/NNS||human-41/JJ	prep_in||kinases-39/NNS||tumors-42/NNS	cancer-9||tyrosine-38||no_rel||analyses of phosphoproteomic data from breast and lung cancer patient samples identified a subset of the src-dependent phosphorylation sites as being strongly correlated with src activation, which represent candidate markers of src activation downstream of receptor tyrosine kinases in human tumors.
nsubj||suggest-2/VBP||we-1/PRP	root||ROOT-0/null||suggest-2/VBP	mark||related-10/VBN||that-3/IN	det||effect-6/NN||the-4/DT	amod||effect-6/NN||chemopreventive-5/JJ	nsubjpass||related-10/VBN||effect-6/NN	prep_of||effect-6/NN||sulindac-8/NN	auxpass||related-10/VBN||is-9/VBZ	ccomp||suggest-2/VBP||related-10/VBN	amod||cox-2-13/NN||decreased-12/VBN	prep_to||related-10/VBN||cox-2-13/NN	prep_to||related-10/VBN||cyclin-15/NN	conj_and||cox-2-13/NN||cyclin-15/NN	amod||expression-17/NN||d1-16/JJ	dep||cox-2-13/NN||expression-17/NN	nsubjpass||influenced-22/VBN||expression-17/NN	aux||influenced-22/VBN||may-20/MD	auxpass||influenced-22/VBN||be-21/VB	rcmod||expression-17/NN||influenced-22/VBN	amod||inflammation-25/NN||reduced-24/VBN	agent||influenced-22/VBN||inflammation-25/NN	inflammation-25||sulindac-8||yes||we suggest that the chemopreventive effect of sulindac is related to decreased cox-2 and cyclin d1 expression, which may be influenced by reduced inflammation.
amod||syndromes-3/NNS||hyper-immunoglobulin-1/JJ	amod||syndromes-3/NNS||e-2/JJ	nsubjpass||characterized-15/VBN||syndromes-3/NNS	appos||syndromes-3/NNS||hies-5/NNS	amod||immunodeficiency-10/NN||compound-8/JJ	amod||immunodeficiency-10/NN||primary-9/JJ	prep_including||syndromes-3/NNS||immunodeficiency-10/NN	amod||abnormalities-13/NNS||nonimmunological-12/JJ	prep_including||syndromes-3/NNS||abnormalities-13/NNS	conj_and||immunodeficiency-10/NN||abnormalities-13/NNS	auxpass||characterized-15/VBN||are-14/VBP	root||ROOT-0/null||characterized-15/VBN	advmod||high-18/JJ||extremely-17/RB	amod||levels-21/NNS||high-18/JJ	amod||levels-21/NNS||serum-19/JJ	nn||levels-21/NNS||ige-20/NN	agent||characterized-15/VBN||levels-21/NNS	appos||levels-21/NNS||eosinophilia-23/NN	appos||levels-21/NNS||eczema-25/NN	conj_and||eosinophilia-23/NN||eczema-25/NN	amod||retention-35/NN||susceptibility-27/JJ	prep_to||susceptibility-27/JJ||infections-29/NNS	amod||appearance-33/NN||distinctive-31/JJ	amod||appearance-33/NN||facial-32/JJ	appos||infections-29/NNS||appearance-33/NN	appos||levels-21/NNS||retention-35/NN	conj_and||eosinophilia-23/NN||retention-35/NN	amod||teeth-38/NNS||deciduous-37/JJ	prep_of||retention-35/NN||teeth-38/NNS	amod||pneumonias-41/NNS||cyst-forming-40/JJ	appos||teeth-38/NNS||pneumonias-41/NNS	amod||abnormalities-45/NNS||skeletal-44/JJ	appos||levels-21/NNS||abnormalities-45/NNS	conj_and||eosinophilia-23/NN||abnormalities-45/NNS	immunodeficiency-10||immunoglobulin--1||yes||hyper-immunoglobulin e syndromes (hies) including compound primary immunodeficiency and nonimmunological abnormalities are characterized by extremely high serum ige levels, eosinophilia, eczema, susceptibility to infections, distinctive facial appearance, retention of deciduous teeth, cyst-forming pneumonias, and skeletal abnormalities.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	det||approach-5/NN||a-3/DT	amod||approach-5/NN||criteria-based-4/JJ	dobj||used-2/VBD||approach-5/NN	aux||determine-7/VB||to-6/TO	vmod||used-2/VBD||determine-7/VB	nsubj||hiv/aids-9/VBZ||which-8/WDT	nsubj||purposive-27/JJ||which-8/WDT	dobj||determine-7/VB||hiv/aids-9/VBZ	nsubj||conduct-30/VB||hiv/aids-9/VBZ	nsubj||have-11/VBP||stakeholders-10/NNS	ccomp||hiv/aids-9/VBZ||have-11/VBP	det||impact-15/NN||the-12/DT	advmod||significant-14/JJ||most-13/RBS	amod||impact-15/NN||significant-14/JJ	dobj||have-11/VBP||impact-15/NN	amod||research-18/NN||hiv/aids-17/JJ	prep_on||impact-15/NN||research-18/NN	prep_on||impact-15/NN||programs-20/NNS	conj_and||research-18/NN||programs-20/NNS	prep_on||impact-15/NN||funding-22/NN	conj_and||research-18/NN||funding-22/NN	prep_on||impact-15/NN||policy-24/NN	conj_and||research-18/NN||policy-24/NN	amod||purposive-27/JJ||stratified-26/JJ	dobj||determine-7/VB||purposive-27/JJ	conj_and||hiv/aids-9/VBZ||purposive-27/JJ	nsubj||conduct-30/VB||purposive-27/JJ	amod||purposive-27/JJ||sampling-28/VBG	aux||conduct-30/VB||to-29/TO	xcomp||determine-7/VB||conduct-30/VB	dobj||conduct-30/VB||interviews-31/NNS	det||subset-34/NN||a-33/DT	prep_with||conduct-30/VB||subset-34/NN	det||individuals-37/NNS||these-36/DT	prep_of||subset-34/NN||individuals-37/NNS	aids--1||hiv--1||no||we used a criteria-based approach to determine which hiv/aids stakeholders have the most significant impact on hiv/aids research, programs, funding and policy and stratified purposive sampling to conduct interviews with a subset of these individuals.
prep_by||was-5/VBD||comparison-2/NN	expl||was-5/VBD||there-4/EX	root||ROOT-0/null||was-5/VBD	number||%-7/NN||65-6/CD	amod||staining-9/NN||%-7/NN	amod||staining-9/NN||positive-8/JJ	nsubj||was-5/VBD||staining-9/NN	nn||receptor-12/NN||estrogen-11/NN	prep_for||staining-9/NN||receptor-12/NN	num||%-15/NN||61-14/CD	nsubj||was-5/VBD||%-15/NN	conj_and||staining-9/NN||%-15/NN	amod||receptor-18/NN||progesterone-17/JJ	prep_for||%-15/NN||receptor-18/NN	num||%-21/NN||67-20/CD	nsubj||was-5/VBD||%-21/NN	conj_and||staining-9/NN||%-21/NN	amod||p53-24/NN||nuclear-23/JJ	prep_for||%-21/NN||p53-24/NN	num||%-28/NN||39-27/CD	nsubj||was-5/VBD||%-28/NN	conj_and||staining-9/NN||%-28/NN	amod||sections-36/NNS||c-erb-b2-30/JJ	det||breast-34/NN||the-32/DT	amod||breast-34/NN||invasive-33/JJ	prep_with||c-erb-b2-30/JJ||breast-34/NN	nn||sections-36/NNS||cancer-35/NN	prep_for||%-28/NN||sections-36/NNS	cancer-35||progesterone-17||no_rel||by comparison, there was 65% positive staining for estrogen receptor, 61% for progesterone receptor, 67% for nuclear p53, and 39% for c-erb-b2 with the invasive breast cancer sections.
nsubj||was-7/VBD||background-1/NN	prep_prior_to||background-1/NN||2003-4/CD	expl||was-7/VBD||there-6/EX	root||ROOT-0/null||was-7/VBD	amod||capacity-9/NN||limited-8/JJ	nsubj||was-7/VBD||capacity-9/NN	det||response-13/NN||an-11/DT	amod||response-13/NN||hiv/aids-12/JJ	prep_for||capacity-9/NN||response-13/NN	prep_in||response-13/NN||china-15/NN	aids--1||hiv--1||no||background prior to 2003, there was limited capacity for an hiv/aids response in china.
det||results-2/NNS||these-1/DT	nsubj||indicate-4/VBP||results-2/NNS	advmod||indicate-4/VBP||clearly-3/RB	root||ROOT-0/null||indicate-4/VBP	det||superiority-6/NN||the-5/DT	dobj||indicate-4/VBP||superiority-6/NN	prep_of||superiority-6/NN||rbcg85c-8/NNS	prep_over||rbcg85c-8/NNS||bcg-10/NN	det||vaccine-15/NN||a-12/DT	amod||vaccine-15/NN||promising-13/JJ	amod||vaccine-15/NN||prophylactic-14/JJ	prep_as||indicate-4/VBP||vaccine-15/NN	prep_against||vaccine-15/NN||tb-17/NN	tb-17||bcg-10||yes||these results clearly indicate the superiority of rbcg85c over bcg as a promising prophylactic vaccine against tb.
prep_during||coordinate-16/VB||cycling-2/NN	det||vector-6/NN||the-4/DT	nn||vector-6/NN||tick-5/NN	prep_between||cycling-2/NN||vector-6/NN	det||mammal-9/NN||a-8/DT	prep_between||cycling-2/NN||mammal-9/NN	conj_and||vector-6/NN||mammal-9/NN	det||borreliaburgdorferi-14/NN||the-11/DT	amod||borreliaburgdorferi-14/NN||lymedisease-12/JJ	nn||borreliaburgdorferi-14/NN||spirochaete-13/NN	nsubj||coordinate-16/VB||borreliaburgdorferi-14/NN	aux||coordinate-16/VB||must-15/MD	root||ROOT-0/null||coordinate-16/VB	dobj||coordinate-16/VB||expression-17/NN	amod||proteins-20/NNS||outer-surface-19/JJ	prep_of||expression-17/NN||proteins-20/NNS	dep||proteins-20/NNS||osps-22/NNS	amod||proteins-20/NNS||a-24/DT	amod||proteins-20/NNS||b-26/JJ	conj_and||a-24/DT||b-26/JJ	aux||respond-29/VB||to-27/TO	advmod||respond-29/VB||quickly-28/RB	vmod||coordinate-16/VB||respond-29/VB	amod||changes-32/NNS||environmental-31/JJ	prep_to||respond-29/VB||changes-32/NNS	lymedisease-12||borreliaburgdorferi-14||no||during cycling between the tick vector and a mammal, the lymedisease spirochaete borreliaburgdorferi must coordinate expression of outer-surface proteins (osps) a and b to quickly respond to environmental changes.
det||study-2/NN||this-1/DT	nsubjpass||done-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||done-4/VBN||was-3/VBD	root||ROOT-0/null||done-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||done-4/VBN||evaluate-6/VB	det||effect-8/NN||the-7/DT	dobj||evaluate-6/VB||effect-8/NN	nn||relief-11/NN||pain-10/NN	prep_on||evaluate-6/VB||relief-11/NN	advmod||added-15/VBN||when-12/WRB	nsubjpass||added-15/VBN||acetaminophen-13/NN	nsubj||lidocaine-17/VB||acetaminophen-13/NN	auxpass||added-15/VBN||was-14/VBD	advcl||evaluate-6/VB||added-15/VBN	aux||lidocaine-17/VB||to-16/TO	xcomp||added-15/VBN||lidocaine-17/VB	amod||anesthesia-21/NN||intravenous-19/JJ	amod||anesthesia-21/NN||regional-20/JJ	prep_for||lidocaine-17/VB||anesthesia-21/NN	appos||anesthesia-21/NN||ivra-23/NNP	pain-10||lidocaine-17||yes||this study was done to evaluate the effect on pain relief when acetaminophen was added to lidocaine for intravenous regional anesthesia (ivra).
det||report-2/NN||this-1/DT	nsubj||discusses-3/VBZ||report-2/NN	root||ROOT-0/null||discusses-3/VBZ	det||case-5/NN||a-4/DT	dobj||discusses-3/VBZ||case-5/NN	amod||psychosis-8/NNS||acute-7/JJ	prep_of||case-5/NN||psychosis-8/NNS	prep_of||case-5/NN||enuresis-10/NNS	conj_and||psychosis-8/NNS||enuresis-10/NNS	det||alcohol-19/NN||a-12/DT	amod||alcohol-19/NN||patient-13/JJ	prep_on||patient-13/JJ||disulfiram-15/NN	nsubj||ingested-18/VBN||disulfiram-15/NN	aux||ingested-18/VBN||had-17/VBD	rcmod||disulfiram-15/NN||ingested-18/VBN	prep_in||case-5/NN||alcohol-19/NN	disulfiram-15||psychosis-8||no_rel||this report discusses a case of acute psychosis and enuresis in a patient on disulfiram who had ingested alcohol.
nsubj||reported-2/VBD||we-1/PRP	root||ROOT-0/null||reported-2/VBD	det||frequency-5/NN||an-3/DT	amod||frequency-5/NN||increased-4/VBN	nsubj||-LSB--18/VBZ||frequency-5/NN	det||g-allele-9/NN||the-7/DT	amod||g-allele-9/NN||minor-8/JJ	prep_of||frequency-5/NN||g-allele-9/NN	amod||rs569356-17/NNS||single-11/JJ	amod||rs569356-17/NNS||nucleotide-12/JJ	nn||rs569356-17/NNS||polymorphism-13/NN	nn||rs569356-17/NNS||snp-15/NN	prep_of||g-allele-9/NN||rs569356-17/NNS	ccomp||reported-2/VBD||-LSB--18/VBZ	det||variant-21/NN||the-19/DT	amod||variant-21/NN||only-20/JJ	dobj||-LSB--18/VBZ||variant-21/NN	vmod||variant-21/NN||identified-22/VBN	advmod||far-24/RB||so-23/RB	advmod||identified-22/VBN||far-24/RB	det||region-28/NN||the-26/DT	nn||region-28/NN||promoter-27/NN	prep_in||identified-22/VBN||region-28/NN	det||´-32/NN||the-30/DT	nn||´-32/NN||î-31/NN	prep_of||region-28/NN||´-32/NN	amod||gene-36/NN||opioid-34/JJ	nn||gene-36/NN||receptor-35/NN	nsubj||-RSB--40/VBD||gene-36/NN	appos||gene-36/NN||oprd1-38/NNP	parataxis||reported-2/VBD||-RSB--40/VBD	prep_in||-RSB--40/VBD||subjects-42/NNS	prep_with||-RSB--40/VBD||opioiddependence-44/NN	opioiddependence-44||opioid-34||no||we reported an increased frequency of the minor g-allele of single nucleotide polymorphism (snp) rs569356 [the only variant identified so far in the promoter region of the î´-opioid receptor gene ( oprd1 )] in subjects with opioiddependence.
det||combination-2/NN||the-1/DT	nsubj||premixed-6/VBD||combination-2/NN	nn||propofol-5/NN||microemulsion-4/NN	prep_of||combination-2/NN||propofol-5/NN	root||ROOT-0/null||premixed-6/VBD	prep_with||premixed-6/VBD||lidocaine-8/NN	mark||effective-16/JJ||after-9/IN	det||pretreatment-11/NN||a-10/DT	nsubj||effective-16/JJ||pretreatment-11/NN	prep_with||pretreatment-11/NN||remifentanil-13/NN	cop||effective-16/JJ||was-14/VBD	advmod||effective-16/JJ||more-15/RBR	advcl||premixed-6/VBD||effective-16/JJ	prepc_in||effective-16/JJ||reducing-18/VBG	det||incidence-20/NN||the-19/DT	dobj||reducing-18/VBG||incidence-20/NN	prep_of||incidence-20/NN||pain-22/NN	det||injection-25/NN||the-24/DT	prep_upon||reducing-18/VBG||injection-25/NN	nn||propofol-28/NN||microemulsion-27/NN	prep_of||injection-25/NN||propofol-28/NN	det||treatment-31/NN||either-30/DT	prep_than||reducing-18/VBG||treatment-31/NN	advmod||effective-16/JJ||alone-32/RB	pain-22||lidocaine-8||yes||the combination of microemulsion propofol premixed with lidocaine after a pretreatment with remifentanil was more effective in reducing the incidence of pain upon the injection of microemulsion propofol than either treatment alone.
det||initiative-4/NN||the-1/DT	amod||initiative-4/NN||joint-2/JJ	nn||initiative-4/NN||learning-3/NN	nsubj||recommended-10/VBD||initiative-4/NN	prep_on||initiative-4/NN||children-6/NNS	prep_on||initiative-4/NN||aids-8/NNS	conj_and||children-6/NNS||aids-8/NNS	advmod||recommended-10/VBD||recently-9/RB	root||ROOT-0/null||recommended-10/VBD	mark||direct-23/VB||that-11/IN	nsubj||direct-23/VB||programmes-12/NNS	prep_for||programmes-12/NNS||children-14/NNS	vmod||children-14/NNS||affected-15/VBN	agent||affected-15/VBN||hiv-17/NN	agent||affected-15/VBN||aids-19/NNS	conj_and||hiv-17/NN||aids-19/NNS	amod||africa-22/NN||sub-saharan-21/JJ	prep_in||affected-15/VBN||africa-22/NN	ccomp||recommended-10/VBD||direct-23/VB	amod||support-25/NN||more-24/JJR	dobj||direct-23/VB||support-25/NN	prep_to||direct-23/VB||families-27/NNS	aids-19||hiv-17||no||the joint learning initiative on children and aids recently recommended that programmes for children affected by hiv and aids in sub-saharan africa direct more support to families.
nn||subjects-3/NNS||method-1/NN	nn||subjects-3/NNS||study-2/NN	nsubj||patients-5/NNS||subjects-3/NNS	cop||patients-5/NNS||were-4/VBD	root||ROOT-0/null||patients-5/NNS	vmod||patients-5/NNS||receiving-6/VBG	dobj||receiving-6/VBG||treatment-7/NN	det||time-11/NN||the-9/DT	amod||time-11/NN||first-10/JJ	prep_for||treatment-7/NN||time-11/NN	amod||odt-14/NN||amlodipine-13/JJ	prep_with||time-11/NN||odt-14/NN	prep_for||odt-14/NN||hypertension-16/NN	amod||care-19/NN||routine-18/JJ	prep_under||receiving-6/VBG||care-19/NN	hypertension-16||amlodipine-13||yes||method study subjects were patients receiving treatment for the first time with amlodipine odt for hypertension under routine care.
aux||review-2/VB||to-1/TO	csubj||use-13/VBP||review-2/VB	det||evidence-5/NN||the-3/DT	amod||evidence-5/NN||published-4/VBN	dobj||review-2/VB||evidence-5/NN	det||efficacy-8/NN||the-7/DT	prep_regarding||evidence-5/NN||efficacy-8/NN	prep_regarding||evidence-5/NN||safety-10/NN	conj_and||efficacy-8/NN||safety-10/NN	prep_of||efficacy-8/NN||dronedarone-12/NN	root||ROOT-0/null||use-13/VBP	prep_in||use-13/VBP||patients-15/NNS	prep_with||patients-15/NNS||atrialfibrillation-17/NN	dronedarone-12||atrialfibrillation-17||no_rel||to review the published evidence regarding the efficacy and safety of dronedarone use in patients with atrialfibrillation.
det||three-2/CD||the-1/DT	nsubjpass||intensified-4/VBN||three-2/CD	auxpass||intensified-4/VBN||are-3/VBP	root||ROOT-0/null||intensified-4/VBN	nn||screening-6/NN||tb-5/NN	dobj||intensified-4/VBN||screening-6/NN	appos||screening-6/NN||icf-8/NN	prep_among||intensified-4/VBN||people-11/NNS	vmod||people-11/NNS||living-12/VBG	prep_with||living-12/VBG||hiv-14/NN	det||provision-17/NN||the-16/DT	appos||hiv-14/NN||provision-17/NN	amod||therapy-21/NN||isoniazid-19/JJ	nn||therapy-21/NN||preventive-20/NN	prep_of||provision-17/NN||therapy-21/NN	appos||therapy-21/NN||ipt-23/NN	nn||control-28/NN||tb-26/NN	nn||control-28/NN||infection-27/NN	prep_of||provision-17/NN||control-28/NN	conj_and||therapy-21/NN||control-28/NN	appos||therapy-21/NN||ic-30/NN	tb-26||isoniazid-19||yes||the three are intensified tb screening (icf) among people living with hiv, the provision of isoniazid preventive therapy (ipt) and tb infection control(ic).
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||demonstrates-4/VBZ||study-3/NN	root||ROOT-0/null||demonstrates-4/VBZ	det||efficacy-6/NN||the-5/DT	dobj||demonstrates-4/VBZ||efficacy-6/NN	advmod||synthesized-9/JJ||biologically-8/RB	amod||nanoparticles-11/NNS||synthesized-9/JJ	nn||nanoparticles-11/NNS||silver-10/NN	prep_of||efficacy-6/NN||nanoparticles-11/NNS	appos||nanoparticles-11/NNS||agnps-13/NNS	det||antitumoragent-17/NN||an-16/DT	prep_as||demonstrates-4/VBZ||antitumoragent-17/NN	vmod||antitumoragent-17/NN||using-18/VBG	num||lines-29/NNS||daltonâ-19/CD	amod||lines-29/NNS||$-20/$	number||s-22/CD||™-21/CD	num||$-20/$||s-22/CD	amod||lines-29/NNS||lymphoma-23/JJ	amod||lines-29/NNS||ascites-24/JJ	appos||lines-29/NNS||dla-26/NN	nn||lines-29/NNS||cell-28/NN	dobj||using-18/VBG||lines-29/NNS	prep_in||lines-29/NNS||vitro-31/NN	prep_in||lines-29/NNS||in-33/IN	conj_and||vitro-31/NN||in-33/IN	pobj||in-33/IN||vivo-34/NN	lymphoma-23||antitumoragent-17||no_rel||the present study demonstrates the efficacy of biologically synthesized silver nanoparticles (agnps) as an antitumoragent using daltonâ€™s lymphoma ascites (dla) cell lines in vitro and in vivo.
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	dobj||included-2/VBD||genes-3/NNS	nsubj||part-6/NN||genes-3/NNS	cop||part-6/NN||are-5/VBP	rcmod||genes-3/NNS||part-6/NN	det||factor-11/NN||the-8/DT	amod||factor-11/NN||hypoxia-inducible-9/JJ	nn||factor-11/NN||transcription-10/NN	prep_of||part-6/NN||factor-11/NN	appos||factor-11/NN||hif-13/NN	advmod||part-6/NN||pathway-15/RB	det||pathway-19/NN||a-17/DT	amod||pathway-19/NN||biochemical-18/JJ	dep||part-6/NN||pathway-19/NN	vmod||pathway-19/NN||involved-20/VBN	nn||homeostasis-23/NNS||oxygen-22/NN	prep_in||involved-20/VBN||homeostasis-23/NNS	num||regions-31/NNS||three-28/CD	amod||regions-31/NNS||other-29/JJ	amod||regions-31/NNS||genomic-30/JJ	dobj||included-2/VBD||regions-31/NNS	conj_and||genes-3/NNS||regions-31/NNS	nsubj||part-6/NN||regions-31/NNS	advmod||known-34/JJ||previously-32/RB	neg||known-34/JJ||not-33/RB	amod||regions-31/NNS||known-34/JJ	aux||associated-37/VBN||to-35/TO	auxpass||associated-37/VBN||be-36/VB	xcomp||known-34/JJ||associated-37/VBN	amod||phenotypes-40/NNS||high-altitude-39/JJ	prep_with||associated-37/VBN||phenotypes-40/NNS	oxygen-22||hypoxia--1||no_rel||these included genes that are part of the hypoxia-inducible transcription factor ( hif ) pathway, a biochemical pathway involved in oxygen homeostasis, as well as three other genomic regions previously not known to be associated with high-altitude phenotypes.
amod||treatment-3/NN||conventional-1/JJ	nn||treatment-3/NN||immunosuppressive-2/NN	nsubj||led-4/VBD||treatment-3/NN	root||ROOT-0/null||led-4/VBD	det||downregulation-8/NN||a-6/DT	amod||downregulation-8/NN||significant-7/JJ	prep_to||led-4/VBD||downregulation-8/NN	amod||tissue-14/NN||cox-2-10/JJ	prep_in||cox-2-10/JJ||myositis-12/NNS	nn||tissue-14/NN||muscle-13/NN	prep_of||downregulation-8/NN||tissue-14/NN	immunosuppressive-2||myositis-12||no_rel||conventional immunosuppressive treatment led to a significant downregulation of cox-2 in myositis muscle tissue.
det||intestine-4/NN||the-2/DT	amod||intestine-4/NN||small-3/JJ	prep_in||trigger-19/VBP||intestine-4/NN	amod||patients-7/NNS||celiacdisease-6/JJ	prep_of||intestine-4/NN||patients-7/NNS	amod||gluten-11/NN||dietary-9/JJ	nn||gluten-11/NN||wheat-10/NN	nsubj||trigger-19/VBP||gluten-11/NN	amod||proteins-14/NNS||similar-13/JJ	conj_and||gluten-11/NN||proteins-14/NNS	nsubj||trigger-19/VBP||proteins-14/NNS	prep_in||gluten-11/NN||barley-16/NN	prep_in||gluten-11/NN||rye-18/NN	conj_and||barley-16/NN||rye-18/NN	root||ROOT-0/null||trigger-19/VBP	det||response-22/NN||an-20/DT	amod||response-22/NN||inflammatory-21/JJ	dobj||trigger-19/VBP||response-22/NN	celiacdisease-6||gluten-11||no||in the small intestine of celiacdisease patients, dietary wheat gluten and similar proteins in barley and rye trigger an inflammatory response.
nsubjpass||allocated-17/VBN||patients-1/NNS	nsubj||receive-19/VB||patients-1/NNS	conj_and||patients-1/NNS||methods-3/NNS	nsubjpass||allocated-17/VBN||methods-3/NNS	nsubj||receive-19/VB||methods-3/NNS	number||hundred-5/CD||two-4/CD	dep||patients-1/NNS||hundred-5/CD	amod||patients-9/NNS||thirty-six-7/JJ	amod||patients-9/NNS||chemotherapy-naive-8/JJ	conj_and||patients-1/NNS||patients-9/NNS	nsubjpass||allocated-17/VBN||patients-9/NNS	nsubj||receive-19/VB||patients-9/NNS	amod||cancer-14/NN||inoperable-11/JJ	amod||cancer-14/NN||non-small-cell-12/JJ	nn||cancer-14/NN||lung-13/NN	prep_with||patients-9/NNS||cancer-14/NN	auxpass||allocated-17/VBN||were-15/VBD	advmod||allocated-17/VBN||randomly-16/RB	root||ROOT-0/null||allocated-17/VBN	aux||receive-19/VB||to-18/TO	xcomp||allocated-17/VBN||receive-19/VB	preconj||mg/m2-22/NNS||either-20/CC	num||mg/m2-22/NNS||200-21/CD	dobj||receive-19/VB||mg/m2-22/NNS	amod||cisplatin-25/NN||liposomal-24/JJ	prep_of||mg/m2-22/NNS||cisplatin-25/NN	num||paclitaxel-29/NN||135-27/CD	amod||paclitaxel-29/NN||mg/m2-28/JJ	prep_of||mg/m2-22/NNS||paclitaxel-29/NN	conj_and||cisplatin-25/NN||paclitaxel-29/NN	dep||paclitaxel-29/NN||arm-31/NN	dep||arm-31/NN||a-32/DT	num||cisplatin-37/NN||75-35/CD	amod||cisplatin-37/NN||mg/m2-36/JJ	dobj||receive-19/VB||cisplatin-37/NN	conj_or||mg/m2-22/NNS||cisplatin-37/NN	num||paclitaxel-41/NN||135-39/CD	amod||paclitaxel-41/NN||mg/m2-40/JJ	conj_or||mg/m2-22/NNS||paclitaxel-41/NN	conj_and||cisplatin-37/NN||paclitaxel-41/NN	appos||paclitaxel-41/NN||arm-43/NN	num||arm-43/NN||b-44/CD	advmod||mg/m2-22/NNS||once-47/RB	det||weeks-50/NNS||every-48/DT	num||weeks-50/NNS||2-49/CD	tmod||receive-19/VB||weeks-50/NNS	det||basis-54/NN||an-52/DT	nn||basis-54/NN||outpatient-53/NN	prep_on||receive-19/VB||basis-54/NN	cancer-14||paclitaxel-41||no_rel||patients and methods two hundred and thirty-six chemotherapy-naive patients with inoperable non-small-cell lung cancer were randomly allocated to receive either 200 mg/m2 of liposomal cisplatin and 135 mg/m2 paclitaxel (arm a) or 75 mg/m2 cisplatin and 135 mg/m2 paclitaxel (arm b), once every 2 weeks on an outpatient basis.
root||ROOT-0/null||artesunateâ-1/VB	dobj||artesunateâ-1/VB||$-2/$	npadvmod||of-10/RB||mefloquine-4/NN	dep||suppression-9/NN||provided-5/RB	det||suppression-9/NN||the-6/DT	dep||post-treatment-8/JJ||greatest-7/JJS	amod||suppression-9/NN||post-treatment-8/JJ	dep||mefloquine-4/NN||suppression-9/NN	dep||malaria-11/CD||of-10/RB	num||$-2/$||malaria-11/CD	malaria-11||mefloquine-4||yes||artesunateâ€“mefloquine provided the greatest post-treatment suppression of malaria.
nsubj||emphasizes-4/VBZ||management-1/NN	prep_of||management-1/NN||statusepilepticus-3/NNS	root||ROOT-0/null||emphasizes-4/VBZ	det||role-6/NN||the-5/DT	dobj||emphasizes-4/VBZ||role-6/NN	prep_of||role-6/NN||pharmacotherapy-8/NN	advmod||use-12/NN||particularly-10/RB	det||use-12/NN||the-11/DT	dobj||emphasizes-4/VBZ||use-12/NN	conj_and||role-6/NN||use-12/NN	prep_of||use-12/NN||diazepam-14/NN	dobj||emphasizes-4/VBZ||phenytoin-16/NN	conj_and||role-6/NN||phenytoin-16/NN	prep_in||phenytoin-16/NN||combination-18/NN	statusepilepticus-3||diazepam-14||yes||management of statusepilepticus emphasizes the role of pharmacotherapy, particularly the use of diazepam and phenytoin in combination.
det||study-4/NN||this-1/DT	nn||study-4/NN||phase-2/NN	nn||study-4/NN||iii-3/NN	nsubj||evaluated-5/VBN||study-4/NN	root||ROOT-0/null||evaluated-5/VBN	det||efficacy-7/NN||the-6/DT	dobj||evaluated-5/VBN||efficacy-7/NN	dobj||evaluated-5/VBN||safety-9/NN	conj_and||efficacy-7/NN||safety-9/NN	prep_of||efficacy-7/NN||rituximab-11/NN	dobj||evaluated-5/VBN||methotrexate-13/NN	conj_plus||efficacy-7/NN||methotrexate-13/NN	appos||methotrexate-13/NN||mtx-15/NN	prep_in||methotrexate-13/NN||patients-18/NNS	amod||rheumatoidarthritis-21/NNS||active-20/JJ	prep_with||evaluated-5/VBN||rheumatoidarthritis-21/NNS	nsubj||had-26/VBD||rheumatoidarthritis-21/NNS	appos||rheumatoidarthritis-21/NNS||ra-23/NN	rcmod||rheumatoidarthritis-21/NNS||had-26/VBD	det||response-29/NN||an-27/DT	amod||response-29/NN||inadequate-28/JJ	dobj||had-26/VBD||response-29/NN	prep_to||response-29/NN||mtx-31/NN	nsubjpass||naã-35/VBN||who-33/WP	auxpass||naã-35/VBN||were-34/VBD	rcmod||rheumatoidarthritis-21/NNS||naã-35/VBN	conj_and||had-26/VBD||naã-35/VBN	amod||ve-37/NN||¯-36/JJ	dobj||naã-35/VBN||ve-37/NN	amod||treatment-41/NN||prior-39/JJ	amod||treatment-41/NN||biological-40/JJ	prep_to||naã-35/VBN||treatment-41/NN	rheumatoidarthritis-21||methotrexate-13||yes||this phase iii study evaluated the efficacy and safety of rituximab plus methotrexate (mtx) in patients with active rheumatoidarthritis (ra) who had an inadequate response to mtx and who were naã¯ve to prior biological treatment.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	prep_with||gene-44/NN||graves-51/NNS	conj_and||type1diabetesmellitus-46/NNS||graves-51/NNS	dep||graves-51/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	interleukin-2-6||graves'disease--1||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves'disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
nsubj||measured-2/VBD||we-1/PRP	root||ROOT-0/null||measured-2/VBD	nn||concentrations-5/NNS||plasma-3/NN	nn||concentrations-5/NNS||glucagon-4/NN	dobj||measured-2/VBD||concentrations-5/NNS	prep_in||measured-2/VBD||patients-7/NNS	prep_with||measured-2/VBD||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||infused-10/VBN	det||insulinglulisine-14/NN||the-12/DT	amod||insulinglulisine-14/NN||zinc-free-13/JJ	prep_with||infused-10/VBN||insulinglulisine-14/NN	num||occasions-17/NNS||three-16/CD	prep_on||insulinglulisine-14/NN||occasions-17/NNS	type1diabetes-9||insulinglulisine-14||yes||we measured plasma glucagon concentrations in patients with type1diabetes infused with the zinc-free insulinglulisine on three occasions.
det||practitioner-4/NN||the-2/DT	amod||practitioner-4/NN||dental-3/JJ	prep_for||is-6/VBZ||practitioner-4/NN	nsubj||is-6/VBZ||it-5/PRP	nsubj||learn-10/VB||it-5/PRP	root||ROOT-0/null||is-6/VBZ	prep_of||is-6/VBZ||interest-8/NN	aux||learn-10/VB||to-9/TO	xcomp||is-6/VBZ||learn-10/VB	mark||generates-18/VBZ||that-11/IN	nsubj||generates-18/VBZ||use-12/NN	nsubjpass||expected-31/VBN||use-12/NN	nsubj||provide-33/VB||use-12/NN	prep_of||use-12/NN||glycine-14/NN	nn||polishing-17/NN||air-16/NN	prep_in||glycine-14/NN||polishing-17/NN	ccomp||learn-10/VB||generates-18/VBZ	det||roughening-22/NN||the-19/DT	amod||roughening-22/NN||least-20/JJS	nn||roughening-22/NN||surface-21/NN	dobj||generates-18/VBZ||roughening-22/NN	det||restorativematerial-26/NN||the-24/DT	amod||restorativematerial-26/NN||considered-25/JJ	prep_on||roughening-22/NN||restorativematerial-26/NN	advmod||expected-31/VBN||thus-29/RB	auxpass||expected-31/VBN||is-30/VBZ	ccomp||learn-10/VB||expected-31/VBN	conj_and||generates-18/VBZ||expected-31/VBN	aux||provide-33/VB||to-32/TO	xcomp||expected-31/VBN||provide-33/VB	det||rate-36/NN||the-34/DT	amod||rate-36/NN||lowest-35/JJS	dobj||provide-33/VB||rate-36/NN	amod||growth-40/NN||bacterial-38/JJ	nn||growth-40/NN||biofilm-39/NN	prep_of||rate-36/NN||growth-40/NN	prep_of||rate-36/NN||dentalplaqueformation-42/NN	conj_and||growth-40/NN||dentalplaqueformation-42/NN	dentalplaqueformation-42||restorativematerial-26||no_rel||for the dental practitioner it is of interest to learn that use of glycine in air polishing generates the least surface roughening on the considered restorativematerial, and thus is expected to provide the lowest rate of bacterial biofilm growth and dentalplaqueformation.
nsubj||worse-18/JJR||aureus-1/NN	appos||aureus-1/NN||mrsa-3/NNP	nsubj||increasing-7/VBG||infection-5/NN	aux||increasing-7/VBG||are-6/VBP	rcmod||aureus-1/NN||increasing-7/VBG	nn||outcomes-10/NNS||treatment-9/NN	conj_and||aureus-1/NN||outcomes-10/NNS	nsubj||worse-18/JJR||outcomes-10/NNS	prep_for||outcomes-10/NNS||bacteraemia-12/NN	vmod||bacteraemia-12/NN||caused-13/VBN	agent||caused-13/VBN||mrsa-15/NN	cop||worse-18/JJR||are-16/VBP	advmod||worse-18/JJR||generally-17/RB	root||ROOT-0/null||worse-18/JJR	mark||observed-21/VBD||than-19/IN	nsubj||observed-21/VBD||those-20/DT	ccomp||worse-18/JJR||observed-21/VBD	amod||s-24/NNS||methicillin-susceptible-23/JJ	prep_with||observed-21/VBD||s-24/NNS	mrsa-15||methicillin--1||no_rel||aureus (mrsa) infection are increasing and treatment outcomes for bacteraemia caused by mrsa are generally worse than those observed with methicillin-susceptible s .
det||design-6/NN||a-2/DT	amod||design-6/NN||double-blinded-3/JJ	amod||design-6/NN||randomized-4/JJ	nn||design-6/NN||crossover-5/NN	prep_in||examined-12/VBN||design-6/NN	amod||function-10/NN||postprandial-8/JJ	amod||function-10/NN||endothelial-9/JJ	nsubjpass||examined-12/VBN||function-10/NN	auxpass||examined-12/VBN||was-11/VBD	root||ROOT-0/null||examined-12/VBN	num||individuals-15/NNS||28-14/CD	prep_in||examined-12/VBN||individuals-15/NNS	amod||type2diabetes-20/NNS||impairedglucosetolerance-17/JJ	conj_or||impairedglucosetolerance-17/JJ||recent-onset-19/JJ	amod||type2diabetes-20/NNS||recent-onset-19/JJ	prep_with||individuals-15/NNS||type2diabetes-20/NNS	det||injection-24/NN||a-22/DT	amod||injection-24/NN||single-23/JJ	prep_after||examined-12/VBN||injection-24/NN	prep_of||injection-24/NN||exenatide-26/NN	prep_of||injection-24/NN||placebo-28/NN	conj_or||exenatide-26/NN||placebo-28/NN	vmod||injection-24/NN||given-29/VBN	advmod||given-29/VBN||just-30/RB	det||meal-34/NN||a-32/DT	amod||meal-34/NN||high-fat-33/JJ	prep_before||given-29/VBN||meal-34/NN	type2diabetes-20||fat--1||no_rel||in a double-blinded randomized crossover design, postprandial endothelial function was examined in 28 individuals with impairedglucosetolerance or recent-onset type2diabetes after a single injection of exenatide or placebo given just before a high-fat meal.
det||study-3/NN||this-2/DT	prep_in||found-6/VBD||study-3/NN	nsubj||found-6/VBD||we-5/PRP	root||ROOT-0/null||found-6/VBD	mark||isolates-11/VBZ||that-7/IN	amod||s.aureus-10/NNS||many-8/JJ	amod||s.aureus-10/NNS||bovine-9/JJ	nsubj||isolates-11/VBZ||s.aureus-10/NNS	ccomp||found-6/VBD||isolates-11/VBZ	dep||isolates-11/VBZ||including-13/VBG	det||strain-16/NN||the-14/DT	amod||strain-16/NN||rf122-15/JJ	pobj||including-13/VBG||strain-16/NN	dep||isolates-11/VBZ||generate-18/VB	amod||amounts-20/NNS||dramatic-19/JJ	dobj||generate-18/VB||amounts-20/NNS	nn||±-23/NNS||î-22/NN	prep_of||amounts-20/NNS||±-23/NNS	dep||amounts-20/NNS||toxin-25/NN	prep_in||toxin-25/NN||vitro-27/NNP	prepc_compared_with||generate-18/VB||with-29/IN	amod||s.aureus-32/NNS||human-30/JJ	amod||s.aureus-32/NNS||clinical-31/JJ	pobj||generate-18/VB||s.aureus-32/NNS	dep||s.aureus-32/NNS||isolates-33/VBZ	nn||wcuh29-37/NNS||mrsa-36/NN	prep_including||s.aureus-32/NNS||wcuh29-37/NNS	nn||usa300-40/NNS||mrsa-39/NN	prep_including||s.aureus-32/NNS||usa300-40/NNS	conj_and||wcuh29-37/NNS||usa300-40/NNS	mrsa-39||s.aureus-32||no||in this study , we found that many bovine s.aureus isolates , including the rf122 strain , generate dramatic amounts of î ± - toxin in vitro compared with human clinical s.aureus isolates , including mrsa wcuh29 and mrsa usa300 .
nsubjpass||treated-27/VBN||individuals-1/NNS	dep||individuals-1/NNS||n-3/VBN	dep||113-5/CD||=-4/SYM	ccomp||n-3/VBN||113-5/CD	amod||depressivedisorder-22/NN||dsm-iv-8/JJ	amod||manual-13/NN||diagnostic-10/JJ	conj_and||diagnostic-10/JJ||statistical-12/JJ	amod||manual-13/NN||statistical-12/JJ	dep||dsm-iv-8/JJ||manual-13/NN	amod||disorders-16/NNS||mental-15/JJ	prep_of||manual-13/NN||disorders-16/NNS	amod||edition-19/NN||fourth-18/JJ	appos||disorders-16/NNS||edition-19/NN	amod||depressivedisorder-22/NN||major-21/JJ	prep_with||individuals-1/NNS||depressivedisorder-22/NN	appos||depressivedisorder-22/NN||mdd-24/NN	auxpass||treated-27/VBN||were-26/VBD	root||ROOT-0/null||treated-27/VBN	prep_with||treated-27/VBN||escitalopram-29/NN	appos||escitalopram-29/NN||esc-31/NN	prep_with||treated-27/VBN||venlafaxine-34/NN	conj_or||escitalopram-29/NN||venlafaxine-34/NN	appos||escitalopram-29/NN||ven-36/NN	num||weeks-40/NNS||8-39/CD	prep_over||treated-27/VBN||weeks-40/NNS	depressivedisorder-22||venlafaxine-34||yes||individuals ( n =113) with dsm-iv (diagnostic and statistical manual of mental disorders, fourth edition) major depressivedisorder (mdd) were treated with escitalopram (esc) or venlafaxine (ven) over 8 weeks.
amod||trials-4/NNS||twenty-five-1/JJ	amod||trials-4/NNS||completed-2/VBN	amod||trials-4/NNS||randomized-3/JJ	nsubjpass||included-12/VBN||trials-4/NNS	nsubj||cilostazol-37/VBP||trials-4/NNS	num||patients-7/NNS||17,383-6/CD	dep||trials-4/NNS||patients-7/NNS	prep_with||patients-7/NNS||ihd-9/NN	auxpass||included-12/VBN||were-11/VBD	root||ROOT-0/null||included-12/VBN	nsubj||involving-14/VBG||which-13/WDT	ccomp||included-12/VBN||involving-14/VBG	det||use-16/NN||the-15/DT	nsubj||clopidogrel-35/JJ||use-16/NN	amod||inhibitors-24/NNS||intravenous-18/JJ	appos||inhibitors-24/NNS||iv-20/NN	amod||inhibitors-24/NNS||gp-22/JJ	nn||inhibitors-24/NNS||iib/iiia-23/NNP	prep_of||use-16/NN||inhibitors-24/NNS	nn||tirofiban-30/NN||abciximab-26/NN	dep||tirofiban-30/NN||eptifibatide-28/NN	appos||use-16/NN||tirofiban-30/NN	appos||use-16/NN||aspirin-33/NN	xcomp||involving-14/VBG||clopidogrel-35/JJ	conj_and/or||included-12/VBN||cilostazol-37/VBP	ihd-9||eptifibatide-28||yes||twenty-five completed randomized trials (17,383 patients with ihd) were included which involving the use of intravenous (iv) gp iib/iiia inhibitors (abciximab, eptifibatide, tirofiban), aspirin, clopidogrel and/or cilostazol.
amod||infection-5/NNS||humantcelllymphotropicvirustype1-1/JJ	dep||infection-5/NNS||htlv-1-3/JJ	nsubj||lead-7/VB||infection-5/NNS	aux||lead-7/VB||can-6/MD	root||ROOT-0/null||lead-7/VB	prep_to||lead-7/VB||development-9/NN	amod||leukemia/lymphoma-14/NN||adult-11/JJ	nn||leukemia/lymphoma-14/NN||t-12/NN	nn||leukemia/lymphoma-14/NN||cell-13/NN	prep_of||development-9/NN||leukemia/lymphoma-14/NN	appos||leukemia/lymphoma-14/NN||atl-16/NN	amod||tropicalspasticparaparesis-21/NNS||htlv-1-associatedmyelopathy-19/JJ	amod||tropicalspasticparaparesis-21/NNS||/-20/JJ	prep_of||development-9/NN||tropicalspasticparaparesis-21/NNS	conj_or||leukemia/lymphoma-14/NN||tropicalspasticparaparesis-21/NNS	appos||leukemia/lymphoma-14/NN||ham/tsp-23/NN	det||subset-27/NN||a-26/DT	prep_in||lead-7/VB||subset-27/NN	amod||subjects-30/NNS||infected-29/JJ	prep_of||subset-27/NN||subjects-30/NNS	htlv-1-associatedmyelopathy-19||htlv-1-3||no||humantcelllymphotropicvirustype1 (htlv-1) infection can lead to development of adult t cell leukemia/lymphoma (atl) or htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) in a subset of infected subjects.
nsubj||improve-14/VB||control-1/NN	prep_of||control-1/NN||pain-3/NN	vmod||pain-3/NN||associated-4/VBN	prep_with||associated-4/VBN||bonetumors-6/NNS	prep_such_as||bonetumors-6/NNS||chondrosarcoma-9/NN	prep_such_as||bonetumors-6/NNS||chondroma-11/NN	conj_and||chondrosarcoma-9/NN||chondroma-11/NN	aux||improve-14/VB||may-12/MD	advmod||improve-14/VB||significantly-13/RB	root||ROOT-0/null||improve-14/VB	prep_from||improve-14/VB||use-16/NN	prep_of||use-16/NN||zoledronicacid-18/NN	advmod||improve-14/VB||independently-20/RB	nn||response-23/NN||tumor-22/NN	prep_from||improve-14/VB||response-23/NN	amod||treatments-26/NNS||other-25/JJ	prep_to||improve-14/VB||treatments-26/NNS	bonetumors-6||zoledronicacid-18||yes||control of pain associated with bonetumors such as chondrosarcoma and chondroma may significantly improve from use of zoledronicacid, independently from tumor response to other treatments.
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBD||study-2/NN	nsubj||investigate-5/VB||study-2/NN	root||ROOT-0/null||aimed-3/VBD	aux||investigate-5/VB||to-4/TO	xcomp||aimed-3/VBD||investigate-5/VB	mark||inhibit-18/VB||whether-6/IN	nsubj||inhibit-18/VB||downregulation-7/NN	nsubj||increase-24/VB||downregulation-7/NN	nsubj||cisplatin-27/VB||downregulation-7/NN	prep_of||downregulation-7/NN||erk1/2-9/NNS	prep_by||erk1/2-9/NNS||sirna-11/NN	amod||rna-15/NN||small-13/JJ	amod||rna-15/NN||interfering-14/JJ	appos||sirna-11/NN||rna-15/NN	aux||inhibit-18/VB||could-17/MD	ccomp||investigate-5/VB||inhibit-18/VB	nn||proliferation-20/NN||cell-19/NN	dobj||inhibit-18/VB||proliferation-20/NN	dobj||inhibit-18/VB||invasion-22/NN	conj_and||proliferation-20/NN||invasion-22/NN	ccomp||investigate-5/VB||increase-24/VB	conj_and||inhibit-18/VB||increase-24/VB	advmod||increase-24/VB||chemosensitivity-25/RB	aux||cisplatin-27/VB||to-26/TO	xcomp||increase-24/VB||cisplatin-27/VB	amod||cells-32/NNS||human-29/JJ	amod||cells-32/NNS||osteosarcoma-30/JJ	amod||cells-32/NNS||u2-os-31/JJ	prep_in||cisplatin-27/VB||cells-32/NNS	prep_in||cells-32/NNS||vitro-34/NNP	osteosarcoma-30||cisplatin-27||yes||this study aimed to investigate whether downregulation of erk1/2 by sirna (small interfering rna) could inhibit cell proliferation and invasion and increase chemosensitivity to cisplatin in human osteosarcoma u2-os cells in vitro .
det||drugs-3/NNS||the-1/DT	amod||drugs-3/NNS||adjuvant-2/JJ	nsubj||effective-16/JJ||drugs-3/NNS	dep||drugs-3/NNS||ketamine-5/JJ	dep||drugs-3/NNS||ntg-7/JJ	conj_or||ketamine-5/JJ||ntg-7/JJ	advmod||added-10/VBD||when-9/WRB	rcmod||drugs-3/NNS||added-10/VBD	aux||lidocaine-12/VB||to-11/TO	xcomp||added-10/VBD||lidocaine-12/VB	prep_in||lidocaine-12/VB||ivra-14/NN	cop||effective-16/JJ||were-15/VBD	root||ROOT-0/null||effective-16/JJ	prepc_in||effective-16/JJ||improving-18/VBG	det||quality-21/NN||the-19/DT	amod||quality-21/NN||overall-20/JJ	dobj||improving-18/VBG||quality-21/NN	prep_of||quality-21/NN||anesthesia-23/NN	prepc_in||effective-16/JJ||reducing-25/VBG	conj_and||improving-18/VBG||reducing-25/VBG	amod||pain-27/NN||tourniquet-26/JJ	dobj||reducing-25/VBG||pain-27/NN	prepc_in||effective-16/JJ||increasing-29/VBG	conj_and||improving-18/VBG||increasing-29/VBG	amod||tolerance-31/NN||tourniquet-30/JJ	dobj||increasing-29/VBG||tolerance-31/NN	prepc_in||effective-16/JJ||improving-33/VBG	conj_and||improving-18/VBG||improving-33/VBG	det||analgesia-36/NN||the-34/DT	amod||analgesia-36/NN||postoperative-35/JJ	dobj||improving-33/VBG||analgesia-36/NN	prep_in||analgesia-36/NN||comparison-38/NN	det||group-42/NN||the-40/DT	nn||group-42/NN||control-41/NN	prep_to||improving-33/VBG||group-42/NN	pain-27||ketamine-5||yes||the adjuvant drugs (ketamine or ntg) when added to lidocaine in ivra were effective in improving the overall quality of anesthesia, reducing tourniquet pain, increasing tourniquet tolerance and improving the postoperative analgesia in comparison to the control group.
nn||457-2/NNS||residue-1/NN	nsubj||malabsorption-19/NN||457-2/NNS	cop||malabsorption-19/NN||is-3/VBZ	amod||malabsorption-19/NN||important-4/JJ	det||function-7/NN||the-6/DT	prep_for||important-4/JJ||function-7/NN	prep_of||function-7/NN||sglt1-9/NN	prep_of||function-7/NN||mutation-11/NN	conj_and||sglt1-9/NN||mutation-11/NN	det||position-14/NN||this-13/DT	prep_at||important-4/JJ||position-14/NN	amod||causes-17/NNS||hsglt1-16/JJ	prep_in||position-14/NN||causes-17/NNS	amod||malabsorption-19/NN||glucose-galactose-18/JJ	root||ROOT-0/null||malabsorption-19/NN	malabsorption-19||glucose--1||no_rel||residue 457 is important for the function of sglt1 and mutation at this position in hsglt1 causes glucose-galactose malabsorption.
nsubj||one-6/CD||isoniazid-1/NN	appos||isoniazid-1/NN||inh-3/NN	cop||one-6/CD||is-5/VBZ	root||ROOT-0/null||one-6/CD	det||drugs-12/NNS||the-8/DT	amod||drugs-12/NNS||main-9/JJ	amod||drugs-12/NNS||first-10/JJ	nn||drugs-12/NNS||line-11/NN	prep_of||one-6/CD||drugs-12/NNS	vmod||drugs-12/NNS||used-13/VBN	prep_in||used-13/VBN||treatment-15/NN	prep_of||treatment-15/NN||tuberculosis-17/NNP	nsubj||result-26/VB||development-19/NN	prep_of||development-19/NN||resistance-21/NN	det||compound-24/NN||this-23/DT	prep_against||resistance-21/NN||compound-24/NN	aux||result-26/VB||can-25/MD	conj_and||one-6/CD||result-26/VB	amod||problems-29/NNS||serious-28/JJ	prep_in||result-26/VB||problems-29/NNS	nn||procedures-32/NNS||treatment-31/NN	prep_in||problems-29/NNS||procedures-32/NNS	tuberculosis-17||inh-3||yes||isoniazid (inh) is one of the main first line drugs used in treatment of tuberculosis and development of resistance against this compound can result in serious problems in treatment procedures.
csubj||humanimmunodeficiencyvirus-8/VBZ||aged-1/VBN	csubj||remained-39/VBD||aged-1/VBN	dep||old-6/JJ||>-3/RB	num||years-5/NNS||50â-4/CD	npadvmod||old-6/JJ||years-5/NNS	dep||humanimmunodeficiencyvirus-8/VBZ||old-6/JJ	root||ROOT-0/null||humanimmunodeficiencyvirus-8/VBZ	dobj||humanimmunodeficiencyvirus-8/VBZ||hiv-10/NN	nsubj||segment-16/NN||patients-12/NNS	cop||segment-16/NN||are-13/VBP	det||segment-16/NN||the-14/DT	amod||segment-16/NN||fastest-growing-15/JJ	rcmod||hiv-10/NN||segment-16/NN	det||population-20/NN||the-18/DT	amod||population-20/NN||hiv-infected-19/JJ	prep_of||segment-16/NN||population-20/NN	det||usa-23/NN||the-22/DT	prep_in||population-20/NN||usa-23/NN	amod||therapy-27/NN||antiretroviral-26/JJ	prep_despite||increased-37/VBN||therapy-27/NN	amod||disorder-31/NN||hiv-associated-29/JJ	nn||disorder-31/NN||neurocognitive-30/NN	nsubj||increased-37/VBN||disorder-31/NN	appos||disorder-31/NN||hand-33/NN	advmod||increased-37/VBN||prevalence-35/RB	aux||increased-37/VBN||has-36/VBZ	rcmod||hiv-10/NN||increased-37/VBN	conj_and||segment-16/NN||increased-37/VBN	conj_or||humanimmunodeficiencyvirus-8/VBZ||remained-39/VBD	det||same-41/JJ||the-40/DT	xcomp||remained-39/VBD||same-41/JJ	det||group-44/NN||this-43/DT	prep_among||remained-39/VBD||group-44/NN	hiv---1||humanimmunodeficiencyvirus-8||no||aged (>50â years old) humanimmunodeficiencyvirus (hiv) patients are the fastest-growing segment of the hiv-infected population in the usa and despite antiretroviral therapy, hiv-associated neurocognitive disorder (hand) prevalence has increased or remained the same among this group.
nsubj||disease-6/NN||melioidosis-1/NNS	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||a-3/DT	amod||disease-6/NN||serious-4/JJ	amod||disease-6/NN||infectious-5/JJ	root||ROOT-0/null||disease-6/NN	vmod||disease-6/NN||caused-7/VBN	det||category-10/NN||the-9/DT	agent||caused-7/VBN||category-10/NN	dep||agent-13/NN||b-11/SYM	amod||agent-13/NN||select-12/JJ	dep||category-10/NN||agent-13/NN	amod||saprophyte-16/NN||environmental-15/JJ	conj_and||disease-6/NN||saprophyte-16/NN	appos||saprophyte-16/NN||burkholderiapseudomallei-18/NNS	melioidosis-1||burkholderiapseudomallei-18||no||melioidosis is a serious infectious disease caused by the category b select agent and environmental saprophyte, burkholderiapseudomallei .
amod||analysis-6/NN||subsequent-2/JJ	amod||analysis-6/NN||multivariate-3/JJ	amod||analysis-6/NN||linear-4/JJ	nn||analysis-6/NN||regression-5/NN	prep_on||associated-22/VBN||analysis-6/NN	nn||duration-9/NN||transplant-8/NN	nsubjpass||associated-22/VBN||duration-9/NN	amod||angiography-12/NN||coronary-11/JJ	prep_before||duration-9/NN||angiography-12/NN	nn||use-15/NN||statin-14/NN	prep_before||duration-9/NN||use-15/NN	conj_and||angiography-12/NN||use-15/NN	nn||fraction-19/NN||ejection-18/NN	prep_before||duration-9/NN||fraction-19/NN	conj_and||angiography-12/NN||fraction-19/NN	auxpass||associated-22/VBN||were-20/VBD	advmod||associated-22/VBN||independently-21/RB	root||ROOT-0/null||associated-22/VBN	det||severity-25/NN||the-24/DT	prep_with||associated-22/VBN||severity-25/NN	prep_of||severity-25/NN||coronaryatherosclerosis-27/NNS	amod||patients-32/NNS||long-term-29/JJ	nn||patients-32/NNS||kidney-30/NN	nn||patients-32/NNS||transplant-31/NN	prep_in||coronaryatherosclerosis-27/NNS||patients-32/NNS	statin-14||coronaryatherosclerosis-27||no_rel||on subsequent multivariate linear regression analysis, transplant duration before coronary angiography, statin use, and ejection fraction were independently associated with the severity of coronaryatherosclerosis in long-term kidney transplant patients.
nn||granulomas-5/NNS||tuberculosis-1/NNP	appos||granulomas-5/NNS||tb-3/NN	nsubj||collections-8/NNS||granulomas-5/NNS	cop||collections-8/NNS||are-6/VBP	amod||collections-8/NNS||organized-7/VBN	root||ROOT-0/null||collections-8/NNS	amod||cells-11/NNS||immune-10/JJ	prep_of||collections-8/NNS||cells-11/NNS	vmod||cells-11/NNS||comprised-12/VBN	prep_of||comprised-12/VBN||macrophages-14/NNS	prep_of||comprised-12/VBN||lymphocytes-16/NNS	conj_and||macrophages-14/NNS||lymphocytes-16/NNS	amod||cells-19/NNS||other-18/JJ	prep_of||comprised-12/VBN||cells-19/NNS	conj_and||macrophages-14/NNS||cells-19/NNS	nsubj||form-21/VBP||cells-19/NNS	rcmod||cells-19/NNS||form-21/VBP	det||lung-24/NN||the-23/DT	prep_in||form-21/VBP||lung-24/NN	det||result-27/NN||a-26/DT	prep_as||lung-24/NN||result-27/NN	amod||response-30/NN||immune-29/JJ	prep_of||result-27/NN||response-30/NN	nn||infection-36/NN||mycobacteriumtuberculosis-32/NNP	appos||infection-36/NN||mtb-34/NN	prep_to||form-21/VBP||infection-36/NN	tb-3||mycobacteriumtuberculosis-32||no||tuberculosis (tb) granulomas are organized collections of immune cells comprised of macrophages, lymphocytes and other cells that form in the lung as a result of immune response to mycobacteriumtuberculosis (mtb) infection.
det||imbalance-2/NN||this-1/DT	nsubj||have-10/VB||imbalance-2/NN	prepc_of||imbalance-2/NN||treg-4/VBG	dobj||treg-4/VBG||cells-5/NNS	amod||cells-8/NNS||th17-7/JJ	prep_to||treg-4/VBG||cells-8/NNS	aux||have-10/VB||might-9/MD	root||ROOT-0/null||have-10/VB	det||role-13/NN||an-11/DT	amod||role-13/NN||important-12/JJ	dobj||have-10/VB||role-13/NN	nn||persistence-16/NN||hbv-15/NN	prep_in||role-13/NN||persistence-16/NN	nn||treatment-19/NN||entecavir-18/NN	prep_during||have-10/VB||treatment-19/NN	hbv-15||entecavir-18||yes||this imbalance of treg cells to th17 cells might have an important role in hbv persistence during entecavir treatment.
poss||results-2/NNS||our-1/PRP$	nsubj||showed-3/VBD||results-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||inhibited-7/VBD||that-4/IN	nsubj||inhibited-7/VBD||anthocyanins-5/NNS	advmod||inhibited-7/VBD||significantly-6/RB	ccomp||showed-3/VBD||inhibited-7/VBD	amod||mediators-10/NNS||lps-induced-8/JJ	amod||mediators-10/NNS||pro-inflammatory-9/JJ	dobj||inhibited-7/VBD||mediators-10/NNS	prep_such_as||mediators-10/NNS||nitricoxide-14/NN	discourse||nitricoxide-14/NN||no-16/UH	prep_such_as||mediators-10/NNS||prostaglandine2-19/NNS	conj_and||nitricoxide-14/NN||prostaglandine2-19/NNS	amod||cytokines-23/NNS||pro-inflammatory-22/JJ	nsubj||necrosis-26/VBZ||cytokines-23/NNS	prep_including||cytokines-23/NNS||tumor-25/NN	conj_and||showed-3/VBD||necrosis-26/VBZ	dobj||necrosis-26/VBZ||factor-27/NN	appos||factor-27/NN||tnf-29/NN	nn||±-33/NN||î-32/NN	dep||factor-27/NN||±-33/NN	dep||factor-27/NN||interleukin-35/NN	conj_and||±-33/NN||interleukin-35/NN	appos||±-33/NN||il-37/NN	num||²-41/NNS||-1-39/CD	nn||²-41/NNS||î-40/NN	dep||±-33/NN||²-41/NNS	amod||cytotoxicity-45/NN||significant-44/JJ	prep_without||necrosis-26/VBZ||cytotoxicity-45/NN	tumor-25||prostaglandine2-19||no_rel||our results showed that anthocyanins significantly inhibited lps-induced pro-inflammatory mediators, such as nitricoxide (no) and prostaglandine2, and pro-inflammatory cytokines including tumor necrosis factor (tnf)-î± and interleukin (il)-1î², without significant cytotoxicity.
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-2/PRP	advmod||investigated-4/VBD||further-3/RBR	root||ROOT-0/null||investigated-4/VBD	nn||toxicity-6/NN||dieldrin-5/NN	dobj||investigated-4/VBD||toxicity-6/NN	det||model-12/NN||a-8/DT	amod||model-12/NN||dopaminergic-9/JJ	amod||model-12/NN||neuronal-10/JJ	nn||model-12/NN||cell-11/NN	prep_in||investigated-4/VBD||model-12/NN	amod||cells-20/NNS||parkinson-14/JJ	nn||cells-20/NNS||sdisease-16/NNP	advmod||cells-20/NNS||namely-18/RB	amod||cells-20/NNS||n27-19/JJ	prep_of||model-12/NN||cells-20/NNS	vmod||investigated-4/VBD||using-22/VBG	dep||cytometric-29/JJ||biochemical-23/JJ	conj_and||cytometric-29/JJ||immunochemical-25/JJ	amod||analyses-30/NNS||immunochemical-25/JJ	conj_and||cytometric-29/JJ||flow-28/NN	amod||analyses-30/NNS||flow-28/NN	amod||analyses-30/NNS||cytometric-29/JJ	dobj||using-22/VBG||analyses-30/NNS	dopaminergic-9||parkinson'sdisease--1||no_rel||here we further investigated dieldrin toxicity in a dopaminergic neuronal cell model of parkinson'sdisease, namely n27 cells, using biochemical, immunochemical, and flow cytometric analyses.
poss||study-2/NN||our-1/PRP$	nsubj||demonstrated-3/VBD||study-2/NN	nsubj||find-17/VB||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	amod||incidence-5/NN||increased-4/VBN	dobj||demonstrated-3/VBD||incidence-5/NN	amod||pancreatitis-8/NNS||acute-7/JJ	prep_of||incidence-5/NN||pancreatitis-8/NNS	prep_in||pancreatitis-8/NNS||diabetic-10/NN	amod||patients-13/NNS||nondiabetic-12/JJ	prep_versus||diabetic-10/NN||patients-13/NNS	aux||find-17/VB||did-15/VBD	neg||find-17/VB||not-16/RB	conj_but||demonstrated-3/VBD||find-17/VB	det||association-19/NN||an-18/DT	dobj||find-17/VB||association-19/NN	det||use-22/NN||the-21/DT	prep_between||association-19/NN||use-22/NN	dep||sitagliptin-26/JJ||exenatide-24/JJ	amod||pancreatitis-29/NNS||sitagliptin-26/JJ	conj_and||sitagliptin-26/JJ||acute-28/JJ	amod||pancreatitis-29/NNS||acute-28/JJ	prep_of||use-22/NN||pancreatitis-29/NNS	pancreatitis-29||exenatide-24||no_rel||our study demonstrated increased incidence of acute pancreatitis in diabetic versus nondiabetic patients but did not find an association between the use of exenatide or sitagliptin and acute pancreatitis.
det||study-6/NN||the-1/DT	amod||study-6/NN||alpha-tocopherol-2/JJ	amod||study-6/NN||beta-carotene-3/JJ	nn||study-6/NN||cancer-4/NN	nn||study-6/NN||prevention-5/NN	nsubj||examined-7/VBD||study-6/NN	root||ROOT-0/null||examined-7/VBD	det||effects-9/NNS||the-8/DT	dobj||examined-7/VBD||effects-9/NNS	amod||carotene-22/NN||vitamine-11/JJ	num||mg-14/NN||50-13/CD	dep||vitamine-11/JJ||mg-14/NN	prep_per||mg-14/NN||day-16/NN	npadvmod||²-20/JJ||î-19/NN	conj_and||vitamine-11/JJ||²-20/JJ	amod||carotene-22/NN||²-20/JJ	prep_of||effects-9/NNS||carotene-22/NN	num||mg-25/NN||20-24/CD	dep||carotene-22/NN||mg-25/NN	prep_per||mg-25/NN||day-27/NN	nn||cancer-31/NN||lung-30/NN	prep_on||examined-7/VBD||cancer-31/NN	num||smokers-35/NNS||29,133-33/CD	amod||smokers-35/NNS||male-34/JJ	prep_in||cancer-31/NN||smokers-35/NNS	vmod||smokers-35/NNS||aged-36/VBN	xcomp||aged-36/VBN||50â-37/VBG	num||years-41/NNS||$-38/$	num||$-38/$||69-40/CD	tmod||50â-37/VBG||years-41/NNS	vmod||50â-37/VBG||using-42/VBG	det||ã-45/NN||a-43/DT	num||ã-45/NN||2-44/CD	dobj||using-42/VBG||ã-45/NN	num||design-49/NN||2-47/CD	amod||design-49/NN||factorial-48/JJ	dep||ã-45/NN||design-49/NN	cancer-31||vitamine-11||no_rel||the alpha-tocopherol beta-carotene cancer prevention study examined the effects of vitamine (50 mg per day) and î²-carotene (20 mg per day) on lung cancer in 29,133 male smokers aged 50â€“69 years using a 2 ã— 2 factorial design.
aux||prevent-2/VB||to-1/TO	advcl||added-23/VBN||prevent-2/VB	dobj||prevent-2/VB||hyperinsulinemia-3/NN	nsubj||cause-7/VB||hyperinsulinemia-3/NN	aux||cause-7/VB||may-6/MD	rcmod||hyperinsulinemia-3/NN||cause-7/VB	dobj||cause-7/VB||atherosclerosis-8/NNS	nsubjpass||added-23/VBN||thiazolidinediones-10/NNS	appos||thiazolidinediones-10/NNS||tzds-12/NNS	advmod||known-16/VBN||also-15/RB	vmod||thiazolidinediones-10/NNS||known-16/VBN	nn||sensitizers-19/NNS||insulin-18/NN	prep_as||known-16/VBN||sensitizers-19/NNS	auxpass||added-23/VBN||are-21/VBP	advmod||added-23/VBN||often-22/RB	root||ROOT-0/null||added-23/VBN	det||regimen-27/NN||the-25/DT	amod||regimen-27/NN||therapeutic-26/JJ	prep_to||added-23/VBN||regimen-27/NN	prep_of||regimen-27/NN||patients-29/NNS	prep_with||added-23/VBN||type2diabetes-31/NNS	nsubj||receiving-34/VBG||type2diabetes-31/NNS	aux||receiving-34/VBG||are-33/VBP	rcmod||type2diabetes-31/NNS||receiving-34/VBG	dobj||receiving-34/VBG||insulin-35/NN	type2diabetes-31||insulin-35||yes||to prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (tzds), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type2diabetes who are receiving insulin.
amod||approaches-3/NNS||available-1/JJ	amod||approaches-3/NNS||automated-2/JJ	nsubj||make-11/VBP||approaches-3/NNS	det||selection-6/NN||the-5/DT	prep_to||approaches-3/NNS||selection-6/NN	amod||data-10/NNS||influenza-8/JJ	amod||data-10/NNS||genetic-9/JJ	prep_of||selection-6/NN||data-10/NNS	root||ROOT-0/null||make-11/VBP	det||tradeoff-13/NN||a-12/DT	dobj||make-11/VBP||tradeoff-13/NN	prep_between||tradeoff-13/NN||speed-15/NN	prep_between||tradeoff-13/NN||simplicity-17/NN	conj_and||speed-15/NN||simplicity-17/NN	det||hand-21/NN||the-19/DT	num||hand-21/NN||one-20/CD	prep_on||tradeoff-13/NN||hand-21/NN	dobj||make-11/VBP||control-23/NN	conj_and||tradeoff-13/NN||control-23/NN	prep_over||control-23/NN||quality-25/NN	prep_over||control-23/NN||contents-27/NNS	conj_and||quality-25/NN||contents-27/NNS	det||dataset-30/NN||the-29/DT	prep_of||control-23/NN||dataset-30/NN	det||hand-34/NN||the-32/DT	amod||hand-34/NN||other-33/JJ	prep_on||dataset-30/NN||hand-34/NN	speed-15||influenza-8||no_rel||available automated approaches to the selection of influenza genetic data make a tradeoff between speed and simplicity on the one hand and control over quality and contents of the dataset on the other hand.
advmod||discuss-4/VB||specifically-1/RB	nsubj||discuss-4/VB||we-3/PRP	nsubj||putative-42/VB||we-3/PRP	root||ROOT-0/null||discuss-4/VB	det||views-6/NNS||these-5/DT	dobj||discuss-4/VB||views-6/NNS	det||context-9/NN||the-8/DT	prep_in||discuss-4/VB||context-9/NN	det||relationship-13/NN||the-11/DT	amod||relationship-13/NN||structure-function-12/JJ	prep_of||context-9/NN||relationship-13/NN	prep_of||relationship-13/NN||chromatin-15/NN	det||ratio-19/NN||the-17/DT	nn||ratio-19/NN||cddna/ncddna-18/NN	prep_of||relationship-13/NN||ratio-19/NN	conj_and||chromatin-15/NN||ratio-19/NN	amod||divergence-24/NN||possible-22/JJ	nn||divergence-24/NN||nucleotide-23/NN	prep_of||relationship-13/NN||divergence-24/NN	conj_and||chromatin-15/NN||divergence-24/NN	det||regions-28/NNS||the-26/DT	amod||regions-28/NNS||untranslated-27/JJ	prep_in||discuss-4/VB||regions-28/NNS	appos||regions-28/NNS||utrs-30/NNS	amod||intronic-35/NN||mature-33/JJ	nn||intronic-35/NN||mrna-34/NN	prep_of||regions-28/NNS||intronic-35/NN	amod||sequences-39/NNS||intergenic-37/JJ	nn||sequences-39/NNS||dna-38/NN	prep_of||regions-28/NNS||sequences-39/NNS	conj_and||intronic-35/NN||sequences-39/NNS	conj_and||discuss-4/VB||putative-42/VB	amod||consequences-44/NNS||catastrophic-43/JJ	dobj||putative-42/VB||consequences-44/NNS	amod||surveillance-47/NN||immune-46/JJ	prep_for||consequences-44/NNS||surveillance-47/NN	det||preservation-50/NN||the-49/DT	dobj||putative-42/VB||preservation-50/NN	conj_and||consequences-44/NNS||preservation-50/NN	prep_of||preservation-50/NN||health-52/NN	prep_in||putative-42/VB||hiv/aids-54/NNS	aids--1||hiv--1||no||specifically, we discuss these views in the context of the structure-function relationship of chromatin, the cddna/ncddna ratio, and possible nucleotide divergence in the untranslated regions (utrs) of mature mrna intronic and intergenic dna sequences, and putative catastrophic consequences for immune surveillance and the preservation of health in hiv/aids.
amod||infection-2/NN||chronic-1/JJ	nsubjpass||associated-9/VBN||infection-2/NN	prep_with||infection-2/NN||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	auxpass||associated-9/VBN||is-8/VBZ	root||ROOT-0/null||associated-9/VBN	det||majority-12/NN||the-11/DT	prep_with||associated-9/VBN||majority-12/NN	prep_of||majority-12/NN||cases-14/NNS	prep_of||cases-14/NNS||livercirrhosis-16/NNS	appos||livercirrhosis-16/NNS||lc-18/NN	prep_in||livercirrhosis-16/NNS||china-21/NN	hbv-6||hepatitisbvirus-4||no||chronic infection with hepatitisbvirus (hbv) is associated with the majority of cases of livercirrhosis (lc) in china.
amod||investigation-2/NN||further-1/JJ	nsubj||lead-12/VB||investigation-2/NN	nsubj||facilitate-23/VB||investigation-2/NN	det||sets-6/NNS||the-4/DT	amod||sets-6/NNS||distinct-5/JJ	prep_of||investigation-2/NN||sets-6/NNS	prep_of||sets-6/NNS||mutations-8/NNS	prep_of||sets-6/NNS||gis-10/NN	conj_and||mutations-8/NNS||gis-10/NN	aux||lead-12/VB||will-11/MD	root||ROOT-0/null||lead-12/VB	nn||insights-15/NNS||novel-14/NN	prep_to||lead-12/VB||insights-15/NNS	amod||evolution-18/NN||genomic-17/JJ	prep_into||lead-12/VB||evolution-18/NN	prep_of||evolution-18/NN||salmonella-20/NN	advmod||facilitate-23/VB||greatly-22/RB	conj_and||lead-12/VB||facilitate-23/VB	det||elucidation-25/NN||the-24/DT	dobj||facilitate-23/VB||elucidation-25/NN	prep_of||elucidation-25/NN||pathogeneses-27/NNS	prep_of||pathogeneses-27/NNS||salmonellainfections-29/NNS	salmonellainfections-29||salmonella-20||no||further investigation of the distinct sets of mutations and gis will lead to novel insights into genomic evolution of salmonella and greatly facilitate the elucidation of pathogeneses of salmonellainfections.
det||report-2/NN||this-1/DT	nsubj||discusses-3/VBZ||report-2/NN	root||ROOT-0/null||discusses-3/VBZ	det||case-5/NN||a-4/DT	dobj||discusses-3/VBZ||case-5/NN	amod||psychosis-8/NNS||acute-7/JJ	prep_of||case-5/NN||psychosis-8/NNS	prep_of||case-5/NN||enuresis-10/NNS	conj_and||psychosis-8/NNS||enuresis-10/NNS	det||alcohol-19/NN||a-12/DT	amod||alcohol-19/NN||patient-13/JJ	prep_on||patient-13/JJ||disulfiram-15/NN	nsubj||ingested-18/VBN||disulfiram-15/NN	aux||ingested-18/VBN||had-17/VBD	rcmod||disulfiram-15/NN||ingested-18/VBN	prep_in||case-5/NN||alcohol-19/NN	enuresis-10||disulfiram-15||no_rel||this report discusses a case of acute psychosis and enuresis in a patient on disulfiram who had ingested alcohol.
nsubj||continues-4/VBZ||background-1/NN	nsubj||commit-6/VB||background-1/NN	prep_as||background-1/NN||china-3/NN	ccomp||become-23/VBN||continues-4/VBZ	aux||commit-6/VB||to-5/TO	xcomp||continues-4/VBZ||commit-6/VB	amod||access-9/NN||universal-8/JJ	prep_to||commit-6/VB||access-9/NN	amod||services-17/NNS||hiv/aids-11/JJ	nn||services-17/NNS||prevention-12/NN	conj_and||prevention-12/NN||treatment-14/NN	nn||services-17/NNS||treatment-14/NN	conj_and||prevention-12/NN||care-16/NN	nn||services-17/NNS||care-16/NN	prep_to||commit-6/VB||services-17/NNS	poss||policies-21/NNS||its-19/PRP$	amod||policies-21/NNS||hiv/aids-20/JJ	nsubj||become-23/VBN||policies-21/NNS	aux||become-23/VBN||have-22/VBP	root||ROOT-0/null||become-23/VBN	advmod||information-25/NN||increasingly-24/RB	xcomp||become-23/VBN||information-25/NN	vmod||information-25/NN||driven-26/VBN	aids--1||hiv--1||no||background as china continues to commit to universal access to hiv/aids prevention, treatment and care services, its hiv/aids policies have become increasingly information driven.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tuberculosis-28||inh-14||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
nsubj||improve-20/VB||addition-1/NN	nsubj||increased-25/VBD||addition-1/NN	amod||cancer-17/NN||oxaliplatin-3/JJ	prep_to||oxaliplatin-3/JJ||fluoropyrimidines-5/NNS	amod||chemoradiotherapy-8/NN||preoperative-7/JJ	prep_for||fluoropyrimidines-5/NNS||chemoradiotherapy-8/NN	prep_in||chemoradiotherapy-8/NN||patients-10/NNS	nn||ii-13/NN||stage-12/NN	prep_with||patients-10/NNS||ii-13/NN	prep_with||patients-10/NNS||iii-15/NN	conj_or||ii-13/NN||iii-15/NN	amod||cancer-17/NN||rectal-16/JJ	prep_of||addition-1/NN||cancer-17/NN	aux||improve-20/VB||did-18/VBD	neg||improve-20/VB||not-19/RB	root||ROOT-0/null||improve-20/VB	amod||response-23/NN||local-21/JJ	nn||response-23/NN||tumor-22/NN	dobj||improve-20/VB||response-23/NN	conj_but||improve-20/VB||increased-25/VBD	dobj||increased-25/VBD||toxicities-26/NNS	oxaliplatin-3||cancer-17||no_rel||addition of oxaliplatin to fluoropyrimidines for preoperative chemoradiotherapy in patients with stage ii or iii rectal cancer did not improve local tumor response but increased toxicities.
aux||understand-3/VB||to-1/TO	advmod||understand-3/VB||better-2/RBR	advcl||exposed-26/VBD||understand-3/VB	det||mechanisms-7/NNS||the-4/DT	amod||mechanisms-7/NNS||cellular-5/JJ	amod||mechanisms-7/NNS||pathogenetic-6/JJ	dobj||understand-3/VB||mechanisms-7/NNS	amod||disorder-12/NN||fetal-9/JJ	nn||disorder-12/NN||alcohol-10/NN	nn||disorder-12/NN||spectrum-11/NN	prep_of||mechanisms-7/NNS||disorder-12/NN	dep||disorder-12/NN||fasd-14/VBN	det||benefit-19/NN||the-17/DT	amod||benefit-19/NN||therapeutic-18/JJ	prep_of||mechanisms-7/NNS||benefit-19/NN	conj_and||disorder-12/NN||benefit-19/NN	nn||treatment-23/NN||stem-21/NN	nn||treatment-23/NN||cell-22/NN	prep_of||benefit-19/NN||treatment-23/NN	nsubj||exposed-26/VBD||we-25/PRP	nsubj||studied-51/VBD||we-25/PRP	root||ROOT-0/null||exposed-26/VBD	amod||rats-28/NNS||pregnant-27/JJ	dobj||exposed-26/VBD||rats-28/NNS	prep_to||exposed-26/VBD||ethanol-30/NN	vmod||ethanol-30/NN||followed-31/VBN	amod||administration-34/NN||intravenous-33/JJ	agent||followed-31/VBN||administration-34/NN	amod||cells-38/NNS||neural-36/JJ	nn||cells-38/NNS||stem-37/NN	prep_of||administration-34/NN||cells-38/NNS	appos||cells-38/NNS||nscs-40/NNS	vmod||cells-38/NNS||complexed-42/VBN	prep_with||complexed-42/VBN||atelocollagen-44/NN	det||rats-49/NNS||the-46/DT	amod||rats-49/NNS||new-47/JJ	amod||rats-49/NNS||born-48/VBN	prep_to||complexed-42/VBN||rats-49/NNS	conj_and||exposed-26/VBD||studied-51/VBD	dobj||studied-51/VBD||recovery-52/NN	amod||numbers-56/NNS||gabaergic-54/JJ	nn||numbers-56/NNS||interneuron-55/NN	prep_of||recovery-52/NN||numbers-56/NNS	amod||density-60/NN||synaptic-58/JJ	nn||density-60/NN||protein-59/NN	dobj||studied-51/VBD||density-60/NN	conj_and||recovery-52/NN||density-60/NN	det||cortex-65/NN||the-62/DT	nn||cortex-65/NN||anterior-63/NN	nn||cortex-65/NN||cingulate-64/NN	prep_in||density-60/NN||cortex-65/NN	prep_in||density-60/NN||hippocampus-67/NNS	conj_and||cortex-65/NN||hippocampus-67/NNS	prep_in||density-60/NN||amygdala-69/NN	conj_and||cortex-65/NN||amygdala-69/NN	ethanol-30||fasd-14||no_rel||to better understand the cellular pathogenetic mechanisms of fetal alcohol spectrum disorder (fasd) and the therapeutic benefit of stem cell treatment, we exposed pregnant rats to ethanol followed by intravenous administration of neural stem cells (nscs) complexed with atelocollagen to the new born rats and studied recovery of gabaergic interneuron numbers and synaptic protein density in the anterior cingulate cortex, hippocampus and amygdala.
nsubjpass||analyzed-3/VBN||data-1/NNS	auxpass||analyzed-3/VBN||was-2/VBD	root||ROOT-0/null||analyzed-3/VBN	amod||regression-7/NN||multivariable-5/JJ	amod||regression-7/NN||logistic-6/JJ	agent||analyzed-3/VBN||regression-7/NN	amod||determinants-10/NNS||potential-9/JJ	prep_for||regression-7/NN||determinants-10/NNS	nn||knowledge-13/NN||clinician-12/NN	prep_of||determinants-10/NNS||knowledge-13/NN	prep_about||analyzed-3/VBN||hiv/aids-15/NNS	amod||adults-18/NNS||older-17/JJR	prep_in||hiv/aids-15/NNS||adults-18/NNS	xcomp||analyzed-3/VBN||estimating-20/VBG	poss||odds-23/NNS||their-21/PRP$	amod||odds-23/NNS||adjusted-22/JJ	dobj||estimating-20/VBG||odds-23/NNS	dep||odds-23/NNS||ratios-24/NNS	appos||ratios-24/NNS||aor-26/NN	number||%-30/NN||95-29/CD	amod||intervals-32/NNS||%-30/NN	nn||intervals-32/NNS||confidence-31/NN	dobj||estimating-20/VBG||intervals-32/NNS	conj_and||odds-23/NNS||intervals-32/NNS	num||%-35/NN||95-34/CD	npadvmod||ci-36/JJ||%-35/NN	dep||estimating-20/VBG||ci-36/JJ	vmod||estimating-20/VBG||using-38/VBG	nn||software-41/NN||stata-39/NN	num||software-41/NN||11.2-40/CD	dobj||using-38/VBG||software-41/NN	aids--1||hiv--1||no||data was analyzed by multivariable logistic regression for potential determinants of clinician knowledge about hiv/aids in older adults, estimating their adjusted odds ratios (aor) and 95% confidence intervals (95% ci) using stata 11.2 software.
advmod||investigated-4/VBD||therefore-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	xcomp||investigated-4/VBD||using-5/VBG	amod||technology-8/NN||luciferase-6/JJ	nn||technology-8/NN||immunoprecipitation-7/NN	dobj||using-5/VBG||technology-8/NN	dep||investigated-4/VBD||lips-10/VB	nn||responses-13/NNS||antibody-12/NN	dobj||investigated-4/VBD||responses-13/NNS	num||proteins-17/NNS||seven-15/CD	amod||proteins-17/NNS||htlv-i-16/JJ	prep_to||responses-13/NNS||proteins-17/NNS	amod||controls-20/NNS||non-infected-19/JJ	prep_in||proteins-17/NNS||controls-20/NNS	amod||htlv-i-carriers-23/NNS||asymptomatic-22/JJ	prep_in||proteins-17/NNS||htlv-i-carriers-23/NNS	conj_and||controls-20/NNS||htlv-i-carriers-23/NNS	prep_in||proteins-17/NNS||atll-25/NN	conj_and||controls-20/NNS||atll-25/NN	nn||samples-29/NNS||ham/tsp-27/NN	nn||samples-29/NNS||sera-28/NN	prep_in||proteins-17/NNS||samples-29/NNS	conj_and||controls-20/NNS||samples-29/NNS	antibody-12||ham--1||no_rel||therefore, we investigated using luciferase immunoprecipitation technology (lips) antibody responses to seven htlv-i proteins in non-infected controls, asymptomatic htlv-i-carriers, atll and ham/tsp sera samples.
det||earliest-3/JJS||the-2/DT	prep_among||imposition-16/NN||earliest-3/JJS	det||responses-8/NNS||the-5/DT	amod||responses-8/NNS||most-6/JJS	amod||responses-8/NNS||enduring-7/VBG	conj_and||earliest-3/JJS||responses-8/NNS	prep_among||imposition-16/NN||responses-8/NNS	det||hiv/aids-11/NNS||the-10/DT	prep_to||responses-8/NNS||hiv/aids-11/NNS	nsubj||imposition-16/NN||epidemic-12/NN	aux||imposition-16/NN||has-13/VBZ	cop||imposition-16/NN||been-14/VBN	det||imposition-16/NN||the-15/DT	root||ROOT-0/null||imposition-16/NN	prep_by||imposition-16/NN||governments-18/NNS	nn||stay-22/NN||entry-20/NN	prep_of||governments-18/NNS||stay-22/NN	nn||restrictions-26/NNS||residence-25/NN	prep_of||governments-18/NNS||restrictions-26/NNS	conj_and||stay-22/NN||restrictions-26/NNS	prep_for||imposition-16/NN||non-nationals-28/NNS	vmod||non-nationals-28/NNS||living-29/VBG	prep_with||living-29/VBG||hiv-31/NN	prep_with||living-29/VBG||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||among the earliest and the most enduring responses to the hiv/aids epidemic has been the imposition by governments of entry, stay, and residence restrictions for non-nationals living with hiv and aids.
csubj||raises-24/VBZ||encouraging-1/VBG	dobj||encouraging-1/VBG||data-2/NNS	amod||efficacy-6/NN||potential-4/JJ	nn||efficacy-6/NN||equivalent-5/NN	prep_of||data-2/NNS||efficacy-6/NN	amod||administration-9/NN||easier-8/JJR	prep_of||data-2/NNS||administration-9/NN	conj_and||efficacy-6/NN||administration-9/NN	amod||grade-13/NN||fewer-12/JJR	prep_of||data-2/NNS||grade-13/NN	conj_and||efficacy-6/NN||grade-13/NN	num||reactions-18/NNS||3-14/CD	conj_and||3-14/CD||4-16/CD	num||reactions-18/NNS||4-16/CD	amod||reactions-18/NNS||adverse-17/JJ	dep||grade-13/NN||reactions-18/NNS	prepc_compared_with||encouraging-1/VBG||with-20/IN	amod||interferon-23/NN||high-dose-21/JJ	amod||interferon-23/NN||intravenous-22/JJ	pobj||encouraging-1/VBG||interferon-23/NN	root||ROOT-0/null||raises-24/VBZ	det||question-26/NN||the-25/DT	dobj||raises-24/VBZ||question-26/NN	poss||role-30/NN||its-28/PRP$	amod||role-30/NN||potential-29/JJ	prep_of||question-26/NN||role-30/NN	nn||melanoma-34/NN||stage-32/NN	nn||melanoma-34/NN||iii-33/NN	prep_in||role-30/NN||melanoma-34/NN	det||setting-38/NN||the-36/DT	amod||setting-38/NN||adjuvant-37/JJ	prep_in||melanoma-34/NN||setting-38/NN	melanoma-34||interferon-23||yes||encouraging data of potential equivalent efficacy, easier administration, and fewer grade 3 and 4 adverse reactions compared with high-dose intravenous interferon raises the question of its potential role in stage iii melanoma in the adjuvant setting.
nsubj||drug-20/NN||doxycycline-1/NN	det||tetracycline-6/NN||a-3/DT	advmod||derived-5/JJ||synthetically-4/RB	amod||tetracycline-6/NN||derived-5/JJ	appos||doxycycline-1/NN||tetracycline-6/NN	cop||drug-20/NN||is-8/VBZ	det||drug-20/NN||a-9/DT	advmod||efficacious-11/JJ||partially-10/RB	amod||drug-20/NN||efficacious-11/JJ	amod||drug-20/NN||causal-12/JJ	nn||drug-20/NN||prophylactic-13/NN	nn||stage-16/NN||liver-15/NN	dep||drug-20/NN||stage-16/NN	prep_of||stage-16/NN||plasmodium-18/NN	root||ROOT-0/null||drug-20/NN	det||agent-27/NN||a-22/DT	amod||agent-27/NN||slow-23/JJ	amod||agent-27/NN||acting-24/JJ	nn||agent-27/NN||blood-25/NN	nn||agent-27/NN||schizontocidal-26/NN	conj_and||drug-20/NN||agent-27/NN	advmod||effective-29/JJ||highly-28/RB	amod||agent-27/NN||effective-29/JJ	det||prevention-32/NN||the-31/DT	prep_for||agent-27/NN||prevention-32/NN	prep_of||prevention-32/NN||malaria-34/NN	malaria-34||doxycycline-1||yes||doxycycline, a synthetically derived tetracycline, is a partially efficacious causal prophylactic (liver stage of plasmodium ) drug and a slow acting blood schizontocidal agent highly effective for the prevention of malaria.
nsubj||keystone-5/NN||ivermectin-1/NN	aux||keystone-5/NN||has-2/VBZ	cop||keystone-5/NN||been-3/VBN	det||keystone-5/NN||the-4/DT	root||ROOT-0/null||keystone-5/NN	amod||control-8/NN||onchocerciasis-7/JJ	prep_of||keystone-5/NN||control-8/NN	det||years-13/NNS||the-10/DT	amod||years-13/NNS||last-11/JJ	num||years-13/NNS||25-12/CD	prep_for||keystone-5/NN||years-13/NNS	onchocerciasis-7||ivermectin-1||yes||ivermectin has been the keystone of onchocerciasis control for the last 25 years.
amod||patients-2/NNS||twenty-two-1/JJ	nsubj||received-5/VBD||patients-2/NNS	nsubjpass||evaluated-12/VBN||patients-2/NNS	prep_with||patients-2/NNS||melanoma-4/NN	root||ROOT-0/null||received-5/VBD	nn||treatment-9/NN||ifn-î-6/NNP	nn||treatment-9/NN||±-7/NNP	amod||treatment-9/NN||2b-8/JJ	dobj||received-5/VBD||treatment-9/NN	auxpass||evaluated-12/VBN||were-11/VBD	conj_and||received-5/VBD||evaluated-12/VBN	amod||levels-15/NNS||treg-14/VBG	prep_for||evaluated-12/VBN||levels-15/NNS	melanoma-4||ifn--1||yes||twenty-two patients with melanoma received ifn-î± 2b treatment and were evaluated for treg levels.
det||groups-3/NNS||the-1/DT	num||groups-3/NNS||two-2/CD	nsubj||comparable-11/JJ||groups-3/NNS	dep||groups-3/NNS||dexamethasone-6/JJ	dep||groups-3/NNS||ondansetron-8/JJ	conj_and||dexamethasone-6/JJ||ondansetron-8/JJ	cop||comparable-11/JJ||were-10/VBD	root||ROOT-0/null||comparable-11/JJ	prep_in||comparable-11/JJ||outcome-13/NN	prep_in||comparable-11/JJ||terms-16/NNS	amod||nausea-19/NN||post-operative-18/JJ	prep_of||terms-16/NNS||nausea-19/NN	prep_of||terms-16/NNS||vomiting-21/NN	conj_and||nausea-19/NN||vomiting-21/NN	prep_in||terms-16/NNS||patients-24/NNS	vmod||patients-24/NNS||undergoing-25/VBG	amod||cholecystectomy-27/NN||laparoscopic-26/JJ	dobj||undergoing-25/VBG||cholecystectomy-27/NN	nausea-19||dexamethasone-6||yes||the two groups, (dexamethasone and ondansetron) were comparable in outcome, in terms of post-operative nausea and vomiting, in patients undergoing laparoscopic cholecystectomy.
amod||cases-2/NNS||culture-confirmed-1/JJ	nsubjpass||identified-23/VBN||cases-2/NNS	prep_of||cases-2/NNS||mtb-4/NN	prep_in||mtb-4/NN||children-6/NNS	num||years-9/NNS||14-8/CD	prep_under||children-6/NNS||years-9/NNS	vmod||mtb-4/NN||attending-11/VBG	num||hospitals-14/NNS||two-12/CD	amod||hospitals-14/NNS||academic-13/JJ	dobj||attending-11/VBG||hospitals-14/NNS	amod||africa-19/NN||johannesburg-16/JJ	amod||africa-19/NN||south-18/JJ	prep_in||hospitals-14/NNS||africa-19/NN	prep_during||attending-11/VBG||2008-21/CD	auxpass||identified-23/VBN||were-22/VBD	root||ROOT-0/null||identified-23/VBN	nn||records-26/NNS||hospital-25/NN	nsubjpass||reviewed-34/VBN||records-26/NNS	prep_of||records-26/NNS||children-28/NNS	vmod||children-28/NNS||diagnosed-29/VBN	amod||tb-32/NN||drug-resistant-31/JJ	prep_with||diagnosed-29/VBN||tb-32/NN	auxpass||reviewed-34/VBN||were-33/VBD	conj_and||identified-23/VBN||reviewed-34/VBN	amod||outcomes-40/NNS||clinical-37/JJ	conj_and||clinical-37/JJ||radiological-39/JJ	amod||outcomes-40/NNS||radiological-39/JJ	prep_including||reviewed-34/VBN||outcomes-40/NNS	num||post-diagnosis-46/NNS||6-42/CD	num||months-45/NNS||12-44/CD	conj_and||6-42/CD||months-45/NNS	num||post-diagnosis-46/NNS||months-45/NNS	prep_at||outcomes-40/NNS||post-diagnosis-46/NNS	tb-32||mtb-4||no||culture-confirmed cases of mtb in children under 14 years, attending two academic hospitals in johannesburg, south africa during 2008 were identified and hospital records of children diagnosed with drug-resistant tb were reviewed, including clinical and radiological outcomes at 6 and 12 months post-diagnosis.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||screened-115/VBN||study-4/NN	num||alkaloids-8/NNS||13-6/CD	amod||alkaloids-8/NNS||bromopyrrole-7/JJ	appos||study-4/NN||alkaloids-8/NNS	det||oroidin-12/NN||the-11/DT	prep_including||study-4/NN||oroidin-12/NN	rcmod||oroidin-12/NN||analogs-13/VBZ	dep||analogs-13/VBZ||hymenidin-14/VB	number||2-16/CD||-lrb--15/CD	num||-rrb--17/NNS||2-16/CD	dobj||hymenidin-14/VB||-rrb--17/NNS	dep||analogs-13/VBZ||dispacamide-19/VB	conj_and||hymenidin-14/VB||dispacamide-19/VB	dobj||dispacamide-19/VB||b-20/SYM	vmod||b-20/SYM||-lrb--21/VBG	number||-rrb--23/CD||3-22/CD	dobj||-lrb--21/VBG||-rrb--23/CD	dep||analogs-13/VBZ||dispacamide-25/VB	conj_and||hymenidin-14/VB||dispacamide-25/VB	dobj||dispacamide-25/VB||d-26/SYM	vmod||d-26/SYM||-lrb--27/VBG	num||-rrb--29/NNS||4-28/CD	dobj||-lrb--27/VBG||-rrb--29/NNS	dep||analogs-13/VBZ||stevensine-31/VB	conj_and||hymenidin-14/VB||stevensine-31/VB	number||5-33/CD||-lrb--32/CD	num||-rrb--34/NNS||5-33/CD	dobj||stevensine-31/VB||-rrb--34/NNS	dep||analogs-13/VBZ||spongiacidin-36/VB	conj_and||hymenidin-14/VB||spongiacidin-36/VB	dobj||spongiacidin-36/VB||b-37/SYM	number||6-39/CD||-lrb--38/CD	num||-rrb--40/NNS||6-39/CD	dep||b-37/SYM||-rrb--40/NNS	poss||derivatives-43/NNS||their-42/PRP$	appos||b-37/SYM||derivatives-43/NNS	vmod||derivatives-43/NNS||lacking-44/VBG	det||bromoaldisin-48/NN||the-45/DT	amod||bromoaldisin-48/NN||imidazole-46/JJ	nn||bromoaldisin-48/NN||ring-47/NN	dobj||lacking-44/VBG||bromoaldisin-48/NN	vmod||lacking-44/VBG||-lrb--49/VBG	num||-rrb--51/NNS||7-50/CD	dobj||-lrb--49/VBG||-rrb--51/NNS	dep||analogs-13/VBZ||longamide-53/VB	conj_and||hymenidin-14/VB||longamide-53/VB	dobj||longamide-53/VB||b-54/SYM	vmod||b-54/SYM||-lrb--55/VBG	number||-rrb--57/CD||8-56/CD	dobj||-lrb--55/VBG||-rrb--57/CD	dep||analogs-13/VBZ||longamide-59/VB	conj_and||hymenidin-14/VB||longamide-59/VB	det||-rrb--63/NN||a-60/DT	number||9-62/CD||-lrb--61/CD	num||-rrb--63/NN||9-62/CD	dobj||longamide-59/VB||-rrb--63/NN	det||-rrb--72/NNS||the-65/DT	amod||-rrb--72/NNS||dimeric-66/JJ	nn||-rrb--72/NNS||oroidin-67/NN	nn||-rrb--72/NNS||derivatives-68/NNS	nn||-rrb--72/NNS||sceptrin-69/NN	amod||-rrb--72/NNS||-lrb--70/JJ	num||-rrb--72/NNS||10-71/CD	dobj||longamide-59/VB||-rrb--72/NNS	conj_and||-rrb--63/NN||-rrb--72/NNS	num||-rrb--80/NNS||dibromopalauâ-74/CD	amod||-rrb--80/NNS||$-75/$	num||$-75/$||™-76/CD	amod||-rrb--80/NNS||amine-77/JJ	number||11-79/CD||-lrb--78/CD	num||-rrb--80/NNS||11-79/CD	dobj||longamide-59/VB||-rrb--80/NNS	conj_and||-rrb--63/NN||-rrb--80/NNS	det||bromopyrrolohomoarginin-85/NN||the-83/DT	amod||bromopyrrolohomoarginin-85/NN||non-oroidin-84/JJ	dobj||longamide-59/VB||bromopyrrolohomoarginin-85/NN	conj_and||-rrb--63/NN||bromopyrrolohomoarginin-85/NN	number||12-87/CD||-lrb--86/CD	num||-rrb--88/NNS||12-87/CD	dep||bromopyrrolohomoarginin-85/NN||-rrb--88/NNS	dep||analogs-13/VBZ||manzacidin-90/VB	conj_and||hymenidin-14/VB||manzacidin-90/VB	det||-rrb--94/NNS||a-91/DT	amod||-rrb--94/NNS||-lrb--92/JJ	num||-rrb--94/NNS||13-93/CD	dobj||manzacidin-90/VB||-rrb--94/NNS	dep||analogs-13/VBZ||agelongine-97/VB	conj_and||hymenidin-14/VB||agelongine-97/VB	number||14-99/CD||-lrb--98/CD	num||-rrb--100/NNS||14-99/CD	dobj||agelongine-97/VB||-rrb--100/NNS	csubjpass||screened-115/VBN||obtained-102/VBN	amod||sponges-105/NNS||marine-104/JJ	prep_from||obtained-102/VBN||sponges-105/NNS	vmod||sponges-105/NNS||belonging-106/VBG	prep_to||belonging-106/VBG||axinella-108/NN	det||genera-112/NN||a-110/DT	amod||genera-112/NN||gelas-111/JJ	prep_to||belonging-106/VBG||genera-112/NN	conj_and||axinella-108/NN||genera-112/NN	aux||screened-115/VBN||have-113/VBP	auxpass||screened-115/VBN||been-114/VBN	dep||rhodesiense-131/VBP||screened-115/VBN	amod||brucei-130/NNS||vitro-117/NN	num||-lrb--128/NNS||four-119/CD	amod||-lrb--128/NNS||parasitic-120/JJ	nn||-lrb--128/NNS||protozoa-121/NN	dep||-lrb--128/NNS||i.e.-123/NNS	num||-lrb--128/NNS||two-125/CD	nn||-lrb--128/NNS||trypanosoma-126/NN	nn||-lrb--128/NNS||species-127/NNS	prep_against||vitro-117/NN||-lrb--128/NNS	nn||brucei-130/NNS||t.-129/NN	prep_in||screened-115/VBN||brucei-130/NNS	root||ROOT-0/null||rhodesiense-131/VBP	conj_and||rhodesiense-131/VBP||t.-133/VBP	amod||-rrb--135/NNS||cruzi-134/JJ	dobj||rhodesiense-131/VBP||-rrb--135/NNS	nn||donovani-138/NNS||leishmania-137/NN	dobj||rhodesiense-131/VBP||donovani-138/NNS	conj_and||-rrb--135/NNS||donovani-138/NNS	nn||falciparum-141/NN||plasmodium-140/NN	dobj||rhodesiense-131/VBP||falciparum-141/NN	conj_and||-rrb--135/NNS||falciparum-141/NN	amod||strain-144/NN||-lrb--142/JJ	amod||strain-144/NN||k1-143/JJ	nsubj||rhodesiense-131/VBP||strain-144/NN	nsubj||t.-133/VBP||strain-144/NN	det||mortality-168/NN||a-146/DT	amod||resistant-148/JJ||chloroquine-147/JJ	amod||mortality-168/NN||resistant-148/JJ	nn||mortality-168/NN||strain-149/NN	nn||mortality-168/NN||-rrb--150/NN	amod||mortality-168/NN||responsible-152/JJ	amod||diseases-155/NNS||human-154/JJ	prep_of||responsible-152/JJ||diseases-155/NNS	amod||morbidity-158/NN||high-157/JJ	prep_with||diseases-155/NNS||morbidity-158/NN	dep||responsible-152/JJ||in-161/IN	det||case-163/NN||the-162/DT	pobj||in-161/IN||case-163/NN	prep_of||case-163/NN||malaria-165/NN	conj_and||responsible-152/JJ||high-167/JJ	amod||mortality-168/NN||high-167/JJ	appos||strain-144/NN||mortality-168/NN	malaria-165||chloroquine-147||yes||in the present study , 13 bromopyrrole alkaloids , including the oroidin analogs hymenidin -lrb- 2 -rrb- , dispacamide b -lrb- 3 -rrb- and dispacamide d -lrb- 4 -rrb- , stevensine -lrb- 5 -rrb- and spongiacidin b -lrb- 6 -rrb- , their derivatives lacking the imidazole ring bromoaldisin -lrb- 7 -rrb- , longamide b -lrb- 8 -rrb- and longamide a -lrb- 9 -rrb- , the dimeric oroidin derivatives sceptrin -lrb- 10 -rrb- and dibromopalauâ $ ™ amine -lrb- 11 -rrb- , and the non-oroidin bromopyrrolohomoarginin -lrb- 12 -rrb- , manzacidin a -lrb- 13 -rrb- , and agelongine -lrb- 14 -rrb- , obtained from marine sponges belonging to axinella and a gelas genera have been screened in vitro against four parasitic protozoa , i.e. , two trypanosoma species -lrb- t. brucei rhodesiense and t. cruzi -rrb- , leishmania donovani and plasmodium falciparum -lrb- k1 strain , a chloroquine resistant strain -rrb- , responsible of human diseases with high morbidity and , in the case of malaria , high mortality .
aux||observe-2/VB||to-1/TO	advcl||followed-31/VBN||observe-2/VB	det||prognosis-5/NN||the-3/DT	amod||prognosis-5/NN||long-4/JJ	dobj||observe-2/VB||prognosis-5/NN	amod||patients-11/NNS||chronichepatitisc-7/JJ	appos||patients-11/NNS||chc-9/NN	prep_of||prognosis-5/NN||patients-11/NNS	nn||fibrosis-15/NN||stage-13/NN	num||fibrosis-15/NN||3-14/CD	prep_with||observe-2/VB||fibrosis-15/NN	appos||fibrosis-15/NN||f3-17/NNP	num||patients-22/NNS||55-20/CD	nn||patients-22/NNS||chc-21/NN	nsubjpass||followed-31/VBN||patients-22/NNS	amod||interferon-25/NN||initial-24/JJ	prep_after||patients-22/NNS||interferon-25/NN	dep||patients-22/NNS||ifn-27/VBN	dep||patients-22/NNS||therapy-29/NN	auxpass||followed-31/VBN||were-30/VBD	root||ROOT-0/null||followed-31/VBN	prt||followed-31/VBN||up-32/RP	quantmod||12-36/CD||up-34/IN	dep||12-36/CD||to-35/TO	num||years-37/NNS||12-36/CD	prep_for||followed-31/VBN||years-37/NNS	nn||±-42/NN||average-39/NN	num||±-42/NN||9.8-40/CD	nn||±-42/NN||â-41/NN	dep||years-37/NNS||±-42/NN	num||years-44/NNS||2.3-43/CD	dep||±-42/NN||years-44/NNS	chronichepatitisc-7||ifn-27||yes||to observe the long prognosis of chronichepatitisc (chc) patients with stage 3 fibrosis (f3), 55 chc patients after initial interferon (ifn) therapy were followed up for up to 12 years (average 9.8 â± 2.3 years).
advmod||characterised-22/NN||principally-1/RB	det||result-4/NN||a-3/DT	prep_as||characterised-22/NN||result-4/NN	det||difficulty-7/NN||the-6/DT	prep_of||result-4/NN||difficulty-7/NN	prepc_in||difficulty-7/NN||identifying-9/VBG	amod||agonists-13/NNS||potent-10/JJ	conj_and||potent-10/JJ||selective-12/JJ	amod||agonists-13/NNS||selective-12/JJ	dobj||identifying-9/VBG||agonists-13/NNS	det||ar-17/NN||the-15/DT	amod||ar-17/NN||a2b-16/JJ	nsubj||characterised-22/NN||ar-17/NN	cop||characterised-22/NN||is-18/VBZ	det||characterised-22/NN||the-19/DT	dep||extensively-21/JJ||least-20/JJS	amod||characterised-22/NN||extensively-21/JJ	root||ROOT-0/null||characterised-22/NN	det||family-27/NN||the-24/DT	amod||family-27/NN||adenosine-25/JJ	nn||family-27/NN||receptors-26/NNS	prep_of||characterised-22/NN||family-27/NN	adenosine-25||ar-17||no_rel||principally as a result of the difficulty in identifying potent and selective agonists, the a2b ar is the least extensively characterised of the adenosine receptors family.
amod||levels-3/NNS||s100a12-1/JJ	nn||levels-3/NNS||serum-2/NN	nsubjpass||determined-5/VBN||levels-3/NNS	auxpass||determined-5/VBN||were-4/VBD	root||ROOT-0/null||determined-5/VBN	num||patients-8/NNS||64-7/CD	prep_in||determined-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	prep_in||determined-5/VBN||64-15/CD	conj_and||patients-8/NNS||64-15/CD	prep_with||64-15/CD||crohn-17/NN	dep||crohn-17/NN||sdisease-19/NN	appos||crohn-17/NN||cd-21/NN	prep_in||determined-5/VBN||73-24/CD	conj_and||patients-8/NNS||73-24/CD	prep_with||73-24/CD||ibs-26/NN	det||assay-34/NN||an-31/DT	amod||assay-34/NN||enzyme-linked-32/JJ	nn||assay-34/NN||immunosorbent-33/NN	prep_by_means_of||determined-5/VBN||assay-34/NN	cd-21||crohn'sdisease--1||no_rel||s100a12 serum levels were determined in 64 patients with ulcerativecolitis (uc), 64 with crohn'sdisease (cd) and 73 with ibs, by means of an enzyme-linked immunosorbent assay.
det||study-4/NN||this-1/DT	nn||study-4/NN||phase-2/NN	nn||study-4/NN||iii-3/NN	nsubj||evaluated-5/VBN||study-4/NN	root||ROOT-0/null||evaluated-5/VBN	det||efficacy-7/NN||the-6/DT	dobj||evaluated-5/VBN||efficacy-7/NN	dobj||evaluated-5/VBN||safety-9/NN	conj_and||efficacy-7/NN||safety-9/NN	prep_of||efficacy-7/NN||rituximab-11/NN	dobj||evaluated-5/VBN||methotrexate-13/NN	conj_plus||efficacy-7/NN||methotrexate-13/NN	appos||methotrexate-13/NN||mtx-15/NN	prep_in||methotrexate-13/NN||patients-18/NNS	amod||rheumatoidarthritis-21/NNS||active-20/JJ	prep_with||evaluated-5/VBN||rheumatoidarthritis-21/NNS	nsubj||had-26/VBD||rheumatoidarthritis-21/NNS	appos||rheumatoidarthritis-21/NNS||ra-23/NN	rcmod||rheumatoidarthritis-21/NNS||had-26/VBD	det||response-29/NN||an-27/DT	amod||response-29/NN||inadequate-28/JJ	dobj||had-26/VBD||response-29/NN	prep_to||response-29/NN||mtx-31/NN	nsubjpass||naã-35/VBN||who-33/WP	auxpass||naã-35/VBN||were-34/VBD	rcmod||rheumatoidarthritis-21/NNS||naã-35/VBN	conj_and||had-26/VBD||naã-35/VBN	amod||ve-37/NN||¯-36/JJ	dobj||naã-35/VBN||ve-37/NN	amod||treatment-41/NN||prior-39/JJ	amod||treatment-41/NN||biological-40/JJ	prep_to||naã-35/VBN||treatment-41/NN	rheumatoidarthritis-21||mtx-31||yes||this phase iii study evaluated the efficacy and safety of rituximab plus methotrexate (mtx) in patients with active rheumatoidarthritis (ra) who had an inadequate response to mtx and who were naã¯ve to prior biological treatment.
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	nsubj||describe-8/VB||goal-2/NN	det||study-5/NN||this-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||describe-8/VB||to-7/TO	xcomp||was-6/VBD||describe-8/VB	advmod||reflected-32/VBD||how-9/WRB	nsubj||reflected-32/VBD||activists-10/NNS	vmod||activists-10/NNS||engaged-11/VBN	prep_in||engaged-11/VBN||campaigns-13/NNS	aux||change-15/VB||to-14/TO	xcomp||engaged-11/VBN||change-15/VB	nn||policies-17/NNS||alcohol-16/NN	dobj||change-15/VB||policies-17/NNS	dep||change-15/VB||in-18/IN	amod||areas-21/NNS||inner-19/JJ	nn||areas-21/NNS||city-20/NN	pobj||in-18/IN||areas-21/NNS	vmod||areas-21/NNS||framed-22/VBN	nn||problems-24/NNS||alcohol-23/NN	dobj||framed-22/VBN||problems-24/NNS	mark||not-29/RB||whether-27/IN	cc||not-29/RB||or-28/CC	dep||change-15/VB||not-29/RB	conj_and||in-18/IN||not-29/RB	poss||frameworks-31/NN||their-30/PRP$	dep||not-29/RB||frameworks-31/NN	ccomp||describe-8/VB||reflected-32/VBD	amod||models-34/NNS||major-33/JJ	dobj||reflected-32/VBD||models-34/NNS	vmod||models-34/NNS||used-35/VBN	det||field-38/NN||the-37/DT	prep_in||used-35/VBN||field-38/NN	det||alcoholism-43/NN||the-42/DT	prep_such_as||field-38/NN||alcoholism-43/NN	det||model-47/NN||a-45/DT	nn||model-47/NN||disease-46/NN	prep_as||alcoholism-43/NN||model-47/NN	det||perspective-52/NN||an-49/DT	nn||perspective-52/NN||alcohol-50/NN	nn||perspective-52/NN||problems-51/NNS	prep_as||alcoholism-43/NN||perspective-52/NN	conj_or||model-47/NN||perspective-52/NN	det||approach-58/NN||a-55/DT	amod||approach-58/NN||public-56/JJ	nn||approach-58/NN||health-57/NN	prep_as||alcoholism-43/NN||approach-58/NN	conj_or||model-47/NN||approach-58/NN	nn||problems-61/NNS||alcohol-60/NN	prep_to||used-35/VBN||problems-61/NNS	alcoholism-43||alcohol-60||no||the goal of this study was to describe how activists engaged in campaigns to change alcohol policies in inner city areas framed alcohol problems, and whether or not their frameworks reflected major models used in the field, such as the alcoholism as a disease model, an alcohol problems perspective, or a public health approach to alcohol problems.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||remain-19/VB||that-4/IN	mark||vary-9/VB||while-5/IN	amod||interactions-7/NNS||prion-soil-6/JJ	nsubj||vary-9/VB||interactions-7/NNS	aux||vary-9/VB||can-8/MD	advcl||remain-19/VB||vary-9/VB	nn||chemistry-12/NN||solution-11/NN	prep_with||vary-9/VB||chemistry-12/NN	nsubj||remain-19/VB||prions-14/NNS	vmod||prions-14/NNS||bound-15/VBN	prep_to||bound-15/VBN||soil-17/NN	aux||remain-19/VB||could-18/MD	ccomp||suggest-3/VBP||remain-19/VB	det||risk-21/NN||a-20/DT	xcomp||remain-19/VB||risk-21/NN	prepc_for||remain-19/VB||transmitting-23/VBG	dobj||transmitting-23/VBG||priondiseases-24/NNS	prep_after||transmitting-23/VBG||months-26/NNS	det||environment-29/NN||the-28/DT	prep_in||months-26/NNS||environment-29/NN	priondiseases-24||prion--1||no||our results suggest that while prion-soil interactions can vary with solution chemistry, prions bound to soil could remain a risk for transmitting priondiseases after months in the environment.
prep_in||improved-18/VBD||conclusion-2/NN	dep||improved-18/VBD||initiating-4/VBG	dobj||initiating-4/VBG||therapy-5/NN	det||combination-8/NN||a-7/DT	prep_with||initiating-4/VBG||combination-8/NN	nn||results-14/NNS||valsartan-10/NN	conj_and||valsartan-10/NN||low-dose-12/JJ	nn||results-14/NNS||low-dose-12/JJ	nn||results-14/NNS||hctz-13/NN	prep_of||combination-8/NN||results-14/NNS	prep_in||initiating-4/VBG||early-16/JJ	root||ROOT-0/null||improved-18/VBD	nn||efficacy-20/NN||bp-19/NN	dobj||improved-18/VBD||efficacy-20/NN	amod||tolerability-23/NN||similar-22/JJ	prep_with||improved-18/VBD||tolerability-23/NN	prep||improved-18/VBD||as-24/IN	prepc_compared_with||improved-18/VBD||with-26/IN	pcomp||improved-18/VBD||starting-27/VBG	dobj||starting-27/VBG||treatment-28/NN	det||dose-34/NN||a-30/DT	amod||dose-34/NN||low-31/JJ	conj_or||low-31/JJ||higher-33/JJR	amod||dose-34/NN||higher-33/JJR	prep_with||starting-27/VBG||dose-34/NN	prep_of||dose-34/NN||valsartan-36/NN	prep_for||valsartan-36/NN||patients-38/NNS	amod||hypertension-43/NN||stage-1-40/JJ	conj_and||stage-1-40/JJ||stage-2-42/JJ	amod||hypertension-43/NN||stage-2-42/JJ	prep_with||patients-38/NNS||hypertension-43/NN	hypertension-43||valsartan-36||yes||in conclusion, initiating therapy with a combination of valsartan and low-dose hctz results in early, improved bp efficacy with similar tolerability as compared with starting treatment with a low or higher dose of valsartan for patients with stage-1 and stage-2 hypertension.
aux||investigate-2/VB||to-1/TO	csubj||features-22/NNS||investigate-2/VB	mark||and/or-9/VBD||whether-3/IN	amod||cell-7/NN||impaired-4/VBN	amod||cell-7/NN||extrathymic-5/JJ	nn||cell-7/NN||t-6/NN	nsubj||and/or-9/VBD||cell-7/NN	vmod||cell-7/NN||maturation-8/VBN	ccomp||investigate-2/VB||and/or-9/VBD	amod||receptor-13/NN||secondary-10/JJ	nn||receptor-13/NN||t-11/NN	nn||receptor-13/NN||cell-12/NN	iobj||and/or-9/VBD||receptor-13/NN	appos||receptor-13/NN||tcr-15/NN	nn||recombination-18/NN||gene-17/NN	dobj||and/or-9/VBD||recombination-18/NN	prep_in||recombination-18/NN||iels-20/NNS	cop||features-22/NNS||are-21/VBP	root||ROOT-0/null||features-22/NNS	nsubj||contribute-27/VB||features-22/NNS	prep_of||features-22/NNS||coeliacdisease-24/NN	aux||contribute-27/VB||could-26/MD	rcmod||features-22/NNS||contribute-27/VB	det||failure-30/NN||the-29/DT	prep_to||contribute-27/VB||failure-30/NN	prepc_of||failure-30/NN||establishing-32/VBG	dobj||establishing-32/VBG||tolerance-33/NN	prep_to||establishing-32/VBG||gluten-35/NN	coeliacdisease-24||gluten-35||no||to investigate whether impaired extrathymic t cell maturation and/or secondary t cell receptor (tcr) gene recombination in iels are features of coeliacdisease which could contribute to the failure of establishing tolerance to gluten.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||artemether--1||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
csubj||gave-15/VBD||attending-1/VBG	det||course-4/NN||an-2/DT	amod||course-4/NN||educational-3/JJ	dobj||attending-1/VBG||course-4/NN	amod||reduction-8/NN||dietary-6/JJ	nn||reduction-8/NN||carbohydrate-7/NN	prep_on||attending-1/VBG||reduction-8/NN	amod||reduction-12/NN||corresponding-10/JJ	nn||reduction-12/NN||insulin-11/NN	prep_on||attending-1/VBG||reduction-12/NN	conj_and||reduction-8/NN||reduction-12/NN	prep_in||reduction-8/NN||type1diabetes-14/CD	root||ROOT-0/null||gave-15/VBD	amod||improvement-17/NN||lasting-16/JJ	dobj||gave-15/VBD||improvement-17/NN	type1diabetes-14||insulin-11||yes||attending an educational course on dietary carbohydrate reduction and corresponding insulin reduction in type1diabetes gave lasting improvement.
amod||supplementation-2/NN||leucine-1/JJ	nsubjpass||carried-4/VBN||supplementation-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	prep_in||carried-4/VBN||noncnzo10/ltj-7/NNS	appos||noncnzo10/ltj-7/NNS||rcs10-9/NNP	det||model-14/NN||a-12/DT	amod||model-14/NN||polygenic-13/JJ	prep_in||carried-4/VBN||model-14/NN	conj_and||noncnzo10/ltj-7/NNS||model-14/NN	vmod||model-14/NN||predisposed-15/VBN	amod||failure-19/NN||beta-17/JJ	nn||failure-19/NN||cell-18/NN	prep_to||predisposed-15/VBN||failure-19/NN	prep_in||carried-4/VBN||type2diabetes-21/NNS	conj_and||noncnzo10/ltj-7/NNS||type2diabetes-21/NNS	amod||j-27/NN||b6.cg-ay-25/JJ	amod||j-27/NN||/-26/JJ	prep_in||carried-4/VBN||j-27/NN	conj_and||noncnzo10/ltj-7/NNS||j-27/NN	det||y-30/NN||a-29/DT	appos||j-27/NN||y-30/NN	det||model-35/NN||a-33/DT	amod||model-35/NN||monogenic-34/JJ	conj_and||noncnzo10/ltj-7/NNS||model-35/NN	conj_and||j-27/NN||model-35/NN	amod||receptor-40/NN||impaired-37/VBN	amod||receptor-40/NN||central-38/JJ	nn||receptor-40/NN||melanocortin-39/NN	prep_for||model-35/NN||receptor-40/NN	vmod||receptor-40/NN||signaling-41/VBG	advmod||signaling-41/VBG||obesity-43/RB	amod||insulinresistance-47/NN||severe-46/JJ	conj_and||noncnzo10/ltj-7/NNS||insulinresistance-47/NN	conj_and||j-27/NN||insulinresistance-47/NN	type2diabetes-21||leucine-1||no_rel||leucine supplementation was carried out in noncnzo10/ltj (rcs10) - a polygenic model predisposed to beta cell failure and type2diabetes, and in b6.cg-ay/j ( a y ) - a monogenic model for impaired central melanocortin receptor signaling, obesity, and severe insulinresistance.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	det||confluence-5/NN||a-3/DT	amod||confluence-5/NN||clear-4/JJ	nsubj||is-2/VBZ||confluence-5/NN	prepc_of||confluence-5/NN||changing-7/VBG	amod||realities-9/NNS||social-8/JJ	dobj||changing-7/VBG||realities-9/NNS	det||needs-12/NNS||the-11/DT	dobj||changing-7/VBG||needs-12/NNS	conj_and||realities-9/NNS||needs-12/NNS	prep_of||needs-12/NNS||children-14/NNS	prep_in||changing-7/VBG||families-16/NNS	vmod||families-16/NNS||affected-17/VBN	agent||affected-17/VBN||hiv-19/NN	agent||affected-17/VBN||aids-21/NNS	conj_and||hiv-19/NN||aids-21/NNS	det||change-25/NN||a-24/DT	nsubj||slow-46/JJ||change-25/NN	nsubj||emerge-48/VB||change-25/NN	prep_of||change-25/NN||paradigm-27/NN	prepc_in||paradigm-27/NN||rendering-29/VBG	dobj||rendering-29/VBG||services-30/NNS	prep_to||rendering-29/VBG||children-32/NNS	prep_through||rendering-29/VBG||families-34/NNS	preconj||high-prevalence-38/JJ||both-37/DT	amod||settings-42/NNS||high-prevalence-38/JJ	conj_and||high-prevalence-38/JJ||concentrated-40/JJ	amod||settings-42/NNS||concentrated-40/JJ	nn||settings-42/NNS||epidemic-41/NN	prep_in||families-34/NNS||settings-42/NNS	aux||slow-46/JJ||has-44/VBZ	cop||slow-46/JJ||been-45/VBN	conj_but||is-2/VBZ||slow-46/JJ	aux||emerge-48/VB||to-47/TO	xcomp||slow-46/JJ||emerge-48/VB	aids-21||hiv-19||no||there is a clear confluence of changing social realities and the needs of children in families affected by hiv and aids, but a change of paradigm in rendering services to children through families, in both high-prevalence and concentrated epidemic settings, has been slow to emerge.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||artemether--1||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
csubj||priority-9/NN||identifying-1/VBG	dobj||identifying-1/VBG||factors-2/NNS	vmod||factors-2/NNS||associated-3/VBN	prep_with||associated-3/VBN||disclosure-5/NN	cop||priority-9/NN||is-6/VBZ	det||priority-9/NN||a-7/DT	nn||priority-9/NN||research-8/NN	root||ROOT-0/null||priority-9/NN	det||proportion-13/NN||a-11/DT	amod||proportion-13/NN||high-12/JJ	prep_as||priority-9/NN||proportion-13/NN	prep_of||proportion-13/NN||people-15/NNS	vmod||people-15/NNS||living-16/VBG	prep_with||living-16/VBG||hiv/aids-18/NNS	neg||disclose-20/VB||never-19/RB	dep||priority-9/NN||disclose-20/VB	prep_in||disclose-20/VB||ethiopia-22/NN	aids--1||hiv--1||no||identifying factors associated with disclosure is a research priority as a high proportion of people living with hiv/aids never disclose in ethiopia.
nsubjpass||used-4/VBN||clozapine-1/NN	aux||used-4/VBN||has-2/VBZ	auxpass||used-4/VBN||been-3/VBN	root||ROOT-0/null||used-4/VBN	det||treatment-7/NN||the-6/DT	prep_in||used-4/VBN||treatment-7/NN	prep_of||treatment-7/NN||schizophrenia-9/NN	quantmod||two-12/CD||about-11/RB	num||decades-13/NNS||two-12/CD	prep_for||schizophrenia-9/NN||decades-13/NNS	amod||data-16/NNS||extensive-15/JJ	nsubjpass||accumulated-19/VBN||data-16/NNS	aux||accumulated-19/VBN||have-17/VBP	auxpass||accumulated-19/VBN||been-18/VBN	conj_and||used-4/VBN||accumulated-19/VBN	prep_with||accumulated-19/VBN||regard-21/NN	poss||use-24/NN||its-23/PRP$	prep_to||accumulated-19/VBN||use-24/NN	amod||parts-27/NNS||various-26/JJ	prep_in||use-24/NN||parts-27/NNS	det||world-30/NN||the-29/DT	prep_of||parts-27/NNS||world-30/NN	schizophrenia-9||clozapine-1||yes||clozapine has been used in the treatment of schizophrenia for about two decades and extensive data have been accumulated with regard to its use in various parts of the world.
aux||prevent-2/VB||to-1/TO	advcl||added-23/VBN||prevent-2/VB	dobj||prevent-2/VB||hyperinsulinemia-3/NN	nsubj||cause-7/VB||hyperinsulinemia-3/NN	aux||cause-7/VB||may-6/MD	rcmod||hyperinsulinemia-3/NN||cause-7/VB	dobj||cause-7/VB||atherosclerosis-8/NNS	nsubjpass||added-23/VBN||thiazolidinediones-10/NNS	appos||thiazolidinediones-10/NNS||tzds-12/NNS	advmod||known-16/VBN||also-15/RB	vmod||thiazolidinediones-10/NNS||known-16/VBN	nn||sensitizers-19/NNS||insulin-18/NN	prep_as||known-16/VBN||sensitizers-19/NNS	auxpass||added-23/VBN||are-21/VBP	advmod||added-23/VBN||often-22/RB	root||ROOT-0/null||added-23/VBN	det||regimen-27/NN||the-25/DT	amod||regimen-27/NN||therapeutic-26/JJ	prep_to||added-23/VBN||regimen-27/NN	prep_of||regimen-27/NN||patients-29/NNS	prep_with||added-23/VBN||type2diabetes-31/NNS	nsubj||receiving-34/VBG||type2diabetes-31/NNS	aux||receiving-34/VBG||are-33/VBP	rcmod||type2diabetes-31/NNS||receiving-34/VBG	dobj||receiving-34/VBG||insulin-35/NN	insulin-35||type2diabetes-31||no_rel||to prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (tzds), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type2diabetes who are receiving insulin.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-14/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||infants-7/NNS	vmod||infants-7/NNS||using-8/VBG	acomp||using-8/VBG||sulfadoxine-pyrimethamine-9/JJ	appos||treatment-3/NN||sp-ipti-11/NNP	auxpass||recommended-14/VBN||is-13/VBZ	root||ROOT-0/null||recommended-14/VBN	agent||recommended-14/VBN||who-16/WP	prep_for||recommended-14/VBN||implementation-18/NN	prep_in||implementation-18/NN||settings-20/NNS	advmod||high-27/JJ||where-21/WRB	nsubj||high-27/JJ||resistance-22/NN	prep_to||resistance-22/NN||sp-24/NN	cop||high-27/JJ||is-25/VBZ	neg||high-27/JJ||not-26/RB	rcmod||settings-20/NNS||high-27/JJ	malaria-5||pyrimethamine--1||yes||intermittent preventive treatment of malaria in infants using sulfadoxine-pyrimethamine (sp-ipti) is recommended by who for implementation in settings where resistance to sp is not high.
amod||conjugates-4/NNS||vivo-2/JJ	nn||conjugates-4/NNS||antibody-3/NN	prep_in||caused-5/VBD||conjugates-4/NNS	root||ROOT-0/null||caused-5/VBD	dobj||caused-5/VBD||suppression-6/NN	amod||growth-11/NN||human-8/JJ	nn||growth-11/NN||lovo-9/NN	nn||growth-11/NN||tumour-10/NN	prep_of||suppression-6/NN||growth-11/NN	amod||nih-14/NN||immunodeficient-13/JJ	prep_in||caused-5/VBD||nih-14/NN	nn||mice-16/NNS||iii-15/NN	nsubj||caused-5/VBD||mice-16/NNS	amod||doses-35/NNS||similar-18/JJ	det||therapy-23/NN||the-20/DT	amod||therapy-23/NN||commercial-21/JJ	amod||therapy-23/NN||photodynamic-22/JJ	prep_to||similar-18/JJ||therapy-23/NN	appos||therapy-23/NN||pdt-25/NN	nn||doses-35/NNS||agent-27/NN	amod||doses-35/NNS||photofrinâ-28/JJ	amod||doses-35/NNS||®-29/JJ	conj_but||®-29/JJ||at-32/IN	amod||doses-35/NNS||at-32/IN	amod||doses-35/NNS||administered-33/JJ	nn||doses-35/NNS||photosensitizer-34/NN	appos||mice-16/NNS||doses-35/NNS	nsubj||lower-44/JJR||doses-35/NNS	cop||lower-44/JJR||were-37/VBD	mwe||than-39/IN||more-38/JJR	quantmod||two-40/CD||than-39/IN	num||orders-41/NNS||two-40/CD	npadvmod||lower-44/JJR||orders-41/NNS	prep_of||orders-41/NNS||magnitude-43/NN	rcmod||doses-35/NNS||lower-44/JJR	immunodeficient-13||antibody-3||no_rel||in vivo antibody conjugates caused suppression of human lovo tumour growth in immunodeficient nih iii mice, similar to the commercial photodynamic therapy (pdt) agent photofrinâ®, but at administered photosensitizer doses that were more than two orders of magnitude lower.
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubjpass||validated-9/VBN||plus-5/NN	nsubj||mdr-tb-32/JJ||plus-5/NN	advmod||validated-9/VBN||assay-6/RB	aux||validated-9/VBN||has-7/VBZ	auxpass||validated-9/VBN||been-8/VBN	root||ROOT-0/null||validated-9/VBN	mark||isolates-23/VBZ||as-10/IN	det||test-17/NN||a-11/DT	amod||test-17/NN||rapid-12/JJ	conj_and||rapid-12/JJ||reliable-14/JJ	amod||test-17/NN||reliable-14/JJ	amod||test-17/NN||first-line-15/JJ	amod||test-17/NN||diagnostic-16/JJ	nsubj||isolates-23/VBZ||test-17/NN	amod||sputum-20/NN||afb-positive-19/JJ	prep_on||test-17/NN||sputum-20/NN	prep_on||test-17/NN||mtb-22/NN	conj_or||sputum-20/NN||mtb-22/NN	advcl||validated-9/VBN||isolates-23/VBZ	nn||resistance-26/NN||inh-25/NN	prep_for||isolates-23/VBZ||resistance-26/NN	nn||resistance-29/NN||rif-28/NN	appos||resistance-26/NN||resistance-29/NN	conj_and||validated-9/VBN||mdr-tb-32/JJ	prep_in||mdr-tb-32/JJ||bangkok-34/NN	dep||validated-9/VBN||thailand-36/VBN	tb--1||rif-28||yes||the genotypeâ® mtbdr plus assay has been validated as a rapid and reliable first-line diagnostic test on afb-positive sputum or mtb isolates for inh resistance, rif resistance, and mdr-tb in bangkok, thailand.
amod||levels-4/NNS||low-1/JJ	nn||levels-4/NNS||blood-2/NN	nn||levels-4/NNS||testosterone-3/NN	nsubj||confirm-10/VBP||levels-4/NNS	amod||levels-9/NNS||low-6/JJ	amod||levels-9/NNS||pituitary-7/JJ	nn||levels-9/NNS||hormone-8/NN	conj_and||levels-4/NNS||levels-9/NNS	nsubj||confirm-10/VBP||levels-9/NNS	root||ROOT-0/null||confirm-10/VBP	det||diagnosis-14/NN||the-11/DT	amod||diagnosis-14/NN||hypogonadotropic-12/JJ	nn||diagnosis-14/NN||hypogonadism-13/NN	dobj||confirm-10/VBP||diagnosis-14/NN	hypogonadism-13||testosterone-3||yes||low blood testosterone levels and low pituitary hormone levels confirm the hypogonadotropic hypogonadism diagnosis.
amod||advances-2/NNS||newer-1/JJR	nsubj||include-3/VBP||advances-2/NNS	ccomp||revolutionized-63/VBD||include-3/VBP	dobj||include-3/VBP||introduction-4/NN	amod||techniques-7/NNS||newer-6/JJR	prep_of||introduction-4/NN||techniques-7/NNS	amod||epidurals-11/NNS||combined-9/VBN	amod||epidurals-11/NNS||spinal-10/JJ	prep_like||techniques-7/NNS||epidurals-11/NNS	amod||epidurals-14/NNS||low-dose-13/JJ	dobj||include-3/VBP||epidurals-14/NNS	conj_and||introduction-4/NN||epidurals-14/NNS	vmod||epidurals-14/NNS||facilitating-15/VBG	dobj||facilitating-15/VBG||ambulation-16/NN	amod||advances-19/NNS||pharmacological-18/JJ	dobj||include-3/VBP||advances-19/NNS	conj_and||introduction-4/NN||advances-19/NNS	prep_like||advances-19/NNS||introduction-21/NN	prep_of||introduction-21/NN||remifentanil-23/NN	amod||analgesia-27/NN||patient-controlled-25/JJ	amod||analgesia-27/NN||intravenous-26/JJ	prep_for||remifentanil-23/NN||analgesia-27/NN	dobj||include-3/VBP||introduction-29/NN	conj_and||introduction-4/NN||introduction-29/NN	amod||anaesthetics-33/NNS||newer-31/JJR	amod||anaesthetics-33/NNS||local-32/JJ	prep_of||introduction-29/NN||anaesthetics-33/NNS	dobj||include-3/VBP||adjuvants-35/NNS	conj_and||introduction-4/NN||adjuvants-35/NNS	prep_like||adjuvants-35/NNS||ropivacaine-37/JJ	prep_like||adjuvants-35/NNS||levobupivacaine-39/JJ	conj_and||ropivacaine-37/JJ||levobupivacaine-39/JJ	prep_like||adjuvants-35/NNS||sufentanil-41/JJ	conj_and||ropivacaine-37/JJ||sufentanil-41/JJ	prep_like||adjuvants-35/NNS||clonidine-43/JJ	conj_and||ropivacaine-37/JJ||clonidine-43/JJ	prep_like||adjuvants-35/NNS||neostigmine-45/JJ	conj_and||ropivacaine-37/JJ||neostigmine-45/JJ	appos||introduction-4/NN||use-47/NN	amod||agents-50/NNS||inhalational-49/JJ	prep_of||use-47/NN||agents-50/NNS	prep_like||agents-50/NNS||sevoflourane-52/NN	amod||analgesia-56/NN||patient-controlled-54/JJ	amod||analgesia-56/NN||inhalational-55/JJ	prep_for||sevoflourane-52/NN||analgesia-56/NN	vmod||analgesia-56/NN||using-57/VBG	amod||vaporizers-59/NNS||special-58/JJ	dobj||using-57/VBG||vaporizers-59/NNS	nsubj||revolutionized-63/VBD||all-61/DT	aux||revolutionized-63/VBD||have-62/VBP	root||ROOT-0/null||revolutionized-63/VBD	det||practice-65/NN||the-64/DT	dobj||revolutionized-63/VBD||practice-65/NN	nn||management-68/NN||pain-67/NN	prep_of||practice-65/NN||management-68/NN	prepc_in||revolutionized-63/VBD||labouring-70/VBG	dobj||labouring-70/VBG||parturients-71/NNS	pain-67||ropivacaine-37||yes||newer advances include introduction of newer techniques like combined spinal epidurals, low-dose epidurals facilitating ambulation, pharmacological advances like introduction of remifentanil for patient-controlled intravenous analgesia, introduction of newer local anaesthetics and adjuvants like ropivacaine, levobupivacaine, sufentanil, clonidine and neostigmine, use of inhalational agents like sevoflourane for patient-controlled inhalational analgesia using special vaporizers, all have revolutionized the practice of pain management in labouring parturients.
det||phenotype-2/NN||the-1/DT	nsubjpass||extended-12/VBN||phenotype-2/NN	nsubj||include-14/VB||phenotype-2/NN	vmod||phenotype-2/NN||associated-3/VBN	amod||mutations-8/NNS||heterozygous-5/JJ	amod||mutations-8/NNS||hnf4a-6/JJ	nn||mutations-8/NNS||gene-7/NN	prep_with||associated-3/VBN||mutations-8/NNS	aux||extended-12/VBN||has-9/VBZ	advmod||extended-12/VBN||recently-10/RB	auxpass||extended-12/VBN||been-11/VBN	root||ROOT-0/null||extended-12/VBN	aux||include-14/VB||to-13/TO	xcomp||extended-12/VBN||include-14/VB	amod||responsive-16/JJ||diazoxide-15/JJ	amod||hypoglycemia-18/NN||responsive-16/JJ	amod||hypoglycemia-18/NN||neonatal-17/JJ	dobj||include-14/VB||hypoglycemia-18/NN	prep_in||include-14/VB||addition-20/NN	prep_to||include-14/VB||maturity-onsetdiabetes-22/NNS	det||mody-27/NN||the-24/DT	amod||mody-27/NN||young-25/JJ	prep_of||maturity-onsetdiabetes-22/NNS||mody-27/NN	maturity-onsetdiabetes-22||diazoxide-15||no_rel||the phenotype associated with heterozygous hnf4a gene mutations has recently been extended to include diazoxide responsive neonatal hypoglycemia in addition to maturity-onsetdiabetes of the young (mody).
det||goals-2/NNS||the-1/DT	nsubj||include-3/VBP||goals-2/NNS	root||ROOT-0/null||include-3/VBP	nsubj||eradicating-7/VB||1-5/CD	ccomp||include-3/VBP||eradicating-7/VB	amod||poverty-9/NN||extreme-8/JJ	dobj||eradicating-7/VB||poverty-9/NN	dobj||eradicating-7/VB||hunger-11/NN	conj_and||poverty-9/NN||hunger-11/NN	dep||eradicating-7/VB||2-14/CD	dep||eradicating-7/VB||achieving-16/VBG	amod||education-19/NN||universal-17/JJ	amod||education-19/NN||primary-18/JJ	dobj||achieving-16/VBG||education-19/NN	dep||gender-25/NN||3-22/LS	amod||gender-25/NN||promoting-24/VBN	dobj||eradicating-7/VB||gender-25/NN	parataxis||eradicating-7/VB||gender-25/NN	dep||gender-25/NN||equality-26/NN	dep||child-32/NN||4-29/LS	amod||child-32/NN||reducing-31/VBN	dep||equality-26/NN||child-32/NN	dep||child-32/NN||mortality-33/NN	appos||maternal-39/NN||5-36/CD	amod||maternal-39/NN||improving-38/JJ	dep||mortality-33/NN||maternal-39/NN	dep||maternal-39/NN||health-40/NN	appos||mortality-33/NN||6-43/CD	vmod||mortality-33/NN||combating-45/VBG	nn||malaria-48/NN||hiv/aids-46/NN	nn||diseases-51/NNS||malaria-48/NN	conj_and||malaria-48/NN||other-50/JJ	nn||diseases-51/NNS||other-50/JJ	dobj||combating-45/VBG||diseases-51/NNS	appos||mortality-33/NN||7-54/CD	vmod||mortality-33/NN||ensuring-56/VBG	amod||sustainability-58/NN||environmental-57/JJ	dobj||ensuring-56/VBG||sustainability-58/NN	dobj||eradicating-7/VB||8-62/CD	parataxis||eradicating-7/VB||8-62/CD	conj_and||gender-25/NN||8-62/CD	vmod||8-62/CD||developing-64/VBG	det||partnership-67/NN||a-65/DT	amod||partnership-67/NN||global-66/JJ	dobj||developing-64/VBG||partnership-67/NN	prep_for||partnership-67/NN||development-69/NN	aids--1||hiv--1||no||the goals include (1) eradicating extreme poverty and hunger; (2) achieving universal primary education; (3) promoting gender equality; (4) reducing child mortality; (5) improving maternal health; (6) combating hiv/aids, malaria and other diseases; (7) ensuring environmental sustainability; and (8) developing a global partnership for development.
amod||transmembrane-4/NN||fibronectin-1/JJ	amod||transmembrane-4/NN||leucine-2/JJ	amod||transmembrane-4/NN||rich-3/JJ	nn||proteins-8/NNS||transmembrane-4/NN	appos||proteins-8/NNS||flrt-6/NN	nsubj||have-9/VBP||proteins-8/NNS	root||ROOT-0/null||have-9/VBP	amod||properties-11/NNS||dual-10/JJ	dobj||have-9/VBP||properties-11/NNS	prep_as||properties-11/NNS||regulators-13/NNS	nn||adhesion-16/NN||cell-15/NN	prep_of||regulators-13/NNS||adhesion-16/NN	prep_as||properties-11/NNS||potentiators-18/NNS	conj_and||regulators-13/NNS||potentiators-18/NNS	amod||factor-22/NN||fibroblast-20/JJ	nn||factor-22/NN||growth-21/NN	prep_of||potentiators-18/NNS||factor-22/NN	appos||factor-22/NN||fgf-24/NN	vmod||factor-22/NN||mediated-26/VBN	xcomp||mediated-26/VBN||signalling-27/VBG	leucine-2||adhesion-16||no_rel||fibronectin leucine rich transmembrane (flrt) proteins have dual properties as regulators of cell adhesion and potentiators of fibroblast growth factor (fgf) mediated signalling.
poss||laboratory-3/NN||our-2/PRP$	prep_in||address-6/VBP||laboratory-3/NN	nsubj||address-6/VBP||we-5/PRP	root||ROOT-0/null||address-6/VBP	advmod||unsettled-8/VBN||still-7/RB	amod||questions-9/NNS||unsettled-8/VBN	nsubj||ellipticine-47/VBP||questions-9/NNS	nsubj||mechanism-51/NN||questions-9/NNS	prep_of||ellipticine-47/VBP||mechanisms-13/NNS	prep_of||mechanisms-13/NNS||action-15/NN	amod||drugs-18/NNS||dna-damaging-17/JJ	prep_of||action-15/NN||drugs-18/NNS	nsubj||use-21/VBP||both-19/DT	advmod||use-21/VBP||currently-20/RB	rcmod||mechanisms-13/NNS||use-21/VBP	prep_for||use-21/VBP||treatment-23/NN	amod||neuroblastomas-26/NNS||human-25/JJ	prep_of||treatment-23/NN||neuroblastomas-26/NNS	dep||mechanisms-13/NNS||doxorubicin-28/NN	dep||mechanisms-13/NNS||cis-platin-30/NN	conj_and||doxorubicin-28/NN||cis-platin-30/NN	dep||mechanisms-13/NNS||cyclophosphamide-32/NN	conj_and||doxorubicin-28/NN||cyclophosphamide-32/NN	dep||mechanisms-13/NNS||etoposide-34/NN	conj_and||doxorubicin-28/NN||etoposide-34/NN	det||growth-41/NN||another-37/DT	amod||growth-41/NN||anticancer-38/JJ	nn||growth-41/NN||agent-39/NN	amod||growth-41/NN||decreasing-40/VBG	conj_and||mechanisms-13/NNS||growth-41/NN	prep_of||ellipticine-47/VBP||growth-41/NN	prep_of||growth-41/NN||neuroblastomas-43/NNS	prep_in||neuroblastomas-43/NNS||vitro-45/NNP	rcmod||questions-9/NNS||ellipticine-47/VBP	cop||mechanism-51/NN||are-49/VBP	amod||mechanism-51/NN||predominant-50/JJ	ccomp||address-6/VBP||mechanism-51/NN	dep||mechanism-51/NN||s-53/PRP	amod||mechanism-51/NN||responsible-55/JJ	poss||action-59/NN||their-57/PRP$	nn||action-59/NN||antitumor-58/NN	prep_for||responsible-55/JJ||action-59/NN	nn||lines-63/NNS||neuroblastoma-61/NN	nn||lines-63/NNS||cell-62/NN	prep_in||mechanism-51/NN||lines-63/NNS	prep_in||mechanism-51/NN||vitro-65/NN	neuroblastoma-61||cyclophosphamide-32||yes||in our laboratory, we address still unsettled questions, which of mechanisms of action of dna-damaging drugs both currently use for treatment of human neuroblastomas (doxorubicin, cis-platin, cyclophosphamide and etoposide) and another anticancer agent decreasing growth of neuroblastomas in vitro , ellipticine, are predominant mechanism(s) responsible for their antitumor action in neuroblastoma cell lines in vitro .
nsubj||sought-2/VBD||we-1/PRP	nsubj||characterise-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||characterise-4/VB||to-3/TO	xcomp||sought-2/VBD||characterise-4/VB	mark||enhance-11/VB||whether-5/IN	nsubj||enhance-11/VB||dexamethasone-6/NN	appos||dexamethasone-6/NN||dex-8/NN	aux||enhance-11/VB||may-10/MD	ccomp||characterise-4/VB||enhance-11/VB	nn||response-13/NN||tumour-12/NN	dobj||enhance-11/VB||response-13/NN	aux||docetaxel-15/VB||to-14/TO	vmod||enhance-11/VB||docetaxel-15/VB	prt||docetaxel-15/VB||in-16/RP	amod||cancer-26/NN||vitro-18/NN	conj_and||vitro-18/NN||in-20/IN	amod||cancer-26/NN||in-20/IN	nn||models-22/NNS||vivo-21/NN	pobj||in-20/IN||models-22/NNS	amod||prostate-25/NN||metastatic-24/JJ	prep_of||models-22/NNS||prostate-25/NN	prep_in||docetaxel-15/VB||cancer-26/NN	appos||cancer-26/NN||cap-28/NN	tumour-12||dexamethasone-6||yes||we sought to characterise whether dexamethasone (dex) may enhance tumour response to docetaxel in in vitro and in vivo models of metastatic prostate cancer (cap).
amod||viral/bacterialinfection-3/NN||combined-2/JJ	prep_during||interact-13/VBP||viral/bacterialinfection-3/NN	det||virus-6/NN||the-5/DT	nsubj||interact-13/VBP||virus-6/NN	det||bacterium-9/NN||the-8/DT	conj_and||virus-6/NN||bacterium-9/NN	nsubj||interact-13/VBP||bacterium-9/NN	det||host-12/NN||the-11/DT	conj_and||virus-6/NN||host-12/NN	nsubj||interact-13/VBP||host-12/NN	root||ROOT-0/null||interact-13/VBP	det||other-16/JJ||each-15/DT	prep_with||interact-13/VBP||other-16/JJ	bacterialinfection--1||bacterium-9||no||during combined viral/bacterialinfection, the virus, the bacterium and the host interact with each other.
prep_in||mandated-8/VBD||2006-2/CD	det||agency-7/NN||the-4/DT	nn||agency-7/NN||norwegian-5/NN	nn||agency-7/NN||medicines-6/NNS	nsubj||mandated-8/VBD||agency-7/NN	root||ROOT-0/null||mandated-8/VBD	det||switch-10/NN||a-9/DT	dobj||mandated-8/VBD||switch-10/NN	prep_from||mandated-8/VBD||desloratadine-12/NN	prep_from||mandated-8/VBD||ebastine-14/NN	conj_or||desloratadine-12/NN||ebastine-14/NN	prep_from||mandated-8/VBD||fexofenadine-17/NN	conj_or||desloratadine-12/NN||fexofenadine-17/NN	prep_to||desloratadine-12/NN||cetirizine-19/NN	prep_to||desloratadine-12/NN||loratadine-21/NN	conj_or||cetirizine-19/NN||loratadine-21/NN	prep_in||mandated-8/VBD||patients-23/NNS	amod||rhinitis-26/NNS||allergic-25/JJ	prep_with||patients-23/NNS||rhinitis-26/NNS	appos||rhinitis-26/NNS||ar-28/NN	amod||urticaria-32/NN||chronic-31/JJ	prep_with||patients-23/NNS||urticaria-32/NN	conj_or||rhinitis-26/NNS||urticaria-32/NN	appos||rhinitis-26/NNS||cu-34/NN	urticaria-32||fexofenadine-17||yes||in 2006, the norwegian medicines agency mandated a switch from desloratadine, ebastine, or fexofenadine to cetirizine or loratadine in patients with allergic rhinitis (ar) or chronic urticaria (cu).
nsubj||conclude-5/VBP||most-1/JJS	det||studies-4/NNS||these-3/DT	prep_of||most-1/JJS||studies-4/NNS	root||ROOT-0/null||conclude-5/VBP	mark||cause-8/VBP||that-6/IN	nsubj||cause-8/VBP||bisphosphonates-7/NNS	ccomp||conclude-5/VBP||cause-8/VBP	det||reduction-10/NN||a-9/DT	dobj||cause-8/VBP||reduction-10/NN	nn||burden-13/NN||tumour-12/NN	prep_in||reduction-10/NN||burden-13/NN	mark||repeated-25/VBD||that-16/IN	amod||intervention-18/NN||early-17/JJ	nsubj||repeated-25/VBD||intervention-18/NN	det||use-21/NN||the-20/DT	conj_and||intervention-18/NN||use-21/NN	nsubj||repeated-25/VBD||use-21/NN	amod||and/or-24/NNS||high-23/JJ	prep_of||use-21/NN||and/or-24/NNS	ccomp||conclude-5/VBP||repeated-25/VBD	conj_but||cause-8/VBP||repeated-25/VBD	nsubjpass||required-28/VBN||dosing-26/NN	auxpass||required-28/VBN||is-27/VBZ	ccomp||repeated-25/VBD||required-28/VBN	tumour-12||bisphosphonates-7||no_rel||most of these studies conclude that bisphosphonates cause a reduction in tumour burden, but that early intervention and the use of high and/or repeated dosing is required.
det||seconds-4/NNS||the-2/DT	num||seconds-4/NNS||10-3/CD	prep_during||measured-12/VBN||seconds-4/NNS	amod||injection-7/NN||propofol-6/JJ	prep_after||seconds-4/NNS||injection-7/NN	nn||intensity-10/NN||pain-9/NN	nsubjpass||measured-12/VBN||intensity-10/NN	auxpass||measured-12/VBN||was-11/VBD	root||ROOT-0/null||measured-12/VBN	det||scale-18/NN||an-14/DT	amod||scale-18/NN||11-point-15/JJ	amod||scale-18/NN||numerical-16/JJ	nn||scale-18/NN||rating-17/NN	prep_on||measured-12/VBN||scale-18/NN	dep||scale-18/NN||0-20/CD	dep||pain-23/NN||=-21/SYM	neg||pain-23/NN||no-22/DT	rcmod||0-20/CD||pain-23/NN	num||=-26/NNS||10-25/CD	dep||scale-18/NN||=-26/NNS	conj_and||0-20/CD||=-26/NNS	dep||possible-28/JJ||worst-27/JJS	amod||pain-29/NN||possible-28/JJ	dep||=-26/NNS||pain-29/NN	pain-29||propofol-6||yes||during the 10 seconds after propofol injection, pain intensity was measured on an 11-point numerical rating scale (0 = no pain and 10 = worst possible pain).
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tuberculosis--1||isoniazid-27||yes||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
mark||knew-4/VBD||although-1/IN	num||%-3/NN||91.4-2/CD	nsubj||knew-4/VBD||%-3/NN	advcl||know-15/VB||knew-4/VBD	nsubjpass||transmitted-7/VBN||tb-5/NN	auxpass||transmitted-7/VBN||was-6/VBD	ccomp||knew-4/VBD||transmitted-7/VBN	prep_via||transmitted-7/VBN||aerosols-9/NNS	quantmod||one-third-12/NN||about-11/RB	nsubj||know-15/VB||one-third-12/NN	aux||know-15/VB||did-13/VBD	neg||know-15/VB||not-14/RB	root||ROOT-0/null||know-15/VB	det||method-17/NN||the-16/DT	dobj||know-15/VB||method-17/NN	prepc_for||know-15/VB||administering-19/VBG	dobj||administering-19/VBG||tuberculin-20/NN	det||vaccine-28/NN||that-23/DT	amod||vaccine-28/NN||bacilluscalmette-guerin-24/JJ	nn||vaccine-28/NN||bcg-26/NN	nsubj||contraindication-32/NN||vaccine-28/NN	cop||contraindication-32/NN||was-29/VBD	neg||contraindication-32/NN||not-30/RB	det||contraindication-32/NN||a-31/DT	conj_or||know-15/VB||contraindication-32/NN	aux||tb-34/VB||to-33/TO	vmod||contraindication-32/NN||tb-34/VB	nn||testing-36/NN||skin-35/NN	dobj||tb-34/VB||testing-36/NN	tb-34||bacilluscalmette-guerin-24||no||although 91.4% knew tb was transmitted via aerosols, about one-third did not know the method for administering tuberculin, or that bacilluscalmette-guerin (bcg) vaccine was not a contraindication to tb skin testing.
amod||dye-3/NNS||evans-1/JJ	amod||dye-3/NNS||blue-2/JJ	nsubj||elicits-7/VBZ||dye-3/NNS	appos||dye-3/NNS||eb-5/NN	root||ROOT-0/null||elicits-7/VBZ	det||fluorescence-10/NN||a-8/DT	nn||fluorescence-10/NN||violet-9/NN	dobj||elicits-7/VBZ||fluorescence-10/NN	prep_by||elicits-7/VBZ||excitation-12/NN	prep_at||excitation-12/NN||345-nm-14/NN	prep_at||excitation-12/NN||emission-16/NN	conj_and||345-nm-14/NN||emission-16/NN	prep_at||elicits-7/VBZ||420-nm-18/JJ	det||reddish-brown-22/NN||a-21/DT	nsubj||fluorescence-23/VBP||reddish-brown-22/NN	conj_and||elicits-7/VBZ||fluorescence-23/VBP	prep_by||fluorescence-23/VBP||excitation-25/NN	prep_at||excitation-25/NN||470-nm-27/NN	prep_at||excitation-25/NN||emission-29/NN	conj_and||470-nm-27/NN||emission-29/NN	amod||characteristic-32/NN||515-nm-31/JJ	prep_at||fluorescence-23/VBP||characteristic-32/NN	prep_of||characteristic-32/NN||oxldl-34/NN	advmod||oxldl-34/NN||only-35/RB	evans-1||dye-3||no_rel||evans blue dye (eb) elicits a violet fluorescence by excitation at 345-nm and emission at 420-nm, and a reddish-brown fluorescence by excitation at 470-nm and emission at 515-nm characteristic of oxldl only.
vmod||found-13/VBD||focusing-1/VBG	dep||resistant-3/NN||on-2/IN	amod||viruses-4/NNS||resistant-3/NN	dobj||focusing-1/VBG||viruses-4/NNS	vmod||focusing-1/VBG||carrying-5/VBG	det||mutation-8/NN||the-6/DT	amod||mutation-8/NN||v38a-7/JJ	dobj||carrying-5/VBG||mutation-8/NN	prep_in||carrying-5/VBG||gp41-10/CD	nsubj||found-13/VBD||we-12/PRP	root||ROOT-0/null||found-13/VBD	amod||virus-15/NN||enf-resistant-14/JJ	dobj||found-13/VBD||virus-15/NN	aux||less-22/JJR||to-16/TO	cop||less-22/JJR||be-17/VB	amod||±-19/NNS||17â-18/JJ	npadvmod||less-22/JJR||±-19/NNS	number||%-21/NN||3-20/CD	amod||±-19/NNS||%-21/NN	vmod||found-13/VBD||less-22/JJR	ccomp||less-22/JJR||fit-23/VBP	amod||virus-26/NN||enf-sensitive-25/JJ	prep_than||fit-23/VBP||virus-26/NN	det||absence-29/NN||the-28/DT	prep_in||fit-23/VBP||absence-29/NN	det||drug-32/NN||the-31/DT	prep_of||absence-29/NN||drug-32/NN	mark||due-46/JJ||that-35/IN	det||loss-37/NN||the-36/DT	nsubj||due-46/JJ||loss-37/NN	amod||virus-40/NN||resistant-39/JJ	prep_of||loss-37/NN||virus-40/NN	nn||interruption-43/NN||therapy-42/NN	prep_during||virus-40/NN||interruption-43/NN	cop||due-46/JJ||was-44/VBD	advmod||due-46/JJ||primarily-45/RB	ccomp||less-22/JJR||due-46/JJ	conj_and||fit-23/VBP||due-46/JJ	det||cost-50/NN||this-48/DT	nn||cost-50/NN||fitness-49/NN	prep_to||due-46/JJ||cost-50/NN	virus-40||viruses-4||no||focusing on resistant viruses carrying the v38a mutation in gp41, we found enf-resistant virus to be 17â±3% less fit than enf-sensitive virus in the absence of the drug, and that the loss of resistant virus during therapy interruption was primarily due to this fitness cost.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	det||study-11/NN||a-8/DT	amod||study-11/NN||quasi-experimental-9/JJ	amod||study-11/NN||two-group-10/JJ	nsubjpass||undertaken-13/VBN||study-11/NN	auxpass||undertaken-13/VBN||was-12/VBD	rcmod||$-6/$||undertaken-13/VBN	num||participants-16/NNS||122-15/CD	prep_with||undertaken-13/VBN||participants-16/NNS	nn||factors-20/NNS||diabetes-18/NN	nn||factors-20/NNS||risk-19/NN	prep_with||participants-16/NNS||factors-20/NNS	num||%-23/NN||36.9-22/CD	nsubj||had-24/VBD||%-23/NN	parataxis||â-5/VBP||had-24/VBD	dobj||had-24/VBD||impairedglucosetolerance-25/NN	discourse||impairedglucosetolerance-25/NN||igt-27/UH	amod||glucose-32/NN||impaired-30/VBN	amod||glucose-32/NN||fasting-31/JJ	dobj||had-24/VBD||glucose-32/NN	conj_or||impairedglucosetolerance-25/NN||glucose-32/NN	discourse||glucose-32/NN||ifg-34/UH	prep_at||had-24/VBD||baseline-37/NN	impairedglucosetolerance-25||glucose-32||no_rel||research design and methods â€”a quasi-experimental two-group study was undertaken with 122 participants with diabetes risk factors; 36.9% had impairedglucosetolerance (igt) or impaired fasting glucose (ifg) at baseline.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	det||method-6/NN||a-3/DT	amod||method-6/NN||validated-4/JJ	amod||method-6/NN||mathematical-5/JJ	dobj||used-2/VBD||method-6/NN	aux||estimate-8/VB||to-7/TO	vmod||used-2/VBD||estimate-8/VB	det||rate-10/NN||the-9/DT	dobj||estimate-8/VB||rate-10/NN	amod||hivinfections-13/NNS||new-12/JJ	prep_of||rate-10/NN||hivinfections-13/NNS	nn||incidence-16/NN||hiv-15/NN	appos||hivinfections-13/NNS||incidence-16/NN	amod||africa-20/NN||south-19/JJ	prep_in||estimate-8/VB||africa-20/NN	vmod||africa-20/NN||using-21/VBG	advmod||representative-23/JJ||nationally-22/RB	amod||data-26/NNS||representative-23/JJ	amod||data-26/NNS||hiv-24/JJ	nn||data-26/NNS||prevalence-25/NN	dobj||using-21/VBG||data-26/NNS	vmod||data-26/NNS||collected-27/VBN	prep_in||collected-27/VBN||2002-29/CD	num||2002-29/CD||2005-31/CD	prep_in||collected-27/VBN||2008-33/CD	conj_and||2002-29/CD||2008-33/CD	hivinfections-13||hiv-24||no||we used a validated mathematical method to estimate the rate of new hivinfections (hiv incidence) in south africa using nationally representative hiv prevalence data collected in 2002, 2005 and 2008.
det||alemtuzumab-4/NN||the-1/DT	amod||alemtuzumab-4/NN||cd52-targeting-2/JJ	nn||alemtuzumab-4/NN||antibody-3/NN	nsubjpass||established-6/VBN||alemtuzumab-4/NN	auxpass||established-6/VBN||is-5/VBZ	root||ROOT-0/null||established-6/VBN	amod||practice-9/NN||clinical-8/JJ	prep_in||established-6/VBN||practice-9/NN	prepc_with||established-6/VBN||convincing-11/VBG	dobj||convincing-11/VBG||activity-12/NN	amod||chroniclymphocyticleukemia-17/NN||relapsed-14/JJ	conj_and||relapsed-14/JJ||refractory-16/JJ	amod||chroniclymphocyticleukemia-17/NN||refractory-16/JJ	prep_in||convincing-11/VBG||chroniclymphocyticleukemia-17/NN	appos||chroniclymphocyticleukemia-17/NN||cll-19/NN	dep||convincing-11/VBG||particularly-22/RB	prep_in||convincing-11/VBG||patients-24/NNS	amod||features-27/NNS||high-risk-26/JJ	prep_with||patients-24/NNS||features-27/NNS	amod||prognosis-30/NN||adverse-29/JJ	prep_with||patients-24/NNS||prognosis-30/NN	conj_and||features-27/NNS||prognosis-30/NN	chroniclymphocyticleukemia-17||alemtuzumab-4||yes||the cd52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chroniclymphocyticleukemia (cll), particularly in patients with high-risk features and adverse prognosis.
det||concentration-3/NN||the-1/DT	nn||concentration-3/NN||serum-2/NN	nsubj||different-8/JJ||concentration-3/NN	nsubj||advanced-17/VBD||concentration-3/NN	prep_of||concentration-3/NN||a2m-5/CD	cop||different-8/JJ||was-6/VBD	advmod||different-8/JJ||significantly-7/RB	root||ROOT-0/null||different-8/JJ	amod||f1/f2-14/NN||normal-10/JJ	amod||f1/f2-14/NN||mild-12/JJ	prep_among||different-8/JJ||f1/f2-14/NN	conj_and||different-8/JJ||advanced-17/VBD	dobj||advanced-17/VBD||fibrosis-18/NN	appos||fibrosis-18/NN||f3/f4-20/NNP	nn||0.01-25/NNP||p-23/NNP	nn||0.01-25/NNP||<-24/NNP	appos||fibrosis-18/NN||0.01-25/NNP	fibrosis-18||f3--1||no_rel||the serum concentration of a2m was significantly different among normal, mild (f1/f2) and advanced fibrosis (f3/f4) ( p < 0.01).
dep||expected-32/VBN||improving-1/VBG	nn||awareness-3/NN||community-2/NN	dobj||improving-1/VBG||awareness-3/NN	det||role-6/NN||the-5/DT	prep_about||improving-1/VBG||role-6/NN	prep_of||role-6/NN||primaquine-8/NN	aux||prevent-10/VB||to-9/TO	vmod||improving-1/VBG||prevent-10/VB	amod||transmission-13/NN||further-11/JJ	nn||transmission-13/NN||malaria-12/NN	dobj||prevent-10/VB||transmission-13/NN	conj_and||improving-1/VBG||fostering-15/VBG	dep||expected-32/VBN||fostering-15/VBG	det||system-18/NN||a-16/DT	amod||system-18/NN||realistic-17/JJ	dobj||fostering-15/VBG||system-18/NN	amod||observed-21/JJ||direct-20/JJ	amod||intake-23/NN||observed-21/JJ	nn||intake-23/NN||treatment-22/NN	prep_of||system-18/NN||intake-23/NN	parataxis||expected-32/VBN||organized-25/VBN	nn||level-28/NN||community-27/NN	prep_at||organized-25/VBN||level-28/NN	aux||expected-32/VBN||can-30/MD	auxpass||expected-32/VBN||be-31/VB	root||ROOT-0/null||expected-32/VBN	aux||improve-34/VB||to-33/TO	xcomp||expected-32/VBN||improve-34/VB	dobj||improve-34/VB||adherence-35/NN	det||cure-39/NN||the-37/DT	amod||cure-39/NN||radical-38/JJ	prep_to||improve-34/VB||cure-39/NN	nn||vivax-42/NN||p.-41/NN	prep_of||cure-39/NN||vivax-42/NN	det||area-45/NN||this-44/DT	prep_in||vivax-42/NN||area-45/NN	malaria-12||primaquine-8||yes||improving community awareness about the role of primaquine to prevent further malaria transmission and fostering a realistic system of direct observed treatment intake , organized at community level , can be expected to improve adherence to the radical cure of p. vivax in this area .
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||efficacy-10/NN||the-9/DT	dobj||compare-8/VB||efficacy-10/NN	prep_of||efficacy-10/NN||ketorolac-12/NNP	prep_of||efficacy-10/NN||paracetamol-14/NNP	conj_and||ketorolac-12/NNP||paracetamol-14/NNP	prep_of||efficacy-10/NN||paracetamol-17/NNP	conj_and||ketorolac-12/NNP||paracetamol-17/NNP	dobj||compare-8/VB||morphine-19/NN	conj_plus||efficacy-10/NN||morphine-19/NN	nn||relief-22/NN||pain-21/NN	prep_on||morphine-19/NN||relief-22/NN	prep_after||compare-8/VB||thyroidectomy-24/NN	pain-21||paracetamol-17||yes||the aim of this study was to compare the efficacy of ketorolac, paracetamol, and paracetamol plus morphine on pain relief after thyroidectomy.
nn||analysis-6/NN||retrospective-1/NN	amod||analysis-6/NN||reverse-2/JJ	amod||analysis-6/NN||transcription-polymerase-3/JJ	nn||analysis-6/NN||chain-4/NN	nn||analysis-6/NN||reaction-5/NN	root||ROOT-0/null||analysis-6/NN	prep_of||analysis-6/NN||influenza-8/NN	det||viruses-11/NNS||a-9/DT	amod||viruses-11/NNS||h1-10/JJ	nsubj||isolated-12/VBD||viruses-11/NNS	dep||analysis-6/NN||isolated-12/VBD	det||u.k.-15/NN||the-14/DT	prep_in||isolated-12/VBD||u.k.-15/NN	det||winter-19/NN||the-17/DT	amod||winter-19/NN||previous-18/JJ	prep_during||isolated-12/VBD||winter-19/NN	vmod||winter-19/NN||identified-20/VBN	det||virus-24/NN||a-21/DT	amod||virus-24/NN||single-22/JJ	amod||virus-24/NN||h1n2-23/JJ	dobj||identified-20/VBN||virus-24/NN	vmod||analysis-6/NN||isolated-26/VBN	prep_in||isolated-26/VBN||march-28/NN	num||march-28/NN||2001-29/CD	vmod||analysis-6/NN||indicating-31/VBG	mark||circulate-38/VB||that-32/IN	amod||viruses-34/NNS||h1n2-33/JJ	nsubj||circulate-38/VB||viruses-34/NNS	aux||circulate-38/VB||did-35/VBD	neg||circulate-38/VB||not-36/RB	advmod||circulate-38/VB||widely-37/RB	ccomp||indicating-31/VBG||circulate-38/VB	det||u.k.-41/NN||the-40/DT	prep_in||circulate-38/VB||u.k.-41/NN	prep_before||analysis-6/NN||september-43/NNP	num||september-43/NNP||2001-44/CD	virus-24||viruses-34||no||retrospective reverse transcription-polymerase chain reaction analysis of influenza a h1 viruses isolated in the u.k. during the previous winter identified a single h1n2 virus , isolated in march 2001 , indicating that h1n2 viruses did not widely circulate in the u.k. before september 2001 .
det||study-2/NN||the-1/DT	nsubj||suggested-3/VBD||study-2/NN	root||ROOT-0/null||suggested-3/VBD	det||exposure-6/NN||that-4/DT	amod||exposure-6/NN||short-term-5/JJ	dobj||suggested-3/VBD||exposure-6/NN	nn||±-9/NNS||î-8/NN	prep_to||suggested-3/VBD||±-9/NNS	dep||±-9/NNS||cp-11/NN	nn||mice-14/NNS||albino-13/NN	prep_in||cp-11/NN||mice-14/NNS	vmod||mice-14/NNS||induced-15/VBN	amod||lesions-17/NNS||toxicopathological-16/JJ	dobj||induced-15/VBN||lesions-17/NNS	nn||tissue-20/NN||testicular-19/NN	prep_in||induced-15/VBN||tissue-20/NN	vmod||tissue-20/NN||leading-21/VBG	amod||levels-26/NNS||decreased-23/VBN	nn||levels-26/NNS||plasma-24/NN	nn||levels-26/NNS||testosterone-25/NN	prep_to||leading-21/VBG||levels-26/NNS	testosterone-25||albino-13||no_rel||the study suggested that short-term exposure to î±-cp in albino mice induced toxicopathological lesions in testicular tissue leading to decreased plasma testosterone levels.
advmod||deciphered-5/VBD||there-1/RB	nn||myers-4/NNS||dr.-3/NN	nsubj||deciphered-5/VBD||myers-4/NNS	root||ROOT-0/null||deciphered-5/VBD	dobj||deciphered-5/VBD||many-6/JJ	det||insulin-9/NN||the-8/DT	prep_of||many-6/JJ||insulin-9/NN	vmod||insulin-9/NN||signaling-10/VBG	dobj||signaling-10/VBG||pathways-11/NNS	vmod||pathways-11/NNS||engaged-12/VBN	nn||proteins-17/NNS||insulin-14/NN	nn||proteins-17/NNS||receptor-15/NN	nn||proteins-17/NNS||substrate-16/NN	agent||engaged-12/VBN||proteins-17/NNS	insulin-14||dr--1||no_rel||there , dr. myers deciphered many of the insulin signaling pathways engaged by insulin receptor substrate proteins .
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||propofol-18||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
det||constellation-2/NN||the-1/DT	nsubjpass||classified-27/VBN||constellation-2/NN	prep_of||constellation-2/NN||dyslipidemia-4/NN	amod||levels-9/NNS||hypertriglyceridemia-6/JJ	conj_and||hypertriglyceridemia-6/JJ||low-8/JJ	amod||levels-9/NNS||low-8/JJ	dep||dyslipidemia-4/NN||levels-9/NNS	amod||cholesterol-13/NN||high-density-11/JJ	nn||cholesterol-13/NN||lipoprotein-12/NN	prep_of||levels-9/NNS||cholesterol-13/NN	amod||pressure-18/NN||elevated-16/JJ	nn||pressure-18/NN||blood-17/NN	prep_of||constellation-2/NN||pressure-18/NN	conj_and||dyslipidemia-4/NN||pressure-18/NN	prep_of||constellation-2/NN||impairedglucosetolerance-20/NN	conj_and||dyslipidemia-4/NN||impairedglucosetolerance-20/NN	amod||obesity-24/NN||central-23/JJ	prep_of||constellation-2/NN||obesity-24/NN	conj_and||dyslipidemia-4/NN||obesity-24/NN	auxpass||classified-27/VBN||is-25/VBZ	advmod||classified-27/VBN||now-26/RB	root||ROOT-0/null||classified-27/VBN	amod||syndrome-30/NN||metabolic-29/JJ	prep_as||classified-27/VBN||syndrome-30/NN	advmod||called-33/VBN||also-32/RB	vmod||syndrome-30/NN||called-33/VBN	nn||x.-35/NN||syndrome-34/NN	dobj||called-33/VBN||x.-35/NN	cholesterol-13||obesity-24||no_rel||the constellation of dyslipidemia (hypertriglyceridemia and low levels of high-density lipoprotein cholesterol), elevated blood pressure, impairedglucosetolerance, and central obesity is now classified as metabolic syndrome, also called syndrome x.
amod||patients-2/NNS||sixty-1/JJ	nsubjpass||divided-12/VBN||patients-2/NNS	prep_with||patients-2/NNS||psychoticdisorder-4/NN	nsubjpass||assigned-7/VBN||psychoticdisorder-4/NN	auxpass||assigned-7/VBN||were-6/VBD	rcmod||psychoticdisorder-4/NN||assigned-7/VBN	amod||treatment-10/NN||6-month-9/JJ	prep_to||assigned-7/VBN||treatment-10/NN	auxpass||divided-12/VBN||were-11/VBD	root||ROOT-0/null||divided-12/VBN	num||groups-15/NNS||two-14/CD	prep_in||divided-12/VBN||groups-15/NNS	num||haloperidol-18/NN||30-16/CD	amod||haloperidol-18/NN||received-17/VBN	dobj||divided-12/VBN||haloperidol-18/NN	amod||antipsychotic-22/NN||first-20/JJ	nn||antipsychotic-22/NN||generation-21/NN	appos||haloperidol-18/NN||antipsychotic-22/NN	num||olanzapine-27/NN||30-25/CD	amod||olanzapine-27/NN||received-26/VBN	dobj||divided-12/VBN||olanzapine-27/NN	conj_and||haloperidol-18/NN||olanzapine-27/NN	amod||antipsychotic-31/NN||second-29/JJ	nn||antipsychotic-31/NN||generation-30/NN	appos||olanzapine-27/NN||antipsychotic-31/NN	haloperidol-18||psychoticdisorder-4||no_rel||sixty patients with psychoticdisorder who were assigned to 6-month treatment were divided in two groups 30 received haloperidol (first generation antipsychotic) and 30 received olanzapine (second generation antipsychotic).
amod||antibody-3/NN||anti-dengue-1/JJ	nn||antibody-3/NN||igm-2/NN	nsubj||detectable-5/JJ||antibody-3/NN	cop||detectable-5/JJ||was-4/VBD	root||ROOT-0/null||detectable-5/JJ	det||day-9/NN||the-7/DT	amod||day-9/NN||third-8/JJ	prep_on||detectable-5/JJ||day-9/NN	prepc_of||day-9/NN||onset-11/VBG	det||rate-15/NN||the-13/DT	amod||rate-15/NN||positive-14/JJ	prep_with||onset-11/VBG||rate-15/NN	num||%-18/NN||42.9-17/CD	prep_of||rate-15/NN||%-18/NN	advmod||increasing-22/VBG||rapidly-21/RB	prepc_of||day-9/NN||increasing-22/VBG	conj_and||onset-11/VBG||increasing-22/VBG	num||%-25/NN||100-24/CD	prep_to||increasing-22/VBG||%-25/NN	prep_by||increasing-22/VBG||day-27/NN	num||day-27/NN||8-28/CD	prep_of||day-27/NN||illness-30/NN	antibody-3||dengue--1||no_rel||anti-dengue igm antibody was detectable on the third day of onset with the positive rate of 42.9%, and rapidly increasing to 100% by day 8 of illness.
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||study-5/NN||a-3/DT	amod||study-5/NN||cross-sectional-4/JJ	dobj||performed-2/VBD||study-5/NN	poss||referral-center-8/NN||our-7/PRP$	prep_at||performed-2/VBD||referral-center-8/NN	prep_for||referral-center-8/NN||mmc-10/NN	aux||determine-12/VB||to-11/TO	vmod||performed-2/VBD||determine-12/VB	det||outcome-14/NN||the-13/DT	dobj||determine-12/VB||outcome-14/NN	poss||patients-19/NNS||our-16/PRP$	advmod||managed-18/VBN||expectantly-17/RB	amod||patients-19/NNS||managed-18/VBN	prep_for||outcome-14/NN||patients-19/NNS	cross--1||mmc-10||no_rel||we performed a cross-sectional study at our referral-center for mmc to determine the outcome for our expectantly managed patients.
det||conclusion-2/NN||this-1/DT	nsubjpass||supported-4/VBN||conclusion-2/NN	auxpass||supported-4/VBN||is-3/VBZ	ccomp||observed-28/VBD||supported-4/VBN	det||loss-9/NN||the-6/DT	amod||loss-9/NN||well-described-7/JJ	amod||loss-9/NN||extensive-8/JJ	agent||supported-4/VBN||loss-9/NN	amod||cells-16/NNS||intestinal-11/JJ	amod||cells-16/NNS||mucosal-12/JJ	amod||cells-16/NNS||cd4-13/JJ	amod||cells-16/NNS||+-14/JJ	nn||cells-16/NNS||t-15/NN	prep_of||loss-9/NN||cells-16/NNS	vmod||cells-16/NNS||associated-17/VBN	amod||hivinfection-20/NN||primary-19/JJ	prep_with||associated-17/VBN||hivinfection-20/NN	det||load-27/NN||the-22/DT	advmod||high-24/JJ||extremely-23/RB	amod||load-27/NN||high-24/JJ	nn||load-27/NN||hiv-25/NN	amod||load-27/NN||viral-26/JJ	nsubj||observed-28/VBD||load-27/NN	root||ROOT-0/null||observed-28/VBD	poss||patient-31/NN||our-30/PRP$	prep_in||observed-28/VBD||patient-31/NN	det||improvement-36/NN||the-34/DT	amod||improvement-36/NN||rapid-35/JJ	prep_in||observed-28/VBD||improvement-36/NN	conj_and||patient-31/NN||improvement-36/NN	det||ulcer-39/NN||the-38/DT	prep_of||improvement-36/NN||ulcer-39/NN	prep_after||observed-28/VBD||initiation-41/NN	advmod||active-44/JJ||highly-43/RB	amod||therapy-46/NN||active-44/JJ	amod||therapy-46/NN||antiretroviral-45/JJ	prep_of||initiation-41/NN||therapy-46/NN	hivinfection-20||hiv-25||no||this conclusion is supported by the well-described extensive loss of intestinal mucosal cd4+ t cells associated with primary hivinfection, the extremely high hiv viral load observed in our patient, and the rapid improvement of the ulcer after initiation of highly active antiretroviral therapy.
det||increase-2/NN||an-1/DT	nsubjpass||associated-12/VBN||increase-2/NN	nsubjpass||associated-12/VBN||increase-2/NN	amod||adiposity-9/NN||total-4/JJ	conj_and||total-4/JJ||visceral-8/JJ	amod||adiposity-9/NN||visceral-8/JJ	prep_in||increase-2/NN||adiposity-9/NN	auxpass||associated-12/VBN||is-10/VBZ	advmod||associated-12/VBN||probably-11/RB	root||ROOT-0/null||associated-12/VBN	conj_negcc||associated-12/VBN||associated-12/VBN	det||decrease-15/NN||a-14/DT	prep_with||associated-12/VBN||decrease-15/NN	nn||distensibility-18/NN||vascular-17/NN	prep_in||decrease-15/NN||distensibility-18/NN	det||boys-24/NNS||the-20/DT	nn||boys-24/NNS||gujarati-21/NN	nn||boys-24/NNS||indian-22/NN	amod||boys-24/NNS||adolescent-23/JJ	prep_in||distensibility-18/NN||boys-24/NNS	prep_in||associated-12/VBN||girls-28/NNS	advmod||indicating-31/VBG||thus-30/RB	xcomp||associated-12/VBN||indicating-31/VBG	det||role-34/NN||a-32/DT	amod||role-34/NN||protective-33/JJ	dobj||indicating-31/VBG||role-34/NN	amod||estrogen-38/NN||female-36/JJ	nn||estrogen-38/NN||sexhormone-37/NN	prep_of||role-34/NN||estrogen-38/NN	nsubjpass||shown-42/VBN||estrogen-38/NN	nsubj||protect-45/VB||estrogen-38/NN	aux||shown-42/VBN||has-40/VBZ	auxpass||shown-42/VBN||been-41/VBN	rcmod||estrogen-38/NN||shown-42/VBN	advmod||shown-42/VBN||earlier-43/RBR	aux||protect-45/VB||to-44/TO	xcomp||shown-42/VBN||protect-45/VB	det||vasculature-47/NN||the-46/DT	dobj||protect-45/VB||vasculature-47/NN	prep_from||protect-45/VB||atherosclerosis-49/NNS	amod||dysfunction-52/NN||endothelial-51/JJ	appos||atherosclerosis-49/NNS||dysfunction-52/NN	nsubj||occurs-54/VBZ||dysfunction-52/NN	rcmod||dysfunction-52/NN||occurs-54/VBZ	prep_with||occurs-54/VBZ||increase-56/NN	prep_in||increase-56/NN||adiposity-58/NN	sexhormone-37||adiposity-58||no_rel||an increase in total as well as visceral adiposity is probably associated with a decrease in vascular distensibility in the gujarati indian adolescent boys but not in girls, thus indicating a protective role of female sexhormone estrogen which has been shown earlier to protect the vasculature from atherosclerosis, endothelial dysfunction which occurs with increase in adiposity.
nsubjpass||treated-6/VBN||he-1/PRP	aux||treated-6/VBN||was-2/VBD	advmod||treated-6/VBN||also-3/RB	advmod||treated-6/VBN||concomitantly-4/RB	auxpass||treated-6/VBN||being-5/VBG	root||ROOT-0/null||treated-6/VBN	amod||infections-10/NNS||other-8/JJ	amod||infections-10/NNS||opportunistic-9/JJ	prep_for||treated-6/VBN||infections-10/NNS	amod||retinitis-16/NNS||cytomegalovirus-12/JJ	nn||retinitis-16/NNS||-lrb--13/NN	nn||retinitis-16/NNS||cmv-14/NN	nn||retinitis-16/NNS||-rrb--15/NN	prep_including||infections-10/NNS||retinitis-16/NNS	nn||foscarnet-19/NN||i.v.-18/NN	prep_with||retinitis-16/NNS||foscarnet-19/NN	quantmod||2-22/CD||almost-21/RB	num||months-23/NNS||2-22/CD	prep_for||foscarnet-19/NN||months-23/NNS	det||presentation-28/NN||the-26/DT	nn||presentation-28/NN||index-27/NN	prep_prior_to||months-23/NNS||presentation-28/NN	cytomegalovirus-12||foscarnet-19||yes||he was also concomitantly being treated for other opportunistic infections including cytomegalovirus -lrb- cmv -rrb- retinitis with i.v. foscarnet for almost 2 months prior to the index presentation .
num||patients-6/NNS||49-1/CD	amod||patients-6/NNS||non-insulin-2/JJ	amod||patients-6/NNS||dependent-3/JJ	amod||patients-6/NNS||male-4/JJ	amod||patients-6/NNS||t2d-5/JJ	nsubjpass||enrolled-13/VBN||patients-6/NNS	num||subjects-11/NNS||54-8/CD	amod||subjects-11/NNS||male-9/JJ	nn||subjects-11/NNS||control-10/NN	conj_and||patients-6/NNS||subjects-11/NNS	nsubjpass||enrolled-13/VBN||subjects-11/NNS	auxpass||enrolled-13/VBN||were-12/VBD	root||ROOT-0/null||enrolled-13/VBN	det||clamp-18/NN||a-16/DT	amod||clamp-18/NN||hyperinsulinemic-euglycemic-17/JJ	nsubjpass||performed-23/VBN||clamp-18/NN	amod||calorimetry-21/NN||indirect-20/JJ	conj_and||clamp-18/NN||calorimetry-21/NN	nsubjpass||performed-23/VBN||calorimetry-21/NN	auxpass||performed-23/VBN||were-22/VBD	conj_and||enrolled-13/VBN||performed-23/VBN	t2d-5||insulin--1||yes||49 non-insulin dependent male t2d patients and 54 male control subjects were enrolled, and a hyperinsulinemic-euglycemic clamp and indirect calorimetry were performed.
nsubj||drug-8/NN||ethambutol-1/NN	appos||ethambutol-1/NN||emb-3/NN	cop||drug-8/NN||is-5/VBZ	det||drug-8/NN||a-6/DT	amod||drug-8/NN||first-line-7/JJ	root||ROOT-0/null||drug-8/NN	det||treatment-11/NN||the-10/DT	prep_for||drug-8/NN||treatment-11/NN	prep_of||treatment-11/NN||tuberculosis-13/NNP	appos||tuberculosis-13/NNP||tb-15/NN	tb-15||ethambutol-1||yes||ethambutol (emb) is a first-line drug for the treatment of tuberculosis (tb).
det||paper-2/NN||this-1/DT	nsubj||focuses-3/VBZ||paper-2/NN	root||ROOT-0/null||focuses-3/VBZ	det||role-6/NN||a-5/DT	prep_on||focuses-3/VBZ||role-6/NN	nn||neurotransmission-9/NN||atp-8/NN	prep_for||role-6/NN||neurotransmission-9/NN	prep_for||role-6/NN||gliotransmission-11/NN	conj_and||neurotransmission-9/NN||gliotransmission-11/NN	det||pathophysiology-14/NN||the-13/DT	prep_in||focuses-3/VBZ||pathophysiology-14/NN	prep_of||pathophysiology-14/NN||epilepticseizures-16/NNS	atp-8||epilepticseizures-16||no_rel||this paper focuses on a role for atp neurotransmission and gliotransmission in the pathophysiology of epilepticseizures.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	mark||change-16/VB||whether-3/IN	num||minutes-5/NNS||60-4/CD	nsubj||change-16/VB||minutes-5/NNS	prep_of||minutes-5/NNS||ischemia-7/NN	vmod||ischemia-7/NN||followed-8/VBN	num||minutes-11/NNS||30-10/CD	agent||followed-8/VBN||minutes-11/NNS	prep_of||minutes-11/NNS||reperfusion-13/NN	aux||change-16/VB||do-14/VBP	neg||change-16/VB||not-15/RB	ccomp||investigated-2/VBD||change-16/VB	det||relaxation-18/NN||the-17/DT	dobj||change-16/VB||relaxation-18/NN	amod||arteries-21/NNS||visceral-20/JJ	prep_of||relaxation-18/NN||arteries-21/NNS	det||plasma-24/NN||the-23/DT	dobj||change-16/VB||plasma-24/NN	conj_nor||relaxation-18/NN||plasma-24/NN	amod||levels-27/NNS||renal-26/JJ	conj_nor||relaxation-18/NN||levels-27/NNS	conj_and||plasma-24/NN||levels-27/NNS	prep_of||levels-27/NNS||malondialdehyde-29/NN	appos||malondialdehyde-29/NN||mda-31/NN	amod||nitrate-36/NN||nitrite-34/JJ	nn||nitrate-36/NN||plus-35/NN	prep_of||levels-27/NNS||nitrate-36/NN	conj_and||malondialdehyde-29/NN||nitrate-36/NN	appos||malondialdehyde-29/NN||nox-38/NN	ischemia-7||nitrate-36||no_rel||we investigated whether 60 minutes of ischemia followed by 30 minutes of reperfusion do not change the relaxation of visceral arteries nor the plasma and renal levels of malondialdehyde (mda) and nitrite plus nitrate (nox).
amod||slymphoma-3/NNS||endemicburkitt-1/JJ	nsubjpass||associated-9/VBN||slymphoma-3/NNS	discourse||slymphoma-3/NNS||ebl-5/UH	aux||associated-9/VBN||has-7/VBZ	auxpass||associated-9/VBN||been-8/VBN	root||ROOT-0/null||associated-9/VBN	nn||ebv-17/NN||epsteinâ-11/NNP	nn||ebv-17/NN||$-12/NNP	nn||ebv-17/NN||barr-14/NN	nn||ebv-17/NN||virus-15/NN	prep_with||associated-9/VBN||ebv-17/NN	amod||falciparummalaria-22/NN||holoendemic-20/JJ	nn||falciparummalaria-22/NN||plasmodium-21/NN	prep_with||associated-9/VBN||falciparummalaria-22/NN	conj_and||ebv-17/NN||falciparummalaria-22/NN	endemicburkitt'slymphoma--1||ebv-17||no||endemicburkitt'slymphoma (ebl) has been associated with epsteinâ€“barr virus (ebv) and holoendemic plasmodium falciparummalaria.
amod||agents-4/NNS||recommended-1/VBN	amod||agents-4/NNS||parenteral-2/JJ	nn||agents-4/NNS||anticoagulant-3/NN	nsubj||include-16/VBP||agents-4/NNS	amod||indications-7/NNS||different-6/JJ	prep_with||agents-4/NNS||indications-7/NNS	det||prevention-10/NN||the-9/DT	prep_for||indications-7/NNS||prevention-10/NN	prep_for||indications-7/NNS||treatment-12/NN	conj_and||prevention-10/NN||treatment-12/NN	amod||thromboembolism-15/NN||venous-14/JJ	prep_of||prevention-10/NN||thromboembolism-15/NN	root||ROOT-0/null||include-16/VBP	dobj||include-16/VBP||unfractionatedheparin-17/NN	amod||heparins-20/NNS||low-molecular-weight-19/JJ	dobj||include-16/VBP||heparins-20/NNS	conj_and||unfractionatedheparin-17/NN||heparins-20/NNS	dobj||include-16/VBP||fondaparinux-22/NN	conj_and||unfractionatedheparin-17/NN||fondaparinux-22/NN	thromboembolism-15||fondaparinux-22||yes||recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include unfractionatedheparin, low-molecular-weight heparins and fondaparinux.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||paucity-4/NN||a-3/DT	nsubj||was-2/VBD||paucity-4/NN	prep_of||paucity-4/NN||evidence-6/NN	prep_on||evidence-6/NN||behaviour-8/NN	aux||avoid-10/VB||to-9/TO	vmod||paucity-4/NN||avoid-10/VB	dobj||avoid-10/VB||hypoglycaemia-11/NN	expl||were-15/VBD||there-14/EX	conj_but||was-2/VBD||were-15/VBD	det||suggestions-17/NNS||some-16/DT	nsubj||were-15/VBD||suggestions-17/NNS	mark||permitted-27/VBN||that-18/IN	nsubjpass||permitted-27/VBN||higher-19/JJR	nsubj||avoid-31/VB||higher-19/JJR	amod||levels-24/NNS||desirable-21/JJ	nn||levels-24/NNS||blood-22/NN	nn||levels-24/NNS||glucose-23/NN	prep_than||higher-19/JJR||levels-24/NNS	aux||permitted-27/VBN||might-25/MD	auxpass||permitted-27/VBN||be-26/VB	ccomp||were-15/VBD||permitted-27/VBN	prep_in||permitted-27/VBN||order-29/NN	aux||avoid-31/VB||to-30/TO	xcomp||permitted-27/VBN||avoid-31/VB	dobj||avoid-31/VB||hypoglycaemia-32/NN	glucose-23||hypoglycaemia-32||no_rel||there was a paucity of evidence on behaviour to avoid hypoglycaemia, but there were some suggestions that higher than desirable blood glucose levels might be permitted in order to avoid hypoglycaemia.
nn||rates-2/NNS||success-1/NN	nsubj||%-9/NN||rates-2/NNS	prep_for||rates-2/NNS||daptomycin-4/NN	prep_versus||daptomycin-4/NN||vancomycin/gentamicin-6/NN	cop||%-9/NN||were-7/VBD	num||%-9/NN||45-8/CD	root||ROOT-0/null||%-9/NN	num||%-12/NN||27-11/CD	prep_versus||%-9/NN||%-12/NN	amod||bacteraemia-15/NN||complicated-14/JJ	prep_in||%-12/NN||bacteraemia-15/NN	num||%-18/NN||60-17/CD	prep_versus||%-9/NN||%-18/NN	conj_and||%-12/NN||%-18/NN	num||%-21/NN||45-20/CD	prep_versus||%-18/NN||%-21/NN	amod||bacteraemia-24/NN||uncomplicated-23/JJ	prep_in||%-21/NN||bacteraemia-24/NN	num||%-27/NN||50-26/CD	prep_versus||%-9/NN||%-27/NN	conj_and||%-12/NN||%-27/NN	num||%-30/NN||50-29/CD	prep_versus||%-27/NN||%-30/NN	amod||endocarditis-34/NNS||right-sided-32/JJ	nn||endocarditis-34/NNS||mrsa-33/NN	prep_in||%-30/NN||endocarditis-34/NNS	vancomycin--1||bacteraemia-24||no_rel||success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided mrsa endocarditis.
nsubj||revealed-2/VBD||msp-1/NN	nsubj||identified-21/VBD||msp-1/NN	root||ROOT-0/null||revealed-2/VBD	num||viruses-6/NNS||two-3/CD	amod||viruses-6/NNS||unreported-4/JJ	nn||viruses-6/NNS||rna-5/NN	dobj||revealed-2/VBD||viruses-6/NNS	nn||bees-11/NNS||north-8/NN	nn||bees-11/NNS||american-9/NN	nn||bees-11/NNS||honey-10/NN	prep_in||revealed-2/VBD||bees-11/NNS	amod||virus-15/NN||varroa-13/JJ	amod||virus-15/NN||destructor-1-14/JJ	prep_in||revealed-2/VBD||virus-15/NN	conj_and||bees-11/NNS||virus-15/NN	nn||virus-18/NN||kakugo-17/NN	prep_in||revealed-2/VBD||virus-18/NN	conj_and||bees-11/NNS||virus-18/NN	conj_and||revealed-2/VBD||identified-21/VBD	det||virus-25/NN||an-22/DT	amod||virus-25/NN||invertebrate-23/JJ	nn||virus-25/NN||iridescent-24/NN	dobj||identified-21/VBD||virus-25/NN	dep||virus-25/NN||iiv-27/NN	amod||virus-25/NN||iridoviridae-30/JJ	vmod||virus-25/NN||associated-32/VBN	nn||colonies-35/NNS||ccd-34/NN	prep_with||associated-32/VBN||colonies-35/NNS	virus-25||viruses-6||no||msp revealed two unreported rna viruses in north american honey bees, varroa destructor-1 virus and kakugo virus, and identified an invertebrate iridescent virus (iiv) ( iridoviridae ) associated with ccd colonies.
poss||studies-2/NNS||our-1/PRP$	nsubj||demonstrated-11/VBD||studies-2/NNS	nn||effects-5/NNS||nm-4/NN	prep_on||studies-2/NNS||effects-5/NNS	amod||metastasis-10/NNS||hepatic-7/JJ	conj_and||hepatic-7/JJ||pulmonary-9/JJ	amod||metastasis-10/NNS||pulmonary-9/JJ	prep_on||effects-5/NNS||metastasis-10/NNS	root||ROOT-0/null||demonstrated-11/VBD	amod||suppression-15/NN||profound-12/JJ	amod||suppression-15/NN||significant-14/JJ	dobj||demonstrated-11/VBD||suppression-15/NN	prep_of||suppression-15/NN||metastasis-17/NNS	det||model-21/NN||a-19/DT	amod||model-21/NN||murine-20/JJ	prep_in||demonstrated-11/VBD||model-21/NN	metastasis-17||nm-4||yes||our studies on nm effects on hepatic and pulmonary metastasis demonstrated profound, significant suppression of metastasis in a murine model.
advmod||became-13/VBD||overall-1/RB	num||%-4/NN||46-3/CD	nsubj||became-13/VBD||%-4/NN	det||cadets-8/NNS||the-6/DT	num||cadets-8/NNS||437-7/CD	prep_of||%-4/NN||cadets-8/NNS	vmod||cadets-8/NNS||entering-9/VBG	nn||antibody-12/NN||ebv-11/NN	prep_without||entering-9/VBG||antibody-12/NN	root||ROOT-0/null||became-13/VBD	acomp||became-13/VBD||infected-14/VBN	num||mo-17/NN||40-16/CD	prep_over||infected-14/VBN||mo-17/NN	amod||observation-20/NN||serologic-19/JJ	prep_of||mo-17/NN||observation-20/NN	amod||infectiousmononucleosis-24/NNS||definite-22/JJ	amod||infectiousmononucleosis-24/NNS||clinical-23/JJ	nsubj||developed-25/VBD||infectiousmononucleosis-24/NNS	parataxis||became-13/VBD||developed-25/VBD	num||cadets-28/NNS||53-27/CD	prep_in||developed-25/VBD||cadets-28/NNS	det||rate-33/NN||a-30/DT	amod||rate-33/NN||clinical-31/JJ	nn||rate-33/NN||attack-32/NN	appos||cadets-28/NNS||rate-33/NN	prep_of||rate-33/NN||12.1-35/NNP	prep_per||12.1-35/NNP||100-37/CD	num||yr-40/NN||4-39/CD	prep_for||developed-25/VBD||yr-40/NN	infectiousmononucleosis-24||ebv-11||no||overall, 46% of the 437 cadets entering without ebv antibody became infected over 40 mo of serologic observation; definite clinical infectiousmononucleosis developed in 53 cadets, a clinical attack rate of 12.1 per 100 for 4 yr.
det||correlation-3/NN||a-1/DT	amod||correlation-3/NN||significant-2/JJ	nsubj||estimated-9/VBD||correlation-3/NN	nsubj||mr-15/VBP||correlation-3/NN	advmod||visible-6/JJ||microscopically-5/RB	amod||droplets-8/NNS||visible-6/JJ	nn||droplets-8/NNS||lipid-7/NN	prep_between||correlation-3/NN||droplets-8/NNS	root||ROOT-0/null||estimated-9/VBD	amod||staining-13/NN||nile-11/JJ	amod||staining-13/NN||red-12/JJ	prep_by||estimated-9/VBD||staining-13/NN	conj_and||estimated-9/VBD||mr-15/VBP	amod||signals-18/NNS||visible-16/JJ	nn||signals-18/NNS||lipid-17/NN	nsubjpass||observed-20/VBN||signals-18/NNS	auxpass||observed-20/VBN||was-19/VBD	ccomp||mr-15/VBP||observed-20/VBN	amod||carcinomas-24/NNS||metastatic-22/JJ	nn||carcinomas-24/NNS||lung-23/NN	prep_in||observed-20/VBN||carcinomas-24/NNS	dep||carcinomas-24/NNS||p-26/VBN	dep||0.01-28/CD||=-27/SYM	ccomp||p-26/VBN||0.01-28/CD	vmod||estimated-9/VBD||indicating-31/VBG	mark||mr-35/VBP||that-32/IN	det||proton-34/NN||the-33/DT	nsubj||mr-35/VBP||proton-34/NN	ccomp||indicating-31/VBG||mr-35/VBP	amod||signals-38/NNS||visible-36/JJ	nn||signals-38/NNS||lipid-37/NN	nsubj||arise-39/VBP||signals-38/NNS	ccomp||mr-35/VBP||arise-39/VBP	amod||droplets-43/NNS||cytoplasmic-41/JJ	nn||droplets-43/NNS||lipid-42/NN	prep_from||arise-39/VBP||droplets-43/NNS	lipid-42||carcinomas-24||no_rel||a significant correlation between microscopically visible lipid droplets estimated by nile red staining and mr visible lipid signals was observed in metastatic lung carcinomas ( p = 0.01), indicating that the proton mr visible lipid signals arise from cytoplasmic lipid droplets.
nsubjpass||managed-7/VBN||type2diabetes-1/NNS	prep_in||type2diabetes-1/NNS||children-3/NNS	auxpass||managed-7/VBN||is-4/VBZ	advmod||commonly-6/RB||most-5/RBS	advmod||managed-7/VBN||commonly-6/RB	ccomp||approved-22/VBD||managed-7/VBN	nn||modification-10/NN||lifestyle-9/NN	prep_with||managed-7/VBN||modification-10/NN	prep_with||managed-7/VBN||medications-12/NNS	conj_and||modification-10/NN||medications-12/NNS	amod||insulin-16/NN||metformin-14/JJ	amod||insulin-16/NN||and/or-15/JJ	appos||modification-10/NN||insulin-16/NN	det||medications-20/NNS||the-18/DT	amod||medications-20/NNS||only-19/JJ	nsubj||approved-22/VBD||medications-20/NNS	advmod||approved-22/VBD||currently-21/RB	root||ROOT-0/null||approved-22/VBD	prep_for||approved-22/VBD||use-24/NN	prep_in||approved-22/VBD||children-26/NNS	type2diabetes-1||metformin-14||yes||type2diabetes in children is most commonly managed with lifestyle modification and medications, metformin and/or insulin, the only medications currently approved for use in children.
nn||analyses-2/NNS||ihc-1/NN	nsubjpass||performed-4/VBN||analyses-2/NNS	auxpass||performed-4/VBN||were-3/VBD	root||ROOT-0/null||performed-4/VBN	det||block-8/NN||each-6/DT	nn||block-8/NN||cell-7/NN	prep_on||performed-4/VBN||block-8/NN	prep_with||block-8/NN||antibodies-10/NNS	nn||receptor-13/NN||estrogen-12/NN	prep_to||performed-4/VBN||receptor-13/NN	appos||receptor-13/NN||er-15/NN	amod||receptor-19/NN||progesterone-18/JJ	appos||receptor-13/NN||receptor-19/NN	appos||receptor-19/NN||pr-21/NN	amod||receptor-33/NN||her2-24/JJ	conj_and||her2-24/JJ||egfr-26/JJ	amod||receptor-33/NN||egfr-26/JJ	conj_and||her2-24/JJ||ck5/6-28/JJ	amod||receptor-33/NN||ck5/6-28/JJ	conj_and||her2-24/JJ||ki-67-30/JJ	amod||receptor-33/NN||ki-67-30/JJ	conj_and||her2-24/JJ||androgen-32/JJ	amod||receptor-33/NN||androgen-32/JJ	appos||receptor-13/NN||receptor-33/NN	appos||receptor-13/NN||ar-35/NN	progesterone-18||ar-35||no_rel||ihc analyses were performed on each cell block with antibodies to estrogen receptor (er), progesterone receptor (pr), her2, egfr, ck5/6, ki-67 and androgen receptor (ar).
amod||array-2/NN||bac-based-1/JJ	nsubj||identified-3/VBD||array-2/NN	nsubj||tumors-18/VB||array-2/NN	root||ROOT-0/null||identified-3/VBD	num||regions-6/NNS||27-4/CD	amod||regions-6/NNS||chromosomal-5/JJ	dobj||identified-3/VBD||regions-6/NNS	advmod||different-9/JJ||significantly-8/RB	amod||changes-12/NNS||different-9/JJ	nn||changes-12/NNS||copy-10/NN	nn||changes-12/NNS||number-11/NN	prep_with||identified-3/VBD||changes-12/NNS	det||aa-15/NN||the-14/DT	prep_between||changes-12/NNS||aa-15/NN	aux||tumors-18/VB||ca-17/MD	conj_and||identified-3/VBD||tumors-18/VB	det||cohort-22/NN||the-20/DT	amod||cohort-22/NN||first-21/JJ	prep_in||tumors-18/VB||cohort-22/NN	poss||test-27/NN||fisher-24/NN	amod||test-27/NN||exact-26/JJ	dep||cohort-22/NN||test-27/NN	nn||0.05-31/NNP||p-29/NNP	nn||0.05-31/NNP||<-30/NNP	appos||test-27/NN||0.05-31/NNP	tumors-18||bac--1||no_rel||bac-based array identified 27 chromosomal regions with significantly different copy number changes between the aa and ca tumors in the first cohort (fisher's exact test, p < 0.05).
amod||evidence-2/NN||accumulated-1/VBN	nsubj||shows-3/VBZ||evidence-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||elevated-9/VBG||that-4/IN	amod||concentrations-7/NNS||endogenous-5/JJ	nn||concentrations-7/NNS||formaldehyde-6/NN	nsubj||elevated-9/VBG||concentrations-7/NNS	aux||elevated-9/VBG||are-8/VBP	ccomp||shows-3/VBZ||elevated-9/VBG	det||blood-12/NN||the-11/DT	prep_in||elevated-9/VBG||blood-12/NN	prep_in||elevated-9/VBG||urine-14/NN	conj_or||blood-12/NN||urine-14/NN	prep_of||blood-12/NN||patients-16/NNS	prep_with||elevated-9/VBG||breast-18/NN	prep_with||elevated-9/VBG||prostate-20/NN	conj_or||breast-18/NN||prostate-20/NN	nn||cancer-23/NN||bladder-22/NN	prep_with||elevated-9/VBG||cancer-23/NN	conj_or||breast-18/NN||cancer-23/NN	formaldehyde-6||cancer-23||no_rel||accumulated evidence shows that endogenous formaldehyde concentrations are elevated in the blood or urine of patients with breast, prostate or bladder cancer.
amod||patients-3/NNS||chronic-1/JJ	nn||patients-3/NNS||hbv-2/NN	nsubjpass||treated-5/VBN||patients-3/NNS	nsubjpass||examined-9/VBN||patients-3/NNS	auxpass||treated-5/VBN||were-4/VBD	root||ROOT-0/null||treated-5/VBN	prep_with||treated-5/VBN||adefovirdipivoxil-7/NN	conj_and||treated-5/VBN||examined-9/VBN	nn||loads-14/NNS||serum-11/NN	nn||loads-14/NNS||hbv-12/NN	nn||loads-14/NNS||dna-13/NN	prep_for||examined-9/VBN||loads-14/NNS	appos||loads-14/NNS||cytokines-16/NNS	nn||helper-20/NN||t-19/NN	nsubj||cytokine-29/VBP||helper-20/NN	appos||helper-20/NN||th1-22/NNP	conj_and||helper-20/NN||2-25/CD	nsubj||cytokine-29/VBP||2-25/CD	appos||2-25/CD||th2-27/NNP	conj_and||treated-5/VBN||cytokine-29/VBP	xcomp||cytokine-29/VBP||producing-30/VBG	nn||cells-32/NNS||t-31/NN	dobj||producing-30/VBG||cells-32/NNS	num||weeks-35/NNS||104-34/CD	prep_during||producing-30/VBG||weeks-35/NNS	det||treatment-38/NN||the-37/DT	prep_of||weeks-35/NNS||treatment-38/NN	hbv-12||adefovirdipivoxil-7||yes||chronic hbv patients were treated with adefovirdipivoxil and examined for serum hbv dna loads, cytokines, and t helper (th1) and 2 (th2) cytokine producing t cells during 104 weeks of the treatment.
mark||+-3/VBD||although-1/IN	nsubj||+-3/VBD||chf-2/NN	advcl||prevented-27/VBN||+-3/VBD	dep||+-3/VBD||f-4/SYM	xcomp||+-3/VBD||feeding-5/VBG	amod||ampkî-8/NNS||increased-6/JJ	amod||ampkî-8/NNS||hepatic-7/JJ	iobj||feeding-5/VBG||ampkî-8/NNS	number||2-10/CD||±-9/CD	num||activity-11/NN||2-10/CD	dobj||feeding-5/VBG||activity-11/NN	det||gain-16/NN||the-13/DT	nn||gain-16/NN||body-14/NN	nn||gain-16/NN||weight-15/NN	nsubjpass||prevented-27/VBN||gain-16/NN	conj_and||gain-16/NN||dyslipidemia-18/NN	nsubjpass||prevented-27/VBN||dyslipidemia-18/NN	det||accumulation-22/NN||the-21/DT	conj_and||gain-16/NN||accumulation-22/NN	nsubjpass||prevented-27/VBN||accumulation-22/NN	amod||triglycerides-25/NNPS||hepatic-24/JJ	prep_of||accumulation-22/NN||triglycerides-25/NNPS	auxpass||prevented-27/VBN||were-26/VBD	root||ROOT-0/null||prevented-27/VBN	det||diet-33/NN||the-29/DT	nn||diet-33/NN||chf-30/NNP	nn||diet-33/NN||+-31/NNP	nn||diet-33/NN||f-32/NNP	agent||prevented-27/VBN||diet-33/NN	det||degree-37/NN||a-35/DT	amod||degree-37/NN||similar-36/JJ	prep_to||prevented-27/VBN||degree-37/NN	det||2âˆ-42/NNP||both-39/DT	nn||2âˆ-42/NNP||ampkî-40/NNP	nn||2âˆ-42/NNP||±-41/NNP	poss||âˆ-45/NN||2âˆ-42/NNP	amod||âˆ-45/NN||/-44/JJ	prep_in||degree-37/NN||âˆ-45/NN	amod||mice-49/NNS||wild-type-48/JJ	prep_to||prevented-27/VBN||mice-49/NNS	conj_and||degree-37/NN||mice-49/NNS	nn||state-53/NN||ad-51/NN	amod||state-53/NN||libitum-fed-52/JJ	prep_in||mice-49/NNS||state-53/NN	chf-30||triglycerides-25||no_rel||although chf+f feeding increased hepatic ampkî±2 activity, the body weight gain, dyslipidemia, and the accumulation of hepatic triglycerides were prevented by the chf+f diet to a similar degree in both ampkî±2âˆ’/âˆ’ and wild-type mice in ad libitum-fed state.
mark||were-4/VBD||although-1/IN	nn||levels-3/NNS||immunoglobulin-2/NN	nsubj||were-4/VBD||levels-3/NNS	advcl||observed-24/JJ||were-4/VBD	det||limits-8/NNS||the-6/DT	amod||limits-8/NNS||normal-7/JJ	prep_within||were-4/VBD||limits-8/NNS	amod||anemia-13/NN||thrombocytopenia-10/JJ	amod||anemia-13/NN||slight-12/JJ	nsubj||observed-24/JJ||anemia-13/NN	amod||levels-16/NNS||increased-15/JJ	conj_and||anemia-13/NN||levels-16/NNS	nsubj||observed-24/JJ||levels-16/NNS	amod||protein-19/NN||c-reactive-18/JJ	prep_of||anemia-13/NN||protein-19/NN	nn||phosphatase-22/NN||alkaline-21/NN	prep_of||anemia-13/NN||phosphatase-22/NN	conj_and||protein-19/NN||phosphatase-22/NN	cop||observed-24/JJ||were-23/VBD	root||ROOT-0/null||observed-24/JJ	anemia-13||immunoglobulin-2||no_rel||although immunoglobulin levels were within the normal limits, thrombocytopenia, slight anemia and increased levels of c-reactive protein and alkaline phosphatase were observed.
mark||trigger-9/NN||since-1/IN	nsubj||trigger-9/NN||inflammation-2/NN	amod||fat-5/NN||visceral-4/JJ	prep_of||inflammation-2/NN||fat-5/NN	cop||trigger-9/NN||is-6/VBZ	det||trigger-9/NN||a-7/DT	amod||trigger-9/NN||crucial-8/JJ	advcl||explain-23/VB||trigger-9/NN	prep_of||trigger-9/NN||atherogenesis-11/NNS	amod||fat-15/NN||decreased-13/VBN	amod||fat-15/NN||visceral-14/JJ	appos||atherogenesis-11/NNS||fat-15/NN	amod||±-18/NNS||pgc-1î-17/JJ	prep_in||fat-15/NN||±-18/NNS	nn||mice-21/NNS||deficient-20/NN	nsubj||explain-23/VB||mice-21/NNS	aux||explain-23/VB||may-22/MD	root||ROOT-0/null||explain-23/VB	advmod||develop-29/VB||why-24/WRB	det||mice-26/NNS||these-25/DT	nsubj||develop-29/VB||mice-26/NNS	aux||develop-29/VB||do-27/VBP	neg||develop-29/VB||not-28/RB	advcl||explain-23/VB||develop-29/VB	amod||atherosclerosis-31/NNS||enhanced-30/JJ	dobj||develop-29/VB||atherosclerosis-31/NNS	inflammation-2||fat-15||no_rel||since inflammation of visceral fat is a crucial trigger of atherogenesis, decreased visceral fat in pgc-1î± -deficient mice may explain why these mice do not develop enhanced atherosclerosis.
aux||elucidate-2/VB||to-1/TO	advcl||investigated-25/VBD||elucidate-2/VB	nn||mechanisms-4/NNS||novel-3/NN	dobj||elucidate-2/VB||mechanisms-4/NNS	vmod||mechanisms-4/NNS||contributing-5/VBG	det||complex-10/NN||the-7/DT	amod||complex-10/NN||htlv-1-8/JJ	amod||complex-10/NN||neurological-9/JJ	prep_to||contributing-5/VBG||complex-10/NN	poss||presentation-15/NN||its-12/PRP$	amod||presentation-15/NN||classic-13/JJ	amod||presentation-15/NN||neurological-14/JJ	prep_to||contributing-5/VBG||presentation-15/NN	conj_and||complex-10/NN||presentation-15/NN	vmod||presentation-15/NN||called-16/VBN	dobj||called-16/VBN||ham/tsp-17/NN	amod||myelopathy/tropicalspasticparaparesis-21/NNS||htlv-1-19/JJ	amod||myelopathy/tropicalspasticparaparesis-21/NNS||associated-20/JJ	appos||ham/tsp-17/NN||myelopathy/tropicalspasticparaparesis-21/NNS	nsubj||investigated-25/VBD||we-24/PRP	root||ROOT-0/null||investigated-25/VBD	det||expression-27/NN||the-26/DT	dobj||investigated-25/VBD||expression-27/NN	det||receptor-31/NN||the-29/DT	amod||receptor-31/NN||tim-3-30/JJ	prep_of||expression-27/NN||receptor-31/NN	amod||cells-36/NNS||cd8-33/JJ	amod||cells-36/NNS||+-34/JJ	nn||cells-36/NNS||t-35/NN	prep_on||receptor-31/NN||cells-36/NNS	det||cohort-39/NN||a-38/DT	prep_from||investigated-25/VBD||cohort-39/NN	amod||patients-46/NNS||htlv-1-41/JJ	amod||patients-46/NNS||seropositive-42/JJ	amod||patients-46/NNS||asymptomatic-43/JJ	conj_and||asymptomatic-43/JJ||symptomatic-45/JJ	amod||patients-46/NNS||symptomatic-45/JJ	prep_of||cohort-39/NN||patients-46/NNS	ham--1||htlv-1-41||no||to elucidate novel mechanisms contributing to the htlv-1 neurological complex and its classic neurological presentation called ham/tsp (htlv-1 associated myelopathy/tropicalspasticparaparesis), we investigated the expression of the tim-3 receptor on cd8+ t cells from a cohort of htlv-1 seropositive asymptomatic and symptomatic patients.
nsubjpass||collected-22/VBN||information-1/NN	prep_on||information-1/NN||gender-3/NN	prep_on||information-1/NN||age-5/NN	conj_and||gender-3/NN||age-5/NN	prep_on||information-1/NN||workplace-7/NN	conj_and||gender-3/NN||workplace-7/NN	nn||title-10/NN||job-9/NN	prep_on||information-1/NN||title-10/NN	conj_and||gender-3/NN||title-10/NN	nn||vaccination-13/NN||bcg-12/NN	prep_on||information-1/NN||vaccination-13/NN	conj_and||gender-3/NN||vaccination-13/NN	prep_on||information-1/NN||history-15/NN	conj_and||gender-3/NN||history-15/NN	preconj||tb-18/NN||both-17/DT	prep_of||history-15/NN||tb-18/NN	prep_of||history-15/NN||tst-20/NN	conj_and||tb-18/NN||tst-20/NN	auxpass||collected-22/VBN||were-21/VBD	root||ROOT-0/null||collected-22/VBN	xcomp||collected-22/VBN||using-23/VBG	det||questionnaire-26/NN||a-24/DT	amod||questionnaire-26/NN||standardised-25/JJ	dobj||using-23/VBG||questionnaire-26/NN	tb-18||bcg-12||no||information on gender, age, workplace, job title, bcg vaccination and history of both tb and tst were collected using a standardised questionnaire.
poss||study-2/NN||our-1/PRP$	nsubj||indicates-3/VBZ||study-2/NN	root||ROOT-0/null||indicates-3/VBZ	mark||important-18/JJ||that-4/IN	det||determinants-8/NNS||the-5/DT	amod||determinants-8/NNS||composite-6/JJ	amod||determinants-8/NNS||genetic-7/JJ	nsubj||important-18/JJ||determinants-8/NNS	vmod||determinants-8/NNS||related-9/VBN	det||conversion-16/NN||the-11/DT	amod||conversion-16/NN||androgenâ-12/JJ	amod||conversion-16/NN||$-13/JJ	nn||conversion-16/NN||estrogen-15/NN	prep_to||related-9/VBN||conversion-16/NN	cop||important-18/JJ||are-17/VBP	ccomp||indicates-3/VBZ||important-18/JJ	det||induction-21/NN||the-20/DT	prep_for||important-18/JJ||induction-21/NN	num||cancers-25/NNS||two-23/CD	amod||cancers-25/NNS||hormone-associated-24/JJ	prep_of||induction-21/NN||cancers-25/NNS	advmod||important-18/JJ||particularly-27/RB	det||subtypes-32/NNS||the-29/DT	amod||subtypes-32/NNS||hormone-driven-30/JJ	nn||subtypes-32/NNS||breasttumour-31/NN	prep_for||important-18/JJ||subtypes-32/NNS	breasttumour-31||estrogen-15||yes||our study indicates that the composite genetic determinants related to the androgenâ€“estrogen conversion are important for the induction of two hormone-associated cancers, particularly for the hormone-driven breasttumour subtypes.
nsubj||indicate-2/VBP||results-1/NNS	root||ROOT-0/null||indicate-2/VBP	mark||associated-9/JJ||that-3/IN	amod||stigma-6/NN||shame-related-4/JJ	nn||stigma-6/NN||hiv-5/NN	nsubj||associated-9/JJ||stigma-6/NN	aux||associated-9/JJ||is-7/VBZ	advmod||associated-9/JJ||strongly-8/RB	ccomp||indicate-2/VBP||associated-9/JJ	amod||beliefs-12/NNS||religious-11/JJ	prep_with||associated-9/JJ||beliefs-12/NNS	det||belief-16/NN||the-15/DT	prep_such_as||beliefs-12/NNS||belief-16/NN	mark||punishment-21/NN||that-17/IN	nsubj||punishment-21/NN||hiv-18/NN	cop||punishment-21/NN||is-19/VBZ	det||punishment-21/NN||a-20/DT	ccomp||associated-9/JJ||punishment-21/NN	prep_from||punishment-21/NN||god-23/NN	nn||0.01-27/NNP||p-25/NNP	nn||0.01-27/NNP||<-26/NNP	appos||god-23/NN||0.01-27/NNP	mark||followed-40/VBN||that-30/IN	nsubj||followed-40/VBN||people-31/NNS	vmod||people-31/NNS||living-32/VBG	prep_with||living-32/VBG||hiv/aids-34/NNS	appos||hiv/aids-34/NNS||plwha-36/NNP	aux||followed-40/VBN||have-38/VBP	neg||followed-40/VBN||not-39/RB	ccomp||associated-9/JJ||followed-40/VBN	conj_or||punishment-21/NN||followed-40/VBN	det||word-42/NN||the-41/DT	dobj||followed-40/VBN||word-42/NN	prep_of||word-42/NN||god-44/NN	appos||god-44/NN||p-46/NNP	number||0.001-48/CD||<-47/CD	num||p-46/NNP||0.001-48/CD	aids--1||hiv-18||no||results indicate that shame-related hiv stigma is strongly associated with religious beliefs such as the belief that hiv is a punishment from god (p < 0.01) or that people living with hiv/aids (plwha) have not followed the word of god (p < 0.001).
prep_in||are-5/VBP||contrast-2/NN	expl||are-5/VBP||there-4/EX	root||ROOT-0/null||are-5/VBP	amod||factors-7/NNS||numerous-6/JJ	nsubj||are-5/VBP||factors-7/NNS	dep||factors-7/NNS||suggesting-8/VBG	mark||increasing-12/VBG||that-9/IN	nsubj||increasing-12/VBG||hiv-10/NN	aux||increasing-12/VBG||is-11/VBZ	ccomp||suggesting-8/VBG||increasing-12/VBG	dep||factors-7/NNS||ready-14/JJ	conj_and||suggesting-8/VBG||ready-14/JJ	aux||emerge-16/VB||to-15/TO	xcomp||ready-14/JJ||emerge-16/VB	amod||rates-19/NNS||high-18/JJ	prep_at||emerge-16/VB||rates-19/NNS	det||rates-25/NNS||the-22/DT	amod||rates-25/NNS||lowest-23/JJS	amod||rates-25/NNS||documented-24/VBN	prep_including||emerge-16/VB||rates-25/NNS	nn||use-28/NN||condom-27/NN	prep_of||rates-25/NNS||use-28/NN	prep_in||use-28/NN||asia-30/NN	dep||factors-7/NNS||increasing-32/VBG	amod||activity-35/NN||casual-33/JJ	amod||activity-35/NN||sexual-34/JJ	dobj||increasing-32/VBG||activity-35/NN	parataxis||increasing-32/VBG||returning-37/VBG	amod||workers-40/NNS||overseas-38/JJ	nn||workers-40/NNS||filipino-39/NN	dobj||returning-37/VBG||workers-40/NNS	amod||settings-43/NNS||high-prevalence-42/JJ	prep_from||returning-37/VBG||settings-43/NNS	amod||misconceptions-46/NNS||widespread-45/JJ	nsubj||are-5/VBP||misconceptions-46/NNS	conj_and||factors-7/NNS||misconceptions-46/NNS	prep_about||misconceptions-46/NNS||hiv/aids-48/NNS	amod||rates-53/NNS||high-51/JJ	amod||rates-53/NNS||needle-sharing-52/JJ	nsubj||are-5/VBP||rates-53/NNS	conj_and||factors-7/NNS||rates-53/NNS	amod||users-57/NNS||injecting-55/VBG	nn||users-57/NNS||drug-56/NN	prep_among||rates-53/NNS||users-57/NNS	aids--1||hiv-10||no||in contrast, there are numerous factors suggesting that hiv is increasing and ready to emerge at high rates, including the lowest documented rates of condom use in asia; increasing casual sexual activity; returning overseas filipino workers from high-prevalence settings; widespread misconceptions about hiv/aids; and high needle-sharing rates among injecting drug users.
amod||methods-2/NNS||other-1/JJ	nsubj||helpful-4/JJ||methods-2/NNS	cop||helpful-4/JJ||are-3/VBP	root||ROOT-0/null||helpful-4/JJ	amod||studies-9/NNS||epidemiological-6/JJ	amod||studies-9/NNS||respiratory-7/JJ	nn||studies-9/NNS||health-8/NN	prep_in||helpful-4/JJ||studies-9/NNS	amod||nitricoxide-13/NN||fractional-11/JJ	amod||nitricoxide-13/NN||exhaled-12/JJ	prep_including||studies-9/NNS||nitricoxide-13/NN	appos||nitricoxide-13/NN||feno-15/NNP	amod||percentage-19/NN||eosinophils-18/JJ	prep_including||studies-9/NNS||percentage-19/NN	conj_and||nitricoxide-13/NN||percentage-19/NN	appos||nitricoxide-13/NN||ep-21/NN	amod||markers-28/NNS||nasal-24/JJ	amod||markers-28/NNS||lavage-25/JJ	amod||markers-28/NNS||fluid-26/JJ	nn||markers-28/NNS||measuring-27/NN	prep_in||studies-9/NNS||markers-28/NNS	amod||inflammation-31/NN||airway-30/JJ	prep_for||markers-28/NNS||inflammation-31/NN	det||technique-37/NN||the-34/DT	amod||technique-37/NN||forced-35/VBN	nn||technique-37/NN||oscillatory-36/NN	prep_along_with||studies-9/NNS||technique-37/NN	vmod||technique-37/NN||measuring-38/VBG	amod||resistance-40/NN||airway-39/JJ	dobj||measuring-38/VBG||resistance-40/NN	appos||resistance-40/NN||ar-42/NN	nitricoxide-13||inflammation-31||no_rel||other methods are helpful in epidemiological respiratory health studies including fractional exhaled nitricoxide (feno) and eosinophils percentage (ep) in nasal lavage fluid measuring markers for airway inflammation along with the forced oscillatory technique measuring airway resistance (ar).
nsubj||component-5/NN||pyrazinamide-1/NN	nsubj||most-14/JJS||pyrazinamide-1/NN	cop||component-5/NN||is-2/VBZ	det||component-5/NN||an-3/DT	amod||component-5/NN||essential-4/JJ	root||ROOT-0/null||component-5/NN	amod||regimen-10/NN||first-7/JJ	nn||regimen-10/NN||line-8/NN	nn||regimen-10/NN||anti-tuberculosis-9/NNS	prep_of||component-5/NN||regimen-10/NN	conj_and||component-5/NN||most-14/JJS	det||regimens-19/NNS||the-16/DT	amod||regimens-19/NNS||second-17/JJ	nn||regimens-19/NNS||line-18/NN	prep_of||most-14/JJS||regimens-19/NNS	tuberculosis--1||pyrazinamide-1||yes||pyrazinamide is an essential component of first line anti-tuberculosis regimen as well as most of the second line regimens.
advmod||show-12/VBP||simultaneously-1/RB	prepc_compared_with||show-12/VBP||with-4/IN	nn||rats-7/NNS||zucker-5/NN	nn||rats-7/NNS||obese-6/NN	pobj||show-12/VBP||rats-7/NNS	det||rats-11/NNS||the-9/DT	nn||rats-11/NNS||gk-10/NN	nsubj||show-12/VBP||rats-11/NNS	root||ROOT-0/null||show-12/VBP	amod||levels-14/NNS||decreased-13/VBN	dobj||show-12/VBP||levels-14/NNS	prep_of||levels-14/NNS||trimethylamine-16/JJ	prep_of||levels-14/NNS||acetate-18/JJ	conj_and||trimethylamine-16/JJ||acetate-18/JJ	prep_of||levels-14/NNS||choline-21/JJ	conj_and||trimethylamine-16/JJ||choline-21/JJ	amod||levels-27/NNS||increased-26/VBN	dobj||show-12/VBP||levels-27/NNS	conj_and||levels-14/NNS||levels-27/NNS	prep_of||levels-27/NNS||creatine/creatinine-29/JJ	prep_of||levels-27/NNS||acetoacetate-31/JJ	conj_and||creatine/creatinine-29/JJ||acetoacetate-31/JJ	prep_of||levels-27/NNS||alanine-33/JJ	conj_and||creatine/creatinine-29/JJ||alanine-33/JJ	prep_of||levels-27/NNS||citrate-35/JJ	conj_and||creatine/creatinine-29/JJ||citrate-35/JJ	prep_of||levels-27/NNS||2-ketoglutarate-37/JJ	conj_and||creatine/creatinine-29/JJ||2-ketoglutarate-37/JJ	prep_of||levels-27/NNS||succinate-39/JJ	conj_and||creatine/creatinine-29/JJ||succinate-39/JJ	prep_of||levels-27/NNS||lactate-41/JJ	conj_and||creatine/creatinine-29/JJ||lactate-41/JJ	prep_of||levels-27/NNS||hippurate-44/JJ	conj_and||creatine/creatinine-29/JJ||hippurate-44/JJ	obese-6||alanine-33||no_rel||simultaneously, compared with zucker obese rats, the gk rats show decreased levels of trimethylamine, acetate, and choline, as well as increased levels of creatine/creatinine, acetoacetate, alanine, citrate, 2-ketoglutarate, succinate, lactate, and hippurate.
advmod||treatment-9/NN||moreover-1/RB	prep_in||treatment-9/NN||japan-4/NN	nsubj||treatment-9/NN||s-1-5/JJ	cop||treatment-9/NN||is-6/VBZ	det||treatment-9/NN||a-7/DT	amod||treatment-9/NN||standard-8/JJ	root||ROOT-0/null||treatment-9/NN	prep_for||treatment-9/NN||patients-11/NNS	nn||ii/iii-14/NNS||stage-13/NN	prep_with||patients-11/NNS||ii/iii-14/NNS	amod||cancer-16/NN||gastric-15/JJ	dep||patients-11/NNS||cancer-16/NN	amod||resection-19/NN||curative-18/JJ	prep_after||cancer-16/NN||resection-19/NN	det||option-23/NN||a-21/DT	amod||option-23/NN||promising-22/JJ	prep_for||treatment-9/NN||option-23/NN	conj_and||patients-11/NNS||option-23/NN	prep_for||option-23/NN||patients-25/NNS	amod||metastases-29/NNS||colorectal-27/JJ	nn||metastases-29/NNS||liver-28/NN	prep_with||patients-25/NNS||metastases-29/NNS	det||setting-33/NN||an-31/DT	amod||setting-33/NN||adjuvant-32/JJ	prep_in||metastases-29/NNS||setting-33/NN	cancer-16||adjuvant-32||no_rel||moreover, in japan s-1 is a standard treatment for patients with stage ii/iii gastric cancer after curative resection and a promising option for patients with colorectal liver metastases in an adjuvant setting.
prep_in||cause-5/VB||children-2/NNS	nsubj||cause-5/VB||fungi-3/NNS	aux||cause-5/VB||can-4/MD	root||ROOT-0/null||cause-5/VB	amod||infection-7/NN||superficial-6/JJ	dobj||cause-5/VB||infection-7/NN	nsubj||nails-14/VBZ||i.e.-9/NNP	prep_on||nails-14/VBZ||skin-12/NN	ccomp||cause-5/VB||nails-14/VBZ	conj_and||cause-5/VB||nails-14/VBZ	nsubj||types-33/NNS||hair-17/NN	amod||thrush-20/NN||oral-19/JJ	prep_like||hair-17/NN||thrush-20/NN	nn||rash-24/NN||candida-22/NN	nn||rash-24/NN||diaper-23/NN	appos||thrush-20/NN||rash-24/NN	nn||infections-27/NNS||tinea-26/NN	appos||thrush-20/NN||infections-27/NNS	dep||thrush-20/NN||etc.-29/FW	cop||types-33/NNS||are-31/VBP	amod||types-33/NNS||various-32/JJ	ccomp||cause-5/VB||types-33/NNS	conj_and||cause-5/VB||types-33/NNS	conj_and||nails-14/VBZ||types-33/NNS	amod||fungalinfections-36/NNS||superficial-35/JJ	prep_of||types-33/NNS||fungalinfections-36/NNS	nsubj||fungalinfection-39/VBN||subcutaneous-38/NNS	conj_and||cause-5/VB||fungalinfection-39/VBN	prep_in||fungalinfection-39/VBN||tissues-41/NNS	det||skin-44/NN||the-43/DT	prep_under||tissues-41/NNS||skin-44/NN	advmod||causes-48/VBZ||lastly-46/RB	nsubj||causes-48/VBZ||it-47/PRP	conj_and||cause-5/VB||causes-48/VBZ	amod||infection-50/NN||systemic-49/JJ	dobj||causes-48/VBZ||infection-50/NN	amod||tissues-53/NNS||deeper-52/JJR	prep_in||infection-50/NN||tissues-53/NNS	fungalinfections-36||fungi-3||no||in children fungi can cause superficial infection, i.e., on skin, nails, and hair like oral thrush, candida diaper rash, tinea infections, etc., are various types of superficial fungalinfections, subcutaneous fungalinfection in tissues under the skin and lastly it causes systemic infection in deeper tissues.
advmod||seen-15/VBN||irondeficiency-1/RB	nn||depletion-8/NN||anemia-3/NN	conj_and||depletion-8/NN||irondeficiencyanemia-5/NN	nsubjpass||seen-15/VBN||irondeficiencyanemia-5/NN	conj_and||depletion-8/NN||iron-7/NN	nsubjpass||seen-15/VBN||iron-7/NN	nsubjpass||seen-15/VBN||depletion-8/NN	conj_and||depletion-8/NN||lack-10/NN	nsubjpass||seen-15/VBN||lack-10/NN	nn||resources-13/NNS||iron-12/NN	prep_of||depletion-8/NN||resources-13/NNS	auxpass||seen-15/VBN||were-14/VBD	root||ROOT-0/null||seen-15/VBN	prep_in||seen-15/VBN||2.3-17/CD	prep_in||seen-15/VBN||4.08-19/CD	conj_and||2.3-17/CD||4.08-19/CD	prep_in||seen-15/VBN||2.14-21/CD	conj_and||2.3-17/CD||2.14-21/CD	prep_in||seen-15/VBN||22.76-23/NNP	conj_and||2.3-17/CD||22.76-23/NNP	amod||percent-26/NN||4.66-25/JJ	prep_in||seen-15/VBN||percent-26/NN	conj_and||2.3-17/CD||percent-26/NN	advmod||seen-15/VBN||respectively-27/RB	irondeficiencyanemia-5||iron-12||yes||irondeficiency, anemia, irondeficiencyanemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
nsubj||explore-2/VB||we-1/PRP	root||ROOT-0/null||explore-2/VB	dobj||explore-2/VB||reasons-3/NNS	prep_for||reasons-3/NNS||this-5/DT	amod||doubts-10/NNS||prevailing-9/VBG	prep_such_as||this-5/DT||doubts-10/NNS	det||efficacy-13/NN||the-12/DT	prep_about||doubts-10/NNS||efficacy-13/NN	prep_of||doubts-10/NNS||fondaparinux-15/NN	det||setting-18/NN||the-17/DT	prep_in||doubts-10/NNS||setting-18/NN	prep_of||setting-18/NN||angioplasty-20/NN	det||problem-23/NN||the-22/DT	prep_such_as||this-5/DT||problem-23/NN	conj_and||doubts-10/NNS||problem-23/NN	nn||thrombosis-26/NNS||catheter-25/NN	prep_of||problem-23/NN||thrombosis-26/NNS	det||lack-30/NN||the-29/DT	prep_such_as||this-5/DT||lack-30/NN	conj_and||doubts-10/NNS||lack-30/NN	prep_of||lack-30/NN||antidote-32/NN	amod||complications-37/NNS||bleeding-36/VBG	prep_in_case_of||antidote-32/NN||complications-37/NNS	thrombosis-26||antidote-32||no_rel||we explore reasons for this, such as prevailing doubts about the efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and the lack of antidote in case of bleeding complications.
det||study-3/NN||this-2/DT	prep_in||is-13/VBZ||study-3/NN	det||prevalence-6/NN||the-5/DT	nsubj||is-13/VBZ||prevalence-6/NN	nn||abnormalities-9/NNS||glucose-8/NN	prep_of||prevalence-6/NN||abnormalities-9/NNS	amod||children-12/NNS||obese-11/JJ	prep_in||abnormalities-9/NNS||children-12/NNS	root||ROOT-0/null||is-13/VBZ	dep||than-15/IN||higher-14/JJR	advmod||is-13/VBZ||than-15/IN	amod||series-18/NN||other-17/JJ	prep_in||is-13/VBZ||series-18/NN	advmod||present-25/JJ||furthermore-20/RB	det||correlation-23/NN||a-22/DT	nsubj||present-25/JJ||correlation-23/NN	cop||present-25/JJ||is-24/VBZ	parataxis||is-13/VBZ||present-25/JJ	prep_between||present-25/JJ||markers-27/NNS	amod||inflammation-32/NN||systemic-29/JJ	conj_and||systemic-29/JJ||intestinal-31/JJ	amod||inflammation-32/NN||intestinal-31/JJ	prep_of||markers-27/NNS||inflammation-32/NN	nn||abnormalities-35/NNS||glucose-34/NN	prep_of||markers-27/NNS||abnormalities-35/NNS	conj_and||inflammation-32/NN||abnormalities-35/NNS	obese-11||glucose-34||no_rel||in this study, the prevalence of glucose abnormalities in obese children is higher than in other series; furthermore, a correlation is present between markers of systemic and intestinal inflammation and glucose abnormalities.
nsubjpass||spread-3/VBN||vzv-1/NN	nsubj||cause-7/VB||vzv-1/NN	auxpass||spread-3/VBN||is-2/VBZ	root||ROOT-0/null||spread-3/VBN	agent||spread-3/VBN||aerosol-5/NN	aux||cause-7/VB||to-6/TO	xcomp||spread-3/VBN||cause-7/VB	dobj||cause-7/VB||chickenpox-8/NN	nsubj||infection-21/NN||chickenpox-8/NN	amod||countries-14/NNS||temperate-13/JJ	prep_in||infection-21/NN||countries-14/NNS	cop||infection-21/NN||is-16/VBZ	det||infection-21/NN||a-17/DT	advmod||benign-19/JJ||relatively-18/RB	amod||infection-21/NN||benign-19/JJ	nn||infection-21/NN||childhood-20/NN	rcmod||chickenpox-8/NN||infection-21/NN	advmod||tends-28/VBZ||yet-23/RB	amod||countries-26/NNS||tropical-25/JJ	prep_in||tends-28/VBZ||countries-26/NNS	nsubj||tends-28/VBZ||it-27/PRP	nsubj||occur-30/VB||it-27/PRP	parataxis||spread-3/VBN||tends-28/VBZ	aux||occur-30/VB||to-29/TO	xcomp||tends-28/VBZ||occur-30/VB	advmod||age-33/NN||later-32/RB	prep_at||occur-30/VB||age-33/NN	det||trend-36/NN||a-35/DT	appos||age-33/NN||trend-36/NN	vmod||trend-36/NN||associated-37/VBN	advmod||increased-40/JJ||markedly-39/RB	amod||severity-41/NN||increased-40/JJ	prep_with||associated-37/VBN||severity-41/NN	prep_including||severity-41/NN||complications-43/NNS	prep_including||severity-41/NN||hospitalization-45/NN	conj_and||complications-43/NNS||hospitalization-45/NN	amod||burden-49/NN||overall-48/JJ	prep_including||severity-41/NN||burden-49/NN	conj_and||complications-43/NNS||burden-49/NN	prep_of||burden-49/NN||care-51/NN	chickenpox-8||vzv-1||no||vzv is spread by aerosol to cause chickenpox, which, in temperate countries, is a relatively benign childhood infection; yet in tropical countries it tends to occur at later age, a trend associated with markedly increased severity including complications, hospitalization, and overall burden of care.
aux||estimate-2/VB||to-1/TO	advcl||took-10/VBD||estimate-2/VB	amod||risks-7/NNS||subtype-specific-3/JJ	nn||risks-7/NNS||lifetime-4/NN	nn||risks-7/NNS||breast-5/NN	nn||risks-7/NNS||cancer-6/NN	dobj||estimate-2/VB||risks-7/NNS	nsubj||took-10/VBD||we-9/PRP	root||ROOT-0/null||took-10/VBD	dobj||took-10/VBD||advantage-11/NN	prep_for||available-40/JJ||advantage-11/NN	amod||data-14/NNS||population-based-13/JJ	prep_of||advantage-11/NN||data-14/NNS	nsubj||available-40/JJ||information-17/NN	nn||expression-20/NN||tumor-19/NN	prep_regarding||information-17/NN||expression-20/NN	nn||receptor-23/NN||estrogen-22/NN	prep_of||expression-20/NN||receptor-23/NN	appos||receptor-23/NN||er-25/NN	amod||receptor-29/NN||progesterone-28/JJ	prep_of||expression-20/NN||receptor-29/NN	conj_and||receptor-23/NN||receptor-29/NN	appos||receptor-29/NN||pr-31/NN	prep_of||expression-20/NN||her2/neu-34/NNS	conj_and||receptor-23/NN||her2/neu-34/NNS	appos||her2/neu-34/NNS||her2-36/NNP	cop||available-40/JJ||was-38/VBD	advmod||available-40/JJ||newly-39/RB	rcmod||advantage-11/NN||available-40/JJ	cancer-6||estrogen-22||no_rel||to estimate subtype-specific lifetime breast cancer risks, we took advantage of population-based data for which information regarding tumor expression of estrogen receptor (er), progesterone receptor (pr) and her2/neu (her2) was newly available.
det||findings-2/NNS||these-1/DT	nsubj||include-5/VB||findings-2/NNS	aux||include-5/VB||do-3/VBP	neg||include-5/VB||not-4/RB	root||ROOT-0/null||include-5/VB	amod||arc-8/NN||aids-relatedcomplex-6/JJ	dobj||include-5/VB||arc-8/NN	amod||manifestations-12/NNS||other-11/JJ	dobj||include-5/VB||manifestations-12/NNS	conj_or||arc-8/NN||manifestations-12/NNS	nn||infection-18/NN||humanimmunodeficiencyvirus-14/NNP	appos||infection-18/NN||hiv-16/NN	prep_of||manifestations-12/NNS||infection-18/NN	aids-relatedcomplex-6||humanimmunodeficiencyvirus-14||no||these findings do not include aids-relatedcomplex (arc) or other manifestations of humanimmunodeficiencyvirus (hiv) infection.
nn||bovis-2/NNS||m.-1/NN	nsubj||bacille-3/VBP||bovis-2/NNS	root||ROOT-0/null||bacille-3/VBP	nn||-rrb--9/NNP||calmette-guã-4/NNP	nn||-rrb--9/NNP||©-5/NNP	nn||-rrb--9/NNP||rin-6/NNP	nn||-rrb--9/NNP||-lrb--7/NNP	nn||-rrb--9/NNP||bcg-8/NNP	nsubj||fails-22/VBZ||-rrb--9/NNP	nsubj||protect-25/VB||-rrb--9/NNP	advmod||vaccine-15/NN||currently-11/RB	det||vaccine-15/NN||the-12/DT	advmod||available-14/JJ||only-13/RB	amod||vaccine-15/NN||available-14/JJ	appos||-rrb--9/NNP||vaccine-15/NN	nn||-rrb--20/NNP||tuberculosis-17/NNP	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||tb-19/NNP	prep_against||vaccine-15/NN||-rrb--20/NNP	ccomp||bacille-3/VBP||fails-22/VBZ	aux||protect-25/VB||to-23/TO	advmod||protect-25/VB||adequately-24/RB	xcomp||fails-22/VBZ||protect-25/VB	dobj||protect-25/VB||individuals-26/NNS	amod||infection-32/NN||active-28/JJ	conj_and||active-28/JJ||latent-30/JJ	amod||infection-32/NN||latent-30/JJ	nn||infection-32/NN||tb-31/NN	prep_from||protect-25/VB||infection-32/NN	tuberculosis-17||bcg-8||yes||m. bovis bacille calmette-guã © rin -lrb- bcg -rrb- , currently the only available vaccine against tuberculosis -lrb- tb -rrb- , fails to adequately protect individuals from active and latent tb infection .
aux||prevent-2/VB||to-1/TO	advcl||added-23/VBN||prevent-2/VB	dobj||prevent-2/VB||hyperinsulinemia-3/NN	nsubj||cause-7/VB||hyperinsulinemia-3/NN	aux||cause-7/VB||may-6/MD	rcmod||hyperinsulinemia-3/NN||cause-7/VB	dobj||cause-7/VB||atherosclerosis-8/NNS	nsubjpass||added-23/VBN||thiazolidinediones-10/NNS	appos||thiazolidinediones-10/NNS||tzds-12/NNS	advmod||known-16/VBN||also-15/RB	vmod||thiazolidinediones-10/NNS||known-16/VBN	nn||sensitizers-19/NNS||insulin-18/NN	prep_as||known-16/VBN||sensitizers-19/NNS	auxpass||added-23/VBN||are-21/VBP	advmod||added-23/VBN||often-22/RB	root||ROOT-0/null||added-23/VBN	det||regimen-27/NN||the-25/DT	amod||regimen-27/NN||therapeutic-26/JJ	prep_to||added-23/VBN||regimen-27/NN	prep_of||regimen-27/NN||patients-29/NNS	prep_with||added-23/VBN||type2diabetes-31/NNS	nsubj||receiving-34/VBG||type2diabetes-31/NNS	aux||receiving-34/VBG||are-33/VBP	rcmod||type2diabetes-31/NNS||receiving-34/VBG	dobj||receiving-34/VBG||insulin-35/NN	type2diabetes-31||thiazolidinediones-10||no_rel||to prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (tzds), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type2diabetes who are receiving insulin.
nsubj||experience-9/VBP||patients-1/NNS	prep_with||patients-1/NNS||schizophrenia-3/NN	nsubjpass||treated-6/VBN||schizophrenia-3/NN	auxpass||treated-6/VBN||are-5/VBP	rcmod||schizophrenia-3/NN||treated-6/VBN	prep_with||treated-6/VBN||aripiprazole-8/NN	root||ROOT-0/null||experience-9/VBP	det||benefits-11/NNS||some-10/DT	dobj||experience-9/VBP||benefits-11/NNS	det||improvement-14/NN||an-13/DT	prep_including||benefits-11/NNS||improvement-14/NN	amod||competence-17/NN||social-16/JJ	prep_of||improvement-14/NN||competence-17/NN	det||mechanism-22/NN||the-20/DT	amod||mechanism-22/NN||underlying-21/VBG	nsubjpass||investigated-29/VBN||mechanism-22/NN	det||improvement-25/NN||this-24/DT	prep_of||mechanism-22/NN||improvement-25/NN	aux||investigated-29/VBN||has-26/VBZ	neg||investigated-29/VBN||not-27/RB	auxpass||investigated-29/VBN||been-28/VBN	conj_but||experience-9/VBP||investigated-29/VBN	advmod||investigated-29/VBN||yet-30/RB	schizophrenia-3||aripiprazole-8||yes||patients with schizophrenia who are treated with aripiprazole experience some benefits including an improvement of social competence, but the underlying mechanism of this improvement has not been investigated yet.
amod||changes-2/NNS||key-1/JJ	nsubj||encompassed-3/VBD||changes-2/NNS	root||ROOT-0/null||encompassed-3/VBD	mark||include-10/VBP||in-4/IN	det||version-6/NN||this-5/DT	nsubj||include-10/VBP||version-6/NN	det||guideline-9/NN||the-8/DT	prep_of||version-6/NN||guideline-9/NN	advcl||encompassed-3/VBD||include-10/VBP	amod||recommendations-12/NNS||new-11/JJ	dobj||include-10/VBP||recommendations-12/NNS	nn||support-15/NN||coagulation-14/NN	prep_on||recommendations-12/NNS||support-15/NN	prep_on||recommendations-12/NNS||monitoring-17/NN	conj_and||support-15/NN||monitoring-17/NN	det||use-21/NN||the-19/DT	amod||use-21/NN||appropriate-20/JJ	dobj||include-10/VBP||use-21/NN	conj_and||recommendations-12/NNS||use-21/NN	amod||measures-25/NNS||local-23/JJ	amod||measures-25/NNS||haemostatic-24/JJ	prep_of||use-21/NN||measures-25/NNS	prep_of||use-21/NN||tourniquets-27/NN	conj_and||measures-25/NNS||tourniquets-27/NN	prep_of||use-21/NN||calcium-29/NN	conj_and||measures-25/NNS||calcium-29/NN	prep_of||use-21/NN||desmopressin-31/NN	conj_and||measures-25/NNS||desmopressin-31/NN	det||patient-36/NN||the-33/DT	amod||patient-36/NN||bleeding-34/VBG	nn||patient-36/NN||trauma-35/NN	prep_in||include-10/VBP||patient-36/NN	bleeding-34||desmopressin-31||yes||key changes encompassed in this version of the guideline include new recommendations on coagulation support and monitoring and the appropriate use of local haemostatic measures, tourniquets, calcium and desmopressin in the bleeding trauma patient.
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||modulate-8/VB||that-4/IN	nsubj||modulate-8/VB||pde5inhibitors-5/NNS	nsubj||enhance-13/VB||pde5inhibitors-5/NNS	aux||modulate-8/VB||may-6/MD	advmod||modulate-8/VB||effectively-7/RB	ccomp||suggest-3/VBP||modulate-8/VB	dobj||modulate-8/VB||btb-9/NN	advmod||modulate-8/VB||permeability-10/RB	ccomp||suggest-3/VBP||enhance-13/VB	conj_and||modulate-8/VB||enhance-13/VB	nn||efficacy-17/NN||delivery-14/NN	conj_and||delivery-14/NN||therapeutic-16/JJ	nn||efficacy-17/NN||therapeutic-16/JJ	dobj||enhance-13/VB||efficacy-17/NN	amod||antibodies-20/NNS||monoclonal-19/JJ	prep_of||efficacy-17/NN||antibodies-20/NNS	amod||metastases-24/NNS||hard-to-treat-22/JJ	nn||metastases-24/NNS||brain-23/NN	prep_in||antibodies-20/NNS||metastases-24/NNS	amod||tumors-28/NNS||different-26/JJ	amod||tumors-28/NNS||primary-27/JJ	prep_from||enhance-13/VB||tumors-28/NNS	nsubj||metastasized-31/VBN||tumors-28/NNS	aux||metastasized-31/VBN||had-30/VBD	rcmod||tumors-28/NNS||metastasized-31/VBN	det||brain-34/NN||the-33/DT	prep_to||metastasized-31/VBN||brain-34/NN	tumors-28||pde5inhibitors-5||no_rel||these findings suggest that pde5inhibitors may effectively modulate btb permeability, and enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary tumors that had metastasized to the brain.
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||reported-2/JJ	nsubj||growing-10/VBG||incidence-3/NN	amod||isolates-6/NNS||drug-resistant-5/JJ	prep_of||incidence-3/NN||isolates-6/NNS	prep_of||isolates-6/NNS||m.tuberculosis-8/NNS	aux||growing-10/VBG||is-9/VBZ	root||ROOT-0/null||growing-10/VBG	advmod||growing-10/VBG||steadily-11/RB	advmod||reported-52/VBN||however-13/RB	nsubjpass||reported-52/VBN||data-15/NNS	det||variation-19/NN||the-17/DT	amod||variation-19/NN||genetic-18/JJ	prep_on||data-15/NNS||variation-19/NN	prep_of||variation-19/NN||isolates-21/NNP	prep_of||isolates-21/NNP||m.tuberculosis-23/NNS	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	conj_and||circulating-24/VBG||circulating-24/VBG	amod||ukraine-27/NN||northern-26/JJ	prep_in||circulating-24/VBG||ukraine-27/NN	det||spectrum-31/NN||the-30/DT	prep_on||circulating-24/VBG||spectrum-31/NN	prep_on||circulating-24/VBG||frequency-33/NN	conj_and||spectrum-31/NN||frequency-33/NN	prep_of||spectrum-31/NN||occurrence-35/NN	prep_of||occurrence-35/NN||mutations-37/NNS	vmod||mutations-37/NNS||determining-38/VBG	dobj||determining-38/VBG||resistance-39/NN	det||drugs-44/NNS||the-41/DT	amod||drugs-44/NNS||principal-42/JJ	amod||drugs-44/NNS||anti-tuberculosis-43/JJ	prep_to||determining-38/VBG||drugs-44/NNS	amod||drugs-44/NNS||isoniazid-45/JJ	amod||drugs-44/NNS||rifampicin-47/JJ	conj_and||isoniazid-45/JJ||rifampicin-47/JJ	aux||reported-52/VBN||have-48/VBP	neg||reported-52/VBN||not-49/RB	advmod||reported-52/VBN||yet-50/RB	auxpass||reported-52/VBN||been-51/VBN	parataxis||growing-10/VBG||reported-52/VBN	tuberculosis--1||rifampicin-47||yes||the reported incidence of drug-resistant isolates of m.tuberculosis is growing steadily ; however , data on the genetic variation of isolates of m.tuberculosis circulating in northern ukraine and on the spectrum and frequency of occurrence of mutations determining resistance to the principal anti-tuberculosis drugs isoniazid and rifampicin have not yet been reported .
amod||analysis-3/NN||multivariate-2/JJ	prep_on||have-22/VBP||analysis-3/NN	det||weight-6/NN||the-4/DT	amod||weight-6/NN||normal-5/JJ	prep_to||likely-20/JJ||weight-6/NN	nsubj||have-22/VBP||weight-6/NN	advmod||obese-8/JJ||centrally-7/RB	amod||children-9/NNS||obese-8/JJ	nsubj||1.66-11/CD||children-9/NNS	nsubj||likely-20/JJ||children-9/NNS	cop||1.66-11/CD||were-10/VBD	rcmod||weight-6/NN||1.66-11/CD	rcmod||weight-6/NN||2.01-13/CD	conj_and||1.66-11/CD||2.01-13/CD	rcmod||weight-6/NN||1.47-15/CD	conj_and||1.66-11/CD||1.47-15/CD	num||times-18/NNS||2.05-17/CD	npadvmod||more-19/RBR||times-18/NNS	advmod||likely-20/JJ||more-19/RBR	rcmod||weight-6/NN||likely-20/JJ	conj_and||1.66-11/CD||likely-20/JJ	root||ROOT-0/null||have-22/VBP	amod||levels-25/NNS||significant-23/JJ	amod||levels-25/NNS||adverse-24/JJ	dobj||have-22/VBP||levels-25/NNS	nn||cholesterol-28/NN||ldl-27/NN	prep_of||levels-25/NNS||cholesterol-28/NN	nn||cholesterol-31/NN||hdl-30/NN	prep_of||levels-25/NNS||cholesterol-31/NN	conj_and||cholesterol-28/NN||cholesterol-31/NN	prep_of||levels-25/NNS||triglycerides-33/NNPS	conj_and||cholesterol-28/NN||triglycerides-33/NNPS	prep_of||levels-25/NNS||insulin-35/NN	conj_and||cholesterol-28/NN||insulin-35/NN	advmod||have-22/VBP||respectively-37/RB	insulin-35||obese-8||no_rel||on multivariate analysis the normal weight centrally obese children were 1.66, 2.01, 1.47 and 2.05 times more likely to have significant adverse levels of ldl cholesterol, hdl cholesterol, triglycerides and insulin, respectively.
det||2003-3/CD||the-2/DT	prep_during||randomised-26/VBN||2003-3/CD	num||seasons-8/NNS||2004-5/CD	nn||seasons-8/NNS||malaria-6/NN	nn||seasons-8/NNS||transmission-7/NN	conj_and||2003-3/CD||seasons-8/NNS	prep_during||randomised-26/VBN||seasons-8/NNS	num||children-12/NNS||1200-10/CD	nn||children-12/NNS||gambian-11/NN	nsubjpass||randomised-26/VBN||children-12/NNS	nsubj||receive-28/VB||children-12/NNS	amod||anaemia-17/NN||moderate-14/JJ	conj_or||moderate-14/JJ||severe-16/JJ	amod||anaemia-17/NN||severe-16/JJ	prep_with||children-12/NNS||anaemia-17/NN	nn||<-21/NNS||hb-19/NN	nn||<-21/NNS||concentration-20/NN	dep||g/dl-23/JJ||<-21/NNS	number||g/dl-23/JJ||7-22/CD	dep||anaemia-17/NN||g/dl-23/JJ	auxpass||randomised-26/VBN||were-25/VBD	root||ROOT-0/null||randomised-26/VBN	aux||receive-28/VB||to-27/TO	xcomp||randomised-26/VBN||receive-28/VB	det||sulfadoxine-pyrimethamine-31/NN||either-29/DT	amod||sulfadoxine-pyrimethamine-31/NN||monthly-30/JJ	dobj||receive-28/VB||sulfadoxine-pyrimethamine-31/NN	appos||sulfadoxine-pyrimethamine-31/NN||sp-33/NN	dobj||receive-28/VB||placebo-36/NN	conj_or||sulfadoxine-pyrimethamine-31/NN||placebo-36/NN	det||end-39/NN||the-38/DT	prep_until||receive-28/VB||end-39/NN	det||season-44/NN||the-41/DT	nn||season-44/NN||malaria-42/NN	nn||season-44/NN||transmission-43/NN	prep_of||end-39/NN||season-44/NN	prep_in||enrolled-49/VBN||season-44/NN	nsubjpass||enrolled-49/VBN||they-47/PRP	auxpass||enrolled-49/VBN||were-48/VBD	rcmod||season-44/NN||enrolled-49/VBN	det||trial-54/NN||a-52/DT	amod||trial-54/NN||double-blind-53/JJ	prep_in||enrolled-49/VBN||trial-54/NN	malaria-42||pyrimethamine--1||yes||during the 2003 and 2004 malaria transmission seasons, 1200 gambian children with moderate or severe anaemia (hb concentration <7 g/dl) were randomised to receive either monthly sulfadoxine-pyrimethamine (sp) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial.
num||characteristics-4/NNS||six-1/CD	nn||characteristics-4/NNS||baseline-2/NN	nn||characteristics-4/NNS||participant-3/NN	nsubjpass||designated-6/VBN||characteristics-4/NNS	nsubj||participantsâ-60/VBZ||characteristics-4/NNS	auxpass||designated-6/VBN||were-5/VBD	root||ROOT-0/null||designated-6/VBN	amod||predictors-9/NNS||putative-8/JJ	prep_as||designated-6/VBN||predictors-9/NNS	nn||response-12/NN||treatment-11/NN	prep_of||predictors-9/NNS||response-12/NN	appos||response-12/NN||1-14/CD	dep||response-12/NN||gender-16/NN	appos||gender-16/NN||2-19/CD	dep||gender-16/NN||education-21/NN	dep||use-27/NN||3-24/LS	amod||use-27/NN||internet-26/VBN	appos||education-21/NN||use-27/NN	amod||sociodemographics-30/NNS||competence-28/JJ	dep||use-27/NN||sociodemographics-30/NNS	appos||sociodemographics-30/NNS||4-34/CD	amod||consumption-39/NN||mean-36/JJ	amod||consumption-39/NN||weekly-37/JJ	nn||consumption-39/NN||alcohol-38/NN	dep||sociodemographics-30/NNS||consumption-39/NN	appos||consumption-39/NN||5-42/CD	amod||help-46/NN||prior-44/JJ	amod||help-46/NN||professional-45/JJ	dep||consumption-39/NN||help-46/NN	nn||problems-49/NNS||alcohol-48/NN	prep_for||help-46/NN||problems-49/NNS	dep||problems-49/NNS||level-51/NN	prep_of||level-51/NN||problemdrinking-53/VBG	dep||participantsâ-60/VBZ||6-58/CD	conj_and||designated-6/VBN||participantsâ-60/VBZ	dep||expectancies-63/NNS||$-61/$	num||expectancies-63/NNS||™-62/CD	dobj||participantsâ-60/VBZ||expectancies-63/NNS	amod||interventions-66/NNS||web-based-65/JJ	prep_of||expectancies-63/NNS||interventions-66/NNS	prep_for||interventions-66/NNS||problemdrinking-68/VBG	problemdrinking-68||alcohol-48||no||six baseline participant characteristics were designated as putative predictors of treatment response (1) gender, (2) education, (3) internet use competence (sociodemographics), (4) mean weekly alcohol consumption, (5) prior professional help for alcohol problems (level of problemdrinking), and (6) participantsâ€™ expectancies of web-based interventions for problemdrinking.
advmod||predicts-5/VBZ||moreover-1/RB	det||model-4/NN||the-3/DT	nsubj||predicts-5/VBZ||model-4/NN	root||ROOT-0/null||predicts-5/VBZ	amod||characteristics-7/NNS||desirable-6/JJ	dobj||predicts-5/VBZ||characteristics-7/NNS	det||protein-11/NN||a-9/DT	nn||protein-11/NN||buffer-10/NN	prep_for||characteristics-7/NNS||protein-11/NN	nsubj||keeps-20/VBZ||protein-11/NN	amod||removal-15/NN||effective-14/JJ	prep_such_as||protein-11/NN||removal-15/NN	prep_of||removal-15/NN||excessiron-17/NN	rcmod||protein-11/NN||keeps-20/VBZ	nn||levels-23/NNS||intracellular-21/NN	nn||levels-23/NNS||clip-22/NN	nsubjpass||introduced-31/VBN||levels-23/NNS	advmod||constant-25/JJ||approximately-24/RB	dep||introduced-31/VBN||constant-25/JJ	advmod||introduced-31/VBN||even-26/RB	advmod||introduced-31/VBN||when-27/WRB	amod||perturbations-29/NNS||large-28/JJ	nsubjpass||introduced-31/VBN||perturbations-29/NNS	auxpass||introduced-31/VBN||are-30/VBP	xcomp||keeps-20/VBZ||introduced-31/VBN	det||source-37/NN||a-34/DT	advmod||available-36/JJ||freely-35/RB	amod||source-37/NN||available-36/JJ	dobj||predicts-5/VBZ||source-37/NN	conj_and||characteristics-7/NNS||source-37/NN	prep_of||source-37/NN||iron-39/NN	nn||starvation-42/NN||iron-41/NN	prep_under||iron-39/NN||starvation-42/NN	excessiron-17||iron-41||no||moreover, the model predicts desirable characteristics for a buffer protein such as effective removal of excessiron, which keeps intracellular clip levels approximately constant even when large perturbations are introduced, and a freely available source of iron under iron starvation.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||the-3/DT	dobj||report-2/VBP||case-4/NN	det||patient-7/NN||a-6/DT	prep_of||case-4/NN||patient-7/NN	nsubj||received-9/VBD||patient-7/NN	rcmod||patient-7/NN||received-9/VBD	amod||treatment-11/NN||prolonged-10/JJ	dobj||received-9/VBD||treatment-11/NN	amod||ciprofloxacin-14/NN||high-dose-13/JJ	prep_with||received-9/VBD||ciprofloxacin-14/NN	amod||osteomyelitis-18/NNS||extensive-16/JJ	amod||osteomyelitis-18/NNS||pelvic-17/JJ	prep_for||received-9/VBD||osteomyelitis-18/NNS	osteomyelitis-18||ciprofloxacin-14||yes||we report the case of a patient who received prolonged treatment with high-dose ciprofloxacin for extensive pelvic osteomyelitis.
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubjpass||validated-9/VBN||plus-5/NN	nsubj||mdr-tb-32/JJ||plus-5/NN	advmod||validated-9/VBN||assay-6/RB	aux||validated-9/VBN||has-7/VBZ	auxpass||validated-9/VBN||been-8/VBN	root||ROOT-0/null||validated-9/VBN	mark||isolates-23/VBZ||as-10/IN	det||test-17/NN||a-11/DT	amod||test-17/NN||rapid-12/JJ	conj_and||rapid-12/JJ||reliable-14/JJ	amod||test-17/NN||reliable-14/JJ	amod||test-17/NN||first-line-15/JJ	amod||test-17/NN||diagnostic-16/JJ	nsubj||isolates-23/VBZ||test-17/NN	amod||sputum-20/NN||afb-positive-19/JJ	prep_on||test-17/NN||sputum-20/NN	prep_on||test-17/NN||mtb-22/NN	conj_or||sputum-20/NN||mtb-22/NN	advcl||validated-9/VBN||isolates-23/VBZ	nn||resistance-26/NN||inh-25/NN	prep_for||isolates-23/VBZ||resistance-26/NN	nn||resistance-29/NN||rif-28/NN	appos||resistance-26/NN||resistance-29/NN	conj_and||validated-9/VBN||mdr-tb-32/JJ	prep_in||mdr-tb-32/JJ||bangkok-34/NN	dep||validated-9/VBN||thailand-36/VBN	tb--1||mtb-22||no||the genotypeâ® mtbdr plus assay has been validated as a rapid and reliable first-line diagnostic test on afb-positive sputum or mtb isolates for inh resistance, rif resistance, and mdr-tb in bangkok, thailand.
det||range-4/NN||this-2/DT	nn||range-4/NN||dose-3/NN	prep_within||reduced-15/VBD||range-4/NN	det||population-9/NN||this-7/DT	nn||population-9/NN||patients-8/NNS	prep_in||reduced-15/VBD||population-9/NN	amod||dosage-13/NN||increasing-11/JJ	nn||dosage-13/NN||lidocaine-12/NN	nsubj||reduced-15/VBD||dosage-13/NN	nsubj||reduced-15/VBD||dosage-13/NN	advmod||reduced-15/VBD||significantly-14/RB	root||ROOT-0/null||reduced-15/VBD	conj_and||reduced-15/VBD||reduced-15/VBD	dobj||reduced-15/VBD||pain-16/NN	prep_during||reduced-15/VBD||injection-18/NN	nn||propofol-21/NN||microemulsion-20/NN	prep_of||injection-18/NN||propofol-21/NN	pain-16||lidocaine-12||yes||within this dose range and in this patients population, increasing lidocaine dosage significantly reduced pain during injection of microemulsion propofol.
nsubj||agent-5/NN||yersiniapestis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	det||plague-8/NN||the-7/DT	prep_of||agent-5/NN||plague-8/NN	plague-8||yersiniapestis-1||no||yersiniapestis is the causative agent of the plague.
amod||fever-3/NN||african-1/JJ	amod||fever-3/NN||tick-bite-2/JJ	nsubj||disease-8/NN||fever-3/NN	cop||disease-8/NN||is-4/VBZ	det||disease-8/NN||an-5/DT	amod||disease-8/NN||emerging-6/VBG	amod||disease-8/NN||infectious-7/JJ	root||ROOT-0/null||disease-8/NN	dep||disease-8/NN||caused-9/VBN	det||rickettsia-14/NN||the-11/DT	nn||rickettsia-14/NN||spottedfever-12/NN	nn||rickettsia-14/NN||group-13/NN	prep_by||caused-9/VBN||rickettsia-14/NN	nn||africae-17/NN||rickettsia-16/NN	appos||rickettsia-14/NN||africae-17/NN	auxpass||transmitted-21/VBN||is-20/VBZ	dep||disease-8/NN||transmitted-21/VBN	conj_and||caused-9/VBN||transmitted-21/VBN	agent||transmitted-21/VBN||ticks-23/NNS	det||amblyomma-27/NN||the-25/DT	amod||amblyomma-27/NN||genus-26/JJ	prep_of||ticks-23/NNS||amblyomma-27/NN	spottedfever-12||rickettsia-16||no||african tick-bite fever is an emerging infectious disease caused by the spottedfever group rickettsia , rickettsia africae, and is transmitted by ticks of the genus amblyomma.
det||data-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||expressed-8/VBN||that-4/IN	nn||proteins-6/NNS||socs-5/NNS	nsubjpass||expressed-8/VBN||proteins-6/NNS	auxpass||expressed-8/VBN||are-7/VBP	ccomp||demonstrate-3/VBP||expressed-8/VBN	amod||lines-13/NNS||human-10/JJ	nn||lines-13/NNS||melanoma-11/NN	nn||lines-13/NNS||cell-12/NN	prep_in||expressed-8/VBN||lines-13/NNS	poss||modulation-16/NN||their-15/PRP$	nsubj||influence-18/VB||modulation-16/NN	aux||influence-18/VB||can-17/MD	conj_and||demonstrate-3/VBP||influence-18/VB	det||responsiveness-20/NNS||the-19/DT	dobj||influence-18/VB||responsiveness-20/NNS	nn||cells-23/NNS||melanoma-22/NN	prep_of||responsiveness-20/NNS||cells-23/NNS	nn||±-26/NNP||ifn-î-25/NNP	prep_to||influence-18/VB||±-26/NNP	nn||³-29/NNP||ifn-î-28/NNP	prep_to||influence-18/VB||³-29/NNP	conj_and||±-26/NNP||³-29/NNP	melanoma-22||ifn--1||yes||these data demonstrate that socs proteins are expressed in human melanoma cell lines and their modulation can influence the responsiveness of melanoma cells to ifn-î± and ifn-î³.
amod||outcomes-2/NNS||secondary-1/JJ	nsubjpass||assessed-5/VBN||outcomes-2/NNS	auxpass||assessed-5/VBN||were-3/VBD	advmod||assessed-5/VBN||nausea-4/RB	root||ROOT-0/null||assessed-5/VBN	det||scale-10/NN||a-7/DT	amod||scale-10/NN||visual-8/JJ	amod||scale-10/NN||analog-9/JJ	agent||assessed-5/VBN||scale-10/NN	discourse||scale-10/NN||vas-12/UH	nsubj||31â-22/VBG||baseline-15/NN	amod||$-18/$||0â-17/JJ	appos||baseline-15/NN||$-18/$	num||$-18/$||30-20/CD	prepc_at||assessed-5/VBN||31â-22/VBG	dobj||31â-22/VBG||$-23/$	num||$-23/$||60-25/CD	dobj||31â-22/VBG||61â-28/NNS	conj_and||$-23/$||61â-28/NNS	num||minutes-32/NNS||$-29/$	num||$-29/$||120-31/CD	dep||61â-28/NNS||minutes-32/NNS	det||administration-35/NN||the-34/DT	prep_after||31â-22/VBG||administration-35/NN	prep_of||administration-35/NN||ondansetron-37/NN	prep_of||administration-35/NN||prochlorperazine-39/NN	conj_or||ondansetron-37/NN||prochlorperazine-39/NN	det||percentage-42/NN||the-41/DT	prep_after||31â-22/VBG||percentage-42/NN	conj_and||administration-35/NN||percentage-42/NN	prep_of||percentage-42/NN||patients-44/NNS	amod||effects-47/NNS||adverse-46/JJ	prep_with||patients-44/NNS||effects-47/NNS	nn||akathisia-53/NN||sedation-49/NN	dep||akathisia-53/NN||headache-51/NN	appos||effects-47/NNS||akathisia-53/NN	dep||akathisia-53/NN||dystonia-55/NNP	det||drug-59/NN||either-58/DT	prep_to||31â-22/VBG||drug-59/NN	nausea-4||prochlorperazine-39||yes||secondary outcomes were nausea assessed by a visual analog scale (vas) at baseline, 0â€“30, 31â€“60, and 61â€“120 minutes after the administration of ondansetron or prochlorperazine and the percentage of patients with adverse effects (sedation, headache, akathisia, dystonia) to either drug.
advmod||reported-15/VBN||bartonellahenselae-1/RB	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	nsubjpass||reported-15/VBN||agent-5/NN	prep_of||agent-5/NN||catscratchdisease-7/NN	amod||species-12/NNS||other-10/JJ	nn||species-12/NNS||bartonella-11/NN	prep_of||agent-5/NN||species-12/NNS	conj_and||catscratchdisease-7/NN||species-12/NNS	aux||reported-15/VBN||have-13/VBP	auxpass||reported-15/VBN||been-14/VBN	root||ROOT-0/null||reported-15/VBN	prep_in||reported-15/VBN||fleas-17/NNS	prep_in||reported-15/VBN||ticks-19/NNS	conj_and||fleas-17/NNS||ticks-19/NNS	catscratchdisease-7||bartonella-11||no||bartonellahenselae , the causative agent of catscratchdisease, and other bartonella species have been reported in fleas and ticks.
aux||examine-2/VB||to-1/TO	advcl||performed-10/VBN||examine-2/VB	det||question-4/NN||this-3/DT	dobj||examine-2/VB||question-4/NN	amod||clamps-8/NNS||euglycemic-6/JJ	nn||clamps-8/NNS||glucose-7/NN	nsubjpass||performed-10/VBN||clamps-8/NNS	auxpass||performed-10/VBN||were-9/VBD	root||ROOT-0/null||performed-10/VBN	advmod||performed-10/VBN||twice-11/RB	amod||order-15/NN||random-14/JJ	prep_in||performed-10/VBN||order-15/NN	num||youth-19/NN||11-18/CD	prep_in||performed-10/VBN||youth-19/NN	prep_with||youth-19/NN||type1diabetes-21/CD	nn||15.1-24/NNS||age-23/NN	nsubj||â-25/VBP||15.1-24/NNS	dep||youth-19/NN||â-25/VBP	number||3-27/CD||±-26/CD	num||years-28/NNS||3-27/CD	tmod||â-25/VBP||years-28/NNS	amod||â-32/NN||a1c-30/JJ	num||â-32/NN||7.6-31/CD	nsubj||±-33/VBG||â-32/NN	vmod||â-25/VBP||±-33/VBG	num||%-35/NN||0.6-34/CD	dobj||±-33/VBG||%-35/NN	num||lispro-40/NN||0.2-38/CD	amod||lispro-40/NN||units/kg-39/VBG	prep_with||youth-19/NN||lispro-40/NN	num||glargine-44/NN||0.4-42/CD	amod||glargine-44/NN||units/kg-43/VBG	prep_with||youth-19/NN||glargine-44/NN	conj_and||lispro-40/NN||glargine-44/NN	vmod||lispro-40/NN||given-46/VBN	preconj||given-46/VBN||either-47/CC	prep_as||given-46/VBN||separate-49/JJ	det||injection-55/NN||a-52/DT	amod||injection-55/NN||single-53/JJ	amod||injection-55/NN||mixed-54/JJ	prep_as||given-46/VBN||injection-55/NN	conj_or||separate-49/JJ||injection-55/NN	lispro-40||type1diabetes-21||no_rel||to examine this question, euglycemic glucose clamps were performed twice, in random order, in 11 youth with type1diabetes (age 15.1 â± 3 years, a1c 7.6 â± 0.6%) with 0.2 units/kg lispro and 0.4 units/kg glargine, given either as separate or as a single mixed injection.
amod||rats-5/NNS||goto-kakizaki-1/JJ	appos||rats-5/NNS||gk-3/NN	nsubj||model-9/NN||rats-5/NNS	cop||model-9/NN||are-6/VBP	det||model-9/NN||a-7/DT	amod||model-9/NN||polygenic-8/JJ	root||ROOT-0/null||model-9/NN	amod||glucose-13/NN||elevated-11/JJ	nn||glucose-13/NN||blood-12/NN	prep_with||model-9/NN||glucose-13/NN	amod||insulinresistance-16/NN||peripheral-15/JJ	prep_with||model-9/NN||insulinresistance-16/NN	conj_and||glucose-13/NN||insulinresistance-16/NN	det||phenotype-20/NN||a-18/DT	amod||phenotype-20/NN||non-obese-19/JJ	prep_with||model-9/NN||phenotype-20/NN	conj_and||glucose-13/NN||phenotype-20/NN	prep_with||model-9/NN||exhibit-23/NN	conj_and||glucose-13/NN||exhibit-23/NN	amod||changes-26/NNS||many-24/JJ	nn||changes-26/NNS||degenerative-25/NN	nsubj||observed-27/VBD||changes-26/NNS	rcmod||model-9/NN||observed-27/VBD	amod||t2dm-30/NNS||human-29/JJ	prep_in||observed-27/VBD||t2dm-30/NNS	glucose-13||insulinresistance-16||no_rel||goto-kakizaki (gk) rats are a polygenic model with elevated blood glucose, peripheral insulinresistance, a non-obese phenotype, and exhibit many degenerative changes observed in human t2dm.
nsubjpass||analyzed-16/VBN||isolates-1/NNP	prep_of||isolates-1/NNP||m.tuberculosis-3/NNS	num||patients-7/NNS||98-5/CD	nn||patients-7/NNS||tuberculosis-6/NNP	prep_from||m.tuberculosis-3/NNS||patients-7/NNS	vmod||m.tuberculosis-3/NNS||living-8/VBG	num||-rrb--14/NNS||kharkiv-10/CD	amod||-rrb--14/NNS||oblast-11/JJ	amod||-rrb--14/NNS||-lrb--12/JJ	nn||-rrb--14/NNS||ukraine-13/NN	prep_in||living-8/VBG||-rrb--14/NNS	auxpass||analyzed-16/VBN||were-15/VBD	root||ROOT-0/null||analyzed-16/VBN	xcomp||analyzed-16/VBN||using-17/VBG	amod||methods-22/NNS||vntr-18/JJ	conj_and||vntr-18/JJ||rflp-is6110-typing-21/JJ	amod||methods-22/NNS||rflp-is6110-typing-21/JJ	dobj||using-17/VBG||methods-22/NNS	tuberculosis-6||m.tuberculosis-3||no||isolates of m.tuberculosis from 98 tuberculosis patients living in kharkiv oblast -lrb- ukraine -rrb- were analyzed using vntr - and rflp-is6110-typing methods .
nsubj||increases-14/VBZ||ozone-1/NN	det||pollutant-4/NN||a-3/DT	appos||ozone-1/NN||pollutant-4/NN	vmod||pollutant-4/NN||known-5/VBN	aux||induce-7/VB||to-6/TO	xcomp||known-5/VBN||induce-7/VB	amod||hyper-responsiveness-9/NNS||airway-8/JJ	dobj||induce-7/VB||hyper-responsiveness-9/NNS	appos||hyper-responsiveness-9/NNS||ahr-11/NN	root||ROOT-0/null||increases-14/VBZ	dobj||increases-14/VBZ||morbidity-15/NN	dobj||increases-14/VBZ||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prep_in||increases-14/VBZ||patients-19/NNS	amod||diseases-23/NNS||obstructive-21/JJ	nn||diseases-23/NNS||airway-22/NN	prep_with||patients-19/NNS||diseases-23/NNS	prep_with||patients-19/NNS||asthma-25/NN	conj_and||diseases-23/NNS||asthma-25/NN	ozone-1||asthma-25||no_rel||ozone, a pollutant known to induce airway hyper-responsiveness (ahr), increases morbidity and mortality in patients with obstructive airway diseases and asthma.
prepc_by||develop-10/VB||altering-2/VBG	nn||patterns-5/NNS||gene-3/NN	nn||patterns-5/NNS||expression-4/NN	dobj||altering-2/VBG||patterns-5/NNS	nn||cells-8/NNS||cancer-7/NN	nsubj||develop-10/VB||cells-8/NNS	aux||develop-10/VB||can-9/MD	root||ROOT-0/null||develop-10/VB	amod||phenotypes-12/NNS||specific-11/JJ	dobj||develop-10/VB||phenotypes-12/NNS	nsubj||allow-14/VBP||phenotypes-12/NNS	rcmod||phenotypes-12/NNS||allow-14/VBP	dobj||allow-14/VBP||them-15/PRP	nsubj||proliferate-17/VB||them-15/PRP	nsubj||survive-19/VB||them-15/PRP	nsubj||secure-21/VB||them-15/PRP	nsubj||evade-26/VB||them-15/PRP	nsubj||invade-30/VB||them-15/PRP	nsubj||metastasize-34/VB||them-15/PRP	aux||proliferate-17/VB||to-16/TO	xcomp||allow-14/VBP||proliferate-17/VB	xcomp||allow-14/VBP||survive-19/VB	conj_and||proliferate-17/VB||survive-19/VB	xcomp||allow-14/VBP||secure-21/VB	conj_and||proliferate-17/VB||secure-21/VB	dobj||secure-21/VB||oxygen-22/NN	dobj||secure-21/VB||nutrients-24/NNS	conj_and||oxygen-22/NN||nutrients-24/NNS	xcomp||allow-14/VBP||evade-26/VB	conj_and||proliferate-17/VB||evade-26/VB	amod||recognition-28/NN||immune-27/JJ	dobj||evade-26/VB||recognition-28/NN	xcomp||allow-14/VBP||invade-30/VB	conj_and||proliferate-17/VB||invade-30/VB	amod||tissues-32/NNS||other-31/JJ	dobj||invade-30/VB||tissues-32/NNS	xcomp||allow-14/VBP||metastasize-34/VB	conj_and||proliferate-17/VB||metastasize-34/VB	oxygen-22||cancer-7||no_rel||by altering gene expression patterns, cancer cells can develop specific phenotypes that allow them to proliferate, survive, secure oxygen and nutrients, evade immune recognition, invade other tissues and metastasize.
nsubj||represent-2/VBP||statins-1/NNS	root||ROOT-0/null||represent-2/VBP	det||class-4/NN||a-3/DT	dobj||represent-2/VBP||class-4/NN	prep_of||class-4/NN||drugs-6/NNS	nsubjpass||used-10/VBN||drugs-6/NNS	nsubj||treat-12/VB||drugs-6/NNS	auxpass||used-10/VBN||are-8/VBP	advmod||used-10/VBN||widely-9/RB	rcmod||drugs-6/NNS||used-10/VBN	aux||treat-12/VB||to-11/TO	xcomp||used-10/VBN||treat-12/VB	dobj||treat-12/VB||hypercholesterolemia-13/NN	poss||ability-16/NN||their-15/PRP$	prep_for||treat-12/VB||ability-16/NN	aux||inhibit-18/VB||to-17/TO	dep||ability-16/NN||inhibit-18/VB	nn||biosynthesis-20/NNS||cholesterol-19/NN	dobj||inhibit-18/VB||biosynthesis-20/NNS	aux||up-regulate-23/VB||to-22/TO	dep||ability-16/NN||up-regulate-23/VB	conj_and||inhibit-18/VB||up-regulate-23/VB	det||synthesis-25/NN||the-24/DT	dobj||up-regulate-23/VB||synthesis-25/NN	amod||receptors-33/NNS||low-27/JJ	nn||receptors-33/NNS||density-28/NN	nn||receptors-33/NNS||lipoprotein-29/NN	appos||receptors-33/NNS||ldl-31/NN	prep_of||synthesis-25/NN||receptors-33/NNS	det||liver-36/NN||the-35/DT	prep_in||receptors-33/NNS||liver-36/NN	hypercholesterolemia-13||cholesterol-19||no||statins represent a class of drugs that are widely used to treat hypercholesterolemia for their ability to inhibit cholesterol biosynthesis and to up-regulate the synthesis of low density lipoprotein (ldl) receptors in the liver.
nsubj||preserved-9/VBD||attachment-1/NN	amod||chains-5/NNS||neutral-3/JJ	amod||chains-5/NNS||amide-linked-4/JJ	prep_of||attachment-1/NN||chains-5/NNS	amod||chains-8/NNS||thiourea-containing-7/JJ	prep_of||attachment-1/NN||chains-8/NNS	conj_or||chains-5/NNS||chains-8/NNS	root||ROOT-0/null||preserved-9/VBD	det||affinity-12/NN||the-10/DT	amod||affinity-12/NN||moderate-11/JJ	dobj||preserved-9/VBD||affinity-12/NN	dobj||preserved-9/VBD||efficacy-14/NN	conj_and||affinity-12/NN||efficacy-14/NN	det||subtype-19/NN||the-16/DT	amod||subtype-19/NN||a1-17/JJ	nn||subtype-19/NN||ar-18/NN	prep_at||preserved-9/VBD||subtype-19/NN	expl||was-23/VBD||there-22/EX	conj_but||preserved-9/VBD||was-23/VBD	neg||selectivity-25/NN||no-24/DT	nsubj||was-23/VBD||selectivity-25/NN	det||ar-29/NN||the-27/DT	amod||ar-29/NN||a3-28/JJ	prep_for||selectivity-25/NN||ar-29/NN	ar-29||amide--1||no_rel||attachment of neutral amide-linked chains or thiourea-containing chains preserved the moderate affinity and efficacy at the a1 ar subtype, but there was no selectivity for the a3 ar.
det||results-2/NNS||these-1/DT	nsubj||reveal-3/VBP||results-2/NNS	nsubj||affect-28/VB||results-2/NNS	root||ROOT-0/null||reveal-3/VBP	det||mechanism-6/NN||a-4/DT	nn||mechanism-6/NN||novel-5/NN	dobj||reveal-3/VBP||mechanism-6/NN	aux||explain-8/VB||to-7/TO	vmod||reveal-3/VBP||explain-8/VB	advmod||fails-13/VBZ||why-9/WRB	nsubj||fails-13/VBZ||infection-10/NN	nsubj||trigger-15/VB||infection-10/NN	nsubj||develop-22/VB||infection-10/NN	prep_of||infection-10/NN||n.gonorrhoeae-12/NN	advcl||explain-8/VB||fails-13/VBZ	aux||trigger-15/VB||to-14/TO	xcomp||fails-13/VBZ||trigger-15/VB	det||response-20/NN||an-16/DT	amod||response-20/NN||effective-17/JJ	amod||response-20/NN||specific-18/JJ	amod||response-20/NN||immune-19/JJ	dobj||trigger-15/VB||response-20/NN	xcomp||fails-13/VBZ||develop-22/VB	conj_or||trigger-15/VB||develop-22/VB	amod||memory-24/NN||immune-23/JJ	dobj||develop-22/VB||memory-24/NN	aux||affect-28/VB||may-27/MD	conj_and||reveal-3/VBP||affect-28/VB	det||synergy-31/NN||the-29/DT	amod||synergy-31/NN||potent-30/JJ	dobj||affect-28/VB||synergy-31/NN	nn||infection-36/NN||gonorrhea-33/NN	conj_and||gonorrhea-33/NN||hiv-1-35/JJ	nn||infection-36/NN||hiv-1-35/JJ	prep_between||synergy-31/NN||infection-36/NN	gonorrhea-33||n.gonorrhoeae-12||no||these results reveal a novel mechanism to explain why infection of n.gonorrhoeae fails to trigger an effective specific immune response or develop immune memory , and may affect the potent synergy between gonorrhea and hiv-1 infection .
det||chc-4/NN||these-1/DT	nn||chc-4/NN||qualitatively-2/NN	amod||chc-4/NN||differing-3/VBG	nsubjpass||found-7/VBN||chc-4/NN	advmod||found-7/VBN||compounds-5/RB	auxpass||found-7/VBN||were-6/VBD	root||ROOT-0/null||found-7/VBN	amod||classes-11/NNS||various-9/JJ	nn||classes-11/NNS||substance-10/NN	prep_across||found-7/VBN||classes-11/NNS	prep_including||classes-11/NNS||alkanes-13/NNS	appos||alkanes-13/NNS||alkenes-15/NNS	appos||alkanes-13/NNS||mono-17/NN	conj_and||alkenes-15/NNS||mono-17/NN	amod||alkanes-24/NNS||di-20/JJ	conj_and||di-20/JJ||trimethyl-branched-23/JJ	amod||alkanes-24/NNS||trimethyl-branched-23/JJ	appos||alkanes-13/NNS||alkanes-24/NNS	alkanes-24||di-20||no_rel||these qualitatively differing chc compounds were found across various substance classes including alkanes, alkenes and mono-, di- and trimethyl-branched alkanes.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	nsubj||suffering-8/VBG||study-4/NN	num||patients-7/NNS||131-6/CD	prep_on||study-4/NN||patients-7/NNS	prepc_in||found-17/VBD||suffering-8/VBG	prep_from||suffering-8/VBG||alcoholdependency-10/NN	num||volunteers-14/NNS||185-12/CD	amod||volunteers-14/NNS||healthy-13/JJ	prep_from||suffering-8/VBG||volunteers-14/NNS	conj_and||alcoholdependency-10/NN||volunteers-14/NNS	nsubj||found-17/VBD||we-16/PRP	root||ROOT-0/null||found-17/VBD	mark||had-22/VBD||that-18/IN	nn||patients-21/NNS||alcohol-19/NN	amod||patients-21/NNS||dependent-20/JJ	nsubj||had-22/VBD||patients-21/NNS	ccomp||found-17/VBD||had-22/VBD	amod||2dâˆ-24/NNS||smaller-23/JJR	dobj||had-22/VBD||2dâˆ-24/NNS	dep||2dâˆ-24/NNS||¶-25/VBG	amod||ratios-27/NNS||4d-26/JJ	dobj||¶-25/VBG||ratios-27/NNS	prepc_compared_to||¶-25/VBG||to-29/TO	pobj||¶-25/VBG||controls-30/NNS	amod||dimorphism-34/NN||preserved-32/JJ	amod||dimorphism-34/NN||sexual-33/JJ	prep_with||controls-30/NNS||dimorphism-34/NN	dep||2dâˆ-24/NNS||with-36/IN	conj_but||¶-25/VBG||with-36/IN	amod||differences-39/NNS||reduced-37/VBN	amod||differences-39/NNS||right-left-38/JJ	pobj||with-36/IN||differences-39/NNS	alcoholdependency-10||alcohol-19||no||in the present study on 131 patients suffering from alcoholdependency and 185 healthy volunteers, we found that alcohol dependent patients had smaller 2dâˆ¶4d ratios compared to controls with preserved sexual dimorphism but with reduced right-left differences.
amod||causes-2/NNS||potential-1/JJ	nsubj||include-12/VBP||causes-2/NNS	amod||deterioration-5/NN||clinical-4/JJ	prep_for||causes-2/NNS||deterioration-5/NN	prep_in||deterioration-5/NN||settings-7/NNS	amod||prevalence-11/NN||high-9/JJ	amod||prevalence-11/NN||hiv-1-10/JJ	prep_of||settings-7/NNS||prevalence-11/NN	root||ROOT-0/null||include-12/VBP	npadvmod||resistant-14/JJ||drug-13/NN	amod||mycobacteriumtuberculosis-15/NNS||resistant-14/JJ	dobj||include-12/VBP||mycobacteriumtuberculosis-15/NNS	appos||mycobacteriumtuberculosis-15/NNS||m.tb-17/NN	amod||illnesses-21/NNS||co-morbid-20/JJ	dobj||include-12/VBP||illnesses-21/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||illnesses-21/NNS	amod||adherence-24/NN||poor-23/JJ	dobj||include-12/VBP||adherence-24/NN	conj_and||mycobacteriumtuberculosis-15/NNS||adherence-24/NN	nn||syndrome-32/NN||therapy-26/NN	nn||syndrome-32/NN||tuberculosis-28/NNP	amod||syndrome-32/NN||associated-immune-29/JJ	amod||syndrome-32/NN||reconstitution-30/JJ	amod||syndrome-32/NN||inflammatory-31/JJ	prep_to||adherence-24/NN||syndrome-32/NN	appos||syndrome-32/NN||tb-iris-34/NNS	amod||levels-40/NNS||subtherapeutic-37/JJ	nn||levels-40/NNS||antitubercular-38/NN	nn||levels-40/NNS||drug-39/NN	dobj||include-12/VBP||levels-40/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||levels-40/NNS	tb--1||antitubercular-38||yes||potential causes for clinical deterioration in settings of high hiv-1 prevalence include drug resistant mycobacteriumtuberculosis (m.tb) , co-morbid illnesses, poor adherence to therapy, tuberculosis associated-immune reconstitution inflammatory syndrome (tb-iris) and subtherapeutic antitubercular drug levels.
nn||treatment-2/NN||drug-1/NN	nsubjpass||targeted-5/VBN||treatment-2/NN	aux||targeted-5/VBN||has-3/VBZ	auxpass||targeted-5/VBN||been-4/VBN	root||ROOT-0/null||targeted-5/VBN	det||level-11/NN||the-7/DT	amod||level-11/NN||hypothalamic-8/JJ	conj_or||hypothalamic-8/JJ||pituitary-10/JJ	amod||level-11/NN||pituitary-10/JJ	prep_at||targeted-5/VBN||level-11/NN	det||gland-16/NN||the-14/DT	amod||gland-16/NN||adrenal-15/JJ	prep_at||targeted-5/VBN||gland-16/NN	advmod||targeted-5/VBN||also-19/RB	det||level-24/NN||the-21/DT	amod||level-24/NN||glucocorticoid-22/JJ	nn||level-24/NN||receptor-23/NN	prep_at||targeted-5/VBN||level-24/NN	conj_and||gland-16/NN||level-24/NN	pituitary-10||glucocorticoid-22||no_rel||drug treatment has been targeted at the hypothalamic or pituitary level, at the adrenal gland, and also at the glucocorticoid receptor level.
amod||analysis-3/NN||multivariate-2/JJ	prep_on||have-22/VBP||analysis-3/NN	det||weight-6/NN||the-4/DT	amod||weight-6/NN||normal-5/JJ	prep_to||likely-20/JJ||weight-6/NN	nsubj||have-22/VBP||weight-6/NN	advmod||obese-8/JJ||centrally-7/RB	amod||children-9/NNS||obese-8/JJ	nsubj||1.66-11/CD||children-9/NNS	nsubj||likely-20/JJ||children-9/NNS	cop||1.66-11/CD||were-10/VBD	rcmod||weight-6/NN||1.66-11/CD	rcmod||weight-6/NN||2.01-13/CD	conj_and||1.66-11/CD||2.01-13/CD	rcmod||weight-6/NN||1.47-15/CD	conj_and||1.66-11/CD||1.47-15/CD	num||times-18/NNS||2.05-17/CD	npadvmod||more-19/RBR||times-18/NNS	advmod||likely-20/JJ||more-19/RBR	rcmod||weight-6/NN||likely-20/JJ	conj_and||1.66-11/CD||likely-20/JJ	root||ROOT-0/null||have-22/VBP	amod||levels-25/NNS||significant-23/JJ	amod||levels-25/NNS||adverse-24/JJ	dobj||have-22/VBP||levels-25/NNS	nn||cholesterol-28/NN||ldl-27/NN	prep_of||levels-25/NNS||cholesterol-28/NN	nn||cholesterol-31/NN||hdl-30/NN	prep_of||levels-25/NNS||cholesterol-31/NN	conj_and||cholesterol-28/NN||cholesterol-31/NN	prep_of||levels-25/NNS||triglycerides-33/NNPS	conj_and||cholesterol-28/NN||triglycerides-33/NNPS	prep_of||levels-25/NNS||insulin-35/NN	conj_and||cholesterol-28/NN||insulin-35/NN	advmod||have-22/VBP||respectively-37/RB	obese-8||triglycerides-33||no_rel||on multivariate analysis the normal weight centrally obese children were 1.66, 2.01, 1.47 and 2.05 times more likely to have significant adverse levels of ldl cholesterol, hdl cholesterol, triglycerides and insulin, respectively.
det||study-3/NN||a-1/DT	amod||study-3/NN||record-linkage-2/JJ	nsubjpass||carried-5/VBN||study-3/NN	nsubj||compare-18/VB||study-3/NN	nsubj||compare-18/VB||study-3/NN	auxpass||carried-5/VBN||was-4/VBD	root||ROOT-0/null||carried-5/VBN	prt||carried-5/VBN||out-6/RP	det||registry-11/NN||the-8/DT	amod||registry-11/NN||italian-9/JJ	nn||registry-11/NN||aids-10/NNS	prep_between||carried-5/VBN||registry-11/NN	num||registries-16/NNS||24-13/CD	amod||registries-16/NNS||italian-14/JJ	nn||registries-16/NNS||cancer-15/NN	prep_between||carried-5/VBN||registries-16/NNS	conj_and||registry-11/NN||registries-16/NNS	aux||compare-18/VB||to-17/TO	xcomp||carried-5/VBN||compare-18/VB	xcomp||carried-5/VBN||compare-18/VB	conj_and||compare-18/VB||compare-18/VB	nn||excess-20/NN||cancer-19/NN	dobj||compare-18/VB||excess-20/NN	prep_among||excess-20/NN||persons-22/NNS	prep_with||persons-22/NNS||hiv/aids-24/NNS	appos||hiv/aids-24/NNS||pwha-26/NNP	det||introduction-32/NN||the-31/DT	prep_after||compare-18/VB||introduction-32/NN	prep_before||compare-18/VB||introduction-32/NN	advmod||active-35/JJ||highly-34/RB	amod||therapy-37/NN||active-35/JJ	amod||therapy-37/NN||antiretroviral-36/JJ	prep_of||introduction-32/NN||therapy-37/NN	appos||therapy-37/NN||haart-39/NN	prep_in||compare-18/VB||1996-42/CD	aids-10||hiv--1||no||a record-linkage study was carried out between the italian aids registry and 24 italian cancer registries to compare cancer excess among persons with hiv/aids (pwha) before and after the introduction of highly active antiretroviral therapy (haart) in 1996.
det||part-4/NN||this-1/DT	nn||part-4/NN||paper-2/NN	nn||part-4/NN||forms-3/NNS	nsubj||â-21/VBP||part-4/NN	nsubj||changing-38/VBG||part-4/NN	det||review-7/NN||a-6/DT	prep_of||part-4/NN||review-7/NN	advmod||commissioned-11/VBN||â-8/RB	pobj||â-8/RB||$-9/$	vmod||review-7/NN||commissioned-11/VBN	det||initiative-16/NN||the-13/DT	amod||initiative-16/NN||joint-14/JJ	nn||initiative-16/NN||learning-15/NN	agent||commissioned-11/VBN||initiative-16/NN	prep_on||initiative-16/NN||children-18/NNS	prep_on||initiative-16/NN||hiv/aids-20/NNS	conj_and||children-18/NNS||hiv/aids-20/NNS	root||ROOT-0/null||â-21/VBP	dobj||â-21/VBP||$-22/$	amod||studies-26/NNS||qualitative-25/JJ	prep_of||$-22/$||studies-26/NNS	advmod||changed-34/VBN||how-28/WRB	nsubj||changed-34/VBN||families-29/NNS	amod||africa-32/NN||southern-31/JJ	prep_in||families-29/NNS||africa-32/NN	aux||changed-34/VBN||have-33/VBP	prepc_of||studies-26/NNS||changed-34/VBN	aux||changing-38/VBG||are-37/VBP	conj_and||â-21/VBP||changing-38/VBG	det||result-42/NN||a-41/DT	prep_as||changing-38/VBG||result-42/NN	det||impact-45/NN||the-44/DT	prep_of||result-42/NN||impact-45/NN	prep_of||impact-45/NN||hiv-47/NN	prep_of||impact-45/NN||aids-49/NNS	conj_and||hiv-47/NN||aids-49/NNS	aids-49||hiv-47||no||this paper forms part of a review â€” commissioned by the joint learning initiative on children and hiv/aids â€” of qualitative studies of how families in southern africa have changed, and are changing, as a result of the impact of hiv and aids.
num||subjects-4/NNS||one-1/CD	num||subjects-4/NNS||hundred-2/CD	amod||subjects-4/NNS||fifty-one-3/JJ	nsubj||received-8/VBD||subjects-4/NNS	amod||falciparummalaria-7/NN||uncomplicated-6/JJ	prep_with||subjects-4/NNS||falciparummalaria-7/NN	root||ROOT-0/null||received-8/VBD	advmod||observed-10/JJ||directly-9/RB	amod||therapy-11/NN||observed-10/JJ	dobj||received-8/VBD||therapy-11/NN	num||artesunate-15/NN||12-13/CD	amod||artesunate-15/NN||mg/kg-14/VBG	prep_with||received-8/VBD||artesunate-15/NN	num||days-19/NNS||three-18/CD	prep_over||artesunate-15/NN||days-19/NNS	number||mg/kg-23/JJ||25-22/CD	amod||mefloquine-37/NN||mg/kg-23/JJ	amod||mefloquine-37/NN||mefloquine-24/JJ	amod||mefloquine-37/NN||up-26/IN	det||dose-30/NN||a-28/DT	amod||dose-30/NN||maximum-29/JJ	prep_to||up-26/IN||dose-30/NN	num||mg-33/NN||600-32/CD	prep_of||dose-30/NN||mg-33/NN	amod||mefloquine-37/NN||artesunate/1-34/JJ	num||mefloquine-37/NN||,000-35/CD	nn||mefloquine-37/NN||mg-36/NN	prep_with||received-8/VBD||mefloquine-37/NN	conj_and||artesunate-15/NN||mefloquine-37/NN	falciparummalaria-7||mefloquine-37||yes||one hundred fifty-one subjects with uncomplicated falciparummalaria received directly observed therapy with 12 mg/kg artesunate (over three days) and 25 mg/kg mefloquine, up to a maximum dose of 600 mg artesunate/1,000 mg mefloquine.
det||review-2/NN||this-1/DT	nsubj||discusses-3/VBZ||review-2/NN	root||ROOT-0/null||discusses-3/VBZ	det||studies-6/NNS||some-4/DT	amod||studies-6/NNS||recent-5/JJ	dobj||discusses-3/VBZ||studies-6/NNS	nsubj||explored-9/VBN||studies-6/NNS	aux||explored-9/VBN||have-8/VBP	rcmod||studies-6/NNS||explored-9/VBN	advmod||affect-14/VB||how-10/WRB	amod||dynamics-12/NNS||endo/lysosomal-11/JJ	nsubj||affect-14/VB||dynamics-12/NNS	aux||affect-14/VB||can-13/MD	ccomp||explored-9/VBN||affect-14/VB	det||efficacy-16/NN||the-15/DT	dobj||affect-14/VB||efficacy-16/NN	amod||antibodies-20/NNS||engineered-18/JJ	amod||antibodies-20/NNS||therapeutic-19/JJ	prep_of||efficacy-16/NN||antibodies-20/NNS	prep_including||efficacy-16/NN||adcs-23/NNS	endo--1||antibodies-20||no_rel||this review discusses some recent studies that have explored how endo/lysosomal dynamics can affect the efficacy of engineered therapeutic antibodies, including adcs.
nsubjpass||targeted-4/VBN||it-1/PRP	aux||targeted-4/VBN||has-2/VBZ	auxpass||targeted-4/VBN||been-3/VBN	root||ROOT-0/null||targeted-4/VBN	amod||antibodies-7/NNS||monoclonal-6/JJ	agent||targeted-4/VBN||antibodies-7/NNS	amod||models-11/NNS||preclinical-9/JJ	nn||models-11/NNS||animal-10/NN	prep_in||antibodies-7/NNS||models-11/NNS	advmod||recently-14/RB||more-13/RBR	conj_and||targeted-4/VBN||recently-14/RB	det||trial-18/NN||a-16/DT	amod||trial-18/NN||clinical-17/JJ	prep_in||recently-14/RB||trial-18/NN	nn||patients-22/NNS||prostate-20/NN	nn||patients-22/NNS||cancer-21/NN	prep_in||trial-18/NN||patients-22/NNS	cancer-21||antibodies-7||no_rel||it has been targeted by monoclonal antibodies in preclinical animal models and more recently in a clinical trial in prostate cancer patients.
nsubj||causes-2/VBZ||salmonellatyphi-1/NNS	root||ROOT-0/null||causes-2/VBZ	det||cases-8/NNS||an-3/DT	amod||cases-8/NNS||estimated-4/JJ	num||cases-8/NNS||21-5/CD	num||cases-8/NNS||million-6/CD	amod||cases-8/NNS||new-7/JJ	dobj||causes-2/VBZ||cases-8/NNS	prep_of||cases-8/NNS||typhoidfever-10/NN	num||deaths-13/NNS||216,000-12/CD	dobj||causes-2/VBZ||deaths-13/NNS	conj_and||cases-8/NNS||deaths-13/NNS	det||year-15/NN||every-14/DT	dep||deaths-13/NNS||year-15/NN	typhoidfever-10||salmonellatyphi-1||no||salmonellatyphi causes an estimated 21 million new cases of typhoidfever and 216,000 deaths every year.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||indicates-4/VBZ||study-3/NN	root||ROOT-0/null||indicates-4/VBZ	mark||improves-9/VBZ||that-5/IN	amod||abstinence-8/NN||total-6/JJ	nn||abstinence-8/NN||alcohol-7/NN	nsubj||improves-9/VBZ||abstinence-8/NN	ccomp||indicates-4/VBZ||improves-9/VBZ	amod||features-11/NNS||psychometric-10/JJ	dobj||improves-9/VBZ||features-11/NNS	nn||severity-16/NN||alcoholaddiction-15/NN	prep_such_as||features-11/NNS||severity-16/NN	amod||rating-19/NN||psychiatric-18/JJ	prep_such_as||features-11/NNS||rating-19/NN	conj_and||severity-16/NN||rating-19/NN	amod||behavior-22/NN||social-21/JJ	prep_such_as||features-11/NNS||behavior-22/NN	conj_and||severity-16/NN||behavior-22/NN	prep_such_as||features-11/NNS||aggressiveness-24/NN	conj_and||severity-16/NN||aggressiveness-24/NN	prep_such_as||features-11/NNS||disability-27/NN	conj_and||severity-16/NN||disability-27/NN	alcoholaddiction-15||alcohol-7||no||the present study indicates that total alcohol abstinence improves psychometric features, such as alcoholaddiction severity, psychiatric rating, social behavior, aggressiveness, and disability.
amod||evidence-2/NN||further-1/JJ	nsubjpass||observed-8/VBN||evidence-2/NN	amod||influenzavirusinfections-6/NNS||occupational-4/JJ	nn||influenzavirusinfections-6/NNS||swine-5/NNS	prep_of||evidence-2/NN||influenzavirusinfections-6/NNS	auxpass||observed-8/VBN||was-7/VBD	root||ROOT-0/null||observed-8/VBN	amod||data-13/NNS||self-reported-10/JJ	amod||data-13/NNS||influenza-like-11/JJ	nn||data-13/NNS||illness-12/NN	prep_through||observed-8/VBN||data-13/NNS	prep_through||observed-8/VBN||comparisons-15/NNS	conj_and||data-13/NNS||comparisons-15/NNS	nn||samples-21/NNS||enrollment-17/NN	conj_and||enrollment-17/NN||follow-up-19/NN	nn||samples-21/NNS||follow-up-19/NN	nn||samples-21/NNS||serum-20/NN	prep_of||comparisons-15/NNS||samples-21/NNS	det||isolation-25/NN||the-24/DT	prep_through||observed-8/VBN||isolation-25/NN	conj_and||data-13/NNS||isolation-25/NN	det||virus-34/NN||a-27/DT	amod||virus-34/NN||reassortant-28/JJ	nn||virus-34/NN||swine-29/NNS	nn||virus-34/NN||influenza-30/NN	appos||virus-34/NN||h1n1-32/NNP	prep_of||isolation-25/NN||virus-34/NN	det||farmer-39/NN||an-36/DT	amod||farmer-39/NN||ill-37/JJ	nn||farmer-39/NN||swine-38/NNS	prep_from||observed-8/VBN||farmer-39/NN	influenza-30||influenzavirus--1||no||further evidence of occupational swine influenzavirusinfections was observed through self-reported influenza-like illness data, comparisons of enrollment and follow-up serum samples, and the isolation of a reassortant swine influenza (h1n1) virus from an ill swine farmer.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||level-4/NN||the-3/DT	dobj||evaluate-2/VB||level-4/NN	prep_of||level-4/NN||pain-6/NN	prep_during||evaluate-2/VB||phacoemulsification-8/NN	amod||implantation-13/NN||foldable-10/JJ	amod||implantation-13/NN||intraocular-11/JJ	nn||implantation-13/NN||lens-12/NN	prep_during||evaluate-2/VB||implantation-13/NN	conj_and||phacoemulsification-8/NN||implantation-13/NN	prep_under||evaluate-2/VB||instillation-15/NN	amod||eyedrops-20/NNS||tetracaine-17/JJ	number||%-19/NN||0.5-18/CD	amod||eyedrops-20/NNS||%-19/NN	prep_of||instillation-15/NN||eyedrops-20/NNS	det||combination-23/NN||a-22/DT	prep_versus||eyedrops-20/NNS||combination-23/NN	dep||%-27/NN||lidocaine-25/JJ	number||%-27/NN||2-26/CD	amod||gel-28/NN||%-27/NN	prep_of||combination-23/NN||gel-28/NN	prep_of||combination-23/NN||instillation-30/NN	conj_and||gel-28/NN||instillation-30/NN	amod||eyedrops-33/NNS||tetracaine-32/JJ	prep_of||eyedrops-20/NNS||eyedrops-33/NNS	pain-6||lidocaine-25||yes||to evaluate the level of pain during phacoemulsification and foldable intraocular lens implantation under instillation of tetracaine 0.5% eyedrops versus a combination of lidocaine 2% gel and instillation of tetracaine eyedrops.
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-37/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-37/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-37/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-37/NN||were-20/VBD	nn||congestion-37/NN||somnolence-21/NN	dep||congestion-37/NN||restlessness-23/NNS	dep||congestion-37/NN||nausea-25/NN	dep||congestion-37/NN||anxiety-27/NN	amod||congestion-37/NN||salivary-29/JJ	nn||congestion-37/NN||hypersecretion-30/NN	conj_and||hypersecretion-30/NN||akathisia-32/NN	nn||congestion-37/NN||akathisia-32/NN	conj_and||hypersecretion-30/NN||dizziness-34/NN	nn||congestion-37/NN||dizziness-34/NN	conj_and||hypersecretion-30/NN||nasal-36/NN	nn||congestion-37/NN||nasal-36/NN	root||ROOT-0/null||congestion-37/NN	risperidone-19||restlessness-23||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivary hypersecretion, akathisia, dizziness and nasal congestion.
nsubj||disorders-5/NNS||priondiseases-1/NNS	cop||disorders-5/NNS||are-2/VBP	amod||disorders-5/NNS||fatal-3/JJ	nn||disorders-5/NNS||neurodegenerative-4/NN	root||ROOT-0/null||disorders-5/NNS	nsubj||accompany-7/VB||disorders-5/NNS	rcmod||disorders-5/NNS||accompany-7/VB	det||accumulation-9/NN||an-8/DT	dobj||accompany-7/VB||accumulation-9/NN	det||form-13/NN||the-11/DT	amod||form-13/NN||disease-associated-12/JJ	prep_of||accumulation-9/NN||form-13/NN	dep||form-13/NN||s-15/PRP	prep_of||form-13/NN||prionprotein-18/NN	dep||prionprotein-18/NN||prpsc-20/JJ	det||system-26/NN||the-23/DT	amod||system-26/NN||central-24/JJ	amod||system-26/NN||nervous-25/JJ	prep_in||prionprotein-18/NN||system-26/NN	priondiseases-1||prionprotein-18||no||priondiseases are fatal neurodegenerative disorders that accompany an accumulation of the disease-associated form(s) of prionprotein (prpsc) in the central nervous system.
det||study-3/NN||this-1/DT	amod||study-3/NN||open-label-2/JJ	nsubj||compared-4/VBD||study-3/NN	ccomp||used-17/VBD||compared-4/VBD	det||efficacy-6/NN||the-5/DT	dobj||compared-4/VBD||efficacy-6/NN	dobj||compared-4/VBD||tolerability-8/NN	conj_and||efficacy-6/NN||tolerability-8/NN	prep_of||efficacy-6/NN||aripiprazole-10/NN	prep_with||compared-4/VBD||haloperidol-12/NN	det||typicalantipsychotic-15/NN||a-14/DT	nsubj||used-17/VBD||typicalantipsychotic-15/NN	nsubj||treat-19/VB||typicalantipsychotic-15/NN	advmod||used-17/VBD||widely-16/RB	root||ROOT-0/null||used-17/VBD	aux||treat-19/VB||to-18/TO	xcomp||used-17/VBD||treat-19/VB	dobj||treat-19/VB||patients-20/NNS	prep_with||treat-19/VB||ticdisorders-22/NNS	haloperidol-12||ticdisorders-22||no_rel||this open-label study compared the efficacy and tolerability of aripiprazole with haloperidol, a typicalantipsychotic widely used to treat patients with ticdisorders.
det||combination-2/NN||the-1/DT	nsubj||reduced-12/VBD||combination-2/NN	amod||propofol-5/NN||cold-4/JJ	prep_of||combination-2/NN||propofol-5/NN	prep_of||combination-2/NN||pretreatment-7/NN	conj_and||propofol-5/NN||pretreatment-7/NN	prep_with||propofol-5/NN||remifentanil-9/NN	advmod||effectively-11/RB||more-10/RBR	advmod||reduced-12/VBD||effectively-11/RB	root||ROOT-0/null||reduced-12/VBD	det||incidence-14/NN||the-13/DT	dobj||reduced-12/VBD||incidence-14/NN	prep_of||incidence-14/NN||pain-16/NN	det||injection-19/NN||the-18/DT	prep_upon||reduced-12/VBD||injection-19/NN	prep_of||injection-19/NN||propofol-21/NN	det||treatment-24/NN||either-23/DT	prep_than||reduced-12/VBD||treatment-24/NN	advmod||reduced-12/VBD||alone-25/RB	pain-16||propofol-21||yes||the combination of cold propofol and pretreatment with remifentanil more effectively reduced the incidence of pain upon the injection of propofol than either treatment alone.
aux||evaluate-2/VB||to-1/TO	advcl||conducted-18/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	prep_of||effects-4/NNS||hivinfection-6/NN	amod||precursors-9/NNS||intra-thymic-8/JJ	prep_on||evaluate-2/VB||precursors-9/NNS	nn||cells-12/NNS||t-11/NN	prep_of||precursors-9/NNS||cells-12/NNS	amod||adults-15/NNS||hiv-infected-14/JJ	prep_in||evaluate-2/VB||adults-15/NNS	nsubj||conducted-18/VBD||we-17/PRP	root||ROOT-0/null||conducted-18/VBD	det||study-22/NN||a-19/DT	amod||study-22/NN||detailed-20/JJ	amod||study-22/NN||immunophenotypic-21/JJ	dobj||conducted-18/VBD||study-22/NN	amod||tissue-25/NN||thymic-24/JJ	prep_of||study-22/NN||tissue-25/NN	vmod||tissue-25/NN||isolated-26/VBN	num||hiv-infected-29/NN||7-28/CD	prep_from||isolated-26/VBN||hiv-infected-29/NN	num||adults-33/NNS||10-31/CD	amod||adults-33/NNS||hiv-negative-32/JJ	prep_from||isolated-26/VBN||adults-33/NNS	conj_and||hiv-infected-29/NN||adults-33/NNS	nsubj||were-35/VBD||adults-33/NNS	nsubj||undergo-37/VB||adults-33/NNS	rcmod||adults-33/NNS||were-35/VBD	aux||undergo-37/VB||to-36/TO	xcomp||were-35/VBD||undergo-37/VB	nn||surgery-39/NN||heart-38/NN	dobj||undergo-37/VB||surgery-39/NN	hivinfection-6||hiv--1||no||to evaluate the effects of hivinfection on intra-thymic precursors of t cells in hiv-infected adults, we conducted a detailed immunophenotypic study of thymic tissue isolated from 7 hiv-infected and 10 hiv-negative adults who were to undergo heart surgery.
det||seconds-4/NNS||the-2/DT	num||seconds-4/NNS||10-3/CD	prep_during||measured-12/VBN||seconds-4/NNS	amod||injection-7/NN||propofol-6/JJ	prep_after||seconds-4/NNS||injection-7/NN	nn||intensity-10/NN||pain-9/NN	nsubjpass||measured-12/VBN||intensity-10/NN	auxpass||measured-12/VBN||was-11/VBD	root||ROOT-0/null||measured-12/VBN	det||scale-18/NN||an-14/DT	amod||scale-18/NN||11-point-15/JJ	amod||scale-18/NN||numerical-16/JJ	nn||scale-18/NN||rating-17/NN	prep_on||measured-12/VBN||scale-18/NN	dep||scale-18/NN||0-20/CD	dep||pain-23/NN||=-21/SYM	neg||pain-23/NN||no-22/DT	rcmod||0-20/CD||pain-23/NN	num||=-26/NNS||10-25/CD	dep||scale-18/NN||=-26/NNS	conj_and||0-20/CD||=-26/NNS	dep||possible-28/JJ||worst-27/JJS	amod||pain-29/NN||possible-28/JJ	dep||=-26/NNS||pain-29/NN	pain-29||propofol-6||yes||during the 10 seconds after propofol injection, pain intensity was measured on an 11-point numerical rating scale (0 = no pain and 10 = worst possible pain).
nn||cisplatin-3/NN||background-1/NN	nn||cisplatin-3/NN||liposomal-2/NN	nsubj||formulation-7/NN||cisplatin-3/NN	cop||formulation-7/NN||is-4/VBZ	det||formulation-7/NN||a-5/DT	amod||formulation-7/NN||new-6/JJ	root||ROOT-0/null||formulation-7/NN	vmod||formulation-7/NN||developed-8/VBN	aux||reduce-10/VB||to-9/TO	xcomp||developed-8/VBN||reduce-10/VB	det||toxicity-13/NN||the-11/DT	amod||toxicity-13/NN||systemic-12/JJ	dobj||reduce-10/VB||toxicity-13/NN	prep_of||toxicity-13/NN||cisplatin-15/NN	mark||improving-18/VBG||while-16/IN	advmod||improving-18/VBG||simultaneously-17/RB	advcl||reduce-10/VB||improving-18/VBG	det||targeting-20/NN||the-19/DT	dobj||improving-18/VBG||targeting-20/NN	det||drug-23/NN||the-22/DT	prep_of||targeting-20/NN||drug-23/NN	det||tumor-27/NN||the-25/DT	amod||tumor-27/NN||primary-26/JJ	prep_to||improving-18/VBG||tumor-27/NN	prep_to||improving-18/VBG||metastases-30/NNS	conj_and||tumor-27/NN||metastases-30/NNS	amod||time-34/NN||increasing-32/VBG	nn||time-34/NN||circulation-33/NN	prep_by||improving-18/VBG||time-34/NN	det||fluids-38/NNS||the-36/DT	nn||fluids-38/NNS||body-37/NN	prep_in||time-34/NN||fluids-38/NNS	prep_in||time-34/NN||tissues-40/NNS	conj_and||fluids-38/NNS||tissues-40/NNS	tumor-27||cisplatin-15||no_rel||background liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while simultaneously improving the targeting of the drug to the primary tumor and to metastases by increasing circulation time in the body fluids and tissues.
nsubjpass||found-3/VBN||albendazole-1/NN	nsubj||effective-8/JJ||albendazole-1/NN	auxpass||found-3/VBN||was-2/VBD	root||ROOT-0/null||found-3/VBN	aux||effective-8/JJ||to-4/TO	cop||effective-8/JJ||be-5/VB	advmod||effective-8/JJ||equally-6/RB	advmod||effective-8/JJ||as-7/RB	xcomp||found-3/VBN||effective-8/JJ	prep_as||effective-8/JJ||metronidazole-10/NN	det||treatment-13/NN||the-12/DT	prep_in||metronidazole-10/NN||treatment-13/NN	prep_of||treatment-13/NN||giardiasis-15/NNS	prep_in||giardiasis-15/NNS||humans-17/NNS	dep||effective-8/JJ||rr-19/NN	num||rr-19/NN||0.97-20/CD	number||%-23/NN||95-22/CD	amod||ci-24/NN||%-23/NN	dep||rr-19/NN||ci-24/NN	amod||rr-19/NN||0.93-26/CD	dep||rr-19/NN||1.01-28/FW	giardiasis-15||metronidazole-10||yes||albendazole was found to be equally as effective as metronidazole in the treatment of giardiasis in humans (rr 0.97; 95% ci, 0.93, 1.01).
amod||women-2/NNS||pregnant-1/JJ	nsubjpass||assigned-7/VBN||women-2/NNS	vmod||women-2/NNS||attending-3/VBG	amod||clinics-5/NNS||antenatal-4/JJ	dobj||attending-3/VBG||clinics-5/NNS	auxpass||assigned-7/VBN||were-6/VBD	root||ROOT-0/null||assigned-7/VBN	prep_to||assigned-7/VBN||groups-9/NNS	vmod||groups-9/NNS||based-10/VBN	det||drug-13/NN||the-12/DT	prep_on||based-10/VBN||drug-13/NN	vmod||drug-13/NN||used-14/VBN	aux||treat-16/VB||to-15/TO	xcomp||used-14/VBN||treat-16/VB	poss||malaria-20/NN||their-17/PRP$	advmod||recent-19/JJ||most-18/RBS	amod||malaria-20/NN||recent-19/JJ	nn||al-23/NNP||malaria-20/NN	nn||al-23/NNP||episode-21/NN	nn||al-23/NNP||-lrb--22/NNP	dobj||treat-16/VB||al-23/NNP	amod||-rrb--28/NNS||sulphadoxine-pyrimethamine-25/JJ	amod||-rrb--28/NNS||sp-27/JJ	prep_vs.||al-23/NNP||-rrb--28/NNS	malaria-20||pyrimethamine--1||no||pregnant women attending antenatal clinics were assigned to groups based on the drug used to treat their most recent malaria episode -lrb- al vs. sulphadoxine-pyrimethamine , sp -rrb- .
det||reliance-3/NN||the-2/DT	prep_despite||studies-18/NNS||reliance-3/NN	prep_on||reliance-3/NN||plants-5/NNS	aux||manage-7/VB||to-6/TO	vmod||plants-5/NNS||manage-7/VB	dobj||manage-7/VB||hiv/aids-8/NNS	nn||mulilo-11/NN||katima-10/NN	prep_in||manage-7/VB||mulilo-11/NN	expl||studies-18/NNS||there-13/EX	aux||studies-18/NNS||have-14/VBP	cop||studies-18/NNS||been-15/VBN	neg||studies-18/NNS||no-16/DT	amod||studies-18/NNS||empirical-17/JJ	root||ROOT-0/null||studies-18/NNS	aux||document-20/VB||to-19/TO	vmod||studies-18/NNS||document-20/VB	det||species-24/NN||the-21/DT	amod||species-24/NN||specific-22/JJ	nn||species-24/NN||plant-23/NN	dobj||document-20/VB||species-24/NN	vmod||species-24/NN||used-25/VBN	amod||healers-28/NNS||traditional-27/JJ	agent||used-25/VBN||healers-28/NNS	aux||treat-30/VB||to-29/TO	xcomp||used-25/VBN||treat-30/VB	amod||infections-33/NNS||aids-related-31/JJ	amod||infections-33/NNS||opportunistic-32/JJ	dobj||treat-30/VB||infections-33/NNS	aids--1||hiv--1||no||despite the reliance on plants to manage hiv/aids in katima mulilo, there have been no empirical studies to document the specific plant species used by traditional healers to treat aids-related opportunistic infections.
amod||size-3/NN||fat-1/JJ	nn||size-3/NN||cell-2/NN	nsubjpass||determined-10/VBN||size-3/NN	conj_and||size-3/NN||expression-5/NN	nsubjpass||determined-10/VBN||expression-5/NN	amod||genes-8/NNS||hypoxia-dependent-7/JJ	prep_of||size-3/NN||genes-8/NNS	auxpass||determined-10/VBN||were-9/VBD	root||ROOT-0/null||determined-10/VBN	prep_in||determined-10/VBN||adipocytes-12/NNS	det||depots-16/NNS||both-14/DT	amod||depots-16/NNS||fat-15/JJ	prep_from||adipocytes-12/NNS||depots-16/NNS	fat-15||hypoxia--1||no_rel||fat cell size and expression of hypoxia-dependent genes were determined in adipocytes from both fat depots.
nsubj||disease-8/NN||lupuserythematosus-1/NNS	appos||lupuserythematosus-1/NNS||le-3/NNP	cop||disease-8/NN||is-5/VBZ	det||disease-8/NN||a-6/DT	amod||disease-8/NN||heterogeneous-7/JJ	root||ROOT-0/null||disease-8/NN	vmod||disease-8/NN||ranging-9/VBG	advmod||skin-restricted-12/JJ||mainly-11/RB	amod||manifestations-13/NNS||skin-restricted-12/JJ	prep_from||ranging-9/VBG||manifestations-13/NNS	nn||-RSB--19/NNPS||discoid-15/NNP	nn||-RSB--19/NNPS||le-16/FW	nn||-RSB--19/NNPS||-LSB--17/NNP	nn||-RSB--19/NNPS||dle-18/NNP	dep||manifestations-13/NNS||-RSB--19/NNPS	amod||le-23/NNS||subacute-21/JJ	nn||le-23/NNS||cutaneous-22/NNS	dep||manifestations-13/NNS||le-23/NNS	conj_and||-RSB--19/NNPS||le-23/NNS	det||disease-29/NN||a-26/DT	amod||disease-29/NN||progressive-27/JJ	nn||disease-29/NN||multisystem-28/NN	prep_to||ranging-9/VBG||disease-29/NN	amod||-RSB--35/NNP||systemic-31/JJ	nn||-RSB--35/NNP||le-32/NNP	nn||-RSB--35/NNP||-LSB--33/NNP	nn||-RSB--35/NNP||sle-34/NN	appos||disease-29/NN||-RSB--35/NNP	dle-18||lupuserythematosus-1||no||lupuserythematosus (le) is a heterogeneous disease ranging from mainly skin-restricted manifestations (discoid le [dle] and subacute cutaneous le) to a progressive multisystem disease (systemic le [sle]).
amod||studies-2/NNS||recent-1/JJ	nsubj||indicate-3/VBP||studies-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||reduced-13/VBN||that-4/IN	prep_during||reduced-13/VBN||hantavirusinfection-6/NN	amod||responses-11/NNS||proinflammatory-8/JJ	conj_and||proinflammatory-8/JJ||antiviral-10/JJ	amod||responses-11/NNS||antiviral-10/JJ	nsubjpass||reduced-13/VBN||responses-11/NNS	auxpass||reduced-13/VBN||are-12/VBP	ccomp||indicate-3/VBP||reduced-13/VBN	amod||responses-16/NNS||regulatory-15/JJ	nsubj||elevated-18/JJ||responses-16/NNS	cop||elevated-18/JJ||are-17/VBP	ccomp||indicate-3/VBP||elevated-18/JJ	conj_and||reduced-13/VBN||elevated-18/JJ	prep_at||elevated-18/JJ||sites-20/NNS	amod||replication-24/NN||increased-22/VBN	nn||replication-24/NN||virus-23/NN	prep_of||sites-20/NNS||replication-24/NN	prep_in||replication-24/NN||rodents-26/NNS	antiviral-10||virus-23||no_rel||recent studies indicate that during hantavirusinfection, proinflammatory and antiviral responses are reduced and regulatory responses are elevated at sites of increased virus replication in rodents.
nsubj||agent-8/NN||5-fluorouracil-1/NN	dep||5-fluorouracil-1/NN||5-fu-3/JJ	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||chemotherapeutic-7/JJ	root||ROOT-0/null||agent-8/NN	amod||choice-11/NN||first-10/JJ	prep_of||agent-8/NN||choice-11/NN	amod||cancer-14/NN||colorectal-13/JJ	prep_in||choice-11/NN||cancer-14/NN	amod||cases-19/NNS||most-18/JJS	prep_in||develops-24/VBZ||cases-19/NNS	nsubj||develops-24/VBZ||resistance-21/NN	prep_to||resistance-21/NN||5-fu-23/CD	conj_but||agent-8/NN||develops-24/VBZ	amod||mechanisms-27/NNS||various-26/JJ	prep_through||develops-24/VBZ||mechanisms-27/NNS	cancer-14||5-fu-23||no_rel||5-fluorouracil (5-fu) is the chemotherapeutic agent of first choice in colorectal cancer, but in most cases, resistance to 5-fu develops through various mechanisms.
advmod||highlighting-3/VBG||briefly-2/RB	prepc_after||discusses-27/VBZ||highlighting-3/VBG	det||risk-5/NN||the-4/DT	dobj||highlighting-3/VBG||risk-5/NN	prep_of||risk-5/NN||stroke-7/NN	prep_with||stroke-7/NN||af-9/NN	dobj||highlighting-3/VBG||problems-11/NNS	conj_and||risk-5/NN||problems-11/NNS	prep_with||problems-11/NNS||warfarin-13/NN	det||role-17/NN||the-16/DT	dobj||highlighting-3/VBG||role-17/NN	conj_and||risk-5/NN||role-17/NN	det||laa-20/NN||the-19/DT	prep_of||role-17/NN||laa-20/NN	amod||formation-23/NN||clot-22/JJ	prep_in||laa-20/NN||formation-23/NN	det||article-26/NN||this-25/DT	nsubj||discusses-27/VBZ||article-26/NN	root||ROOT-0/null||discusses-27/VBZ	det||feasibility-29/NN||the-28/DT	dobj||discusses-27/VBZ||feasibility-29/NN	nsubjpass||developed-38/VBN||feasibility-29/NN	dobj||discusses-27/VBZ||efficacy-31/NN	conj_and||feasibility-29/NN||efficacy-31/NN	nsubjpass||developed-38/VBN||efficacy-31/NN	amod||devices-34/NNS||various-33/JJ	prep_of||feasibility-29/NN||devices-34/NNS	aux||developed-38/VBN||have-36/VBP	auxpass||developed-38/VBN||been-37/VBN	rcmod||feasibility-29/NN||developed-38/VBN	amod||occlusion-42/NN||percutaneous-40/JJ	nn||occlusion-42/NN||laa-41/NN	prep_for||developed-38/VBN||occlusion-42/NN	stroke-7||warfarin-13||yes||after briefly highlighting the risk of stroke with af, problems with warfarin, and the role of the laa in clot formation, this article discusses the feasibility and efficacy of various devices which have been developed for percutaneous laa occlusion.
nsubjpass||used-4/VBN||modelling-1/NN	nsubj||inform-6/VB||modelling-1/NN	auxpass||used-4/VBN||is-2/VBZ	advmod||used-4/VBN||widely-3/RB	root||ROOT-0/null||used-4/VBN	aux||inform-6/VB||to-5/TO	xcomp||used-4/VBN||inform-6/VB	dobj||inform-6/VB||decisions-7/NNS	prep_about||inform-6/VB||management-9/NN	nn||illnesses-15/NNS||malaria-11/NN	conj_and||malaria-11/NN||acute-13/JJ	nn||illnesses-15/NNS||acute-13/JJ	nn||illnesses-15/NNS||febrile-14/NN	prep_of||management-9/NN||illnesses-15/NNS	inform-6||malaria-11||no_rel||modelling is widely used to inform decisions about management of malaria and acute febrile illnesses.
det||changes-3/NNS||the-1/DT	amod||changes-3/NNS||dynamic-2/JJ	nsubj||suggest-13/VBP||changes-3/NNS	nsubj||offers-24/VBZ||changes-3/NNS	amod||currents-6/NNS||electric-5/JJ	prep_of||changes-3/NNS||currents-6/NNS	amod||fluxes-10/NNS||specific-8/JJ	nn||fluxes-10/NNS||ion-9/NN	conj_and||changes-3/NNS||fluxes-10/NNS	nsubj||suggest-13/VBP||fluxes-10/NNS	prep_after||fluxes-10/NNS||wounding-12/NN	root||ROOT-0/null||suggest-13/VBP	mark||response-20/NN||that-14/IN	amod||signaling-16/NNS||electrical-15/JJ	nsubj||response-20/NN||signaling-16/NNS	cop||response-20/NN||is-17/VBZ	det||response-20/NN||an-18/DT	amod||response-20/NN||active-19/JJ	ccomp||suggest-13/VBP||response-20/NN	prep_to||response-20/NN||injury-22/NN	conj_and||suggest-13/VBP||offers-24/VBZ	amod||approaches-27/NNS||potential-25/JJ	nn||approaches-27/NNS||novel-26/NN	dobj||offers-24/VBZ||approaches-27/NNS	amod||healing-31/NN||modulate-29/JJ	nn||healing-31/NN||wound-30/NN	prep_to||offers-24/VBZ||healing-31/NN	nn||eye-drops-35/NNS||example-34/NN	prep_for||suggest-13/VBP||eye-drops-35/NNS	vmod||eye-drops-35/NNS||targeting-36/VBG	nn||transport-38/NN||ion-37/NN	dobj||targeting-36/VBG||transport-38/NN	aux||aid-40/VB||to-39/TO	vmod||targeting-36/VBG||aid-40/VB	det||management-44/NN||the-42/DT	amod||management-44/NN||challenging-43/JJ	prep_in||aid-40/VB||management-44/NN	amod||cornealulcers-47/NNS||non-healing-46/JJ	prep_of||management-44/NN||cornealulcers-47/NNS	ion-37||cornealulcers-47||no_rel||the dynamic changes of electric currents and specific ion fluxes after wounding suggest that electrical signaling is an active response to injury and offers potential novel approaches to modulate wound healing, for example eye-drops targeting ion transport to aid in the challenging management of non-healing cornealulcers.
amod||tomography-4/NN||near-infrared-1/JJ	amod||tomography-4/NN||three-dimensional-2/JJ	amod||tomography-4/NN||fluorescent-mediated-3/JJ	nsubjpass||used-6/VBN||tomography-4/NN	nsubj||image-8/VB||tomography-4/NN	nsubj||collect-14/VB||tomography-4/NN	nsubj||calculate-20/VB||tomography-4/NN	auxpass||used-6/VBN||was-5/VBD	root||ROOT-0/null||used-6/VBN	aux||image-8/VB||to-7/TO	xcomp||used-6/VBN||image-8/VB	det||model-12/NN||the-9/DT	amod||model-12/NN||ls174t-10/JJ	nn||model-12/NN||tumor-11/NN	dobj||image-8/VB||model-12/NN	xcomp||used-6/VBN||collect-14/VB	conj_and||image-8/VB||collect-14/VB	amod||data-17/NNS||antibody-alone-15/JJ	nn||data-17/NNS||pk-16/NN	dobj||collect-14/VB||data-17/NNS	xcomp||used-6/VBN||calculate-20/VB	conj_and||image-8/VB||calculate-20/VB	det||number-22/NN||the-21/DT	dobj||calculate-20/VB||number-22/NN	prep_of||number-22/NN||copies-24/NNS	amod||epitope-27/NN||ve-cad-26/JJ	prep_of||copies-24/NNS||epitope-27/NN	prep_per||epitope-27/NN||cell-29/NN	antibody--1||cad--1||no_rel||near-infrared three-dimensional fluorescent-mediated tomography was used to image the ls174t tumor model, collect antibody-alone pk data, and calculate the number of copies of ve-cad epitope per cell.
nn||identification-2/NN||species-1/NN	nsubj||seems-12/VBZ||identification-2/NN	nsubj||important-15/JJ||identification-2/NN	prep_of||identification-2/NN||isolates-4/NNP	vmod||isolates-4/NNP||belonging-5/VBG	det||-rrb--11/NN||the-7/DT	amod||-rrb--11/NN||mycobacteriumtuberculosiscomplex-8/JJ	amod||-rrb--11/NN||-lrb--9/JJ	nn||-rrb--11/NN||mtc-10/NN	prep_to||belonging-5/VBG||-rrb--11/NN	root||ROOT-0/null||seems-12/VBZ	aux||important-15/JJ||to-13/TO	cop||important-15/JJ||be-14/VB	xcomp||seems-12/VBZ||important-15/JJ	det||treatment-19/NN||the-17/DT	amod||treatment-19/NN||appropriate-18/JJ	prep_for||important-15/JJ||treatment-19/NN	prep_of||treatment-19/NN||patients-21/NNS	mark||resistant-28/JJ||since-23/IN	nn||bovis-25/NNS||m.-24/NN	nsubj||resistant-28/JJ||bovis-25/NNS	cop||resistant-28/JJ||is-26/VBZ	advmod||resistant-28/JJ||naturally-27/RB	advcl||important-15/JJ||resistant-28/JJ	det||drug-37/NN||a-30/DT	amod||drug-37/NN||first-31/JJ	nn||drug-37/NN||line-32/NN	amod||drug-37/NN||anti-tuberculosis-33/JJ	nn||drug-37/NN||-lrb--34/NNP	nn||drug-37/NN||tb-35/NN	nn||drug-37/NN||-rrb--36/NN	prep_to||resistant-28/JJ||drug-37/NN	appos||drug-37/NN||pyrazinamide-39/NN	mark||susceptible-49/JJ||while-41/IN	nsubj||susceptible-49/JJ||most-42/JJS	det||members-47/NNS||the-44/DT	amod||members-47/NNS||other-45/JJ	nn||members-47/NNS||mtc-46/NN	prep_of||most-42/JJS||members-47/NNS	cop||susceptible-49/JJ||are-48/VBP	advcl||resistant-28/JJ||susceptible-49/JJ	det||agent-53/NN||this-51/DT	amod||agent-53/NN||antimicrobial-52/JJ	prep_to||susceptible-49/JJ||agent-53/NN	tuberculosis--1||mycobacteriumtuberculosiscomplex-8||no||species identification of isolates belonging to the mycobacteriumtuberculosiscomplex -lrb- mtc -rrb- seems to be important for the appropriate treatment of patients , since m. bovis is naturally resistant to a first line anti-tuberculosis -lrb- tb -rrb- drug , pyrazinamide , while most of the other mtc members are susceptible to this antimicrobial agent .
nsubj||exerts-2/VBZ||melatonin-1/NN	root||ROOT-0/null||exerts-2/VBZ	det||effect-5/NN||an-3/DT	amod||effect-5/NN||inhibitory-4/JJ	dobj||exerts-2/VBZ||effect-5/NN	nn||invasion-10/NN||breast-7/NN	nn||invasion-10/NN||cancer-8/NN	nn||invasion-10/NN||cell-9/NN	prep_on||effect-5/NN||invasion-10/NN	prep_through||exerts-2/VBZ||down-regulation-12/NN	det||pathway-16/NN||the-14/DT	amod||pathway-16/NN||p38-15/JJ	prep_of||down-regulation-12/NN||pathway-16/NN	prep_through||exerts-2/VBZ||inhibition-19/NN	conj_and||down-regulation-12/NN||inhibition-19/NN	amod||expression-24/NN||mmp-2-21/JJ	conj_and||mmp-2-21/JJ||mmp-9-23/JJ	amod||expression-24/NN||mmp-9-23/JJ	prep_of||inhibition-19/NN||expression-24/NN	prep_of||inhibition-19/NN||activity-26/NN	conj_and||expression-24/NN||activity-26/NN	cancer-8||melatonin-1||no_rel||melatonin exerts an inhibitory effect on breast cancer cell invasion through down-regulation of the p38 pathway, and inhibition of mmp-2 and mmp-9 expression and activity.
amod||coronaviruses-2/NNS||feline-1/JJ	nsubj||comprise-6/VBP||coronaviruses-2/NNS	appos||coronaviruses-2/NNS||fcov-4/NNP	root||ROOT-0/null||comprise-6/VBP	num||biotypes-8/NNS||two-7/CD	dobj||comprise-6/VBP||biotypes-8/NNS	amod||coronaviruses-11/NNS||feline-9/JJ	amod||coronaviruses-11/NNS||enteric-10/JJ	dep||biotypes-8/NNS||coronaviruses-11/NNS	appos||coronaviruses-11/NNS||fecv-13/NNP	amod||viruses-17/NNS||felineinfectiousperitonitis-16/JJ	dobj||comprise-6/VBP||viruses-17/NNS	conj_and||biotypes-8/NNS||viruses-17/NNS	appos||viruses-17/NNS||fipv-19/NNP	felineinfectiousperitonitis-16||fipv-19||no||feline coronaviruses (fcov) comprise two biotypes feline enteric coronaviruses (fecv) and felineinfectiousperitonitis viruses (fipv).
nsubjpass||injected-3/VBN||rats-1/NNS	nsubjpass||killed-25/VBN||rats-1/NNS	auxpass||injected-3/VBN||were-2/VBD	root||ROOT-0/null||injected-3/VBN	num||injections-7/NNS||two-5/CD	nn||injections-7/NNS||s/c-6/NN	prep_with||injected-3/VBN||injections-7/NNS	prep_of||injections-7/NNS||aom-9/NN	nn||weeks-14/NNS||7-11/CD	conj_and||7-11/CD||8-13/CD	nn||weeks-14/NNS||8-13/CD	prep_at||injected-3/VBN||weeks-14/NNS	prep_of||weeks-14/NNS||age-16/NN	nn||weight-23/NN||16â-18/NNP	amod||weight-23/NN||$-19/$	dep||$-19/$||‰-20/JJ	amod||weight-23/NN||mg/kg-21/JJ	nn||weight-23/NN||body-22/NN	prep_at||injected-3/VBN||weight-23/NN	conj_and||injected-3/VBN||killed-25/VBN	num||weeks-28/NNS||17-27/CD	prep_at||killed-25/VBN||weeks-28/NNS	amod||asphyxiation-31/NN||co2-30/JJ	prep_by||killed-25/VBN||asphyxiation-31/NN	asphyxiation-31||co2-30||no||rats were injected with two s/c injections of aom at 7 and 8 weeks of age at 16â€‰mg/kg body weight and killed at 17 weeks by co2 asphyxiation.
amod||injection-3/NN||propofol-2/JJ	prep_before||injected-10/VBD||injection-3/NN	prep_for||injection-3/NN||induction-5/NN	prep_of||induction-5/NN||anesthesia-7/NN	nsubj||injected-10/VBD||we-9/PRP	root||ROOT-0/null||injected-10/VBD	number||%-12/NN||1-11/CD	amod||iv-16/NN||%-12/NN	amod||iv-16/NN||lidocaine-13/JJ	num||iv-16/NN||50-14/CD	nn||iv-16/NN||mg-15/NN	dobj||injected-10/VBD||iv-16/NN	nn||relief-19/NN||pain-18/NN	prep_for||iv-16/NN||relief-19/NN	pain-18||lidocaine-13||yes||before propofol injection for induction of anesthesia, we injected 1% lidocaine 50 mg iv for pain relief.
amod||inhibitor-3/NN||urinary-1/JJ	nn||inhibitor-3/NN||trypsin-2/NN	nsubjpass||used-16/VBN||inhibitor-3/NN	appos||inhibitor-3/NN||uti-5/NN	det||inhibitor-11/NN||a-8/DT	amod||inhibitor-11/NN||serine-9/JJ	nn||inhibitor-11/NN||protease-10/NN	appos||inhibitor-3/NN||inhibitor-11/NN	aux||used-16/VBN||has-13/VBZ	auxpass||used-16/VBN||been-14/VBN	advmod||used-16/VBN||widely-15/RB	root||ROOT-0/null||used-16/VBN	prep_in||used-16/VBN||japan-18/NN	det||drug-21/NN||a-20/DT	prep_as||used-16/VBN||drug-21/NN	prep_for||drug-21/NN||patients-23/NNS	amod||inflammatory-26/JJ||acute-25/JJ	amod||disorders-27/NNS||inflammatory-26/JJ	prep_with||patients-23/NNS||disorders-27/NNS	amod||coagulation-32/NN||disseminated-30/JJ	nn||coagulation-32/NN||intravascular-31/NN	prep_such_as||disorders-27/NNS||coagulation-32/NN	appos||coagulation-32/NN||dic-34/NN	prep_such_as||disorders-27/NNS||shock-37/NN	conj_and||coagulation-32/NN||shock-37/NN	prep_such_as||disorders-27/NNS||pancreatitis-40/NNS	conj_and||coagulation-32/NN||pancreatitis-40/NNS	dic-34||uti-5||no_rel||urinary trypsin inhibitor (uti), a serine protease inhibitor, has been widely used in japan as a drug for patients with acute inflammatory disorders such as disseminated intravascular coagulation (dic), shock, and pancreatitis.
nsubjpass||treated-7/VBN||pmvec-1/NN	vmod||pmvec-1/NN||isolated-2/VBN	amod||lung-5/NN||human-4/JJ	prep_from||isolated-2/VBN||lung-5/NN	auxpass||treated-7/VBN||were-6/VBD	root||ROOT-0/null||treated-7/VBN	amod||albumin-45/NN||vitro-9/NN	amod||stimulation-12/NN||septic-11/JJ	prep_with||vitro-9/NN||stimulation-12/NN	amod||-RSB--17/NNS||lipopolysaccharide-14/JJ	amod||-RSB--17/NNS||-LSB--15/JJ	nn||-RSB--17/NNS||lps-16/NN	dep||stimulation-12/NN||-RSB--17/NNS	det||mixture-20/NN||a-19/DT	dep||stimulation-12/NN||mixture-20/NN	conj_or||-RSB--17/NNS||mixture-20/NN	amod||-RSB--26/NNS||clinically-relevant-22/JJ	nn||-RSB--26/NNS||cytokines-23/NNS	nn||-RSB--26/NNS||-LSB--24/NN	nn||-RSB--26/NNS||cytomix-25/NN	prep_of||mixture-20/NN||-RSB--26/NNS	dep||stimulation-12/NN||plasma-29/NN	conj_or||-RSB--17/NNS||plasma-29/NN	prep_from||plasma-29/NN||patients-31/NNS	amod||sepsis-34/NN||severe-33/JJ	prep_with||patients-31/NNS||sepsis-34/NN	det||leak-40/NN||the-38/DT	amod||leak-40/NN||trans-pmvec-39/JJ	prep_with||vitro-9/NN||leak-40/NN	conj_and||stimulation-12/NN||leak-40/NN	prep_of||leak-40/NN||evans-42/NNS	amod||albumin-45/NN||blue-43/JJ	amod||albumin-45/NN||dye-labeled-44/JJ	prep_in||treated-7/VBN||albumin-45/NN	vmod||albumin-45/NN||assessed-46/VBN	evans-42||albumin-45||no_rel||pmvec isolated from human lung were treated in vitro with septic stimulation (lipopolysaccharide [lps], a mixture of clinically-relevant cytokines [cytomix], or plasma from patients with severe sepsis), and the trans-pmvec leak of evans blue dye-labeled albumin assessed.
nsubj||reported-6/VBD||none-1/NN	det||other-4/JJ||the-3/DT	prep_of||none-1/NN||other-4/JJ	advmod||reported-6/VBD||previously-5/RB	root||ROOT-0/null||reported-6/VBD	nsubjpass||associated-9/VBN||snps-7/NNS	auxpass||associated-9/VBN||were-8/VBD	ccomp||reported-6/VBD||associated-9/VBN	prep_with||associated-9/VBN||type2diabetes-11/CD	advmod||found-17/VBN||however-13/RB	nsubjpass||found-17/VBN||associations-15/NNS	auxpass||found-17/VBN||were-16/VBD	parataxis||reported-6/VBD||found-17/VBN	amod||variants-22/NNS||cdkal1-19/JJ	conj_and||cdkal1-19/JJ||hhex-21/JJ	amod||variants-22/NNS||hhex-21/JJ	prep_between||found-17/VBN||variants-22/NNS	amod||response-26/NN||acute-24/JJ	nn||response-26/NN||insulin-25/NN	prep_between||found-17/VBN||response-26/NN	conj_and||variants-22/NNS||response-26/NN	appos||response-26/NN||air-28/NN	advmod||associated-39/VBN||where-31/WRB	det||alleles-35/NNS||the-32/DT	amod||alleles-35/NNS||caucasian-33/JJ	nn||alleles-35/NNS||risk-34/NN	nsubjpass||associated-39/VBN||alleles-35/NNS	prep_for||alleles-35/NNS||type2diabetes-37/CD	auxpass||associated-39/VBN||were-38/VBD	rcmod||response-26/NN||associated-39/VBN	amod||secretion-43/NN||reduced-41/VBN	nn||secretion-43/NN||insulin-42/NN	prep_with||associated-39/VBN||secretion-43/NN	amod||indians-47/NNS||normoglycemic-45/JJ	nn||indians-47/NNS||pima-46/NN	prep_in||secretion-43/NN||indians-47/NNS	type2diabetes-37||insulin-42||yes||none of the other previously reported snps were associated with type2diabetes; however, associations were found between cdkal1 and hhex variants and acute insulin response (air), where the caucasian risk alleles for type2diabetes were associated with reduced insulin secretion in normoglycemic pima indians.
amod||injection-3/NN||conclusions-1/JJ	amod||injection-3/NN||intra-articular-2/JJ	nsubj||beneficial-7/JJ||injection-3/NN	prep_of||injection-3/NN||celecoxib-5/NN	cop||beneficial-7/JJ||is-6/VBZ	root||ROOT-0/null||beneficial-7/JJ	nn||osteoarthritis-10/NNS||knee-9/NN	prep_for||beneficial-7/JJ||osteoarthritis-10/NNS	osteoarthritis-10||celecoxib-5||yes||conclusions intra-articular injection of celecoxib is beneficial for knee osteoarthritis.
nsubj||lower-15/JJR||results-1/NNS	det||intention-4/NN||an-3/DT	prep_in||results-1/NNS||intention-4/NN	aux||treat-6/VB||to-5/TO	vmod||intention-4/NN||treat-6/VB	dobj||treat-6/VB||analysis-7/NN	det||risk-10/NN||the-9/DT	appos||analysis-7/NN||risk-10/NN	prep_of||risk-10/NN||death-12/NN	cop||lower-15/JJR||was-13/VBD	advmod||lower-15/JJR||significantly-14/RB	root||ROOT-0/null||lower-15/JJR	det||arm-20/NN||the-17/DT	amod||arm-20/NN||titrated-18/JJ	nn||arm-20/NN||oxygen-19/NN	prep_in||lower-15/JJR||arm-20/NN	prepc_compared_with||lower-15/JJR||with-22/IN	det||arm-27/NN||the-23/DT	amod||arm-27/NN||high-24/JJ	nn||arm-27/NN||flow-25/NN	nn||arm-27/NN||oxygen-26/NN	pobj||lower-15/JJR||arm-27/NN	det||patients-30/NNS||all-29/DT	prep_for||arm-27/NN||patients-30/NNS	amod||oxygen-34/NN||high-32/JJ	nn||oxygen-34/NN||flow-33/NN	nsubj||n-35/VBP||oxygen-34/NN	dep||arm-27/NN||n-35/VBP	number||226-37/CD||=-36/CD	dobj||n-35/VBP||226-37/CD	amod||n-41/NN||titrated-39/JJ	nn||n-41/NN||oxygen-40/NN	dep||226-37/CD||n-41/NN	number||179-43/CD||=-42/CD	dep||n-41/NN||179-43/CD	det||subgroup-48/NN||the-47/DT	prep_for||arm-27/NN||subgroup-48/NN	conj_and||patients-30/NNS||subgroup-48/NN	prep_of||subgroup-48/NN||patients-50/NNS	amod||obstructivepulmonarydisease-54/NN||confirmed-52/JJ	amod||obstructivepulmonarydisease-54/NN||chronic-53/JJ	prep_with||patients-50/NNS||obstructivepulmonarydisease-54/NN	amod||n-58/NN||high-56/JJ	nn||n-58/NN||flow-57/NN	nsubj||titrated-62/VBD||n-58/NN	number||117-60/CD||=-59/CD	dep||n-58/NN||117-60/CD	dep||subgroup-48/NN||titrated-62/VBD	nsubj||97-65/CD||n-63/NN	dep||97-65/CD||=-64/SYM	ccomp||titrated-62/VBD||97-65/CD	obstructivepulmonarydisease-54||oxygen-40||yes||results in an intention to treat analysis, the risk of death was significantly lower in the titrated oxygen arm compared with the high flow oxygen arm for all patients (high flow oxygen n=226; titrated oxygen n=179) and for the subgroup of patients with confirmed chronic obstructivepulmonarydisease (high flow n=117; titrated n=97).
num||trials-3/NNS||three-1/CD	amod||trials-3/NNS||quasi-experimental-2/JJ	nsubj||matched-4/VBD||trials-3/NNS	root||ROOT-0/null||matched-4/VBD	det||criteria-7/NNS||the-5/DT	nn||criteria-7/NNS||inclusion-6/NN	nsubj||found-10/VBD||criteria-7/NNS	num||trials-9/NNS||two-8/CD	dep||criteria-7/NNS||trials-9/NNS	ccomp||matched-4/VBD||found-10/VBD	det||reduction-12/NN||a-11/DT	dobj||found-10/VBD||reduction-12/NN	prep_in||found-10/VBD||pain-14/NN	det||use-17/NN||the-16/DT	prep_for||found-10/VBD||use-17/NN	nn||needling-22/NN||trigger-19/NN	nn||needling-22/NN||point-20/NN	amod||needling-22/NN||dry-21/JJ	prep_of||use-17/NN||needling-22/NN	advmod||found-30/VBD||when-23/WRB	csubj||found-30/VBD||combined-24/VBN	prep_with||combined-24/VBN||acupuncture-26/NN	det||third-29/JJ||the-28/DT	prep_with||combined-24/VBN||third-29/JJ	conj_and||acupuncture-26/NN||third-29/JJ	advcl||found-10/VBD||found-30/VBD	det||reduction-32/NN||a-31/DT	dobj||found-30/VBD||reduction-32/NN	prep_in||found-30/VBD||pain-34/NN	xcomp||found-30/VBD||using-35/VBG	number||%-37/NN||1-36/CD	amod||injections-39/NNS||%-37/NN	amod||injections-39/NNS||lidocaine-38/JJ	dobj||using-35/VBG||injections-39/NNS	advmod||combined-41/VBN||when-40/WRB	advcl||using-35/VBG||combined-41/VBN	amod||therapy-44/NN||physical-43/JJ	prep_with||combined-41/VBN||therapy-44/NN	pain-34||lidocaine-38||yes||three quasi-experimental trials matched the inclusion criteria  two trials found a reduction in pain for the use of trigger point dry needling when combined with acupuncture and the third found a reduction in pain using 1% lidocaine injections when combined with physical therapy.
amod||features-2/NNS||clinical-1/JJ	nsubj||alert-24/VB||features-2/NNS	prep_of||features-2/NNS||headache-4/NN	amod||consciousness-7/NN||altered-6/JJ	prep_of||features-2/NNS||consciousness-7/NN	conj_and||headache-4/NN||consciousness-7/NN	amod||deficit-11/NN||focal-9/JJ	amod||deficit-11/NN||neurological-10/JJ	prep_of||features-2/NNS||deficit-11/NN	conj_and||headache-4/NN||deficit-11/NN	prep_of||features-2/NNS||seizures-14/NNS	conj_and||headache-4/NN||seizures-14/NNS	dep||features-2/NNS||developing-15/VBG	prep||developing-15/VBG||during-16/IN	dep||features-2/NNS||immediately-18/RB	conj_or||developing-15/VBG||immediately-18/RB	prep_after||immediately-18/RB||treatment-20/NN	prep_with||immediately-18/RB||l-asparaginase-22/NN	aux||alert-24/VB||should-23/MD	root||ROOT-0/null||alert-24/VB	det||physician-27/NN||the-25/DT	amod||physician-27/NN||treating-26/JJ	dobj||alert-24/VB||physician-27/NN	det||possibility-30/NN||the-29/DT	prep_to||alert-24/VB||possibility-30/NN	prep_of||possibility-30/NN||csvt-32/NN	l-asparaginase-22||deficit-11||no_rel||clinical features of headache, altered consciousness, focal neurological deficit, and seizures developing during or immediately after treatment with l-asparaginase should alert the treating physician to the possibility of csvt.
nn||acetylsalicylicacid-4/NN||background-1/NN	conj_and||background-1/NN||aim-3/NN	nn||acetylsalicylicacid-4/NN||aim-3/NN	nsubj||drug-16/NN||acetylsalicylicacid-4/NN	num||-RSB--9/NNS||asa-6/CD	nn||-RSB--9/NNS||-LSB--7/NNP	nn||-RSB--9/NNS||aspirin-8/NN	appos||acetylsalicylicacid-4/NN||-RSB--9/NNS	cop||drug-16/NN||is-11/VBZ	det||drug-16/NN||a-12/DT	advmod||used-14/VBN||commonly-13/RB	amod||drug-16/NN||used-14/VBN	amod||drug-16/NN||over-the-counter-15/JJ	root||ROOT-0/null||drug-16/NN	det||treatment-19/NN||the-18/DT	prep_for||drug-16/NN||treatment-19/NN	prep_of||treatment-19/NN||pain-21/NN	prep_of||treatment-19/NN||fever-23/NN	conj_or||pain-21/NN||fever-23/NN	prep_of||treatment-19/NN||colds-26/NNS	conj_or||pain-21/NN||colds-26/NNS	nsubj||limited-38/JJ||data-29/NNS	det||safety-32/NN||the-31/DT	prep_on||data-29/NNS||safety-32/NN	det||use-35/NN||this-34/DT	prep_of||safety-32/NN||use-35/NN	cop||limited-38/JJ||are-36/VBP	advmod||limited-38/JJ||very-37/RB	conj_but||drug-16/NN||limited-38/JJ	pain-21||asa-6||yes||background and aim acetylsalicylicacid (asa [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	oil--1||chf-60||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
nsubjpass||thought-3/VBN||these-1/DT	nsubj||drugeruption-7/NN||these-1/DT	nsubjpass||resolved-9/VBN||these-1/DT	auxpass||thought-3/VBN||were-2/VBD	root||ROOT-0/null||thought-3/VBN	aux||drugeruption-7/NN||to-4/TO	cop||drugeruption-7/NN||be-5/VB	det||drugeruption-7/NN||a-6/DT	xcomp||thought-3/VBN||drugeruption-7/NN	conj_and||thought-3/VBN||resolved-9/VBN	advmod||stopped-13/VBN||when-10/WRB	nsubjpass||stopped-13/VBN||teicoplanin-11/NN	auxpass||stopped-13/VBN||was-12/VBD	advcl||resolved-9/VBN||stopped-13/VBN	teicoplanin-11||drugeruption-7||no_rel||these were thought to be a drugeruption and resolved when teicoplanin was stopped.
num||years-3/NNS||2-2/CD	prep_over||-LSB--9/VBZ||years-3/NNS	nsubj||-LSB--9/VBZ||rates-5/NNS	amod||hypoglycaemia-8/NN||minor-7/JJ	prep_of||rates-5/NNS||hypoglycaemia-8/NN	root||ROOT-0/null||-LSB--9/VBZ	amod||<-13/NNS||self-treated-10/JJ	nn||<-13/NNS||plasma-11/NN	nn||<-13/NNS||glucose-12/NN	nsubj||lower-24/JJR||<-13/NNS	number||mmol/l-15/JJ||3.1-14/CD	dep||lower-24/JJR||mmol/l-15/JJ	dep||mg/dl-19/JJ||<-17/RB	npadvmod||mg/dl-19/JJ||56-18/CD	dep||lower-24/JJR||mg/dl-19/JJ	nsubj||lower-24/JJR||-RSB--21/NNP	cop||lower-24/JJR||were-22/VBD	advmod||lower-24/JJR||significantly-23/RB	xcomp||-LSB--9/VBZ||lower-24/JJR	nn||mg-28/NN||liraglutide-26/NN	num||mg-28/NN||1.2-27/CD	prep_with||lower-24/JJR||mg-28/NN	num||mg-31/NN||1.8-30/CD	prep_with||lower-24/JJR||mg-31/NN	conj_and||mg-28/NN||mg-31/NN	prepc_compared_with||lower-24/JJR||with-33/IN	pobj||lower-24/JJR||glimepiride-34/NN	appos||glimepiride-34/NN||p-36/NNP	number||0.0001-38/CD||<-37/CD	num||p-36/NNP||0.0001-38/CD	hypoglycaemia-8||glucose-12||yes||over 2 years, rates of minor hypoglycaemia [self-treated plasma glucose <3.1 mmol/l (<56 mg/dl)] were significantly lower with liraglutide 1.2 mg and 1.8 mg compared with glimepiride (p < 0.0001).
det||study-3/NN||the-1/DT	nn||study-3/NN||action-2/NN	nsubj||trial-8/NN||study-3/NN	cop||trial-8/NN||is-4/VBZ	det||trial-8/NN||the-5/DT	amod||trial-8/NN||first-6/JJ	amod||trial-8/NN||controlled-7/JJ	root||ROOT-0/null||trial-8/NN	aux||investigate-10/VB||to-9/TO	vmod||trial-8/NN||investigate-10/VB	det||efficacy-12/NN||the-11/DT	dobj||investigate-10/VB||efficacy-12/NN	prep_of||efficacy-12/NN||atomoxetine-14/NN	ccomp||investigate-10/VB||using-15/VBG	amod||cognitive-17/NN||objective-16/JJ	dobj||using-15/VBG||cognitive-17/NN	amod||markers-21/NNS||emotional-19/JJ	nn||markers-21/NNS||function-20/NN	dobj||using-15/VBG||markers-21/NNS	conj_and||cognitive-17/NN||markers-21/NNS	mark||predict-28/VBP||whether-24/IN	det||measures-27/NNS||these-25/DT	amod||measures-27/NNS||objective-26/JJ	nsubj||predict-28/VBP||measures-27/NNS	nsubj||predict-28/VBP||measures-27/NNS	ccomp||investigate-10/VB||predict-28/VBP	conj_and||using-15/VBG||predict-28/VBP	conj_and||using-15/VBG||predict-28/VBP	conj_and||predict-28/VBP||predict-28/VBP	dobj||predict-28/VBP||outcomes-29/NNS	prep_with||predict-28/VBP||atomoxetine-31/NN	prep_in||atomoxetine-31/NN||adhd-33/NN	amod||anxiety-38/NN||comorbid-37/JJ	prep_with||predict-28/VBP||anxiety-38/NN	prep_without||predict-28/VBP||anxiety-38/NN	adhd-33||atomoxetine-31||yes||the action study is the first controlled trial to investigate the efficacy of atomoxetine using objective cognitive and emotional function markers, and whether these objective measures predict outcomes with atomoxetine in adhd with and without comorbid anxiety.
nsubjpass||caused-3/VBN||leptospirosis-1/NNS	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	amod||spirochetes-6/NNS||pathogenic-5/JJ	agent||caused-3/VBN||spirochetes-6/NNS	det||genusleptospira-9/NN||the-8/DT	prep_of||spirochetes-6/NNS||genusleptospira-9/NN	leptospirosis-1||genusleptospira-9||no||leptospirosis is caused by pathogenic spirochetes of the genusleptospira .
nsubj||similar-3/JJ||results-1/NNS	cop||similar-3/JJ||were-2/VBD	root||ROOT-0/null||similar-3/JJ	advmod||restricted-6/VBN||when-4/WRB	nsubj||restricted-6/VBN||we-5/PRP	advcl||similar-3/JJ||restricted-6/VBN	det||analyses-8/NNS||the-7/DT	dobj||restricted-6/VBN||analyses-8/NNS	nsubj||estrogen-10/VB||analyses-8/NNS	aux||estrogen-10/VB||to-9/TO	xcomp||restricted-6/VBN||estrogen-10/VB	amod||tumors-15/NNS||receptor-positive-11/JJ	conj_and||receptor-positive-11/JJ||progesterone-13/JJ	amod||tumors-15/NNS||progesterone-13/JJ	amod||tumors-15/NNS||receptor-positive-14/JJ	dobj||estrogen-10/VB||tumors-15/NNS	progesterone-13||tumors-15||no_rel||results were similar when we restricted the analyses to estrogen receptor-positive and progesterone receptor-positive tumors.
det||study-3/NN||this-2/DT	prep_in||determined-6/VBD||study-3/NN	nsubj||determined-6/VBD||we-5/PRP	nsubj||assessed-36/VBD||we-5/PRP	root||ROOT-0/null||determined-6/VBD	det||percentage-8/NN||the-7/DT	nsubj||isolates-19/VBZ||percentage-8/NN	prep_of||percentage-8/NN||strains-10/NNS	vmod||strains-10/NNS||possessing-11/VBG	amod||resistance-13/NN||pyrazinamide-12/JJ	dobj||possessing-11/VBG||resistance-13/NN	amod||m.tuberculosis-16/NNS||pan-susceptible-15/JJ	prep_among||possessing-11/VBG||m.tuberculosis-16/NNS	prep_among||possessing-11/VBG||mdr-tb-18/NN	conj_and||m.tuberculosis-16/NNS||mdr-tb-18/NN	ccomp||determined-6/VBD||isolates-19/VBZ	prepc_by||isolates-19/VBZ||using-21/VBG	det||method-30/NN||the-22/DT	amod||method-30/NN||pyrazinamidase-23/JJ	amod||method-30/NN||assay-24/JJ	amod||method-30/NN||bactec-26/JJ	nn||method-30/NN||mgit-27/NN	num||method-30/NN||960-28/CD	nn||method-30/NN||pza-29/NNP	dobj||using-21/VBG||method-30/NN	nn||sequencing-33/NN||pnca-32/NN	dobj||using-21/VBG||sequencing-33/NN	conj_and||method-30/NN||sequencing-33/NN	conj_and||determined-6/VBD||assessed-36/VBD	det||correlation-38/NN||the-37/DT	dobj||assessed-36/VBD||correlation-38/NN	det||data-41/NNS||the-40/DT	prep_in||assessed-36/VBD||data-41/NNS	vmod||data-41/NNS||generated-42/VBN	xcomp||generated-42/VBN||using-43/VBG	det||methods-45/NNS||these-44/DT	dobj||using-43/VBG||methods-45/NNS	tb--1||m.tuberculosis-16||no||in this study , we determined the percentage of strains possessing pyrazinamide resistance among pan-susceptible m.tuberculosis and mdr-tb isolates by using the pyrazinamidase assay , bactec mgit 960 pza method and pnca sequencing , and assessed the correlation in the data generated using these methods .
amod||rhinitis-2/NNS||allergic-1/JJ	nsubj||prevalent-10/JJ||rhinitis-2/NNS	conj_and||rhinitis-2/NNS||atopic/non-atopicasthma-4/NN	nsubj||prevalent-10/JJ||atopic/non-atopicasthma-4/NN	conj_and||rhinitis-2/NNS||atopicdermatitis-7/NNS	nsubj||prevalent-10/JJ||atopicdermatitis-7/NNS	cop||prevalent-10/JJ||were-8/VBD	advmod||prevalent-10/JJ||equally-9/RB	root||ROOT-0/null||prevalent-10/JJ	det||groups-14/NNS||the-12/DT	nn||groups-14/NNS||study-13/NN	prep_among||prevalent-10/JJ||groups-14/NNS	det||group-19/NN||the-17/DT	nn||group-19/NN||crs/rom-18/NN	prep_except_for||prevalent-10/JJ||group-19/NN	prep_in||prevalent-25/JJ||group-19/NN	nsubj||prevalent-25/JJ||non-atopicasthma-22/NN	cop||prevalent-25/JJ||was-23/VBD	advmod||prevalent-25/JJ||more-24/RBR	rcmod||group-19/NN||prevalent-25/JJ	num||%-28/NN||52.6-27/CD	appos||group-19/NN||%-28/NN	atopicasthma--1||atopic--1||no||allergic rhinitis, atopic/non-atopicasthma, and atopicdermatitis were equally prevalent among the study groups except for the crs/rom group in which non-atopicasthma was more prevalent (52.6%).
det||antibody-3/NN||the-1/DT	amod||antibody-3/NN||e4g10-2/JJ	nsubj||targeted-5/VBD||antibody-3/NN	advmod||targeted-5/VBD||specifically-4/RB	root||ROOT-0/null||targeted-5/VBD	det||endothelial-cadherin-9/NN||the-6/DT	amod||endothelial-cadherin-9/NN||monomeric-7/JJ	nn||endothelial-cadherin-9/NN||vascular-8/NN	nsubj||expressed-14/VBD||endothelial-cadherin-9/NN	dep||endothelial-cadherin-9/NN||ve-cad-11/JJ	advmod||expressed-14/VBD||epitope-13/RB	ccomp||targeted-5/VBD||expressed-14/VBD	det||vessels-19/NNS||the-16/DT	nn||vessels-19/NNS||tumor-17/NN	amod||vessels-19/NNS||angiogenic-18/JJ	prep_in||expressed-14/VBD||vessels-19/NNS	antibody-3||cad--1||no_rel||the e4g10 antibody specifically targeted the monomeric vascular endothelial-cadherin (ve-cad) epitope expressed in the tumor angiogenic vessels.
det||total-2/NN||a-1/DT	nsubj||received-9/VBD||total-2/NN	number||hospitalized-5/CD||180-4/CD	num||patients-6/NNS||hospitalized-5/CD	prep_of||total-2/NN||patients-6/NNS	prep_with||patients-6/NNS||type2diabetes-8/CD	root||ROOT-0/null||received-9/VBD	advmod||received-9/VBD||either-10/RB	dep||received-9/VBD||glulisine-11/VB	dep||glulisine-11/VB||n-13/VBN	dep||88-15/CD||=-14/SYM	ccomp||n-13/VBN||88-15/CD	dep||received-9/VBD||regularinsulin-18/VB	conj_or||glulisine-11/VB||regularinsulin-18/VB	dep||glulisine-11/VB||n-20/VBN	dep||92-22/CD||=-21/SYM	ccomp||n-20/VBN||92-22/CD	dep||received-9/VBD||before-24/IN	conj_or||glulisine-11/VB||before-24/IN	det||meal-26/NN||each-25/DT	prep_before||glulisine-11/VB||meal-26/NN	prep_in||meal-26/NN||combination-28/NN	prep_with||combination-28/NN||insulinglargine-30/NN	prep_at||insulinglargine-30/NN||bedtime-32/NN	det||fashion-37/NN||a-34/DT	amod||fashion-37/NN||randomized-35/JJ	amod||fashion-37/NN||double-blind-36/JJ	prep_in||bedtime-32/NN||fashion-37/NN	type2diabetes-8||regularinsulin-18||yes||a total of 180 hospitalized patients with type2diabetes received either glulisine ( n = 88) or regularinsulin ( n = 92) before each meal in combination with insulinglargine at bedtime in a randomized double-blind fashion.
det||genotype-3/NN||the-1/DT	amod||genotype-3/NN||beijing-2/VBG	nsubj||lineage-8/NN||genotype-3/NN	cop||lineage-8/NN||is-4/VBZ	det||lineage-8/NN||a-5/DT	amod||lineage-8/NN||distinct-6/JJ	amod||lineage-8/NN||genetic-7/JJ	root||ROOT-0/null||lineage-8/NN	prep_of||lineage-8/NN||mycobacteriumtuberculosis-10/NNS	nsubjpass||distributed-14/VBN||mycobacteriumtuberculosis-10/NNS	nsubjpass||caused-19/VBN||mycobacteriumtuberculosis-10/NNS	auxpass||distributed-14/VBN||is-13/VBZ	rcmod||mycobacteriumtuberculosis-10/NNS||distributed-14/VBN	advmod||distributed-14/VBN||worldwide-15/RB	aux||caused-19/VBN||has-18/VBZ	rcmod||mycobacteriumtuberculosis-10/NNS||caused-19/VBN	conj_and||distributed-14/VBN||caused-19/VBN	amod||outbreaks-21/NNS||large-20/JJ	dobj||caused-19/VBN||outbreaks-21/NNS	prep_of||outbreaks-21/NNS||mdr-tb-23/NN	tb--1||mycobacteriumtuberculosis-10||no||the beijing genotype is a distinct genetic lineage of mycobacteriumtuberculosis , which is distributed worldwide, and has caused large outbreaks of mdr-tb.
advmod||inhibits-4/VBZ||moreover-1/RB	nsubj||inhibits-4/VBZ||curcumin-3/NN	root||ROOT-0/null||inhibits-4/VBZ	amod||angiogenesis-8/NNS||microvascular-5/JJ	amod||angiogenesis-8/NNS||endothelial-6/JJ	nn||angiogenesis-8/NNS||cell-7/NN	dobj||inhibits-4/VBZ||angiogenesis-8/NNS	prep_through||inhibits-4/VBZ||inhibition-10/NN	amod||expression-13/NN||cox-2-12/JJ	prep_of||inhibition-10/NN||expression-13/NN	amod||production-16/NN||pge2-15/JJ	prep_of||inhibition-10/NN||production-16/NN	conj_and||expression-13/NN||production-16/NN	vmod||inhibits-4/VBZ||suggesting-18/VBG	mark||possesses-23/VBZ||that-19/IN	det||product-22/NN||this-20/DT	amod||product-22/NN||natural-21/JJ	nsubj||possesses-23/VBZ||product-22/NN	ccomp||suggesting-18/VBG||possesses-23/VBZ	amod||properties-25/NNS||antiangiogenic-24/JJ	dobj||possesses-23/VBZ||properties-25/NNS	nsubj||warrants-28/VBZ||properties-25/NNS	rcmod||properties-25/NNS||warrants-28/VBZ	amod||investigation-30/NN||further-29/JJ	dobj||warrants-28/VBZ||investigation-30/NN	amod||treatment-33/NN||adjuvant-32/JJ	prep_as||warrants-28/VBZ||treatment-33/NN	prep_of||treatment-33/NN||ibd-35/NN	prep_of||treatment-33/NN||cancer-37/NN	conj_and||ibd-35/NN||cancer-37/NN	cancer-37||adjuvant-32||no_rel||moreover, curcumin inhibits microvascular endothelial cell angiogenesis through inhibition of cox-2 expression and pge2 production, suggesting that this natural product possesses antiangiogenic properties, which warrants further investigation as adjuvant treatment of ibd and cancer.
nsubj||threat-5/NN||tuberculosis-1/NNP	cop||threat-5/NN||is-2/VBZ	det||threat-5/NN||a-3/DT	amod||threat-5/NN||worldwide-4/JJ	root||ROOT-0/null||threat-5/NN	nsubj||requires-13/VBZ||development-8/NN	det||vaccine-12/NN||an-10/DT	amod||vaccine-12/NN||effective-11/JJ	prep_of||development-8/NN||vaccine-12/NN	conj_and||threat-5/NN||requires-13/VBZ	mark||dissected-25/VBN||that-14/IN	det||response-18/NN||the-15/DT	amod||response-18/NN||protective-16/JJ	amod||response-18/NN||immune-17/JJ	nsubjpass||dissected-25/VBN||response-18/NN	prep_to||response-18/NN||mycobacteriumtuberculosis-20/NNS	appos||mycobacteriumtuberculosis-20/NNS||mtb-22/NN	auxpass||dissected-25/VBN||be-24/VB	ccomp||requires-13/VBZ||dissected-25/VBN	det||response-30/NN||the-27/DT	amod||response-30/NN||pathological-28/JJ	amod||response-30/NN||immune-29/JJ	prep_from||dissected-25/VBN||response-30/NN	tuberculosis-1||mycobacteriumtuberculosis-20||no||tuberculosis is a worldwide threat, and development of an effective vaccine requires that the protective immune response to mycobacteriumtuberculosis (mtb) be dissected from the pathological immune response.
aux||investigate-2/VB||to-1/TO	advcl||studied-22/VBD||investigate-2/VB	mark||factor-14/NN||whether-3/IN	amod||density-7/NN||increased-4/VBN	amod||density-7/NN||lymphatic-5/JJ	nn||density-7/NN||vessel-6/NN	nsubj||factor-14/NN||density-7/NN	appos||density-7/NN||lvd-9/NN	cop||factor-14/NN||is-11/VBZ	det||factor-14/NN||a-12/DT	amod||factor-14/NN||prognostic-13/JJ	ccomp||investigate-2/VB||factor-14/NN	amod||metastasis-17/NNS||nodal-16/JJ	prep_for||factor-14/NN||metastasis-17/NNS	prep_for||factor-14/NN||survival-19/NN	conj_and||metastasis-17/NNS||survival-19/NN	nsubj||studied-22/VBD||we-21/PRP	root||ROOT-0/null||studied-22/VBD	amod||lvd-24/NN||peritumoral-23/JJ	dobj||studied-22/VBD||lvd-24/NN	dep||lvd-24/NN||p-lvd-26/JJ	amod||lvd-30/NN||intratumoral-29/JJ	dobj||studied-22/VBD||lvd-30/NN	conj_and||lvd-24/NN||lvd-30/NN	dep||lvd-30/NN||i-lvd-32/JJ	prep_in||lvd-24/NN||samples-35/NNS	num||patients-38/NNS||102-37/CD	prep_from||samples-35/NNS||patients-38/NNS	amod||carcinoma-41/NN||endometrial-40/JJ	prep_with||patients-38/NNS||carcinoma-41/NN	amod||tissues-45/NNS||endometrial-43/JJ	nn||tissues-45/NNS||carcinoma-44/NN	nsubjpass||analyzed-47/VBN||tissues-45/NNS	auxpass||analyzed-47/VBN||were-46/VBD	dobj||studied-22/VBD||analyzed-47/VBN	conj_and||lvd-24/NN||analyzed-47/VBN	amod||vessels-50/NNS||lymphatic-49/JJ	prep_for||analyzed-47/VBN||vessels-50/NNS	amod||staining-53/NN||immunohistochemical-52/JJ	agent||analyzed-47/VBN||staining-53/NN	det||antibody-56/NN||an-55/DT	prep_with||analyzed-47/VBN||antibody-56/NN	prep_against||antibody-56/NN||lyve-1-58/CD	carcinoma-44||antibody-56||no_rel||to investigate whether increased lymphatic vessel density (lvd) is a prognostic factor for nodal metastasis and survival, we studied peritumoral lvd (p-lvd) and intratumoral lvd (i-lvd) in samples from 102 patients with endometrial carcinoma; endometrial carcinoma tissues were analyzed for lymphatic vessels by immunohistochemical staining with an antibody against lyve-1.
nsubjpass||quantified-38/VBN||plasma-1/NN	nn||triglycerides-4/NNPS||liver-3/NNP	conj_and||plasma-1/NN||triglycerides-4/NNPS	nsubjpass||quantified-38/VBN||triglycerides-4/NNPS	dep||triglycerides-4/NNPS||concentration-6/NN	dep||triglycerides-4/NNPS||composition-8/NN	conj_and||concentration-6/NN||composition-8/NN	conj_and||plasma-1/NN||liverinflammation-11/NN	conj_and||triglycerides-4/NNPS||liverinflammation-11/NN	dep||liverinflammation-11/NN||ccl2-13/NNS	appos||ccl2-13/NNS||cd68-15/NNS	nn||mrna-19/NNP||tnf-î-17/NNP	nn||mrna-19/NNP||±-18/NNP	appos||ccl2-13/NNS||mrna-19/NNP	conj_and||plasma-1/NN||infiltration-23/NN	conj_and||triglycerides-4/NNPS||infiltration-23/NN	prep_of||infiltration-23/NN||macrophages-25/NNS	dep||macrophages-25/NNS||cd68-27/NNS	amod||immunohistochemistry-30/NN||cd11b-29/JJ	appos||cd68-27/NNS||immunohistochemistry-30/NN	prep_of||infiltration-23/NN||neutrophils-33/NNS	conj_and||macrophages-25/NNS||neutrophils-33/NNS	appos||macrophages-25/NNS||mpo-35/NN	auxpass||quantified-38/VBN||were-37/VBD	root||ROOT-0/null||quantified-38/VBN	liverinflammation-11||triglycerides-4||no_rel||plasma and liver triglycerides (concentration and composition), liverinflammation ( ccl2 , cd68 , tnf-î± mrna), and infiltration of macrophages (cd68, cd11b immunohistochemistry) and neutrophils (mpo) were quantified.
det||program-3/NN||the-1/DT	amod||program-3/NN||j2j-2/JJ	nsubj||helps-4/VBZ||program-3/NN	nsubj||increase-6/VB||program-3/NN	root||ROOT-0/null||helps-4/VBZ	aux||increase-6/VB||to-5/TO	xcomp||helps-4/VBZ||increase-6/VB	amod||awareness-8/NN||global-7/JJ	dobj||increase-6/VB||awareness-8/NN	amod||concepts-12/NNS||pertinent-10/JJ	nn||concepts-12/NNS||hiv/aids-11/NNS	prep_of||awareness-8/NN||concepts-12/NNS	aids--1||hiv--1||no||the j2j program helps to increase global awareness of pertinent hiv/aids concepts.
det||structure-3/NN||the-1/DT	nn||structure-3/NN||crystal-2/NN	nsubj||consists-16/VBZ||structure-3/NN	nsubj||consists-16/VBZ||structure-3/NN	det||compound-7/NN||the-5/DT	nn||compound-7/NN||title-6/NN	prep_of||structure-3/NN||compound-7/NN	nn||-RSB--14/NNP||-LSB--9/NNP	nn||-RSB--14/NNP||zncl2-10/NNP	appos||-RSB--14/NNP||c10h8n2s-12/NNP	appos||structure-3/NN||-RSB--14/NNP	root||ROOT-0/null||consists-16/VBZ	conj_and||consists-16/VBZ||consists-16/VBZ	det||ring-21/NN||a-18/DT	amod||ring-21/NN||six-membered-19/JJ	nn||ring-21/NN||chelate-20/NN	prep_of||consists-16/VBZ||ring-21/NN	prep_in||tetraâhedrally-29/JJ||ring-21/NN	det||atom-26/NN||the-24/DT	nn||atom-26/NN||zn-25/NN	nsubj||tetraâhedrally-29/JJ||atom-26/NN	cop||tetraâhedrally-29/JJ||is-27/VBZ	advmod||tetraâhedrally-29/JJ||approximately-28/RB	rcmod||ring-21/NN||tetraâhedrally-29/JJ	dep||tetraâhedrally-29/JJ||coordinated-30/VBN	num||chlorideions-33/NNS||two-32/CD	prep_by||coordinated-30/VBN||chlorideions-33/NNS	det||atoms-40/NNS||the-36/DT	num||atoms-40/NNS||two-37/CD	amod||atoms-40/NNS||pyridyl-38/JJ	nn||atoms-40/NNS||n-39/NN	prep_by||consists-16/VBZ||atoms-40/NNS	det||sulfide-45/NN||a-42/DT	amod||sulfide-45/NN||single-43/JJ	amod||sulfide-45/NN||di-2-pyridyl-44/JJ	prep_of||atoms-40/NNS||sulfide-45/NN	vmod||sulfide-45/NN||ligand-46/VBN	sulfide-45||di--1||no_rel||the crystal structure of the title compound, [zncl2(c10h8n2s)], consists of a six-membered chelate ring in which the zn atom is approximately tetraâ­hedrally coordinated by two chlorideions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand.
det||study-4/NN||a-2/DT	amod||study-4/NN||population-based-3/JJ	prep_in||quantified-20/VBN||study-4/NN	number||cks-7/CD||119-6/CD	num||cases-8/NNS||cks-7/CD	prep_of||study-4/NN||cases-8/NNS	num||controls-12/NNS||105-10/CD	amod||controls-12/NNS||kshv-seropositive-11/JJ	prep_of||study-4/NN||controls-12/NNS	conj_and||cases-8/NNS||controls-12/NNS	num||controls-17/NNS||155-15/CD	amod||controls-17/NNS||kshv-seronegative-16/JJ	prep_of||study-4/NN||controls-17/NNS	conj_and||cases-8/NNS||controls-17/NNS	nsubj||quantified-20/VBN||we-19/PRP	root||ROOT-0/null||quantified-20/VBN	nn||cluster-23/NN||plasma-21/NN	amod||cluster-23/NN||soluble-22/JJ	dobj||quantified-20/VBN||cluster-23/NN	amod||levels-29/NNS||differentiation-25/JJ	appos||levels-29/NNS||scd-27/NN	prep_of||cluster-23/NN||levels-29/NNS	dobj||quantified-20/VBN||antibodies-31/NNS	conj_and||cluster-23/NN||antibodies-31/NNS	amod||antigen-1-35/NN||epstein-barrvirus-33/JJ	amod||antigen-1-35/NN||nuclear-34/JJ	prep_against||antibodies-31/NNS||antigen-1-35/NN	dep||antigen-1-35/NN||anti-ebna-1-37/JJ	amod||antigen-42/NN||viral-40/JJ	amod||antigen-42/NN||capsid-41/JJ	prep_against||antibodies-31/NNS||antigen-42/NN	conj_and||antigen-1-35/NN||antigen-42/NN	appos||antigen-1-35/NN||anti-vca-44/NNP	scd-27||antibodies-31||no_rel||in a population-based study of 119 cks cases, 105 kshv-seropositive controls, and 155 kshv-seronegative controls, we quantified plasma soluble cluster of differentiation (scd) levels and antibodies against epstein-barrvirus nuclear antigen-1 (anti-ebna-1) and viral capsid antigen (anti-vca).
prep_in||represents-14/VBZ||italy-2/NN	advmod||southern-5/JJ||particularly-4/RB	amod||infection-13/NN||southern-5/JJ	amod||infection-13/NN||italy-6/JJ	amod||infection-13/NN||chronichepatitisc-8/JJ	nn||infection-13/NN||virus-9/NN	appos||infection-13/NN||hcv-11/NN	nsubj||represents-14/VBZ||infection-13/NN	root||ROOT-0/null||represents-14/VBZ	det||cause-17/NN||the-15/DT	amod||cause-17/NN||main-16/JJ	dobj||represents-14/VBZ||cause-17/NN	prep_of||cause-17/NN||hcc-19/NN	chronichepatitisc-8||hcv-11||no||in italy, particularly southern italy, chronichepatitisc virus (hcv) infection represents the main cause of hcc.
amod||prophylaxis-3/NNS||post-transplant-1/JJ	nn||prophylaxis-3/NNS||hbv-2/NN	nsubj||effective-31/JJ||prophylaxis-3/NNS	prep_with||prophylaxis-3/NNS||lamivudine-5/NN	prep_with||prophylaxis-3/NNS||intramuscular-7/NN	conj_and||lamivudine-5/NN||intramuscular-7/NN	vmod||prophylaxis-3/NNS||hbig-8/VBG	amod||dosage-11/NN||appropriate-10/JJ	prep_with||hbig-8/VBG||dosage-11/NN	aux||keep-13/VB||to-12/TO	xcomp||hbig-8/VBG||keep-13/VB	amod||titer-16/NN||anti-hbs-14/JJ	nn||titer-16/NN||antibody-15/NN	dobj||keep-13/VB||titer-16/NN	num||iu/l-19/NN||300-18/CD	prep_above||keep-13/VB||iu/l-19/NN	det||months-24/NNS||the-21/DT	amod||months-24/NNS||first-22/JJ	num||months-24/NNS||six-23/CD	prep_in||iu/l-19/NN||months-24/NNS	num||iu/l-28/NN||100-27/CD	prep_above||keep-13/VB||iu/l-28/NN	conj_and||iu/l-19/NN||iu/l-28/NN	dep||keep-13/VB||afterwards-29/RB	cop||effective-31/JJ||is-30/VBZ	root||ROOT-0/null||effective-31/JJ	prep_for||effective-31/JJ||prevention-33/NN	nn||recurrence-36/NN||hbv-35/NN	prep_of||prevention-33/NN||recurrence-36/NN	prep_after||effective-31/JJ||lt.-38/NN	hbv-35||hbig-8||yes||post-transplant hbv prophylaxis with lamivudine and intramuscular hbig with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l in the first six months and above 100 iu/l afterwards is effective for prevention of hbv recurrence after lt.
poss||role-5/NN||its-3/PRP$	amod||role-5/NN||principal-4/JJ	prep_apart_from||attributed-16/VBN||role-5/NN	nn||metabolism-8/NN||bone-7/NN	prep_in||role-5/NN||metabolism-8/NN	nn||homeostasis-11/NNS||calcium-10/NN	prep_in||role-5/NN||homeostasis-11/NNS	conj_and||metabolism-8/NN||homeostasis-11/NNS	nsubjpass||attributed-16/VBN||vitamind-13/NN	aux||attributed-16/VBN||has-14/VBZ	auxpass||attributed-16/VBN||been-15/VBN	root||ROOT-0/null||attributed-16/VBN	amod||effects-18/NNS||additional-17/JJ	dobj||attributed-16/VBN||effects-18/NNS	det||capacity-29/NN||an-20/DT	amod||capacity-29/NN||immunomodulatory-21/JJ	amod||capacity-29/NN||anti-inflammatory-23/JJ	advmod||neuroprotective-28/JJ||possibly-26/RB	advmod||neuroprotective-28/JJ||even-27/RB	conj_and||anti-inflammatory-23/JJ||neuroprotective-28/JJ	amod||capacity-29/NN||neuroprotective-28/JJ	prep_including||effects-18/NNS||capacity-29/NN	nsubj||implicates-31/VBZ||which-30/WDT	ccomp||capacity-29/NN||implicates-31/VBZ	det||role-34/NN||a-32/DT	amod||role-34/NN||possible-33/JJ	dobj||implicates-31/VBZ||role-34/NN	prep_of||role-34/NN||vitamind-36/NN	prep_in||implicates-31/VBZ||autoimmunediseases-38/NNS	prep_like||autoimmunediseases-38/NNS||multiplesclerosis-40/NNS	appos||multiplesclerosis-40/NNS||ms-42/NN	autoimmunediseases-38||vitamind-36||no_rel||apart from its principal role in bone metabolism and calcium homeostasis, vitamind has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamind in autoimmunediseases like multiplesclerosis (ms).
nsubj||similar-6/JJ||risk-1/NN	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||risk-1/NN||pancreatitis-4/NNS	cop||similar-6/JJ||was-5/VBD	root||ROOT-0/null||similar-6/JJ	det||exenatide-9/NN||the-8/DT	prep_in||similar-6/JJ||exenatide-9/NN	prep||exenatide-9/NN||versus-10/FW	amod||group-13/NN||diabetic-11/JJ	nn||group-13/NN||control-12/NN	pobj||versus-10/FW||group-13/NN	num||-LSB--16/NNS||0.9-15/CD	dep||exenatide-9/NN||-LSB--16/NNS	num||â-18/NN||0.6-17/CD	dep||-LSB--16/NNS||â-18/NN	num||-RSB--22/NNS||$-19/$	num||$-19/$||1.5-21/CD	dep||â-18/NN||-RSB--22/NNS	prep_in||similar-6/JJ||sitagliptin-25/NNS	conj_and||exenatide-9/NN||sitagliptin-25/NNS	prep||sitagliptin-25/NNS||versus-26/FW	amod||group-29/NN||diabetic-27/JJ	nn||group-29/NN||control-28/NN	pobj||versus-26/FW||group-29/NN	num||-LSB--32/NNS||1.0-31/CD	dep||exenatide-9/NN||-LSB--32/NNS	num||â-34/NN||0.7-33/CD	dep||-LSB--32/NNS||â-34/NN	num||-RSB--38/NNS||$-35/$	num||$-35/$||1.3-37/CD	dep||â-34/NN||-RSB--38/NNS	exenatide-9||pancreatitis-4||no_rel||risk of acute pancreatitis was similar in the exenatide versus diabetic control group (0.9 [0.6â€“1.5]) and sitagliptin versus diabetic control group (1.0 [0.7â€“1.3]).
prep_among||used-6/VBN||them-2/PRP	nsubjpass||used-6/VBN||doxycycline-4/NN	nsubjpass||used-6/VBN||doxycycline-4/NN	auxpass||used-6/VBN||is-5/VBZ	root||ROOT-0/null||used-6/VBN	conj_or||used-6/VBN||used-6/VBN	advmod||used-6/VBN||alone-7/RB	nn||chemoprophylaxis-10/NNS||malaria-9/NN	prep_for||used-6/VBN||chemoprophylaxis-10/NNS	prep_in||used-6/VBN||combination-13/NN	nn||derivatives-18/NNS||quinine-15/NN	conj_or||quinine-15/NN||artemisinin-17/NN	nn||derivatives-18/NNS||artemisinin-17/NN	prep_with||used-6/VBN||derivatives-18/NNS	nn||treatment-21/NN||malaria-20/NN	prep_for||derivatives-18/NNS||treatment-21/NN	malaria-20||doxycycline-4||yes||among them, doxycycline is used alone for malaria chemoprophylaxis or in combination with quinine or artemisinin derivatives for malaria treatment.
nsubj||high-8/JJ||misconceptions-1/NNS	det||transmission-4/NN||the-3/DT	prep_about||misconceptions-1/NNS||transmission-4/NN	prep_of||transmission-4/NN||hiv-6/NN	cop||high-8/JJ||were-7/VBD	root||ROOT-0/null||high-8/JJ	amod||knowledge-11/NN||comprehensive-10/JJ	nsubj||low-17/JJ||knowledge-11/NN	prep_about||knowledge-11/NN||hiv-13/NNP	prep_about||knowledge-11/NN||aids-15/NNP	conj_and||hiv-13/NNP||aids-15/NNP	cop||low-17/JJ||was-16/VBD	conj_and||high-8/JJ||low-17/JJ	advmod||low-17/JJ||particularly-19/RB	prep_among||low-17/JJ||pastoralists-21/NNS	aids-15||hiv-13||no||misconceptions about the transmission of hiv were high and comprehensive knowledge about hiv & aids was low, particularly among pastoralists.
num||phogrin-4/NNS||objectiveâ-1/CD	amod||phogrin-4/NNS||$-2/JJ	nsubjpass||shown-14/VBN||phogrin-4/NNS	nsubjpass||involved-17/VBN||phogrin-4/NNS	conj_and||phogrin-4/NNS||ia-2-6/NNS	nsubjpass||shown-14/VBN||ia-2-6/NNS	nsubjpass||involved-17/VBN||ia-2-6/NNS	appos||phogrin-4/NNS||autoantigens-8/NNS	prep_in||autoantigens-8/NNS||insulin-dependentdiabetes-10/NNS	aux||shown-14/VBN||have-12/VBP	auxpass||shown-14/VBN||been-13/VBN	root||ROOT-0/null||shown-14/VBN	aux||involved-17/VBN||to-15/TO	auxpass||involved-17/VBN||be-16/VB	xcomp||shown-14/VBN||involved-17/VBN	nn||secretion-20/NN||insulin-19/NN	prep_in||involved-17/VBN||secretion-20/NN	amod||î-23/NN||pancreatic-22/JJ	prep_in||involved-17/VBN||î-23/NN	punct||î-23/NN||²-24/''	dep||î-23/NN||cells-26/NNS	advmod||confusing-36/VBG||however-28/RB	nsubj||confusing-36/VBG||implications-30/NNS	det||level-34/NN||a-32/DT	amod||level-34/NN||molecular-33/JJ	prep_at||implications-30/NNS||level-34/NN	aux||confusing-36/VBG||are-35/VBP	parataxis||shown-14/VBN||confusing-36/VBG	prep_from||confusing-36/VBG||experiment-38/NN	prep_to||confusing-36/VBG||experiment-40/NN	insulin-dependentdiabetes-10||insulin-19||yes||objectiveâ€” phogrin and ia-2, autoantigens in insulin-dependentdiabetes, have been shown to be involved in insulin secretion in pancreatic î²-cells; however, implications at a molecular level are confusing from experiment to experiment.
amod||2â-4/NNS||neuacî-2/JJ	amod||2â-4/NNS||±-3/JJ	prep_as||has-28/VBZ||2â-4/NNS	nsubj||has-28/VBZ||$-5/$	num||play-10/NN||6-7/CD	amod||play-10/NN||polylactosamine-8/JJ	nn||play-10/NN||glycans-9/NNS	npadvmod||in-23/RB||play-10/NN	amod||roles-12/NNS||major-11/JJ	advmod||play-10/NN||roles-12/NNS	amod||virusinfection-15/NN||human-14/JJ	prep_in||roles-12/NNS||virusinfection-15/NN	det||importance-18/NN||the-17/DT	appos||virusinfection-15/NN||importance-18/NN	det||components-22/NNS||these-20/DT	nn||components-22/NNS||receptor-21/NN	prep_of||importance-18/NN||components-22/NNS	dep||virusinfection-24/CD||in-23/RB	num||$-5/$||virusinfection-24/CD	amod||cells-27/NNS||swine-26/JJ	prep_of||$-5/$||cells-27/NNS	root||ROOT-0/null||has-28/VBZ	dobj||has-28/VBZ||implications-29/NNS	prep_for||implications-29/NNS||transmission-31/NN	prep_of||transmission-31/NN||viruses-33/NNS	prep_between||viruses-33/NNS||humans-35/NNS	prep_between||viruses-33/NNS||pigs-37/NNS	conj_and||humans-35/NNS||pigs-37/NNS	prep_for||implications-29/NNS||pigs-40/NNS	conj_and||transmission-31/NN||pigs-40/NNS	amod||hosts-44/NNS||possible-42/JJ	nn||hosts-44/NNS||adaptation-43/NN	prep_as||pigs-40/NNS||hosts-44/NNS	nn||humaninfluenzaviruses-47/NNS||novel-46/NN	prep_of||hosts-44/NNS||humaninfluenzaviruses-47/NNS	virusinfection-24||viruses-33||no||as neuacî±2â€“6 polylactosamine glycans play major roles in human virusinfection, the importance of these receptor components in virusinfection of swine cells has implications for transmission of viruses between humans and pigs and for pigs as possible adaptation hosts of novel humaninfluenzaviruses.
nn||design-2/NN||research-1/NN	nsubj||$-6/VB||design-2/NN	nsubj||abdominal-59/VB||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||$-6/VB||methods-4/NNS	aux||$-6/VB||â-5/MD	root||ROOT-0/null||$-6/VB	det||total-9/NN||a-8/DT	dobj||$-6/VB||total-9/NN	num||adolescents-13/NNS||12-11/CD	amod||adolescents-13/NNS||obese-12/JJ	prep_of||total-9/NN||adolescents-13/NNS	prep_with||adolescents-13/NNS||ngt-15/NN	dobj||$-6/VB||19-17/CD	conj_and||total-9/NN||19-17/CD	prep_with||19-17/CD||igt-19/NN	dobj||$-6/VB||17-22/CD	conj_and||total-9/NN||17-22/CD	amod||evaluation-26/NN||type2diabetes-24/VBD	amod||evaluation-26/NN||underwent-25/JJ	prep_with||17-22/CD||evaluation-26/NN	nn||sensitivity-29/NN||insulin-28/NN	prep_of||evaluation-26/NN||sensitivity-29/NN	amod||-RSB--35/NNS||3-h-31/JJ	amod||-RSB--35/NNS||hyperinsulinemic-32/JJ	amod||-RSB--35/NNS||-LSB--33/JJ	amod||-RSB--35/NNS||80mu/m2/min-34/JJ	dep||evaluation-26/NN||-RSB--35/NNS	dep||clamp-40/NN||$-37/$	amod||clamp-40/NN||euglycemic-39/JJ	dep||evaluation-26/NN||clamp-40/NN	conj_â||-RSB--35/NNS||clamp-40/NN	amod||insulin-44/NN||first-phase-43/JJ	prep_with||17-22/CD||insulin-44/NN	conj_and||evaluation-26/NN||insulin-44/NN	amod||secretion-48/NN||second-phase-46/JJ	nn||secretion-48/NN||insulin-47/NN	prep_with||17-22/CD||secretion-48/NN	conj_and||evaluation-26/NN||secretion-48/NN	amod||clamp-52/NN||2-h-50/JJ	amod||clamp-52/NN||hyperglycemic-51/JJ	appos||secretion-48/NN||clamp-52/NN	nn||composition-56/NN||body-55/NN	appos||secretion-48/NN||composition-56/NN	conj_and||$-6/VB||abdominal-59/VB	dobj||$-6/VB||adiposity-60/NN	type2diabetes-24||insulin-47||yes||research design and methods â€”a total of 12 obese adolescents with ngt, 19 with igt, and 17 with type2diabetes underwent evaluation of insulin sensitivity (3-h hyperinsulinemic [80mu/m2/min]â€“euglycemic clamp), first-phase insulin and second-phase insulin secretion (2-h hyperglycemic clamp), body composition, and abdominal adiposity.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||trials-6/NNS||the-4/DT	amod||trials-6/NNS||clinical-5/JJ	dobj||reviews-3/VBZ||trials-6/NNS	amod||therapies-10/NNS||ai-8/JJ	nn||therapies-10/NNS||adjuvant-9/NN	prep_of||trials-6/NNS||therapies-10/NNS	amod||cancer-14/NN||hormone-sensitive-12/JJ	nn||cancer-14/NN||breast-13/NN	prep_for||reviews-3/VBZ||cancer-14/NN	dep||reviews-3/VBZ||particularly-16/RB	det||context-19/NN||the-18/DT	prep_in||reviews-3/VBZ||context-19/NN	advmod||compare-23/VBP||how-21/WRB	nsubj||compare-23/VBP||they-22/PRP	prepc_of||context-19/NN||compare-23/VBP	amod||deaths-40/NNS||tamoxifen-25/JJ	prepc_in||tamoxifen-25/JJ||minimizing-27/VBG	det||risk-29/NN||the-28/DT	dobj||minimizing-27/VBG||risk-29/NN	prep_of||risk-29/NN||relapse-31/NN	dobj||minimizing-27/VBG||occurrence-33/NN	conj_and||risk-29/NN||occurrence-33/NN	prep_of||occurrence-33/NN||dm-35/NN	dobj||minimizing-27/VBG||breast-38/NN	conj_and||risk-29/NN||breast-38/NN	amod||deaths-40/NNS||cancer-related-39/JJ	prep_with||compare-23/VBP||deaths-40/NNS	cancer-14||hormone--1||no_rel||this article reviews the clinical trials of ai adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of dm, and breast cancer-related deaths.
amod||studies-2/NNS||forty-nine-1/JJ	nsubj||met-3/VBD||studies-2/NNS	root||ROOT-0/null||met-3/VBD	det||criteria-6/NNS||the-4/DT	nn||criteria-6/NNS||inclusion-5/NN	dobj||met-3/VBD||criteria-6/NNS	num||indicators-10/NNS||30-8/CD	amod||indicators-10/NNS||different-9/JJ	nsubjpass||extracted-12/VBN||indicators-10/NNS	nsubjpass||categorized-14/VBN||indicators-10/NNS	auxpass||extracted-12/VBN||were-11/VBD	parataxis||met-3/VBD||extracted-12/VBN	parataxis||met-3/VBD||categorized-14/VBN	conj_and||extracted-12/VBN||categorized-14/VBN	num||categories-18/NNS||four-16/CD	amod||categories-18/NNS||nonorthogonal-17/JJ	prep_into||extracted-12/VBN||categories-18/NNS	nn||zones-21/NNS||blood-19/NN	nn||zones-21/NNS||glucose-20/NN	dep||categories-18/NNS||zones-21/NNS	prep_for||zones-21/NNS||example-24/NN	dep||example-24/NN||hypoglycaemia-27/NN	nn||levels-33/NNS||blood-31/NN	nn||levels-33/NNS||glucose-32/NN	prep_into||extracted-12/VBN||levels-33/NNS	conj_and||categories-18/NNS||levels-33/NNS	prep_for||levels-33/NNS||example-36/NN	amod||level-42/NN||mean-39/JJ	nn||level-42/NN||blood-40/NN	nn||level-42/NN||glucose-41/NN	dep||example-36/NN||level-42/NN	nn||intervals-47/NNS||time-46/NN	prep_into||extracted-12/VBN||intervals-47/NNS	conj_and||categories-18/NNS||intervals-47/NNS	prep_for||intervals-47/NNS||example-50/NN	dep||example-50/NN||time-53/NN	prep_to||time-53/NN||occurrence-55/NN	det||event-58/NN||an-57/DT	prep_of||occurrence-55/NN||event-58/NN	nn||characteristics-64/NNS||protocol-63/NN	prep_into||extracted-12/VBN||characteristics-64/NNS	conj_and||categories-18/NNS||characteristics-64/NNS	prep_for||categories-18/NNS||example-67/NN	nn||glucose-71/NN||blood-70/NN	nsubj||sampling-72/VBG||glucose-71/NN	dep||example-67/NN||sampling-72/VBG	dobj||sampling-72/VBG||frequency-73/NN	hypoglycaemia-27||glucose-71||yes||forty-nine studies met the inclusion criteria; 30 different indicators were extracted and categorized into four nonorthogonal categories blood glucose zones (for example, 'hypoglycaemia'); blood glucose levels (for example, 'mean blood glucose level'); time intervals (for example, 'time to occurrence of an event'); and protocol characteristics (for example, 'blood glucose sampling frequency').
nsubj||have-11/VBP||adults-1/NNS	amod||origin-5/NN||south-3/JJ	nn||origin-5/NN||asian-4/NN	prep_of||adults-1/NNS||origin-5/NN	vmod||origin-5/NN||living-6/VBG	det||kingdom-10/NN||the-8/DT	amod||kingdom-10/NN||united-9/VBN	prep_in||living-6/VBG||kingdom-10/NN	root||ROOT-0/null||have-11/VBP	amod||risks-13/NNS||high-12/JJ	nsubj||raised-20/VBD||risks-13/NNS	amod||obesity-18/NN||type2diabetes-15/JJ	conj_and||type2diabetes-15/JJ||central-17/JJ	amod||obesity-18/NN||central-17/JJ	prep_of||risks-13/NNS||obesity-18/NN	ccomp||have-11/VBP||raised-20/VBD	xcomp||raised-20/VBD||circulating-21/VBG	dobj||circulating-21/VBG||insulin-22/NN	dobj||circulating-21/VBG||triglyceride-24/NN	conj_and||insulin-22/NN||triglyceride-24/NN	amod||concentrations-29/NNS||c-reactive-27/JJ	nn||concentrations-29/NNS||protein-28/NN	dobj||circulating-21/VBG||concentrations-29/NNS	conj_and||insulin-22/NN||concentrations-29/NNS	amod||hdl-cholesterol-33/NN||low-32/JJ	dobj||circulating-21/VBG||hdl-cholesterol-33/NN	conj_and||insulin-22/NN||hdl-cholesterol-33/NN	dep||circulating-21/VBG||when-34/WRB	prepc_compared_with||raised-20/VBD||with-36/IN	amod||europeans-38/NNS||white-37/JJ	pobj||raised-20/VBD||europeans-38/NNS	cholesterol--1||obesity-18||no_rel||adults of south asian origin living in the united kingdom have high risks of type2diabetes and central obesity; raised circulating insulin, triglyceride, and c-reactive protein concentrations; and low hdl-cholesterol when compared with white europeans.
amod||disease-3/NN||cytomegalovirus-1/JJ	amod||disease-3/NN||end-organ-2/JJ	nsubjpass||prevented-6/VBN||disease-3/NN	aux||prevented-6/VBN||can-4/MD	auxpass||prevented-6/VBN||be-5/VB	root||ROOT-0/null||prevented-6/VBN	agent||prevented-6/VBN||giving-8/VBG	dobj||giving-8/VBG||ganciclovir-9/NN	advmod||detected-13/VBN||when-10/WRB	nsubjpass||detected-13/VBN||viraemia-11/NN	auxpass||detected-13/VBN||is-12/VBZ	advcl||giving-8/VBG||detected-13/VBN	amod||recipients-16/NNS||allograft-15/JJ	prep_in||detected-13/VBN||recipients-16/NNS	cytomegalovirus-1||ganciclovir-9||yes||cytomegalovirus end-organ disease can be prevented by giving ganciclovir when viraemia is detected in allograft recipients.
det||report-3/NN||this-2/DT	prep_in||demonstrated-7/VBN||report-3/NN	nsubj||demonstrated-7/VBN||we-5/PRP	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||due-21/JJ||that-8/IN	amod||interaction-10/NN||synergistic-9/JJ	nsubj||due-21/JJ||interaction-10/NN	prep_between||interaction-10/NN||phyvv-12/NNP	prep_between||interaction-10/NN||pepgmv-14/NNP	conj_and||phyvv-12/NNP||pepgmv-14/NNP	det||infection-18/NN||a-16/DT	amod||infection-18/NN||mixed-17/JJ	prep_during||interaction-10/NN||infection-18/NN	cop||due-21/JJ||is-19/VBZ	advmod||due-21/JJ||mainly-20/RB	ccomp||demonstrated-7/VBN||due-21/JJ	det||concentration-26/NN||an-23/DT	amod||concentration-26/NN||increased-24/VBN	nn||concentration-26/NN||dna-25/NN	prep_to||due-21/JJ||concentration-26/NN	det||viruses-29/NNS||both-28/DT	prep_of||concentration-26/NN||viruses-29/NNS	det||effect-34/NN||any-32/DT	amod||effect-34/NN||noticeable-33/JJ	prep_without||due-21/JJ||effect-34/NN	det||localization-37/NN||the-36/DT	prep_on||effect-34/NN||localization-37/NN	det||virus-40/NN||either-39/DT	prep_of||localization-37/NN||virus-40/NN	amod||tissue-44/NN||infected-42/JJ	nn||tissue-44/NN||plant-43/NN	prep_on||virus-40/NN||tissue-44/NN	virus-40||viruses-29||no||in this report, we have demonstrated that synergistic interaction between phyvv and pepgmv during a mixed infection is mainly due to an increased dna concentration of both viruses, without any noticeable effect on the localization of either virus on infected plant tissue.
det||paper-3/NN||this-2/DT	prep_in||review-6/VBP||paper-3/NN	nsubj||review-6/VBP||we-5/PRP	root||ROOT-0/null||review-6/VBP	amod||research-8/NN||recent-7/JJ	dobj||review-6/VBP||research-8/NN	prep_with||review-6/VBP||exenatide-10/NN	amod||therapy-13/NN||adjunctive-12/JJ	prep_as||exenatide-10/NN||therapy-13/NN	prep_in||therapy-13/NN||type2diabetesmellitus-15/CD	type2diabetesmellitus-15||exenatide-10||yes||in this paper, we review recent research with exenatide as adjunctive therapy in type2diabetesmellitus.
nsubj||sans-18/VBZ||concerns-1/NNS	amod||results-4/NNS||false-positivehiv-3/JJ	prep_about||concerns-1/NNS||results-4/NNS	vmod||results-4/NNS||led-5/VBN	det||review-8/NN||a-7/DT	prep_to||led-5/VBN||review-8/NN	nn||procedures-11/NNS||testing-10/NN	prep_of||review-8/NN||procedures-11/NNS	vmod||procedures-11/NNS||used-12/VBN	det||decins-17/NNS||a-14/DT	amod||decins-17/NNS||mã-15/JJ	num||decins-17/NNS||©-16/CD	prep_in||used-12/VBN||decins-17/NNS	root||ROOT-0/null||sans-18/VBZ	number||¨-20/CD||frontiã-19/CD	num||programme-26/NN||¨-20/CD	nn||programme-26/NN||res-21/NNP	appos||programme-26/NN||msf-23/NN	nn||programme-26/NN||hiv-25/NN	dobj||sans-18/VBZ||programme-26/NN	amod||republic-32/NN||bukavu-28/JJ	amod||republic-32/NN||eastern-30/JJ	amod||republic-32/NN||democratic-31/JJ	prep_in||programme-26/NN||republic-32/NN	prep_of||republic-32/NN||congo-34/NN	positivehiv--1||hiv-25||no||concerns about false-positivehiv results led to a review of testing procedures used in a mã©decins sans frontiã¨res (msf) hiv programme in bukavu, eastern democratic republic of congo.
det||patient-2/NN||the-1/DT	nsubjpass||diagnosed-4/VBN||patient-2/NN	auxpass||diagnosed-4/VBN||was-3/VBD	root||ROOT-0/null||diagnosed-4/VBN	amod||endophthalmitis-7/NNS||postoperative-6/JJ	prep_with||diagnosed-4/VBN||endophthalmitis-7/NNS	amod||endophthalmitis-7/NNS||secondary-8/JJ	det||strain-13/NN||a-10/DT	advmod||resistant-12/JJ||highly-11/RB	amod||strain-13/NN||resistant-12/JJ	prep_to||secondary-8/JJ||strain-13/NN	amod||uberis-16/NNS||streptococcus-15/JJ	prep_of||strain-13/NN||uberis-16/NNS	nsubj||respond-20/VB||uberis-16/NNS	aux||respond-20/VB||did-18/VBD	neg||respond-20/VB||not-19/RB	rcmod||uberis-16/NNS||respond-20/VB	amod||antibiotics-23/NNS||intravitreal-22/JJ	prep_to||respond-20/VB||antibiotics-23/NNS	endophthalmitis-7||antibiotics-23||no_rel||the patient was diagnosed with postoperative endophthalmitis secondary to a highly resistant strain of streptococcus uberis that did not respond to intravitreal antibiotics.
det||infusion-5/NN||an-2/DT	amod||infusion-5/NN||intravenous-3/JJ	nn||infusion-5/NN||alteplase-4/NN	prep_after||complained-13/VBD||infusion-5/NN	num||h-7/NN||2.5-6/CD	npadvmod||later-8/RBR||h-7/NN	advmod||infusion-5/NN||later-8/RBR	det||patient-11/NN||the-10/DT	nsubj||complained-13/VBD||patient-11/NN	advmod||complained-13/VBD||first-12/RB	root||ROOT-0/null||complained-13/VBD	prep_of||complained-13/VBD||numbness-15/NNS	poss||arm-19/NN||his-17/PRP$	amod||arm-19/NN||right-18/JJ	prep_in||numbness-15/NNS||arm-19/NN	advmod||complained-13/VBD||then-21/RB	nn||pain-23/NN||neck-22/NN	dobj||complained-13/VBD||pain-23/NN	amod||numbness-29/NNS||left-27/JJ	nn||numbness-29/NNS||leg-28/NN	prep_followed_by||pain-23/NN||numbness-29/NNS	advmod||progressing-32/VBG||slowly-31/RB	dobj||complained-13/VBD||progressing-32/VBG	conj_and||pain-23/NN||progressing-32/VBG	dobj||progressing-32/VBG||paraparesis-33/NNS	pain-23||alteplase-4||no_rel||after an intravenous alteplase infusion 2.5 h later, the patient first complained of numbness in his right arm, then neck pain, followed by left leg numbness and slowly progressing paraparesis.
det||time-2/NN||the-1/DT	nsubj||shorter-17/JJR||time-2/NN	nsubj||aldrete-25/JJ||time-2/NN	prep_to||time-2/NN||response-4/NN	amod||stimuli-7/NNS||painful-6/JJ	prep_to||time-2/NN||stimuli-7/NNS	amod||commands-11/NNS||obeying-9/JJ	amod||commands-11/NNS||verbal-10/JJ	prep_to||time-2/NN||commands-11/NNS	conj_and||stimuli-7/NNS||commands-11/NNS	amod||opening-15/NN||spontaneous-13/JJ	nn||opening-15/NN||eye-14/NN	prep_to||time-2/NN||opening-15/NN	conj_and||stimuli-7/NNS||opening-15/NN	cop||shorter-17/JJR||was-16/VBD	root||ROOT-0/null||shorter-17/JJR	dep||shorter-17/JJR||p-19/VBN	dep||0.001-21/CD||=-20/SYM	ccomp||p-19/VBN||0.001-21/CD	advmod||aldrete-25/JJ||modified-24/RB	conj_and||shorter-17/JJR||aldrete-25/JJ	nsubj||higher-28/JJR||score-26/NN	cop||higher-28/JJR||was-27/VBD	ccomp||aldrete-25/JJ||higher-28/JJR	amod||anesthesia-31/NN||desflurane-30/JJ	prep_after||higher-28/JJR||anesthesia-31/NN	prep||higher-28/JJR||than-32/IN	pcomp||than-32/IN||after-33/IN	amod||anesthesia-35/NN||sevoflurane-34/JJ	pobj||after-33/IN||anesthesia-35/NN	dep||shorter-17/JJR||p-37/VBN	dep||0.049-39/CD||=-38/SYM	ccomp||p-37/VBN||0.049-39/CD	painful-6||desflurane-30||yes||the time to response to painful stimuli, obeying verbal commands and spontaneous eye opening was shorter ( p = 0.001) and modified aldrete score was higher after desflurane anesthesia than after sevoflurane anesthesia ( p = 0.049).
amod||spirochetes-2/NNS||lymedisease-1/JJ	nsubj||similar-5/JJ||spirochetes-2/NNS	cop||similar-5/JJ||are-3/VBP	advmod||similar-5/JJ||also-4/RB	root||ROOT-0/null||similar-5/JJ	prep_to||similar-5/JJ||borrelia-7/NN	cop||bacteria-13/NNS||being-9/VBG	amod||bacteria-13/NNS||microaerophilic-10/JJ	amod||bacteria-13/NNS||catalase-negative-12/JJ	prepc_in||borrelia-7/NN||bacteria-13/NNS	lymedisease-1||bacteria-13||no||lymedisease spirochetes are also similar to borrelia in being microaerophilic, catalase-negative bacteria.
det||distribution-2/NN||the-1/DT	nsubj||is-15/VBZ||distribution-2/NN	nsubjpass||associated-23/VBN||distribution-2/NN	prep_of||distribution-2/NN||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	det||populations-10/NNS||the-9/DT	prep_in||hepatitisbvirus-4/NNS||populations-10/NNS	nn||asia-14/NN||island-12/NN	nn||asia-14/NN||southeast-13/NN	prep_of||populations-10/NNS||asia-14/NN	root||ROOT-0/null||is-15/VBZ	amod||interest-20/NN||medical-17/JJ	conj_and||medical-17/JJ||anthropological-19/JJ	amod||interest-20/NN||anthropological-19/JJ	prep_of||is-15/VBZ||interest-20/NN	auxpass||associated-23/VBN||is-22/VBZ	conj_and||is-15/VBZ||associated-23/VBN	det||diversity-29/NN||an-25/DT	advmod||high-27/JJ||unusually-26/RB	amod||diversity-29/NN||high-27/JJ	amod||diversity-29/NN||genetic-28/JJ	prep_with||associated-23/VBN||diversity-29/NN	hbv-6||hepatitisbvirus-4||no||the distribution of hepatitisbvirus (hbv) in the populations of island southeast asia is of medical and anthropological interest and is associated with an unusually high genetic diversity.
det||gas-19/NN||the-1/DT	nn||gas-19/NN||impacts-2/NNS	amod||treatments-5/NNS||post-metallisation-4/JJ	prep_of||impacts-2/NNS||treatments-5/NNS	amod||acid-9/NN||phosphoric-8/JJ	prep_such_as||treatments-5/NNS||acid-9/NN	appos||impacts-2/NNS||h3po4-11/NNP	amod||gas-19/NN||etching-13/JJ	dep||gas-19/NN||nitrogen-15/NN	appos||gas-19/NN||n2-17/NNP	nsubj||anneal-20/VBP||gas-19/NN	root||ROOT-0/null||anneal-20/VBP	dep||investigated-39/VBN||forming-22/VBG	dobj||forming-22/VBG||gas-23/NN	appos||gas-23/NN||ar-25/NN	num||ar-25/NN||h2-26/CD	amod||gas-23/NN||anneal-28/JJ	det||$-32/$||the-30/DT	amod||$-32/$||cellsâ-31/JJ	prep_on||anneal-28/JJ||$-32/$	num||$-32/$||™-33/CD	amod||properties-37/NNS||electrical-34/JJ	conj_and||electrical-34/JJ||photovoltaic-36/JJ	amod||properties-37/NNS||photovoltaic-36/JJ	nsubjpass||investigated-39/VBN||properties-37/NNS	auxpass||investigated-39/VBN||are-38/VBP	conj_and||anneal-20/VBP||investigated-39/VBN	ar-25||gas-23||no_rel||the impacts of post-metallisation treatments such as phosphoric acid (h3po4) etching, nitrogen (n2) gas anneal and forming gas (ar h2) anneal on the cellsâ€™ electrical and photovoltaic properties are investigated.
amod||as2o3-3/NNS||arsenictrioxide-1/JJ	nsubj||triggers-11/VBZ||as2o3-3/NNS	vmod||as2o3-3/NNS||used-6/VBN	aux||treat-8/VB||to-7/TO	xcomp||used-6/VBN||treat-8/VB	dobj||treat-8/VB||promyelocyticleukemia-9/NN	root||ROOT-0/null||triggers-11/VBZ	nn||death-13/NN||cell-12/NN	dobj||triggers-11/VBZ||death-13/NN	amod||mechanisms-16/NNS||unknown-15/JJ	prep_via||death-13/NN||mechanisms-16/NNS	promyelocyticleukemia-9||as2o3-3||yes||arsenictrioxide (as2o3), used to treat promyelocyticleukemia, triggers cell death via unknown mechanisms.
num||cycles-3/NNS||twelve-2/CD	prep_after||revealed-11/VBD||cycles-3/NNS	amod||chemotherapy-6/NN||oxaliplatin-capecitabine-5/JJ	prep_of||cycles-3/NNS||chemotherapy-6/NN	amod||tomography-10/NN||abdominopelvic-8/JJ	amod||tomography-10/NN||computed-9/JJ	nsubj||revealed-11/VBD||tomography-10/NN	root||ROOT-0/null||revealed-11/VBD	amod||shrinkage-13/NN||marked-12/JJ	nsubj||showed-22/VBD||shrinkage-13/NN	det||metastases-17/NNS||the-15/DT	nn||metastases-17/NNS||liver-16/NN	prep_of||shrinkage-13/NN||metastases-17/NNS	nn||tomography-21/NN||positron-19/NN	nn||tomography-21/NN||emission-20/NN	prep_of||shrinkage-13/NN||tomography-21/NN	conj_and||metastases-17/NNS||tomography-21/NN	ccomp||revealed-11/VBD||showed-22/VBD	neg||uptake-24/NN||no-23/DT	dobj||showed-22/VBD||uptake-24/NN	amod||fdg-28/NN||18f-fluoro-deoxy-glucose-26/JJ	prep_of||uptake-24/NN||fdg-28/NN	advmod||fdg-28/NN||either-30/RB	det||liver-33/NN||the-32/DT	prep_in||showed-22/VBD||liver-33/NN	prep_in||showed-22/VBD||peritoneum-35/NN	conj_or||liver-33/NN||peritoneum-35/NN	amod||uptake-38/NN||localized-37/VBN	prep_except||liver-33/NN||uptake-38/NN	det||colon-42/NN||the-40/DT	amod||colon-42/NN||sigmoid-41/JJ	prep_in||uptake-38/NN||colon-42/NN	oxaliplatin--1||metastases-17||no_rel||after twelve cycles of oxaliplatin-capecitabine chemotherapy, abdominopelvic computed tomography revealed marked shrinkage of the liver metastases and positron emission tomography showed no uptake of 18f-fluoro-deoxy-glucose (fdg) either in the liver or peritoneum except localized uptake in the sigmoid colon.
det||kits-5/NNS||the-1/DT	num||kits-5/NNS||70-2/CD	amod||kits-5/NNS||hbsag-3/JJ	nn||kits-5/NNS||test-4/NN	nsubjpass||evaluated-11/VBN||kits-5/NNS	advmod||world-9/NN||around-7/RB	det||world-9/NN||the-8/DT	prep_from||kits-5/NNS||world-9/NN	auxpass||evaluated-11/VBN||were-10/VBD	root||ROOT-0/null||evaluated-11/VBN	amod||a-f-56/NNS||comparatively-12/RB	poss||sensitivity-16/NN||their-14/PRP$	amod||sensitivity-16/NN||clinical-15/JJ	prep_for||comparatively-12/RB||sensitivity-16/NN	amod||sensitivity-19/NN||analytical-18/JJ	prep_for||comparatively-12/RB||sensitivity-19/NN	conj_and||sensitivity-16/NN||sensitivity-19/NN	prep_for||comparatively-12/RB||sensitivity-21/NN	conj_and||sensitivity-16/NN||sensitivity-21/NN	nn||genotypes-24/NNS||hbv-23/NN	prep_to||sensitivity-21/NN||genotypes-24/NNS	nn||subtypes-27/NNS||hbsag-26/NN	prep_to||sensitivity-21/NN||subtypes-27/NNS	conj_and||genotypes-24/NNS||subtypes-27/NNS	prep_for||comparatively-12/RB||specificity-30/NN	conj_and||sensitivity-16/NN||specificity-30/NN	vmod||specificity-30/NN||using-31/VBG	amod||icbs-43/NNS||394-32/JJ	num||clinical-35/NNS||146-34/CD	dep||icbs-43/NNS||clinical-35/NNS	num||analytical-38/NNS||48-37/CD	conj_and||clinical-35/NNS||analytical-38/NNS	dep||icbs-43/NNS||analytical-38/NNS	num||negative-41/NN||200-40/CD	conj_and||clinical-35/NNS||negative-41/NN	dep||icbs-43/NNS||negative-41/NN	dobj||using-31/VBG||icbs-43/NNS	nn||members-46/NNS||master-44/NN	nn||members-46/NNS||panel-45/NN	dep||specificity-30/NN||members-46/NNS	amod||origin-50/NN||diverse-48/JJ	amod||origin-50/NN||geographical-49/JJ	prep_of||members-46/NNS||origin-50/NN	vmod||origin-50/NN||comprising-51/VBG	det||genotypes-55/NNS||the-52/DT	amod||genotypes-55/NNS||major-53/JJ	nn||genotypes-55/NNS||hbv-54/NN	dobj||comprising-51/VBG||genotypes-55/NNS	dobj||evaluated-11/VBN||a-f-56/NNS	det||subtypes-60/NNS||the-58/DT	amod||subtypes-60/NNS||hbsag-59/VBG	dobj||evaluated-11/VBN||subtypes-60/NNS	conj_and||a-f-56/NNS||subtypes-60/NNS	amod||subtypes-60/NNS||adw2-61/JJ	dep||adw2-61/JJ||,4-62/CD	num||,4-62/CD||adr-64/CD	dep||adw2-61/JJ||ayw1-4-66/CD	conj_and||,4-62/CD||ayw1-4-66/CD	hbv-54||hbsag-59||yes||the 70 hbsag test kits from around the world were evaluated comparatively for their clinical sensitivity, analytical sensitivity, sensitivity to hbv genotypes and hbsag subtypes, and specificity using 394 (146 clinical, 48 analytical and 200 negative) icbs master panel members of diverse geographical origin comprising the major hbv genotypes a-f and the hbsag subtypes adw2,4 , adr and ayw1-4 .
nsubj||1.9-22/CD||incidence-1/NN	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||incidence-1/NN||pancreatitis-4/NNS	det||group-9/NN||the-6/DT	amod||group-9/NN||nondiabetic-7/JJ	nn||group-9/NN||control-8/NN	prep_in||pancreatitis-4/NNS||group-9/NN	amod||group-13/NN||diabetic-11/JJ	nn||group-13/NN||control-12/NN	prep_in||pancreatitis-4/NNS||group-13/NN	conj_and||group-9/NN||group-13/NN	amod||group-16/NN||exenatide-15/JJ	prep_in||pancreatitis-4/NNS||group-16/NN	conj_and||group-9/NN||group-16/NN	nn||group-20/NN||sitagliptin-19/NN	prep_in||pancreatitis-4/NNS||group-20/NN	conj_and||group-9/NN||group-20/NN	cop||1.9-22/CD||was-21/VBD	root||ROOT-0/null||1.9-22/CD	conj_and||1.9-22/CD||5.6-24/CD	conj_and||1.9-22/CD||5.7-26/CD	num||cases-30/NNS||5.6-29/CD	conj_and||1.9-22/CD||cases-30/NNS	num||years-34/NNS||1,000-32/CD	amod||years-34/NNS||patient-33/JJ	prep_per||cases-30/NNS||years-34/NNS	advmod||1.9-22/CD||respectively-36/RB	pancreatitis-4||sitagliptin-19||no_rel||incidence of acute pancreatitis in the nondiabetic control group, diabetic control group, exenatide group, and sitagliptin group was 1.9, 5.6, 5.7, and 5.6 cases per 1,000 patient years, respectively.
amod||guidelines-2/NNS||clinical-1/JJ	nsubj||recommend-21/VBP||guidelines-2/NNS	det||management-5/NN||the-4/DT	prep_for||guidelines-2/NNS||management-5/NN	prep_of||management-5/NN||bipolaraffectivedisorder-7/NN	vmod||bipolaraffectivedisorder-7/NN||published-8/VBN	det||institute-12/NN||the-10/DT	amod||institute-12/NN||national-11/JJ	agent||published-8/VBN||institute-12/NN	nn||excellence-17/NN||health-14/NN	conj_and||health-14/NN||clinical-16/JJ	nn||excellence-17/NN||clinical-16/JJ	prep_for||institute-12/NN||excellence-17/NN	dep||excellence-17/NN||nice-19/JJ	root||ROOT-0/null||recommend-21/VBP	dobj||recommend-21/VBP||checks-22/NNS	amod||function-27/NN||renal-24/JJ	conj_and||renal-24/JJ||thyroid-26/JJ	amod||function-27/NN||thyroid-26/JJ	prep_of||checks-22/NNS||function-27/NN	mark||prescribed-31/VBN||before-28/IN	nsubjpass||prescribed-31/VBN||lithium-29/NN	auxpass||prescribed-31/VBN||is-30/VBZ	advcl||recommend-21/VBP||prescribed-31/VBN	bipolaraffectivedisorder-7||lithium-29||yes||clinical guidelines for the management of bipolaraffectivedisorder published by the national institute for health and clinical excellence (nice) recommend checks of renal and thyroid function before lithium is prescribed.
advmod||associated-8/VBN||however-1/RB	det||haplotype-4/NN||this-3/DT	nsubjpass||associated-8/VBN||haplotype-4/NN	auxpass||associated-8/VBN||was-5/VBD	neg||associated-8/VBN||not-6/RB	advmod||associated-8/VBN||significantly-7/RB	root||ROOT-0/null||associated-8/VBN	amod||phenotypes-11/NNS||obesity-10/JJ	nsubj||suggesting-25/VBG||phenotypes-11/NNS	amod||mass-17/NN||bmi-14/JJ	conj_or||bmi-14/JJ||fat-16/JJ	amod||mass-17/NN||fat-16/JJ	prep_including||suggesting-25/VBG||mass-17/NN	dep||mass-17/NN||p-19/VBN	num||0.05-21/CD||>-20/CD	dobj||p-19/VBN||0.05-21/CD	advmod||suggesting-25/VBG||thereby-24/RB	prepc_with||associated-8/VBN||suggesting-25/VBG	mark||independent-33/JJ||that-26/IN	poss||association-28/NN||its-27/PRP$	nsubj||independent-33/JJ||association-28/NN	nn||pressure-31/NN||blood-30/NN	prep_with||association-28/NN||pressure-31/NN	cop||independent-33/JJ||was-32/VBD	ccomp||suggesting-25/VBG||independent-33/JJ	amod||phenotypes-36/NNS||obesity-35/JJ	prep_of||independent-33/JJ||phenotypes-36/NNS	fat-16||obesity-35||no_rel||however, this haplotype was not significantly associated with obesity phenotypes, including bmi or fat mass ( p >0.05), thereby suggesting that its association with blood pressure was independent of obesity phenotypes.
nsubj||gambiae-2/VBP||anopheles-1/NNS	ccomp||developed-11/VBN||gambiae-2/VBP	det||vector-7/NN||the-4/DT	amod||vector-7/NN||main-5/JJ	nn||vector-7/NN||malaria-6/NN	nsubj||developed-11/VBN||vector-7/NN	prep_in||vector-7/NN||benin-9/NN	aux||developed-11/VBN||has-10/VBZ	root||ROOT-0/null||developed-11/VBN	amod||level-13/NN||high-12/JJ	dobj||developed-11/VBN||level-13/NN	prep_of||level-13/NN||resistance-15/NN	amod||insecticides-18/NNS||pyrethroid-17/JJ	prep_to||developed-11/VBN||insecticides-18/NNS	nsubj||concern-24/NN||insecticides-18/NNS	cop||concern-24/NN||is-21/VBZ	det||concern-24/NN||a-22/DT	amod||concern-24/NN||serious-23/JJ	rcmod||insecticides-18/NNS||concern-24/NN	det||use-28/NN||the-26/DT	amod||use-28/NN||future-27/JJ	prep_to||concern-24/NN||use-28/NN	amod||nets-32/NNS||long-lasting-30/JJ	amod||nets-32/NNS||insecticidal-31/JJ	prep_of||use-28/NN||nets-32/NNS	appos||nets-32/NNS||llin-34/NN	amod||spraying-39/NNS||indoor-37/JJ	amod||spraying-39/NNS||residual-38/JJ	prep_of||use-28/NN||spraying-39/NNS	conj_and||nets-32/NNS||spraying-39/NNS	appos||nets-32/NNS||irs-41/NN	insecticides-18||malaria-6||no_rel||anopheles gambiae , the main malaria vector in benin has developed high level of resistance to pyrethroid insecticides, which is a serious concern to the future use of long-lasting insecticidal nets (llin) and indoor residual spraying (irs).
nn||self-management-2/NN||diabetes-1/NN	nsubjpass||assessed-6/VBN||self-management-2/NN	conj_and||self-management-2/NN||education-4/NN	nsubjpass||assessed-6/VBN||education-4/NN	auxpass||assessed-6/VBN||was-5/VBD	root||ROOT-0/null||assessed-6/VBN	agent||assessed-6/VBN||asking-8/VBG	advmod||recognized-11/VBD||how-9/WRB	nsubj||recognized-11/VBD||patients-10/NNS	nsubj||responded-13/VBD||patients-10/NNS	advcl||asking-8/VBG||recognized-11/VBD	advcl||asking-8/VBG||responded-13/VBD	conj_and||recognized-11/VBD||responded-13/VBD	prep_to||recognized-11/VBD||hypo-15/NN	prep_to||recognized-11/VBD||hyperglycaemia-18/NN	conj_and||hypo-15/NN||hyperglycaemia-18/NN	mark||developed-24/VBN||if-21/IN	nsubj||developed-24/VBN||they-22/PRP	aux||developed-24/VBN||had-23/VBD	advcl||asking-8/VBG||developed-24/VBN	conj_and||recognized-11/VBD||developed-24/VBN	dobj||developed-24/VBN||strategies-25/NNS	aux||maintain-27/VB||to-26/TO	vmod||developed-24/VBN||maintain-27/VB	amod||levels-31/NNS||stable-28/JJ	nn||levels-31/NNS||blood-29/NN	nn||levels-31/NNS||glucose-30/NN	dobj||maintain-27/VB||levels-31/NNS	hyperglycaemia-18||glucose-30||no||diabetes self-management and education was assessed by asking how patients recognized and responded to hypo- and hyperglycaemia, and if they had developed strategies to maintain stable blood glucose levels.
det||evidence-2/NN||the-1/DT	nsubj||parasitophorous-4/VBZ||evidence-2/NN	nsubj||suggests-23/VBZ||evidence-2/NN	rcmod||evidence-2/NN||parasitophorous-4/VBZ	amod||swelling-6/NNS||vacuole-5/JJ	nsubj||dependent-15/JJ||swelling-6/NNS	det||stage-9/NN||a-8/DT	appos||swelling-6/NNS||stage-9/NN	amod||egress-12/NNS||unaffected-11/JJ	prep_of||stage-9/NN||egress-12/NNS	cop||dependent-15/JJ||is-14/VBZ	ccomp||parasitophorous-4/VBZ||dependent-15/JJ	det||rise-18/NN||a-17/DT	prep_upon||dependent-15/JJ||rise-18/NN	amod||+-22/NNS||intracellular-20/JJ	amod||+-22/NNS||ca2-21/JJ	prep_in||rise-18/NN||+-22/NNS	root||ROOT-0/null||suggests-23/VBZ	det||mechanism-25/NN||a-24/DT	dobj||suggests-23/VBZ||mechanism-25/NN	amod||egress-28/NNS||ionophore-inducible-27/JJ	prep_for||mechanism-25/NN||egress-28/NNS	det||target-32/NN||a-30/DT	amod||target-32/NN||new-31/JJ	dobj||suggests-23/VBZ||target-32/NN	conj_and||mechanism-25/NN||target-32/NN	amod||+-35/NNS||ca2-34/JJ	prep_for||target-32/NN||+-35/NNS	det||programme-38/NN||the-37/DT	npadvmod||liberating-39/JJ||programme-38/NN	amod||parasites-40/NNS||liberating-39/JJ	prep_in||+-35/NNS||parasites-40/NNS	det||cell-44/NN||the-42/DT	nn||cell-44/NN||host-43/NN	prep_from||suggests-23/VBZ||cell-44/NN	rise-18||swelling-6||no_rel||the evidence that parasitophorous vacuole swelling, a stage of unaffected egress, is dependent upon a rise in intracellular ca2+ suggests a mechanism for ionophore-inducible egress and a new target for ca2+ in the programme liberating parasites from the host cell.
amod||m.tb-2/NN||rifampin-resistant-1/JJ	nsubjpass||found-37/VBN||m.tb-2/NN	dep||m.tb-2/NN||nâ-4/NN	num||â-8/NN||$-5/$	number||=-7/CD||š-6/CD	num||$-5/$||=-7/CD	dep||nâ-4/NN||â-8/NN	dep||â-8/NN||$-9/$	num||$-9/$||š41-10/CD	conj_and||m.tb-2/NN||tb-iris-13/NNS	nsubjpass||found-37/VBN||tb-iris-13/NNS	dep||tb-iris-13/NNS||nâ-15/NN	num||â-19/NN||$-16/$	number||=-18/CD||š-17/CD	num||$-16/$||=-18/CD	dep||nâ-15/NN||â-19/NN	dep||â-19/NN||$-20/$	num||$-20/$||š51-21/CD	npadvmod||resistant-25/JJ||drug-24/NN	amod||bacterialinfections-26/NNS||resistant-25/JJ	conj_and||m.tb-2/NN||bacterialinfections-26/NNS	nsubjpass||found-37/VBN||bacterialinfections-26/NNS	dep||m.tb-2/NN||nâ-28/NN	num||â-32/NN||$-29/$	number||=-31/CD||š-30/CD	num||$-29/$||=-31/CD	dep||nâ-28/NN||â-32/NN	dep||â-32/NN||$-33/$	num||$-33/$||š12-34/CD	auxpass||found-37/VBN||were-36/VBD	root||ROOT-0/null||found-37/VBN	num||%-40/NN||12-39/CD	prep_in||found-37/VBN||%-40/NN	num||%-43/NN||14-42/CD	prep_in||found-37/VBN||%-43/NN	conj_and||%-40/NN||%-43/NN	num||%-46/NN||3.4-45/CD	prep_in||found-37/VBN||%-46/NN	conj_and||%-40/NN||%-46/NN	det||cases-50/NNS||the-48/DT	amod||cases-50/NNS||352-49/JJ	prep_of||%-46/NN||cases-50/NNS	advmod||found-37/VBN||respectively-52/RB	bacterialinfections-26||rifampin--1||yes||rifampin-resistant m.tb (nâ€š=â€š41), tb-iris (nâ€š=â€š51) and drug resistant bacterialinfections (nâ€š=â€š12) were found in 12%, 14% and 3.4% of the 352 cases, respectively.
nsubj||have-3/VB||dronedarone-1/NN	aux||have-3/VB||may-2/MD	root||ROOT-0/null||have-3/VB	det||role-5/NN||a-4/DT	dobj||have-3/VB||role-5/NN	nn||control-10/NN||rate-7/NN	conj_and||rate-7/NN||rhythm-9/NN	nn||control-10/NN||rhythm-9/NN	prep_in||role-5/NN||control-10/NN	prep_for||have-3/VB||patients-12/NNS	prep_with||patients-12/NNS||atrialfibrillation-14/NN	dronedarone-1||atrialfibrillation-14||no_rel||dronedarone may have a role in rate and rhythm control for patients with atrialfibrillation.
expl||is-3/VBZ||there-1/EX	advmod||is-3/VBZ||still-2/RB	root||ROOT-0/null||is-3/VBZ	det||lack-5/NN||a-4/DT	nsubj||is-3/VBZ||lack-5/NN	amod||studies-8/NNS||prospective-7/JJ	prep_of||lack-5/NN||studies-8/NNS	nn||development-12/NN||bone-10/NN	nn||development-12/NN||mineral-11/NN	prep_on||studies-8/NNS||development-12/NN	prep_in||development-12/NN||patients-14/NNS	det||history-17/NN||a-16/DT	prep_with||patients-14/NNS||history-17/NN	amod||anorexianervosa-21/NN||early-19/JJ	nn||anorexianervosa-21/NN||onset-20/NN	prep_of||history-17/NN||anorexianervosa-21/NN	dep||anorexianervosa-21/NN||an-23/DT	mineral-11||anorexianervosa-21||no_rel||there still is a lack of prospective studies on bone mineral development in patients with a history of early onset anorexianervosa (an).
quantmod||70-2/CD||approximately-1/RB	num||%-3/NN||70-2/CD	nsubj||express-6/VBP||%-3/NN	prep_of||%-3/NN||breasttumors-5/NNS	root||ROOT-0/null||express-6/VBP	det||receptor-9/NN||the-7/DT	nn||receptor-9/NN||estrogen-8/NN	dobj||express-6/VBP||receptor-9/NN	appos||receptor-9/NN||er-11/NN	breasttumors-5||estrogen-8||no||approximately 70% of breasttumors express the estrogen receptor (er).
nsubjpass||caused-3/VBN||type1diabetesmellitus-1/NNS	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	amod||destruction-6/NN||immune-mediated-5/JJ	agent||caused-3/VBN||destruction-6/NN	amod||²-10/NNS||pancreatic-8/JJ	nn||²-10/NNS||î-9/NN	prep_of||destruction-6/NN||²-10/NNS	dep||destruction-6/NN||cells-12/NNS	vmod||cells-12/NNS||leading-13/VBG	nn||deficiency-16/NN||insulin-15/NN	prep_to||leading-13/VBG||deficiency-16/NN	amod||intermediary-19/JJ||impaired-18/JJ	amod||metabolism-20/NN||intermediary-19/JJ	agent||caused-3/VBN||metabolism-20/NN	conj_and||destruction-6/NN||metabolism-20/NN	amod||concentrations-26/NNS||elevated-23/JJ	nn||concentrations-26/NNS||blood-24/NN	nn||concentrations-26/NNS||glucose-25/NN	agent||caused-3/VBN||concentrations-26/NNS	conj_and||destruction-6/NN||concentrations-26/NNS	type1diabetesmellitus-1||insulin-15||yes||type1diabetesmellitus is caused by immune-mediated destruction of pancreatic î²-cells leading to insulin deficiency, impaired intermediary metabolism, and elevated blood glucose concentrations.
nsubj||signals-2/VBZ||it-1/PRP	root||ROOT-0/null||signals-2/VBZ	det||spreading-4/NN||the-3/DT	dobj||signals-2/VBZ||spreading-4/NN	amod||resistant-7/JJ||chloroquine-6/JJ	amod||strains-13/NNS||resistant-7/JJ	nn||strains-13/NNS||p.-8/NN	nn||strains-13/NNS||vivax-9/NN	nn||strains-13/NNS||-lrb--10/NNP	nn||strains-13/NNS||crpv-11/NNP	nn||strains-13/NNS||-rrb--12/NN	prep_of||spreading-4/NN||strains-13/NNS	amod||areas-17/NNS||malaria-15/JJ	amod||areas-17/NNS||endemic-16/JJ	prep_to||strains-13/NNS||areas-17/NNS	prep_of||areas-17/NNS||ethiopia-19/NN	malaria-15||chloroquine-6||yes||it signals the spreading of chloroquine resistant p. vivax -lrb- crpv -rrb- strains to malaria endemic areas of ethiopia .
advmod||tested-3/VBD||here-1/RB	nsubj||tested-3/VBD||we-2/PRP	root||ROOT-0/null||tested-3/VBD	mark||express-10/VBP||whether-4/IN	amod||mice-9/NNS||nk1r-5/JJ	dep||mice-9/NNS||/-7/NNP	nsubj||express-10/VBP||mice-9/NNS	ccomp||tested-3/VBD||express-10/VBP	amod||features-13/NNS||other-11/JJ	nn||features-13/NNS||core-12/NN	dobj||express-10/VBP||features-13/NNS	prep_of||features-13/NNS||adhd-15/NN	appos||adhd-15/NN||impulsivity-17/NN	appos||adhd-15/NN||inattentiveness-19/NNS	conj_and||impulsivity-17/NN||inattentiveness-19/NNS	ccomp||tested-3/VBD||if-23/IN	conj_and||express-10/VBP||if-23/IN	advmod||if-23/IN||so-24/RB	mark||diminished-29/VBN||whether-26/IN	nsubjpass||diminished-29/VBN||they-27/PRP	auxpass||diminished-29/VBN||are-28/VBP	ccomp||if-23/IN||diminished-29/VBN	agent||diminished-29/VBN||d-31/SYM	dep||d-31/SYM||amphetamine-33/NN	advmod||amphetamine-33/NN||as-35/RB	prep_in||as-35/RB||adhd-37/JJ	adhd-37||amphetamine-33||yes||here we tested whether nk1r-/- mice express other core features of adhd (impulsivity and inattentiveness) and, if so, whether they are diminished by d -amphetamine, as in adhd.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||recently-3/RB	root||ROOT-0/null||shown-4/VBN	mark||induces-13/VBZ||that-5/IN	det||meal-12/NN||a-6/DT	amod||meal-12/NN||high-fat-7/JJ	nn||meal-12/NN||high-carbohydrate-8/NN	dep||meal-12/NN||hfhc-10/JJ	nsubj||induces-13/VBZ||meal-12/NN	ccomp||shown-4/VBN||induces-13/VBZ	det||increase-15/NN||an-14/DT	dobj||induces-13/VBZ||increase-15/NN	nn||concentrations-18/NNS||plasma-17/NN	prep_in||increase-15/NN||concentrations-18/NNS	prep_of||concentrations-18/NNS||endotoxin-20/NN	amod||-RSB--25/NNP||lipopolysaccharide-22/JJ	nn||-RSB--25/NNP||-LSB--23/NNP	nn||-RSB--25/NNP||lps-24/NN	appos||endotoxin-20/NN||-RSB--25/NNP	det||expression-29/NN||the-28/DT	prep_in||increase-15/NN||expression-29/NN	conj_and||concentrations-18/NNS||expression-29/NN	amod||receptor-4-32/NN||toll-like-31/JJ	prep_of||expression-29/NN||receptor-4-32/NN	dep||receptor-4-32/NN||tlr-4-34/JJ	dobj||induces-13/VBZ||suppresser-37/NN	conj_and||increase-15/NN||suppresser-37/NN	amod||socs3-42/NNS||cytokine-39/JJ	amod||socs3-42/NNS||signaling-3-40/JJ	prep_of||suppresser-37/NN||socs3-42/NNS	nn||cells-46/NNS||mononuclear-45/NN	prep_in||socs3-42/NNS||cells-46/NNS	appos||cells-46/NNS||mncs-48/NNS	prep_in||cells-46/NNS||addition-51/NN	amod||stress-54/NN||oxidative-53/JJ	prep_to||induces-13/VBZ||stress-54/NN	amod||inflammation-57/NN||cellular-56/JJ	prep_to||induces-13/VBZ||inflammation-57/NN	conj_and||stress-54/NN||inflammation-57/NN	inflammation-57||fat--1||no_rel||we have recently shown that a high-fat high-carbohydrate (hfhc) meal induces an increase in plasma concentrations of endotoxin (lipopolysaccharide [lps]) and the expression of toll-like receptor-4 (tlr-4) and suppresser of cytokine signaling-3 (socs3) in mononuclear cells (mncs) in addition to oxidative stress and cellular inflammation.
nsubj||had-9/VBD||thirty-nine-1/NN	amod||participants-4/NNS||137-3/JJ	prep_of||thirty-nine-1/NN||participants-4/NNS	num||%-7/NN||28-6/CD	appos||participants-4/NNS||%-7/NN	root||ROOT-0/null||had-9/VBD	det||uti-12/NN||an-10/DT	amod||uti-12/NN||antibiotic-treated-11/JJ	dobj||had-9/VBD||uti-12/NN	dep||uti-12/NN||25-14/CD	det||group-18/NN||the-16/DT	nn||group-18/NN||cranberry-17/NN	prep_in||25-14/CD||group-18/NN	dep||uti-12/NN||14-20/CD	conj_and||25-14/CD||14-20/CD	det||group-24/NN||the-22/DT	nn||group-24/NN||trimethoprim-23/NN	prep_in||14-20/CD||group-24/NN	nsubj||risk-31/VBP||difference-27/NN	prep_in||difference-27/NN||proportions-29/NNS	advmod||risk-31/VBP||relative-30/JJ	parataxis||had-9/VBD||risk-31/VBP	nsubj||p-41/VBP||1.616-32/CD	num||%-35/NN||95-34/CD	dep||1.616-32/CD||%-35/NN	dep||%-35/NN||ci-36/NNP	num||ci-36/NNP||0.93-37/CD	num||ci-36/NNP||2.79-39/CD	ccomp||risk-31/VBP||p-41/VBP	dep||0.084-43/CD||=-42/SYM	ccomp||p-41/VBP||0.084-43/CD	uti-12||trimethoprim-23||yes||thirty-nine of 137 participants (28%) had an antibiotic-treated uti (25 in the cranberry group and 14 in the trimethoprim group); difference in proportions relative risk 1.616 (95% ci 0.93, 2.79) p = 0.084.
det||improvement-2/NN||the-1/DT	nsubj||suggests-14/VBZ||improvement-2/NN	det||effect-6/NN||the-4/DT	amod||effect-6/NN||protective-5/JJ	prep_of||improvement-2/NN||effect-6/NN	prep_of||effect-6/NN||bcgvaccine-8/NN	vmod||bcgvaccine-8/NN||mediated-9/VBN	det||booster-13/NN||a-11/DT	amod||booster-13/NN||dna-hsp65-12/JJ	agent||mediated-9/VBN||booster-13/NN	root||ROOT-0/null||suggests-14/VBZ	mark||hold-19/VB||that-15/IN	poss||strategy-17/NN||our-16/PRP$	nsubj||hold-19/VB||strategy-17/NN	aux||hold-19/VB||may-18/MD	ccomp||suggests-14/VBZ||hold-19/VB	dobj||hold-19/VB||promise-20/NN	det||vaccine-26/NN||a-22/DT	amod||vaccine-26/NN||safe-23/JJ	conj_and||safe-23/JJ||effective-25/JJ	amod||vaccine-26/NN||effective-25/JJ	prep_as||hold-19/VB||vaccine-26/NN	prep_against||vaccine-26/NN||tb-28/NN	tb-28||bcgvaccine-8||no||the improvement of the protective effect of bcgvaccine mediated by a dna-hsp65 booster suggests that our strategy may hold promise as a safe and effective vaccine against tb.
amod||herpesvirus-2/NNS||human-1/JJ	nsubj||angiogenesis-21/VBZ||herpesvirus-2/NNS	appos||herpesvirus-2/NNS||hhv-4/NN	num||oncogenesis-8/NNS||-8-6/CD	amod||oncogenesis-8/NNS||associated-7/JJ	dep||herpesvirus-2/NNS||oncogenesis-8/NNS	det||state-11/NN||a-10/DT	appos||herpesvirus-2/NNS||state-11/NN	amod||impairment-14/NN||immune-13/JJ	prep_of||state-11/NN||impairment-14/NN	det||environment-19/NN||a-16/DT	amod||environment-19/NN||local-17/JJ	amod||environment-19/NN||inflammatory-18/JJ	appos||herpesvirus-2/NNS||environment-19/NN	root||ROOT-0/null||angiogenesis-21/VBZ	nsubj||factors-28/NNS||hivinfection-23/NN	vmod||hivinfection-23/NN||occurring-24/VBG	advmod||occurring-24/VBG||concurrently-25/RB	cop||factors-28/NNS||are-26/VBP	amod||factors-28/NNS||important-27/JJ	conj_and||angiogenesis-21/VBZ||factors-28/NNS	det||development-31/NN||the-30/DT	prep_for||factors-28/NNS||development-31/NN	amod||sarcoma-35/NN||hiv-associated-33/JJ	nn||sarcoma-35/NN||kaposi-34/NN	prep_of||development-31/NN||sarcoma-35/NN	appos||sarcoma-35/NN||ks-37/NN	hivinfection-23||hiv--1||no||human herpesvirus (hhv)-8 associated oncogenesis, a state of immune impairment, a local inflammatory environment, angiogenesis and hivinfection occurring concurrently are important factors for the development of hiv-associated kaposi sarcoma (ks).
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||propofol-46||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
nn||content-3/NN||bone-1/NN	nn||content-3/NN||mineral-2/NN	nsubj||different-21/JJ||content-3/NN	appos||content-3/NN||bmc-5/NN	nn||density-10/NN||bone-8/NN	nn||density-10/NN||mineral-9/NN	conj_and||content-3/NN||density-10/NN	nsubj||different-21/JJ||density-10/NN	appos||density-10/NN||bmd-12/NN	det||group-17/NN||the-15/DT	nn||group-17/NN||sle-16/NN	prep_in||density-10/NN||group-17/NN	cop||different-21/JJ||was-18/VBD	neg||different-21/JJ||not-19/RB	advmod||different-21/JJ||significantly-20/RB	root||ROOT-0/null||different-21/JJ	det||controls-24/NNS||the-23/DT	prep_from||different-21/JJ||controls-24/NNS	neg||relationship-28/NN||no-27/DT	nsubjpass||found-30/VBN||relationship-28/NN	auxpass||found-30/VBN||was-29/VBD	conj_and||different-21/JJ||found-30/VBN	det||exposure-34/NN||the-32/DT	amod||exposure-34/NN||glucocorticoid-33/JJ	prep_between||found-30/VBN||exposure-34/NN	det||bmc/bmd-37/NN||the-36/DT	prep_between||found-30/VBN||bmc/bmd-37/NN	conj_and||exposure-34/NN||bmc/bmd-37/NN	mineral-9||sle-16||no_rel||bone mineral content (bmc) and bone mineral density (bmd) in the sle group was not significantly different from the controls, and no relationship was found between the glucocorticoid exposure and the bmc/bmd.
amod||association-2/NN||significant-1/JJ	nsubjpass||noted-45/VBN||association-2/NN	appos||association-2/NN||p-4/NNP	number||0.001-6/CD||<-5/CD	num||p-4/NNP||0.001-6/CD	amod||use-10/NN||prior-9/JJ	prep_of||association-2/NN||use-10/NN	prep_of||use-10/NN||antibiotics-12/NNS	prep_in||antibiotics-12/NNS||males-14/NNS	conj_and||association-2/NN||uti-16/NN	nsubjpass||noted-45/VBN||uti-16/NN	prep_in||uti-16/NN||adults-18/NNS	amod||surgery-21/NN||gynaecological-20/JJ	conj_and||association-2/NN||surgery-21/NN	nsubjpass||noted-45/VBN||surgery-21/NN	prep_in||surgery-21/NN||females-23/NNS	amod||uropathy-26/NN||obstructive-25/JJ	conj_and||association-2/NN||uropathy-26/NN	nsubjpass||noted-45/VBN||uropathy-26/NN	prep_in||uropathy-26/NN||males-28/NNS	amod||uti-31/NN||complicated-30/JJ	conj_and||association-2/NN||uti-31/NN	nsubjpass||noted-45/VBN||uti-31/NN	prep_in||uti-31/NN||females-33/NNS	det||occurrence-36/NN||the-35/DT	prep_with||females-33/NNS||occurrence-36/NN	prep_of||occurrence-36/NN||uti-38/NN	amod||resistant-41/JJ||ciprofloxacin-40/JJ	amod||coli-43/NNS||resistant-41/JJ	nn||coli-43/NNS||escherichia-42/NN	prep_with||uti-38/NN||coli-43/NNS	auxpass||noted-45/VBN||was-44/VBD	root||ROOT-0/null||noted-45/VBN	uti-38||ciprofloxacin-40||yes||significant association ( p <0.001) of prior use of antibiotics in males, uti in adults, gynaecological surgery in females, obstructive uropathy in males and complicated uti in females with the occurrence of uti with ciprofloxacin resistant escherichia coli was noted.
det||increase-2/NN||an-1/DT	nsubjpass||associated-12/VBN||increase-2/NN	nsubjpass||associated-12/VBN||increase-2/NN	amod||adiposity-9/NN||total-4/JJ	conj_and||total-4/JJ||visceral-8/JJ	amod||adiposity-9/NN||visceral-8/JJ	prep_in||increase-2/NN||adiposity-9/NN	auxpass||associated-12/VBN||is-10/VBZ	advmod||associated-12/VBN||probably-11/RB	root||ROOT-0/null||associated-12/VBN	conj_negcc||associated-12/VBN||associated-12/VBN	det||decrease-15/NN||a-14/DT	prep_with||associated-12/VBN||decrease-15/NN	nn||distensibility-18/NN||vascular-17/NN	prep_in||decrease-15/NN||distensibility-18/NN	det||boys-24/NNS||the-20/DT	nn||boys-24/NNS||gujarati-21/NN	nn||boys-24/NNS||indian-22/NN	amod||boys-24/NNS||adolescent-23/JJ	prep_in||distensibility-18/NN||boys-24/NNS	prep_in||associated-12/VBN||girls-28/NNS	advmod||indicating-31/VBG||thus-30/RB	xcomp||associated-12/VBN||indicating-31/VBG	det||role-34/NN||a-32/DT	amod||role-34/NN||protective-33/JJ	dobj||indicating-31/VBG||role-34/NN	amod||estrogen-38/NN||female-36/JJ	nn||estrogen-38/NN||sexhormone-37/NN	prep_of||role-34/NN||estrogen-38/NN	nsubjpass||shown-42/VBN||estrogen-38/NN	nsubj||protect-45/VB||estrogen-38/NN	aux||shown-42/VBN||has-40/VBZ	auxpass||shown-42/VBN||been-41/VBN	rcmod||estrogen-38/NN||shown-42/VBN	advmod||shown-42/VBN||earlier-43/RBR	aux||protect-45/VB||to-44/TO	xcomp||shown-42/VBN||protect-45/VB	det||vasculature-47/NN||the-46/DT	dobj||protect-45/VB||vasculature-47/NN	prep_from||protect-45/VB||atherosclerosis-49/NNS	amod||dysfunction-52/NN||endothelial-51/JJ	appos||atherosclerosis-49/NNS||dysfunction-52/NN	nsubj||occurs-54/VBZ||dysfunction-52/NN	rcmod||dysfunction-52/NN||occurs-54/VBZ	prep_with||occurs-54/VBZ||increase-56/NN	prep_in||increase-56/NN||adiposity-58/NN	adiposity-58||estrogen-38||no_rel||an increase in total as well as visceral adiposity is probably associated with a decrease in vascular distensibility in the gujarati indian adolescent boys but not in girls, thus indicating a protective role of female sexhormone estrogen which has been shown earlier to protect the vasculature from atherosclerosis, endothelial dysfunction which occurs with increase in adiposity.
det||aliskiren-3/NN||the-2/DT	prep_in||received-23/VBD||aliskiren-3/NN	det||evaluation-6/NN||the-5/DT	prep_in||aliskiren-3/NN||evaluation-6/NN	prep_of||evaluation-6/NN||proteinuria-8/NN	nn||study-14/NN||diabetes-10/NNP	appos||study-14/NN||avoid-12/NNP	prep_in||proteinuria-8/NN||study-14/NN	num||patients-18/NNS||599-16/CD	amod||patients-18/NNS||hypertensive-17/JJ	nsubj||received-23/VBD||patients-18/NNS	prep_with||patients-18/NNS||type2diabetes-20/NN	prep_with||patients-18/NNS||nephropathy-22/NN	conj_and||type2diabetes-20/NN||nephropathy-22/NN	root||ROOT-0/null||received-23/VBD	num||months-25/NNS||6-24/CD	dobj||received-23/VBD||months-25/NNS	prep_of||months-25/NNS||aliskiren-27/NN	num||mg-30/NN||150-29/CD	dep||months-25/NNS||mg-30/NN	advmod||titrated-32/VBN||daily-31/RB	vmod||mg-30/NN||titrated-32/VBN	number||mg-35/CD||300-34/CD	prep_to||titrated-32/VBN||mg-35/CD	advmod||titrated-32/VBN||daily-36/RB	num||months-39/NNS||3-38/CD	prep_after||titrated-32/VBN||months-39/NNS	nn||therapy-51/NN||placebo-42/NN	dep||therapy-51/NN||added-43/VBN	num||losartan-47/NN||100-45/CD	nn||losartan-47/NN||mg-46/NN	prep_to||added-43/VBN||losartan-47/NN	amod||antihypertensive-50/JJ||optimal-49/JJ	conj_and||added-43/VBN||antihypertensive-50/JJ	dep||therapy-51/NN||antihypertensive-50/JJ	dobj||received-23/VBD||therapy-51/NN	conj_or||months-25/NNS||therapy-51/NN	nephropathy-22||losartan-47||no_rel||in the aliskiren in the evaluation of proteinuria in diabetes (avoid) study, 599 hypertensive patients with type2diabetes and nephropathy received 6 months of aliskiren (150 mg daily titrated to 300 mg daily after 3 months) or placebo added to 100 mg losartan and optimal antihypertensive therapy.
det||translation-2/NN||the-1/DT	nsubj||failed-12/VBN||translation-2/NN	nsubj||produce-14/VB||translation-2/NN	amod||agents-5/NNS||neuroprotective-4/JJ	prep_of||translation-2/NN||agents-5/NNS	prep_for||agents-5/NNS||ischemicstroke-7/NN	prep_from||ischemicstroke-7/NN||bench-to-bedside-9/NN	aux||failed-12/VBN||has-10/VBZ	advmod||failed-12/VBN||largely-11/RB	root||ROOT-0/null||failed-12/VBN	aux||produce-14/VB||to-13/TO	xcomp||failed-12/VBN||produce-14/VB	amod||treatments-16/NNS||improved-15/VBN	dobj||produce-14/VB||treatments-16/NNS	det||development-19/NN||the-18/DT	prep_since||produce-14/VB||development-19/NN	prep_of||development-19/NN||tissueplasminogenactivator-21/NN	appos||tissueplasminogenactivator-21/NN||tpa-23/NN	tissueplasminogenactivator-21||ischemicstroke-7||no_rel||the translation of neuroprotective agents for ischemicstroke from bench-to-bedside has largely failed to produce improved treatments since the development of tissueplasminogenactivator (tpa).
nsubj||erythroid-5/VBD||activation-1/NN	amod||factor-4/NN||nuclear-3/JJ	prep_of||activation-1/NN||factor-4/NN	root||ROOT-0/null||erythroid-5/VBD	amod||factor-7/NN||2-related-6/JJ	nsubj||belongs-13/VBZ||factor-7/NN	nsubj||strategy-25/NN||factor-7/NN	appos||factor-7/NN||nrf2-9/NNP	rcmod||factor-7/NN||belongs-13/VBZ	det||family-21/NN||the-15/DT	amod||family-21/NN||basic-16/JJ	amod||family-21/NN||leucine-17/JJ	nn||family-21/NN||zipper-18/NN	nn||family-21/NN||transcription-19/NN	nn||family-21/NN||factor-20/NN	prep_to||belongs-13/VBZ||family-21/NN	cop||strategy-25/NN||is-23/VBZ	det||strategy-25/NN||a-24/DT	ccomp||erythroid-5/VBD||strategy-25/NN	nn||phytochemicals-29/NNS||cancer-27/NN	nn||phytochemicals-29/NNS||chemopreventive-28/NN	prep_for||strategy-25/NN||phytochemicals-29/NNS	cancer-27||basic-16||no_rel||activation of nuclear factor erythroid 2-related factor (nrf2), which belongs to the basic leucine zipper transcription factor family, is a strategy for cancer chemopreventive phytochemicals.
prep_in||proved-9/VBN||patients-2/NNS	amod||hypertension-5/NN||mild-to-moderate-4/JJ	prep_with||patients-2/NNS||hypertension-5/NN	nsubj||proved-9/VBN||telmisartan-7/NN	aux||proved-9/VBN||has-8/VBZ	root||ROOT-0/null||proved-9/VBN	acomp||proved-9/VBN||superior-10/JJ	amod||antihypertensiveagents-13/NNS||other-12/JJ	prep_to||superior-10/JJ||antihypertensiveagents-13/NNS	dep||antihypertensiveagents-13/NNS||valsartan-15/NN	dep||antihypertensiveagents-13/NNS||losartan-17/NN	conj_and||valsartan-15/NN||losartan-17/NN	dep||antihypertensiveagents-13/NNS||ramipril-19/NN	conj_and||valsartan-15/NN||ramipril-19/NN	dep||antihypertensiveagents-13/NNS||perindopril-21/NN	conj_and||valsartan-15/NN||perindopril-21/NN	dep||antihypertensiveagents-13/NNS||atenolol-24/NN	conj_and||valsartan-15/NN||atenolol-24/NN	amod||pressure-29/NN||controlling-27/JJ	nn||pressure-29/NN||blood-28/NN	prep_in||antihypertensiveagents-13/NNS||pressure-29/NN	advmod||proved-9/VBN||particularly-30/RB	det||end-33/NN||the-32/DT	prep_towards||proved-9/VBN||end-33/NN	det||interval-37/NN||the-35/DT	amod||interval-37/NN||dosing-36/JJ	prep_of||end-33/NN||interval-37/NN	hypertension-5||ramipril-19||yes||in patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensiveagents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval.
num||days-2/NNS||two-1/CD	npadvmod||developed-17/VBD||days-2/NNS	amod||administration-5/NN||intravenous-4/JJ	prep_after||developed-17/VBD||administration-5/NN	det||course-9/NN||a-7/DT	amod||course-9/NN||first-8/JJ	prep_of||administration-5/NN||course-9/NN	amod||mg/m2-13/NNS||bortezomib-11/JJ	dep||bortezomib-11/JJ||1-12/CD	prep_of||course-9/NN||mg/m2-13/NNS	det||patient-16/NN||the-15/DT	nsubj||developed-17/VBD||patient-16/NN	root||ROOT-0/null||developed-17/VBD	amod||numbness-19/NNS||rapidly-progressive-18/JJ	dobj||developed-17/VBD||numbness-19/NNS	dobj||developed-17/VBD||pain-21/NN	conj_and||numbness-19/NNS||pain-21/NN	dobj||developed-17/VBD||muscleweakness-23/NNS	conj_and||numbness-19/NNS||muscleweakness-23/NNS	det||upper-27/JJ||the-25/DT	amod||upper-27/JJ||bilateral-26/JJ	prep_in||developed-17/VBD||upper-27/JJ	amod||limbs-30/NNS||lower-29/JJR	prep_in||developed-17/VBD||limbs-30/NNS	conj_and||upper-27/JJ||limbs-30/NNS	muscleweakness-23||bortezomib-11||no_rel||two days after intravenous administration of a first course of bortezomib 1 mg/m2, the patient developed rapidly-progressive numbness, pain and muscleweakness in the bilateral upper and lower limbs.
nsubj||compared-2/VBD||we-1/PRP	root||ROOT-0/null||compared-2/VBD	num||groups-4/NNS||three-3/CD	dobj||compared-2/VBD||groups-4/NNS	amod||placebo-8/NN||pregnant-6/JJ	nn||placebo-8/NN||women-7/NNS	prep_of||groups-4/NNS||placebo-8/NN	amod||women-11/NNS||normotensive-10/JJ	prep_with||compared-2/VBD||women-11/NNS	appos||women-11/NNS||group-13/NN	nsubj||included-16/VBD||group-13/NN	dep||group-13/NN||a-14/DT	rcmod||group-13/NN||included-16/VBD	dobj||included-16/VBD||preeclamptics-17/NNS	nsubj||comprised-22/VBN||groupb-20/NN	nsubj||â-41/VBP||groupb-20/NN	rcmod||groupb-20/NN||comprised-22/VBN	dobj||comprised-22/VBN||preeclamptics-23/NNS	nsubjpass||supplemented-26/VBN||preeclamptics-23/NNS	auxpass||supplemented-26/VBN||were-25/VBD	rcmod||preeclamptics-23/NNS||supplemented-26/VBN	poss||diets-28/NNS||their-27/PRP$	dobj||supplemented-26/VBN||diets-28/NNS	amod||c-31/NN||vitamins-30/JJ	prep_with||supplemented-26/VBN||c-31/NN	nn||mda-34/NN||e.-33/NN	prep_with||supplemented-26/VBN||mda-34/NN	conj_and||c-31/NN||mda-34/NN	vmod||c-31/NN||increased-35/VBN	num||±-40/NNS||6.22-37/CD	nn||±-40/NNS||â-38/NN	nn||±-40/NNS||â-39/NN	prep_from||increased-35/VBN||±-40/NNS	conj_and||compared-2/VBD||â-41/VBP	num||-rrb--45/NNS||2.8-42/CD	amod||-rrb--45/NNS||-lrb--43/JJ	nn||-rrb--45/NNS||placebo-44/NN	nsubj||â-51/VBP||-rrb--45/NNS	num||±-50/NNS||8.48-47/CD	nn||±-50/NNS||â-48/NN	nn||±-50/NNS||â-49/NN	prep_to||-rrb--45/NNS||±-50/NNS	ccomp||â-41/VBP||â-51/VBP	number||-lrb--53/CD||1.2-52/CD	dobj||â-51/VBP||-lrb--53/CD	det||-rrb--55/NN||a-54/DT	dep||-lrb--53/CD||-rrb--55/NN	num||±-60/NNS||8.02-57/CD	nn||±-60/NNS||â-58/NN	nn||±-60/NNS||â-59/NN	dobj||â-51/VBP||±-60/NNS	conj_and||-lrb--53/CD||±-60/NNS	number||1.8-62/CD||â-61/CD	num||-lrb--65/NNS||1.8-62/CD	amod||-lrb--65/NNS||â-63/JJ	nn||-lrb--65/NNS||nmol/ghb-64/NN	dep||±-60/NNS||-lrb--65/NNS	dep||-rrb--67/NNP||b-66/SYM	dep||â-51/VBP||-rrb--67/NNP	groupb-20||vitamins-30||no_rel||we compared three groups of pregnant women placebo with normotensive women , group a which included preeclamptics , and groupb which comprised preeclamptics who were supplemented their diets with vitamins c and e. mda increased from 6.22 â â ± â 2.8 -lrb- placebo -rrb- to 8.48 â â ± â 1.2 -lrb- a -rrb- and 8.02 â â ± â 1.8 â nmol/ghb -lrb- b -rrb- .
amod||chemotherapeutics-2/NNS||first-line-1/JJ	nsubj||dacarbazine-11/NN||chemotherapeutics-2/NNS	vmod||chemotherapeutics-2/NNS||used-3/VBN	nn||therapy-6/NN||melanoma-5/NN	prep_in||used-3/VBN||therapy-6/NN	cop||dacarbazine-11/NN||are-7/VBP	det||dacarbazine-11/NN||the-8/DT	amod||dacarbazine-11/NN||methylating-9/VBG	nn||dacarbazine-11/NN||agents-10/NNS	root||ROOT-0/null||dacarbazine-11/NN	dep||dacarbazine-11/NN||dtic-13/JJ	conj_and||dacarbazine-11/NN||temozolomide-16/NN	appos||temozolomide-16/NN||tmz-18/NN	det||agents-23/NNS||the-21/DT	amod||agents-23/NNS||chloroethylating-22/VBG	conj_and||dacarbazine-11/NN||agents-23/NNS	conj_and||temozolomide-16/NN||agents-23/NNS	amod||agents-23/NNS||bcnu-24/JJ	amod||agents-23/NNS||fotemustine-26/JJ	conj_and||bcnu-24/JJ||fotemustine-26/JJ	melanoma-5||dtic-13||yes||first-line chemotherapeutics used in melanoma therapy are the methylating agents dacarbazine (dtic) and temozolomide (tmz) and the chloroethylating agents bcnu and fotemustine.
det||interview-4/NN||the-2/DT	amod||interview-4/NN||same-3/JJ	prep_in||conduct-8/VB||interview-4/NN	nsubj||conduct-8/VB||we-6/PRP	aux||conduct-8/VB||will-7/MD	root||ROOT-0/null||conduct-8/VB	amod||exercises-10/NNS||preference-elicitation-9/JJ	dobj||conduct-8/VB||exercises-10/NNS	vmod||exercises-10/NNS||using-11/VBG	det||thermometer-14/NN||the-12/DT	nn||thermometer-14/NN||feeling-13/NN	dobj||using-11/VBG||thermometer-14/NN	aux||identify-16/VB||to-15/TO	vmod||using-11/VBG||identify-16/VB	det||utilities-18/NNS||the-17/DT	dobj||identify-16/VB||utilities-18/NNS	mark||place-21/VBP||that-19/IN	nsubj||place-21/VBP||patients-20/NNS	ccomp||identify-16/VB||place-21/VBP	prepc_on||place-21/VBP||taking-23/VBG	dobj||taking-23/VBG||medication-24/NN	dep||medication-24/NN||warfarin-26/NN	dep||medication-24/NN||aspirin-28/NN	conj_and||warfarin-26/NN||aspirin-28/NN	prepc_on||place-21/VBP||having-33/VBG	conj_and||taking-23/VBG||having-33/VBG	det||stroke-36/NN||a-34/DT	amod||stroke-36/NN||mild-35/JJ	dobj||having-33/VBG||stroke-36/NN	det||stroke-40/NN||a-38/DT	amod||stroke-40/NN||severe-39/JJ	dobj||having-33/VBG||stroke-40/NN	conj_and||stroke-36/NN||stroke-40/NN	det||bleed-45/NN||a-43/DT	amod||bleed-45/NN||major-44/JJ	dobj||having-33/VBG||bleed-45/NN	conj_and||stroke-36/NN||bleed-45/NN	stroke-40||warfarin-26||yes||in the same interview, we will conduct preference-elicitation exercises using the feeling thermometer to identify the utilities that patients place on taking medication (warfarin and aspirin), and on having a mild stroke, a severe stroke, and a major bleed.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||effect-10/NN||the-9/DT	dobj||investigate-8/VB||effect-10/NN	amod||polyphenols-14/NNS||dietary-12/JJ	amod||polyphenols-14/NNS||lemon-13/JJ	prep_of||effect-10/NN||polyphenols-14/NNS	amod||obesity-18/NN||high-fat-16/JJ	amod||obesity-18/NN||diet-induced-17/JJ	prep_on||investigate-8/VB||obesity-18/NN	prep_in||obesity-18/NN||mice-20/NNS	det||regulation-25/NN||the-24/DT	prep_on||investigate-8/VB||regulation-25/NN	conj_and||obesity-18/NN||regulation-25/NN	det||expression-28/NN||the-27/DT	prep_of||regulation-25/NN||expression-28/NN	det||genes-31/NNS||the-30/DT	prep_of||expression-28/NN||genes-31/NNS	vmod||genes-31/NNS||involved-32/VBN	nn||metabolism-35/NN||lipid-34/NN	prep_in||involved-32/VBN||metabolism-35/NN	aux||elucidate-37/VB||to-36/TO	xcomp||involved-32/VBN||elucidate-37/VB	det||mechanisms-39/NNS||the-38/DT	dobj||elucidate-37/VB||mechanisms-39/NNS	lipid-34||obesity-18||no_rel||the aim of this study was to investigate the effect of dietary lemon polyphenols on high-fat diet-induced obesity in mice, and on the regulation of the expression of the genes involved in lipid metabolism to elucidate the mechanisms.
aux||understand-2/VB||to-1/TO	ccomp||studied-30/VBD||understand-2/VB	det||mechanism-5/NN||the-3/DT	amod||mechanism-5/NN||molecular-4/JJ	dobj||understand-2/VB||mechanism-5/NN	nn||responses-8/NNS||host-7/NN	prep_of||mechanism-5/NN||responses-8/NNS	advmod||pathogenic-11/JJ||highly-10/RB	amod||avianinfluenzavirusinfection-12/NN||pathogenic-11/JJ	prep_to||understand-2/VB||avianinfluenzavirusinfection-12/NN	aux||get-15/VB||to-14/TO	conj_and||understand-2/VB||get-15/VB	ccomp||studied-30/VBD||get-15/VB	det||insight-17/NN||an-16/DT	dobj||get-15/VB||insight-17/NN	det||means-20/NN||the-19/DT	prep_into||get-15/VB||means-20/NN	prep_through||overcomes-24/VBZ||means-20/NN	nsubj||overcomes-24/VBZ||virus-23/NN	rcmod||means-20/NN||overcomes-24/VBZ	nn||mechanism-27/NN||host-25/NN	nn||mechanism-27/NN||defense-26/NN	dobj||overcomes-24/VBZ||mechanism-27/NN	nsubj||studied-30/VBD||we-29/PRP	nsubj||compared-60/VBD||we-29/PRP	root||ROOT-0/null||studied-30/VBD	amod||response-34/NN||global-31/JJ	nn||response-34/NN||gene-32/NN	nn||response-34/NN||expression-33/NN	nsubj||virus-58/NN||response-34/NN	amod||cells-39/NNS||human-36/JJ	nn||cells-39/NNS||lung-37/NN	nn||cells-39/NNS||carcinoma-38/NN	prep_of||response-34/NN||cells-39/NNS	appos||cells-39/NNS||a549-41/NNP	amod||stages-47/NNS||early-44/JJ	conj_and||early-44/JJ||late-46/JJ	amod||stages-47/NNS||late-46/JJ	prep_at||cells-39/NNS||stages-47/NNS	prep_of||cells-39/NNS||infection-49/NN	advmod||pathogenic-52/JJ||highly-51/RB	amod||avianinfluenza-53/NN||pathogenic-52/JJ	prep_with||infection-49/NN||avianinfluenza-53/NN	det||virus-58/NN||a-54/DT	nn||virus-58/NN||h5n1-56/NN	xcomp||studied-30/VBD||virus-58/NN	conj_and||studied-30/VBD||compared-60/VBD	dobj||compared-60/VBD||it-61/PRP	det||genetics-65/NNS||a-63/DT	amod||genetics-65/NNS||reverse-64/JJ	prep_with||compared-60/VBD||genetics-65/NNS	vmod||genetics-65/NNS||modified-66/VBN	xcomp||modified-66/VBN||recombinant-67/VBG	det||virus-73/NN||a-68/DT	appos||virus-73/NN||h5n1-70/NNP	nn||virus-73/NN||vaccine-72/NN	dobj||recombinant-67/VBG||virus-73/NN	vmod||virus-73/NN||using-74/VBG	amod||platform-76/NN||microarray-75/JJ	dobj||using-74/VBG||platform-76/NN	h5n1-70||avianinfluenzavirus--1||no||to understand the molecular mechanism of host responses to highly pathogenic avianinfluenzavirusinfection and to get an insight into the means through which virus overcomes host defense mechanism, we studied global gene expression response of human lung carcinoma cells (a549) at early and late stages of infection with highly pathogenic avianinfluenza a (h5n1) virus and compared it with a reverse genetics modified recombinant a (h5n1) vaccine virus using microarray platform.
nsubj||effective-18/JJ||methotrexate-1/NN	nsubj||brings-20/VBZ||methotrexate-1/NN	appos||methotrexate-1/NN||mtx-3/NN	det||treatment-8/NN||the-6/DT	amod||treatment-8/NN||primary-7/JJ	appos||methotrexate-1/NN||treatment-8/NN	det||juvenileidiopathicarthritis-12/NNS||the-10/DT	amod||juvenileidiopathicarthritis-12/NNS||articular-type-11/JJ	prep_for||treatment-8/NN||juvenileidiopathicarthritis-12/NNS	appos||juvenileidiopathicarthritis-12/NNS||jia-14/NN	cop||effective-18/JJ||is-17/VBZ	root||ROOT-0/null||effective-18/JJ	conj_and||effective-18/JJ||brings-20/VBZ	amod||improvement-23/NN||radiological-22/JJ	prep_about||brings-20/VBZ||improvement-23/NN	jia-14||methotrexate-1||yes||methotrexate (mtx), the primary treatment for the articular-type juvenileidiopathicarthritis (jia), is effective and brings about radiological improvement.
det||organization-4/NN||the-1/DT	nn||organization-4/NN||world-2/NN	nn||organization-4/NN||health-3/NN	nsubj||estimated-6/VBN||organization-4/NN	aux||estimated-6/VBN||has-5/VBZ	root||ROOT-0/null||estimated-6/VBN	mark||develop-12/VBP||that-7/IN	number||million-9/CD||8-8/CD	nsubj||develop-12/VBP||million-9/CD	prep_of||million-9/CD||people-11/NNS	ccomp||estimated-6/VBN||develop-12/VBP	amod||tb-14/NN||active-13/JJ	dobj||develop-12/VBP||tb-14/NN	det||year-16/NN||every-15/DT	tmod||develop-12/VBP||year-16/NN	det||situation-19/NN||the-18/DT	nsubjpass||complicated-21/VBN||situation-19/NN	auxpass||complicated-21/VBN||is-20/VBZ	ccomp||estimated-6/VBN||complicated-21/VBN	conj_and||develop-12/VBP||complicated-21/VBN	det||increase-24/NN||an-23/DT	agent||complicated-21/VBN||increase-24/NN	amod||strains-27/NNS||mycobacteriumtuberculosis-26/JJ	prep_of||increase-24/NN||strains-27/NNS	amod||strains-27/NNS||resistant-28/JJ	prep_to||resistant-28/JJ||drugs-30/NNS	vmod||drugs-30/NNS||used-31/VBN	nn||mdr-35/NN||antitubercular-33/NN	nn||mdr-35/NN||therapy-34/NN	prep_in||used-31/VBN||mdr-35/NN	amod||strains-27/NNS||xdr-tb-37/JJ	conj_and||resistant-28/JJ||xdr-tb-37/JJ	tb-14||mycobacteriumtuberculosis-26||no||the world health organization has estimated that 8 million of people develop active tb every year and the situation is complicated by an increase of mycobacteriumtuberculosis strains resistant to drugs used in antitubercular therapy mdr and xdr-tb.
det||review-2/NN||this-1/DT	nsubj||concludes-3/VBZ||review-2/NN	root||ROOT-0/null||concludes-3/VBZ	mark||factors-16/NNS||that-4/IN	amod||osmolarilty-6/JJ||low-5/JJ	amod||supplementation-10/NN||osmolarilty-6/JJ	amod||supplementation-10/NN||ors-7/JJ	dep||supplementation-10/NN||zinc-9/NN	nsubj||factors-16/NNS||supplementation-10/NN	nn||vaccine-13/NN||rotavirus-12/NNS	conj_and||supplementation-10/NN||vaccine-13/NN	nsubj||factors-16/NNS||vaccine-13/NN	cop||factors-16/NNS||are-14/VBP	amod||factors-16/NNS||major-15/JJ	ccomp||concludes-3/VBZ||factors-16/NNS	prepc_in||factors-16/NNS||reducing-18/VBG	det||morbidity-20/NN||the-19/DT	dobj||reducing-18/VBG||morbidity-20/NN	dobj||reducing-18/VBG||mortality-22/NN	conj_and||morbidity-20/NN||mortality-22/NN	dobj||reducing-18/VBG||hospitalization-24/NN	conj_and||morbidity-20/NN||hospitalization-24/NN	vmod||reducing-18/VBG||resulting-25/VBG	prep||resulting-25/VBG||from-26/IN	pcomp||from-26/IN||to-27/TO	amod||gastroenteritis-29/NNS||acute-28/JJ	pobj||to-27/TO||gastroenteritis-29/NNS	prep_in||gastroenteritis-29/NNS||childhood-31/NN	zinc-9||gastroenteritis-29||no_rel||this review concludes that low osmolarilty ors, zinc supplementation and rotavirus vaccine are major factors in reducing the morbidity, mortality and hospitalization resulting from to acute gastroenteritis in childhood.
nsubj||drug-10/NN||lamotrigine-1/NN	appos||lamotrigine-1/NN||ltg-3/NN	cop||drug-10/NN||is-5/VBZ	det||drug-10/NN||a-6/DT	amod||drug-10/NN||broad-7/JJ	nn||drug-10/NN||spectrum-8/NN	nn||drug-10/NN||antiepileptic-9/NN	root||ROOT-0/null||drug-10/NN	appos||drug-10/NN||aed-12/NN	amod||drug-10/NN||effective-15/JJ	preconj||generalized-18/JJ||both-17/DT	amod||seizures-21/NNS||generalized-18/JJ	conj_and||generalized-18/JJ||partial-20/JJ	amod||seizures-21/NNS||partial-20/JJ	prep_against||effective-15/JJ||seizures-21/NNS	seizures-21||lamotrigine-1||yes||lamotrigine (ltg) is a broad spectrum antiepileptic drug (aed), effective against both generalized and partial seizures.
preconj||loss-3/NN||both-1/DT	nn||loss-3/NN||weight-2/NN	nsubj||vldlâ-31/VBD||loss-3/NN	conj_and||loss-3/NN||ezetimibe-5/NN	nsubj||vldlâ-31/VBD||ezetimibe-5/NN	nn||loss-8/NN||weight-7/NN	conj_plus||loss-3/NN||loss-8/NN	nsubj||vldlâ-31/VBD||loss-8/NN	advmod||loss-3/NN||significantly-9/RB	det||p-12/NN||all-11/DT	nsubj||<-13/VBZ||p-12/NN	parataxis||vldlâ-31/VBD||<-13/VBZ	dobj||<-13/VBZ||0.05-14/CD	amod||tissues-24/NNS||reduced-16/JJ	nn||tissues-24/NNS||body-17/NN	nn||visceral-20/NN||weight-18/NN	nn||tissues-24/NNS||visceral-20/NN	conj_and||visceral-20/NN||subcutaneous-22/JJ	nn||tissues-24/NNS||subcutaneous-22/JJ	nn||tissues-24/NNS||adipose-23/NN	nsubj||vldlâ-31/VBD||tissues-24/NNS	nn||triglycerides-29/NNS||insulinresistance-26/NN	conj_and||insulinresistance-26/NN||plasma-28/NN	nn||triglycerides-29/NNS||plasma-28/NN	appos||tissues-24/NNS||triglycerides-29/NNS	root||ROOT-0/null||vldlâ-31/VBD	dobj||vldlâ-31/VBD||$-32/$	nn||fetuin-a-38/NN||apob-100-34/NNP	appos||fetuin-a-38/NN||apoc-iii-36/NNP	npadvmod||plasma-45/RB||fetuin-a-38/NN	dep||protein-4-42/JJ||retinol-binding-41/RB	dep||fetuin-a-38/NN||protein-4-42/JJ	dep||fetuin-a-38/NN||increased-44/JJ	conj_and||protein-4-42/JJ||increased-44/JJ	dep||adiponectin-46/CD||plasma-45/RB	num||$-32/$||adiponectin-46/CD	advmod||vldlâ-31/VBD||concentrations-47/RB	retinol--1||insulinresistance-26||no_rel||both weight loss and ezetimibe plus weight loss significantly (all p < 0.05) reduced body weight, visceral and subcutaneous adipose tissues, insulinresistance and plasma triglycerides, vldlâ€“apob-100, apoc-iii, fetuin-a, and retinol-binding protein-4 and increased plasma adiponectin concentrations.
nsubjpass||divided-3/VBN||patients-1/NNS	auxpass||divided-3/VBN||were-2/VBD	root||ROOT-0/null||divided-3/VBN	num||groups-6/NNS||two-5/CD	prep_into||divided-3/VBN||groups-6/NNS	prepc_according_to||divided-3/VBN||to-8/TO	det||centre-10/NN||the-9/DT	pobj||divided-3/VBN||centre-10/NN	nn||control-13/NN||disease-12/NN	prep_for||centre-10/NN||control-13/NN	nn||criteria-19/NNS||prevention-15/NN	nn||criteria-19/NNS||cdc-17/NN	prep_for||centre-10/NN||criteria-19/NNS	conj_and||control-13/NN||criteria-19/NNS	amod||patients-24/NNS||aids-related-21/JJ	nn||patients-24/NNS||te-22/NN	nn||patients-24/NNS||aids-23/NNS	prep_for||divided-3/VBN||patients-24/NNS	amod||neurotoxoplasmosis-27/NNS||suspected-26/VBN	prep_with||divided-3/VBN||neurotoxoplasmosis-27/NNS	prep_with||divided-3/VBN||aids-29/NNS	conj_and||neurotoxoplasmosis-27/NNS||aids-29/NNS	amod||patients-32/NNS||hiv-negative-31/JJ	nsubj||confirmed-35/VBD||patients-32/NNS	prep_with||patients-32/NNS||other-34/JJ	conj_and||divided-3/VBN||confirmed-35/VBD	amod||diseases-37/NNS||neurological-36/JJ	dobj||confirmed-35/VBD||diseases-37/NNS	prep||diseases-37/NNS||but-38/CC	neg||suspicions-40/NNS||no-39/DT	pobj||but-38/CC||suspicions-40/NNS	prep_of||suspicions-40/NNS||te-42/NN	aids-29||hiv--1||no||patients were divided into two groups according to the centre for disease control and prevention (cdc) criteria for aids-related te aids patients with suspected neurotoxoplasmosis and aids and hiv-negative patients with other confirmed neurological diseases but no suspicions of te.
prep_in||practiced-6/VBN||conclusion-2/NN	nsubjpass||practiced-6/VBN||self-medication-4/NN	auxpass||practiced-6/VBN||was-5/VBD	root||ROOT-0/null||practiced-6/VBN	det||range-9/NN||a-8/DT	prep_with||practiced-6/VBN||range-9/NN	prep_of||range-9/NN||drugs-11/NNS	det||anti-pains-15/NNS||the-13/DT	amod||anti-pains-15/NNS||conventional-14/JJ	prep_from||drugs-11/NNS||anti-pains-15/NNS	prep_to||practiced-6/VBN||antibiotics-17/NNS	pains--1||antibiotics-17||no_rel||in conclusion, self-medication was practiced with a range of drugs from the conventional anti-pains to antibiotics.
nsubj||report-4/NN||this-1/DT	cop||report-4/NN||is-2/VBZ	det||report-4/NN||a-3/DT	root||ROOT-0/null||report-4/NN	det||technique-7/NN||a-6/DT	prep_of||report-4/NN||technique-7/NN	prep_in||used-12/VBN||technique-7/NN	nsubjpass||used-12/VBN||r-tpa-10/NN	nsubj||target-18/VB||r-tpa-10/NN	auxpass||used-12/VBN||is-11/VBZ	rcmod||technique-7/NN||used-12/VBN	det||space-16/NN||the-14/DT	amod||space-16/NN||intrachoroidal-15/JJ	prep_in||used-12/VBN||space-16/NN	aux||target-18/VB||to-17/TO	xcomp||used-12/VBN||target-18/VB	det||clot-21/NN||the-19/DT	amod||clot-21/NN||organized-20/JJ	dobj||target-18/VB||clot-21/NN	amod||hemorrhage-24/NN||suprachoroidal-23/JJ	prep_of||clot-21/NN||hemorrhage-24/NN	advmod||target-18/VB||prior-25/RB	aux||drainage-27/VB||to-26/TO	dep||prior-25/RB||drainage-27/VB	hemorrhage-24||clot-21||no_rel||this is a report of a technique in which r-tpa is used in the intrachoroidal space to target the organized clot of suprachoroidal hemorrhage prior to drainage.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	toxicshocksyndrome-33||cu-63||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||formoterol-16||yes||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-37/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-37/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-37/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-37/NN||were-20/VBD	nn||congestion-37/NN||somnolence-21/NN	dep||congestion-37/NN||restlessness-23/NNS	dep||congestion-37/NN||nausea-25/NN	dep||congestion-37/NN||anxiety-27/NN	amod||congestion-37/NN||salivary-29/JJ	nn||congestion-37/NN||hypersecretion-30/NN	conj_and||hypersecretion-30/NN||akathisia-32/NN	nn||congestion-37/NN||akathisia-32/NN	conj_and||hypersecretion-30/NN||dizziness-34/NN	nn||congestion-37/NN||dizziness-34/NN	conj_and||hypersecretion-30/NN||nasal-36/NN	nn||congestion-37/NN||nasal-36/NN	root||ROOT-0/null||congestion-37/NN	risperidone-19||tachycardia-14||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivary hypersecretion, akathisia, dizziness and nasal congestion.
amod||analysis-4/NN||univariate-1/JJ	amod||analysis-4/NN||logistic-2/JJ	nn||analysis-4/NN||regression-3/NN	nsubj||showed-5/VBD||analysis-4/NN	root||ROOT-0/null||showed-5/VBD	neg||association-7/NN||no-6/DT	dobj||showed-5/VBD||association-7/NN	amod||ratio-12/NN||stavudine-9/JJ	amod||ratio-12/NN||geometric-10/VBN	amod||ratio-12/NN||mean-11/JJ	prep_between||association-7/NN||ratio-12/NN	amod||ratio-12/NN||>-13/JJ	dep||>-13/JJ||1-14/CD	amod||glucose-18/NN||impaired-16/VBN	amod||glucose-18/NN||fasting-17/JJ	prep_between||association-7/NN||glucose-18/NN	conj_and||ratio-12/NN||glucose-18/NN	nsubj||ratio-21/VBZ||odds-20/NNS	dep||glucose-18/NN||ratio-21/VBZ	dep||2.00-25/CD||or-23/CC	dep||ratio-21/VBZ||2.00-25/CD	num||%-28/NN||95-27/CD	appos||2.00-25/CD||%-28/NN	vmod||%-28/NN||ci-29/VBN	dobj||ci-29/VBN||0.44-30/CD	prep_to||ci-29/VBN||9.19-32/CD	prep_between||association-7/NN||impairedglucosetolerance-35/NN	conj_and||ratio-12/NN||impairedglucosetolerance-35/NN	cc||0.07-43/NNS||or-37/CC	num||0.07-43/NNS||1.14-38/CD	num||0.07-43/NNS||95-40/CD	nn||0.07-43/NNS||%-41/NN	nn||0.07-43/NNS||ci-42/NN	dep||impairedglucosetolerance-35/NN||0.07-43/NNS	prep_to||0.07-43/NNS||19.42-45/CD	conj_and||ratio-12/NN||hyperlactataemia-48/NN	conj_and||impairedglucosetolerance-35/NN||hyperlactataemia-48/NN	cc||2.19-51/CD||or-50/CC	dep||hyperlactataemia-48/NN||2.19-51/CD	num||%-54/NN||95-53/CD	appos||2.19-51/CD||%-54/NN	number||0.63-56/CD||ci-55/CD	num||%-54/NN||0.63-56/CD	prep_to||%-54/NN||7.66-58/CD	conj_and||ratio-12/NN||hypertriglyceridaemia-61/NN	conj_and||impairedglucosetolerance-35/NN||hypertriglyceridaemia-61/NN	cc||ci-68/VBP||or-63/CC	nsubj||ci-68/VBP||1.75-64/CD	number||%-67/NN||95-66/CD	amod||1.75-64/CD||%-67/NN	dep||hypertriglyceridaemia-61/NN||ci-68/VBP	number||7.04-71/CD||0.44-69/CD	dep||7.04-71/CD||to-70/TO	dobj||ci-68/VBP||7.04-71/CD	conj_and||ratio-12/NN||lipoatrophy-75/NN	conj_and||impairedglucosetolerance-35/NN||lipoatrophy-75/NN	cc||0.83-78/CD||or-77/CC	dep||lipoatrophy-75/NN||0.83-78/CD	number||%-81/NN||95-80/CD	amod||ci-82/NN||%-81/NN	appos||0.83-78/CD||ci-82/NN	num||2.79-85/CD||0.25-83/CD	dep||2.79-85/CD||to-84/TO	dep||0.83-78/CD||2.79-85/CD	stavudine-9||impairedglucosetolerance-35||no_rel||univariate logistic regression analysis showed no association between stavudine geometric mean ratio >1 and impaired fasting glucose (odds ratio (or) 2.00, 95% ci 0.44 to 9.19), impairedglucosetolerance (or 1.14, 95% ci 0.07 to 19.42), hyperlactataemia (or 2.19, 95%ci 0.63 to 7.66), hypertriglyceridaemia (or 1.75, 95%ci 0.44 to 7.04), and lipoatrophy (or 0.83, 95% ci 0.25 to 2.79).
det||initiative-7/NN||the-1/DT	amod||initiative-7/NN||womenâ-2/JJ	amod||initiative-7/NN||$-3/$	number||s-5/CD||™-4/CD	num||$-3/$||s-5/CD	nn||initiative-7/NN||health-6/NN	nsubj||found-8/VBD||initiative-7/NN	root||ROOT-0/null||found-8/VBD	mark||increases-17/VBZ||that-9/IN	nn||estrogen-11/NN||combination-10/NN	nsubj||increases-17/VBZ||estrogen-11/NN	amod||therapy-16/NN||progesterone-13/JJ	nn||therapy-16/NN||hormone-14/NN	nn||therapy-16/NN||replacement-15/NN	conj_and||estrogen-11/NN||therapy-16/NN	nsubj||increases-17/VBZ||therapy-16/NN	ccomp||found-8/VBD||increases-17/VBZ	nn||cancer-19/NN||breast-18/NN	dobj||increases-17/VBZ||cancer-19/NN	nsubj||compelled-25/VBN||cancer-19/NN	nn||risk-22/NN||cardiovasculardisease-21/NN	dobj||increases-17/VBZ||risk-22/NN	conj_and||cancer-19/NN||risk-22/NN	nsubj||compelled-25/VBN||risk-22/NN	rcmod||cancer-19/NN||compelled-25/VBN	amod||women-27/NNS||many-26/JJ	dobj||compelled-25/VBN||women-27/NNS	nsubj||seek-29/VB||women-27/NNS	aux||seek-29/VB||to-28/TO	xcomp||compelled-25/VBN||seek-29/VB	amod||alternatives-31/NNS||herbal-30/JJ	dobj||seek-29/VB||alternatives-31/NNS	prep_such_as||alternatives-31/NNS||blackcohoshextract-34/NN	appos||blackcohoshextract-34/NN||bce-36/NN	aux||relieve-39/VB||to-38/TO	vmod||blackcohoshextract-34/NN||relieve-39/VB	poss||symptoms-42/NNS||their-40/PRP$	amod||symptoms-42/NNS||menopausal-41/JJ	dobj||relieve-39/VB||symptoms-42/NNS	hormone-14||cardiovasculardisease-21||no_rel||the womenâ€™s health initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovasculardisease risk, which compelled many women to seek herbal alternatives such as blackcohoshextract (bce) to relieve their menopausal symptoms.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||efficacy-4/NN||the-3/DT	dobj||compare-2/VB||efficacy-4/NN	prep_of||efficacy-4/NN||pregabalin-6/NN	prep_of||efficacy-4/NN||gabapentin-8/NN	conj_and||pregabalin-6/NN||gabapentin-8/NN	amod||effective-11/JJ||comparable-10/JJ	amod||levels-13/NNS||effective-11/JJ	nn||levels-13/NNS||dose-12/NN	prep_at||compare-2/VB||levels-13/NNS	prep_in||compare-2/VB||patients-15/NNS	amod||partialepilepsy-18/NN||refractory-17/JJ	prep_with||patients-15/NNS||partialepilepsy-18/NN	partialepilepsy-18||gabapentin-8||yes||to compare the efficacy of pregabalin and gabapentin at comparable effective dose levels in patients with refractory partialepilepsy.
det||increase-3/NN||the-1/DT	amod||increase-3/NN||observed-2/JJ	nsubj||indicates-10/VBZ||increase-3/NN	amod||ratio-9/NN||serum-5/JJ	amod||ratio-9/NN||igf-1-6/JJ	conj_and||igf-1-6/JJ||insulin-to-glucose-8/JJ	amod||ratio-9/NN||insulin-to-glucose-8/JJ	prep_of||increase-3/NN||ratio-9/NN	root||ROOT-0/null||indicates-10/VBZ	mark||result-15/VB||that-11/IN	nn||restriction-13/NN||sleep-12/NN	nsubj||result-15/VB||restriction-13/NN	aux||result-15/VB||may-14/MD	ccomp||indicates-10/VBZ||result-15/VB	det||risk-19/NN||an-17/DT	amod||risk-19/NN||increased-18/VBN	prep_in||result-15/VB||risk-19/NN	aux||develop-21/VB||to-20/TO	vmod||risk-19/NN||develop-21/VB	dobj||develop-21/VB||type2diabetes-22/NNS	type2diabetes-22||insulin--1||yes||the observed increase of serum igf-1 and insulin-to-glucose ratio indicates that sleep restriction may result in an increased risk to develop type2diabetes.
det||demonstration-2/NN||the-1/DT	nsubj||suggests-13/VBZ||demonstration-2/NN	nsubj||serves-18/VBZ||demonstration-2/NN	nsubj||consider-23/VB||demonstration-2/NN	advmod||different-5/JJ||genetically-4/RB	amod||sarcomas-8/NNS||different-5/JJ	amod||sarcomas-8/NNS||soft-6/JJ	nn||sarcomas-8/NNS||tissue-7/NN	prep_of||demonstration-2/NN||sarcomas-8/NNS	det||patient-12/NN||the-10/DT	amod||patient-12/NN||same-11/JJ	prep_in||sarcomas-8/NNS||patient-12/NN	root||ROOT-0/null||suggests-13/VBZ	amod||origin-16/NN||independent-14/JJ	nn||origin-16/NN||tumor-15/NN	dobj||suggests-13/VBZ||origin-16/NN	conj_and||suggests-13/VBZ||serves-18/VBZ	det||reminder-21/NN||a-20/DT	prep_as||serves-18/VBZ||reminder-21/NN	aux||consider-23/VB||to-22/TO	xcomp||serves-18/VBZ||consider-23/VB	dobj||consider-23/VB||development-24/NN	amod||sts-28/NN||second-26/JJ	amod||sts-28/NN||primary-27/JJ	prep_of||development-24/NN||sts-28/NN	nsubj||has-31/VBZ||sts-28/NN	rcmod||sts-28/NN||has-31/VBZ	amod||implications-35/NNS||prognostic-32/JJ	conj_and||prognostic-32/JJ||therapeutic-34/JJ	amod||implications-35/NNS||therapeutic-34/JJ	dobj||has-31/VBZ||implications-35/NNS	tumor-15||sts-28||no||the demonstration of genetically different soft tissue sarcomas in the same patient suggests independent tumor origin and serves as a reminder to consider development of second primary sts, which has prognostic and therapeutic implications.
det||rate-6/NN||the-1/DT	amod||rate-6/NN||minimum-2/JJ	amod||rate-6/NN||estimated-3/JJ	nn||rate-6/NN||population-4/NN	nn||rate-6/NN||mortality-5/NN	nsubj||8.63-12/CD||rate-6/NN	prep_from||rate-6/NN||melioidosis-8/NNS	prep_in||melioidosis-8/NNS||2006-10/CD	cop||8.63-12/CD||was-11/VBD	root||ROOT-0/null||8.63-12/CD	num||people-15/NNS||100,000-14/CD	prep_per||8.63-12/CD||people-15/NNS	num||%-18/NN||95-17/CD	dep||people-15/NNS||%-18/NN	nn||â-22/FW||ci-19/FW	nn||â-22/FW||=-20/FW	nn||â-22/FW||7.33-21/FW	dep||%-18/NN||â-22/FW	dep||â-22/FW||$-23/$	num||$-23/$||10.11-25/CD	det||cause-32/NN||the-28/DT	amod||cause-32/NN||third-29/JJ	advmod||common-31/JJ||most-30/RBS	amod||cause-32/NN||common-31/JJ	appos||people-15/NNS||cause-32/NN	prep_of||cause-32/NN||death-34/NN	amod||diseases-37/NNS||infectious-36/JJ	prep_from||death-34/NN||diseases-37/NNS	prep_in||diseases-37/NNS||northeast-39/NN	vmod||northeast-39/NN||thailand-40/VBN	prep_after||thailand-40/VBN||humanimmunodeficiencyvirus-42/NNS	discourse||humanimmunodeficiencyvirus-42/NNS||hiv-44/UH	punct||aids-49/NNS||/-46/:	amod||aids-49/NNS||acquiredimmunodeficiencysyndrome-47/JJ	dep||humanimmunodeficiencyvirus-42/NNS||aids-49/NNS	dep||humanimmunodeficiencyvirus-42/NNS||tuberculosis-52/NNP	conj_and||aids-49/NNS||tuberculosis-52/NNP	aids-49||humanimmunodeficiencyvirus-42||no||the minimum estimated population mortality rate from melioidosis in 2006 was 8.63 per 100,000 people (95% ci = 7.33â€“10.11), the third most common cause of death from infectious diseases in northeast thailand after humanimmunodeficiencyvirus (hiv)/acquiredimmunodeficiencysyndrome (aids) and tuberculosis.
advmod||bolster-4/VB||additionally-1/RB	nsubj||bolster-4/VB||we-3/PRP	root||ROOT-0/null||bolster-4/VB	poss||reclassification-7/NN||our-5/PRP$	amod||reclassification-7/NN||recent-6/JJ	dobj||bolster-4/VB||reclassification-7/NN	prep_of||reclassification-7/NN||rickettsia-9/NN	prepc_by||bolster-4/VB||identifying-11/VBG	dobj||identifying-11/VBG||ogs-12/NN	nsubj||define-14/VB||ogs-12/NN	rcmod||ogs-12/NN||define-14/VB	det||ag-16/NN||the-15/DT	nsubj||rickettsiae-40/JJ||ag-16/NN	amod||group-19/NN||ancestral-18/JJ	appos||ag-16/NN||group-19/NN	conj_and||ag-16/NN||tg-22/NN	nsubj||rickettsiae-40/JJ||tg-22/NN	amod||group-25/NN||typhus-24/JJ	appos||tg-22/NN||group-25/NN	conj_and||ag-16/NN||trg-28/NN	nsubj||rickettsiae-40/JJ||trg-28/NN	amod||group-31/NN||transitional-30/JJ	appos||trg-28/NN||group-31/NN	conj_and||ag-16/NN||sfg-35/NN	nsubj||rickettsiae-40/JJ||sfg-35/NN	nn||group-38/NN||spottedfever-37/NN	appos||ag-16/NN||group-38/NN	xcomp||define-14/VB||rickettsiae-40/JJ	spottedfever-37||rickettsiae-40||no||additionally, we bolster our recent reclassification of rickettsia by identifying ogs that define the ag (ancestral group), tg (typhus group), trg (transitional group), and sfg (spottedfever group) rickettsiae.
amod||fibers-3/NNS||viscous-1/JJ	nn||fibers-3/NNS||dietary-2/NN	nsubj||blunt-4/VB||fibers-3/NNS	root||ROOT-0/null||blunt-4/VB	det||rise-7/NN||the-5/DT	amod||rise-7/NN||postprandial-6/JJ	dobj||blunt-4/VB||rise-7/NN	nn||glucose-10/NN||blood-9/NN	prep_in||blunt-4/VB||glucose-10/NN	advmod||known-22/VBN||however-12/RB	poss||effect-14/NN||their-13/PRP$	nsubjpass||known-22/VBN||effect-14/NN	prep_on||effect-14/NN||type2diabetes-16/NN	prep_on||effect-14/NN||obesity-18/NN	conj_and||type2diabetes-16/NN||obesity-18/NN	auxpass||known-22/VBN||are-19/VBP	neg||known-22/VBN||not-20/RB	advmod||known-22/VBN||entirely-21/RB	parataxis||blunt-4/VB||known-22/VBN	obesity-18||glucose-10||no_rel||viscous dietary fibers blunt the postprandial rise in blood glucose, however their effect on type2diabetes and obesity are not entirely known.
det||studies-3/NNS||a-1/DT	amod||studies-3/NNS||few-2/JJ	nsubj||reported-4/VBD||studies-3/NNS	root||ROOT-0/null||reported-4/VBD	mark||is-7/VBZ||that-5/IN	expl||is-7/VBZ||there-6/EX	ccomp||reported-4/VBD||is-7/VBZ	det||association-10/NN||a-8/DT	amod||association-10/NN||mysterious-9/JJ	nsubj||is-7/VBZ||association-10/NN	det||polymorphism-14/NN||the-12/DT	amod||polymorphism-14/NN||il28b-13/JJ	prep_between||association-10/NN||polymorphism-14/NN	det||virus-18/NN||the-16/DT	amod||virus-18/NN||hepatitisc-17/JJ	nsubj||genotype-22/VBP||virus-18/NN	appos||virus-18/NN||hcv-20/NN	conj_and||reported-4/VBD||genotype-22/VBP	prep_in||genotype-22/VBP||patients-24/NNS	prep_with||patients-24/NNS||chronichepatitisc-26/NN	nsubj||give-31/VB||they-28/PRP	aux||give-31/VB||did-29/VBD	neg||give-31/VB||not-30/RB	conj_but||reported-4/VBD||give-31/VB	det||reason-33/NN||any-32/DT	dobj||give-31/VB||reason-33/NN	det||phenomenon-36/NN||this-35/DT	prep_for||reason-33/NN||phenomenon-36/NN	chronichepatitisc-26||hcv-20||no||a few studies reported that there is a mysterious association between the il28b polymorphism and the hepatitisc virus (hcv) genotype in patients with chronichepatitisc but they did not give any reason for this phenomenon.
det||study-2/NN||a-1/DT	nsubj||assess-4/VB||study-2/NN	nsubj||identify-23/VB||study-2/NN	aux||assess-4/VB||to-3/TO	root||ROOT-0/null||assess-4/VB	det||susceptibility-6/NN||the-5/DT	dobj||assess-4/VB||susceptibility-6/NN	prep_of||susceptibility-6/NN||nursing-8/NN	amod||students-11/NNS||medical-10/JJ	dobj||assess-4/VB||students-11/NNS	conj_and||susceptibility-6/NN||students-11/NNS	prep_towards||students-11/NNS||varicellainfection-13/NN	prepc_by||assess-4/VB||screening-15/VBG	nn||antibodies-18/NNS||igg-17/NN	prep_for||screening-15/VBG||antibodies-18/NNS	prep_against||antibodies-18/NNS||varicellavirus-20/NNS	aux||identify-23/VB||to-22/TO	conj_and||assess-4/VB||identify-23/VB	det||factors-26/NNS||any-24/DT	nn||factors-26/NNS||risk-25/NN	dobj||identify-23/VB||factors-26/NNS	det||same-29/JJ||the-28/DT	prep_for||identify-23/VB||same-29/JJ	varicellainfection-13||varicellavirus-20||yes||a study to assess the susceptibility of nursing and medical students towards varicellainfection by screening for igg antibodies against varicellavirus and to identify any risk factors for the same.
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tb--1||m.tuberculosis--1||no||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
poss||adiponectin-5/NN||results-1/NNS	amod||adiponectin-5/NN||$-3/JJ	nsubj||showed-6/VBD||adiponectin-5/NN	root||ROOT-0/null||showed-6/VBD	det||dimorphism-9/NN||a-7/DT	nn||dimorphism-9/NN||sex-8/NN	dobj||showed-6/VBD||dimorphism-9/NN	prep_with||showed-6/VBD||girls-12/NNS	vmod||girls-12/NNS||having-13/VBG	amod||values-15/NNS||higher-14/JJR	dobj||having-13/VBG||values-15/NNS	nn||g/ml-20/NN||î-18/NN	num||g/ml-20/NN||1/4-19/CD	prep_in||values-15/NNS||g/ml-20/NN	num||5.0-26/NNS||10.3-23/CD	nn||5.0-26/NNS||â-24/NNP	nn||5.0-26/NNS||±-25/NN	appos||values-15/NNS||5.0-26/NNS	prep_than||values-15/NNS||boys-29/NNS	dep||boys-29/NNS||8.4-31/CD	vmod||8.4-31/CD||â-32/VBN	dep||3.5-34/CD||±-33/SYM	ccomp||â-32/VBN||3.5-34/CD	dep||girls-12/NNS||p-37/VBN	dep||0.0001-39/CD||<-38/SYM	ccomp||p-37/VBN||0.0001-39/CD	nsubj||showed-44/VBD||it-43/PRP	conj_and||showed-6/VBD||showed-44/VBD	det||correlation-47/NN||a-45/DT	amod||correlation-47/NN||positive-46/JJ	dobj||showed-44/VBD||correlation-47/NN	nn||cholesterol-50/NN||hdl-49/NN	prep_with||showed-44/VBD||cholesterol-50/NN	prep_in||showed-44/VBD||boys-52/NNS	advmod||boys-52/NNS||only-53/RB	advmod||boys-52/NNS||not-55/RB	conj_and||only-53/RB||not-55/RB	amod||anthropometry-65/NN||other-57/JJ	nn||anthropometry-65/NN||lipid-58/NN	nn||anthropometry-65/NN||parameters-59/NNS	dep||anthropometry-65/NN||insulinresistance-61/NN	dep||anthropometry-65/NN||proinsulin-63/NN	prep_with||boys-52/NNS||anthropometry-65/NN	nn||history-69/NN||family-68/NN	prep_with||boys-52/NNS||history-69/NN	conj_and||anthropometry-65/NN||history-69/NN	prep_of||boys-52/NNS||diabetes-71/NN	lipid-58||insulinresistance-61||no_rel||results â€”adiponectin showed a sex dimorphism, with girls having higher values (in î¼g/ml) (10.3 â± 5.0) than boys (8.4 â± 3.5) ( p < 0.0001), and it showed a positive correlation with hdl cholesterol in boys only and not with other lipid parameters, insulinresistance, proinsulin, anthropometry, and family history of diabetes.
det||increase-3/NN||a-1/DT	amod||increase-3/NN||significant-2/JJ	nsubjpass||reported-10/VBN||increase-3/NN	prep_in||increase-3/NN||congestiveheartfailure-5/NN	appos||increase-3/NN||chf-7/NN	auxpass||reported-10/VBN||was-9/VBD	root||ROOT-0/null||reported-10/VBN	advmod||used-17/VBN||when-11/WRB	det||trastuzumab-15/NN||the-12/DT	amod||trastuzumab-15/NN||anti-erbb2-13/JJ	nn||trastuzumab-15/NN||antibody-14/NN	nsubjpass||used-17/VBN||trastuzumab-15/NN	auxpass||used-17/VBN||was-16/VBD	advcl||reported-10/VBN||used-17/VBN	prep_in||used-17/VBN||combination-19/NN	det||doxorubicin-24/NN||the-21/DT	amod||doxorubicin-24/NN||chemotherapy-22/JJ	nn||doxorubicin-24/NN||drug-23/NN	prep_with||used-17/VBN||doxorubicin-24/NN	appos||doxorubicin-24/NN||dox-26/NN	chf-7||doxorubicin-24||no||a significant increase in congestiveheartfailure (chf) was reported when the anti-erbb2 antibody trastuzumab was used in combination with the chemotherapy drug doxorubicin (dox).
nsubjpass||emphasized-4/VBN||it-1/PRP	aux||emphasized-4/VBN||should-2/MD	auxpass||emphasized-4/VBN||be-3/VB	root||ROOT-0/null||emphasized-4/VBN	mark||severe-17/JJ||that-5/IN	det||dysfunctions-9/NNS||the-6/DT	amod||dysfunctions-9/NNS||voiding-7/JJ	nn||dysfunctions-9/NNS||phase-8/NN	nsubj||severe-17/JJ||dysfunctions-9/NNS	appos||dysfunctions-9/NNS||dv-11/NNP	appos||dysfunctions-9/NNS||des-13/NNP	conj_and||dv-11/NNP||des-13/NNP	cop||severe-17/JJ||are-15/VBP	advmod||severe-17/JJ||more-16/RBR	ccomp||emphasized-4/VBN||severe-17/JJ	det||dysfunction-23/NN||the-19/DT	amod||dysfunction-23/NN||genuine-20/JJ	nn||dysfunction-23/NN||filling-21/NN	nn||dysfunction-23/NN||phase-22/NN	prep_than||severe-17/JJ||dysfunction-23/NN	appos||dysfunction-23/NN||oab-25/NN	det||frequency-31/NN||an-29/DT	amod||frequency-31/NN||increased-30/VBN	prep_with||dysfunction-23/NN||frequency-31/NN	nn||damage-36/NN||uti-33/NN	conj_and||uti-33/NN||renal-35/JJ	nn||damage-36/NN||renal-35/JJ	prep_of||frequency-31/NN||damage-36/NN	det||groups-40/NNS||the-38/DT	amod||groups-40/NNS||former-39/JJ	prep_in||damage-36/NN||groups-40/NNS	uti-33||des-13||no_rel||it should be emphasized that the voiding phase dysfunctions (dv and des) are more severe than the genuine filling phase dysfunction (oab), with an increased frequency of uti and renal damage in the former groups.
det||study-3/NN||the-1/DT	amod||study-3/NN||first-2/JJ	nsubjpass||reviewed-19/VBN||study-3/NN	det||form-7/NN||the-5/DT	amod||form-7/NN||pegylated-6/JJ	prep_of||study-3/NN||form-7/NN	amod||melanoma-13/NN||interferonalpha-2b-9/JJ	nn||iii-12/NN||stage-11/NN	prep_in||interferonalpha-2b-9/JJ||iii-12/NN	prep_of||form-7/NN||melanoma-13/NN	amod||study-3/NN||eortc-15/JJ	dep||eortc-15/JJ||18991-16/CD	auxpass||reviewed-19/VBN||is-18/VBZ	root||ROOT-0/null||reviewed-19/VBN	advmod||reviewed-19/VBN||here-20/RB	melanoma-13||interferonalpha-2b-9||yes||the first study of the pegylated form of interferonalpha-2b in stage iii melanoma, eortc 18991, is reviewed here.
det||group-4/NN||the-2/DT	amod||group-4/NN||met-anov-3/JJ	prep_in||observed-10/VBN||group-4/NN	neg||correlation-8/NN||no-6/DT	amod||correlation-8/NN||significant-7/JJ	nsubjpass||observed-10/VBN||correlation-8/NN	auxpass||observed-10/VBN||was-9/VBD	root||ROOT-0/null||observed-10/VBN	nn||concentrations-13/NNS||amh-12/NN	prep_between||observed-10/VBN||concentrations-13/NNS	det||fluid-17/NN||the-15/DT	nn||fluid-17/NN||follicular-16/NN	prep_in||concentrations-13/NNS||fluid-17/NN	prep_in||concentrations-13/NNS||variation-19/NN	conj_and||fluid-17/NN||variation-19/NN	nn||androgens-22/NNS||serum-21/NN	prep_in||fluid-17/NN||androgens-22/NNS	amod||indexes-27/NNS||amh-24/JJ	conj_and||amh-24/JJ||insulinresistance-26/JJ	amod||indexes-27/NNS||insulinresistance-26/JJ	appos||fluid-17/NN||indexes-27/NNS	mark||detected-36/VBN||whereas-29/IN	amod||group-32/NN||met-ov-31/JJ	prep_in||detected-36/VBN||group-32/NN	amod||correlations-34/NNS||significant-33/JJ	nsubjpass||detected-36/VBN||correlations-34/NNS	auxpass||detected-36/VBN||were-35/VBD	advcl||observed-10/VBN||detected-36/VBN	nn||levels-39/NNS||amh-38/NN	prep_between||detected-36/VBN||levels-39/NNS	det||fluid-43/NN||the-41/DT	nn||fluid-43/NN||follicular-42/NN	prep_in||levels-39/NNS||fluid-43/NN	prep_in||levels-39/NNS||variation-45/NN	conj_and||fluid-43/NN||variation-45/NN	amod||indexes-53/NNS||serum-47/JJ	nn||indexes-53/NNS||androgens-48/NNS	conj_and||androgens-48/NNS||amh-50/NN	nn||indexes-53/NNS||amh-50/NN	conj_and||androgens-48/NNS||insulinresistance-52/NN	nn||indexes-53/NNS||insulinresistance-52/NN	prep_in||fluid-43/NN||indexes-53/NNS	androgens-48||insulinresistance-52||no_rel||in the met-anov group, no significant correlation was observed between amh concentrations in the follicular fluid and variation in serum androgens, amh and insulinresistance indexes; whereas in met-ov group significant correlations were detected between amh levels in the follicular fluid and variation in serum androgens, amh and insulinresistance indexes.
advmod||absent-19/JJ||however-1/RB	det||effects-6/NNS||the-3/DT	amod||effects-6/NNS||expected-4/JJ	amod||effects-6/NNS||beneficial-5/JJ	nsubj||absent-19/JJ||effects-6/NNS	amod||fgf21-9/NNS||endogenous-8/JJ	prep_of||effects-6/NNS||fgf21-9/NNS	aux||increase-11/VB||to-10/TO	vmod||effects-6/NNS||increase-11/VB	nn||tolerance-13/NN||glucose-12/NN	dobj||increase-11/VB||tolerance-13/NN	vmod||effects-6/NNS||reduce-15/VB	conj_and||increase-11/VB||reduce-15/VB	xcomp||reduce-15/VB||circulating-16/VBG	dobj||circulating-16/VBG||triglycerides-17/NNPS	cop||absent-19/JJ||are-18/VBP	root||ROOT-0/null||absent-19/JJ	prep_in||absent-19/JJ||obesity-21/NN	obesity-21||triglycerides-17||no_rel||however, the expected beneficial effects of endogenous fgf21 to increase glucose tolerance and reduce circulating triglycerides are absent in obesity.
amod||disease-3/NN||cytomegalovirus-1/JJ	amod||disease-3/NN||end-organ-2/JJ	nsubjpass||prevented-6/VBN||disease-3/NN	aux||prevented-6/VBN||can-4/MD	auxpass||prevented-6/VBN||be-5/VB	root||ROOT-0/null||prevented-6/VBN	agent||prevented-6/VBN||giving-8/VBG	dobj||giving-8/VBG||ganciclovir-9/NN	advmod||detected-13/VBN||when-10/WRB	nsubjpass||detected-13/VBN||viraemia-11/NN	auxpass||detected-13/VBN||is-12/VBZ	advcl||giving-8/VBG||detected-13/VBN	amod||recipients-16/NNS||allograft-15/JJ	prep_in||detected-13/VBN||recipients-16/NNS	cytomegalovirus-1||ganciclovir-9||yes||cytomegalovirus end-organ disease can be prevented by giving ganciclovir when viraemia is detected in allograft recipients.
det||results-2/NNS||these-1/DT	nsubj||indicate-4/VBP||results-2/NNS	advmod||indicate-4/VBP||clearly-3/RB	root||ROOT-0/null||indicate-4/VBP	det||superiority-6/NN||the-5/DT	dobj||indicate-4/VBP||superiority-6/NN	prep_of||superiority-6/NN||rbcg85c-8/NNS	prep_over||rbcg85c-8/NNS||bcg-10/NN	det||vaccine-15/NN||a-12/DT	amod||vaccine-15/NN||promising-13/JJ	amod||vaccine-15/NN||prophylactic-14/JJ	prep_as||indicate-4/VBP||vaccine-15/NN	prep_against||vaccine-15/NN||tb-17/NN	tb-17||bcg-10||no||these results clearly indicate the superiority of rbcg85c over bcg as a promising prophylactic vaccine against tb.
det||t-allele-2/NN||the-1/DT	nsubjpass||associated-9/VBN||t-allele-2/NN	amod||polymorphism-6/NN||tcf7l2-4/JJ	amod||polymorphism-6/NN||rs7903146-5/JJ	prep_of||t-allele-2/NN||polymorphism-6/NN	auxpass||associated-9/VBN||was-7/VBD	advmod||associated-9/VBN||independently-8/RB	root||ROOT-0/null||associated-9/VBN	prepc_with||associated-9/VBN||increasing-11/VBG	amod||values-14/NNS||fasting-12/JJ	nn||values-14/NNS||glucose-13/NN	dobj||increasing-11/VBG||values-14/NNS	prep_toward||increasing-11/VBG||hyperglycemia-16/NN	det||follow-up-19/NN||the-18/DT	prep_in||hyperglycemia-16/NN||follow-up-19/NN	hyperglycemia-16||glucose-13||no||the t-allele of tcf7l2 rs7903146 polymorphism was independently associated with increasing fasting glucose values toward hyperglycemia in the follow-up.
advmod||known-5/VBN||additionally-1/RB	nsubjpass||known-5/VBN||tam-3/NN	nsubj||promote-7/VB||tam-3/NN	auxpass||known-5/VBN||are-4/VBP	root||ROOT-0/null||known-5/VBN	aux||promote-7/VB||to-6/TO	xcomp||known-5/VBN||promote-7/VB	nn||progression-9/NN||tumor-8/NN	dobj||promote-7/VB||progression-9/NN	amod||types-13/NNS||most-11/JJS	nn||types-13/NNS||cancer-12/NN	prep_for||progression-9/NN||types-13/NNS	prep_including||progression-9/NN||lymphomas-16/NNS	tam-3||tumor-8||no_rel||additionally, tam are known to promote tumor progression for most cancer types, including lymphomas.
advmod||classified-3/VBN||histology-1/RB	auxpass||classified-3/VBN||was-2/VBD	root||ROOT-0/null||classified-3/VBN	prepc_according_to||classified-3/VBN||to-5/TO	pobj||classified-3/VBN||metavir-6/NN	det||ludwig-9/NN||the-8/DT	poss||classification-11/NN||ludwig-9/NN	pobj||classified-3/VBN||classification-11/NN	conj_and||metavir-6/NN||classification-11/NN	dep||classification-11/NN||f0-f4-13/JJ	prep_for||classification-11/NN||patients-16/NNS	amod||virus-21/NN||chronichepatitisc-18/JJ	conj_and||chronichepatitisc-18/JJ||b-20/SYM	amod||virus-21/NN||b-20/SYM	prep_with||patients-16/NNS||virus-21/NN	dep||virus-21/NN||hcv-23/NN	appos||hcv-23/NN||hbv-25/NN	nsubjpass||classified-3/VBN||infection-27/NN	nsubjpass||classified-3/VBN||primarybiliarycirrhosis-29/NNS	conj_and||infection-27/NN||primarybiliarycirrhosis-29/NNS	appos||infection-27/NN||pbc-31/NN	advmod||classified-3/VBN||respectively-34/RB	chronichepatitisc-18||hcv-23||no||histology was classified according to metavir and the ludwig's classification (f0-f4) for patients with chronichepatitisc and b virus (hcv, hbv) infection and primarybiliarycirrhosis (pbc), respectively.
nsubjpass||reported-39/VBN||conclusion-1/NN	amod||exposure-6/NN||short-term-2/JJ	advmod||single-dose-5/JJ||mostly-4/RB	amod||exposure-6/NN||single-dose-5/JJ	nsubjpass||associated-20/VBN||exposure-6/NN	prep_to||exposure-6/NN||asa-8/NN	det||treatment-11/NN||the-10/DT	prep_for||asa-8/NN||treatment-11/NN	prep_of||treatment-11/NN||pain-13/NN	prep_of||treatment-11/NN||fever-15/NN	conj_or||pain-13/NN||fever-15/NN	prep_of||treatment-11/NN||colds-18/NNS	conj_or||pain-13/NN||colds-18/NNS	auxpass||associated-20/VBN||was-19/VBD	rcmod||conclusion-1/NN||associated-20/VBN	det||increase-26/NN||a-22/DT	amod||increase-26/NN||small-23/JJ	conj_but||small-23/JJ||significant-25/JJ	amod||increase-26/NN||significant-25/JJ	prep_with||associated-20/VBN||increase-26/NN	det||risk-29/NN||the-28/DT	prep_in||increase-26/NN||risk-29/NN	prep_of||risk-29/NN||dyspepsia-31/NN	advmod||reported-39/VBN||relative-32/JJ	amod||complications-37/NNS||placebo.no-34/JJ	amod||complications-37/NNS||serious-35/JJ	nn||complications-37/NNS||gi-36/NN	prep_to||relative-32/JJ||complications-37/NNS	auxpass||reported-39/VBN||were-38/VBD	root||ROOT-0/null||reported-39/VBN	pain-13||asa-8||yes||conclusion short-term, mostly single-dose exposure to asa for the treatment of pain, fever, or colds was associated with a small but significant increase in the risk of dyspepsia relative to placebo.no serious gi complications were reported.
det||development-2/NN||the-1/DT	nsubjpass||prevented-8/VBN||development-2/NN	amod||hypertension-5/NN||sustained-4/JJ	prep_of||development-2/NN||hypertension-5/NN	auxpass||prevented-8/VBN||was-6/VBD	advmod||prevented-8/VBN||completely-7/RB	root||ROOT-0/null||prevented-8/VBN	agent||prevented-8/VBN||losartan-10/NN	mark||caused-15/VBD||whereas-12/IN	nsubj||caused-15/VBD||hydralazine-13/NN	advmod||caused-15/VBD||only-14/RB	advcl||prevented-8/VBN||caused-15/VBD	det||decrease-18/NN||a-16/DT	amod||decrease-18/NN||partial-17/JJ	dobj||caused-15/VBD||decrease-18/NN	prep_in||caused-15/VBD||bp-20/NN	hypertension-5||losartan-10||yes||the development of sustained hypertension was completely prevented by losartan, whereas hydralazine only caused a partial decrease in bp.
det||cdc-2/NN||the-1/DT	nsubj||recommends-3/VBZ||cdc-2/NN	root||ROOT-0/null||recommends-3/VBZ	mark||provide-7/VBP||that-4/IN	nn||settings-6/NNS||healthcare-5/NN	nsubj||provide-7/VBP||settings-6/NNS	ccomp||recommends-3/VBZ||provide-7/VBP	nn||patients-9/NNS||influenza-8/NN	dobj||provide-7/VBP||patients-9/NNS	prep_with||provide-7/VBP||facemasks-11/NNS	det||means-14/NN||a-13/DT	prep_as||facemasks-11/NNS||means-14/NN	prepc_of||means-14/NN||reducing-16/VBG	dobj||reducing-16/VBG||transmission-17/NN	nn||patients-22/NNS||staff-19/NN	conj_and||staff-19/NN||other-21/JJ	nn||patients-22/NNS||other-21/JJ	prep_to||reducing-16/VBG||patients-22/NNS	det||report-27/NN||a-25/DT	amod||report-27/NN||recent-26/JJ	nsubj||suggested-28/VBD||report-27/NN	conj_and||recommends-3/VBZ||suggested-28/VBD	mark||capture-33/VB||that-29/IN	amod||masks-31/NNS||surgical-30/JJ	nsubj||capture-33/VB||masks-31/NNS	aux||capture-33/VB||can-32/MD	ccomp||suggested-28/VBD||capture-33/VB	dobj||capture-33/VB||influenzavirus-34/NNS	amod||spray-38/NN||large-36/JJ	nn||spray-38/NN||droplet-37/NN	prep_in||capture-33/VB||spray-38/NN	influenza-8||influenzavirus-34||no||the cdc recommends that healthcare settings provide influenza patients with facemasks as a means of reducing transmission to staff and other patients, and a recent report suggested that surgical masks can capture influenzavirus in large droplet spray.
nsubjpass||induced-3/VBN||diarrhoea-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	amod||administration-6/NN||oral-5/JJ	agent||induced-3/VBN||administration-6/NN	num||castoroil-10/NN||0.5-8/CD	nn||castoroil-10/NN||ml-9/NN	prep_of||administration-6/NN||castoroil-10/NN	det||mouse-13/NN||each-12/DT	prep_to||induced-3/VBN||mouse-13/NN	num||h-16/NN||1-15/CD	appos||mouse-13/NN||h-16/NN	det||treatments-20/NNS||the-18/DT	amod||treatments-20/NNS||above-19/JJ	prep_after||induced-3/VBN||treatments-20/NNS	diarrhoea-1||castoroil-10||no||diarrhoea was induced by oral administration of 0.5 ml castoroil to each mouse, 1 h after the above treatments.
det||test-4/NN||the-1/DT	amod||test-4/NN||xpert-2/JJ	nn||test-4/NN||mtb/rif-3/NN	nsubj||detect-15/VB||test-4/NN	dep||test-4/NN||cepheid-6/VBN	dobj||cepheid-6/VBN||sunnyvale-8/NN	dep||sunnyvale-8/NN||ca-10/MD	appos||sunnyvale-8/NN||usa-12/NN	aux||detect-15/VB||can-14/MD	root||ROOT-0/null||detect-15/VB	dobj||detect-15/VB||tuberculosis-16/NNP	poss||form-20/NN||its-18/PRP$	amod||form-20/NN||multidrug-resistant-19/JJ	dobj||detect-15/VB||form-20/NN	conj_and||tuberculosis-16/NNP||form-20/NN	advmod||high-23/JJ||very-22/RB	amod||sensitivity-24/NN||high-23/JJ	prep_with||detect-15/VB||sensitivity-24/NN	prep_with||detect-15/VB||specificity-26/NN	conj_and||sensitivity-24/NN||specificity-26/NN	amod||studies-29/NNS||controlled-28/JJ	prep_in||detect-15/VB||studies-29/NNS	neg||data-34/NNS||no-32/DT	nn||data-34/NNS||performance-33/NN	nsubj||exist-35/VBP||data-34/NNS	conj_but||detect-15/VB||exist-35/VBP	nn||facilities-41/NNS||district-37/NN	conj_and||district-37/NN||subdistrict-39/NN	nn||facilities-41/NNS||subdistrict-39/NN	nn||facilities-41/NNS||health-40/NN	prep_from||exist-35/VBP||facilities-41/NNS	amod||countries-44/NNS||tuberculosis-endemic-43/JJ	prep_in||exist-35/VBP||countries-44/NNS	tuberculosis-16||mtb--1||no||the xpert mtb/rif test (cepheid, sunnyvale, ca, usa) can detect tuberculosis and its multidrug-resistant form with very high sensitivity and specificity in controlled studies, but no performance data exist from district and subdistrict health facilities in tuberculosis-endemic countries.
amod||grants-2/NNS||most-1/JJS	nsubj||funded-3/VBD||grants-2/NNS	root||ROOT-0/null||funded-3/VBD	amod||research-7/NN||basic-4/JJ	conj_and||basic-4/JJ||applied-6/JJ	amod||research-7/NN||applied-6/JJ	dobj||funded-3/VBD||research-7/NN	amod||areas-12/NNS||major-10/JJ	nn||areas-12/NNS||focus-11/NN	nsubj||hiv/aids-14/NNS||areas-12/NNS	cop||hiv/aids-14/NNS||being-13/VBG	prepc_with||funded-3/VBD||hiv/aids-14/NNS	num||%-17/NN||44-16/CD	appos||hiv/aids-14/NNS||%-17/NN	appos||hiv/aids-14/NNS||malaria-20/NN	num||%-23/NN||19-22/CD	appos||malaria-20/NN||%-23/NN	nn||health-29/NN||maternal-26/NN	conj_and||maternal-26/NN||child-28/NN	nn||health-29/NN||child-28/NN	appos||hiv/aids-14/NNS||health-29/NN	conj_and||malaria-20/NN||health-29/NN	num||%-32/NN||14-31/CD	appos||health-29/NN||%-32/NN	appos||hiv/aids-14/NNS||tuberculosis-35/NNP	conj_and||malaria-20/NN||tuberculosis-35/NNP	num||%-38/NN||11-37/CD	appos||tuberculosis-35/NNP||%-38/NN	amod||health-42/NN||mental-41/JJ	appos||hiv/aids-14/NNS||health-42/NN	conj_and||malaria-20/NN||health-42/NN	num||%-45/NN||3-44/CD	appos||health-42/NN||%-45/NN	appos||hiv/aids-14/NNS||others-49/NNS	conj_and||malaria-20/NN||others-49/NNS	num||%-52/NN||8-51/CD	appos||others-49/NNS||%-52/NN	aids--1||hiv--1||no||most grants funded basic and applied research, with major focus areas being hiv/aids (44%), malaria (19%), maternal and child health (14%), tuberculosis (11%), mental health (3%), and others (8%).
nsubj||investigated-3/VBN||we-1/PRP	aux||investigated-3/VBN||have-2/VBP	root||ROOT-0/null||investigated-3/VBN	det||effect-5/NN||the-4/DT	dobj||investigated-3/VBN||effect-5/NN	amod||treatment-9/NN||intermittent-7/JJ	nn||treatment-9/NN||preventive-8/NN	prep_of||effect-5/NN||treatment-9/NN	prep_with||treatment-9/NN||sulphadoxine-pyrimethamine-11/NN	prep_with||treatment-9/NN||artesunate-13/NN	conj_or||sulphadoxine-pyrimethamine-11/NN||artesunate-13/NN	dobj||investigated-3/VBN||amodiaquine-15/NN	conj_plus||effect-5/NN||amodiaquine-15/NN	prep_on||amodiaquine-15/NN||anaemia-17/NN	prep_on||amodiaquine-15/NN||malaria-19/NN	conj_and||anaemia-17/NN||malaria-19/NN	prep_in||investigated-3/VBN||children-21/NNS	det||area-24/NN||an-23/DT	prep_in||children-21/NNS||area-24/NN	amod||transmission-32/NN||intense-26/JJ	amod||transmission-32/NN||prolonged-28/JJ	amod||transmission-32/NN||seasonal-30/JJ	nn||transmission-32/NN||malaria-31/NN	prep_of||area-24/NN||transmission-32/NN	prep_in||investigated-3/VBN||ghana-34/NN	malaria-31||pyrimethamine--1||yes||we have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in ghana.
det||aminosalicylates-2/NNS||the-1/DT	nsubjpass||considered-14/VBN||aminosalicylates-2/NNS	dep||aminosalicylates-2/NNS||5-asa-4/JJ	advmod||referred-7/NN||also-6/RB	dep||5-asa-4/JJ||referred-7/NN	dep||referred-7/NN||to-8/TO	advmod||mesalamine-based-10/JJ||as-9/RB	amod||agents-11/NNS||mesalamine-based-10/JJ	dep||referred-7/NN||agents-11/NNS	auxpass||considered-14/VBN||are-13/VBP	root||ROOT-0/null||considered-14/VBN	prep_as||considered-14/VBN||first-line-16/NN	det||maintenance-19/NN||the-18/DT	prep_in||considered-14/VBN||maintenance-19/NN	prep_of||maintenance-19/NN||remission-21/NN	amod||moderate-25/JJ||mild-23/JJ	dep||moderate-25/JJ||to-24/TO	amod||ulcerativecolitis-26/NNS||moderate-25/JJ	prep_of||remission-21/NN||ulcerativecolitis-26/NNS	appos||ulcerativecolitis-26/NNS||uc-28/NN	uc-28||5-asa-4||yes||the aminosalicylates (5-asa; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerativecolitis (uc).
det||humanimmunodeficiencyvirus-2/NNS||the-1/DT	nsubj||acquired-7/VBD||humanimmunodeficiencyvirus-2/NNS	appos||humanimmunodeficiencyvirus-2/NNS||hiv-4/NN	advmod||acquired-7/VBD||/-6/RB	root||ROOT-0/null||acquired-7/VBD	amod||syndrome-9/NN||immunedeficiency-8/JJ	nsubj||has-14/VBZ||syndrome-9/NN	appos||syndrome-9/NN||aids-11/NNS	amod||syndrome-9/NN||pandemic-13/JJ	ccomp||acquired-7/VBD||has-14/VBZ	amod||effects-16/NNS||pervasive-15/JJ	dobj||has-14/VBZ||effects-16/NNS	prep_on||effects-16/NNS||culture-18/NN	prep_on||effects-16/NNS||economics-20/NNS	conj_and||culture-18/NN||economics-20/NNS	prep_on||effects-16/NNS||policy-22/NN	conj_and||culture-18/NN||policy-22/NN	amod||development-26/NN||human-25/JJ	prep_on||effects-16/NNS||development-26/NN	conj_and||culture-18/NN||development-26/NN	aids-11||humanimmunodeficiencyvirus-2||no||the humanimmunodeficiencyvirus (hiv)/ acquired immunedeficiency syndrome (aids) pandemic has pervasive effects on culture, economics, policy, and human development.
mark||improve-4/VB||in-1/IN	dep||improve-4/VB||order-2/NN	aux||improve-4/VB||to-3/TO	advcl||treating-15/VBG||improve-4/VB	det||effects-7/NNS||the-5/DT	amod||effects-7/NNS||systemic-6/JJ	dobj||improve-4/VB||effects-7/NNS	amod||therapy-10/NN||adjuvant-9/JJ	prep_of||effects-7/NNS||therapy-10/NN	nsubj||treating-15/VBG||we-12/PRP	aux||treating-15/VBG||have-13/VBP	aux||treating-15/VBG||been-14/VBN	root||ROOT-0/null||treating-15/VBG	dobj||treating-15/VBG||patients-16/NNS	amod||cancer-20/NN||resected-18/JJ	amod||cancer-20/NN||gastric-19/JJ	prep_with||patients-16/NNS||cancer-20/NN	prep_with||treating-15/VBG||carboplatin-22/NN	prep_with||treating-15/VBG||paclitaxel-24/NN	conj_and||carboplatin-22/NN||paclitaxel-24/NN	vmod||carboplatin-22/NN||followed-25/VBN	amod||analogue-28/NN||fluoropyrimidine-27/JJ	agent||followed-25/VBN||analogue-28/NN	agent||followed-25/VBN||radiation-30/NN	conj_and||analogue-28/NN||radiation-30/NN	cancer-20||paclitaxel-24||no_rel||in order to improve the systemic effects of adjuvant therapy, we have been treating patients with resected gastric cancer with carboplatin and paclitaxel followed by fluoropyrimidine analogue and radiation.
det||method-2/NN||a-1/DT	nsubjpass||used-23/VBN||method-2/NN	prepc_for||method-2/NN||genotyping-4/VBG	prepc_for||method-2/NN||subtyping-6/VBG	conj_and||genotyping-4/VBG||subtyping-6/VBG	dobj||genotyping-4/VBG||hbv-7/NN	amod||gene-11/NN||partial-9/JJ	amod||gene-11/NN||hbsag-10/VBG	prep_by||hbv-7/NN||gene-11/NN	vmod||gene-11/NN||sequencing-12/VBG	vmod||sequencing-12/VBG||using-13/VBG	dobj||using-13/VBG||primers-14/NNS	nsubj||complementary-17/JJ||primers-14/NNS	cop||complementary-17/JJ||are-16/VBP	rcmod||primers-14/NNS||complementary-17/JJ	advmod||known-20/VBN||all-19/RB	amod||genotypes-21/NNS||known-20/VBN	prep_to||complementary-17/JJ||genotypes-21/NNS	auxpass||used-23/VBN||was-22/VBD	root||ROOT-0/null||used-23/VBN	hbsag-10||hbv-7||no_rel||a method for genotyping and subtyping hbv by partial hbsag gene sequencing using primers that are complementary to all known genotypes was used.
amod||risks-4/NNS||gastrointestinal-3/JJ	prep_because_of||propose-30/VBP||risks-4/NNS	nn||complications-8/NNS||ulcer-7/NN	prep_including||risks-4/NNS||complications-8/NNS	amod||risks-12/NNS||cardiovascular-11/JJ	conj_and||risks-4/NNS||risks-12/NNS	prep_because_of||propose-30/VBP||risks-12/NNS	nn||events-18/NNS||hypertension-15/NN	conj_and||hypertension-15/NN||thrombotic-17/JJ	nn||events-18/NNS||thrombotic-17/JJ	prep_including||risks-12/NNS||events-18/NNS	vmod||events-18/NNS||associated-19/VBN	amod||anti-inflammatorydrugs-22/NNS||nonsteroidal-21/JJ	prep_with||associated-19/VBN||anti-inflammatorydrugs-22/NNS	num||nsaids-24/NNS||-LSB--23/CD	npadvmod||-RSB--25/JJ||nsaids-24/NNS	amod||anti-inflammatorydrugs-22/NNS||-RSB--25/JJ	det||guidelines-29/NNS||these-28/DT	nsubj||propose-30/VBP||guidelines-29/NNS	root||ROOT-0/null||propose-30/VBP	dobj||propose-30/VBP||acetaminophen-31/NN	det||anti-inflammatoryagents-36/NNS||the-33/DT	amod||anti-inflammatoryagents-36/NNS||first-34/JJ	nn||anti-inflammatoryagents-36/NNS||choice-35/NN	prep_as||propose-30/VBP||anti-inflammatoryagents-36/NNS	ulcer-7||nsaids-24||no_rel||because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidal anti-inflammatorydrugs [nsaids]), these guidelines propose acetaminophen as the first choice anti-inflammatoryagents.
nsubj||therapy-7/NN||tamoxifen-1/NN	cop||therapy-7/NN||is-2/VBZ	det||therapy-7/NN||the-3/DT	advmod||prescribed-6/JJ||most-4/RBS	advmod||prescribed-6/JJ||commonly-5/RB	amod||therapy-7/NN||prescribed-6/JJ	root||ROOT-0/null||therapy-7/NN	prep_for||therapy-7/NN||patients-9/NNS	nn||receptor-12/NN||estrogen-11/NN	prep_with||patients-9/NNS||receptor-12/NN	dep||therapy-7/NN||er-14/VBN	nn||±-17/NNS||î-16/NN	dep||therapy-7/NN||±-17/NNS	amod||breasttumors-20/NNS||positive-19/JJ	dep||±-17/NNS||breasttumors-20/NNS	breasttumors-20||estrogen-11||no||tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (er)î±-positive breasttumors.
prep_in||belonged-8/VBD||total-2/NN	num||%-5/NN||77-4/CD	nsubj||belonged-8/VBD||%-5/NN	prep_of||%-5/NN||isolates-7/NNP	root||ROOT-0/null||belonged-8/VBD	det||mycobacteriumtuberculosiscomplex-11/NN||the-10/DT	prep_to||belonged-8/VBD||mycobacteriumtuberculosiscomplex-11/NN	num||%-15/NN||23-14/CD	nsubj||mycobacteria-18/NN||%-15/NN	cop||mycobacteria-18/NN||were-16/VBD	amod||mycobacteria-18/NN||non-tuberculous-17/JJ	conj_and||belonged-8/VBD||mycobacteria-18/NN	tuberculous--1||mycobacteriumtuberculosiscomplex-11||no||in total, 77% of isolates belonged to the mycobacteriumtuberculosiscomplex, and 23% were non-tuberculous mycobacteria.
det||aminoacids-5/NNS||the-2/DT	num||aminoacids-5/NNS||fourteen-3/CD	amod||aminoacids-5/NNS||aromatic-4/JJ	prep_of||conserved-16/VBN||aminoacids-5/NNS	det||gorge-9/NN||the-7/DT	amod||gorge-9/NN||catalytic-8/JJ	prep_in||aminoacids-5/NNS||gorge-9/NN	amod||ache-12/NN||vertebrate-11/JJ	prep_of||gorge-9/NN||ache-12/NN	nsubjpass||conserved-16/VBN||ten-14/CD	auxpass||conserved-16/VBN||are-15/VBP	root||ROOT-0/null||conserved-16/VBN	det||bche-20/NN||the-18/DT	amod||bche-20/NN||atypical-19/JJ	prep_in||conserved-16/VBN||bche-20/NN	nn||latipes-23/NNS||o.-22/NN	prep_of||bche-20/NN||latipes-23/NNS	agent||conserved-31/VBN||contrast-26/NN	advmod||eight-29/CD||only-28/RB	nsubjpass||conserved-31/VBN||eight-29/CD	auxpass||conserved-31/VBN||are-30/VBP	parataxis||conserved-16/VBN||conserved-31/VBN	amod||bche-34/NN||vertebrate-33/JJ	prep_in||conserved-31/VBN||bche-34/NN	ten-14||aminoacids-5||no_rel||of the fourteen aromatic aminoacids in the catalytic gorge of vertebrate ache , ten are conserved in the atypical bche of o. latipes ; by contrast , only eight are conserved in vertebrate bche .
amod||responses-2/NNS||immune-1/JJ	nsubj||lead-31/VB||responses-2/NNS	amod||lymphocytes-6/NNS||cytotoxic-4/JJ	nn||lymphocytes-6/NNS||t-5/NN	prep_of||responses-2/NNS||lymphocytes-6/NNS	amod||ctls-8/NNS||-lrb--7/JJ	dep||lymphocytes-6/NNS||ctls-8/NNS	nsubjpass||implicated-11/VBN||-rrb--9/NNP	auxpass||implicated-11/VBN||are-10/VBP	rcmod||ctls-8/NNS||implicated-11/VBN	amod||eradication-14/NN||viral-13/JJ	prep_in||implicated-11/VBN||eradication-14/NN	det||pathogenesis-17/NNS||the-16/DT	prep_in||implicated-11/VBN||pathogenesis-17/NNS	conj_and||eradication-14/NN||pathogenesis-17/NNS	prep_of||pathogenesis-17/NNS||hepatitisc-19/NN	amod||response-23/NN||weak-21/JJ	nn||response-23/NN||ctl-22/NN	dep||ctls-8/NNS||response-23/NN	amod||-rrb--29/NNP||hepatitisc-25/JJ	nn||-rrb--29/NNP||virus-26/NN	nn||-rrb--29/NNP||-lrb--27/NNP	nn||-rrb--29/NNP||hcv-28/NNP	prep_against||response-23/NN||-rrb--29/NNP	aux||lead-31/VB||may-30/MD	root||ROOT-0/null||lead-31/VB	det||infection-35/NN||a-33/DT	amod||infection-35/NN||persistent-34/JJ	prep_to||lead-31/VB||infection-35/NN	hepatitisc-25||hepatitiscvirus--1||no||immune responses of cytotoxic t lymphocytes -lrb- ctls -rrb- are implicated in viral eradication and the pathogenesis of hepatitisc. weak ctl response against hepatitisc virus -lrb- hcv -rrb- may lead to a persistent infection .
advmod||seen-16/VBN||irondeficiency-1/RB	nsubjpass||seen-16/VBN||anemia-3/NN	amod||anemia-6/NN||irondeficiency-5/JJ	conj_and||anemia-3/NN||anemia-6/NN	nsubjpass||seen-16/VBN||anemia-6/NN	nn||depletion-9/NN||iron-8/NN	conj_and||anemia-3/NN||depletion-9/NN	nsubjpass||seen-16/VBN||depletion-9/NN	conj_and||anemia-3/NN||lack-11/NN	nsubjpass||seen-16/VBN||lack-11/NN	nn||resources-14/NNS||iron-13/NN	prep_of||lack-11/NN||resources-14/NNS	auxpass||seen-16/VBN||were-15/VBD	root||ROOT-0/null||seen-16/VBN	prep_in||seen-16/VBN||2.3-18/CD	prep_in||seen-16/VBN||4.08-20/CD	conj_and||2.3-18/CD||4.08-20/CD	prep_in||seen-16/VBN||2.14-22/CD	conj_and||2.3-18/CD||2.14-22/CD	prep_in||seen-16/VBN||22.76-24/NNP	conj_and||2.3-18/CD||22.76-24/NNP	amod||percent-27/NN||4.66-26/JJ	prep_in||seen-16/VBN||percent-27/NN	conj_and||2.3-18/CD||percent-27/NN	advmod||seen-16/VBN||respectively-28/RB	anemia-6||irondeficiency-5||yes||irondeficiency, anemia, irondeficiency anemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
amod||trials-4/NNS||twenty-five-1/JJ	amod||trials-4/NNS||completed-2/VBN	amod||trials-4/NNS||randomized-3/JJ	nsubjpass||included-12/VBN||trials-4/NNS	nsubj||cilostazol-37/VBP||trials-4/NNS	num||patients-7/NNS||17,383-6/CD	dep||trials-4/NNS||patients-7/NNS	prep_with||patients-7/NNS||ihd-9/NN	auxpass||included-12/VBN||were-11/VBD	root||ROOT-0/null||included-12/VBN	nsubj||involving-14/VBG||which-13/WDT	ccomp||included-12/VBN||involving-14/VBG	det||use-16/NN||the-15/DT	nsubj||clopidogrel-35/JJ||use-16/NN	amod||inhibitors-24/NNS||intravenous-18/JJ	appos||inhibitors-24/NNS||iv-20/NN	amod||inhibitors-24/NNS||gp-22/JJ	nn||inhibitors-24/NNS||iib/iiia-23/NNP	prep_of||use-16/NN||inhibitors-24/NNS	nn||tirofiban-30/NN||abciximab-26/NN	dep||tirofiban-30/NN||eptifibatide-28/NN	appos||use-16/NN||tirofiban-30/NN	appos||use-16/NN||aspirin-33/NN	xcomp||involving-14/VBG||clopidogrel-35/JJ	conj_and/or||included-12/VBN||cilostazol-37/VBP	ihd-9||tirofiban-30||yes||twenty-five completed randomized trials (17,383 patients with ihd) were included which involving the use of intravenous (iv) gp iib/iiia inhibitors (abciximab, eptifibatide, tirofiban), aspirin, clopidogrel and/or cilostazol.
amod||studies-2/NNS||clinical-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||effective-12/JJ||that-5/IN	nsubj||effective-12/JJ||naproxen-6/NN	conj_and||naproxen-6/NN||ibuprofen-8/NN	nsubj||effective-12/JJ||ibuprofen-8/NN	cop||effective-12/JJ||are-9/VBP	advmod||effective-12/JJ||significantly-10/RB	advmod||effective-12/JJ||more-11/RBR	ccomp||shown-4/VBN||effective-12/JJ	prepc_at||effective-12/JJ||reducing-14/VBG	nn||pain-16/NN||oa-15/NN	dobj||reducing-14/VBG||pain-16/NN	mark||acetaminophen-19/NN||than-17/IN	cop||acetaminophen-19/NN||is-18/VBZ	ccomp||effective-12/JJ||acetaminophen-19/NN	nsubj||has-27/VBZ||acetaminophen-19/NN	det||therapy-24/NN||the-21/DT	amod||therapy-24/NN||traditional-22/JJ	amod||therapy-24/NN||first-line-23/JJ	appos||acetaminophen-19/NN||therapy-24/NN	rcmod||acetaminophen-19/NN||has-27/VBZ	neg||activity-31/NN||no-28/DT	amod||activity-31/NN||apparent-29/JJ	amod||activity-31/NN||anti-inflammatory-30/JJ	dobj||has-27/VBZ||activity-31/NN	det||joints-34/NNS||the-33/DT	prep_in||activity-31/NN||joints-34/NNS	pain-16||acetaminophen-19||yes||clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing oa pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints.
nsubj||suggest-5/VBP||results-1/NNS	det||study-4/NN||this-3/DT	prep_from||results-1/NNS||study-4/NN	root||ROOT-0/null||suggest-5/VBP	mark||investigated-16/VBN||that-6/IN	amod||treatment-9/NN||nutrient-7/JJ	nn||treatment-9/NN||starvation-8/NN	nsubjpass||investigated-16/VBN||treatment-9/NN	amod||bcgvaccines-12/NNS||live-11/JJ	prep_of||treatment-9/NN||bcgvaccines-12/NNS	aux||investigated-16/VBN||should-13/MD	auxpass||investigated-16/VBN||be-14/VB	advmod||investigated-16/VBN||further-15/RBR	ccomp||suggest-5/VBP||investigated-16/VBN	det||way-19/NN||a-18/DT	prep_as||investigated-16/VBN||way-19/NN	aux||increase-21/VB||to-20/TO	vmod||way-19/NN||increase-21/VB	nn||induction-23/NN||host-22/NN	dobj||increase-21/VB||induction-23/NN	amod||cytokines-27/NNS||th-1-25/JJ	amod||cytokines-27/NNS||related-26/JJ	prep_of||induction-23/NN||cytokines-27/NNS	det||development-30/NN||the-29/DT	prep_in||increase-21/VB||development-30/NN	amod||vaccines-34/NNS||experimental-32/JJ	amod||vaccines-34/NNS||anti-tb-33/JJ	prep_of||development-30/NN||vaccines-34/NNS	tb--1||bcgvaccines-12||no||results from this study suggest that nutrient starvation treatment of live bcgvaccines should be further investigated as a way to increase host induction of th-1 related cytokines in the development of experimental anti-tb vaccines.
nsubj||strategy-15/NN||suppression-1/NN	amod||virus-5/NN||herpes-3/JJ	nn||virus-5/NN||simplex-4/NN	prep_of||suppression-1/NN||virus-5/NN	amod||virus-5/NN||type-6/NN	number||type-6/NN||2-7/CD	dep||virus-5/NN||hsv-2-9/JJ	aux||strategy-15/NN||may-11/MD	cop||strategy-15/NN||be-12/VB	det||strategy-15/NN||a-13/DT	nn||strategy-15/NN||novel-14/NN	dep||associated-23/VBN||strategy-15/NN	prepc_for||strategy-15/NN||achieving-17/VBG	det||goal-19/NN||this-18/DT	dobj||achieving-17/VBG||goal-19/NN	prep_because||achieving-17/VBG||hsv-2-21/JJ	auxpass||associated-23/VBN||is-22/VBZ	root||ROOT-0/null||associated-23/VBN	advmod||significant-26/JJ||clinically-25/RB	amod||increases-27/NNS||significant-26/JJ	prep_with||associated-23/VBN||increases-27/NNS	prep_in||increases-27/NNS||hiv-29/NN	amod||load-31/NN||viral-30/JJ	nsubjpass||associated-23/VBN||load-31/NN	det||driver-35/NN||the-33/DT	amod||driver-35/NN||primary-34/JJ	appos||load-31/NN||driver-35/NN	amod||progression-38/NN||hivdisease-37/JJ	prep_of||driver-35/NN||progression-38/NN	hivdisease-37||hiv-29||no||suppression of herpes simplex virus type 2 (hsv-2) may be a novel strategy for achieving this goal because hsv-2 is associated with clinically significant increases in hiv viral load, the primary driver of hivdisease progression.
advmod||confers-7/VBZ||finally-1/RB	det||lack-4/NN||the-3/DT	nsubj||confers-7/VBZ||lack-4/NN	prep_of||lack-4/NN||ptp1b-6/CD	root||ROOT-0/null||confers-7/VBZ	dobj||confers-7/VBZ||protection-8/NN	amod||tests-40/NNS||il-6â-10/JJ	dep||il-6â-10/JJ||$-11/$	advmod||insulinresistance-14/RB||induced-13/RB	dep||observed-34/CD||insulinresistance-14/RB	amod||muscle-17/NN||skeletal-16/JJ	prep_in||insulinresistance-14/RB||muscle-17/NN	prep_in||muscle-17/NN||vitro-19/NN	prep_in||muscle-17/NN||in-21/IN	conj_and||vitro-19/NN||in-21/IN	pobj||in-21/IN||vivo-22/NN	prep_in||insulinresistance-14/RB||agreement-25/NN	det||protection-28/NN||the-27/DT	prep_with||agreement-25/NN||protection-28/NN	det||effect-33/NN||the-30/DT	amod||effect-33/NN||il-6-31/JJ	amod||effect-33/NN||hyperglycemic-32/JJ	prep_against||protection-28/NN||effect-33/NN	num||$-11/$||observed-34/CD	prep_on||$-11/$||glucose-36/NN	prep_on||$-11/$||insulin-38/NN	conj_and||glucose-36/NN||insulin-38/NN	nn||tests-40/NNS||tolerance-39/NN	prep_against||protection-8/NN||tests-40/NNS	amod||mice-44/NNS||adult-42/JJ	amod||mice-44/NNS||male-43/JJ	prep_in||tests-40/NNS||mice-44/NNS	insulin-38||insulinresistance-14||no_rel||finally, the lack of ptp1b confers protection against il-6â€“induced insulinresistance in skeletal muscle in vitro and in vivo, in agreement with the protection against the il-6 hyperglycemic effect observed on glucose and insulin tolerance tests in adult male mice.
nsubj||sought-2/VBD||we-1/PRP	nsubj||determine-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||determine-4/VB||to-3/TO	xcomp||sought-2/VBD||determine-4/VB	mark||altered-36/VBN||if-5/IN	nsubjpass||altered-36/VBN||upa-6/NN	nn||inhibitor-9/NN||pa-8/NN	appos||upa-6/NN||inhibitor-9/NN	appos||inhibitor-9/NN||pai-11/NN	dep||inhibitor-9/NN||-1-13/CD	num||expression-20/NN||prostaglandin-15/CD	nn||expression-20/NN||pg-17/NN	amod||expression-20/NN||e2-19/JJ	appos||upa-6/NN||expression-20/NN	conj_and||inhibitor-9/NN||expression-20/NN	amod||fluid-24/NN||nipple-22/JJ	nn||fluid-24/NN||aspirate-23/NN	prep_in||expression-20/NN||fluid-24/NN	appos||fluid-24/NN||naf-26/NN	nn||expression-32/NN||upa-29/NN	conj_and||upa-29/NN||pge2-31/JJ	nn||expression-32/NN||pge2-31/JJ	prep_in||expression-20/NN||expression-32/NN	conj_and||fluid-24/NN||expression-32/NN	prep_in||expression-32/NN||plasma-34/NN	auxpass||altered-36/VBN||were-35/VBD	advcl||determine-4/VB||altered-36/VBN	nn||dose-39/NN||celecoxib-38/NN	agent||altered-36/VBN||dose-39/NN	agent||altered-36/VBN||concentration-41/NN	conj_and||dose-39/NN||concentration-41/NN	prep_in||altered-36/VBN||women-43/NNS	amod||risk-48/NN||increased-45/VBN	nn||risk-48/NN||breast-46/NN	nn||risk-48/NN||cancer-47/NN	prep_at||women-43/NNS||risk-48/NN	cancer-47||upa-29||no_rel||we sought to determine if upa, pa inhibitor (pai)-1 and prostaglandin (pg)e2 expression in nipple aspirate fluid (naf) and upa and pge2 expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk.
nsubj||follow-6/VB||infectiousmononucleosis-1/NNS	nsubjpass||shown-19/VBN||infectiousmononucleosis-1/NNS	nsubj||increase-21/VB||infectiousmononucleosis-1/NNS	appos||infectiousmononucleosis-1/NNS||im-3/NN	aux||follow-6/VB||can-5/MD	root||ROOT-0/null||follow-6/VB	amod||infection-9/NN||late-7/JJ	amod||infection-9/NN||primary-8/JJ	dobj||follow-6/VB||infection-9/NN	prep_with||follow-6/VB||epstein-barrvirus-11/NNS	appos||epstein-barrvirus-11/NNS||ebv-13/NN	aux||shown-19/VBN||has-17/VBZ	auxpass||shown-19/VBN||been-18/VBN	conj_and||follow-6/VB||shown-19/VBN	aux||increase-21/VB||to-20/TO	xcomp||shown-19/VBN||increase-21/VB	det||risk-23/NN||the-22/DT	dobj||increase-21/VB||risk-23/NN	prep_of||risk-23/NN||multiplesclerosis-25/NNS	poss||disease-29/NN||hodgkin-27/NN	prep_of||risk-23/NN||disease-29/NN	conj_and||multiplesclerosis-25/NNS||disease-29/NN	infectiousmononucleosis-1||epstein-barrvirus-11||no||infectiousmononucleosis (im) can follow late primary infection with epstein-barrvirus (ebv), and has been shown to increase the risk of multiplesclerosis and hodgkin's disease.
nsubj||disease-9/NN||pml-1/NN	cop||disease-9/NN||is-2/VBZ	det||disease-9/NN||a-3/DT	amod||disease-9/NN||progressive-4/JJ	advmod||fatal-7/JJ||mostly-6/RB	conj_and||progressive-4/JJ||fatal-7/JJ	amod||disease-9/NN||fatal-7/JJ	nn||disease-9/NN||demyelinating-8/NN	root||ROOT-0/null||disease-9/NN	vmod||disease-9/NN||caused-10/VBN	agent||caused-10/VBN||jcvirusinfection-12/NN	agent||caused-10/VBN||destruction-14/NN	conj_and||jcvirusinfection-12/NN||destruction-14/NN	amod||oligodendrocytes-17/NNS||infected-16/JJ	prep_of||jcvirusinfection-12/NN||oligodendrocytes-17/NNS	amod||foci-21/NNS||multiple-19/JJ	nn||foci-21/NNS||brain-20/NN	prep_in||caused-10/VBN||foci-21/NNS	amod||individuals-24/NNS||susceptible-23/JJ	prep_of||foci-21/NNS||individuals-24/NNS	pml-1||jcvirus--1||no||pml is a progressive and mostly fatal demyelinating disease caused by jcvirusinfection and destruction of infected oligodendrocytes in multiple brain foci of susceptible individuals.
aux||prevent-2/VB||to-1/TO	advcl||added-23/VBN||prevent-2/VB	dobj||prevent-2/VB||hyperinsulinemia-3/NN	nsubj||cause-7/VB||hyperinsulinemia-3/NN	aux||cause-7/VB||may-6/MD	rcmod||hyperinsulinemia-3/NN||cause-7/VB	dobj||cause-7/VB||atherosclerosis-8/NNS	nsubjpass||added-23/VBN||thiazolidinediones-10/NNS	appos||thiazolidinediones-10/NNS||tzds-12/NNS	advmod||known-16/VBN||also-15/RB	vmod||thiazolidinediones-10/NNS||known-16/VBN	nn||sensitizers-19/NNS||insulin-18/NN	prep_as||known-16/VBN||sensitizers-19/NNS	auxpass||added-23/VBN||are-21/VBP	advmod||added-23/VBN||often-22/RB	root||ROOT-0/null||added-23/VBN	det||regimen-27/NN||the-25/DT	amod||regimen-27/NN||therapeutic-26/JJ	prep_to||added-23/VBN||regimen-27/NN	prep_of||regimen-27/NN||patients-29/NNS	prep_with||added-23/VBN||type2diabetes-31/NNS	nsubj||receiving-34/VBG||type2diabetes-31/NNS	aux||receiving-34/VBG||are-33/VBP	rcmod||type2diabetes-31/NNS||receiving-34/VBG	dobj||receiving-34/VBG||insulin-35/NN	type2diabetes-31||insulin-35||yes||to prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (tzds), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type2diabetes who are receiving insulin.
nn||design-2/NN||research-1/NN	nsubjpass||assigned-21/VBN||design-2/NN	poss||patients-8/NNS||methods-4/NNS	amod||patients-8/NNS||$-6/JJ	conj_and||design-2/NN||patients-8/NNS	nsubjpass||assigned-21/VBN||patients-8/NNS	dep||patients-8/NNS||type2diabetes-10/NNS	amod||30â-13/NNS||aged-12/JJ	appos||type2diabetes-10/NNS||30â-13/NNS	num||years-17/NNS||$-14/$	num||$-14/$||75-16/CD	dep||30â-13/NNS||years-17/NNS	auxpass||assigned-21/VBN||were-19/VBD	advmod||assigned-21/VBN||randomly-20/RB	root||ROOT-0/null||assigned-21/VBN	num||days-24/NNS||21-23/CD	prep_within||assigned-21/VBN||days-24/NNS	amod||strategy-32/NN||ami-26/JJ	det||prandial-31/NNS||the-28/DT	num||prandial-31/NNS||1-29/CD	prep_to||ami-26/JJ||prandial-31/NNS	prep_after||days-24/NNS||strategy-32/NN	dep||days-24/NNS||prandial-34/VB	num||doses-39/NNS||three-37/CD	amod||doses-39/NNS||premeal-38/JJ	dep||days-24/NNS||doses-39/NNS	nn||lispro-42/NN||insulin-41/NN	prep_of||doses-39/NNS||lispro-42/NN	vmod||lispro-42/NN||targeting-43/VBG	amod||glucose-47/NN||2-h-44/JJ	amod||glucose-47/NN||postprandial-45/JJ	nn||glucose-47/NN||blood-46/NN	dobj||targeting-43/VBG||glucose-47/NN	punct||glucose-47/NN||<-48/``	number||mmol/l-50/JJ||7.5-49/CD	amod||glucose-47/NN||mmol/l-50/JJ	det||strategy-57/NN||the-53/DT	nn||strategy-57/NN||2-54/NN	amod||strategy-57/NN||basal-56/JJ	prep_within||assigned-21/VBN||strategy-57/NN	conj_or||days-24/NNS||strategy-57/NN	dep||strategy-57/NN||basal-59/JJ	dep||strategy-57/NN||nph-62/VBN	advmod||daily-64/JJ||twice-63/RB	advmod||nph-62/VBN||daily-64/JJ	dep||daily-68/RB||insulinglargine-66/NN	advmod||daily-68/RB||once-67/RB	advmod||nph-62/VBN||daily-68/RB	conj_or||daily-64/JJ||daily-68/RB	xcomp||nph-62/VBN||targeting-69/VBG	amod||glucose-72/NN||fasting/premeal-70/JJ	nn||glucose-72/NN||blood-71/NN	nsubj||mmol/l-75/NN||glucose-72/NN	dep||mmol/l-75/NN||<-73/SYM	num||mmol/l-75/NN||6.7-74/CD	ccomp||targeting-69/VBG||mmol/l-75/NN	type2diabetes-10||insulinglargine-66||yes||research design and methods â€”patients (type2diabetes, aged 30â€“75 years) were randomly assigned within 21 days after ami to the 1 ) prandial strategy (prandial) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l) or the 2 ) basal strategy (basal) (nph twice daily or insulinglargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l).
det||agonist-8/NN||a-1/DT	amod||adenosine-3/JJ||known-2/JJ	amod||agonist-8/NN||adenosine-3/JJ	nn||agonist-8/NN||receptor-4/NN	appos||agonist-8/NN||ar-6/NN	nsubjpass||conjugated-10/VBN||agonist-8/NN	nsubj||polyamidoamine-12/VB||agonist-8/NN	auxpass||conjugated-10/VBN||was-9/VBD	root||ROOT-0/null||conjugated-10/VBN	aux||polyamidoamine-12/VB||to-11/TO	xcomp||conjugated-10/VBN||polyamidoamine-12/VB	appos||carriers-17/NNS||pamam-14/NNP	amod||carriers-17/NNS||dendrimer-16/JJ	dobj||polyamidoamine-12/VB||carriers-17/NNS	prep_for||polyamidoamine-12/VB||delivery-19/NN	det||conjugate-24/NN||the-21/DT	amod||covalent-23/JJ||intact-22/JJ	amod||conjugate-24/NN||covalent-23/JJ	prep_of||delivery-19/NN||conjugate-24/NN	prep||polyamidoamine-12/VB||to-25/TO	pcomp||to-25/TO||on-26/IN	det||surface-29/NN||the-27/DT	nn||surface-29/NN||cell-28/NN	pobj||on-26/IN||surface-29/NN	adenosine-3||ar-6||no_rel||a known adenosine receptor (ar) agonist was conjugated to polyamidoamine (pamam) dendrimer carriers for delivery of the intact covalent conjugate to on the cell surface.
advmod||analyzed-4/VBD||first-1/RB	nsubj||analyzed-4/VBD||we-3/PRP	root||ROOT-0/null||analyzed-4/VBD	nsubj||confirmed-6/VBD||culture-5/NN	ccomp||analyzed-4/VBD||confirmed-6/VBD	nn||disease-8/NN||tb-7/NN	dobj||confirmed-6/VBD||disease-8/NN	prepc_compared_to||confirmed-6/VBD||to-10/TO	nn||infection-13/NN||latent-11/NN	nn||infection-13/NN||mtb-12/NN	pobj||confirmed-6/VBD||infection-13/NN	appos||infection-13/NN||ltbi-15/NNP	pobj||confirmed-6/VBD||lack-18/NN	conj_or||infection-13/NN||lack-18/NN	nn||infection-21/NN||mtb-20/NN	prep_of||lack-18/NN||infection-21/NN	tb-7||mtb-20||no||first, we analyzed culture confirmed tb disease compared to latent mtb infection (ltbi) or lack of mtb infection.
amod||type-5/NN||human-1/JJ	amod||type-5/NN||t-cell-2/JJ	amod||type-5/NN||lymphotropic-3/JJ	nn||type-5/NN||virus-4/NN	nsubj||agent-13/NN||type-5/NN	dep||type-5/NN||1-6/CD	dep||type-5/NN||htlv-1-8/JJ	cop||agent-13/NN||is-10/VBZ	det||agent-13/NN||the-11/DT	amod||agent-13/NN||etiological-12/JJ	root||ROOT-0/null||agent-13/NN	amod||leukemia-17/NN||adult-15/JJ	amod||leukemia-17/NN||t-cell-16/JJ	prep_of||agent-13/NN||leukemia-17/NN	appos||leukemia-17/NN||atl-19/NN	amod||tropicalspasticparaparesis-24/NNS||htlv-1-associatedmyelopathy-22/JJ	amod||tropicalspasticparaparesis-24/NNS||/-23/JJ	prep_of||agent-13/NN||tropicalspasticparaparesis-24/NNS	conj_and||leukemia-17/NN||tropicalspasticparaparesis-24/NNS	appos||leukemia-17/NN||ham/tsp-26/NN	ham--1||htlv-1-8||no||human t-cell lymphotropic virus type 1 (htlv-1) is the etiological agent of adult t-cell leukemia (atl) and htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
nsubjpass||observed-3/VBN||it-1/PRP	auxpass||observed-3/VBN||was-2/VBD	root||ROOT-0/null||observed-3/VBN	mark||reversed-22/VBD||that-4/IN	nsubj||reversed-22/VBD||pa-5/NN	det||doses-9/NNS||the-7/DT	amod||doses-9/NNS||above-mentioned-8/JJ	prep_at||pa-5/NN||doses-9/NNS	nn||days-14/NNS||7-11/CD	conj_and||7-11/CD||14-13/CD	nn||days-14/NNS||14-13/CD	prep_after||doses-9/NNS||days-14/NNS	prep_of||days-14/NNS||administration-16/NN	det||groups-20/NNS||the-18/DT	amod||groups-20/NNS||respective-19/JJ	prep_in||administration-16/NN||groups-20/NNS	advmod||reversed-22/VBD||significantly-21/RB	ccomp||observed-3/VBN||reversed-22/VBD	dobj||reversed-22/VBD||scopolamine-23/NN	num||i.p.-27/NN||1-25/CD	nn||i.p.-27/NN||mg/kg-26/NN	appos||scopolamine-23/NN||i.p.-27/NN	amod||amnesia-31/NN||induced-30/JJ	dep||scopolamine-23/NN||amnesia-31/NN	mark||evidenced-34/VBN||as-33/IN	dep||scopolamine-23/NN||evidenced-34/VBN	det||decrease-37/NN||a-36/DT	prep_by||evidenced-34/VBN||decrease-37/NN	det||latency-41/NN||the-39/DT	nn||latency-41/NN||transfer-40/NN	prep_in||decrease-37/NN||latency-41/NN	det||task-45/NN||the-43/DT	nn||task-45/NN||epm-44/NN	prep_in||evidenced-34/VBN||task-45/NN	nn||latency-48/NN||step-down-47/NN	prep_in||evidenced-34/VBN||latency-48/NN	conj_and||task-45/NN||latency-48/NN	det||task-53/NN||the-50/DT	amod||task-53/NN||passive-51/JJ	nn||task-53/NN||avoidance-52/NN	prep_in||evidenced-34/VBN||task-53/NN	amnesia-31||scopolamine-23||no||it was observed that pa at the above-mentioned doses after 7 and 14 days of administration in the respective groups significantly reversed scopolamine (1 mg/kg i.p.)-induced amnesia, as evidenced by a decrease in the transfer latency in the epm task and step-down latency in the passive avoidance task.
nsubj||endocrinedisease-6/NN||endogenous-1/NNS	vmod||endogenous-1/NNS||cushing-2/VBG	dobj||cushing-2/VBG||syndrome-3/NN	cop||endocrinedisease-6/NN||is-4/VBZ	det||endocrinedisease-6/NN||an-5/DT	root||ROOT-0/null||endocrinedisease-6/NN	vmod||endocrinedisease-6/NN||caused-7/VBN	amod||secretion-10/NN||excessive-9/JJ	agent||caused-7/VBN||secretion-10/NN	nn||hormone-13/NN||adrenocorticotropin-12/NN	prep_of||secretion-10/NN||hormone-13/NN	quantmod||80-16/CD||approximately-15/RB	num||%-17/NN||80-16/CD	prep_in||caused-7/VBN||%-17/NN	prep_of||%-17/NN||cases-19/NNS	advmod||caused-7/VBN||usually-21/RB	det||adenoma-26/NN||a-23/DT	advmod||corticotroph-25/JJ||pituitary-24/RB	amod||adenoma-26/NN||corticotroph-25/JJ	agent||caused-7/VBN||adenoma-26/NN	amod||-RSB--31/NNP||cushingdisease-28/JJ	nn||-RSB--31/NNP||-LSB--29/NNP	nn||-RSB--31/NNP||cd-30/NN	appos||adenoma-26/NN||-RSB--31/NNP	cushingdisease-28||hormone-13||no_rel||endogenous cushing syndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nn||equivalence-2/NNS||conclusion-1/NN	nsubjpass||found-4/VBN||equivalence-2/NNS	auxpass||found-4/VBN||was-3/VBD	root||ROOT-0/null||found-4/VBN	amod||bcgvaccine-7/NN||intradermal-6/JJ	prep_between||found-4/VBN||bcgvaccine-7/NN	nn||bcg-10/NN||percutaneous-9/NNS	prep_between||found-4/VBN||bcg-10/NN	conj_and||bcgvaccine-7/NN||bcg-10/NN	det||incidence-13/NN||the-12/DT	prep_in||bcgvaccine-7/NN||incidence-13/NN	prep_of||incidence-13/NN||tuberculosis-15/NNP	amod||infants-19/NNS||south-17/JJ	nn||infants-19/NNS||african-18/NN	prep_in||found-4/VBN||infants-19/NNS	dep||infants-19/NNS||vaccinated-20/VBN	prep_at||vaccinated-20/VBN||birth-22/NN	dep||infants-19/NNS||followed-24/VBN	conj_and||vaccinated-20/VBN||followed-24/VBN	prt||followed-24/VBN||up-25/RP	num||years-28/NNS||two-27/CD	prep_for||followed-24/VBN||years-28/NNS	tuberculosis-15||bcgvaccine-7||no||conclusion equivalence was found between intradermal bcgvaccine and percutaneous bcg in the incidence of tuberculosis in south african infants vaccinated at birth and followed up for two years.
amod||responses-2/NNS||immune-1/JJ	nsubj||lead-31/VB||responses-2/NNS	amod||lymphocytes-6/NNS||cytotoxic-4/JJ	nn||lymphocytes-6/NNS||t-5/NN	prep_of||responses-2/NNS||lymphocytes-6/NNS	amod||ctls-8/NNS||-lrb--7/JJ	dep||lymphocytes-6/NNS||ctls-8/NNS	nsubjpass||implicated-11/VBN||-rrb--9/NNP	auxpass||implicated-11/VBN||are-10/VBP	rcmod||ctls-8/NNS||implicated-11/VBN	amod||eradication-14/NN||viral-13/JJ	prep_in||implicated-11/VBN||eradication-14/NN	det||pathogenesis-17/NNS||the-16/DT	prep_in||implicated-11/VBN||pathogenesis-17/NNS	conj_and||eradication-14/NN||pathogenesis-17/NNS	prep_of||pathogenesis-17/NNS||hepatitisc-19/NN	amod||response-23/NN||weak-21/JJ	nn||response-23/NN||ctl-22/NN	dep||ctls-8/NNS||response-23/NN	amod||-rrb--29/NNP||hepatitisc-25/JJ	nn||-rrb--29/NNP||virus-26/NN	nn||-rrb--29/NNP||-lrb--27/NNP	nn||-rrb--29/NNP||hcv-28/NNP	prep_against||response-23/NN||-rrb--29/NNP	aux||lead-31/VB||may-30/MD	root||ROOT-0/null||lead-31/VB	det||infection-35/NN||a-33/DT	amod||infection-35/NN||persistent-34/JJ	prep_to||lead-31/VB||infection-35/NN	hepatitisc-25||hcv-28||no||immune responses of cytotoxic t lymphocytes -lrb- ctls -rrb- are implicated in viral eradication and the pathogenesis of hepatitisc. weak ctl response against hepatitisc virus -lrb- hcv -rrb- may lead to a persistent infection .
det||analysis-2/NN||this-1/DT	nsubjpass||carried-4/VBN||analysis-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	det||context-8/NN||the-7/DT	prep_in||carried-4/VBN||context-8/NN	det||trial-11/NN||a-10/DT	prep_of||context-8/NN||trial-11/NN	amod||treatment-16/NN||malaria-13/JJ	amod||treatment-16/NN||intermittent-14/JJ	nn||treatment-16/NN||preventive-15/NN	prep_of||trial-11/NN||treatment-16/NN	prep_in||treatment-16/NN||pregnancy-18/NN	amod||iptp-sp-22/NN||sulphadoxine-pyrimethamine-20/JJ	prep_with||carried-4/VBN||iptp-sp-22/NN	advmod||received-29/VBD||where-25/WRB	det||groups-28/NNS||both-26/DT	nn||groups-28/NNS||intervention-27/NN	nsubj||received-29/VBD||groups-28/NNS	rcmod||iptp-sp-22/NN||received-29/VBD	det||insecticide-31/NN||an-30/DT	nsubj||treated-32/VBD||insecticide-31/NN	ccomp||received-29/VBD||treated-32/VBD	dobj||treated-32/VBD||net-33/NN	det||clinic-37/NN||the-35/DT	amod||clinic-37/NN||antenatal-36/JJ	prep_through||treated-32/VBD||clinic-37/NN	appos||clinic-37/NN||anc-39/NN	prep_in||treated-32/VBD||mozambique-42/NN	malaria-13||pyrimethamine--1||yes||this analysis was carried out in the context of a trial of malaria intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (iptp-sp), where both intervention groups received an insecticide treated net through the antenatal clinic (anc) in mozambique.
mark||cause-7/NN||although-1/IN	nsubj||cause-7/NN||alcoholabuse-2/NN	cop||cause-7/NN||is-3/VBZ	det||cause-7/NN||the-4/DT	advmod||common-6/JJ||most-5/RBS	amod||cause-7/NN||common-6/JJ	advcl||related-30/VBD||cause-7/NN	prep_of||cause-7/NN||livercirrhosis-9/NNS	det||states-13/NNS||the-11/DT	amod||states-13/NNS||united-12/VBN	prep_in||livercirrhosis-9/NNS||states-13/NNS	det||effects-17/NNS||the-15/DT	amod||effects-17/NNS||enhancing-16/JJ	nsubj||related-30/VBD||effects-17/NNS	prep_of||effects-17/NNS||alcohol-19/NN	det||prognosis-23/NN||the-21/DT	amod||prognosis-23/NN||long-term-22/JJ	prep_on||alcohol-19/NN||prognosis-23/NN	amod||virus-26/NN||hepatitisc-25/JJ	prep_of||prognosis-23/NN||virus-26/NN	appos||virus-26/NN||hcv-28/NN	root||ROOT-0/null||related-30/VBD	nsubjpass||clarified-35/VBN||livercirrhosis-31/NNS	aux||clarified-35/VBN||has-32/VBZ	neg||clarified-35/VBN||not-33/RB	auxpass||clarified-35/VBN||been-34/VBN	ccomp||related-30/VBD||clarified-35/VBN	alcohol-19||livercirrhosis-31||no_rel||although alcoholabuse is the most common cause of livercirrhosis in the united states, the enhancing effects of alcohol on the long-term prognosis of hepatitisc virus (hcv) related livercirrhosis has not been clarified.
nsubj||suggests-2/VBZ||evidence-1/NN	root||ROOT-0/null||suggests-2/VBZ	mark||characterized-9/VBN||that-3/IN	det||epidemic-7/NN||the-4/DT	nn||epidemic-7/NN||mozambican-5/NN	nn||epidemic-7/NN||hiv-6/NN	nsubjpass||characterized-9/VBN||epidemic-7/NN	nsubj||hiv-41/VB||epidemic-7/NN	auxpass||characterized-9/VBN||is-8/VBZ	ccomp||suggests-2/VBZ||characterized-9/VBN	det||preponderance-12/NN||a-11/DT	agent||characterized-9/VBN||preponderance-12/NN	amod||infections-15/NNS||heterosexual-14/JJ	prep_of||preponderance-12/NN||infections-15/NNS	det||world-19/NN||the-18/DT	poss||shortages-25/NNS||world-19/NN	advmod||severe-22/JJ||most-21/RBS	amod||shortages-25/NNS||severe-22/JJ	nn||shortages-25/NNS||health-23/NN	nn||shortages-25/NNS||worker-24/NN	prep_among||preponderance-12/NN||shortages-25/NNS	advmod||poor-28/JJ||relatively-27/RB	amod||knowledge-29/NN||poor-28/JJ	prep_among||preponderance-12/NN||knowledge-29/NN	conj_and||shortages-25/NNS||knowledge-29/NN	prep_of||knowledge-29/NN||hiv/aids-31/NNS	det||population-35/NN||the-33/DT	amod||population-35/NN||general-34/JJ	prep_in||hiv/aids-31/NNS||population-35/NN	amod||access-39/NN||lagging-38/VBG	prep_among||preponderance-12/NN||access-39/NN	conj_and||shortages-25/NNS||access-39/NN	aux||hiv-41/VB||to-40/TO	xcomp||characterized-9/VBN||hiv-41/VB	amod||services-45/NNS||preventive-42/JJ	conj_and||preventive-42/JJ||therapeutic-44/JJ	amod||services-45/NNS||therapeutic-44/JJ	dobj||hiv-41/VB||services-45/NNS	prepc_compared_to||hiv-41/VB||to-47/TO	nn||nations-49/NNS||counterpart-48/NN	pobj||hiv-41/VB||nations-49/NNS	amod||africa-52/NN||southern-51/JJ	prep_in||nations-49/NNS||africa-52/NN	aids--1||hiv-41||no||evidence suggests that the mozambican hiv epidemic is characterized by a preponderance of heterosexual infections, among the world's most severe health worker shortages, relatively poor knowledge of hiv/aids in the general population, and lagging access to hiv preventive and therapeutic services compared to counterpart nations in southern africa.
nsubj||ileocolitis-10/NNS||case-1/NN	num||case-1/NN||2-2/CD	det||male-5/NN||a-3/DT	amod||male-5/NN||38-year-old-4/JJ	dep||case-1/NN||male-5/NN	amod||crohn-8/NN||well-characterized-7/JJ	prep_with||case-1/NN||crohn-8/NN	cop||ileocolitis-10/NNS||'s-9/VBZ	root||ROOT-0/null||ileocolitis-10/NNS	num||years-13/NNS||15-12/CD	prep_for||ileocolitis-10/NNS||years-13/NNS	nsubjpass||treated-18/VBN||years-13/NNS	aux||treated-18/VBN||had-16/VBD	auxpass||treated-18/VBN||been-17/VBN	rcmod||years-13/NNS||treated-18/VBN	prep_with||treated-18/VBN||prednisone-20/NN	prep_with||treated-18/VBN||mesalamine-22/NN	conj_and||prednisone-20/NN||mesalamine-22/NN	prep_with||treated-18/VBN||sulfasalazine-24/NN	conj_and||prednisone-20/NN||sulfasalazine-24/NN	prep_with||treated-18/VBN||azathioprine-27/NN	conj_and||prednisone-20/NN||azathioprine-27/NN	vmod||prednisone-20/NN||presented-28/VBN	prep_with||presented-28/VBN||chest-30/NN	amod||back-33/NN||upper-32/JJ	prep_with||presented-28/VBN||back-33/NN	conj_and||chest-30/NN||back-33/NN	prep_with||presented-28/VBN||abdominalpain-35/NN	conj_and||chest-30/NN||abdominalpain-35/NN	crohn's--1||azathioprine-27||yes||case 2 a 38-year-old male with well-characterized crohn's ileocolitis for 15 years, who had been treated with prednisone, mesalamine, sulfasalazine, and azathioprine presented with chest, upper back and abdominalpain.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	type2diabetes-33||rosiglitazone-10||yes||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
expl||are-2/VBP||there-1/EX	root||ROOT-0/null||are-2/VBP	amod||issues-5/NNS||many-3/JJ	amod||issues-5/NNS||confounding-4/VBG	nsubj||are-2/VBP||issues-5/NNS	vmod||issues-5/NNS||regarding-6/VBG	mark||increases-11/VBZ||whether-7/IN	ccomp||regarding-6/VBG||not-9/RB	conj_or||increases-11/VBZ||not-9/RB	nsubj||increases-11/VBZ||etanercept-10/NN	ccomp||regarding-6/VBG||increases-11/VBZ	det||risk-13/NN||the-12/DT	dobj||increases-11/VBZ||risk-13/NN	prep_of||risk-13/NN||malignancy-15/NN	advmod||lymphomas-18/JJ||specifically-17/RB	amod||risk-13/NN||lymphomas-18/JJ	det||rate-23/NN||the-21/DT	nn||rate-23/NN||background-22/NN	prep_above||increases-11/VBZ||rate-23/NN	prep_of||rate-23/NN||cancer-25/NN	prep_in||cancer-25/NN||children-27/NNS	prep_with||children-27/NNS||juvenileidiopathicarthritis-29/NNS	nsubjpass||treated-34/VBN||juvenileidiopathicarthritis-29/NNS	aux||treated-34/VBN||are-31/VBP	neg||treated-34/VBN||not-32/RB	auxpass||treated-34/VBN||being-33/VBG	rcmod||juvenileidiopathicarthritis-29/NNS||treated-34/VBN	amod||agents-37/NNS||biologic-36/JJ	prep_with||treated-34/VBN||agents-37/NNS	juvenileidiopathicarthritis-29||etanercept-10||yes||there are many confounding issues regarding whether or not etanercept increases the risk of malignancy, specifically lymphomas, above the background rate of cancer in children with juvenileidiopathicarthritis who are not being treated with biologic agents.
det||hand-4/NN||the-2/DT	amod||hand-4/NN||other-3/JJ	prep_on||shown-22/VBN||hand-4/NN	det||era-9/NN||the-7/DT	amod||era-9/NN||stent-8/JJ	prep_in||shown-22/VBN||era-9/NN	nsubjpass||shown-22/VBN||bivalirudin-11/NN	nsubj||provide-24/VB||bivalirudin-11/NN	det||inhibitor-17/NN||a-13/DT	amod||inhibitor-17/NN||semi-synthetic-14/JJ	amod||inhibitor-17/NN||direct-15/JJ	nn||inhibitor-17/NN||thrombin-16/NN	appos||bivalirudin-11/NN||inhibitor-17/NN	aux||shown-22/VBN||has-19/VBZ	advmod||shown-22/VBN||recently-20/RB	auxpass||shown-22/VBN||been-21/VBN	root||ROOT-0/null||shown-22/VBN	aux||provide-24/VB||to-23/TO	xcomp||shown-22/VBN||provide-24/VB	amod||efficacy-26/NN||similar-25/JJ	dobj||provide-24/VB||efficacy-26/NN	amod||bleeding-29/NN||less-28/JJR	prep_with||provide-24/VB||bleeding-29/NN	prepc_compared_with||bleeding-29/NN||with-31/IN	pobj||bleeding-29/NN||unfractionatedheparin-32/NN	prep||unfractionatedheparin-32/NN||plus-33/CC	amod||inhibitors-37/NNS||platelet-34/JJ	nn||inhibitors-37/NNS||gp-35/NN	nn||inhibitors-37/NNS||iib/iiia-36/NN	pobj||plus-33/CC||inhibitors-37/NNS	nn||patients-40/NNS||ami-39/NN	prep_in||inhibitors-37/NNS||patients-40/NNS	vmod||patients-40/NNS||treated-41/VBN	amod||pci-44/NN||primary-43/JJ	prep_with||treated-41/VBN||pci-44/NN	ami-39||unfractionatedheparin-32||yes||on the other hand, in the stent era, bivalirudin, a semi-synthetic direct thrombin inhibitor, has recently been shown to provide similar efficacy with less bleeding compared with unfractionatedheparin plus platelet gp iib/iiia inhibitors in ami patients treated with primary pci.
det||studies-6/NNS||the-2/DT	amod||studies-6/NNS||subsequent-3/JJ	num||studies-6/NNS||26-4/CD	amod||studies-6/NNS||patient-5/JJ	prep_during||occurred-10/VBD||studies-6/NNS	nn||shutoff-9/NN||pump-8/NN	nsubj||occurred-10/VBD||shutoff-9/NN	root||ROOT-0/null||occurred-10/VBD	advmod||predicted-31/VBD||when-11/WRB	advmod||three-13/CD||either-12/RB	nsubj||predicted-31/VBD||three-13/CD	prep_of||three-13/CD||five-15/CD	dep||three-13/CD||n-17/VBN	dep||10-19/CD||=-18/SYM	ccomp||n-17/VBN||10-19/CD	conj_or||three-13/CD||two-22/CD	nsubj||predicted-31/VBD||two-22/CD	prep_of||two-22/CD||five-24/CD	dep||two-22/CD||n-26/VBN	dep||16-28/CD||=-27/SYM	ccomp||n-26/VBN||16-28/CD	advmod||predicted-31/VBD||algorithms-30/RB	advcl||occurred-10/VBD||predicted-31/VBD	dobj||predicted-31/VBD||hypoglycemia-32/NN	prepc_based_on||predicted-31/VBD||on-34/IN	det||levels-37/NNS||the-35/DT	nn||levels-37/NNS||glucose-36/NN	pobj||predicted-31/VBD||levels-37/NNS	vmod||levels-37/NNS||measured-38/VBN	det||navigator-42/NN||the-40/DT	amod||navigator-42/NN||freestyle-41/JJ	prep_with||measured-38/VBN||navigator-42/NN	amod||care-46/NN||abbott-44/JJ	nn||care-46/NN||diabetes-45/NN	appos||navigator-42/NN||care-46/NN	glucose-36||hypoglycemia-32||no_rel||during the subsequent 26 patient studies, pump shutoff occurred when either three of five ( n = 10) or two of five ( n = 16) algorithms predicted hypoglycemia based on the glucose levels measured with the freestyle navigator (abbott diabetes care).
nn||design-2/NN||research-1/NN	nsubj||$-6/VB||design-2/NN	nsubj||abdominal-59/VB||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||$-6/VB||methods-4/NNS	aux||$-6/VB||â-5/MD	root||ROOT-0/null||$-6/VB	det||total-9/NN||a-8/DT	dobj||$-6/VB||total-9/NN	num||adolescents-13/NNS||12-11/CD	amod||adolescents-13/NNS||obese-12/JJ	prep_of||total-9/NN||adolescents-13/NNS	prep_with||adolescents-13/NNS||ngt-15/NN	dobj||$-6/VB||19-17/CD	conj_and||total-9/NN||19-17/CD	prep_with||19-17/CD||igt-19/NN	dobj||$-6/VB||17-22/CD	conj_and||total-9/NN||17-22/CD	amod||evaluation-26/NN||type2diabetes-24/VBD	amod||evaluation-26/NN||underwent-25/JJ	prep_with||17-22/CD||evaluation-26/NN	nn||sensitivity-29/NN||insulin-28/NN	prep_of||evaluation-26/NN||sensitivity-29/NN	amod||-RSB--35/NNS||3-h-31/JJ	amod||-RSB--35/NNS||hyperinsulinemic-32/JJ	amod||-RSB--35/NNS||-LSB--33/JJ	amod||-RSB--35/NNS||80mu/m2/min-34/JJ	dep||evaluation-26/NN||-RSB--35/NNS	dep||clamp-40/NN||$-37/$	amod||clamp-40/NN||euglycemic-39/JJ	dep||evaluation-26/NN||clamp-40/NN	conj_â||-RSB--35/NNS||clamp-40/NN	amod||insulin-44/NN||first-phase-43/JJ	prep_with||17-22/CD||insulin-44/NN	conj_and||evaluation-26/NN||insulin-44/NN	amod||secretion-48/NN||second-phase-46/JJ	nn||secretion-48/NN||insulin-47/NN	prep_with||17-22/CD||secretion-48/NN	conj_and||evaluation-26/NN||secretion-48/NN	amod||clamp-52/NN||2-h-50/JJ	amod||clamp-52/NN||hyperglycemic-51/JJ	appos||secretion-48/NN||clamp-52/NN	nn||composition-56/NN||body-55/NN	appos||secretion-48/NN||composition-56/NN	conj_and||$-6/VB||abdominal-59/VB	dobj||$-6/VB||adiposity-60/NN	type2diabetes-24||insulin-47||yes||research design and methods â€”a total of 12 obese adolescents with ngt, 19 with igt, and 17 with type2diabetes underwent evaluation of insulin sensitivity (3-h hyperinsulinemic [80mu/m2/min]â€“euglycemic clamp), first-phase insulin and second-phase insulin secretion (2-h hyperglycemic clamp), body composition, and abdominal adiposity.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||cases-4/NNS||295-3/JJ	nsubj||were-2/VBD||cases-4/NNS	prep_of||diagnosed-31/VBN||cases-4/NNS	prep_of||cases-4/NNS||ibd-6/NN	dep||cases-4/NNS||uc-8/VBN	dep||240-10/CD||=-9/SYM	ccomp||uc-8/VBN||240-10/CD	ccomp||uc-8/VBN||cd-12/VB	dep||55-14/CD||=-13/SYM	ccomp||cd-12/VB||55-14/CD	nsubjpass||diagnosed-31/VBN||34-19/CD	dep||34-19/CD||uc-21/VBN	dep||30-23/CD||=-22/SYM	ccomp||uc-21/VBN||30-23/CD	ccomp||uc-21/VBN||cd-25/VB	dep||4-27/CD||=-26/SYM	ccomp||cd-25/VB||4-27/CD	auxpass||diagnosed-31/VBN||were-29/VBD	advmod||diagnosed-31/VBN||newly-30/RB	rcmod||cases-4/NNS||diagnosed-31/VBN	det||year-35/NN||the-33/DT	nn||year-35/NN||study-34/NN	prep_during||diagnosed-31/VBN||year-35/NN	uc-21||cd-25||no_rel||there were 295 cases of ibd (uc = 240, cd = 55), of which 34 (uc = 30, cd = 4) were newly diagnosed during the study year.
det||study-3/NN||a-1/DT	amod||study-3/NN||record-linkage-2/JJ	nsubjpass||carried-5/VBN||study-3/NN	nsubj||compare-18/VB||study-3/NN	nsubj||compare-18/VB||study-3/NN	auxpass||carried-5/VBN||was-4/VBD	root||ROOT-0/null||carried-5/VBN	prt||carried-5/VBN||out-6/RP	det||registry-11/NN||the-8/DT	amod||registry-11/NN||italian-9/JJ	nn||registry-11/NN||aids-10/NNS	prep_between||carried-5/VBN||registry-11/NN	num||registries-16/NNS||24-13/CD	amod||registries-16/NNS||italian-14/JJ	nn||registries-16/NNS||cancer-15/NN	prep_between||carried-5/VBN||registries-16/NNS	conj_and||registry-11/NN||registries-16/NNS	aux||compare-18/VB||to-17/TO	xcomp||carried-5/VBN||compare-18/VB	xcomp||carried-5/VBN||compare-18/VB	conj_and||compare-18/VB||compare-18/VB	nn||excess-20/NN||cancer-19/NN	dobj||compare-18/VB||excess-20/NN	prep_among||excess-20/NN||persons-22/NNS	prep_with||persons-22/NNS||hiv/aids-24/NNS	appos||hiv/aids-24/NNS||pwha-26/NNP	det||introduction-32/NN||the-31/DT	prep_after||compare-18/VB||introduction-32/NN	prep_before||compare-18/VB||introduction-32/NN	advmod||active-35/JJ||highly-34/RB	amod||therapy-37/NN||active-35/JJ	amod||therapy-37/NN||antiretroviral-36/JJ	prep_of||introduction-32/NN||therapy-37/NN	appos||therapy-37/NN||haart-39/NN	prep_in||compare-18/VB||1996-42/CD	aids-10||hiv--1||no||a record-linkage study was carried out between the italian aids registry and 24 italian cancer registries to compare cancer excess among persons with hiv/aids (pwha) before and after the introduction of highly active antiretroviral therapy (haart) in 1996.
nsubj||interesting-4/JJ||it-1/PRP	nsubj||investigate-6/VB||it-1/PRP	aux||interesting-4/JJ||will-2/MD	cop||interesting-4/JJ||be-3/VB	root||ROOT-0/null||interesting-4/JJ	aux||investigate-6/VB||to-5/TO	xcomp||interesting-4/JJ||investigate-6/VB	mark||has-22/VBZ||whether-7/IN	nsubjpass||used-15/VBN||mefloquine-8/NN	nsubj||has-22/VBZ||mefloquine-8/NN	auxpass||used-15/VBN||is-11/VBZ	advmod||used-15/VBN||widely-12/RB	conj_and||widely-12/RB||effectively-14/RB	advmod||used-15/VBN||effectively-14/RB	rcmod||mefloquine-8/NN||used-15/VBN	det||treatment-18/NN||the-17/DT	prep_for||used-15/VBN||treatment-18/NN	prep_of||treatment-18/NN||malaria-20/NN	ccomp||investigate-6/VB||has-22/VBZ	det||impact-24/NN||an-23/DT	dobj||has-22/VBZ||impact-24/NN	prep_on||impact-24/NN||schistosomiasis-26/NNS	prep_in||schistosomiasis-26/NNS||areas-28/NNS	advmod||co-exist-34/VB||where-29/WRB	det||malaria-31/NN||both-30/DT	nsubj||co-exist-34/VB||malaria-31/NN	conj_and||malaria-31/NN||schistosomiasis-33/NNS	nsubj||co-exist-34/VB||schistosomiasis-33/NNS	advcl||interesting-4/JJ||co-exist-34/VB	malaria-31||mefloquine-8||yes||it will be interesting to investigate whether mefloquine, which is widely and effectively used for the treatment of malaria, has an impact on schistosomiasis in areas where both malaria and schistosomiasis co-exist.
num||patients-3/NNS||131-2/CD	nsubjpass||hbv-6/VBN||patients-3/NNS	prep_of||did-14/VBD||patients-3/NNS	auxpass||hbv-6/VBN||were-5/VBD	rcmod||patients-3/NNS||hbv-6/VBN	nn||antigen-8/NN||surface-7/NN	nsubj||positive-9/JJ||antigen-8/NN	xcomp||hbv-6/VBN||positive-9/JJ	nsubj||did-14/VBD||55-11/CD	nsubj||receive-18/VB||55-11/CD	conj_and||55-11/CD||76-13/CD	nsubj||did-14/VBD||76-13/CD	root||ROOT-0/null||did-14/VBD	aux||receive-18/VB||did-16/VBD	neg||receive-18/VB||not-17/RB	conj_and||did-14/VBD||receive-18/VB	amod||lamivudine-20/NN||prophylactic-19/JJ	dobj||receive-18/VB||lamivudine-20/NN	advmod||receive-18/VB||respectively-22/RB	hbv-6||lamivudine-20||yes||of 131 patients who were hbv surface antigen positive, 55 and 76 did and did not receive prophylactic lamivudine, respectively.
amod||use-2/NN||therapeutic-1/JJ	nsubj||proven-7/VBN||use-2/NN	amod||compounds-5/NNS||vitamind-4/JJ	prep_of||use-2/NN||compounds-5/NNS	aux||proven-7/VBN||has-6/VBZ	root||ROOT-0/null||proven-7/VBN	acomp||proven-7/VBN||beneficial-8/JJ	amod||types-12/NNS||several-10/JJ	nn||types-12/NNS||cancer-11/NN	prep_in||proven-7/VBN||types-12/NNS	advmod||recently-16/RB||more-15/RBR	advmod||shown-21/VBN||recently-16/RB	det||compounds-18/NNS||these-17/DT	nsubjpass||shown-21/VBN||compounds-18/NNS	nsubj||prevent-23/VB||compounds-18/NNS	aux||shown-21/VBN||have-19/VBP	auxpass||shown-21/VBN||been-20/VBN	conj_but||proven-7/VBN||shown-21/VBN	aux||prevent-23/VB||to-22/TO	xcomp||shown-21/VBN||prevent-23/VB	amod||death-26/NN||uv-induced-24/JJ	nn||death-26/NN||cell-25/NN	dobj||prevent-23/VB||death-26/NN	nn||damage-29/NN||dna-28/NN	dobj||prevent-23/VB||damage-29/NN	conj_and||death-26/NN||damage-29/NN	amod||cells-33/NNS||human-31/JJ	nn||cells-33/NNS||skin-32/NN	prep_in||prevent-23/VB||cells-33/NNS	cancer-11||vitamind-4||no_rel||therapeutic use of vitamind compounds has proven beneficial in several cancer types, but more recently these compounds have been shown to prevent uv-induced cell death and dna damage in human skin cells.
nsubjpass||involved-5/VBN||it-1/PRP	nsubjpass||had-21/VBN||it-1/PRP	auxpass||involved-5/VBN||is-2/VBZ	advmod||involved-5/VBN||now-3/RB	advmod||involved-5/VBN||widely-4/RB	root||ROOT-0/null||involved-5/VBN	quantmod||all-8/DT||nearly-7/RB	num||aspects-9/NNS||all-8/DT	prep_in||involved-5/VBN||aspects-9/NNS	amod||efforts-17/NNS||hiv/aids-related-11/JJ	nn||efforts-17/NNS||prevention-12/NN	conj_and||prevention-12/NN||treatment-14/NN	nn||efforts-17/NNS||treatment-14/NN	conj_and||prevention-12/NN||care-16/NN	nn||efforts-17/NNS||care-16/NN	prep_of||aspects-9/NNS||efforts-17/NNS	aux||had-21/VBN||has-20/VBZ	conj_and||involved-5/VBN||had-21/VBN	det||impact-24/NN||a-22/DT	amod||impact-24/NN||positive-23/JJ	dobj||had-21/VBN||impact-24/NN	prep_for||impact-24/NN||example-27/NN	amod||adherence-30/NN||increased-29/VBN	appos||example-27/NN||adherence-30/NN	amod||treatment-33/NN||anti-retroviral-32/JJ	prep_of||adherence-30/NN||treatment-33/NN	nn||testing-36/NN||hiv-35/NN	prep_of||adherence-30/NN||testing-36/NN	conj_and||treatment-33/NN||testing-36/NN	amod||groups-39/NNS||hard-to-reach-38/JJ	prep_among||treatment-33/NN||groups-39/NNS	aids--1||hiv-35||no||it is now widely involved in nearly all aspects of hiv/aids-related prevention, treatment and care efforts, and has had a positive impact; for example, increased adherence of anti-retroviral treatment and hiv testing among hard-to-reach groups.
nn||levels-2/NNS||hgf-1/NN	nsubj||increased-3/VBD||levels-2/NNS	root||ROOT-0/null||increased-3/VBD	nn||pneumonia-6/NN||severer-5/NN	prep_in||increased-3/VBD||pneumonia-6/NN	vmod||pneumonia-6/NN||caused-7/VBN	agent||caused-7/VBN||legionella-9/NN	xcomp||increased-3/VBD||suggesting-11/VBG	mark||play-15/VB||that-12/IN	nsubj||play-15/VB||hgf-13/NN	aux||play-15/VB||might-14/MD	ccomp||suggesting-11/VBG||play-15/VB	det||role-18/NN||a-16/DT	amod||role-18/NN||significant-17/JJ	dobj||play-15/VB||role-18/NN	det||legionellapneumonia-21/NN||the-20/DT	prep_in||play-15/VB||legionellapneumonia-21/NN	legionellapneumonia-21||legionella-9||no||hgf levels increased in severer pneumonia caused by legionella , suggesting that hgf might play a significant role in the legionellapneumonia.
nsubj||revealed-10/VBD||assessment-1/NN	det||patients-5/NNS||the-3/DT	num||patients-5/NNS||69-4/CD	prep_of||assessment-1/NN||patients-5/NNS	amod||cancers-9/NNS||metastatic-7/JJ	nn||cancers-9/NNS||gi-8/NN	prep_with||patients-5/NNS||cancers-9/NNS	root||ROOT-0/null||revealed-10/VBD	dobj||revealed-10/VBD||cr-11/NN	dobj||revealed-10/VBD||pr-13/NN	conj_and||cr-11/NN||pr-13/NN	dobj||revealed-10/VBD||cr-16/NN	conj_and||cr-11/NN||cr-16/NN	xcomp||revealed-10/VBD||+-17/VBG	nn||rates-19/NNS||pr-18/NN	dobj||+-17/VBG||rates-19/NNS	num||%-22/NN||18-21/CD	prep_of||rates-19/NNS||%-22/NN	num||%-25/NN||42-24/CD	prep_of||rates-19/NNS||%-25/NN	conj_and||%-22/NN||%-25/NN	num||%-29/NN||61-28/CD	prep_of||rates-19/NNS||%-29/NN	conj_and||%-22/NN||%-29/NN	num||weeks-32/NNS||4-31/CD	prep_at||%-29/NN||weeks-32/NNS	num||%-35/NN||22-34/CD	prep_of||rates-19/NNS||%-35/NN	conj_and||%-22/NN||%-35/NN	num||%-38/NN||35-37/CD	prep_of||rates-19/NNS||%-38/NN	conj_and||%-22/NN||%-38/NN	num||%-42/NN||57-41/CD	prep_of||rates-19/NNS||%-42/NN	conj_and||%-22/NN||%-42/NN	num||weeks-45/NNS||8-44/CD	prep_at||%-42/NN||weeks-45/NNS	num||%-49/NN||50-48/CD	prep_of||rates-19/NNS||%-49/NN	conj_and||%-22/NN||%-49/NN	num||%-52/NN||21-51/CD	prep_of||rates-19/NNS||%-52/NN	conj_and||%-22/NN||%-52/NN	num||%-56/NN||71-55/CD	prep_of||rates-19/NNS||%-56/NN	conj_and||%-22/NN||%-56/NN	num||weeks-59/NNS||12-58/CD	prep_at||+-17/VBG||weeks-59/NNS	amod||patients-62/NNS||evaluable-61/JJ	prep_for||weeks-59/NNS||patients-62/NNS	cancers-9||cr-16||no_rel||assessment of the 69 patients with metastatic gi cancers revealed cr , pr , and cr + pr rates of 18%, 42%, and 61% at 4 weeks; 22%, 35%, and 57% at 8 weeks; and 50%, 21%, and 71% at 12 weeks for evaluable patients.
amod||augmenter-3/NN||transpedicle-1/JJ	nn||augmenter-3/NN||body-2/NN	nsubjpass||reported-12/VBN||augmenter-3/NN	nsubj||reconstruct-18/VB||augmenter-3/NN	nsubj||kã-29/VB||augmenter-3/NN	det||spacer-8/NN||a-5/DT	amod||spacer-8/NN||porous-6/JJ	nn||spacer-8/NN||titanium-7/NN	appos||augmenter-3/NN||spacer-8/NN	aux||reported-12/VBN||has-10/VBZ	auxpass||reported-12/VBN||been-11/VBN	root||ROOT-0/null||reported-12/VBN	det||support-16/NN||an-14/DT	amod||support-16/NN||internal-15/JJ	prep_as||reported-12/VBN||support-16/NN	aux||reconstruct-18/VB||to-17/TO	xcomp||reported-12/VBN||reconstruct-18/VB	det||body-21/NN||the-19/DT	amod||body-21/NN||vertebral-20/JJ	dobj||reconstruct-18/VB||body-21/NN	xcomp||reconstruct-18/VB||combining-22/VBG	amod||fixation-24/NN||short-segment-23/JJ	dobj||combining-22/VBG||fixation-24/NN	nn||fracture-27/NN||burst-26/NN	prep_in||combining-22/VBG||fracture-27/NN	xcomp||reported-12/VBN||kã-29/VB	conj_and||reconstruct-18/VB||kã-29/VB	num||mmell-31/NN||1/4-30/CD	dep||sdisease-33/JJ||mmell-31/NN	dep||kã-29/VB||sdisease-33/JJ	nn||compression-36/NN||cord-35/NN	prep_with||sdisease-33/JJ||compression-36/NN	titanium-7||kã¼mmell'sdisease--1||no_rel||transpedicle body augmenter (a porous titanium spacer) has been reported as an internal support to reconstruct the vertebral body combining short-segment fixation in burst fracture and kã¼mmell'sdisease with cord compression.
num||%-2/NN||18.1-1/CD	nsubj||performed-11/VBN||%-2/NN	appos||%-2/NN||799/4416-4/CD	det||respondents-8/NNS||the-7/DT	prep_of||%-2/NN||respondents-8/NNS	aux||performed-11/VBN||had-9/VBD	advmod||performed-11/VBN||ever-10/RB	root||ROOT-0/null||performed-11/VBN	det||self-test-13/NN||a-12/DT	dobj||performed-11/VBN||self-test-13/NN	det||tests-19/NNS||the-15/DT	advmod||frequently-17/RB||most-16/RBS	advmod||used-18/VBN||frequently-17/RB	amod||tests-19/NNS||used-18/VBN	appos||self-test-13/NN||tests-19/NNS	aux||those-21/DT||being-20/VBG	vmod||tests-19/NNS||those-21/DT	prep_for||those-21/DT||diabetes-23/NN	num||%-26/NN||5.3-25/CD	appos||diabetes-23/NN||%-26/NN	prep_for||those-21/DT||kidneydisease-29/NN	conj_and||diabetes-23/NN||kidneydisease-29/NN	num||%-32/NN||4.9-31/CD	appos||kidneydisease-29/NN||%-32/NN	prep_for||those-21/DT||cholesterol-35/NN	conj_and||diabetes-23/NN||cholesterol-35/NN	num||%-38/NN||4.5-37/CD	appos||cholesterol-35/NN||%-38/NN	prep_for||those-21/DT||urinarytractinfection-41/NN	conj_and||diabetes-23/NN||urinarytractinfection-41/NN	num||%-44/NN||1.9-43/CD	appos||urinarytractinfection-41/NN||%-44/NN	prep_for||those-21/DT||hiv/aids-47/NNS	conj_and||diabetes-23/NN||hiv/aids-47/NNS	conj_and||diabetes-23/NN||chlamydia-49/NNS	conj_and||hiv/aids-47/NNS||chlamydia-49/NNS	dep||%-53/NN||both-51/DT	number||%-53/NN||1.6-52/CD	dep||hiv/aids-47/NNS||%-53/NN	cholesterol-35||urinarytractinfection-41||no_rel||18.1% (799/4416) of the respondents had ever performed a self-test, the most frequently used tests being those for diabetes (5.3%), kidneydisease (4.9%), cholesterol (4.5%), urinarytractinfection (1.9%) and hiv/aids and chlamydia (both 1.6%).
amod||carriers-2/NNS||inactive-1/JJ	nsubj||have-8/VBP||carriers-2/NNS	amod||levels-7/NNS||lower-4/JJR	nn||levels-7/NNS||baseline-5/NN	nn||levels-7/NNS||hbsag-6/NN	prep_with||carriers-2/NNS||levels-7/NNS	root||ROOT-0/null||have-8/VBP	det||decline-14/NN||a-9/DT	amod||decline-14/NN||greater-10/JJR	advmod||hbsag-13/JJ||accelerating-12/RB	conj_and||greater-10/JJR||hbsag-13/JJ	amod||decline-14/NN||hbsag-13/JJ	dobj||have-8/VBP||decline-14/NN	prep_over||decline-14/NN||time-16/NN	nn||genotypes-21/NNS||hbv-20/NN	prep_regardless_of||have-8/VBP||genotypes-21/NNS	hbv-20||hbsag-13||yes||inactive carriers with lower baseline hbsag levels have a greater and accelerating hbsag decline over time, regardless of hbv genotypes.
nsubj||showed-19/VBD||mining-1/NN	dep||transcriptomic-4/JJ||available-3/JJ	amod||data-7/NNS||transcriptomic-4/JJ	conj_and||transcriptomic-4/JJ||proteomic-6/JJ	amod||data-7/NNS||proteomic-6/JJ	prep_of||mining-1/NN||data-7/NNS	vmod||data-7/NNS||pertaining-8/VBG	amod||models-12/NNS||established-10/VBN	nn||models-12/NNS||rodent-11/NN	prep_to||pertaining-8/VBG||models-12/NNS	nn||patients-18/NNS||epilepsy-14/NN	conj_and||epilepsy-14/NN||human-16/JJ	nn||patients-18/NNS||human-16/JJ	amod||patients-18/NNS||epileptic-17/JJ	prep_of||models-12/NNS||patients-18/NNS	root||ROOT-0/null||showed-19/VBD	dobj||showed-19/VBD||overrepresentation-20/NN	prep_of||overrepresentation-20/NN||epilepsy-22/NN	vmod||epilepsy-22/NN||associated-23/VBN	dobj||associated-23/VBN||genes-24/NNS	poss||set-29/NN||our-26/PRP$	amod||set-29/NN||ptz-27/JJ	amod||set-29/NN||regulated-28/JJ	prep_in||genes-24/NNS||set-29/NN	epilepsy-22||ptz-27||no||mining of available transcriptomic and proteomic data pertaining to established rodent models of epilepsy and human epileptic patients showed overrepresentation of epilepsy associated genes in our ptz regulated set.
amod||coldwaterdisease-2/NN||bacterial-1/JJ	nsubj||bacterialdiseases-13/NNS||coldwaterdisease-2/NN	amod||disease-7/NN||enteric-4/JJ	amod||disease-7/NN||red-5/JJ	nn||disease-7/NN||mouth-6/NN	conj_and||coldwaterdisease-2/NN||disease-7/NN	nsubj||bacterialdiseases-13/NNS||disease-7/NN	conj_and||coldwaterdisease-2/NN||frunculosis-9/NNS	nsubj||bacterialdiseases-13/NNS||frunculosis-9/NNS	cop||bacterialdiseases-13/NNS||are-10/VBP	det||bacterialdiseases-13/NNS||the-11/DT	amod||bacterialdiseases-13/NNS||common-12/JJ	root||ROOT-0/null||bacterialdiseases-13/NNS	prep_of||bacterialdiseases-13/NNS||fish-15/NN	advmod||bacterialdiseases-13/NNS||worldwide-16/RB	coldwaterdisease-2||bacterial-1||no||bacterial coldwaterdisease, enteric red mouth disease and frunculosis are the common bacterialdiseases of fish worldwide.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	det||safety-4/NN||the-3/DT	dobj||assessed-2/VBD||safety-4/NN	amod||therapy-7/NN||cabergoline-6/JJ	prep_of||safety-4/NN||therapy-7/NN	prep_during||assessed-2/VBD||pregnancy-9/NN	det||lady-12/NN||a-11/DT	prep_in||assessed-2/VBD||lady-12/NN	nn||intolerant-15/NN||hyperprolactinemia-14/NN	prep_with||lady-12/NN||intolerant-15/NN	aux||bromocriptine-17/VB||to-16/TO	vmod||assessed-2/VBD||bromocriptine-17/VB	hyperprolactinemia-14||bromocriptine-17||yes||we assessed the safety of cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to bromocriptine.
nsubj||intraindividual-10/NN||this-1/DT	cop||intraindividual-10/NN||was-2/VBD	det||intraindividual-10/NN||an-3/DT	amod||intraindividual-10/NN||open-label-4/JJ	amod||intraindividual-10/NN||multicenter-6/JJ	amod||intraindividual-10/NN||bilateral-8/JJ	root||ROOT-0/null||intraindividual-10/NN	amod||study-14/NN||active-controlled-13/JJ	conj_and||intraindividual-10/NN||study-14/NN	prep_in||changed-36/VBN||study-14/NN	num||patients-20/NNS||20-17/CD	amod||patients-20/NNS||japanese-18/JJ	nn||patients-20/NNS||american-19/NN	nsubjpass||changed-36/VBN||patients-20/NNS	nsubj||monotherapy-38/VB||patients-20/NNS	amod||open-angleglaucoma-23/NN||primary-22/JJ	prep_with||patients-20/NNS||open-angleglaucoma-23/NN	nsubj||%-33/NN||open-angleglaucoma-23/NN	nn||hypertension-26/NN||ocular-25/NN	prep_with||patients-20/NNS||hypertension-26/NN	conj_or||open-angleglaucoma-23/NN||hypertension-26/NN	nsubj||%-33/NN||hypertension-26/NN	aux||%-33/NN||had-28/VBD	cop||%-33/NN||been-29/VBN	prep_on||%-33/NN||latanoprost-31/NN	num||%-33/NN||0.005-32/CD	rcmod||open-angleglaucoma-23/NN||%-33/NN	advmod||%-33/NN||monotherapy-34/RB	auxpass||changed-36/VBN||were-35/VBD	rcmod||study-14/NN||changed-36/VBN	aux||monotherapy-38/VB||to-37/TO	xcomp||changed-36/VBN||monotherapy-38/VB	amod||daily-44/NN||travoprost-40/JJ	num||%-42/NN||0.004-41/CD	dep||travoprost-40/JJ||%-42/NN	amod||daily-44/NN||bak-free-43/JJ	prep_with||monotherapy-38/VB||daily-44/NN	num||weeks-47/NNS||12-46/CD	prep_for||daily-44/NN||weeks-47/NNS	open-angleglaucoma-23||latanoprost-31||yes||this was an open-label, multicenter, bilateral, intraindividual, and active-controlled study in which 20 japanese american patients with primary open-angleglaucoma or ocular hypertension who had been on latanoprost 0.005% monotherapy were changed to monotherapy with travoprost 0.004% bak-free daily for 12 weeks.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||factors-5/NNS||the-3/DT	amod||factors-5/NNS||clinical-4/JJ	dobj||evaluated-2/VBN||factors-5/NNS	nsubj||affect-7/VBP||factors-5/NNS	rcmod||factors-5/NNS||affect-7/VBP	det||pain-9/NN||the-8/DT	dobj||affect-7/VBP||pain-9/NN	prep_on||affect-7/VBP||injection-11/NN	prep_of||injection-11/NN||propofol-13/NN	aux||develop-15/VB||to-14/TO	vmod||evaluated-2/VBN||develop-15/VB	det||strategy-17/NN||a-16/DT	dobj||develop-15/VB||strategy-17/NN	aux||prevent-19/VB||to-18/TO	vmod||strategy-17/NN||prevent-19/VB	vmod||strategy-17/NN||reduce-21/VB	conj_or||prevent-19/VB||reduce-21/VB	dobj||prevent-19/VB||pain-22/NN	pain-22||propofol-13||yes||we evaluated the clinical factors that affect the pain on injection of propofol to develop a strategy to prevent or reduce pain.
mark||demonstrated-5/VBN||since-1/IN	neg||studies-3/NNS||no-2/DT	nsubj||demonstrated-5/VBN||studies-3/NNS	aux||demonstrated-5/VBN||have-4/VBP	advcl||observed-28/VBD||demonstrated-5/VBN	dobj||demonstrated-5/VBN||efficacy-6/NN	amod||³-10/NNS||standard-8/JJ	nn||³-10/NNS||î-9/NN	prep_of||efficacy-6/NN||³-10/NNS	dep||efficacy-6/NN||globulin-12/NN	dep||efficacy-6/NN||hbig-14/NN	conj_or||globulin-12/NN||hbig-14/NN	det||population-18/NN||a-16/DT	amod||population-18/NN||drug-using-17/JJ	prep_in||globulin-12/NN||population-18/NN	advmod||likely-24/JJ||where-19/WRB	amod||exposures-22/NNS||multiple-20/JJ	nn||exposures-22/NNS||hbv-21/NN	nsubj||likely-24/JJ||exposures-22/NNS	cop||likely-24/JJ||are-23/VBP	advcl||demonstrated-5/VBN||likely-24/JJ	det||results-27/NNS||the-26/DT	nsubj||observed-28/VBD||results-27/NNS	root||ROOT-0/null||observed-28/VBD	mark||comparable-34/JJ||in-29/IN	amod||trials-31/NNS||most-30/JJS	nsubj||comparable-34/JJ||trials-31/NNS	nsubj||hepatitisb-36/VB||trials-31/NNS	cop||comparable-34/JJ||are-32/VBP	neg||comparable-34/JJ||not-33/RB	advcl||observed-28/VBD||comparable-34/JJ	aux||hepatitisb-36/VB||to-35/TO	xcomp||comparable-34/JJ||hepatitisb-36/VB	dep||hepatitisb-36/VB||associated-37/VBN	prep_with||associated-37/VBN||drugabuse-39/NN	det||military-42/NN||the-41/DT	prep_in||drugabuse-39/NN||military-42/NN	hepatitisb-36||hbig-14||yes||since no studies have demonstrated efficacy of standard î³-globulin or hbig in a drug-using population where multiple hbv exposures are likely, the results observed in most trials are not comparable to hepatitisb associated with drugabuse in the military.
advmod||studied-144/VBN||therefore-1/RB	mark||gain-6/VB||in-3/IN	dep||gain-6/VB||order-4/NN	aux||gain-6/VB||to-5/TO	advcl||studied-144/VBN||gain-6/VB	amod||knowledge-8/NN||further-7/JJ	dobj||gain-6/VB||knowledge-8/NN	nn||development-12/NN||fish-10/NN	amod||development-12/NN||larval-11/JJ	prep_of||knowledge-8/NN||development-12/NN	poss||disruption-15/NN||its-14/PRP$	prep_of||knowledge-8/NN||disruption-15/NN	conj_and||development-12/NN||disruption-15/NN	amod||imbalance-19/NN||nutritional-17/JJ	nn||imbalance-19/NN||va-18/NN	prep_by||gain-6/VB||imbalance-19/NN	det||expression-23/NN||the-21/DT	amod||expression-23/NN||relative-22/JJ	nsubjpass||studied-144/VBN||expression-23/NN	det||rars-26/NNS||some-25/DT	prep_of||expression-23/NN||rars-26/NNS	prep_of||expression-23/NN||rxrs-28/NNS	conj_and||rars-26/NNS||rxrs-28/NNS	amod||genes-34/NNS||several-33/JJ	prep_of||expression-23/NN||genes-34/NNS	conj_and||rars-26/NNS||genes-34/NNS	vmod||genes-34/NNS||involved-35/VBN	prep_in||involved-35/VBN||morpho-37/NN	conj_and||rars-26/NNS||skeletogenesis-40/NNS	conj_and||genes-34/NNS||skeletogenesis-40/NNS	amod||receptors-45/NNS||peroxisome-43/JJ	amod||receptors-45/NNS||proliferator-activated-44/JJ	prep_such_as||skeletogenesis-40/NNS||receptors-45/NNS	dep||receptors-45/NNS||ppara-47/NN	appos||ppara-47/NN||pparb-49/NN	appos||ppara-47/NN||pparg-51/NN	conj_and||pparb-49/NN||pparg-51/NN	amod||protein-55/NN||retinol-binding-54/JJ	dep||skeletogenesis-40/NNS||protein-55/NN	appos||protein-55/NN||rbp-57/NN	amod||factors-62/NNS||insulin-like-60/JJ	nn||factors-62/NNS||growth-61/NN	dep||skeletogenesis-40/NNS||factors-62/NNS	dep||factors-62/NNS||i-63/NN	dep||factors-62/NNS||ii-65/NN	conj_and||i-63/NN||ii-65/NN	dep||i-63/NN||igf1-67/NNS	dep||i-63/NN||igf2-69/NNS	conj_and||igf1-67/NNS||igf2-69/NNS	advmod||igf1-67/NNS||respectively-71/RB	nn||protein-76/NN||bone-74/NN	amod||protein-76/NN||morphogenetic-75/JJ	dep||skeletogenesis-40/NNS||protein-76/NN	dep||protein-76/NN||2-77/CD	appos||2-77/CD||bmp2-79/NNP	amod||²-86/NNS||transforming-82/JJ	nn||²-86/NNS||growth-83/NN	nn||²-86/NNS||factor-84/NN	nn||²-86/NNS||î-85/NN	dep||skeletogenesis-40/NNS||²-86/NNS	dep||²-86/NNS||-1-87/CD	appos||-1-87/CD||tgfb1-89/NNP	conj_and||rars-26/NNS||genes-93/NNS	conj_and||genes-34/NNS||genes-93/NNS	vmod||genes-93/NNS||encoding-94/VBG	amod||proteins-101/NNS||different-95/JJ	nn||proteins-101/NNS||extracellular-96/NN	nn||proteins-101/NNS||matrix-97/NN	appos||proteins-101/NNS||ecm-99/NN	dobj||encoding-94/VBG||proteins-101/NNS	nn||protein-106/NN||matrix-104/NN	nn||protein-106/NN||gla-105/NN	prep_such_as||proteins-101/NNS||protein-106/NN	appos||protein-106/NN||mgp-108/NN	prep_such_as||proteins-101/NNS||osteocalcin-111/NN	conj_and||protein-106/NN||osteocalcin-111/NN	appos||osteocalcin-111/NN||bglap-113/NN	prep_such_as||proteins-101/NNS||osteopontin-116/NN	conj_and||protein-106/NN||osteopontin-116/NN	appos||osteopontin-116/NN||spp1-118/NNP	amod||acidic-123/NNS||secreted-121/JJ	nn||acidic-123/NNS||protein-122/NN	prep_such_as||proteins-101/NNS||acidic-123/NNS	conj_and||protein-106/NN||acidic-123/NNS	amod||chain-138/NN||rich-125/JJ	prep_in||rich-125/JJ||cysteine-127/NN	dep||cysteine-127/NN||sparc-129/JJ	nn||î-135/NN||type-132/FW	nn||î-135/NN||i-133/FW	nn||î-135/NN||collagen-134/NN	prep_in||rich-125/JJ||î-135/NN	conj_and||cysteine-127/NN||î-135/NN	number||1-137/CD||±-136/CD	dep||î-135/NN||1-137/CD	prep_such_as||proteins-101/NNS||chain-138/NN	conj_and||protein-106/NN||chain-138/NN	appos||chain-138/NN||col1a1-140/NNP	aux||studied-144/VBN||have-142/VBP	auxpass||studied-144/VBN||been-143/VBN	root||ROOT-0/null||studied-144/VBN	amod||bream-148/NN||gilthead-146/JJ	nn||bream-148/NN||sea-147/NN	prep_in||studied-144/VBN||bream-148/NN	insulin--1||gla-105||no_rel||therefore, in order to gain further knowledge of fish larval development and its disruption by nutritional va imbalance, the relative expression of some rars and rxrs , as well as several genes involved in morpho- and skeletogenesis such as peroxisome proliferator-activated receptors ( ppara , pparb and pparg ); retinol-binding protein ( rbp ); insulin-like growth factors i and ii ( igf1 and igf2 , respectively); bone morphogenetic protein 2 ( bmp2 ); transforming growth factor î²-1 ( tgfb1 ); and genes encoding different extracellular matrix (ecm) proteins such as matrix gla protein ( mgp ), osteocalcin ( bglap ), osteopontin ( spp1 ), secreted protein acidic and rich in cysteine ( sparc ) and type i collagen î±1 chain ( col1a1 ) have been studied in gilthead sea bream.
nn||replacement-2/NN||hormone-1/NN	nsubj||treatment-8/NN||replacement-2/NN	prep_with||replacement-2/NN||testosterone-4/NN	cop||treatment-8/NN||is-5/VBZ	det||treatment-8/NN||the-6/DT	amod||treatment-8/NN||classic-7/JJ	root||ROOT-0/null||treatment-8/NN	prep_for||treatment-8/NN||hypogonadism-10/NN	hypogonadism-10||testosterone-4||yes||hormone replacement with testosterone is the classic treatment for hypogonadism.
det||effect-2/NN||the-1/DT	nsubjpass||examined-16/VBN||effect-2/NN	amod||cells-14/NNS||melatonin-4/JJ	det||potential-8/NN||the-6/DT	amod||potential-8/NN||invasive-7/JJ	prep_on||melatonin-4/JJ||potential-8/NN	det||breast-12/NN||these-10/DT	amod||breast-12/NN||human-11/JJ	prep_of||potential-8/NN||breast-12/NN	nn||cells-14/NNS||cancer-13/NN	prep_of||effect-2/NN||cells-14/NNS	auxpass||examined-16/VBN||was-15/VBD	root||ROOT-0/null||examined-16/VBN	amod||assays-21/NNS||matrigel-18/JJ	nn||assays-21/NNS||invasion-19/NN	nn||assays-21/NNS||chamber-20/NN	agent||examined-16/VBN||assays-21/NNS	cancer-13||melatonin-4||no_rel||the effect of melatonin on the invasive potential of these human breast cancer cells was examined by matrigel invasion chamber assays.
det||5-fluorouracil-4/NN||the-1/DT	amod||5-fluorouracil-4/NN||fluorinated-2/JJ	nn||5-fluorouracil-4/NN||pyrimidine-3/NN	nsubj||agent-13/NN||5-fluorouracil-4/NN	dep||5-fluorouracil-4/NN||5-6/CD	dep||5-6/CD||fu-8/NN	cop||agent-13/NN||is-10/VBZ	det||agent-13/NN||an-11/DT	amod||agent-13/NN||anticancer-12/JJ	root||ROOT-0/null||agent-13/NN	vmod||agent-13/NN||used-14/VBN	advmod||adjuvant-17/JJ||most-16/RBS	amod||regimens-21/NNS||adjuvant-17/JJ	conj_and||adjuvant-17/JJ||palliative-19/JJ	amod||regimens-21/NNS||palliative-19/JJ	nn||regimens-21/NNS||treatment-20/NN	prep_in||used-14/VBN||regimens-21/NNS	amod||cancer-24/NN||colorectal-23/JJ	prep_for||regimens-21/NNS||cancer-24/NN	cancer-24||fu-8||no_rel||the fluorinated pyrimidine 5-fluorouracil (5- fu ) is an anticancer agent used in most adjuvant and palliative treatment regimens for colorectal cancer.
nsubj||improves-2/VBZ||methylphenidate-1/NN	root||ROOT-0/null||improves-2/VBZ	amod||memory-4/NN||declarative-3/JJ	dobj||improves-2/VBZ||memory-4/NN	vmod||memory-4/NN||functioning-5/VBG	prep_in||functioning-5/VBG||patients-7/NNS	prep_with||patients-7/NNS||adhd-9/NN	adhd-9||methylphenidate-1||yes||methylphenidate improves declarative memory functioning in patients with adhd.
amod||diodes-5/NNS||phosphor-free-1/JJ	amod||diodes-5/NNS||apple-white-2/JJ	amod||diodes-5/NNS||light-3/JJ	nn||diodes-5/NNS||emitting-4/NN	nsubjpass||fabricated-8/VBN||diodes-5/NNS	aux||fabricated-8/VBN||have-6/VBP	auxpass||fabricated-8/VBN||been-7/VBN	root||ROOT-0/null||fabricated-8/VBN	xcomp||fabricated-8/VBN||using-9/VBG	det||wells-16/NNS||a-10/DT	amod||wells-16/NNS||dual-11/JJ	amod||wells-16/NNS||stacked-12/JJ	amod||wells-16/NNS||ingan/gan-13/JJ	amod||wells-16/NNS||multiple-14/JJ	nn||wells-16/NNS||quantum-15/NN	dobj||using-9/VBG||wells-16/NNS	vmod||wells-16/NNS||comprising-17/VBG	det||set-21/NN||a-19/DT	amod||set-21/NN||lower-20/JJR	prep_of||comprising-17/VBG||set-21/NN	amod||wavelength-24/NN||long-23/JJ	prep_of||set-21/NN||wavelength-24/NN	vmod||comprising-17/VBG||emitting-25/VBG	amod||nanostructures-27/NNS||indium-rich-26/JJ	dobj||emitting-25/VBG||nanostructures-27/NNS	vmod||nanostructures-27/NNS||incorporated-28/VBN	amod||wells-32/NNS||multiple-30/JJ	nn||wells-32/NNS||quantum-31/NN	prep_in||incorporated-28/VBN||wells-32/NNS	det||set-36/NN||an-34/DT	amod||set-36/NN||upper-35/JJ	nsubj||emitting-39/VBG||set-36/NN	prep_of||set-36/NN||cyan-green-38/NN	prepc_with||incorporated-28/VBN||emitting-39/VBG	amod||wells-42/NNS||multiple-40/JJ	nn||wells-42/NNS||quantum-41/NN	dobj||emitting-39/VBG||wells-42/NNS	gan--1||wells-42||no_rel||phosphor-free apple-white light emitting diodes have been fabricated using a dual stacked ingan/gan multiple quantum wells comprising of a lower set of long wavelength emitting indium-rich nanostructures incorporated in multiple quantum wells with an upper set of cyan-green emitting multiple quantum wells.
amod||esophagitis-4/NNS||herpes-1/JJ	amod||esophagitis-4/NNS||simplex-2/JJ	amod||esophagitis-4/NNS||associated-3/JJ	nsubjpass||reported-9/VBN||esophagitis-4/NNS	conj_or||esophagitis-4/NNS||duodenalulcer-6/NN	nsubjpass||reported-9/VBN||duodenalulcer-6/NN	aux||reported-9/VBN||have-7/VBP	auxpass||reported-9/VBN||been-8/VBN	root||ROOT-0/null||reported-9/VBN	amod||patients-12/NNS||immunocompromised-11/JJ	prep_in||reported-9/VBN||patients-12/NNS	prep_due_to||patients-12/NNS||neoplasm-15/NN	prep_due_to||patients-12/NNS||hiv/aids-17/NNS	conj_or||neoplasm-15/NN||hiv/aids-17/NNS	prep_due_to||patients-12/NNS||therapeutically-19/NN	conj_or||neoplasm-15/NN||therapeutically-19/NN	vmod||patients-12/NNS||induced-20/VBN	advmod||induced-20/VBN||immunedeficiency-21/RB	aids--1||hiv--1||no||herpes simplex associated esophagitis or duodenalulcer have been reported in immunocompromised patients due to neoplasm, hiv/aids or therapeutically induced immunedeficiency.
nsubj||have-12/VBP||fluticasone/salmeterol-1/NN	conj_and||fluticasone/salmeterol-1/NN||budesonide/formoterol-3/NN	nsubj||have-12/VBP||budesonide/formoterol-3/NN	det||products-10/NNS||the-5/DT	advmod||available-7/JJ||currently-6/RB	amod||products-10/NNS||available-7/JJ	nn||products-10/NNS||ics/laba-8/NN	nn||products-10/NNS||combination-9/NN	appos||fluticasone/salmeterol-1/NN||products-10/NNS	root||ROOT-0/null||have-12/VBP	amod||efficacy-14/NN||similar-13/JJ	dobj||have-12/VBP||efficacy-14/NN	dobj||have-12/VBP||tolerability-16/NN	conj_and||efficacy-14/NN||tolerability-16/NN	prepc_based_on||have-12/VBP||on-18/IN	det||meta-analysis-21/NNS||a-19/DT	amod||meta-analysis-21/NNS||recent-20/JJ	pobj||have-12/VBP||meta-analysis-21/NNS	nn||trials-24/NNS||asthma-23/NN	prep_of||meta-analysis-21/NNS||trials-24/NNS	asthma-23||salmeterol--1||no||fluticasone/salmeterol and budesonide/formoterol, the currently available ics/laba combination products, have similar efficacy and tolerability based on a recent meta-analysis of asthma trials.
num||sets-5/NNS||twenty-1/CD	amod||sets-5/NNS||stone-2/JJ	amod||sets-5/NNS||cast-wax-3/JJ	nn||sets-5/NNS||base-4/NN	nsubjpass||prepared-7/VBN||sets-5/NNS	auxpass||prepared-7/VBN||were-6/VBD	root||ROOT-0/null||prepared-7/VBN	prepc_for||prepared-7/VBN||flasking-9/VBG	amod||cramp-12/NN||traditional-11/JJ	prep_by||flasking-9/VBG||cramp-12/NN	nn||methods-16/NNS||rs-14/NN	nn||methods-16/NNS||system-15/NN	prep_by||flasking-9/VBG||methods-16/NNS	conj_or||cramp-12/NN||methods-16/NNS	base-4||cramp-12||no_rel||twenty stone cast-wax base sets were prepared for flasking by traditional cramp or rs system methods.
csubj||exacerbated-13/VBD||challenging-1/VBG	dobj||challenging-1/VBG||mice-2/NNS	det||diet-6/NN||an-4/DT	nn||diet-6/NN||hf-5/NN	prep_with||challenging-1/VBG||diet-6/NN	prep_following||diet-6/NN||pre-treatment-8/NN	det||agonist-12/NN||the-10/DT	nn||agonist-12/NN||cb-11/NN	prep_with||pre-treatment-8/NN||agonist-12/NN	root||ROOT-0/null||exacerbated-13/VBD	det||glucoseintolerance-17/NN||the-14/DT	amod||glucoseintolerance-17/NN||hf-15/JJ	amod||glucoseintolerance-17/NN||diet-induced-16/JJ	dobj||exacerbated-13/VBD||glucoseintolerance-17/NN	det||infiltration-22/NN||the-19/DT	nn||infiltration-22/NN||muscle-20/NN	nn||infiltration-22/NN||macrophage-21/NN	dobj||exacerbated-13/VBD||infiltration-22/NN	conj_and||glucoseintolerance-17/NN||infiltration-22/NN	det||muscle-25/NN||the-24/DT	poss||content-28/NN||muscle-25/NN	nn||content-28/NN||lipid-27/NN	dobj||exacerbated-13/VBD||content-28/NN	conj_and||glucoseintolerance-17/NN||content-28/NN	prepc_without||exacerbated-13/VBD||affecting-30/VBG	det||weight-33/NN||the-31/DT	nn||weight-33/NN||body-32/NN	dobj||affecting-30/VBG||weight-33/NN	det||mass-37/NN||the-35/DT	amod||mass-37/NN||fat-36/JJ	dobj||affecting-30/VBG||mass-37/NN	conj_or||weight-33/NN||mass-37/NN	fat-36||glucoseintolerance-17||no_rel||challenging mice with an hf diet following pre-treatment with the cb agonist exacerbated the hf diet-induced glucoseintolerance, the muscle macrophage infiltration and the muscle's lipid content without affecting the body weight or the fat mass.
nn||deficiency-2/NN||insulin-1/NN	nsubjpass||induced-6/VBN||deficiency-2/NN	conj_and||deficiency-2/NN||hyperglycemia-4/NN	nsubjpass||induced-6/VBN||hyperglycemia-4/NN	auxpass||induced-6/VBN||were-5/VBD	root||ROOT-0/null||induced-6/VBN	prep_with||induced-6/VBN||streptozotocin-8/NN	appos||streptozotocin-8/NN||stz-10/NN	amod||mice-16/NNS||c57bl/6-13/JJ	nn||mice-16/NNS||fxr-14/NN	nn||mice-16/NNS||ko-15/NN	prep_in||streptozotocin-8/NN||mice-16/NNS	hyperglycemia-4||insulin-1||yes||insulin deficiency and hyperglycemia were induced with streptozotocin (stz) in c57bl/6 fxr ko mice.
amod||proteinase-3/NN||sarscoronavirus-1/JJ	amod||proteinase-3/NN||main-2/JJ	nsubj||enzyme-11/NN||proteinase-3/NN	amod||covmpro-6/NN||sars-5/JJ	appos||proteinase-3/NN||covmpro-6/NN	cop||enzyme-11/NN||is-8/VBZ	det||enzyme-11/NN||an-9/DT	amod||enzyme-11/NN||important-10/JJ	root||ROOT-0/null||enzyme-11/NN	det||replication-14/NN||the-13/DT	prep_for||enzyme-11/NN||replication-14/NN	prep_of||replication-14/NN||severeacuterespiratorysyndromevirus-16/NNS	sars-5||severeacuterespiratorysyndromevirus-16||no||sarscoronavirus main proteinase (sars covmpro) is an important enzyme for the replication of severeacuterespiratorysyndromevirus.
nsubj||appears-2/VBZ||it-1/PRP	root||ROOT-0/null||appears-2/VBZ	mark||shadows-9/VBD||that-3/IN	det||distribution-6/NN||the-4/DT	nn||distribution-6/NN||age-5/NN	nsubj||shadows-9/VBD||distribution-6/NN	prep_of||distribution-6/NN||hd-8/NN	ccomp||appears-2/VBZ||shadows-9/VBD	dobj||shadows-9/VBD||that-10/DT	prep_of||that-10/DT||susceptibility-12/NN	amod||infections-16/NNS||common-14/JJ	nn||infections-16/NNS||childhood-15/NN	prep_to||shadows-9/VBD||infections-16/NNS	det||epstein-barrvirus-21/NNS||the-20/DT	prep_such_as||shadows-9/VBD||epstein-barrvirus-21/NNS	dep||epstein-barrvirus-21/NNS||ebv-23/VBN	advmod||increased-33/VBN||furthermore-26/RB	det||risk-29/NN||that-28/DT	nsubjpass||increased-33/VBN||risk-29/NN	prep_of||risk-29/NN||hd-31/NN	auxpass||increased-33/VBN||is-32/VBZ	parataxis||appears-2/VBZ||increased-33/VBN	det||parallel-44/NN||those-35/DT	amod||parallel-44/NN||susceptible-36/JJ	det||infection-41/NN||a-38/DT	advmod||late-40/JJ||relatively-39/RB	amod||infection-41/NN||late-40/JJ	prep_to||susceptible-36/JJ||infection-41/NN	advmod||infection-41/NN||in-43/RB	prep_among||increased-33/VBN||parallel-44/NN	prep_with||parallel-44/NN||infectiousmononucleosis-46/NNS	appos||infectiousmononucleosis-46/NNS||im-48/NN	nsubjpass||found-55/VBN||it-52/PRP	aux||found-55/VBN||has-53/VBZ	auxpass||found-55/VBN||been-54/VBN	parataxis||appears-2/VBZ||found-55/VBN	conj_and||increased-33/VBN||found-55/VBN	mark||have-62/VBP||that-56/IN	nsubj||had-60/VBN||people-57/NNS	nsubj||have-62/VBP||people-57/NNS	aux||had-60/VBN||have-59/VBP	rcmod||people-57/NNS||had-60/VBN	dobj||had-60/VBN||im-61/NN	ccomp||found-55/VBN||have-62/VBP	quantmod||times-65/NNS||about-63/RB	number||times-65/NNS||three-64/CD	num||rate-68/NN||times-65/NNS	det||rate-68/NN||the-66/DT	amod||rate-68/NN||expected-67/JJ	dobj||have-62/VBP||rate-68/NN	prep_of||rate-68/NN||hd-70/NN	infectiousmononucleosis-46||epstein-barrvirus-21||no||it appears that the age distribution of hd shadows that of susceptibility to common childhood infections, such as the epstein-barrvirus (ebv); furthermore, that risk of hd is increased among those susceptible to a relatively late infection, in parallel with infectiousmononucleosis (im), and it has been found that people who have had im have about three times the expected rate of hd.
advmod||associated-9/VBN||even-1/RB	mark||associated-9/VBN||though-2/IN	nsubjpass||associated-9/VBN||coronavirusinfection-3/NN	prep_of||coronavirusinfection-3/NN||humans-5/NNS	auxpass||associated-9/VBN||is-6/VBZ	neg||associated-9/VBN||not-7/RB	advmod||associated-9/VBN||normally-8/RB	advcl||showed-25/VBD||associated-9/VBN	amod||diseases-12/NNS||severe-11/JJ	prep_with||associated-9/VBN||diseases-12/NNS	det||identification-15/NN||the-14/DT	nsubj||showed-25/VBD||identification-15/NN	det||coronavirus-18/NNS||the-17/DT	prep_of||identification-15/NN||coronavirus-18/NNS	amod||coronavirus-18/NNS||responsible-19/JJ	det||outbreak-22/NN||the-21/DT	prep_for||responsible-19/JJ||outbreak-22/NN	prep_of||outbreak-22/NN||severeacuterespiratorysyndrome-24/NN	root||ROOT-0/null||showed-25/VBD	mark||enter-31/VB||that-26/IN	advmod||pathogenic-28/JJ||highly-27/RB	amod||coronaviruses-29/NNS||pathogenic-28/JJ	nsubj||enter-31/VB||coronaviruses-29/NNS	aux||enter-31/VB||can-30/MD	ccomp||showed-25/VBD||enter-31/VB	det||population-34/NN||the-32/DT	amod||population-34/NN||human-33/JJ	dobj||enter-31/VB||population-34/NN	coronavirusinfection-3||coronaviruses-29||no||even though coronavirusinfection of humans is not normally associated with severe diseases, the identification of the coronavirus responsible for the outbreak of severeacuterespiratorysyndrome showed that highly pathogenic coronaviruses can enter the human population.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tuberculosis-10||m.tuberculosis-36||no||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
advmod||recommended-6/VBN||therefore-1/RB	nn||ferritin-4/NN||serum-3/NN	nsubjpass||recommended-6/VBN||ferritin-4/NN	nsubj||use-13/VB||ferritin-4/NN	auxpass||recommended-6/VBN||is-5/VBZ	root||ROOT-0/null||recommended-6/VBN	det||index-11/NN||a-8/DT	advmod||adequate-10/JJ||more-9/RBR	amod||index-11/NN||adequate-10/JJ	prep_as||recommended-6/VBN||index-11/NN	aux||use-13/VB||to-12/TO	xcomp||recommended-6/VBN||use-13/VB	amod||screening-16/NN||irondeficiency-15/JJ	prep_for||use-13/VB||screening-16/NN	nn||purposes-19/NNS||planning-18/NN	prep_for||use-13/VB||purposes-19/NNS	conj_and||screening-16/NN||purposes-19/NNS	nn||supplementation-22/NN||iron-21/NN	prep_for||screening-16/NN||supplementation-22/NN	prep_among||use-13/VB||them-24/PRP	irondeficiency-15||iron-21||yes||therefore, serum ferritin is recommended as a more adequate index to use for irondeficiency screening and planning purposes for iron supplementation among them.
det||male-3/NN||a-1/DT	amod||male-3/NN||33-year-old-2/JJ	nsubj||sustained-12/VBD||male-3/NN	vmod||male-3/NN||involved-5/VBN	det||crash-10/NN||a-7/DT	nn||crash-10/NN||motor-8/NN	nn||crash-10/NN||vehicle-9/NN	prep_in||involved-5/VBN||crash-10/NN	root||ROOT-0/null||sustained-12/VBD	det||fracture/dislocation-16/NN||an-13/DT	amod||fracture/dislocation-16/NN||irreducible-14/JJ	nn||fracture/dislocation-16/NN||acetabulum-15/NN	dobj||sustained-12/VBD||fracture/dislocation-16/NN	amod||fracture-21/NN||displaced-18/JJ	amod||fracture-21/NN||proximal-19/JJ	nn||fracture-21/NN||humerus-20/NNS	dobj||sustained-12/VBD||fracture-21/NN	conj_and||fracture/dislocation-16/NN||fracture-21/NN	det||fracture-27/NN||an-24/DT	amod||fracture-27/NN||impacted-25/JJ	nn||fracture-27/NN||pilon-26/NN	dobj||sustained-12/VBD||fracture-27/NN	conj_and||fracture/dislocation-16/NN||fracture-27/NN	vehicle-9||impacted-25||no_rel||a 33-year-old male, involved in a motor vehicle crash, sustained an irreducible acetabulum fracture/dislocation, displaced proximal humerus fracture, and an impacted pilon fracture.
nsubj||revealed-22/VBD||application-1/NN	det||biomarker-4/NN||this-3/DT	prep_of||application-1/NN||biomarker-4/NN	vmod||biomarker-4/NN||set-5/VBN	det||sample-9/NN||an-7/DT	amod||sample-9/NN||additional-8/JJ	prep_to||set-5/VBN||sample-9/NN	vmod||sample-9/NN||set-10/VBN	amod||areas-14/NNS||onchocerciasis-12/JJ	amod||areas-14/NNS||endemic-13/JJ	prep_from||set-10/VBN||areas-14/NNS	advmod||successful-21/JJ||where-15/WRB	amod||treatment-18/NN||long-term-16/JJ	nn||treatment-18/NN||ivermectin-17/NN	nsubj||successful-21/JJ||treatment-18/NN	aux||successful-21/JJ||has-19/VBZ	cop||successful-21/JJ||been-20/VBN	advcl||set-10/VBN||successful-21/JJ	root||ROOT-0/null||revealed-22/VBD	mark||distinguish-29/VB||that-23/IN	det||set-26/NN||the-24/DT	nn||set-26/NN||biomarker-25/NN	nsubj||distinguish-29/VB||set-26/NN	aux||distinguish-29/VB||may-27/MD	advmod||distinguish-29/VB||also-28/RB	ccomp||revealed-22/VBD||distinguish-29/VB	dobj||distinguish-29/VB||individuals-30/NNS	prep_with||distinguish-29/VB||worms-32/NNS	amod||viability-35/NN||compromised-34/VBN	prep_of||worms-32/NNS||viability-35/NN	prep_from||viability-35/NN||those-37/DT	amod||infection-40/NN||active-39/JJ	prep_with||those-37/DT||infection-40/NN	onchocerciasis-12||ivermectin-17||yes||application of this biomarker set to an additional sample set from onchocerciasis endemic areas where long-term ivermectin treatment has been successful revealed that the biomarker set may also distinguish individuals with worms of compromised viability from those with active infection.
det||data-2/NNS||these-1/DT	nsubj||able-9/JJ||data-2/NNS	nsubj||explain-11/VB||data-2/NNS	aux||able-9/JJ||may-3/MD	prep_in||able-9/JJ||part-6/NN	cop||able-9/JJ||be-8/VB	root||ROOT-0/null||able-9/JJ	aux||explain-11/VB||to-10/TO	xcomp||able-9/JJ||explain-11/VB	det||use-14/NN||the-12/DT	amod||use-14/NN||traditional-13/JJ	dobj||explain-11/VB||use-14/NN	amod||plants-18/NNS||tannin-containing-16/JJ	amod||plants-18/NNS||medicinal-17/JJ	prep_of||use-14/NN||plants-18/NNS	det||treatment-21/NN||the-20/DT	prep_for||explain-11/VB||treatment-21/NN	det||variety-24/NN||a-23/DT	prep_of||treatment-21/NN||variety-24/NN	amod||diseases-27/NNS||inflammatory-26/JJ	prep_of||variety-24/NN||diseases-27/NNS	prep_including||explain-11/VB||inflammatoryboweldisease-30/NN	prep_including||explain-11/VB||celiacdisease-32/NN	conj_and||inflammatoryboweldisease-30/NN||celiacdisease-32/NN	prep_including||explain-11/VB||rheumatoidarthritis-35/NNS	conj_and||inflammatoryboweldisease-30/NN||rheumatoidarthritis-35/NNS	tannin--1||celiacdisease-32||no_rel||these data may, in part, be able to explain the traditional use of tannin-containing medicinal plants for the treatment of a variety of inflammatory diseases, including inflammatoryboweldisease, celiacdisease, and rheumatoidarthritis.
det||hemagglutinin-6/NN||the-1/DT	amod||hemagglutinin-6/NN||main-2/JJ	amod||hemagglutinin-6/NN||influenzavirus-3/JJ	nn||hemagglutinin-6/NN||surface-4/NN	nn||hemagglutinin-6/NN||glycoprotein-5/NN	nsubjpass||shown-18/VBN||hemagglutinin-6/NN	nsubj||susceptible-22/JJ||hemagglutinin-6/NN	appos||hemagglutinin-6/NN||ha-8/NN	advmod||pathogenic-12/JJ||highly-11/RB	amod||avianinfluenzaviruses-13/NNS||pathogenic-12/JJ	prep_of||hemagglutinin-6/NN||avianinfluenzaviruses-13/NNS	appos||avianinfluenzaviruses-13/NNS||hpaiv-15/NNP	auxpass||shown-18/VBN||was-17/VBD	root||ROOT-0/null||shown-18/VBN	aux||susceptible-22/JJ||to-19/TO	cop||susceptible-22/JJ||be-20/VB	advmod||susceptible-22/JJ||more-21/RBR	xcomp||shown-18/VBN||susceptible-22/JJ	amod||treatment-26/NN||acidic-24/JJ	nn||treatment-26/NN||ph-25/NN	prep_to||susceptible-22/JJ||treatment-26/NN	prep_than||treatment-26/NN||that-28/DT	amod||avianinfluenzaviruses-34/NNS||human-30/JJ	conj_or||human-30/JJ||low-32/JJ	amod||avianinfluenzaviruses-34/NNS||low-32/JJ	amod||avianinfluenzaviruses-34/NNS||pathogenic-33/JJ	prep_of||that-28/DT||avianinfluenzaviruses-34/NNS	avianinfluenza--1||influenzavirus-3||no||the main influenzavirus surface glycoprotein hemagglutinin (ha) of highly pathogenic avianinfluenzaviruses (hpaiv) was shown to be more susceptible to acidic ph treatment than that of human or low pathogenic avianinfluenzaviruses.
nsubjpass||induced-3/VBN||hypercholesterolemia-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	amod||rats-6/NNS||normal-5/JJ	prep_in||induced-3/VBN||rats-6/NNS	agent||induced-3/VBN||including-8/VBG	number||%-10/NN||2-9/CD	amod||cholate-18/NN||%-10/NN	amod||cholate-18/NN||w/w-11/JJ	amod||cholate-18/NN||cholesterol-12/JJ	number||%-15/NN||1-14/CD	amod||cholate-18/NN||%-15/NN	nn||cholate-18/NN||w/w-16/NN	nn||cholate-18/NN||sodium-17/NN	dobj||including-8/VBG||cholate-18/NN	number||%-21/NN||2.5-20/CD	amod||oil-24/NN||%-21/NN	amod||oil-24/NN||w/w-22/JJ	amod||oil-24/NN||coconut-23/JJ	dobj||including-8/VBG||oil-24/NN	conj_and||cholate-18/NN||oil-24/NN	det||diet-28/NN||the-26/DT	amod||diet-28/NN||normal-27/JJ	prep_in||oil-24/NN||diet-28/NN	hypercholesterolemia-1||cholesterol-12||no||hypercholesterolemia was induced in normal rats by including 2% w/w cholesterol, 1% w/w sodium cholate and 2.5% w/w coconut oil in the normal diet.
det||clinics-2/NNS||the-1/DT	nsubj||cared-3/VBD||clinics-2/NNS	root||ROOT-0/null||cared-3/VBD	num||patients-12/NNS||400â-5/CD	amod||patients-12/NNS||$-6/$	number||000-8/CD||‰-7/CD	num||$-6/$||000-8/CD	amod||patients-12/NNS||general-9/JJ	amod||patients-12/NNS||primary-10/JJ	nn||patients-12/NNS||care-11/NN	prep_for||cared-3/VBD||patients-12/NNS	prep_for||cared-3/VBD||10â-14/NNS	conj_and||patients-12/NNS||10â-14/NNS	num||patients-18/NNS||$-15/$	number||136-17/CD||‰-16/CD	num||$-15/$||136-17/CD	dep||10â-14/NNS||patients-18/NNS	det||programme-22/NN||an-20/DT	amod||programme-22/NN||hiv/aids/art-21/JJ	prep_in||cared-3/VBD||programme-22/NN	aids--1||hiv--1||no||the clinics cared for 400â€‰000 general primary care patients and 10â€‰136 patients in an hiv/aids/art programme.
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	amod||literature-4/NN||current-3/JJ	dobj||review-2/VB||literature-4/NN	det||benefit-8/NN||the-6/DT	amod||benefit-8/NN||potential-7/JJ	prep_on||review-2/VB||benefit-8/NN	prep_of||benefit-8/NN||cholesterol-10/NN	vmod||cholesterol-10/NN||lowering-11/VBG	nn||reduction-15/NN||chd-13/NN	nn||reduction-15/NN||risk-14/NN	prep_in||lowering-11/VBG||reduction-15/NN	det||focus-19/NN||a-17/DT	amod||focus-19/NN||particular-18/JJ	prep_with||reduction-15/NN||focus-19/NN	det||evidence-22/NN||the-21/DT	prep_on||lowering-11/VBG||evidence-22/NN	amod||management-25/NN||non-pharmacological/lifestyle-24/JJ	prep_of||evidence-22/NN||management-25/NN	prep_of||management-25/NN||hypercholesterolemia-27/NN	hypercholesterolemia-27||cholesterol-10||no||to review current literature on the potential benefit of cholesterol lowering in chd risk reduction with a particular focus on the evidence of non-pharmacological/lifestyle management of hypercholesterolemia.
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||chloroquine-18||yes||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
nn||nn414-4/NNS||resultsâ-1/NNP	nn||nn414-4/NNS||$-2/NNP	nsubj||delivered-5/VBD||nn414-4/NNS	nsubj||showed-14/VBD||nn414-4/NNS	root||ROOT-0/null||delivered-5/VBD	amod||responses-9/NNS||systemically-6/JJ	amod||responses-9/NNS||amplified-7/JJ	nn||responses-9/NNS||epinephrine-8/NN	dobj||delivered-5/VBD||responses-9/NNS	amod||hypoglycemia-12/NN||acute-11/JJ	prep_during||delivered-5/VBD||hypoglycemia-12/NN	conj_and||delivered-5/VBD||showed-14/VBD	det||effect-17/NN||a-15/DT	amod||effect-17/NN||persisting-16/JJ	dobj||showed-14/VBD||effect-17/NN	aux||amplify-19/VB||to-18/TO	vmod||showed-14/VBD||amplify-19/VB	det||response-22/NN||the-20/DT	amod||response-22/NN||epinephrine-21/JJ	dobj||amplify-19/VB||response-22/NN	advmod||given-24/VBN||when-23/WRB	advcl||amplify-19/VB||given-24/VBN	number||h-26/CD||24-25/CD	dobj||given-24/VBN||h-26/CD	det||study-30/NN||the-28/DT	amod||study-30/NN||hypoglycemic-29/JJ	prep_before||given-24/VBN||study-30/NN	hypoglycemia-12||hypoglycemic-29||no_rel||resultsâ€” nn414 delivered systemically amplified epinephrine responses during acute hypoglycemia and showed a persisting effect to amplify the epinephrine response when given 24 h before the hypoglycemic study.
det||total-2/NN||a-1/DT	nsubjpass||studied-13/VBN||total-2/NN	nsubjpass||analyzed-28/VBD||total-2/NN	nsubj||identify-30/VB||total-2/NN	num||patients-5/NNS||170-4/CD	prep_of||total-2/NN||patients-5/NNS	amod||allergies-8/NNS||various-7/JJ	prep_with||patients-5/NNS||allergies-8/NNS	amod||conditions-11/NNS||asthmatic-10/JJ	prep_with||patients-5/NNS||conditions-11/NNS	conj_and||allergies-8/NNS||conditions-11/NNS	auxpass||studied-13/VBN||were-12/VBD	root||ROOT-0/null||studied-13/VBN	nsubj||using-22/VBG||cytokines-16/NNS	det||serum-19/NN||the-18/DT	prep_in||cytokines-16/NNS||serum-19/NN	prep_by||serum-19/NN||elisa-21/NN	prepc_for||studied-13/VBN||using-22/VBG	dobj||using-22/VBG||kits-23/NNS	prep_from||using-22/VBG||immunotech-25/NN	conj_and||studied-13/VBN||analyzed-28/VBD	aux||identify-30/VB||to-29/TO	xcomp||analyzed-28/VBD||identify-30/VB	det||factors-33/NNS||the-31/DT	amod||factors-33/NNS||triggering-32/VBG	dobj||identify-30/VB||factors-33/NNS	amod||contributors-36/NNS||main-35/JJ	dobj||identify-30/VB||contributors-36/NNS	conj_or||factors-33/NNS||contributors-36/NNS	prep_towards||contributors-36/NNS||allergy-38/NN	prep_towards||contributors-36/NNS||asthma-40/NN	conj_and||allergy-38/NN||asthma-40/NN	allergy-38||allergies-8||no||a total of 170 patients with various allergies and asthmatic conditions were studied, for cytokines in the serum by elisa using kits from immunotech, and analyzed to identify the triggering factors or main contributors towards allergy and asthma.
nsubj||atypicalantipsychoticdrug-4/NN||aripiprazole-1/NN	cop||atypicalantipsychoticdrug-4/NN||is-2/VBZ	det||atypicalantipsychoticdrug-4/NN||an-3/DT	root||ROOT-0/null||atypicalantipsychoticdrug-4/NN	vmod||atypicalantipsychoticdrug-4/NN||approved-5/VBN	det||treatment-8/NN||the-7/DT	prep_for||approved-5/VBN||treatment-8/NN	amod||disorders-11/NNS||psychiatric-10/JJ	prep_of||treatment-8/NN||disorders-11/NNS	nn||depressivedisorder-19/NN||schizophrenia-14/NN	prep_such_as||disorders-11/NNS||bipolardisorder-16/NN	conj_and||depressivedisorder-19/NN||bipolardisorder-16/NN	prep_such_as||disorders-11/NNS||major-18/JJ	amod||depressivedisorder-19/NN||major-18/JJ	conj_and||depressivedisorder-19/NN||major-18/JJ	prep_such_as||disorders-11/NNS||depressivedisorder-19/NN	prep_such_as||disorders-11/NNS||autism-21/NN	conj_and||depressivedisorder-19/NN||autism-21/NN	autism-21||antipsychoticdrug--1||no_rel||aripiprazole is an atypicalantipsychoticdrug approved for the treatment of psychiatric disorders such as schizophrenia, bipolardisorder, major depressivedisorder and autism.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||aims-4/VBZ||study-3/NN	nsubj||demonstrate-6/VB||study-3/NN	root||ROOT-0/null||aims-4/VBZ	aux||demonstrate-6/VB||to-5/TO	xcomp||aims-4/VBZ||demonstrate-6/VB	mark||induces-13/VBZ||that-7/IN	det||formaldehyde-12/NN||the-8/DT	amod||formaldehyde-12/NN||tumor-9/JJ	amod||formaldehyde-12/NN||tissue-derived-10/JJ	nn||formaldehyde-12/NN||endogenous-11/NNS	nsubj||induces-13/VBZ||formaldehyde-12/NN	ccomp||demonstrate-6/VB||induces-13/VBZ	nn||pain-16/NN||bone-14/NN	nn||pain-16/NN||cancer-15/NN	dobj||induces-13/VBZ||pain-16/NN	amod||activation-19/NN||trpv1-18/JJ	prep_via||pain-16/NN||activation-19/NN	nn||environment-23/NN||tumor-21/NN	amod||environment-23/NN||acidic-22/JJ	prep_under||induces-13/VBZ||environment-23/NN	formaldehyde-12||tumor-21||no_rel||the present study aims to demonstrate that the tumor tissue-derived endogenous formaldehyde induces bone cancer pain via trpv1 activation under tumor acidic environment.
amod||evidences-2/NNS||recent-1/JJ	nsubj||demonstrated-4/VBN||evidences-2/NNS	aux||demonstrated-4/VBN||have-3/VBP	root||ROOT-0/null||demonstrated-4/VBN	mark||play-16/VB||that-5/IN	det||presence-7/NN||the-6/DT	nsubj||play-16/VB||presence-7/NN	amod||pathogenic-10/JJ||low-9/JJ	amod||avianinfluenzaviruses-11/NNS||pathogenic-10/JJ	prep_of||presence-7/NN||avianinfluenzaviruses-11/NNS	appos||avianinfluenzaviruses-11/NNS||lpaiv-13/NNP	aux||play-16/VB||may-15/MD	ccomp||demonstrated-4/VBN||play-16/VB	det||role-19/NN||an-17/DT	amod||role-19/NN||important-18/JJ	dobj||play-16/VB||role-19/NN	nn||ecology-22/NN||host-21/NN	prep_in||play-16/VB||ecology-22/NN	prep_in||play-16/VB||transmission-24/NN	conj_and||ecology-22/NN||transmission-24/NN	prep_of||ecology-22/NN||avianinfluenzaviruses-26/NNS	appos||avianinfluenzaviruses-26/NNS||aiv-28/NN	avianinfluenza--1||influenzaviruses--1||no||recent evidences have demonstrated that the presence of low pathogenic avianinfluenzaviruses (lpaiv) may play an important role in host ecology and transmission of avianinfluenzaviruses (aiv).
det||hormone-4/NN||the-1/DT	amod||hormone-4/NN||pineal-2/JJ	nn||hormone-4/NN||gland-3/NN	nsubjpass||shown-10/VBN||hormone-4/NN	nsubj||inhibit-15/VB||hormone-4/NN	appos||hormone-4/NN||melatonin-6/NN	aux||shown-10/VBN||has-8/VBZ	auxpass||shown-10/VBN||been-9/VBN	root||ROOT-0/null||shown-10/VBN	amod||studies-13/NNS||numerous-12/JJ	agent||shown-10/VBN||studies-13/NNS	aux||inhibit-15/VB||to-14/TO	xcomp||shown-10/VBN||inhibit-15/VB	det||proliferation-17/NN||the-16/DT	dobj||inhibit-15/VB||proliferation-17/NN	amod||±-22/NNS||estrogen-19/JJ	nn||±-22/NNS||receptor-20/NN	nn||±-22/NNS||î-21/NN	prep_of||proliferation-17/NN||±-22/NNS	nn||±-25/NNP||erî-24/NNP	appos||±-22/NNS||±-25/NNP	amod||lines-32/NNS||positive-28/JJ	nn||lines-32/NNS||breast-29/NN	nn||lines-32/NNS||cancer-30/NN	nn||lines-32/NNS||cell-31/NN	dep||±-22/NNS||lines-32/NNS	cancer-30||hormone-4||no_rel||the pineal gland hormone, melatonin, has been shown by numerous studies to inhibit the proliferation of estrogen receptor î± (erî±)-positive breast cancer cell lines.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||aims-4/VBZ||study-3/NN	nsubj||demonstrate-6/VB||study-3/NN	root||ROOT-0/null||aims-4/VBZ	aux||demonstrate-6/VB||to-5/TO	xcomp||aims-4/VBZ||demonstrate-6/VB	mark||induces-13/VBZ||that-7/IN	det||formaldehyde-12/NN||the-8/DT	amod||formaldehyde-12/NN||tumor-9/JJ	amod||formaldehyde-12/NN||tissue-derived-10/JJ	nn||formaldehyde-12/NN||endogenous-11/NNS	nsubj||induces-13/VBZ||formaldehyde-12/NN	ccomp||demonstrate-6/VB||induces-13/VBZ	nn||pain-16/NN||bone-14/NN	nn||pain-16/NN||cancer-15/NN	dobj||induces-13/VBZ||pain-16/NN	amod||activation-19/NN||trpv1-18/JJ	prep_via||pain-16/NN||activation-19/NN	nn||environment-23/NN||tumor-21/NN	amod||environment-23/NN||acidic-22/JJ	prep_under||induces-13/VBZ||environment-23/NN	cancer-15||formaldehyde-12||no_rel||the present study aims to demonstrate that the tumor tissue-derived endogenous formaldehyde induces bone cancer pain via trpv1 activation under tumor acidic environment.
mark||understood-13/VBN||although-1/IN	det||details-3/NNS||the-2/DT	nsubjpass||understood-13/VBN||details-3/NNS	det||mechanism-6/NN||the-5/DT	prep_of||details-3/NNS||mechanism-6/NN	nn||propagation-9/NN||prion-8/NN	prep_of||mechanism-6/NN||propagation-9/NN	auxpass||understood-13/VBN||are-10/VBP	neg||understood-13/VBN||not-11/RB	advmod||understood-13/VBN||fully-12/RB	advcl||considered-33/VBN||understood-13/VBN	amod||conversion-16/NN||conformational-15/JJ	nsubjpass||considered-33/VBN||conversion-16/NN	amod||prionprotein-19/NN||cellular-18/JJ	prep_of||conversion-16/NN||prionprotein-19/NN	dep||prionprotein-19/NN||prpc-21/JJ	amod||prionprotein-28/NN||misfolded-24/JJ	amod||prionprotein-28/NN||disease-associated-26/JJ	nn||prionprotein-28/NN||scrapie-27/NN	prep_to||prionprotein-19/NN||prionprotein-28/NN	dep||conversion-16/NN||prpsc-30/JJ	auxpass||considered-33/VBN||is-32/VBZ	root||ROOT-0/null||considered-33/VBN	det||event-37/NN||the-34/DT	amod||event-37/NN||essential-35/JJ	amod||event-37/NN||biochemical-36/JJ	dobj||considered-33/VBN||event-37/NN	nn||replication-40/NN||prion-39/NN	prep_for||event-37/NN||replication-40/NN	prionprotein-28||scrapie-27||no_rel||although the details of the mechanism of prion propagation are not fully understood, conformational conversion of cellular prionprotein (prpc) to misfolded, disease-associated scrapie prionprotein (prpsc) is considered the essential biochemical event for prion replication.
advmod||remained-21/VBD||nevertheless-1/RB	amod||health-5/NN||improved-4/VBN	prep_despite||remained-21/VBD||health-5/NN	prepc_from||health-5/NN||taking-7/VBG	dobj||taking-7/VBG||art-8/NN	amod||health-11/NN||worse-10/JJR	conj_and||health-5/NN||health-11/NN	tmod||stopped-15/VBN||health-11/NN	prep_despite||remained-21/VBD||health-11/NN	advmod||stopped-15/VBN||when-12/WRB	nsubjpass||stopped-15/VBN||treatment-13/NN	auxpass||stopped-15/VBN||is-14/VBZ	rcmod||health-11/NN||stopped-15/VBN	amod||barriers-18/NNS||serious-17/JJ	nsubj||remained-21/VBD||barriers-18/NNS	prep_to||barriers-18/NNS||treatment-20/NN	root||ROOT-0/null||remained-21/VBD	nn||costs-23/NNS||transport-22/NN	xcomp||remained-21/VBD||costs-23/NNS	appos||costs-23/NNS||time-25/NN	vmod||time-25/NN||needed-26/VBN	prep_for||needed-26/VBN||treatment-28/NN	amod||challenges-32/NNS||logistical-31/JJ	nsubj||barriers-34/NNS||challenges-32/NNS	cop||barriers-34/NNS||were-33/VBD	conj_and||remained-21/VBD||barriers-34/NNS	prep_to||barriers-34/NNS||treatment-36/NN	mark||influential-51/JJ||whereas-38/IN	nsubj||influential-51/JJ||stigma-39/NN	prep_around||stigma-39/NN||hiv/aids-41/NNS	nn||effects-45/NNS||side-44/NN	prep_around||stigma-39/NN||effects-45/NNS	conj_and||hiv/aids-41/NNS||effects-45/NNS	vmod||effects-45/NNS||associated-46/VBN	prep_with||associated-46/VBN||art-48/NN	cop||influential-51/JJ||were-49/VBD	advmod||influential-51/JJ||less-50/RBR	advcl||barriers-34/NNS||influential-51/JJ	aids--1||hiv--1||no||nevertheless, despite improved health from taking art and worse health when treatment is stopped, serious barriers to treatment remained transport costs, time needed for treatment, and logistical challenges were barriers to treatment, whereas stigma around hiv/aids, and side effects associated with art were less influential.
amod||surveys-2/NNS||epidemiological-1/JJ	nsubj||demonstrated-7/VBN||surveys-2/NNS	nn||experiments-5/NNS||laboratory-4/NN	conj_and||surveys-2/NNS||experiments-5/NNS	nsubj||demonstrated-7/VBN||experiments-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||-lrb--21/VBZ||that-8/IN	det||virulence-12/NN||the-9/DT	advmod||acquired-11/VBN||newly-10/RB	amod||virulence-12/NN||acquired-11/VBN	nsubj||-lrb--21/VBZ||virulence-12/NN	amod||viruses-15/NNS||several-14/JJ	prep_of||virulence-12/NN||viruses-15/NNS	vmod||viruses-15/NNS||belonging-16/VBG	det||dicistroviridae-20/NN||the-18/DT	nn||dicistroviridae-20/NN||family-19/NN	prep_to||belonging-16/VBG||dicistroviridae-20/NN	ccomp||demonstrated-7/VBN||-lrb--21/VBZ	amod||virus-29/NN||acute-22/JJ	nn||virus-29/NN||bee-23/NN	nn||virus-29/NN||paralysis-24/NN	nn||virus-29/NN||virus-25/NN	dep||virus-29/NN||kashmir-27/NN	nn||virus-29/NN||bee-28/NN	dobj||-lrb--21/VBZ||virus-29/NN	amod||-rrb--35/NNS||israeli-31/JJ	amod||-rrb--35/NNS||acute-32/JJ	nn||-rrb--35/NNS||paralysis-33/NN	nn||-rrb--35/NNS||virus-34/NN	dobj||-lrb--21/VBZ||-rrb--35/NNS	conj_and||virus-29/NN||-rrb--35/NNS	prep_in||virus-29/NN||europe-37/NN	det||usa-40/NN||the-39/DT	nsubjpass||observed-43/VBN||usa-40/NN	nsubjpass||observed-43/VBN||usa-40/NN	aux||observed-43/VBN||had-41/VBD	auxpass||observed-43/VBN||been-42/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||observed-43/VBN||observed-43/VBN	prep_in||observed-43/VBN||relation-45/NN	conj_and||demonstrated-7/VBN||destructor-48/NN	conj_v.||observed-43/VBN||destructor-48/NN	prep_with||observed-43/VBN||destructor-48/NN	vmod||destructor-48/NN||acting-49/VBG	vmod||destructor-48/NN||acting-49/VBG	conj_and||acting-49/VBG||acting-49/VBG	det||disseminator-52/NN||a-51/DT	prep_as||acting-49/VBG||disseminator-52/NN	det||viruses-55/NNS||these-54/DT	prep_of||disseminator-52/NN||viruses-55/NNS	nn||colonies-60/NNS||bee-59/NN	prep_between||acting-49/VBG||colonies-60/NNS	prep_within||acting-49/VBG||colonies-60/NNS	det||activator-64/NN||an-63/DT	prep_as||observed-43/VBN||activator-64/NN	prep_of||activator-64/NN||virus-66/NN	vmod||virus-66/NN||multiplication-67/VBN	det||larvae-73/NN||the-69/DT	amod||larvae-73/NN||infected-70/JJ	nn||larvae-73/NN||individuals-71/NNS	nn||larvae-73/NN||bee-72/NN	prep_in||multiplication-67/VBN||larvae-73/NN	prep_in||multiplication-67/VBN||adults-75/NNS	conj_and||larvae-73/NN||adults-75/NNS	virus-66||viruses-55||no||epidemiological surveys and laboratory experiments have demonstrated that the newly acquired virulence of several viruses belonging to the family dicistroviridae -lrb- acute bee paralysis virus , kashmir bee virus and israeli acute paralysis virus -rrb- in europe and the usa had been observed in relation with v. destructor acting as a disseminator of these viruses between and within bee colonies and as an activator of virus multiplication in the infected individuals bee larvae and adults .
det||analysis-2/NN||the-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	num||studies-8/NNS||three-4/CD	amod||studies-8/NNS||randomized-5/JJ	amod||studies-8/NNS||double-blind-7/JJ	dobj||included-3/VBD||studies-8/NNS	prep_in||studies-8/NNS||patients-10/NNS	prep_with||patients-10/NNS||schizophrenia-12/NN	amod||disorder-15/NN||schizoaffective-14/JJ	dobj||included-3/VBD||disorder-15/NN	conj_or||studies-8/NNS||disorder-15/NN	nn||disorder-19/NN||schizophreniform-18/NN	dobj||included-3/VBD||disorder-19/NN	conj_or||studies-8/NNS||disorder-19/NN	dep||disorder-19/NN||diagnosed-20/VBN	prepc_according_to||diagnosed-20/VBN||to-22/TO	det||manual-27/NN||the-23/DT	amod||manual-27/NN||diagnostic-24/JJ	conj_and||diagnostic-24/JJ||statistical-26/JJ	amod||manual-27/NN||statistical-26/JJ	pobj||diagnosed-20/VBN||manual-27/NN	amod||disorders-30/NNS||mental-29/JJ	npadvmod||4th-31/JJ||disorders-30/NNS	amod||edition-32/NN||4th-31/JJ	prep_of||manual-27/NN||edition-32/NN	advmod||assigned-35/VBN||randomly-34/RB	dep||disorder-19/NN||assigned-35/VBN	conj_and||diagnosed-20/VBN||assigned-35/VBN	prep_to||assigned-35/VBN||treatment-37/NN	poss||mg/day-44/NN||olanzapine-39/PRP$	amod||mg/day-44/NN||5â-40/JJ	amod||mg/day-44/NN||$-41/$	num||$-41/$||20-43/CD	prep_with||assigned-35/VBN||mg/day-44/NN	det||antipsychotic-47/NN||another-46/DT	prep_with||assigned-35/VBN||antipsychotic-47/NN	conj_or||mg/day-44/NN||antipsychotic-47/NN	amod||2â-50/NNS||haloperidol-49/JJ	dep||antipsychotic-47/NN||2â-50/NNS	num||mg/day-54/NN||$-51/$	num||$-51/$||20-53/CD	dep||2â-50/NNS||mg/day-54/NN	poss||mg/day-61/NN||risperidone-56/PRP$	amod||mg/day-61/NN||2â-57/JJ	amod||mg/day-61/NN||$-58/$	num||$-58/$||10-60/CD	dep||2â-50/NNS||mg/day-61/NN	conj_or||mg/day-54/NN||mg/day-61/NN	poss||mg/day-69/NN||ziprasidone-64/PRP$	amod||mg/day-69/NN||80â-65/JJ	amod||mg/day-69/NN||$-66/$	num||$-66/$||160-68/CD	dep||2â-50/NNS||mg/day-69/NN	conj_or||mg/day-54/NN||mg/day-69/NN	schizophrenia-12||risperidone-56||yes||the analysis included three randomized, double-blind studies in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder diagnosed according to the diagnostic and statistical manual of mental disorders 4th edition and randomly assigned to treatment with olanzapine 5â€“20 mg/day or another antipsychotic (haloperidol 2â€“20 mg/day, risperidone 2â€“10 mg/day, or ziprasidone 80â€“160 mg/day).
det||finding-3/NN||the-1/DT	amod||finding-3/NN||qualitative-2/JJ	nsubj||revealed-4/VBD||finding-3/NN	root||ROOT-0/null||revealed-4/VBD	amod||awareness-6/NN||low-5/JJ	nsubj||barriers-20/NNS||awareness-6/NN	amod||effects-13/NNS||non-disclosure-8/JJ	amod||effects-13/NNS||perceived-10/JJ	nn||effects-13/NNS||art-11/NN	nn||effects-13/NNS||side-12/NN	conj_and||awareness-6/NN||effects-13/NNS	nsubj||barriers-20/NNS||effects-13/NNS	nn||stigma-16/NN||hiv-15/NN	conj_and||awareness-6/NN||stigma-16/NN	nsubj||barriers-20/NNS||stigma-16/NN	cop||barriers-20/NNS||were-17/VBD	det||barriers-20/NNS||the-18/DT	amod||barriers-20/NNS||major-19/JJ	ccomp||revealed-4/VBD||barriers-20/NNS	amod||presentation-23/NN||late-22/JJ	prep_for||barriers-20/NNS||presentation-23/NN	amod||care-26/NN||hiv/aids-25/JJ	prep_to||barriers-20/NNS||care-26/NN	aids--1||hiv-15||no||the qualitative finding revealed low awareness, non-disclosure, perceived art side effects and hiv stigma were the major barriers for late presentation to hiv/aids care.
amod||patients-2/NNS||forty-eight-1/JJ	nsubjpass||enrolled-18/VBN||patients-2/NNS	nsubjpass||treated-24/VBN||patients-2/NNS	nn||ve-6/NNP||chemo-naã-4/NNP	nn||ve-6/NNP||¯-5/NNP	prep_with||patients-2/NNS||ve-6/NNP	advmod||confirmed-9/VBN||histologically-8/RB	vmod||ve-6/NNP||confirmed-9/VBN	advmod||ve-6/NNP||locally-11/RB	amod||cancer-16/NN||advanced-12/VBN	conj_or||advanced-12/VBN||metastatic-14/JJ	amod||cancer-16/NN||metastatic-14/JJ	amod||cancer-16/NN||gastric-15/JJ	dep||ve-6/NNP||cancer-16/NN	auxpass||enrolled-18/VBN||were-17/VBD	root||ROOT-0/null||enrolled-18/VBN	det||study-21/NN||the-20/DT	prep_for||enrolled-18/VBN||study-21/NN	auxpass||treated-24/VBN||were-23/VBD	conj_and||enrolled-18/VBN||treated-24/VBN	nn||chemotherapy-27/NN||combination-26/NN	prep_with||treated-24/VBN||chemotherapy-27/NN	amod||mg/m2-31/NNS||paclitaxel-29/JJ	dep||paclitaxel-29/JJ||175-30/CD	prep_of||chemotherapy-27/NN||mg/m2-31/NNS	prep_of||chemotherapy-27/NN||cisplatin-33/NN	conj_and||mg/m2-31/NNS||cisplatin-33/NN	num||mg/m2-35/NNS||75-34/CD	dobj||enrolled-18/VBN||mg/m2-35/NNS	prep_for||enrolled-18/VBN||maximum-37/NN	num||cycles-40/NNS||six-39/CD	prep_of||maximum-37/NN||cycles-40/NNS	prepc_after||enrolled-18/VBN||obtaining-42/VBG	dobj||obtaining-42/VBG||specimen-43/NN	prep_for||obtaining-42/VBG||atp-cra-45/NN	cancer-16||cisplatin-33||no_rel||forty-eight patients with chemo-naã¯ve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 for maximum of six cycles after obtaining specimen for atp-cra.
det||mixture-5/NN||the-1/DT	amod||mixture-5/NN||lidocaine-2/JJ	conj_and||lidocaine-2/JJ||propofol-4/JJ	amod||mixture-5/NN||propofol-4/JJ	nsubj||effective-7/JJ||mixture-5/NN	cop||effective-7/JJ||is-6/VBZ	root||ROOT-0/null||effective-7/JJ	prepc_in||effective-7/JJ||alleviating-9/VBG	dobj||alleviating-9/VBG||pain-10/NN	vmod||pain-10/NN||associated-11/VBN	amod||injection-15/NN||microemulsion-13/JJ	amod||injection-15/NN||propofol-14/JJ	prep_with||associated-11/VBN||injection-15/NN	pain-10||lidocaine-2||yes||the lidocaine and propofol mixture is effective in alleviating pain associated with microemulsion propofol injection.
det||study-9/NN||this-1/DT	amod||study-9/NN||prospective-2/JJ	amod||study-9/NN||6-week-4/JJ	amod||study-9/NN||multicenter-6/JJ	amod||study-9/NN||double-blind-8/JJ	nsubj||compared-22/VBD||study-9/NN	vmod||study-9/NN||examined-10/VBN	det||benefits-12/NNS||the-11/DT	dobj||examined-10/VBN||benefits-12/NNS	prepc_of||benefits-12/NNS||initiating-14/VBG	dobj||initiating-14/VBG||treatment-15/NN	nn||valsartan/hydrochlorothiazide-18/NN||combination-17/NN	prep_with||initiating-14/VBG||valsartan/hydrochlorothiazide-18/NN	appos||study-9/NN||hctz-20/NNP	root||ROOT-0/null||compared-22/VBD	amod||monotherapy-26/NN||initial-24/JJ	nn||monotherapy-26/NN||valsartan-25/NN	prep_with||compared-22/VBD||monotherapy-26/NN	num||patients-29/NNS||648-28/CD	prep_for||monotherapy-26/NN||patients-29/NNS	amod||hypertension-34/NN||stage-1-31/JJ	conj_or||stage-1-31/JJ||stage-2-33/JJ	amod||hypertension-34/NN||stage-2-33/JJ	prep_with||compared-22/VBD||hypertension-34/NN	dep||hypertension-34/NN||age-36/NN	dep||years-42/NNS||=-37/SYM	num||years-42/NNS||52.6-38/CD	nn||years-42/NNS||â-39/NNP	nn||years-42/NNS||±-40/NNP	num||years-42/NNS||10-41/CD	rcmod||age-36/NN||years-42/NNS	num||%-45/NN||54-44/CD	dep||age-36/NN||%-45/NN	dep||%-45/NN||male-46/NN	nn||blood-49/NN||baseline-48/NN	dep||age-36/NN||blood-49/NN	rcmod||blood-49/NN||pressure-50/NN	dep||pressure-50/NN||bp-52/NN	amod||stage-66/NN||=-54/JJ	dep||=-54/JJ||161/98-55/CD	amod||stage-66/NN||â-56/JJ	amod||stage-66/NN||$-57/$	dep||$-57/$||‰-58/JJ	amod||stage-66/NN||mmâ-59/JJ	amod||stage-66/NN||$-60/$	number||hg-62/CD||‰-61/CD	num||$-60/$||hg-62/CD	number||%-65/NN||32-64/CD	amod||stage-66/NN||%-65/NN	dobj||pressure-50/NN||stage-66/NN	dep||age-36/NN||1-67/CD	hypertension-34||hydrochlorothiazide--1||yes||this prospective, 6-week, multicenter, double-blind study examined the benefits of initiating treatment with combination valsartan/hydrochlorothiazide (hctz) compared with initial valsartan monotherapy for 648 patients with stage-1 or stage-2 hypertension (age=52.6â±10 years; 54% male; baseline blood pressure (bp)=161/98â€‰mmâ€‰hg, 32% stage 1).
num||percent-2/NN||seventeen-1/CD	nsubj||resistant-8/JJ||percent-2/NN	det||cultures-6/NNS||all-4/DT	amod||cultures-6/NNS||positive-5/JJ	prep_of||percent-2/NN||cultures-6/NNS	cop||resistant-8/JJ||were-7/VBD	root||ROOT-0/null||resistant-8/JJ	preconj||isoniazid-11/NN||both-10/DT	prep_to||resistant-8/JJ||isoniazid-11/NN	prep_to||resistant-8/JJ||rifampin-13/NN	conj_and||isoniazid-11/NN||rifampin-13/NN	dep||resistant-18/NN||i.e.-15/FW	dep||resistant-18/NN||multidrug-17/JJ	dep||isoniazid-11/NN||resistant-18/NN	num||%-22/NN||16-21/CD	nsubjpass||infected-39/VBN||%-22/NN	prep_of||%-22/NN||patients-24/NNS	vmod||patients-24/NNS||dying-25/VBG	det||phase-29/NN||the-27/DT	nn||phase-29/NN||initiation-28/NN	prep_during||dying-25/VBG||phase-29/NN	poss||course-34/NN||their-31/PRP$	amod||course-34/NN||first-32/JJ	advmod||first-32/JJ||ever-33/RB	prep_of||phase-29/NN||course-34/NN	nn||treatment-37/NN||tuberculosis-36/NNP	prep_of||course-34/NN||treatment-37/NN	auxpass||infected-39/VBN||were-38/VBD	parataxis||resistant-8/JJ||infected-39/VBN	amod||bacilli-42/NNS||multidrug-resistant-41/JJ	prep_with||infected-39/VBN||bacilli-42/NNS	tuberculosis-36||rifampin-13||yes||seventeen percent of all positive cultures were resistant to both isoniazid and rifampin (i.e., multidrug resistant); 16% of patients dying during the initiation phase of their first ever course of tuberculosis treatment were infected with multidrug-resistant bacilli.
nsubjpass||determined-64/VBN||levels-1/NNS	prep_of||levels-1/NNS||angiopoietin-2-3/JJ	appos||angiopoietin-2-3/JJ||vonwillebrandfactor-5/NN	appos||vonwillebrandfactor-5/NN||vwf-7/NN	num||molecule-1-19/NNS||vwf-10/CD	amod||molecule-1-19/NNS||propeptide-11/JJ	amod||molecule-1-19/NNS||soluble-13/JJ	amod||molecule-1-19/NNS||p-selectin-14/JJ	amod||molecule-1-19/NNS||soluble-16/JJ	nn||molecule-1-19/NNS||intercellular-17/NN	nn||molecule-1-19/NNS||adhesion-18/NN	appos||vonwillebrandfactor-5/NN||molecule-1-19/NNS	dep||molecule-1-19/NNS||icam-1-21/JJ	amod||endoglin-25/NN||soluble-24/JJ	appos||vonwillebrandfactor-5/NN||endoglin-25/NN	amod||kinase-1-30/NN||soluble-27/JJ	amod||kinase-1-30/NN||fms-like-28/JJ	nn||kinase-1-30/NN||tyrosine-29/NN	appos||endoglin-25/NN||kinase-1-30/NN	dep||kinase-1-30/NN||flt-1-32/JJ	amod||tie-2-36/JJ||soluble-35/JJ	amod||vonwillebrandfactor-5/NN||tie-2-36/JJ	amod||protein-39/NN||c-reactive-38/JJ	appos||vonwillebrandfactor-5/NN||protein-39/NN	appos||protein-39/NN||procalcitonin-41/NN	num||protein-47/NN||10-43/CD	amod||protein-47/NN||kda-44/JJ	amod||protein-47/NN||interferon-45/JJ	amod||protein-47/NN||gamma-induced-46/JJ	appos||protein-39/NN||protein-47/NN	dep||protein-47/NN||ip-10-49/JJ	amod||receptor-55/NN||soluble-53/JJ	amod||receptor-55/NN||triggering-54/VBG	appos||protein-39/NN||receptor-55/NN	conj_and||protein-47/NN||receptor-55/NN	vmod||receptor-55/NN||expressed-56/VBN	amod||cells-1-59/NN||myeloid-58/JJ	prep_on||expressed-56/VBN||cells-1-59/NN	dep||protein-39/NN||trem-1-61/JJ	auxpass||determined-64/VBN||were-63/VBD	root||ROOT-0/null||determined-64/VBN	agent||determined-64/VBN||elisa-66/NN	vonwillebrandfactor-5||adhesion-18||no_rel||levels of angiopoietin-2, vonwillebrandfactor (vwf), vwf propeptide, soluble p-selectin, soluble intercellular adhesion molecule-1 (icam-1), soluble endoglin, soluble fms-like tyrosine kinase-1 (flt-1), soluble tie-2, c-reactive protein, procalcitonin, 10 kda interferon gamma-induced protein (ip-10), and soluble triggering receptor expressed on myeloid cells-1 (trem-1) were determined by elisa.
det||phase-4/NN||the-2/DT	amod||phase-4/NN||first-3/JJ	prep_in||conduct-10/VB||phase-4/NN	det||study-7/NN||this-6/DT	prep_of||phase-4/NN||study-7/NN	nsubj||conduct-10/VB||we-8/PRP	aux||conduct-10/VB||will-9/MD	root||ROOT-0/null||conduct-10/VB	amod||interviews-12/NNS||structured-11/JJ	dobj||conduct-10/VB||interviews-12/NNS	aux||determine-14/VB||to-13/TO	vmod||conduct-10/VB||determine-14/VB	poss||preferences-17/NNS||their-15/PRP$	nn||preferences-17/NNS||treatment-16/NN	dobj||determine-14/VB||preferences-17/NNS	prep_for||determine-14/VB||warfarin-19/NN	prep_vs.||warfarin-19/NN||aspirin-21/NN	aux||prevent-23/VB||to-22/TO	vmod||determine-14/VB||prevent-23/VB	dobj||prevent-23/VB||strokes-24/NNS	vmod||strokes-24/NNS||associated-25/VBN	prep_with||associated-25/VBN||atrialfibrillation-27/NN	xcomp||associated-25/VBN||using-28/VBG	det||technique-32/NN||the-29/DT	nn||technique-32/NN||probability-30/NN	nn||technique-32/NN||trade-off-31/NN	dobj||using-28/VBG||technique-32/NN	atrialfibrillation-27||warfarin-19||yes||in the first phase of this study we will conduct structured interviews to determine their treatment preferences for warfarin vs. aspirin to prevent strokes associated with atrialfibrillation using the probability trade-off technique .
det||practice-2/NN||the-1/DT	nsubj||explanation-14/NN||practice-2/NN	prepc_of||practice-2/NN||combining-4/VBG	dobj||combining-4/VBG||agents-5/NNS	nsubj||counteract-7/VB||agents-5/NNS	rcmod||agents-5/NNS||counteract-7/VB	amod||mechanisms-9/NNS||different-8/JJ	dobj||counteract-7/VB||mechanisms-9/NNS	cop||explanation-14/NN||is-10/VBZ	det||explanation-14/NN||the-11/DT	advmod||likely-13/JJ||most-12/RBS	amod||explanation-14/NN||likely-13/JJ	root||ROOT-0/null||explanation-14/NN	det||fact-17/NN||the-16/DT	prep_for||explanation-14/NN||fact-17/NN	mark||have-23/VBP||that-18/IN	advmod||available-20/JJ||most-19/RBS	amod||combinations-22/NNS||available-20/JJ	amod||combinations-22/NNS||two-drug-21/JJ	nsubj||have-23/VBP||combinations-22/NNS	ccomp||explanation-14/NN||have-23/VBP	det||agent-25/NN||an-24/DT	dobj||have-23/VBP||agent-25/NN	nsubj||addresses-27/VBZ||agent-25/NN	rcmod||agent-25/NN||addresses-27/VBZ	nn||secretion-29/NN||renin-28/NN	dobj||addresses-27/VBZ||secretion-29/NN	dep||secretion-29/NN||beta-blocker-31/NN	dep||secretion-29/NN||angiotensin-33/VBG	conj_or||beta-blocker-31/NN||angiotensin-33/VBG	vmod||angiotensin-33/VBG||converting-34/VBG	amod||inhibitor-36/NN||enzyme-35/JJ	dobj||converting-34/VBG||inhibitor-36/NN	dep||secretion-29/NN||angiotensiniireceptorblocker-38/NN	conj_or||beta-blocker-31/NN||angiotensiniireceptorblocker-38/NN	amod||inhibitor-42/NN||direct-40/JJ	nn||inhibitor-42/NN||renin-41/NN	dep||secretion-29/NN||inhibitor-42/NN	conj_or||beta-blocker-31/NN||inhibitor-42/NN	det||one-46/NN||another-45/DT	dobj||addresses-27/VBZ||one-46/NN	conj_and||secretion-29/NN||one-46/NN	nsubj||effective-50/JJ||one-46/NN	cop||effective-50/JJ||is-48/VBZ	advmod||effective-50/JJ||more-49/RBR	rcmod||one-46/NN||effective-50/JJ	amod||hypertension-53/NN||renin-independent-52/JJ	prep_in||effective-50/JJ||hypertension-53/NN	dep||one-46/NN||diuretic-55/NN	dep||one-46/NN||dihydropyridine-57/NN	conj_or||diuretic-55/NN||dihydropyridine-57/NN	amod||blocker-62/NN||non-dihydropyridine-59/JJ	nn||blocker-62/NN||calcium-60/NN	nn||blocker-62/NN||channel-61/NN	dep||one-46/NN||blocker-62/NN	conj_or||diuretic-55/NN||blocker-62/NN	hypertension-53||angiotensiniireceptorblocker-38||no_rel||the practice of combining agents that counteract different mechanisms is the most likely explanation for the fact that most available two-drug combinations have an agent that addresses renin secretion (beta-blocker, angiotensin converting enzyme inhibitor, angiotensiniireceptorblocker or direct renin inhibitor) and another one that is more effective in renin-independent hypertension (diuretic, dihydropyridine or non-dihydropyridine calcium channel blocker).
amod||administration-2/NN||oral-1/JJ	nsubj||led-14/VBD||administration-2/NN	prep_of||administration-2/NN||pde5inhibitor-4/NNS	appos||pde5inhibitor-4/NNS||vardenafil-6/NN	prep_to||pde5inhibitor-4/NNS||mice-9/NNS	amod||lungtumors-13/NNS||her2-positive-11/JJ	amod||lungtumors-13/NNS||intracranial-12/JJ	prep_with||mice-9/NNS||lungtumors-13/NNS	root||ROOT-0/null||led-14/VBD	det||permeability-19/NN||an-16/DT	amod||permeability-19/NN||increased-17/VBN	nn||permeability-19/NN||tumor-18/NN	prep_to||led-14/VBD||permeability-19/NN	amod||dextran-27/NNS||high-21/JJ	amod||dextran-27/NNS||molecular-22/JJ	nn||dextran-27/NNS||weight-23/NN	amod||dextran-27/NNS||-LSB--24/JJ	amod||dextran-27/NNS||14c-25/JJ	nn||dextran-27/NNS||-RSB--26/NN	prep_to||permeability-19/NN||dextran-27/NNS	amod||increase-30/NN||2.6-fold-29/JJ	appos||dextran-27/NNS||increase-30/NN	prep_to||permeability-19/NN||herceptin-34/NN	conj_and||dextran-27/NNS||herceptin-34/NN	amod||increase-37/NN||2-fold-36/JJ	appos||herceptin-34/NN||increase-37/NN	tumor-18||dextran-27||no_rel||oral administration of pde5inhibitor, vardenafil, to mice with her2-positive intracranial lungtumors led to an increased tumor permeability to high molecular weight [14c]dextran (2.6-fold increase) and to herceptin (2-fold increase).
det||treatment-2/NN||the-1/DT	nsubj||depends-17/VBZ||treatment-2/NN	conj_and||treatment-2/NN||control-4/NN	nsubj||depends-17/VBZ||control-4/NN	prep_of||treatment-2/NN||schistosomiasis-6/NNS	det||disease-12/NN||an-8/DT	advmod||disease-12/NN||often-9/RB	amod||disease-12/NN||neglected-10/VBN	amod||disease-12/NN||tropical-11/JJ	appos||treatment-2/NN||disease-12/NN	nsubj||exacerbates-14/VBZ||disease-12/NN	rcmod||disease-12/NN||exacerbates-14/VBZ	dobj||exacerbates-14/VBZ||poverty-15/NN	root||ROOT-0/null||depends-17/VBZ	det||drug-21/NN||a-19/DT	amod||drug-21/NN||single-20/JJ	prep_on||depends-17/VBZ||drug-21/NN	appos||drug-21/NN||praziquantel-23/NN	schistosomiasis-6||praziquantel-23||yes||the treatment and control of schistosomiasis, an often neglected tropical disease that exacerbates poverty, depends on a single drug, praziquantel.
det||study-2/NN||this-1/DT	nsubj||provides-3/VBZ||study-2/NN	root||ROOT-0/null||provides-3/VBZ	det||measure-6/NN||a-4/DT	amod||measure-6/NN||direct-5/JJ	dobj||provides-3/VBZ||measure-6/NN	prep_of||measure-6/NN||hiv/aids-8/NNS	prep_as||hiv/aids-8/NNS||impact-10/NN	nn||mortality-13/NN||child-12/NN	prep_on||provides-3/VBZ||mortality-13/NN	vmod||mortality-13/NN||using-14/VBG	det||method-19/NN||a-15/DT	amod||method-19/NN||rapid-16/JJ	conj_and||rapid-16/JJ||reliable-18/JJ	amod||method-19/NN||reliable-18/JJ	dobj||using-14/VBG||method-19/NN	aids--1||hiv--1||no||this study provides a direct measure of hiv/aids as impact on child mortality using a rapid and reliable method.
det||utilization-5/NN||the-2/DT	nn||utilization-5/NN||diabetes-3/NN	nn||utilization-5/NN||therapy-4/NN	nsubj||researching-6/VBG||utilization-5/NN	prepc_in||exenatide-41/VBP||researching-6/VBG	dobj||researching-6/VBG||changes-7/NNS	nn||weight-11/NN||a1c-9/NNS	nn||factors-14/NNS||weight-11/NN	conj_and||weight-11/NN||other-13/JJ	nn||factors-14/NNS||other-13/JJ	prep_in||changes-7/NNS||factors-14/NNS	prep_through||researching-6/VBG||intervention-16/NN	amod||study-24/NN||exenatide-18/JJ	advmod||exenatide-18/JJ||once-19/RB	amod||study-24/NN||weekly-20/JJ	dep||study-24/NN||duration-1-22/JJ	prep_with||intervention-16/NN||study-24/NN	det||safety-27/NN||the-26/DT	nsubj||exenatide-41/VBP||safety-27/NN	conj_and||safety-27/NN||efficacy-29/NN	nsubj||exenatide-41/VBP||efficacy-29/NN	num||weeks-32/NNS||30-31/CD	prep_of||safety-27/NN||weeks-32/NNS	prep_of||weeks-32/NNS||treatment-34/NN	det||agonist-40/NN||the-36/DT	amod||agonist-40/NN||glucagon-like-37/JJ	amod||agonist-40/NN||peptide-1-38/JJ	nn||agonist-40/NN||receptor-39/NN	prep_with||treatment-34/NN||agonist-40/NN	root||ROOT-0/null||exenatide-41/VBP	mark||compared-52/VBN||once-42/IN	nsubjpass||compared-52/VBN||weekly-43/JJ	amod||qw-46/NN||exenatide-45/JJ	dep||weekly-43/JJ||qw-46/NN	num||mg-49/NN||2-48/CD	dep||qw-46/NN||mg-49/NN	auxpass||compared-52/VBN||was-51/VBD	advcl||exenatide-41/VBP||compared-52/VBN	amod||bid-55/NN||exenatide-54/JJ	prep_with||compared-52/VBN||bid-55/NN	amod||patients-58/NNS||295-57/JJ	prep_in||bid-55/NN||patients-58/NNS	prep_with||compared-52/VBN||type2diabetes-60/CD	type2diabetes-60||exenatide-54||yes||in the diabetes therapy utilization researching changes in a1c, weight and other factors through intervention with exenatide once weekly (duration-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide qw; 2 mg) was compared with exenatide bid in 295 patients with type2diabetes.
amod||trachoma-2/NN||blinding-1/VBG	nsubjpass||targeted-12/VBN||trachoma-2/NN	vmod||trachoma-2/NN||caused-4/VBN	nn||infection-7/NN||ocular-6/NN	agent||caused-4/VBN||infection-7/NN	prep_with||caused-4/VBN||chlamydiatrachomatis-9/NNS	auxpass||targeted-12/VBN||is-11/VBZ	root||ROOT-0/null||targeted-12/VBN	amod||elimination-15/NN||global-14/JJ	prep_for||targeted-12/VBN||elimination-15/NN	agent||targeted-12/VBN||2020-17/CD	trachoma-2||chlamydiatrachomatis-9||no||blinding trachoma, caused by ocular infection with chlamydiatrachomatis , is targeted for global elimination by 2020.
det||factors-5/NNS||the-1/DT	num||factors-5/NNS||two-2/CD	advmod||consistent-4/JJ||most-3/RBS	amod||factors-5/NNS||consistent-4/JJ	nsubj||having-14/VBG||factors-5/NNS	vmod||factors-5/NNS||associated-6/VBN	nn||testing-9/NN||hiv-8/NN	prep_with||associated-6/VBN||testing-9/NN	det||countries-12/NNS||the-11/DT	prep_across||associated-6/VBN||countries-12/NNS	aux||having-14/VBG||were-13/VBD	root||ROOT-0/null||having-14/VBG	dep||having-14/VBG||heard-15/VBN	prep_about||heard-15/VBN||hiv/aids-17/NNS	det||centre-23/NN||a-19/DT	nn||centre-23/NN||clinic-20/NN	conj_or||clinic-20/NN||health-22/NN	nn||centre-23/NN||health-22/NN	prep_from||hiv/aids-17/NNS||centre-23/NN	aux||talked-27/VBN||having-26/VBG	dep||having-14/VBG||talked-27/VBN	conj_and||heard-15/VBN||talked-27/VBN	prep_to||talked-27/VBN||someone-29/NN	prep_about||someone-29/NN||hiv-31/NN	prep_about||someone-29/NN||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||the two most consistent factors associated with hiv testing across the countries were having heard about hiv/aids from a clinic or health centre, and having talked to someone about hiv and aids.
amod||models-2/NNS||prognostic-1/JJ	nsubj||used-3/VBD||models-2/NNS	root||ROOT-0/null||used-3/VBD	amod||analysis-7/NN||multivariate-4/JJ	nn||analysis-7/NN||cox-5/NN	nn||analysis-7/NN||regression-6/NN	dobj||used-3/VBD||analysis-7/NN	amod||analyses-10/NNS||multivariate-9/JJ	prep_for||analysis-7/NN||analyses-10/NNS	prep_of||analyses-10/NNS||survival-12/NN	poss||study-15/NN||our-14/PRP$	nsubj||showed-16/VBD||study-15/NN	parataxis||used-3/VBD||showed-16/VBD	nsubj||p-lvd-18/JJ||that-17/DT	nsubj||i-lvd-22/JJ||that-17/DT	nsubjpass||correlated-26/VBN||that-17/DT	xcomp||showed-16/VBD||p-lvd-18/JJ	xcomp||showed-16/VBD||i-lvd-22/JJ	conj_negcc||p-lvd-18/JJ||i-lvd-22/JJ	auxpass||correlated-26/VBN||was-24/VBD	advmod||correlated-26/VBN||significantly-25/RB	xcomp||showed-16/VBD||correlated-26/VBN	ccomp||p-lvd-18/JJ||correlated-26/VBN	conj_negcc||p-lvd-18/JJ||correlated-26/VBN	nn||invasion-31/NN||lymph-28/NN	nn||invasion-31/NN||vascular-29/NN	nn||invasion-31/NN||space-30/NN	prep_with||correlated-26/VBN||invasion-31/NN	appos||invasion-31/NN||lvsi-33/NNP	nn||metastasis-38/NNS||lymph-36/NN	nn||metastasis-38/NNS||node-37/NN	prep_with||correlated-26/VBN||metastasis-38/NNS	conj_and||invasion-31/NN||metastasis-38/NNS	nn||stage-41/NN||tumor-40/NN	prep_with||correlated-26/VBN||stage-41/NN	conj_and||invasion-31/NN||stage-41/NN	amod||expression-45/NN||cd44-44/JJ	prep_with||correlated-26/VBN||expression-45/NN	conj_and||invasion-31/NN||expression-45/NN	amod||carcinoma-48/NN||endometrial-47/JJ	prep_in||correlated-26/VBN||carcinoma-48/NN	i---1||tumor-40||no_rel||prognostic models used multivariate cox regression analysis for multivariate analyses of survival; our study showed that p-lvd, but not i-lvd, was significantly correlated with lymph vascular space invasion (lvsi), lymph node metastasis, tumor stage, and cd44 expression in endometrial carcinoma.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	det||therapy-9/NN||a-6/DT	amod||therapy-9/NN||4-week-7/JJ	nn||therapy-9/NN||adjunctive-8/NN	prep_of||effect-4/NN||therapy-9/NN	amod||exe-13/NN||exenatide-11/JJ	prep_of||therapy-9/NN||exe-13/NN	dep||exe-13/NN||5â-16/NNS	nn||metformin-57/NN||$-17/$	num||î-20/NN||10-19/CD	npadvmod||response-37/RB||î-20/NN	num||b.i.d.-23/NNP||1/4-21/CD	nn||b.i.d.-23/NNP||g-22/NNP	npadvmod||in-36/IN||b.i.d.-23/NNP	conj_or||b.i.d.-23/NNP||sitagliptin-26/NN	npadvmod||in-36/IN||sitagliptin-26/NN	appos||sitagliptin-26/NN||sita-28/NNP	num||mg-32/NN||100-31/CD	npadvmod||once-33/RB||mg-32/NN	dep||sitagliptin-26/NN||once-33/RB	dep||once-33/RB||daily-34/RB	advmod||î-20/NN||in-36/IN	dep||+-56/CD||response-37/RB	det||challenge-43/NN||a-39/DT	amod||challenge-43/NN||standardized-40/JJ	nn||challenge-43/NN||breakfast-41/NN	nn||challenge-43/NN||meal-42/NN	prep_to||response-37/RB||challenge-43/NN	num||men-46/NNS||48-45/CD	prep_in||response-37/RB||men-46/NNS	prep_in||response-37/RB||women-48/NNS	conj_or||men-46/NNS||women-48/NNS	amod||insulinglargine-52/NN||type2diabetes-50/JJ	nn||insulinglargine-52/NN||receiving-51/NN	prep_with||men-46/NNS||insulinglargine-52/NN	appos||insulinglargine-52/NN||glar-54/NN	num||$-17/$||+-56/CD	dep||5â-16/NNS||metformin-57/NN	dep||exe-13/NN||met-59/VBN	type2diabetes-50||metformin-57||yes||to assess the effect of a 4-week adjunctive therapy of exenatide (exe) (5â€“10 î¼g b.i.d.) or sitagliptin (sita) (100 mg once daily) in response to a standardized breakfast meal challenge in 48 men or women with type2diabetes receiving insulinglargine (glar) + metformin (met).
det||combination-2/NN||the-1/DT	nsubj||premixed-6/VBD||combination-2/NN	nn||propofol-5/NN||microemulsion-4/NN	prep_of||combination-2/NN||propofol-5/NN	root||ROOT-0/null||premixed-6/VBD	prep_with||premixed-6/VBD||lidocaine-8/NN	mark||effective-16/JJ||after-9/IN	det||pretreatment-11/NN||a-10/DT	nsubj||effective-16/JJ||pretreatment-11/NN	prep_with||pretreatment-11/NN||remifentanil-13/NN	cop||effective-16/JJ||was-14/VBD	advmod||effective-16/JJ||more-15/RBR	advcl||premixed-6/VBD||effective-16/JJ	prepc_in||effective-16/JJ||reducing-18/VBG	det||incidence-20/NN||the-19/DT	dobj||reducing-18/VBG||incidence-20/NN	prep_of||incidence-20/NN||pain-22/NN	det||injection-25/NN||the-24/DT	prep_upon||reducing-18/VBG||injection-25/NN	nn||propofol-28/NN||microemulsion-27/NN	prep_of||injection-25/NN||propofol-28/NN	det||treatment-31/NN||either-30/DT	prep_than||reducing-18/VBG||treatment-31/NN	advmod||effective-16/JJ||alone-32/RB	pain-22||propofol-28||yes||the combination of microemulsion propofol premixed with lidocaine after a pretreatment with remifentanil was more effective in reducing the incidence of pain upon the injection of microemulsion propofol than either treatment alone.
prep_in||amplified-5/VBN||addition-2/NN	nsubj||amplified-5/VBN||nn414-4/NNS	root||ROOT-0/null||amplified-5/VBN	det||response-8/NN||the-6/DT	amod||response-8/NN||epinephrine-7/JJ	dobj||amplified-5/VBN||response-8/NN	prep_to||amplified-5/VBN||hypoglycemia-10/NN	preconj||nondiabetic-13/JJ||both-12/DT	amod||rats-17/NNS||nondiabetic-13/JJ	conj_and||nondiabetic-13/JJ||diabetic-15/JJ	amod||rats-17/NNS||diabetic-15/JJ	nn||rats-17/NNS||bb-16/NN	prep_in||hypoglycemia-10/NN||rats-17/NNS	amod||counterregulation-21/NN||defective-19/JJ	amod||counterregulation-21/NN||hormonal-20/JJ	prep_with||amplified-5/VBN||counterregulation-21/NN	hypoglycemia-10||epinephrine-7||no_rel||in addition, nn414 amplified the epinephrine response to hypoglycemia in both nondiabetic and diabetic bb rats with defective hormonal counterregulation.
det||purpose-2/NN||the-1/DT	nsubj||generation-8/NN||purpose-2/NN	amod||experiment-5/NN||current-4/JJ	prep_of||purpose-2/NN||experiment-5/NN	cop||generation-8/NN||is-6/VBZ	det||generation-8/NN||the-7/DT	root||ROOT-0/null||generation-8/NN	amod||cells-14/NNS||insulin-producing-10/JJ	amod||cells-14/NNS||human-11/JJ	amod||cells-14/NNS||mesenchymal-12/JJ	nn||cells-14/NNS||stem-13/NN	prep_of||generation-8/NN||cells-14/NNS	amod||source-17/NN||therapeutic-16/JJ	prep_as||cells-14/NNS||source-17/NN	det||cure-20/NN||the-19/DT	prep_for||source-17/NN||cure-20/NN	prep_of||cure-20/NN||type1diabetes-22/CD	type1diabetes-22||insulin--1||yes||the purpose of current experiment is the generation of insulin-producing human mesenchymal stem cells as therapeutic source for the cure of type1diabetes.
nsubj||play-18/VBP||retinoicacid-1/NN	prep_including||retinoicacid-1/NN||all-4/DT	dep||all-4/DT||trans-6/NNS	vmod||trans-6/NNS||retinoicacid-7/VBN	num||cis-11/CD||9-9/CD	dep||all-4/DT||cis-11/CD	conj_and||trans-6/NNS||cis-11/CD	dep||all-4/DT||13-13/CD	conj_and||trans-6/NNS||13-13/CD	dep||all-4/DT||cis-15/NN	vmod||cis-15/NN||retinoicacid-16/VBN	root||ROOT-0/null||play-18/VBP	amod||roles-20/NNS||important-19/JJ	dobj||play-18/VBP||roles-20/NNS	amod||processes-24/NNS||various-22/JJ	amod||processes-24/NNS||physiological-23/JJ	prep_in||roles-20/NNS||processes-24/NNS	prepc_such_as||roles-20/NNS||in-28/IN	amod||growth-37/NN||embryonic-29/JJ	nn||growth-37/NN||development-30/NN	pobj||in-28/IN||reproduction-32/NN	conj_and||growth-37/NN||reproduction-32/NN	pobj||in-28/IN||vision-34/NN	conj_and||growth-37/NN||vision-34/NN	pobj||in-28/IN||cell-36/NN	conj_and||growth-37/NN||cell-36/NN	pobj||in-28/IN||growth-37/NN	pobj||in-28/IN||differentiation-39/NN	conj_and||growth-37/NN||differentiation-39/NN	pobj||in-28/IN||apoptosis-41/NNS	conj_and||growth-37/NN||apoptosis-41/NNS	pobj||in-28/IN||inflammation-43/NN	conj_and||growth-37/NN||inflammation-43/NN	retinoicacid-16||inflammation-43||no_rel||retinoicacid, including all- trans retinoicacid, 9- cis and 13- cis retinoicacid, play important roles in various physiological processes, such as in embryonic development, reproduction, vision, cell growth, differentiation, apoptosis and inflammation.
nn||design-2/NN||research-1/NN	nsubj||gain-8/VB||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	nsubj||gain-8/VB||$-5/NNP	aux||gain-8/VB||to-7/TO	advcl||measured-24/VBD||gain-8/VB	dobj||gain-8/VB||insight-9/NN	det||role-12/NN||the-11/DT	prep_into||gain-8/VB||role-12/NN	prep_of||role-12/NN||pref-1-14/JJ	det||onset-17/NN||the-16/DT	prep_on||pref-1-14/JJ||onset-17/NN	prep_of||onset-17/NN||insulinresistance-19/NN	prep_of||onset-17/NN||type2diabetes-21/NNS	conj_and||insulinresistance-19/NN||type2diabetes-21/NNS	nsubj||measured-24/VBD||we-23/PRP	root||ROOT-0/null||measured-24/VBD	nn||composition-26/NN||body-25/NN	dobj||measured-24/VBD||composition-26/NN	amod||metabolism-31/NN||whole-body-28/JJ	amod||metabolism-31/NN||insulin-stimulated-29/JJ	nn||metabolism-31/NN||glucose-30/NN	dobj||measured-24/VBD||metabolism-31/NN	conj_and||composition-26/NN||metabolism-31/NN	det||clamp-35/NN||a-33/DT	amod||clamp-35/NN||hyperinsulinemic-euglycemic-34/JJ	prep_during||measured-24/VBD||clamp-35/NN	amod||transgenic-38/JJ||pref-1-37/JJ	prep_in||clamp-35/NN||transgenic-38/JJ	amod||mice-42/NNS||wild-type-40/JJ	nn||mice-42/NNS||control-41/NN	prep_in||clamp-35/NN||mice-42/NNS	conj_and||transgenic-38/JJ||mice-42/NNS	vmod||clamp-35/NN||fed-43/VBN	det||diet-46/NN||a-44/DT	amod||diet-46/NN||high-fat-45/JJ	dobj||fed-43/VBN||diet-46/NN	type2diabetes-21||glucose-30||no_rel||research design and methodsâ€” to gain insight into the role of pref-1 on the onset of insulinresistance and type2diabetes, we measured body composition and whole-body insulin-stimulated glucose metabolism during a hyperinsulinemic-euglycemic clamp in pref-1 transgenic and wild-type control mice fed a high-fat diet.
amod||models-2/NNS||predator-prey-1/JJ	nsubj||predict-6/VBP||models-2/NNS	amod||interactions-5/NNS||virus-host-4/JJ	prep_for||models-2/NNS||interactions-5/NNS	root||ROOT-0/null||predict-6/VBP	mark||cause-10/VB||that-7/IN	nsubj||cause-10/VB||viruses-8/NNS	aux||cause-10/VB||will-9/MD	ccomp||predict-6/VBP||cause-10/VB	dobj||cause-10/VB||oscillations-11/NNS	amod||densities-15/NNS||microbial-13/JJ	nn||densities-15/NNS||host-14/NN	prep_of||oscillations-11/NNS||densities-15/NNS	det||race-20/NN||an-18/DT	nn||race-20/NN||arms-19/NNS	prep_due_to||cause-10/VB||race-20/NN	prep_between||race-20/NN||resistance-22/NN	prep_between||race-20/NN||virulence-24/NN	conj_and||resistance-22/NN||virulence-24/NN	virus--1||viruses-8||no||predator-prey models for virus-host interactions predict that viruses will cause oscillations of microbial host densities due to an arms race between resistance and virulence.
advmod||approved-5/VBN||recently-1/RB	nsubjpass||approved-5/VBN||olanzapine-3/NN	auxpass||approved-5/VBN||was-4/VBD	root||ROOT-0/null||approved-5/VBN	det||treatment-8/NN||the-7/DT	prep_for||approved-5/VBN||treatment-8/NN	prep_of||treatment-8/NN||adolescents-10/NNS	nn||episodes-16/NNS||schizophrenia-12/NN	conj_or||schizophrenia-12/NN||acute-14/JJ	nn||episodes-16/NNS||acute-14/JJ	nn||episodes-16/NNS||manic/mixed-15/NN	prep_with||adolescents-10/NNS||episodes-16/NNS	prep_in||approved-5/VBN||pedbp-18/NN	schizophrenia-12||olanzapine-3||yes||recently, olanzapine was approved for the treatment of adolescents with schizophrenia or acute manic/mixed episodes in pedbp.
advmod||was-9/VBD||therefore-1/RB	det||aim-5/NN||the-3/DT	amod||aim-5/NN||specific-4/JJ	nsubj||was-9/VBD||aim-5/NN	nsubj||test-11/VB||aim-5/NN	det||study-8/NN||this-7/DT	prep_of||aim-5/NN||study-8/NN	root||ROOT-0/null||was-9/VBD	aux||test-11/VB||to-10/TO	xcomp||was-9/VBD||test-11/VB	det||hypothesis-13/NNS||the-12/DT	dobj||test-11/VB||hypothesis-13/NNS	mark||amplify-22/VB||that-14/IN	amod||use-16/NN||6-week-15/JJ	nsubj||amplify-22/VB||use-16/NN	det||fluoxetine-20/NN||the-18/DT	amod||fluoxetine-20/NN||ssri-19/JJ	prep_of||use-16/NN||fluoxetine-20/NN	aux||amplify-22/VB||would-21/MD	ccomp||test-11/VB||amplify-22/VB	amod||system-25/NN||autonomic-23/JJ	amod||system-25/NN||nervous-24/JJ	dobj||amplify-22/VB||system-25/NN	dep||amplify-22/VB||ans-27/NN	amod||responses-30/NNS||counterregulatory-29/JJ	dobj||amplify-22/VB||responses-30/NNS	prep_to||responses-30/NNS||hypoglycemia-32/NN	prep_in||amplify-22/VB||individuals-34/NNS	prep_with||amplify-22/VB||type1diabetes-36/CD	fluoxetine-20||hypoglycemia-32||no_rel||therefore, the specific aim of this study was to test the hypothesis that 6-week use of the ssri fluoxetine would amplify autonomic nervous system (ans) counterregulatory responses to hypoglycemia in individuals with type1diabetes.
amod||asthma-2/NN||aspirin-intolerant-1/JJ	nsubj||condition-9/NN||asthma-2/NN	appos||asthma-2/NN||aia-4/NN	cop||condition-9/NN||is-6/VBZ	det||condition-9/NN||a-7/DT	amod||condition-9/NN||rare-8/JJ	root||ROOT-0/null||condition-9/NN	nsubjpass||characterized-12/VBN||condition-9/NN	auxpass||characterized-12/VBN||is-11/VBZ	rcmod||condition-9/NN||characterized-12/VBN	det||development-15/NN||the-14/DT	agent||characterized-12/VBN||development-15/NN	prep_of||development-15/NN||bronchoconstriction-17/NN	amod||patients-20/NNS||asthmatic-19/JJ	prep_in||bronchoconstriction-17/NN||patients-20/NNS	prep_after||characterized-12/VBN||ingestion-22/NN	amod||anti-inflammatorydrugs-25/NNS||non-steroidal-24/JJ	prep_of||ingestion-22/NN||anti-inflammatorydrugs-25/NNS	prep_including||anti-inflammatorydrugs-25/NNS||aspirin-27/NN	asthma-2||aspirin-27||no||aspirin-intolerant asthma (aia) is a rare condition that is characterized by the development of bronchoconstriction in asthmatic patients after ingestion of non-steroidal anti-inflammatorydrugs including aspirin.
det||patient-2/NN||the-1/DT	nsubj||was-3/VBD||patient-2/NN	nsubj||had-11/VBD||patient-2/NN	root||ROOT-0/null||was-3/VBD	poss||first-episode-6/NN||his-5/PRP$	prep_in||was-3/VBD||first-episode-6/NN	prep_of||first-episode-6/NN||schizophrenia-8/NN	conj_and||was-3/VBD||had-11/VBD	neg||exposure-14/NN||no-12/DT	amod||exposure-14/NN||previous-13/JJ	dobj||had-11/VBD||exposure-14/NN	amod||antipsychotics-17/NNS||first-generation-16/JJ	prep_to||exposure-14/NN||antipsychotics-17/NNS	antipsychotics-17||schizophrenia-8||no_rel||the patient was in his first-episode of schizophrenia, and had no previous exposure to first-generation antipsychotics.
nsubj||produced-2/VBD||we-1/PRP	root||ROOT-0/null||produced-2/VBD	det||vaccine-5/NN||a-3/DT	amod||vaccine-5/NN||conjugate-4/JJ	nsubj||expressed-11/VBD||vaccine-5/NN	prep_against||vaccine-5/NN||wnv-7/NN	vmod||wnv-7/NN||consisting-8/VBG	prep_of||consisting-8/VBG||recombinantly-10/NN	ccomp||produced-2/VBD||expressed-11/VBD	nn||iii-13/NN||domain-12/NN	dobj||expressed-11/VBD||iii-13/NN	appos||iii-13/NN||diii-15/NNP	det||glycoprotein-20/NN||the-18/DT	amod||glycoprotein-20/NN||e-19/JJ	prep_of||iii-13/NN||glycoprotein-20/NN	advmod||cross-linked-22/VBN||chemically-21/RB	vmod||glycoprotein-20/NN||cross-linked-22/VBN	amod||particles-25/NNS||virus-like-24/JJ	prep_to||cross-linked-22/VBN||particles-25/NNS	vmod||particles-25/NNS||derived-26/VBN	det||ap205-32/NN||the-28/DT	advmod||discovered-30/VBN||recently-29/RB	amod||ap205-32/NN||discovered-30/VBN	nn||ap205-32/NN||bacteriophage-31/NN	prep_from||derived-26/VBN||ap205-32/NN	chemically-21||virus--1||no_rel||we produced a conjugate vaccine against wnv consisting of recombinantly expressed domain iii (diii) of the e glycoprotein chemically cross-linked to virus-like particles derived from the recently discovered bacteriophage ap205.
det||variant-2/NN||the-1/DT	nsubj||apl-3/VBP||variant-2/NN	root||ROOT-0/null||apl-3/VBP	prep_with||apl-3/VBP||t-5/NN	dep||t-5/NN||11-7/CD	dep||11-7/CD||17-9/CD	dep||t-5/NN||q23-12/NNS	dep||q23-12/NNS||q12-14/NNS	amod||subgroup-18/NN||zbtb16-rara-17/JJ	nsubjpass||reported-21/VBN||subgroup-18/NN	nsubj||have-23/VB||subgroup-18/NN	aux||reported-21/VBN||has-19/VBZ	auxpass||reported-21/VBN||been-20/VBN	parataxis||apl-3/VBP||reported-21/VBN	aux||have-23/VB||to-22/TO	xcomp||reported-21/VBN||have-23/VB	amod||cells-25/NNS||leukemic-24/JJ	dobj||have-23/VB||cells-25/NNS	amod||nuclei-28/NNS||regular-27/JJ	prep_with||cells-25/NNS||nuclei-28/NNS	amod||granules-31/NNS||many-30/JJ	dobj||have-23/VB||granules-31/NNS	conj_and||cells-25/NNS||granules-31/NNS	appos||granules-31/NNS||absence-33/NN	nn||rods-36/NNS||auer-35/NN	prep_of||absence-33/NN||rods-36/NNS	det||number-40/NN||an-38/DT	amod||number-40/NN||increased-39/JJ	dobj||have-23/VB||number-40/NN	conj_and||cells-25/NNS||number-40/NN	amod||neutrophils-43/NNS||pelgeroid-42/JJ	prep_of||number-40/NN||neutrophils-43/NNS	amod||myeloperoxidase-46/NN||strong-45/JJ	dobj||have-23/VB||myeloperoxidase-46/NN	conj_and||cells-25/NNS||myeloperoxidase-46/NN	appos||myeloperoxidase-46/NN||mpo-48/NN	dep||myeloperoxidase-46/NN||activity-50/NN	amod||resistance-57/NN||all-trans-retinoic-acid-53/JJ	appos||resistance-57/NN||atra-55/NNP	dobj||have-23/VB||resistance-57/NN	conj_and||cells-25/NNS||resistance-57/NN	apl-3||atra-55||yes||the variant apl with t(11;17)(q23;q12); zbtb16-rara subgroup has been reported to have leukemic cells with regular nuclei, many granules, absence of auer rods, an increased number of pelgeroid neutrophils, strong myeloperoxidase (mpo) activity, and all-trans-retinoic-acid (atra) resistance.
nsubj||complications-9/NNS||denguehemorrhagicfever-1/NN	conj_and||denguehemorrhagicfever-1/NN||dengueshocksyndrome-3/NN	nsubj||complications-9/NNS||dengueshocksyndrome-3/NN	appos||denguehemorrhagicfever-1/NN||dhf/dss-5/NNS	cop||complications-9/NNS||are-7/VBP	amod||complications-9/NNS||life-threatening-8/JJ	root||ROOT-0/null||complications-9/NNS	prep_following||complications-9/NNS||infection-11/NN	prep_with||infection-11/NN||one-13/CD	det||serotypes-17/NNS||the-15/DT	num||serotypes-17/NNS||four-16/CD	prep_of||one-13/CD||serotypes-17/NNS	prep_of||serotypes-17/NNS||denguevirus-19/NNS	appos||denguevirus-19/NNS||denv-21/NNP	dengueshocksyndrome-3||denguevirus-19||no||denguehemorrhagicfever and dengueshocksyndrome (dhf/dss) are life-threatening complications following infection with one of the four serotypes of denguevirus (denv).
amod||studies-2/NNS||clinical-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||effective-12/JJ||that-5/IN	nsubj||effective-12/JJ||naproxen-6/NN	conj_and||naproxen-6/NN||ibuprofen-8/NN	nsubj||effective-12/JJ||ibuprofen-8/NN	cop||effective-12/JJ||are-9/VBP	advmod||effective-12/JJ||significantly-10/RB	advmod||effective-12/JJ||more-11/RBR	ccomp||shown-4/VBN||effective-12/JJ	prepc_at||effective-12/JJ||reducing-14/VBG	nn||pain-16/NN||oa-15/NN	dobj||reducing-14/VBG||pain-16/NN	mark||acetaminophen-19/NN||than-17/IN	cop||acetaminophen-19/NN||is-18/VBZ	ccomp||effective-12/JJ||acetaminophen-19/NN	nsubj||has-27/VBZ||acetaminophen-19/NN	det||therapy-24/NN||the-21/DT	amod||therapy-24/NN||traditional-22/JJ	amod||therapy-24/NN||first-line-23/JJ	appos||acetaminophen-19/NN||therapy-24/NN	rcmod||acetaminophen-19/NN||has-27/VBZ	neg||activity-31/NN||no-28/DT	amod||activity-31/NN||apparent-29/JJ	amod||activity-31/NN||anti-inflammatory-30/JJ	dobj||has-27/VBZ||activity-31/NN	det||joints-34/NNS||the-33/DT	prep_in||activity-31/NN||joints-34/NNS	pain-16||naproxen-6||yes||clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing oa pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints.
det||result-3/NN||a-2/DT	prep_as||come-39/VBN||result-3/NN	det||advances-6/NNS||these-5/DT	prep_of||result-3/NN||advances-6/NNS	det||cluster-11/NN||a-8/DT	nn||cluster-11/NN||breast-9/NN	nn||cluster-11/NN||cancer-10/NN	nsubj||come-39/VBN||cluster-11/NN	amod||prognosis-14/NN||poor-13/JJ	prep_with||cluster-11/NN||prognosis-14/NN	nsubj||negative-17/JJ||prognosis-14/NN	cop||negative-17/JJ||is-16/VBZ	rcmod||prognosis-14/NN||negative-17/JJ	det||receptor-21/NN||the-19/DT	nn||receptor-21/NN||estrogen-20/NN	prep_for||negative-17/JJ||receptor-21/NN	appos||receptor-21/NN||esr1-23/NNP	det||receptor-28/NN||the-26/DT	amod||receptor-28/NN||progesterone-27/JJ	prep_for||negative-17/JJ||receptor-28/NN	conj_and||receptor-21/NN||receptor-28/NN	appos||receptor-28/NN||prgr-30/NN	prep_for||negative-17/JJ||erbb2-33/NNS	conj_and||receptor-21/NN||erbb2-33/NNS	quantmod||negative-36/JJ||triple-35/RB	dep||erbb2-33/NNS||negative-36/JJ	aux||come-39/VBN||has-38/VBZ	root||ROOT-0/null||come-39/VBN	det||forefront-42/NN||the-41/DT	prep_to||come-39/VBN||forefront-42/NN	amod||attention-46/NN||medical-44/JJ	amod||attention-46/NN||therapeutic-45/JJ	prep_of||forefront-42/NN||attention-46/NN	cancer-10||progesterone-27||no_rel||as a result of these advances, a breast cancer cluster with poor prognosis that is negative for the estrogen receptor (esr1), the progesterone receptor (prgr) and erbb2 (triple negative) has come to the forefront of medical therapeutic attention.
advmod||are-4/VBP||moreover-1/RB	expl||are-4/VBP||there-3/EX	root||ROOT-0/null||are-4/VBP	det||reports-9/NNS||a-5/DT	amod||reports-9/NNS||few-6/JJ	amod||reports-9/NNS||previous-7/JJ	nn||reports-9/NNS||case-8/NN	nsubj||are-4/VBP||reports-9/NNS	vmod||reports-9/NNS||showing-10/VBG	mark||occurred-13/VBD||that-11/IN	nsubj||occurred-13/VBD||malignanthyperthermia-12/NN	nsubj||occurred-13/VBD||malignanthyperthermia-12/NN	ccomp||showing-10/VBG||occurred-13/VBD	ccomp||showing-10/VBG||occurred-13/VBD	conj_and||occurred-13/VBD||occurred-13/VBD	det||operation-18/NN||an-17/DT	prep_after||occurred-13/VBD||operation-18/NN	prep_during||occurred-13/VBD||operation-18/NN	prep_in||done-24/VBN||which-20/WDT	det||anesthesia-22/NN||the-21/DT	nsubjpass||done-24/VBN||anesthesia-22/NN	auxpass||done-24/VBN||was-23/VBD	ccomp||occurred-13/VBD||done-24/VBN	nn||agents-27/NNS||inhalation-26/NN	prep_with||done-24/VBN||agents-27/NNS	dep||are-4/VBP||so-29/IN	amod||care-32/NN||special-30/JJ	amod||care-32/NN||anesthetic-31/JJ	nsubjpass||needed-34/VBN||care-32/NN	auxpass||needed-34/VBN||is-33/VBZ	parataxis||are-4/VBP||needed-34/VBN	advmod||operating-36/VBG||when-35/WRB	advcl||needed-34/VBN||operating-36/VBG	det||patient-40/NN||a-38/DT	nn||patient-40/NN||whs-39/NN	prep_on||operating-36/VBG||patient-40/NN	malignanthyperthermia-12||anesthetic-31||no||moreover, there are a few previous case reports showing that malignanthyperthermia occurred during and after an operation in which the anesthesia was done with inhalation agents, so special anesthetic care is needed when operating on a whs patient.
det||time-4/NN||the-2/DT	amod||time-4/NN||first-3/JJ	prep_for||describe-6/VBP||time-4/NN	nsubj||describe-6/VBP||we-5/PRP	root||ROOT-0/null||describe-6/VBP	det||sequence-8/NN||the-7/DT	dobj||describe-6/VBP||sequence-8/NN	det||bacterium-13/NN||an-10/DT	nn||bacterium-13/NN||anthrax-11/NN	amod||bacterium-13/NN||causing-12/VBG	prep_of||sequence-8/NN||bacterium-13/NN	vmod||bacterium-13/NN||possessing-14/VBG	det||plasmids-17/NNS||both-15/DT	nn||plasmids-17/NNS||anthrax-16/NN	dobj||possessing-14/VBG||plasmids-17/NNS	nsubj||belong-22/VB||that-18/WDT	advmod||belong-22/VB||apparently-19/RB	aux||belong-22/VB||does-20/VBZ	neg||belong-22/VB||not-21/RB	dep||possessing-14/VBG||belong-22/VB	det||group-26/NN||the-24/DT	amod||group-26/NN||monophyletic-25/JJ	prep_to||belong-22/VB||group-26/NN	dep||so-29/IN||all-28/DT	advmod||known-31/VBN||so-29/IN	advmod||so-29/IN||far-30/RB	amod||strains-33/NNS||known-31/VBN	amod||strains-33/NNS||b.anthracis-32/JJ	prep_of||group-26/NN||strains-33/NNS	nsubj||differs-36/VBZ||that-35/WDT	dep||possessing-14/VBG||differs-36/VBZ	conj_and||belong-22/VB||differs-36/VBZ	amod||features-40/NNS||important-38/JJ	amod||features-40/NNS||diagnostic-39/JJ	prep_in||differs-36/VBZ||features-40/NNS	anthrax-16||b.anthracis-32||no||for the first time we describe the sequence of an anthrax causing bacterium possessing both anthrax plasmids that apparently does not belong to the monophyletic group of all so far known b.anthracis strains and that differs in important diagnostic features .
poss||estimates-3/NNS||our-1/PRP$	amod||estimates-3/NNS||quantitative-2/JJ	nsubj||reveal-12/VBP||estimates-3/NNS	vmod||estimates-3/NNS||based-5/VBN	nn||methods-8/NNS||bayesian-7/NN	prep_on||based-5/VBN||methods-8/NNS	prep_of||methods-8/NNS||inference-10/NN	root||ROOT-0/null||reveal-12/VBP	mark||short-28/JJ||that-13/IN	dep||short-28/JJ||i-15/VB	det||period-18/NN||the-17/DT	nsubj||short-28/JJ||period-18/NN	prep_of||period-18/NN||latency-20/NN	amod||influenzavirus-23/NNS||h5n1-22/JJ	prep_of||latency-20/NN||influenzavirus-23/NNS	amod||chickens-26/NNS||unvaccinated-25/JJ	prep_in||influenzavirus-23/NNS||chickens-26/NNS	cop||short-28/JJ||is-27/VBZ	ccomp||reveal-12/VBP||short-28/JJ	dep||short-28/JJ||mean-30/VB	num||days-32/NNS||0.24-31/CD	dobj||mean-30/VB||days-32/NNS	num||%-35/NN||95-34/CD	dep||days-32/NNS||%-35/NN	amod||interval-37/JJ||credible-36/JJ	amod||%-35/NN||interval-37/JJ	npadvmod||â-39/RB||0.099-38/CD	advmod||%-35/NN||â-39/RB	num||days-43/NNS||$-40/$	num||$-40/$||0.48-42/CD	dep||%-35/NN||days-43/NNS	ccomp||reveal-12/VBP||ii-47/NN	conj_and||short-28/JJ||ii-47/NN	det||period-51/NN||the-49/DT	amod||period-51/NN||infectious-50/JJ	nsubj||days-61/NNS||period-51/NN	amod||virus-54/NN||h5n1-53/JJ	prep_of||period-51/NN||virus-54/NN	amod||chickens-57/NNS||unvaccinated-56/JJ	prep_in||virus-54/NN||chickens-57/NNS	cop||days-61/NNS||is-58/VBZ	quantmod||2-60/CD||approximately-59/RB	num||days-61/NNS||2-60/CD	rcmod||ii-47/NN||days-61/NNS	dep||ii-47/NN||mean-63/VB	num||days-65/NNS||2.1-64/CD	dobj||mean-63/VB||days-65/NNS	num||%-68/NN||95-67/CD	dep||days-65/NNS||%-68/NN	num||â-71/NN||1.8-70/CD	dobj||mean-63/VB||â-71/NN	conj_ci||days-65/NNS||â-71/NN	num||days-75/NNS||$-72/$	num||$-72/$||2.3-74/CD	dep||â-71/NN||days-75/NNS	ccomp||reveal-12/VBP||iii-79/NN	conj_and||short-28/JJ||iii-79/NN	det||number-83/NN||the-81/DT	nn||number-83/NN||reproduction-82/NN	nsubj||need-90/VBP||number-83/NN	amod||virus-86/NN||h5n1-85/JJ	prep_of||number-83/NN||virus-86/NN	amod||chickens-89/NNS||unvaccinated-88/JJ	prep_in||virus-86/NN||chickens-89/NNS	rcmod||iii-79/NN||need-90/VBP	neg||need-90/VBP||not-91/RB	cop||high-93/JJ||be-92/VB	dep||need-90/VBP||high-93/JJ	parataxis||high-93/JJ||mean-95/VB	dobj||mean-95/VB||1.6-96/CD	number||%-99/NN||95-98/CD	amod||â-102/NNS||%-99/NN	amod||â-102/NNS||ci-100/JJ	num||â-102/NNS||0.90-101/CD	dep||1.6-96/CD||â-102/NNS	num||â-102/NNS||$-103/$	num||$-103/$||2.5-105/CD	mark||expected-112/VBN||although-108/IN	det||virus-110/NN||the-109/DT	nsubjpass||expected-112/VBN||virus-110/NN	nsubj||spread-114/VB||virus-110/NN	auxpass||expected-112/VBN||is-111/VBZ	advcl||high-93/JJ||expected-112/VBN	aux||spread-114/VB||to-113/TO	xcomp||expected-112/VBN||spread-114/VB	advmod||spread-114/VB||rapidly-115/RB	mark||has-118/VBZ||because-116/IN	nsubj||has-118/VBZ||it-117/PRP	advcl||spread-114/VB||has-118/VBZ	det||interval-122/NN||a-119/DT	amod||interval-122/NN||short-120/JJ	nn||interval-122/NN||generation-121/NN	dobj||has-118/VBZ||interval-122/NN	amod||chickens-125/NNS||unvaccinated-124/JJ	prep_in||interval-122/NN||chickens-125/NNS	dep||iii-79/NN||mean-127/VB	num||days-129/NNS||1.3-128/CD	dobj||mean-127/VB||days-129/NNS	num||%-132/NN||95-131/CD	dep||days-129/NNS||%-132/NN	nn||â-135/FW||ci-133/FW	nn||â-135/FW||1.0-134/FW	dep||%-132/NN||â-135/FW	num||days-139/NNS||$-136/$	num||$-136/$||1.5-138/CD	dep||â-135/FW||days-139/NNS	discourse||vaccination-146/NNS||iv-144/UH	ccomp||reveal-12/VBP||vaccination-146/NNS	conj_and||short-28/JJ||vaccination-146/NNS	prep_with||vaccination-146/NNS||genetically-148/NNP	amod||vaccines-153/NNS||antigenically-150/JJ	amod||vaccines-153/NNS||distant-151/JJ	amod||vaccines-153/NNS||h5n2-152/JJ	nsubj||halt-156/VB||vaccines-153/NNS	aux||halt-156/VB||can-154/MD	advmod||halt-156/VB||effectively-155/RB	ccomp||reveal-12/VBP||halt-156/VB	conj_and||short-28/JJ||halt-156/VB	dobj||halt-156/VB||transmission-157/NN	h5n1-85||influenzavirus-23||no||our quantitative estimates, based on bayesian methods of inference, reveal that (i) the period of latency of h5n1 influenzavirus in unvaccinated chickens is short (mean 0.24 days; 95% credible interval 0.099â€“0.48 days); (ii) the infectious period of h5n1 virus in unvaccinated chickens is approximately 2 days (mean 2.1 days; 95%ci 1.8â€“2.3 days); (iii) the reproduction number of h5n1 virus in unvaccinated chickens need not be high (mean 1.6; 95%ci 0.90â€“2.5), although the virus is expected to spread rapidly because it has a short generation interval in unvaccinated chickens (mean 1.3 days; 95%ci 1.0â€“1.5 days); and (iv) vaccination with genetically and antigenically distant h5n2 vaccines can effectively halt transmission.
advmod||observed-10/VBD||furthermore-1/RB	det||structures-4/NNS||the-3/DT	nsubj||observed-10/VBD||structures-4/NNS	det||species-9/NN||the-6/DT	advmod||prevalent-8/JJ||most-7/RBS	amod||species-9/NN||prevalent-8/JJ	prep_for||structures-4/NNS||species-9/NN	root||ROOT-0/null||observed-10/VBD	prep_via||observed-10/VBD||maldi-tims-12/NNS	amod||--15/NNS||d181/c160-14/JJ	amod||maldi-tims-12/NNS||d181/c241-17/JJ	amod||maldi-tims-12/NNS||d181/c240-st-20/JJ	conj_and||d181/c241-17/JJ||d181/c240-st-20/JJ	auxpass||confirmed-23/VBN||were-22/VBD	rcmod||maldi-tims-12/NNS||confirmed-23/VBN	agent||confirmed-23/VBN||maldi-tims/ms-25/NNS	mark||identified-42/VBN||whereas-27/IN	det||ion-31/NN||a-29/DT	amod||ion-31/NN||neighboring-30/JJ	nsubj||specific-40/NN||ion-31/NN	nsubjpass||identified-42/VBN||ion-31/NN	number||885.6-34/CD||m/z-33/CD	dep||ion-31/NN||885.6-34/CD	cop||specific-40/NN||was-37/VBD	neg||specific-40/NN||not-38/RB	nn||specific-40/NN||tumor-39/NN	rcmod||ion-31/NN||specific-40/NN	auxpass||identified-42/VBN||was-41/VBD	advcl||observed-10/VBD||identified-42/VBN	det||phosphatidylinositol-45/NN||a-44/DT	prep_as||identified-42/VBN||phosphatidylinositol-45/NN	ion-31||tumor-39||no_rel||furthermore, the structures for the most prevalent species observed via maldi-tims (d181/c160-, d181/c241- and d181/c240-st) were confirmed by maldi-tims/ms, whereas, a neighboring ion( m/z 885.6) that was not tumor specific was identified as a phosphatidylinositol.
nsubj||receiving-12/VBG||resistance-1/NN	amod||insecticides-4/NNS||pyrethroid-3/JJ	prep_to||resistance-1/NN||insecticides-4/NNS	det||gambiae-10/NN||the-6/DT	nn||gambiae-10/NN||malaria-7/NN	nn||gambiae-10/NN||vector-8/NN	nn||gambiae-10/NN||anopheles-9/NNS	prep_in||insecticides-4/NNS||gambiae-10/NN	aux||receiving-12/VBG||is-11/VBZ	root||ROOT-0/null||receiving-12/VBG	vmod||receiving-12/VBG||increasing-13/VBG	dobj||increasing-13/VBG||attention-14/NN	mark||threatens-17/VBZ||because-15/IN	nsubj||threatens-17/VBZ||it-16/PRP	advcl||increasing-13/VBG||threatens-17/VBZ	det||sustainability-19/NN||the-18/DT	dobj||threatens-17/VBZ||sustainability-19/NN	nn||programs-24/NNS||malaria-21/NN	nn||programs-24/NNS||vector-22/NN	nn||programs-24/NNS||control-23/NN	prep_of||sustainability-19/NN||programs-24/NNS	amod||africa-27/NN||sub-saharan-26/JJ	prep_in||threatens-17/VBZ||africa-27/NN	insecticides-4||malaria-21||no_rel||resistance to pyrethroid insecticides in the malaria vector anopheles gambiae is receiving increasing attention because it threatens the sustainability of malaria vector control programs in sub-saharan africa.
aux||examine-2/VB||to-1/TO	csubj||activation-17/VBN||examine-2/VB	csubj||activation-17/VBN||examine-2/VB	det||effects-4/NNS||the-3/DT	dobj||examine-2/VB||effects-4/NNS	amod||hypoglycemia-8/NN||acute-6/JJ	amod||hypoglycemia-8/NN||insulin-induced-7/JJ	prep_of||effects-4/NNS||hypoglycemia-8/NN	prep_on||examine-2/VB||inflammation-10/NN	amod||dysfunction-13/NN||endothelial-12/JJ	prep_on||examine-2/VB||dysfunction-13/NN	conj_and||inflammation-10/NN||dysfunction-13/NN	prep_on||examine-2/VB||platelet-16/NN	conj_and||inflammation-10/NN||platelet-16/NN	root||ROOT-0/null||activation-17/VBN	conj_and||activation-17/VBN||activation-17/VBN	prep_in||activation-17/VBN||adults-19/NNS	prep_with||activation-17/VBN||type1diabetes-23/CD	prep_without||activation-17/VBN||type1diabetes-23/CD	type1diabetes-23||insulin--1||yes||to examine the effects of acute insulin-induced hypoglycemia on inflammation, endothelial dysfunction, and platelet activation in adults with and without type1diabetes.
advmod||tested-4/VBD||therefore-1/RB	nsubj||tested-4/VBD||we-3/PRP	root||ROOT-0/null||tested-4/VBD	mark||show-10/VBP||whether-5/IN	nn||patients-9/NNS||blood-6/NN	nn||patients-9/NNS||type-7/NN	nn||patients-9/NNS||o-8/NN	nsubj||show-10/VBP||patients-9/NNS	ccomp||tested-4/VBD||show-10/VBP	amod||coagulopathy-12/NN||more-11/JJR	dobj||show-10/VBP||coagulopathy-12/NN	nn||loss-15/NN||blood-14/NN	dobj||show-10/VBP||loss-15/NN	conj_and||coagulopathy-12/NN||loss-15/NN	amod||patients-18/NNS||non-o-17/JJ	prep_than||coagulopathy-12/NN||patients-18/NNS	prep_after||show-10/VBP||infusion-20/NN	number||%-23/NN||6-22/CD	amod||hes-24/NN||%-23/NN	prep_of||infusion-20/NN||hes-24/NN	coagulopathy-12||hes-24||no||therefore, we tested whether blood type o patients show more coagulopathy and blood loss than non-o patients after infusion of 6% hes.
det||concentrations-2/NNS||the-1/DT	nsubj||compounds-5/VBZ||concentrations-2/NNS	prep_of||concentrations-2/NNS||antioxidant-4/NN	root||ROOT-0/null||compounds-5/VBZ	advmod||phenolics-7/NNS||namely-6/RB	dobj||compounds-5/VBZ||phenolics-7/NNS	nsubjpass||correlated-31/VBN||phenolics-7/NNS	dobj||compounds-5/VBZ||carotenoids-9/NNS	conj_and||phenolics-7/NNS||carotenoids-9/NNS	nsubjpass||correlated-31/VBN||carotenoids-9/NNS	dobj||compounds-5/VBZ||flavonoids-11/NNS	conj_and||phenolics-7/NNS||flavonoids-11/NNS	nsubjpass||correlated-31/VBN||flavonoids-11/NNS	dobj||compounds-5/VBZ||tocopherols-13/NNS	conj_and||phenolics-7/NNS||tocopherols-13/NNS	nsubjpass||correlated-31/VBN||tocopherols-13/NNS	vmod||phenolics-7/NNS||estimated-14/VBN	det||oil-18/NN||the-16/DT	nn||oil-18/NN||seed-17/NN	prep_in||estimated-14/VBN||oil-18/NN	vmod||oil-18/NN||increased-19/VBN	acomp||increased-19/VBN||due-20/JJ	amod||proline-23/NN||foliar-applied-22/JJ	prep_to||due-20/JJ||proline-23/NN	nn||conditions-27/NNS||water-25/NN	nn||conditions-27/NNS||deficit-26/NN	prep_under||increased-19/VBN||conditions-27/NNS	auxpass||correlated-31/VBN||was-29/VBD	advmod||correlated-31/VBN||positively-30/RB	rcmod||phenolics-7/NNS||correlated-31/VBN	det||dpph-36/NN||the-33/DT	amod||dpph-36/NN||enhanced-34/JJ	nn||dpph-36/NN||oil-35/NN	nn||activity-40/NN||dpph-36/NN	amod||radical-38/JJ||free-37/JJ	amod||activity-40/NN||radical-38/JJ	nn||activity-40/NN||scavenging-39/NN	prep_with||correlated-31/VBN||activity-40/NN	deficit-26||oil-35||no_rel||the concentrations of antioxidant compounds namely phenolics, carotenoids, flavonoids and tocopherols estimated in the seed oil increased due to foliar-applied proline under water deficit conditions that was positively correlated with the enhanced oil dpph free radical scavenging activity.
poss||objective-2/NN||our-1/PRP$	nsubj||was-3/VBD||objective-2/NN	root||ROOT-0/null||was-3/VBD	aux||examine-5/VB||to-4/TO	ccomp||was-3/VBD||examine-5/VB	det||relationship-7/NN||the-6/DT	dobj||examine-5/VB||relationship-7/NN	amod||indexes-10/NNS||common-9/JJ	nsubj||using-23/VBG||indexes-10/NNS	amod||glycemia-13/NN||postprandial-12/JJ	prep_of||indexes-10/NNS||glycemia-13/NN	amod||hyperglycemia-16/NN||overall-15/JJ	prep_of||indexes-10/NNS||hyperglycemia-16/NN	conj_and||glycemia-13/NN||hyperglycemia-16/NN	nn||variability-19/NN||glucose-18/NN	prep_of||indexes-10/NNS||variability-19/NN	conj_and||glycemia-13/NN||variability-19/NN	prep_of||indexes-10/NNS||a1c-22/NNS	conj_and||glycemia-13/NN||a1c-22/NNS	prepc_among||examine-5/VB||using-23/VBG	amod||measures-26/NNS||detailed-24/JJ	nn||measures-26/NNS||glucose-25/NN	dobj||using-23/VBG||measures-26/NNS	vmod||measures-26/NNS||obtained-27/VBN	amod||life-30/NN||everyday-29/JJ	prep_during||obtained-27/VBN||life-30/NN	aux||study-33/VB||to-32/TO	ccomp||was-3/VBD||study-33/VB	conj_and||examine-5/VB||study-33/VB	dobj||provide-41/VBP||which-34/WDT	nn||values-37/NNS||blood-35/NN	nn||values-37/NNS||glucose-36/NN	nsubj||provide-41/VBP||values-37/NNS	det||day-40/NN||the-39/DT	prep_of||values-37/NNS||day-40/NN	ccomp||study-33/VB||provide-41/VBP	det||prediction-44/NN||the-42/DT	amod||prediction-44/NN||strongest-43/JJS	dobj||provide-41/VBP||prediction-44/NN	prep_of||prediction-44/NN||a1c-46/CD	hyperglycemia-16||glucose-36||no||our objective was to examine the relationship among common indexes of postprandial glycemia, overall hyperglycemia, glucose variability, and a1c using detailed glucose measures obtained during everyday life and to study which blood glucose values of the day provide the strongest prediction of a1c.
amod||publications-2/NNS||additional-1/JJ	nsubjpass||identified-12/VBN||publications-2/NNS	vmod||publications-2/NNS||considered-3/VBN	acomp||considered-3/VBN||relevant-4/JJ	det||population-8/NN||the-6/DT	amod||population-8/NN||sicklecelldisease-7/JJ	prep_to||relevant-4/JJ||population-8/NN	prep_of||population-8/NN||patients-10/NNS	auxpass||identified-12/VBN||were-11/VBD	root||ROOT-0/null||identified-12/VBN	nn||terms-15/NNS||search-14/NN	nsubj||included-16/VBD||terms-15/NNS	parataxis||identified-12/VBN||included-16/VBD	amod||-RSB--19/NNS||-LSB--17/JJ	nn||-RSB--19/NNS||sicklecelldisease-18/NN	dobj||included-16/VBD||-RSB--19/NNS	prep||included-16/VBD||combined-20/VBN	pcomp||combined-20/VBN||with-21/IN	nn||-RSB--24/NNP||-LSB--22/NNP	nn||-RSB--24/NNP||acetaminophen-23/NNP	pobj||with-21/IN||-RSB--24/NNP	amod||-RSB--29/NNS||-LSB--26/JJ	nn||-RSB--29/NNS||pain-27/NN	nn||-RSB--29/NNS||medications-28/NN	pobj||with-21/IN||-RSB--29/NNS	conj_and||-RSB--24/NNP||-RSB--29/NNS	amod||-RSB--33/NNS||-LSB--31/JJ	amod||-RSB--33/NNS||vitamind-32/JJ	pobj||with-21/IN||-RSB--33/NNS	conj_and||-RSB--24/NNP||-RSB--33/NNS	nn||-RSB--38/NNS||-LSB--35/NNP	amod||-RSB--38/NNS||beta-36/JJ	nn||-RSB--38/NNS||agonists-37/NNS	pobj||with-21/IN||-RSB--38/NNS	conj_and||-RSB--24/NNP||-RSB--38/NNS	nn||-RSB--43/NNP||-LSB--40/NNP	nn||-RSB--43/NNP||exhaled-41/NNP	nn||-RSB--43/NNP||nitricoxide-42/NNP	pobj||with-21/IN||-RSB--43/NNP	conj_and||-RSB--24/NNP||-RSB--43/NNP	amod||-RSB--48/NNS||-LSB--46/JJ	nn||-RSB--48/NNS||corticosteroids-47/NNS	pobj||with-21/IN||-RSB--48/NNS	conj_and||-RSB--24/NNP||-RSB--48/NNS	pain-27||acetaminophen-23||yes||additional publications considered relevant to the sicklecelldisease population of patients were identified; search terms included [sicklecelldisease] combined with [acetaminophen], [pain medications], [vitamind], [beta agonists], [exhaled nitricoxide], and [corticosteroids].
det||effect-3/NN||a-1/DT	amod||effect-3/NN||dual-2/JJ	nsubjpass||observed-8/VBN||effect-3/NN	nn||action-6/NN||insulin-5/NN	prep_on||effect-3/NN||action-6/NN	auxpass||observed-8/VBN||was-7/VBD	root||ROOT-0/null||observed-8/VBN	advmod||exposed-14/VBN||when-9/WRB	nsubjpass||exposed-14/VBN||myotubes-10/NNS	conj_and||myotubes-10/NNS||mice-12/NNS	nsubjpass||exposed-14/VBN||mice-12/NNS	auxpass||exposed-14/VBN||were-13/VBD	advcl||observed-8/VBN||exposed-14/VBN	det||additive-18/NN||this-16/DT	amod||additive-18/NN||cytokine-17/JJ	prep_to||exposed-14/VBN||additive-18/NN	amod||insulin-21/NN||short-term-20/JJ	prep_with||additive-18/NN||insulin-21/NN	amod||uptake-25/NN||increased-23/JJ	nn||uptake-25/NN||glucose-24/NN	dep||insulin-21/NN||uptake-25/NN	amod||sensitivity-29/NN||systemic-27/JJ	nn||sensitivity-29/NN||insulin-28/NN	dep||insulin-21/NN||sensitivity-29/NN	conj_and||uptake-25/NN||sensitivity-29/NN	amod||exposure-33/NN||chronic-32/JJ	nsubj||produced-34/VBD||exposure-33/NN	conj_but||observed-8/VBN||produced-34/VBD	dobj||produced-34/VBD||insulinresistance-35/NN	dep||insulinresistance-35/NN||impaired-37/VBN	amod||translocation-39/NN||glut4-38/JJ	dobj||impaired-37/VBN||translocation-39/NN	nn||membrane-42/NNS||plasma-41/NN	prep_to||impaired-37/VBN||membrane-42/NNS	prep_to||impaired-37/VBN||defects-44/NNS	conj_and||membrane-42/NNS||defects-44/NNS	prep_in||impaired-37/VBN||insulin-46/NN	xcomp||impaired-37/VBN||signaling-47/VBG	det||substrate-52/NN||the-49/DT	nn||substrate-52/NN||insulin-50/NN	nn||substrate-52/NN||receptor-51/NN	nn||level-57/NN||substrate-52/NN	num||-LSB--54/NNS||1-53/CD	npadvmod||irs-1-55/JJ||-LSB--54/NNS	amod||level-57/NN||irs-1-55/JJ	nn||level-57/NN||-RSB--56/NN	prep_at||signaling-47/VBG||level-57/NN	glucose-24||insulinresistance-35||no_rel||a dual effect on insulin action was observed when myotubes and mice were exposed to this cytokine additive with short-term insulin (increased glucose uptake and systemic insulin sensitivity) but chronic exposure produced insulinresistance (impaired glut4 translocation to plasma membrane and defects in insulin signaling at the insulin receptor substrate 1 [irs-1] level).
nsubjpass||shown-8/VBN||sitagliptin-1/NN	nsubj||improve-10/VB||sitagliptin-1/NN	aux||shown-8/VBN||has-2/VBZ	amod||studies-6/NNS||several-4/JJ	amod||studies-6/NNS||clinical-5/JJ	prep_in||shown-8/VBN||studies-6/NNS	auxpass||shown-8/VBN||been-7/VBN	root||ROOT-0/null||shown-8/VBN	aux||improve-10/VB||to-9/TO	xcomp||shown-8/VBN||improve-10/VB	amod||control-12/NN||metabolic-11/JJ	dobj||improve-10/VB||control-12/NN	prep_in||improve-10/VB||type2diabetes-14/NNS	appos||type2diabetes-14/NNS||both-16/DT	advmod||used-18/VBN||when-17/WRB	advcl||improve-10/VB||used-18/VBN	prep_as||used-18/VBN||monotherapy-20/NN	advmod||used-23/VBN||when-22/WRB	advcl||improve-10/VB||used-23/VBN	conj_and||used-18/VBN||used-23/VBN	prep_in||used-23/VBN||combination-25/NN	prep_with||used-23/VBN||metformin-27/NN	prep_with||used-23/VBN||sulfonylurea-29/NN	conj_or||metformin-27/NN||sulfonylurea-29/NN	prep_with||used-23/VBN||thiazolidinediones-31/NNS	conj_or||metformin-27/NN||thiazolidinediones-31/NNS	prep_with||used-23/VBN||insulin-33/NN	conj_or||metformin-27/NN||insulin-33/NN	type2diabetes-14||sitagliptin-1||yes||sitagliptin has in several clinical studies been shown to improve metabolic control in type2diabetes, both when used as monotherapy and when used in combination with metformin, sulfonylurea, thiazolidinediones or insulin.
poss||objective-2/NN||our-1/PRP$	nsubj||was-3/VBD||objective-2/NN	nsubj||study-5/VB||objective-2/NN	root||ROOT-0/null||was-3/VBD	aux||study-5/VB||to-4/TO	xcomp||was-3/VBD||study-5/VB	det||incidence-7/NN||the-6/DT	dobj||study-5/VB||incidence-7/NN	dobj||study-5/VB||impact-9/NN	conj_and||incidence-7/NN||impact-9/NN	amod||consumption-13/NN||undisclosed-11/JJ	nn||consumption-13/NN||cocaine-12/NN	prep_of||incidence-7/NN||consumption-13/NN	prep_in||study-5/VB||patients-15/NNS	vmod||patients-15/NNS||attending-16/VBG	det||department-19/NN||the-17/DT	nn||department-19/NN||emergency-18/NN	dobj||attending-16/VBG||department-19/NN	appos||department-19/NN||ed-21/NN	nn||pain-27/NN||trauma-24/NN	conj_or||trauma-24/NN||chest-26/NN	nn||pain-27/NN||chest-26/NN	prep_for||department-19/NN||pain-27/NN	pain-27||cocaine-12||yes||our objective was to study the incidence and impact of undisclosed cocaine consumption in patients attending the emergency department (ed) for trauma or chest pain.
det||netb-5/NN||the-1/DT	amod||netb-5/NN||secreted-2/JJ	amod||netb-5/NN||pore-forming-3/JJ	nn||netb-5/NN||toxin-4/NN	nsubj||factor-10/NN||netb-5/NN	nsubj||similar-18/JJ||netb-5/NN	cop||factor-10/NN||is-6/VBZ	det||factor-10/NN||a-7/DT	amod||factor-10/NN||key-8/JJ	nn||factor-10/NN||virulence-9/NN	root||ROOT-0/null||factor-10/NN	det||pathogenesis-13/NNS||the-12/DT	prep_in||factor-10/NN||pathogenesis-13/NNS	prep_of||pathogenesis-13/NNS||aviannecroticenteritis-15/NNS	cop||similar-18/JJ||is-17/VBZ	conj_and||factor-10/NN||similar-18/JJ	prep_to||similar-18/JJ||alpha-hemolysin-20/NN	det||²-24/NN||a-22/DT	nn||²-24/NN||î-23/NN	appos||alpha-hemolysin-20/NN||²-24/NN	nn||toxin-28/NN||barrel-26/NN	amod||toxin-28/NN||pore-forming-27/JJ	dep||²-24/NN||toxin-28/NN	prep_from||toxin-28/NN||staphylococcusaureus-30/NNS	toxin-28||aviannecroticenteritis-15||no_rel||the secreted pore-forming toxin netb is a key virulence factor in the pathogenesis of aviannecroticenteritis and is similar to alpha-hemolysin, a î²-barrel pore-forming toxin from staphylococcusaureus .
amod||h37rv-2/NNS||mycobacteriumtuberculosis-1/JJ	nsubj||contains-11/VBZ||h37rv-2/NNS	det||pathogen-5/NN||the-4/DT	appos||h37rv-2/NNS||pathogen-5/NN	amod||pathogen-5/NN||responsible-6/JJ	amod||tuberculosis-9/NNP||human-8/JJ	prep_for||responsible-6/JJ||tuberculosis-9/NNP	root||ROOT-0/null||contains-11/VBZ	num||modules-14/NNS||three-12/CD	amod||modules-14/NNS||relbe-like-13/JJ	dobj||contains-11/VBZ||modules-14/NNS	nsubjpass||expressed-28/VBN||modules-14/NNS	appos||modules-14/NNS||relbe-16/NN	appos||modules-14/NNS||relfg-18/NN	conj_and||relbe-16/NN||relfg-18/NN	appos||modules-14/NNS||reljk-21/NN	conj_and||relbe-16/NN||reljk-21/NN	auxpass||expressed-28/VBN||are-24/VBP	advmod||expressed-28/VBN||at-25/IN	pobj||at-25/IN||least-26/JJS	advmod||expressed-28/VBN||partly-27/RB	rcmod||modules-14/NNS||expressed-28/VBN	amod||macrophages-31/NNS||human-30/JJ	prep_in||expressed-28/VBN||macrophages-31/NNS	prep_during||expressed-28/VBN||infection-33/NN	tuberculosis-9||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis h37rv, the pathogen responsible for human tuberculosis, contains three relbe-like modules, relbe, relfg, and reljk, which are at least partly expressed in human macrophages during infection.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||determine-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||determine-4/VB||to-3/TO	xcomp||aimed-2/VBD||determine-4/VB	det||dose-12/NN||an-5/DT	amod||dose-12/NN||effective-6/JJ	conj_and||effective-6/JJ||safe-8/JJ	amod||dose-12/NN||safe-8/JJ	amod||dose-12/NN||glucose-lowering-9/JJ	nn||dose-12/NN||adjuvant-10/NN	nn||dose-12/NN||exenatide-11/NN	dobj||determine-4/VB||dose-12/NN	prep_in||dose-12/NN||adolescents-14/NNS	prep_with||determine-4/VB||type1diabetes-16/CD	type1diabetes-16||exenatide-11||no||we aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type1diabetes.
nsubj||have-11/VBP||adults-1/NNS	amod||origin-5/NN||south-3/JJ	nn||origin-5/NN||asian-4/NN	prep_of||adults-1/NNS||origin-5/NN	vmod||origin-5/NN||living-6/VBG	det||kingdom-10/NN||the-8/DT	amod||kingdom-10/NN||united-9/VBN	prep_in||living-6/VBG||kingdom-10/NN	root||ROOT-0/null||have-11/VBP	amod||risks-13/NNS||high-12/JJ	nsubj||raised-20/VBD||risks-13/NNS	amod||obesity-18/NN||type2diabetes-15/JJ	conj_and||type2diabetes-15/JJ||central-17/JJ	amod||obesity-18/NN||central-17/JJ	prep_of||risks-13/NNS||obesity-18/NN	ccomp||have-11/VBP||raised-20/VBD	xcomp||raised-20/VBD||circulating-21/VBG	dobj||circulating-21/VBG||insulin-22/NN	dobj||circulating-21/VBG||triglyceride-24/NN	conj_and||insulin-22/NN||triglyceride-24/NN	amod||concentrations-29/NNS||c-reactive-27/JJ	nn||concentrations-29/NNS||protein-28/NN	dobj||circulating-21/VBG||concentrations-29/NNS	conj_and||insulin-22/NN||concentrations-29/NNS	amod||hdl-cholesterol-33/NN||low-32/JJ	dobj||circulating-21/VBG||hdl-cholesterol-33/NN	conj_and||insulin-22/NN||hdl-cholesterol-33/NN	dep||circulating-21/VBG||when-34/WRB	prepc_compared_with||raised-20/VBD||with-36/IN	amod||europeans-38/NNS||white-37/JJ	pobj||raised-20/VBD||europeans-38/NNS	insulin-22||type2diabetes-15||no_rel||adults of south asian origin living in the united kingdom have high risks of type2diabetes and central obesity; raised circulating insulin, triglyceride, and c-reactive protein concentrations; and low hdl-cholesterol when compared with white europeans.
nsubj||appears-2/VBZ||eq-5d-1/JJ	nsubj||tool-7/NN||eq-5d-1/JJ	root||ROOT-0/null||appears-2/VBZ	aux||tool-7/NN||to-3/TO	cop||tool-7/NN||be-4/VB	det||tool-7/NN||an-5/DT	amod||tool-7/NN||appropriate-6/JJ	xcomp||appears-2/VBZ||tool-7/NN	prepc_for||tool-7/NN||measuring-9/VBG	prepc_for||tool-7/NN||valuing-11/VBG	conj_and||measuring-9/VBG||valuing-11/VBG	dobj||measuring-9/VBG||hrql-12/NN	prep_of||hrql-12/NN||hiv/aids-14/NNS	prep_in||hiv/aids-14/NNS||africa-16/NN	aids--1||hiv--1||no||eq-5d appears to be an appropriate tool for measuring and valuing hrql of hiv/aids in africa.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||budesonide--1||yes||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
nsubj||disorders-13/NNS||irondeficiency-1/NN	conj_and||irondeficiency-1/NN||excess-5/NN	nsubj||disorders-13/NNS||excess-5/NN	prep_of||excess-5/NN||iron-7/NN	cop||disorders-13/NNS||are-8/VBP	amod||disorders-13/NNS||frequent-9/JJ	conj_and||frequent-9/JJ||serious-11/JJ	amod||disorders-13/NNS||serious-11/JJ	amod||disorders-13/NNS||human-12/JJ	root||ROOT-0/null||disorders-13/NNS	irondeficiency-1||iron-7||yes||irondeficiency as well as excess of iron are frequent and serious human disorders.
nsubj||people-3/NNS||cases-1/NNS	cop||people-3/NNS||were-2/VBD	root||ROOT-0/null||people-3/NNS	vmod||people-3/NNS||living-4/VBG	prep_with||living-4/VBG||hiv/aids-6/NNS	nsubj||had-11/VBD||hiv/aids-6/NNS	appos||hiv/aids-6/NNS||plha-8/NNP	rcmod||hiv/aids-6/NNS||had-11/VBD	dobj||had-11/VBD||a-12/SYM	dep||stage-15/NN||a-12/SYM	amod||stage-15/NN||clinical-14/JJ	rcmod||a-12/SYM||stage-15/NN	prep_of||stage-15/NN||iii-17/NN	prep_of||stage-15/NN||iv-19/NN	conj_or||iii-17/NN||iv-19/NN	det||count-24/NN||a-21/DT	amod||count-24/NN||cd4-22/JJ	nn||count-24/NN||lymphocyte-23/NN	rcmod||a-12/SYM||count-24/NN	conj_or||stage-15/NN||count-24/NN	mwe||than-27/IN||less-26/JJR	quantmod||200/ul-28/CD||than-27/IN	prep_of||count-24/NN||200/ul-28/CD	det||time-31/NN||the-30/DT	prep_at||had-11/VBD||time-31/NN	det||presentation-35/NN||the-33/DT	amod||presentation-35/NN||first-34/JJ	prep_of||time-31/NN||presentation-35/NN	amod||clinics-42/NNS||antiretroviral-37/JJ	nn||clinics-42/NNS||treatment-38/NN	nn||clinics-42/NNS||art-40/NN	prep_to||had-11/VBD||clinics-42/NNS	aids--1||hiv--1||no||cases were people living with hiv/aids (plha) who had a who clinical stage of iii or iv or a cd4 lymphocyte count of less than 200/ul at the time of the first presentation to antiretroviral treatment (art) clinics.
nsubj||inhibitor-14/NN||desvenlafaxine-1/NN	det||metabolite-5/NN||the-3/DT	amod||metabolite-5/NN||active-4/JJ	appos||desvenlafaxine-1/NN||metabolite-5/NN	prep_of||metabolite-5/NN||venlafaxine-7/NN	cop||inhibitor-14/NN||is-9/VBZ	det||inhibitor-14/NN||a-10/DT	amod||inhibitor-14/NN||serotonin-11/JJ	amod||inhibitor-14/NN||norepinephrine-12/JJ	nn||inhibitor-14/NN||reuptake-13/NN	root||ROOT-0/null||inhibitor-14/NN	appos||inhibitor-14/NN||snri-16/NNP	advmod||approved-19/VBN||recently-18/RB	vmod||inhibitor-14/NN||approved-19/VBN	det||treatment-22/NN||the-21/DT	prep_for||approved-19/VBN||treatment-22/NN	amod||depressivedisorder-25/NN||major-24/JJ	prep_of||treatment-22/NN||depressivedisorder-25/NN	depressivedisorder-25||venlafaxine-7||yes||desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (snri) recently approved for the treatment of major depressivedisorder.
nsubj||drug-8/NN||ablc-1/NN	cop||drug-8/NN||is-2/VBZ	det||drug-8/NN||a-3/DT	amod||drug-8/NN||safe-4/JJ	conj_and||safe-4/JJ||effective-6/JJ	amod||drug-8/NN||effective-6/JJ	amod||drug-8/NN||broad-spectrum-7/JJ	root||ROOT-0/null||drug-8/NN	det||treatment-11/NN||the-10/DT	prep_in||drug-8/NN||treatment-11/NN	amod||fungalinfections-14/NNS||invasive-13/JJ	prep_of||treatment-11/NN||fungalinfections-14/NNS	prep_in||fungalinfections-14/NNS||patients-16/NNS	nn||refractory-19/NNS||infection-18/NN	prep_with||patients-16/NNS||refractory-19/NNS	prep_with||patients-16/NNS||refractory-19/NNS	conj_or||refractory-19/NNS||refractory-19/NNS	nn||deoxycholate-22/NN||amb-21/NN	prep_to||refractory-19/NNS||deoxycholate-22/NN	nn||intolerant-26/NN||patients-25/NNS	prep_in||refractory-19/NNS||intolerant-26/NN	det||formulation-30/NN||the-28/DT	amod||formulation-30/NN||same-29/JJ	prep_of||intolerant-26/NN||formulation-30/NN	fungalinfections-14||ablc-1||yes||ablc is a safe and effective broad-spectrum drug in the treatment of invasive fungalinfections in patients with infection refractory to amb deoxycholate or in patients intolerant of the same formulation.
amod||-lrb--2/NNS||epstein-barrvirus-1/JJ	nsubj||ebv-3/VBP||-lrb--2/NNS	root||ROOT-0/null||ebv-3/VBP	amod||infection-5/NN||-rrb--4/JJ	nsubj||finding-10/NN||infection-5/NN	cop||finding-10/NN||is-6/VBZ	det||finding-10/NN||an-7/DT	advmod||finding-10/NN||almost-8/RB	amod||finding-10/NN||universal-9/JJ	ccomp||ebv-3/VBP||finding-10/NN	prep_among||finding-10/NN||individuals-12/NNS	amod||ebvinfection-16/NN||ms.-14/JJ	amod||ebvinfection-16/NN||symptomatic-15/JJ	prep_with||individuals-12/NNS||ebvinfection-16/NN	mark||shown-26/VBN||as-17/IN	amod||-rrb--23/NNS||manifested-18/JJ	prep_by||manifested-18/JJ||infectiousmononucleosis-20/NNS	amod||-rrb--23/NNS||-lrb--21/JJ	nn||-rrb--23/NNS||im-22/NN	nsubjpass||shown-26/VBN||-rrb--23/NNS	nsubjpass||associated-33/VBN||-rrb--23/NNS	aux||shown-26/VBN||has-24/VBZ	auxpass||shown-26/VBN||been-25/VBN	advcl||finding-10/NN||shown-26/VBN	det||meta-analysis-30/NNS||a-28/DT	amod||meta-analysis-30/NNS||previous-29/JJ	prep_in||shown-26/VBN||meta-analysis-30/NNS	aux||associated-33/VBN||to-31/TO	auxpass||associated-33/VBN||be-32/VB	xcomp||shown-26/VBN||associated-33/VBN	det||risk-36/NN||the-35/DT	prep_with||associated-33/VBN||risk-36/NN	prep_of||risk-36/NN||ms-38/NN	advmod||published-50/VBN||however-40/RB	det||number-42/NN||a-41/DT	nsubjpass||published-50/VBN||number-42/NN	advmod||larger-45/JJR||much-44/RB	amod||studies-46/NNS||larger-45/JJR	prep_of||number-42/NN||studies-46/NNS	aux||published-50/VBN||have-47/VBP	advmod||published-50/VBN||since-48/IN	auxpass||published-50/VBN||been-49/VBN	parataxis||ebv-3/VBP||published-50/VBN	infectiousmononucleosis-20||epstein-barrvirus-1||no||epstein-barrvirus -lrb- ebv -rrb- infection is an almost universal finding among individuals with ms. symptomatic ebvinfection as manifested by infectiousmononucleosis -lrb- im -rrb- has been shown in a previous meta-analysis to be associated with the risk of ms , however a number of much larger studies have since been published .
det||strategy-5/NN||this-4/DT	prep_in_addition_to||utilized-21/VBN||strategy-5/NN	amod||bacteria-10/NNS||live-7/JJ	amod||bacteria-10/NNS||attenuated-8/JJ	nn||bacteria-10/NNS||intracellular-9/NN	nsubjpass||utilized-21/VBN||bacteria-10/NNS	prep_such_as||bacteria-10/NNS||shigella-13/NN	prep_such_as||bacteria-10/NNS||salmonella-15/NN	conj_and||shigella-13/NN||salmonella-15/NN	prep_such_as||bacteria-10/NNS||listeria-18/NN	conj_and||shigella-13/NN||listeria-18/NN	aux||utilized-21/VBN||have-19/VBP	auxpass||utilized-21/VBN||been-20/VBN	root||ROOT-0/null||utilized-21/VBN	prep_as||utilized-21/VBN||carriers-23/NNS	nn||vaccines-26/NNS||dna-25/NN	prep_of||carriers-23/NNS||vaccines-26/NNS	nn||models-29/NNS||animal-28/NN	prep_in||vaccines-26/NNS||models-29/NNS	shigella-13||bacteria-10||no||in addition to this strategy, live attenuated intracellular bacteria such as shigella, salmonella , and listeria have been utilized as carriers of dna vaccines in animal models.
det||mito-mice-3/NN||the-2/DT	prep_in||induced-10/VBN||mito-mice-3/NN	nsubj||induced-10/VBN||accumulation-5/NN	nn||mtdna-9/NN||î-7/NN	prep_of||accumulation-5/NN||mtdna-9/NN	root||ROOT-0/null||induced-10/VBN	amod||defects-13/NNS||mitochondrial-11/JJ	nn||defects-13/NNS||respiration-12/NN	dobj||induced-10/VBN||defects-13/NNS	amod||tissues-16/NNS||various-15/JJ	prep_in||defects-13/NNS||tissues-16/NNS	vmod||induced-10/VBN||resulting-18/VBG	amod||phenotypes-22/NNS||mitochondrial-20/JJ	nn||phenotypes-22/NNS||disease-21/NN	prep_in||resulting-18/VBG||phenotypes-22/NNS	amod||weight-28/NN||low-26/JJ	nn||weight-28/NN||body-27/NN	prep_such_as||phenotypes-22/NNS||weight-28/NN	amod||acidosis-31/NNS||lactic-30/JJ	prep_such_as||phenotypes-22/NNS||acidosis-31/NNS	conj_and||weight-28/NN||acidosis-31/NNS	prep_such_as||phenotypes-22/NNS||ischemia-33/NN	conj_and||weight-28/NN||ischemia-33/NN	prep_such_as||phenotypes-22/NNS||myopathy-35/NN	conj_and||weight-28/NN||myopathy-35/NN	prep_such_as||phenotypes-22/NNS||heartblock-37/NN	conj_and||weight-28/NN||heartblock-37/NN	prep_such_as||phenotypes-22/NNS||deafness-39/NNS	conj_and||weight-28/NN||deafness-39/NNS	amod||infertility-42/NN||male-41/JJ	prep_such_as||phenotypes-22/NNS||infertility-42/NN	conj_and||weight-28/NN||infertility-42/NN	prep_such_as||phenotypes-22/NNS||renalfailure-45/NN	conj_and||weight-28/NN||renalfailure-45/NN	mito--1||acidosis-31||no_rel||in the mito-mice, accumulation of î”mtdna induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heartblock, deafness, male infertility, and renalfailure.
amod||association-2/NN||significant-1/JJ	nsubjpass||noted-45/VBN||association-2/NN	appos||association-2/NN||p-4/NNP	number||0.001-6/CD||<-5/CD	num||p-4/NNP||0.001-6/CD	amod||use-10/NN||prior-9/JJ	prep_of||association-2/NN||use-10/NN	prep_of||use-10/NN||antibiotics-12/NNS	prep_in||antibiotics-12/NNS||males-14/NNS	conj_and||association-2/NN||uti-16/NN	nsubjpass||noted-45/VBN||uti-16/NN	prep_in||uti-16/NN||adults-18/NNS	amod||surgery-21/NN||gynaecological-20/JJ	conj_and||association-2/NN||surgery-21/NN	nsubjpass||noted-45/VBN||surgery-21/NN	prep_in||surgery-21/NN||females-23/NNS	amod||uropathy-26/NN||obstructive-25/JJ	conj_and||association-2/NN||uropathy-26/NN	nsubjpass||noted-45/VBN||uropathy-26/NN	prep_in||uropathy-26/NN||males-28/NNS	amod||uti-31/NN||complicated-30/JJ	conj_and||association-2/NN||uti-31/NN	nsubjpass||noted-45/VBN||uti-31/NN	prep_in||uti-31/NN||females-33/NNS	det||occurrence-36/NN||the-35/DT	prep_with||females-33/NNS||occurrence-36/NN	prep_of||occurrence-36/NN||uti-38/NN	amod||resistant-41/JJ||ciprofloxacin-40/JJ	amod||coli-43/NNS||resistant-41/JJ	nn||coli-43/NNS||escherichia-42/NN	prep_with||uti-38/NN||coli-43/NNS	auxpass||noted-45/VBN||was-44/VBD	root||ROOT-0/null||noted-45/VBN	uti-38||ciprofloxacin-40||yes||significant association ( p <0.001) of prior use of antibiotics in males, uti in adults, gynaecological surgery in females, obstructive uropathy in males and complicated uti in females with the occurrence of uti with ciprofloxacin resistant escherichia coli was noted.
nsubj||searched-2/VBD||we-1/PRP	root||ROOT-0/null||searched-2/VBD	det||articles-5/NNS||any-4/DT	prep_for||searched-2/VBD||articles-5/NNS	nsubj||included-7/VBD||articles-5/NNS	rcmod||articles-5/NNS||included-7/VBD	det||keyword-10/NN||the-8/DT	amod||keyword-10/NN||required-9/JJ	dobj||included-7/VBD||keyword-10/NN	det||terms-15/NNS||the-14/DT	dobj||included-7/VBD||terms-15/NNS	conj_and||keyword-10/NN||terms-15/NNS	poss||and/or-56/NN||hiv-17/NNP	nn||and/or-56/NN||and/or-19/NNP	amod||and/or-56/NN||aids-21/JJ	dep||aids-21/JJ||prevalence-25/JJ	dep||aids-21/JJ||behaviors-29/JJ	dep||aids-21/JJ||knowledge-33/NN	appos||knowledge-33/NN||attitudes-37/NNS	appos||knowledge-33/NN||perceptions-41/NNS	appos||knowledge-33/NN||prevention-45/NN	appos||knowledge-33/NN||gender-49/NN	appos||knowledge-33/NN||drugs-52/NNS	appos||knowledge-33/NN||alcohol-54/NN	dobj||searched-2/VBD||and/or-56/NN	iobj||searched-2/VBD||and/or-56/NN	nn||infrastructure-60/NN||health-58/NN	nn||infrastructure-60/NN||care-59/NN	dep||and/or-56/NN||infrastructure-60/NN	aids-21||hiv-17||no||we searched for any articles that included the required keyword as well as the terms 'hiv' and/or 'aids', 'prevalence', 'behaviors', 'knowledge', 'attitudes', 'perceptions', 'prevention', 'gender', drugs, alcohol, and/or 'health care infrastructure'.
det||china-2/NN||each-1/DT	nsubj||cares-3/VBZ||china-2/NN	root||ROOT-0/null||cares-3/VBZ	nsubjpass||required-6/VBN||site-4/NN	nsubj||carry-8/VB||site-4/NN	auxpass||required-6/VBN||was-5/VBD	ccomp||cares-3/VBZ||required-6/VBN	aux||carry-8/VB||to-7/TO	xcomp||required-6/VBN||carry-8/VB	prt||carry-8/VB||out-9/RP	dobj||carry-8/VB||surveillance-10/NN	dobj||carry-8/VB||surveys-12/NNS	conj_and||surveillance-10/NN||surveys-12/NNS	aux||understand-14/VB||to-13/TO	vmod||carry-8/VB||understand-14/VB	det||epidemic-18/NN||the-15/DT	amod||epidemic-18/NN||local-16/JJ	nn||epidemic-18/NN||hiv/aids-17/NN	dobj||understand-14/VB||epidemic-18/NN	aux||deliver-21/VB||to-20/TO	vmod||carry-8/VB||deliver-21/VB	amod||interventions-23/NNS||primary-22/JJ	dobj||deliver-21/VB||interventions-23/NNS	aux||reduce-25/VB||to-24/TO	vmod||deliver-21/VB||reduce-25/VB	vmod||deliver-21/VB||reduce-25/VB	conj_and||reduce-25/VB||reduce-25/VB	amod||hivinfections-27/NNS||new-26/JJ	dobj||reduce-25/VB||hivinfections-27/NNS	amod||groups-32/NNS||high-risk-31/JJ	prep_among||reduce-25/VB||groups-32/NNS	prep_from||reduce-25/VB||groups-32/NNS	aux||prevent-35/VB||to-34/TO	dep||reduce-25/VB||prevent-35/VB	amod||transmission-37/NN||mother-to-child-36/JJ	dobj||prevent-35/VB||transmission-37/NN	aux||treat-40/VB||to-39/TO	dep||reduce-25/VB||treat-40/VB	conj_and||prevent-35/VB||treat-40/VB	nn||patients-42/NNS||aids-41/NNS	dobj||treat-40/VB||patients-42/NNS	amod||medicines-45/NNS||antiretroviral-44/JJ	prep_with||treat-40/VB||medicines-45/NNS	aux||provide-48/VB||to-47/TO	dep||reduce-25/VB||provide-48/VB	conj_and||prevent-35/VB||provide-48/VB	nn||services-50/NNS||support-49/NN	dobj||provide-48/VB||services-50/NNS	prep_to||provide-48/VB||families-52/NNS	vmod||families-52/NNS||affected-53/VBN	agent||affected-53/VBN||hiv/aids-55/NNS	aids-41||hiv--1||no||each china cares site was required to carry out surveillance and surveys to understand the local hiv/aids epidemic, to deliver primary interventions to reduce new hivinfections among and from high-risk groups, to prevent mother-to-child transmission, to treat aids patients with antiretroviral medicines and to provide support services to families affected by hiv/aids.
amod||adjustment-3/NN||further-2/JJ	prep_after||associated-23/VBN||adjustment-3/NN	det||covariates-7/NNS||all-5/DT	amod||covariates-7/NNS||other-6/JJ	prep_for||adjustment-3/NN||covariates-7/NNS	prep_for||adjustment-3/NN||covariates-7/NNS	conj_less||covariates-7/NNS||covariates-7/NNS	det||value-11/NN||a-9/DT	nn||value-11/NN||p-10/NN	prep_with||covariates-7/NNS||value-11/NN	amod||associations-17/NNS||0.3-14/CD	conj_and||0.3-14/CD||nonlinear-16/JJR	amod||associations-17/NNS||nonlinear-16/JJR	prep_than||covariates-7/NNS||associations-17/NNS	prep_with||associations-17/NNS||cancer-19/NN	nsubjpass||associated-23/VBN||a1c-21/NNS	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||risk-28/NN||an-25/DT	amod||risk-28/NN||increased-26/VBN	nn||risk-28/NN||cancer-27/NN	prep_with||associated-23/VBN||risk-28/NN	dep||hr-30/NN||-lrb--29/NN	amod||risk-28/NN||hr-30/NN	prep_per||risk-28/NN||percentage-32/NN	num||percentage-32/NN||1.26-33/CD	num||%-36/NN||95-35/CD	npadvmod||ci-37/RB||%-36/NN	advmod||â-39/NN||ci-37/RB	num||â-39/NN||1.03-38/CD	appos||percentage-32/NN||â-39/NN	dep||-rrb--43/NN||$-40/$	num||$-40/$||1.55-42/CD	amod||â-39/NN||-rrb--43/NN	mark||associated-50/VBN||whereas-45/IN	nsubjpass||associated-50/VBN||use-46/NN	prep_of||use-46/NN||insulin-48/NN	auxpass||associated-50/VBN||was-49/VBD	dep||percentage-32/NN||associated-50/VBN	det||risk-55/NN||a-52/DT	amod||risk-55/NN||decreased-53/VBN	nn||risk-55/NN||cancer-54/NN	prep_with||associated-50/VBN||risk-55/NN	dep||hr-57/NN||-lrb--56/NN	amod||risk-55/NN||hr-57/NN	nn||users-60/NNS||insulin-59/NN	prep_of||risk-55/NN||users-60/NNS	prep_vs.||users-60/NNS||nonusers-62/NNP	num||nonusers-62/NNP||0.17-63/CD	num||nonusers-62/NNP||0.09-65/CD	quantmod||$-67/$||â-66/RB	dep||-rrb--70/NN||$-67/$	num||$-67/$||0.32-69/CD	amod||risk-55/NN||-rrb--70/NN	insulin-59||cancer-54||no_rel||after further adjustment for all other covariates with a p value less than 0.3 and nonlinear associations with cancer , a1c was associated with an increased cancer risk -lrb- hr per percentage 1.26 , 95 % ci 1.03 â $ `` 1.55 -rrb- , whereas use of insulin was associated with a decreased cancer risk -lrb- hr of insulin users vs. nonusers 0.17 , 0.09 â $ `` 0.32 -rrb- .
